gene,variant,MutPred_score,explain,MutPred_pred,nothing
gene,variant,MutPred_score,explain,MutPred_pred,nothing
FGFR1_HUMAN,F9S,0.828,Altered Disordered interface (Pr = 0.25 | P = 0.02); Altered Ordered interface (Pr = 0.24 | P = 0.04); Altered Signal peptide (Pr = 0.12 | P = 1.4e-03), ELME000041|ELME000106|ELME000137|ELME000146,-
FGFR1_HUMAN,W10P,0.922,Altered Ordered interface (Pr = 0.24 | P = 0.04); Altered Signal peptide (Pr = 0.09 | P = 2.8e-03), ELME000041|ELME000137,-
FGFR1_HUMAN,A11R,0.872,Altered Disordered interface (Pr = 0.37 | P = 4.8e-03); Altered Signal peptide (Pr = 0.15 | P = 1.6e-03), ELME000041|ELME000106,-
FGFR1_HUMAN,V12S,0.881,Altered Signal peptide (Pr = 0.16 | P = 4.8e-04), ELME000041|ELME000063|ELME000333|ELME000336,-
FGFR1_HUMAN,V14F,0.895,Altered Signal peptide (Pr = 0.21 | P = 2.6e-04), ELME000041|ELME000052|ELME000080|ELME000333|ELME000336,-
FGFR1_HUMAN,T17C,0.8,Altered Signal peptide (Pr = 0.22 | P = 2.2e-04); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.05), ELME000052|ELME000053,-
FGFR1_HUMAN,L18Y,0.85,Gain of Loop (Pr = 0.26 | P = 0.05); Altered Signal peptide (Pr = 0.20 | P = 3.1e-04); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.04), ELME000052|ELME000053|ELME000182,-
FGFR1_HUMAN,T20A,0.544,Altered Signal peptide (Pr = 0.22 | P = 2.0e-04); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.05); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000053|PS00005,-
FGFR1_HUMAN,T20M,0.478,-,-,-
FGFR1_HUMAN,A21L,0.848,Altered Signal peptide (Pr = 0.21 | P = 2.2e-04); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.05); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000053|ELME000136|ELME000159|ELME000313|PS00005,-
FGFR1_HUMAN,R22G,0.67,Loss of ADP-ribosylation at R22 (Pr = 0.27 | P = 7.2e-03); Gain of Loop (Pr = 0.26 | P = 0.05); Altered Signal peptide (Pr = 0.20 | P = 2.7e-04); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000005|ELME000053|ELME000136|ELME000155|ELME000159|PS00005,-
FGFR1_HUMAN,P23S,0.612,Altered Signal peptide (Pr = 0.25 | P = 1.4e-04); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.05); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000005|ELME000053|ELME000063|ELME000064|ELME000136|ELME000155|ELME000159,-
FGFR1_HUMAN,S24T,0.397,-,-,-
FGFR1_HUMAN,L27Y,0.808,Gain of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.03); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q30 (Pr = 0.09 | P = 0.01); Altered Signal peptide (Pr = 0.05 | P = 2.1e-03), ELME000005|ELME000064|ELME000155|ELME000159|ELME000163|ELME000220|PS00006,-
FGFR1_HUMAN,Q30H,0.27,-,-,-
FGFR1_HUMAN,A31T,0.313,-,-,-
FGFR1_HUMAN,Q32L,0.315,-,-,-
FGFR1_HUMAN,F43L,0.126,-,-,-
FGFR1_HUMAN,F43S,0.311,-,-,-
FGFR1_HUMAN,L50P,0.698,Gain of Loop (Pr = 0.31 | P = 3.6e-03); Altered Metal binding (Pr = 0.28 | P = 0.02); Gain of Strand (Pr = 0.27 | P = 0.02); Gain of Disulfide linkage at C55 (Pr = 0.25 | P = 5.2e-03); Altered Transmembrane protein (Pr = 0.16 | P = 0.01), ELME000155|ELME000335,-
FGFR1_HUMAN,R80H,0.655,Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Gain of N-linked glycosylation at N77 (Pr = 0.20 | P = 2.8e-03); Altered Stability (Pr = 0.17 | P = 0.02), ELME000012|ELME000062|ELME000063|ELME000064|ELME000070|ELME000220|PS00001,-
FGFR1_HUMAN,E84A,0.471,-,-,-
FGFR1_HUMAN,V92A,0.176,-,-,-
FGFR1_HUMAN,V92M,0.133,-,-,-
FGFR1_HUMAN,A94S,0.126,-,-,-
FGFR1_HUMAN,S104N,0.181,-,-,-
FGFR1_HUMAN,S105N,0.525,Loss of Intrinsic disorder (Pr = 0.35 | P = 0.05); Loss of B-factor (Pr = 0.26 | P = 0.03); Altered Metal binding (Pr = 0.24 | P = 0.04); Gain of Disulfide linkage at C101 (Pr = 0.20 | P = 0.02); Altered Transmembrane protein (Pr = 0.19 | P = 6.2e-03); Loss of O-linked glycosylation at T103 (Pr = 0.18 | P = 0.03), ELME000053|ELME000063|ELME000136|ELME000159,-
FGFR1_HUMAN,S107L,0.333,-,-,-
FGFR1_HUMAN,T112S,0.115,-,-,-
FGFR1_HUMAN,E126D,0.37,-,-,-
FGFR1_HUMAN,K163N,0.457,-,-,-
FGFR1_HUMAN,E235K,0.304,-,-,-
FGFR1_HUMAN,Y243F,0.61,Altered Transmembrane protein (Pr = 0.30 | P = 1.3e-04); Gain of Relative solvent accessibility (Pr = 0.23 | P = 0.05); Gain of N-linked glycosylation at N240 (Pr = 0.16 | P = 5.4e-03); Loss of Sulfation at Y243 (Pr = 0.02 | P = 0.04), ELME000052|ELME000070|ELME000246|PS00001,-
FGFR1_HUMAN,V247S,0.946,Altered Ordered interface (Pr = 0.33 | P = 8.0e-03); Gain of Intrinsic disorder (Pr = 0.32 | P = 0.03); Altered Transmembrane protein (Pr = 0.27 | P = 5.4e-04); Altered Stability (Pr = 0.23 | P = 9.5e-03); Loss of Sulfation at Y243 (Pr = 0.01 | P = 0.04), ELME000053|ELME000333,-
FGFR1_HUMAN,K265E,0.635,Altered Metal binding (Pr = 0.37 | P = 3.5e-04); Loss of Relative solvent accessibility (Pr = 0.35 | P = 2.4e-03); Altered Ordered interface (Pr = 0.30 | P = 0.02); Gain of Loop (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.20 | P = 5.3e-03); Gain of N-linked glycosylation at N264 (Pr = 0.19 | P = 3.5e-03); Loss of Ubiquitylation at K265 (Pr = 0.16 | P = 0.04), ELME000052|ELME000070|PS00001|PS00008,-
FGFR1_HUMAN,T313H,0.855,Altered Transmembrane protein (Pr = 0.20 | P = 6.0e-03); Gain of N-linked glycosylation at N317 (Pr = 0.19 | P = 3.5e-03), ELME000052,-
FGFR1_HUMAN,M323T,0.674,Altered Transmembrane protein (Pr = 0.34 | P = 2.4e-05); Gain of Loop (Pr = 0.27 | P = 0.04); Gain of Ubiquitylation at K321 (Pr = 0.15 | P = 0.05), ELME000052|ELME000053|ELME000220|ELME000335,-
FGFR1_HUMAN,H327G,0.775,Altered Transmembrane protein (Pr = 0.30 | P = 1.7e-04); Gain of N-linked glycosylation at N330 (Pr = 0.11 | P = 0.01); Altered Stability (Pr = 0.11 | P = 0.04), ELME000122|ELME000137|ELME000334|ELME000335,-
FGFR1_HUMAN,S332T,0.681,Altered Transmembrane protein (Pr = 0.30 | P = 1.6e-04); Altered Metal binding (Pr = 0.17 | P = 0.04); Gain of N-linked glycosylation at N330 (Pr = 0.12 | P = 8.3e-03), ELME000070|ELME000122|ELME000137|ELME000146|ELME000220|ELME000334|PS00001|PS00006,-
FGFR1_HUMAN,E334A,0.833,Altered Transmembrane protein (Pr = 0.32 | P = 5.8e-05); Altered Ordered interface (Pr = 0.27 | P = 6.5e-03); Loss of Strand (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.18 | P = 0.04); Loss of N-linked glycosylation at N330 (Pr = 0.10 | P = 0.01), ELME000070|ELME000122|ELME000137|ELME000321|PS00006,-
FGFR1_HUMAN,E338D,0.665,Altered Metal binding (Pr = 0.29 | P = 0.01); Altered Transmembrane protein (Pr = 0.27 | P = 6.5e-04); Altered Ordered interface (Pr = 0.25 | P = 0.02); Gain of Disulfide linkage at C341 (Pr = 0.23 | P = 0.01); Gain of Sulfation at Y339 (Pr = 0.01 | P = 0.04), None,-
FGFR1_HUMAN,T340C,0.91,Altered Metal binding (Pr = 0.38 | P = 9.4e-03); Altered Transmembrane protein (Pr = 0.36 | P = 1.9e-05); Loss of Loop (Pr = 0.27 | P = 0.04); Altered Ordered interface (Pr = 0.24 | P = 0.03); Loss of Disulfide linkage at C341 (Pr = 0.19 | P = 0.02); Gain of Catalytic site at N345 (Pr = 0.08 | P = 0.05), ELME000120|ELME000182,-
FGFR1_HUMAN,S346Y,0.902,Altered Metal binding (Pr = 0.35 | P = 8.8e-03); Gain of Strand (Pr = 0.26 | P = 0.05); Altered Transmembrane protein (Pr = 0.25 | P = 1.6e-03); Loss of Disulfide linkage at C341 (Pr = 0.19 | P = 0.02), ELME000053|ELME000083|ELME000120|ELME000182|ELME000239|PS00008,-
FGFR1_HUMAN,I347A,0.886,Altered Stability (Pr = 0.78 | P = 3.6e-04); Altered Transmembrane protein (Pr = 0.29 | P = 2.9e-04); Loss of Strand (Pr = 0.27 | P = 0.03); Loss of Loop (Pr = 0.26 | P = 0.05); Gain of Catalytic site at N345 (Pr = 0.10 | P = 0.04); Gain of GPI-anchor amidation at N345 (Pr = 0.02 | P = 0.02), ELME000053|ELME000085|ELME000239|PS00008,-
FGFR1_HUMAN,S350R,0.845,Altered Transmembrane protein (Pr = 0.30 | P = 1.6e-04); Gain of Strand (Pr = 0.27 | P = 0.03); Altered Ordered interface (Pr = 0.23 | P = 0.05), ELME000053|ELME000063,-
FGFR1_HUMAN,E360R,0.751,Altered Transmembrane protein (Pr = 0.35 | P = 2.4e-05); Gain of Strand (Pr = 0.27 | P = 0.03), ELME000064|ELME000220|ELME000333|PS00006,-
FGFR1_HUMAN,A367T,0.365,-,-,-
FGFR1_HUMAN,A367V,0.451,-,-,-
FGFR1_HUMAN,L373F,0.21,-,-,-
FGFR1_HUMAN,G392V,0.497,-,-,-
FGFR1_HUMAN,G402N,0.127,-,-,-
FGFR1_HUMAN,P483A,0.596,Gain of Helix (Pr = 0.28 | P = 0.03), None,-
FGFR1_HUMAN,I498S,0.715,Gain of Intrinsic disorder (Pr = 0.33 | P = 0.03); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Gain of B-factor (Pr = 0.26 | P = 0.02); Loss of Methylation at K502 (Pr = 0.18 | P = 9.8e-03); Altered Metal binding (Pr = 0.16 | P = 0.02); Altered Stability (Pr = 0.12 | P = 0.03), ELME000085|ELME000239|PS00006|PS00107,-
FGFR1_HUMAN,S518P,0.729,Altered Ordered interface (Pr = 0.33 | P = 9.0e-03); Loss of Relative solvent accessibility (Pr = 0.30 | P = 9.6e-03); Altered DNA binding (Pr = 0.29 | P = 3.9e-03); Gain of Acetylation at K514 (Pr = 0.26 | P = 0.01); Altered Metal binding (Pr = 0.21 | P = 0.03); Loss of Methylation at K517 (Pr = 0.21 | P = 6.0e-03); Loss of Ubiquitylation at K523 (Pr = 0.21 | P = 5.2e-03); Altered Coiled coil (Pr = 0.10 | P = 0.04), ELME000063|ELME000106|ELME000146,-
FGFR1_HUMAN,T521A,0.446,-,-,-
FGFR1_HUMAN,Y572F,0.389,-,-,-
FGFR1_HUMAN,N590H,0.099,-,-,-
FGFR1_HUMAN,P663A,0.855,Altered Ordered interface (Pr = 0.27 | P = 8.3e-03); Altered Transmembrane protein (Pr = 0.10 | P = 0.05), None,-
FGFR1_HUMAN,Q680P,0.917,Loss of Strand (Pr = 0.28 | P = 8.0e-03); Altered Ordered interface (Pr = 0.27 | P = 0.04); Gain of Loop (Pr = 0.26 | P = 0.05); Altered Transmembrane protein (Pr = 0.25 | P = 1.2e-03); Altered Metal binding (Pr = 0.19 | P = 0.04); Loss of Pyrrolidone carboxylic acid at Q680 (Pr = 0.06 | P = 0.03), ELME000048|ELME000053|ELME000163|ELME000182,-
FGFR1_HUMAN,S681I,0.857,Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Transmembrane protein (Pr = 0.24 | P = 1.7e-03); Altered Metal binding (Pr = 0.17 | P = 0.05); Loss of Pyrrolidone carboxylic acid at Q680 (Pr = 0.05 | P = 0.03); Gain of Sulfation at Y677 (Pr = 0.01 | P = 0.05), ELME000052|ELME000053,-
FGFR1_HUMAN,V683R,0.924,Altered Ordered interface (Pr = 0.35 | P = 4.4e-03); Altered Transmembrane protein (Pr = 0.26 | P = 1.2e-03); Loss of Strand (Pr = 0.26 | P = 0.05); Gain of Allosteric site at W684 (Pr = 0.20 | P = 0.04); Altered Metal binding (Pr = 0.18 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q680 (Pr = 0.07 | P = 0.02), ELME000053|ELME000062|PS00005,-
FGFR1_HUMAN,Y701N,0.939,Altered Ordered interface (Pr = 0.30 | P = 4.4e-03); Gain of B-factor (Pr = 0.28 | P = 7.8e-03); Altered Transmembrane protein (Pr = 0.14 | P = 0.02); Loss of Catalytic site at Y701 (Pr = 0.11 | P = 0.03), ELME000120|ELME000136|ELME000155|ELME000159,-
FGFR1_HUMAN,M771I,0.102,-,-,-
FGFR1_HUMAN,Y776D,0.577,Gain of Intrinsic disorder (Pr = 0.45 | P = 3.8e-03); Altered Disordered interface (Pr = 0.28 | P = 0.04); Gain of B-factor (Pr = 0.27 | P = 0.01); Gain of Phosphorylation at S777 (Pr = 0.25 | P = 0.03); Loss of Sulfation at Y776 (Pr = 0.12 | P = 2.1e-03), ELME000053|ELME000136|ELME000155|ELME000159|ELME000197,-
FGFR1_HUMAN,L801F,0.309,-,-,-
FGFR1_HUMAN,H810Q,0.128,-,-,-
FGFR1_HUMAN,L814H,0.351,-,-,-
FGFR1_HUMAN,M719R,0.95,Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered DNA binding (Pr = 0.17 | P = 0.03); Loss of N-linked glycosylation at N724 (Pr = 0.02 | P = 0.03), ELME000102|ELME000108,-
FGFR1_HUMAN,E467K,0.498,-,-,-
FGFR1_HUMAN,R570W,0.86,Altered Ordered interface (Pr = 0.31 | P = 2.5e-03); Loss of Helix (Pr = 0.28 | P = 0.03), None,-
FGFR1_HUMAN,V795I,0.135,-,-,-
FGFR1_HUMAN,R622G,0.863,Loss of Helix (Pr = 0.28 | P = 0.03); Altered Transmembrane protein (Pr = 0.26 | P = 9.5e-04); Altered DNA binding (Pr = 0.25 | P = 8.5e-03); Loss of Allosteric site at R627 (Pr = 0.23 | P = 0.03); Loss of Catalytic site at R627 (Pr = 0.12 | P = 0.03), PS00109,-
FGFR1_HUMAN,N117S,0.34,-,-,-
FGFR1_HUMAN,E274G,0.883,Loss of Relative solvent accessibility (Pr = 0.31 | P = 7.3e-03); Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Altered Ordered interface (Pr = 0.28 | P = 0.04); Loss of Disulfide linkage at C277 (Pr = 0.27 | P = 2.8e-03); Altered Stability (Pr = 0.11 | P = 0.04), ELME000064|PS00006|PS00008,-
FGFR1_HUMAN,G490R,0.949,Gain of Helix (Pr = 0.31 | P = 4.8e-03); Loss of Strand (Pr = 0.29 | P = 4.8e-03), PS00107,-
FGFR1_HUMAN,N330I,0.954,Altered Transmembrane protein (Pr = 0.41 | P = 4.9e-06); Gain of Strand (Pr = 0.26 | P = 0.05); Altered Metal binding (Pr = 0.18 | P = 0.04); Loss of N-linked glycosylation at N330 (Pr = 0.11 | P = 0.01), ELME000070|ELME000122|ELME000137|ELME000333|ELME000334|PS00001,-
FGFR1_HUMAN,R250W,0.864,Altered Transmembrane protein (Pr = 0.32 | P = 8.3e-05); Altered Ordered interface (Pr = 0.27 | P = 0.05), ELME000136|ELME000153|ELME000155|ELME000159,-
FGFR1_HUMAN,K139R,0.283,-,-,-
FGFR1_HUMAN,R148H,0.443,-,-,-
FGFR1_HUMAN,G485R,0.903,, PS00107,-
FGFR1_HUMAN,C277F,0.969,Altered Metal binding (Pr = 0.78 | P = 5.7e-04); Loss of Disulfide linkage at C277 (Pr = 0.58 | P = 2.9e-04); Altered Ordered interface (Pr = 0.28 | P = 0.05); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.24 | P = 1.7e-03), None,-
FGFR1_HUMAN,P483S,0.688,, ELME000064|ELME000336|PS00006,-
FGFR1_HUMAN,C381R,0.892,Gain of Helix (Pr = 0.28 | P = 0.02); Gain of ADP-ribosylation at C381 (Pr = 0.22 | P = 0.02), ELME000182,-
FGFR1_HUMAN,R470L,0.722,, None,-
FGFR1_HUMAN,R475Q,0.688,, ELME000331,-
FGFR1_HUMAN,P745S,0.848,Loss of Loop (Pr = 0.28 | P = 0.02); Altered DNA binding (Pr = 0.16 | P = 0.04), ELME000053|ELME000062|ELME000063|ELME000202,-
FGFR1_HUMAN,A361P,0.861,Altered Transmembrane protein (Pr = 0.27 | P = 7.2e-04), ELME000117|ELME000155|ELME000220,-
FGFR1_HUMAN,R718G,0.94,Altered DNA binding (Pr = 0.19 | P = 0.02), None,-
FGFR1_HUMAN,V607M,0.827,Gain of Helix (Pr = 0.27 | P = 0.03); Altered Ordered interface (Pr = 0.26 | P = 0.01), None,-
FGFR1_HUMAN,G703S,0.811,Altered Ordered interface (Pr = 0.24 | P = 0.05); Altered Transmembrane protein (Pr = 0.14 | P = 0.02); Loss of Catalytic site at Y701 (Pr = 0.11 | P = 0.03), ELME000120|ELME000133|ELME000155|ELME000239,-
FGFR1_HUMAN,L630P,0.974,Gain of Relative solvent accessibility (Pr = 0.35 | P = 1.5e-03); Altered Ordered interface (Pr = 0.34 | P = 5.3e-03); Altered DNA binding (Pr = 0.30 | P = 1.6e-03); Gain of Allosteric site at R627 (Pr = 0.29 | P = 2.9e-03); Altered Metal binding (Pr = 0.27 | P = 0.02); Gain of Strand (Pr = 0.26 | P = 0.05); Altered Transmembrane protein (Pr = 0.24 | P = 1.8e-03); Altered Stability (Pr = 0.23 | P = 9.5e-03); Loss of Catalytic site at R627 (Pr = 0.12 | P = 0.03), ELME000146|ELME000333|PS00109,-
FGFR1_HUMAN,G703R,0.914,Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Transmembrane protein (Pr = 0.14 | P = 0.02); Loss of Catalytic site at Y701 (Pr = 0.12 | P = 0.03), ELME000120|ELME000133|ELME000155,-
FGFR1_HUMAN,P283R,0.803,Altered Transmembrane protein (Pr = 0.26 | P = 1.2e-03); Altered Metal binding (Pr = 0.14 | P = 0.05), ELME000173|PS00005,-
FGFR1_HUMAN,E692G,0.943,Altered Ordered interface (Pr = 0.26 | P = 0.01); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000053,-
FGFR1_HUMAN,M1K,0.957,Altered Disordered interface (Pr = 0.45 | P = 2.3e-03); Altered Signal peptide (Pr = 0.11 | P = 1.6e-03); Altered Stability (Pr = 0.11 | P = 0.04); Loss of N-terminal acetylation at M1 (Pr = 0.02 | P = 6.1e-03), ELME000351|ELME000355,-
FGFR1_HUMAN,W2C,0.732,Altered Ordered interface (Pr = 0.24 | P = 0.04); Altered Disordered interface (Pr = 0.24 | P = 0.03); Altered Signal peptide (Pr = 0.12 | P = 1.5e-03); Loss of N-terminal acetylation at M1 (Pr = 0.02 | P = 6.1e-03), ELME000354|ELME000355,-
FGFR1_HUMAN,L7I,0.558,Altered Disordered interface (Pr = 0.20 | P = 0.03); Altered Signal peptide (Pr = 0.11 | P = 1.6e-03), ELME000106|ELME000137|ELME000146,-
FGFR1_HUMAN,L7M,0.58,Altered Disordered interface (Pr = 0.24 | P = 0.02); Altered Signal peptide (Pr = 0.19 | P = 7.2e-04), ELME000106|ELME000137|ELME000146,-
FGFR1_HUMAN,L8H,0.915,Altered Disordered interface (Pr = 0.20 | P = 0.03); Altered Signal peptide (Pr = 0.11 | P = 1.7e-03), ELME000106|ELME000137|ELME000146,-
FGFR1_HUMAN,L8I,0.52,Altered Disordered interface (Pr = 0.18 | P = 0.04); Altered Signal peptide (Pr = 0.11 | P = 1.6e-03), ELME000106|ELME000137|ELME000146,-
COL4A5_HUMAN,G380D,0.952,Gain of Loop (Pr = 0.27 | P = 0.02), ELME000155,-
COL4A5_HUMAN,G362R,0.941,Altered Disordered interface (Pr = 0.28 | P = 0.03); Gain of Acetylation at K358 (Pr = 0.28 | P = 4.9e-03); Loss of Methylation at K358 (Pr = 0.18 | P = 9.9e-03); Gain of SUMOylation at K358 (Pr = 0.18 | P = 0.05), ELME000155,-
COL4A5_HUMAN,P619L,0.295,-,-,-
COL4A5_HUMAN,G887R,0.947,Loss of Loop (Pr = 0.30 | P = 6.6e-03); Gain of Acetylation at K885 (Pr = 0.25 | P = 0.01); Loss of Methylation at K885 (Pr = 0.21 | P = 5.6e-03); Gain of SUMOylation at K885 (Pr = 0.19 | P = 0.04); Loss of Ubiquitylation at K885 (Pr = 0.16 | P = 0.04), ELME000062|ELME000239,-
COL4A5_HUMAN,G914D,0.964,, ELME000085|ELME000097|ELME000239,-
COL4A5_HUMAN,G472R,0.946,Loss of Loop (Pr = 0.29 | P = 0.01), None,-
COL4A5_HUMAN,G325E,0.939,Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of Acetylation at K330 (Pr = 0.27 | P = 7.4e-03); Loss of Phosphorylation at Y320 (Pr = 0.27 | P = 0.03); Loss of Methylation at K330 (Pr = 0.24 | P = 2.5e-03); Gain of SUMOylation at K330 (Pr = 0.21 | P = 0.03); Gain of Sulfation at Y320 (Pr = 0.04 | P = 9.3e-03), ELME000006,-
COL4A5_HUMAN,G536C,0.95,Loss of B-factor (Pr = 0.27 | P = 0.02), ELME000155,-
COL4A5_HUMAN,G609D,0.953,Gain of Loop (Pr = 0.30 | P = 4.5e-03); Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of B-factor (Pr = 0.26 | P = 0.04), None,-
COL4A5_HUMAN,G1348R,0.95,Loss of B-factor (Pr = 0.29 | P = 0.01), ELME000149,-
COL4A5_HUMAN,G403V,0.961,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Acetylation at K408 (Pr = 0.20 | P = 0.04); Loss of Methylation at K408 (Pr = 0.19 | P = 7.8e-03); Loss of SUMOylation at K408 (Pr = 0.19 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q407 (Pr = 0.06 | P = 0.03), None,-
COL4A5_HUMAN,G638V,0.96,Loss of Acetylation at K634 (Pr = 0.28 | P = 6.1e-03); Loss of Methylation at K634 (Pr = 0.20 | P = 7.2e-03), None,-
COL4A5_HUMAN,G545R,0.943,Loss of B-factor (Pr = 0.29 | P = 0.01); Gain of SUMOylation at K544 (Pr = 0.29 | P = 3.5e-03); Loss of Methylation at K544 (Pr = 0.20 | P = 6.9e-03); Loss of Ubiquitylation at K544 (Pr = 0.16 | P = 0.04); Loss of Proteolytic cleavage at D549 (Pr = 0.13 | P = 0.03), ELME000064|ELME000100|ELME000108|PS00005|PS00006,-
COL4A5_HUMAN,M898V,0.196,-,-,-
COL4A5_HUMAN,G216V,0.946,Loss of B-factor (Pr = 0.29 | P = 0.01); Gain of Loop (Pr = 0.26 | P = 0.05); Loss of Methylation at K215 (Pr = 0.21 | P = 5.7e-03); Gain of SUMOylation at K215 (Pr = 0.20 | P = 0.03), None,-
COL4A5_HUMAN,G530D,0.942,Loss of Methylation at K526 (Pr = 0.23 | P = 3.6e-03); Loss of Acetylation at K526 (Pr = 0.20 | P = 0.04); Gain of Ubiquitylation at K526 (Pr = 0.15 | P = 0.05), ELME000005|ELME000155,-
COL4A5_HUMAN,P649A,0.29,-,-,-
COL4A5_HUMAN,G1164D,0.95,Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Methylation at K1168 (Pr = 0.24 | P = 2.5e-03); Loss of Acetylation at K1166 (Pr = 0.22 | P = 0.03); Loss of SUMOylation at K1166 (Pr = 0.20 | P = 0.03), None,-
COL4A5_HUMAN,G524D,0.927,Loss of Methylation at K526 (Pr = 0.23 | P = 3.6e-03); Gain of Acetylation at K526 (Pr = 0.20 | P = 0.04); Gain of Ubiquitylation at K526 (Pr = 0.16 | P = 0.04), None,-
COL4A5_HUMAN,G656R,0.883,Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Loop (Pr = 0.27 | P = 0.05); Loss of Methylation at K652 (Pr = 0.25 | P = 1.9e-03); Gain of O-linked glycosylation at T660 (Pr = 0.15 | P = 0.03); Gain of Pyrrolidone carboxylic acid at Q657 (Pr = 0.06 | P = 0.03), ELME000062|PS00008,-
COL4A5_HUMAN,G763V,0.948,Loss of B-factor (Pr = 0.34 | P = 2.2e-03); Altered Disordered interface (Pr = 0.30 | P = 0.03); Loss of Acetylation at K768 (Pr = 0.25 | P = 0.01); Loss of SUMOylation at K768 (Pr = 0.18 | P = 0.05); Loss of Methylation at K768 (Pr = 0.17 | P = 0.01), None,-
COL4A5_HUMAN,G629D,0.896,Loss of Acetylation at K634 (Pr = 0.27 | P = 6.7e-03); Loss of Methylation at K634 (Pr = 0.20 | P = 6.3e-03), ELME000155,-
COL4A5_HUMAN,G406S,0.932,Gain of Acetylation at K408 (Pr = 0.19 | P = 0.04); Loss of Methylation at K408 (Pr = 0.19 | P = 8.0e-03); Loss of SUMOylation at K408 (Pr = 0.19 | P = 0.04); Loss of Pyrrolidone carboxylic acid at Q407 (Pr = 0.05 | P = 0.03), ELME000202|PS00005,-
COL4A5_HUMAN,G195V,0.946,Loss of B-factor (Pr = 0.32 | P = 4.2e-03); Altered Disordered interface (Pr = 0.27 | P = 0.04), ELME000155,-
COL4A5_HUMAN,C1638G,0.95,Altered Metal binding (Pr = 0.65 | P = 1.4e-03); Loss of Disulfide linkage at C1638 (Pr = 0.36 | P = 6.8e-04); Altered Ordered interface (Pr = 0.34 | P = 6.2e-03); Altered Transmembrane protein (Pr = 0.28 | P = 3.6e-04), ELME000062|ELME000162|PS00008,-
COL4A5_HUMAN,G787V,0.955,Loss of B-factor (Pr = 0.33 | P = 3.0e-03), ELME000006|ELME000220|ELME000231,-
COL4A5_HUMAN,G576S,0.948,, ELME000136|ELME000155|ELME000159|ELME000358,-
COL4A5_HUMAN,G186S,0.909,Altered Disordered interface (Pr = 0.28 | P = 0.03); Gain of O-linked glycosylation at T188 (Pr = 0.23 | P = 0.01), ELME000136|ELME000159,-
COL4A5_HUMAN,G802V,0.946,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Acetylation at K798 (Pr = 0.19 | P = 0.05); Loss of Methylation at K798 (Pr = 0.18 | P = 9.0e-03); Altered Metal binding (Pr = 0.10 | P = 0.05), None,-
COL4A5_HUMAN,G1214E,0.957,Altered Disordered interface (Pr = 0.27 | P = 0.04); Gain of Loop (Pr = 0.27 | P = 0.03), None,-
COL4A5_HUMAN,G869R,0.934,, None,-
COL4A5_HUMAN,G635C,0.937,Loss of Acetylation at K634 (Pr = 0.33 | P = 2.6e-03); Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Methylation at K634 (Pr = 0.22 | P = 4.7e-03); Gain of SUMOylation at K634 (Pr = 0.18 | P = 0.05), None,-
COL4A5_HUMAN,G687E,0.928,Gain of Loop (Pr = 0.31 | P = 3.0e-03), ELME000155,-
COL4A5_HUMAN,G684V,0.953,Loss of B-factor (Pr = 0.29 | P = 0.01); Gain of Loop (Pr = 0.27 | P = 0.03), ELME000155,-
COL4A5_HUMAN,G615R,0.947,Loss of Loop (Pr = 0.31 | P = 4.7e-03); Altered Disordered interface (Pr = 0.27 | P = 0.05), PS00008,-
COL4A5_HUMAN,G947D,0.946,Gain of Loop (Pr = 0.28 | P = 0.02); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of SUMOylation at K943 (Pr = 0.26 | P = 6.9e-03); Loss of Methylation at K943 (Pr = 0.24 | P = 2.5e-03); Loss of Acetylation at K943 (Pr = 0.23 | P = 0.02), ELME000005|ELME000155,-
COL4A5_HUMAN,G497C,0.941,Loss of B-factor (Pr = 0.29 | P = 0.01); Gain of Loop (Pr = 0.29 | P = 0.01); Gain of Pyrrolidone carboxylic acid at Q495 (Pr = 0.08 | P = 0.02), None,-
COL4A5_HUMAN,G675S,0.941,Gain of Loop (Pr = 0.27 | P = 0.02); Gain of Proteolytic cleavage at D674 (Pr = 0.11 | P = 0.04), ELME000062|ELME000155,-
COL4A5_HUMAN,G772V,0.954,Altered Disordered interface (Pr = 0.30 | P = 0.02); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Acetylation at K768 (Pr = 0.25 | P = 0.01); Gain of SUMOylation at K768 (Pr = 0.18 | P = 0.04); Loss of Methylation at K768 (Pr = 0.17 | P = 0.01), ELME000146,-
COL4A5_HUMAN,G784D,0.926,Gain of Loop (Pr = 0.27 | P = 0.03); Loss of B-factor (Pr = 0.26 | P = 0.04); Altered Metal binding (Pr = 0.10 | P = 0.05), ELME000006,-
COL4A5_HUMAN,G881R,0.958,Loss of B-factor (Pr = 0.27 | P = 0.02); Gain of Acetylation at K885 (Pr = 0.27 | P = 6.8e-03); Loss of Methylation at K885 (Pr = 0.21 | P = 5.4e-03); Gain of SUMOylation at K885 (Pr = 0.18 | P = 0.05); Loss of Ubiquitylation at K885 (Pr = 0.16 | P = 0.04), ELME000006|ELME000136|ELME000155|ELME000159|PS00005,-
COL4A5_HUMAN,G96R,0.937,Loss of Loop (Pr = 0.30 | P = 6.8e-03); Altered Disordered interface (Pr = 0.28 | P = 0.04); Gain of Methylation at R92 (Pr = 0.10 | P = 0.04), ELME000005|ELME000135|ELME000155,-
COL4A5_HUMAN,G1261R,0.953,Loss of Loop (Pr = 0.32 | P = 3.4e-03); Loss of B-factor (Pr = 0.28 | P = 0.02), ELME000006|ELME000012|ELME000102|ELME000108|ELME000135|ELME000155,-
COL4A5_HUMAN,G1229D,0.96,, None,-
COL4A5_HUMAN,G600D,0.933,Gain of Loop (Pr = 0.30 | P = 5.4e-03); Loss of Acetylation at K599 (Pr = 0.27 | P = 7.1e-03); Loss of Methylation at K599 (Pr = 0.19 | P = 7.2e-03); Gain of SUMOylation at K599 (Pr = 0.19 | P = 0.04), ELME000002|ELME000220|PS00006,-
COL4A5_HUMAN,G527V,0.934,Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Methylation at K526 (Pr = 0.23 | P = 3.2e-03); Loss of Acetylation at K526 (Pr = 0.20 | P = 0.04); Gain of SUMOylation at K526 (Pr = 0.19 | P = 0.04), ELME000005|ELME000106|ELME000155,-
COL4A5_HUMAN,G1252S,0.913,Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Methylation at K1251 (Pr = 0.25 | P = 2.4e-03); Loss of Acetylation at K1251 (Pr = 0.23 | P = 0.02); Gain of SUMOylation at K1251 (Pr = 0.23 | P = 0.02), None,-
COL4A5_HUMAN,G558R,0.922,Loss of B-factor (Pr = 0.28 | P = 0.02); Altered Disordered interface (Pr = 0.27 | P = 0.05); Gain of SUMOylation at K560 (Pr = 0.25 | P = 7.8e-03); Gain of Acetylation at K557 (Pr = 0.21 | P = 0.03); Loss of Methylation at K557 (Pr = 0.18 | P = 9.6e-03), ELME000100|ELME000108,-
COL4A5_HUMAN,G896D,0.953,Gain of Loop (Pr = 0.29 | P = 0.01); Gain of SUMOylation at K895 (Pr = 0.26 | P = 6.9e-03); Loss of Acetylation at K895 (Pr = 0.25 | P = 0.01); Loss of Methylation at K895 (Pr = 0.19 | P = 7.4e-03), ELME000064|ELME000220|PS00006,-
COL4A5_HUMAN,G911R,0.962,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of O-linked glycosylation at S916 (Pr = 0.19 | P = 0.02), ELME000006,-
COL4A5_HUMAN,G693R,0.948,Loss of Loop (Pr = 0.27 | P = 0.03); Gain of SUMOylation at K698 (Pr = 0.25 | P = 8.2e-03); Gain of Acetylation at K698 (Pr = 0.21 | P = 0.03); Loss of Methylation at K698 (Pr = 0.18 | P = 9.6e-03), PS00008,-
COL4A5_HUMAN,G1261E,0.946,Gain of Loop (Pr = 0.35 | P = 6.0e-04); Loss of B-factor (Pr = 0.27 | P = 0.03), ELME000155,-
COL4A5_HUMAN,Q1308R,0.265,-,-,-
COL4A5_HUMAN,K664N,0.091,-,-,-
COL4A5_HUMAN,A16S,0.417,-,-,-
COL4A5_HUMAN,G35E,0.591,Gain of Loop (Pr = 0.26 | P = 0.05), ELME000063|ELME000136|ELME000159|PS00008,-
COL4A5_HUMAN,D39E,0.335,-,-,-
COL4A5_HUMAN,K47M,0.782,Loss of SUMOylation at K47 (Pr = 0.38 | P = 1.2e-03); Loss of B-factor (Pr = 0.29 | P = 0.01); Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Acetylation at K44 (Pr = 0.21 | P = 0.03); Loss of Methylation at K44 (Pr = 0.12 | P = 0.03), None,-
COL4A5_HUMAN,Q143P,0.449,-,-,-
COL4A5_HUMAN,M163T,0.208,-,-,-
COL4A5_HUMAN,P185A,0.065,-,-,-
COL4A5_HUMAN,I274M,0.091,-,-,-
COL4A5_HUMAN,P278T,0.56,Loss of B-factor (Pr = 0.32 | P = 4.4e-03); Gain of O-linked glycosylation at P278 (Pr = 0.12 | P = 0.04); Loss of Methylation at R275 (Pr = 0.11 | P = 0.03), ELME000005|ELME000155,-
COL4A5_HUMAN,I355V,0.038,-,-,-
COL4A5_HUMAN,I378M,0.141,-,-,-
COL4A5_HUMAN,V392I,0.044,-,-,-
COL4A5_HUMAN,I418M,0.207,-,-,-
COL4A5_HUMAN,D425E,0.189,-,-,-
COL4A5_HUMAN,A440P,0.081,-,-,-
COL4A5_HUMAN,K477R,0.221,-,-,-
COL4A5_HUMAN,T597A,0.068,-,-,-
COL4A5_HUMAN,F598S,0.24,-,-,-
COL4A5_HUMAN,P623L,0.248,-,-,-
COL4A5_HUMAN,I648V,0.055,-,-,-
COL4A5_HUMAN,D682E,0.113,-,-,-
COL4A5_HUMAN,P738L,0.142,-,-,-
COL4A5_HUMAN,T789A,0.068,-,-,-
COL4A5_HUMAN,I818T,0.144,-,-,-
COL4A5_HUMAN,D847N,0.16,-,-,-
COL4A5_HUMAN,T894A,0.032,-,-,-
COL4A5_HUMAN,I1020E,0.172,-,-,-
COL4A5_HUMAN,T1028S,0.056,-,-,-
COL4A5_HUMAN,S1072G,0.05,-,-,-
COL4A5_HUMAN,T1126I,0.112,-,-,-
COL4A5_HUMAN,V1151I,0.042,-,-,-
COL4A5_HUMAN,Q1159P,0.114,-,-,-
COL4A5_HUMAN,P1245S,0.201,-,-,-
COL4A5_HUMAN,Q1308P,0.256,-,-,-
COL4A5_HUMAN,V1340I,0.03,-,-,-
COL4A5_HUMAN,A1375S,0.054,-,-,-
COL4A5_HUMAN,V1458T,0.231,-,-,-
COL4A5_HUMAN,M1547V,0.188,-,-,-
COL4A5_HUMAN,S1556G,0.234,-,-,-
COL4A5_HUMAN,A1565V,0.494,-,-,-
COL4A5_HUMAN,V1572M,0.079,-,-,-
COL4A5_HUMAN,G1039S,0.926,, ELME000155,-
COL4A5_HUMAN,G135D,0.967,, ELME000005|ELME000136|ELME000155|ELME000159|ELME000197,-
COL4A5_HUMAN,G564C,0.947,Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of SUMOylation at K560 (Pr = 0.26 | P = 6.6e-03); Loss of Acetylation at K560 (Pr = 0.19 | P = 0.05); Loss of Methylation at K560 (Pr = 0.17 | P = 0.01), ELME000136|ELME000155|ELME000159,-
COL4A5_HUMAN,G1140R,0.964,Loss of B-factor (Pr = 0.30 | P = 8.7e-03); Altered Metal binding (Pr = 0.12 | P = 0.03); Gain of O-linked glycosylation at S1136 (Pr = 0.11 | P = 0.05), ELME000135|ELME000155,-
COL4A5_HUMAN,G337V,0.946,Loss of B-factor (Pr = 0.34 | P = 1.6e-03); Loss of Methylation at K333 (Pr = 0.25 | P = 2.4e-03); Gain of Acetylation at K333 (Pr = 0.23 | P = 0.02); Loss of SUMOylation at K333 (Pr = 0.20 | P = 0.04), ELME000155,-
MYO7A_HUMAN,S1105R,0.18,-,-,-
MYO7A_HUMAN,V1107M,0.093,-,-,-
MYO7A_HUMAN,K1128Q,0.367,-,-,-
MYO7A_HUMAN,H1131D,0.463,-,-,-
MYO7A_HUMAN,S1135P,0.475,-,-,-
MYO7A_HUMAN,N1285S,0.159,-,-,-
MYO7A_HUMAN,I1291T,0.66,Altered Metal binding (Pr = 0.20 | P = 0.04); Altered Stability (Pr = 0.09 | P = 0.05), None,-
MYO7A_HUMAN,I1291V,0.187,-,-,-
MYO7A_HUMAN,K1294H,0.669,Altered Metal binding (Pr = 0.26 | P = 8.9e-03); Altered Transmembrane protein (Pr = 0.10 | P = 0.05), ELME000172|ELME000233|PS00005|PS00006,-
MYO7A_HUMAN,S1310V,0.629,Loss of Intrinsic disorder (Pr = 0.34 | P = 0.05); Altered Metal binding (Pr = 0.14 | P = 0.02), ELME000053,-
MYO7A_HUMAN,N1361S,0.137,-,-,-
MYO7A_HUMAN,N1411T,0.388,-,-,-
MYO7A_HUMAN,I1417L,0.542,Altered Transmembrane protein (Pr = 0.15 | P = 0.02), ELME000182,-
MYO7A_HUMAN,I1422V,0.292,-,-,-
MYO7A_HUMAN,L1425M,0.183,-,-,-
MYO7A_HUMAN,L1428R,0.636,Altered Transmembrane protein (Pr = 0.21 | P = 4.6e-03); Altered Stability (Pr = 0.09 | P = 0.05), ELME000233,-
MYO7A_HUMAN,Q1433H,0.373,-,-,-
MYO7A_HUMAN,S1483N,0.275,-,-,-
MYO7A_HUMAN,S1483P,0.637,Altered Transmembrane protein (Pr = 0.32 | P = 7.8e-05); Altered Ordered interface (Pr = 0.30 | P = 0.03); Loss of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Loss of Strand (Pr = 0.28 | P = 0.01); Loss of Loop (Pr = 0.28 | P = 0.02); Gain of B-factor (Pr = 0.25 | P = 0.04), ELME000004|ELME000063|ELME000155,-
MYO7A_HUMAN,K1486R,0.266,-,-,-
MYO7A_HUMAN,D1488E,0.558,Altered Transmembrane protein (Pr = 0.26 | P = 9.8e-04); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03), ELME000002|ELME000335,-
MYO7A_HUMAN,I1516L,0.704,Altered Transmembrane protein (Pr = 0.11 | P = 0.04), None,-
MYO7A_HUMAN,V1527I,0.111,-,-,-
MYO7A_HUMAN,L1531R,0.925,Gain of Strand (Pr = 0.26 | P = 0.05), ELME000007|ELME000051|ELME000053|ELME000233,-
MYO7A_HUMAN,G1532Q,0.748,, ELME000007|ELME000051|ELME000053,-
MYO7A_HUMAN,S1534A,0.461,-,-,-
MYO7A_HUMAN,L1536A,0.363,-,-,-
MYO7A_HUMAN,L1536P,0.577,Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered Stability (Pr = 0.12 | P = 0.03), None,-
MYO7A_HUMAN,L1536V,0.204,-,-,-
MYO7A_HUMAN,A1540S,0.095,-,-,-
MYO7A_HUMAN,P1550L,0.336,-,-,-
MYO7A_HUMAN,P1550M,0.46,-,-,-
MYO7A_HUMAN,A1551T,0.138,-,-,-
MYO7A_HUMAN,D1578E,0.394,-,-,-
MYO7A_HUMAN,N1616S,0.226,-,-,-
MYO7A_HUMAN,A1628V,0.202,-,-,-
MYO7A_HUMAN,N1645S,0.476,-,-,-
MYO7A_HUMAN,N1650S,0.152,-,-,-
MYO7A_HUMAN,N1653S,0.76,Altered DNA binding (Pr = 0.21 | P = 0.02); Altered Transmembrane protein (Pr = 0.15 | P = 0.02); Altered Stability (Pr = 0.09 | P = 0.04), ELME000063|PS00005,-
MYO7A_HUMAN,Q1690P,0.611,Loss of Helix (Pr = 0.29 | P = 0.02); Gain of Phosphorylation at T1687 (Pr = 0.25 | P = 0.03), ELME000118|ELME000159,-
MYO7A_HUMAN,L1697H,0.378,-,-,-
MYO7A_HUMAN,L1698M,0.098,-,-,-
MYO7A_HUMAN,L1700I,0.083,-,-,-
MYO7A_HUMAN,L1700Q,0.242,-,-,-
MYO7A_HUMAN,V1707A,0.107,-,-,-
MYO7A_HUMAN,V1707P,0.242,-,-,-
MYO7A_HUMAN,A1709S,0.065,-,-,-
MYO7A_HUMAN,E1715Q,0.602,Loss of Phosphorylation at Y1719 (Pr = 0.25 | P = 0.04); Loss of Sulfation at Y1719 (Pr = 0.01 | P = 0.04), ELME000064|ELME000117|ELME000163|ELME000182|ELME000220|PS00006,-
MYO7A_HUMAN,Y1721C,0.515,Loss of Phosphorylation at Y1721 (Pr = 0.46 | P = 5.2e-03); Altered Disordered interface (Pr = 0.30 | P = 0.02); Loss of Sulfation at Y1721 (Pr = 0.05 | P = 8.7e-03), ELME000120|ELME000182,-
MYO7A_HUMAN,R1723P,0.921,Gain of B-factor (Pr = 0.28 | P = 8.0e-03); Loss of Helix (Pr = 0.28 | P = 0.02); Loss of Phosphorylation at Y1719 (Pr = 0.27 | P = 0.03); Gain of Sulfation at Y1721 (Pr = 0.06 | P = 6.3e-03), ELME000057|ELME000155|ELME000182,-
MYO7A_HUMAN,R1723S,0.799,Gain of Phosphorylation at R1723 (Pr = 0.37 | P = 7.7e-03); Gain of Sulfation at Y1721 (Pr = 0.06 | P = 5.3e-03), ELME000136|ELME000159|ELME000182,-
MYO7A_HUMAN,P1726G,0.598,Gain of Phosphorylation at Y1721 (Pr = 0.26 | P = 0.03); Gain of Acetylation at K1727 (Pr = 0.24 | P = 0.02); Altered Disordered interface (Pr = 0.18 | P = 0.04); Loss of Sulfation at Y1721 (Pr = 0.05 | P = 9.2e-03), None,-
MYO7A_HUMAN,K1727R,0.444,-,-,-
MYO7A_HUMAN,T1729L,0.548,Gain of Helix (Pr = 0.27 | P = 0.05); Altered Disordered interface (Pr = 0.23 | P = 0.03), ELME000106|ELME000146,-
MYO7A_HUMAN,V1733D,0.751,Altered Disordered interface (Pr = 0.44 | P = 4.7e-03); Gain of Intrinsic disorder (Pr = 0.42 | P = 6.0e-03); Altered Stability (Pr = 0.31 | P = 5.4e-03); Gain of Proteolytic cleavage at V1733 (Pr = 0.14 | P = 0.02), ELME000173,-
MYO7A_HUMAN,M1734A,0.553,Altered Disordered interface (Pr = 0.29 | P = 0.01), None,-
MYO7A_HUMAN,V1735S,0.412,-,-,-
MYO7A_HUMAN,K1737R,0.222,-,-,-
MYO7A_HUMAN,K1741A,0.684,Altered Disordered interface (Pr = 0.37 | P = 8.3e-03); Loss of Proteolytic cleavage at W1745 (Pr = 0.11 | P = 0.04), None,-
MYO7A_HUMAN,R1743H,0.176,-,-,-
MYO7A_HUMAN,W1745G,0.881,Gain of Intrinsic disorder (Pr = 0.55 | P = 7.6e-04); Altered Disordered interface (Pr = 0.40 | P = 6.8e-03); Loss of Proteolytic cleavage at W1745 (Pr = 0.12 | P = 0.03), ELME000173,-
MYO7A_HUMAN,S1746A,0.196,-,-,-
MYO7A_HUMAN,T1748C,0.634,Altered Disordered interface (Pr = 0.29 | P = 0.01); Loss of Proteolytic cleavage at W1745 (Pr = 0.12 | P = 0.04), ELME000173,-
MYO7A_HUMAN,L1756A,0.79,Altered Stability (Pr = 0.38 | P = 3.3e-03), ELME000045|ELME000146,-
MYO7A_HUMAN,L1756C,0.839,Altered Stability (Pr = 0.13 | P = 0.03), ELME000045|ELME000146,-
MYO7A_HUMAN,K1759G,0.627,, ELME000045|ELME000106|ELME000146|PS00008,-
MYO7A_HUMAN,L1760V,0.141,-,-,-
MYO7A_HUMAN,E1764P,0.405,-,-,-
MYO7A_HUMAN,E1765A,0.518,, ELME000053|ELME000202,-
MYO7A_HUMAN,A1770P,0.945,, ELME000202,-
MYO7A_HUMAN,C1771L,0.951,, None,-
MYO7A_HUMAN,F1774P,0.943,Gain of Acetylation at K1779 (Pr = 0.22 | P = 0.03), ELME000041,-
MYO7A_HUMAN,L1778I,0.447,-,-,-
MYO7A_HUMAN,K1779G,0.915,Loss of Acetylation at K1779 (Pr = 0.25 | P = 0.01); Altered Ordered interface (Pr = 0.24 | P = 0.04); Loss of Allosteric site at Y1780 (Pr = 0.23 | P = 0.02); Gain of Proteolytic cleavage at D1783 (Pr = 0.11 | P = 0.04), ELME000041,-
MYO7A_HUMAN,S1786H,0.722,Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Ubiquitylation at K1787 (Pr = 0.15 | P = 0.05); Altered Transmembrane protein (Pr = 0.11 | P = 0.03); Loss of Proteolytic cleavage at D1783 (Pr = 0.11 | P = 0.05), ELME000063|ELME000271|ELME000334|PS00005,-
MYO7A_HUMAN,K1787G,0.861,Altered Ordered interface (Pr = 0.31 | P = 0.02); Gain of ADP-ribosylation at R1790 (Pr = 0.19 | P = 0.04); Loss of Ubiquitylation at K1787 (Pr = 0.18 | P = 0.02); Altered Transmembrane protein (Pr = 0.11 | P = 0.03); Loss of Proteolytic cleavage at D1783 (Pr = 0.11 | P = 0.05), ELME000052|ELME000063|ELME000085|ELME000100|ELME000108|ELME000271|PS00005,-
MYO7A_HUMAN,T1789M,0.137,-,-,-
MYO7A_HUMAN,A1813V,0.19,-,-,-
MYO7A_HUMAN,I1817V,0.216,-,-,-
MYO7A_HUMAN,H1825N,0.503,Altered Transmembrane protein (Pr = 0.11 | P = 0.04), None,-
MYO7A_HUMAN,Y1828S,0.744,Gain of Intrinsic disorder (Pr = 0.37 | P = 0.01); Altered Ordered interface (Pr = 0.26 | P = 0.01); Altered Transmembrane protein (Pr = 0.09 | P = 0.05), ELME000062|ELME000064|ELME000117|PS00006,-
MYO7A_HUMAN,E1830T,0.859,Gain of Loop (Pr = 0.26 | P = 0.05); Altered Ordered interface (Pr = 0.23 | P = 0.05); Altered Transmembrane protein (Pr = 0.09 | P = 0.05), ELME000062|ELME000334|PS00005,-
MYO7A_HUMAN,E1831D,0.55,Gain of Allosteric site at W1834 (Pr = 0.20 | P = 0.04); Gain of Sulfation at Y1828 (Pr = 0.01 | P = 0.05), ELME000062,-
MYO7A_HUMAN,N1848V,0.671,, ELME000335,-
MYO7A_HUMAN,I1849S,0.607,Altered Stability (Pr = 0.13 | P = 0.03), ELME000239,-
MYO7A_HUMAN,R1856V,0.593,, None,-
MYO7A_HUMAN,F1857L,0.785,, ELME000336|PS00029,-
MYO7A_HUMAN,H1863Q,0.381,-,-,-
MYO7A_HUMAN,C1864S,0.242,-,-,-
MYO7A_HUMAN,L1871V,0.22,-,-,-
MYO7A_HUMAN,L1874P,0.944,Loss of Acetylation at K1876 (Pr = 0.19 | P = 0.05); Altered DNA binding (Pr = 0.17 | P = 0.03); Altered Stability (Pr = 0.17 | P = 0.02); Altered Coiled coil (Pr = 0.15 | P = 0.03), ELME000134|ELME000313,-
MYO7A_HUMAN,D1910E,0.543,Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Metal binding (Pr = 0.26 | P = 0.02), ELME000182,-
MYO7A_HUMAN,A1915H,0.761,Altered Metal binding (Pr = 0.52 | P = 4.3e-03); Gain of Intrinsic disorder (Pr = 0.30 | P = 0.05); Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Stability (Pr = 0.25 | P = 7.9e-03); Gain of Relative solvent accessibility (Pr = 0.24 | P = 0.04), None,-
MYO7A_HUMAN,A1915S,0.388,-,-,-
MYO7A_HUMAN,E1917Q,0.68,Altered Metal binding (Pr = 0.30 | P = 0.01); Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered DNA binding (Pr = 0.17 | P = 0.04); Altered Stability (Pr = 0.11 | P = 0.04), None,-
MYO7A_HUMAN,T1922S,0.751,Gain of Intrinsic disorder (Pr = 0.33 | P = 0.02); Gain of B-factor (Pr = 0.27 | P = 8.6e-03); Altered Metal binding (Pr = 0.26 | P = 0.03); Gain of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Altered DNA binding (Pr = 0.18 | P = 0.03), PS00005,-
MYO7A_HUMAN,T1922V,0.883,Altered Metal binding (Pr = 0.32 | P = 0.01); Altered Ordered interface (Pr = 0.30 | P = 0.02); Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered DNA binding (Pr = 0.20 | P = 0.02), ELME000147|PS00005,-
MYO7A_HUMAN,K1923D,0.668,Altered Metal binding (Pr = 0.35 | P = 5.0e-04); Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.04); Altered DNA binding (Pr = 0.20 | P = 0.02), ELME000321|PS00005|PS00006,-
MYO7A_HUMAN,A1924C,0.858,Altered Metal binding (Pr = 0.46 | P = 6.0e-03); Altered Ordered interface (Pr = 0.32 | P = 9.9e-03); Gain of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Altered DNA binding (Pr = 0.19 | P = 0.03), ELME000313,-
MYO7A_HUMAN,D1926F,0.929,Altered Metal binding (Pr = 0.32 | P = 0.01); Altered DNA binding (Pr = 0.18 | P = 0.03), ELME000313,-
SLC26A4_HUMAN,A574T,0.383,-,-,-
SLC26A4_HUMAN,N558I,0.941,Altered Ordered interface (Pr = 0.35 | P = 5.1e-03); Altered DNA binding (Pr = 0.22 | P = 0.01), ELME000020|ELME000084|ELME000120|PS00008,-
SLC26A4_HUMAN,G149R,0.906,Gain of Helix (Pr = 0.29 | P = 0.01); Loss of Strand (Pr = 0.29 | P = 4.9e-03); Gain of ADP-ribosylation at G149 (Pr = 0.25 | P = 8.4e-03), ELME000053|ELME000336,-
SLC26A4_HUMAN,L660R,0.886,Gain of Strand (Pr = 0.29 | P = 4.4e-03); Altered Stability (Pr = 0.17 | P = 0.02); Loss of Catalytic site at D661 (Pr = 0.14 | P = 0.02); Altered Metal binding (Pr = 0.13 | P = 0.05), ELME000333|ELME000335,-
SLC26A4_HUMAN,G114R,0.421,-,-,-
SLC26A4_HUMAN,R409L,0.918,Loss of Intrinsic disorder (Pr = 0.36 | P = 0.04); Loss of Strand (Pr = 0.26 | P = 0.05); Loss of ADP-ribosylation at R409 (Pr = 0.23 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q413 (Pr = 0.04 | P = 0.04), ELME000336,-
SLC26A4_HUMAN,I490A,0.795,Altered Transmembrane protein (Pr = 0.14 | P = 0.02); Altered Stability (Pr = 0.12 | P = 0.03), ELME000085|ELME000335,-
SLC26A4_HUMAN,L117F,0.72,Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.23 | P = 2.3e-03), ELME000328|PS00008|PS01130,-
SLC26A4_HUMAN,A106D,0.835,Altered Transmembrane protein (Pr = 0.42 | P = 0.0e+00); Altered Ordered interface (Pr = 0.25 | P = 0.03), ELME000120|PS00008,-
SLC26A4_HUMAN,G102R,0.938,Altered Transmembrane protein (Pr = 0.25 | P = 1.2e-03); Altered Ordered interface (Pr = 0.24 | P = 0.04); Gain of ADP-ribosylation at G102 (Pr = 0.19 | P = 0.04), PS00008,-
SLC26A4_HUMAN,K77I,0.586,Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.15 | P = 0.02), ELME000080,-
SLC26A4_HUMAN,T485M,0.58,Loss of Strand (Pr = 0.33 | P = 3.5e-04); Gain of Helix (Pr = 0.32 | P = 2.6e-03); Altered Transmembrane protein (Pr = 0.01 | P = 0.01), ELME000052|ELME000053,-
SLC26A4_HUMAN,Q421K,0.878,Loss of Pyrrolidone carboxylic acid at Q421 (Pr = 0.26 | P = 6.9e-04); Gain of B-factor (Pr = 0.24 | P = 0.05); Loss of Ubiquitylation at K419 (Pr = 0.17 | P = 0.03); Loss of Methylation at K419 (Pr = 0.15 | P = 0.02), ELME000202,-
SLC26A4_HUMAN,F141S,0.866,Loss of Strand (Pr = 0.26 | P = 0.04), ELME000053|ELME000136|ELME000148|ELME000159,-
SLC26A4_HUMAN,Y78C,0.9,Altered Ordered interface (Pr = 0.41 | P = 9.1e-04); Altered Transmembrane protein (Pr = 0.18 | P = 7.4e-03), ELME000080,-
SLC26A4_HUMAN,V510D,0.899,Loss of Strand (Pr = 0.28 | P = 7.1e-03); Gain of Helix (Pr = 0.27 | P = 0.04); Loss of Pyrrolidone carboxylic acid at Q514 (Pr = 0.05 | P = 0.03), ELME000047|ELME000052|ELME000137|ELME000155|ELME000333|ELME000335,-
SLC26A4_HUMAN,E622K,0.333,-,-,-
SLC26A4_HUMAN,S137P,0.934,Loss of Strand (Pr = 0.26 | P = 0.05), ELME000005|ELME000053|ELME000065|ELME000155,-
SLC26A4_HUMAN,G497R,0.914,Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000335|PS00008,-
SLC26A4_HUMAN,A725P,0.904,Gain of Allosteric site at H723 (Pr = 0.20 | P = 0.04); Gain of Catalytic site at D724 (Pr = 0.09 | P = 0.04); Altered Metal binding (Pr = 0.06 | P = 0.03), ELME000134|ELME000155|ELME000220,-
SLC26A4_HUMAN,S90L,0.851,Gain of Helix (Pr = 0.28 | P = 0.03); Loss of Strand (Pr = 0.27 | P = 0.03); Altered Metal binding (Pr = 0.23 | P = 0.02); Altered Transmembrane protein (Pr = 0.17 | P = 9.6e-03), ELME000053|ELME000063|ELME000085|ELME000333|ELME000335|ELME000336,-
SLC26A4_HUMAN,Q383E,0.857,Altered Metal binding (Pr = 0.38 | P = 8.8e-04); Altered Transmembrane protein (Pr = 0.28 | P = 4.8e-04); Altered Ordered interface (Pr = 0.27 | P = 0.05); Loss of Catalytic site at E384 (Pr = 0.19 | P = 0.01), None,-
SLC26A4_HUMAN,R24G,0.747,Gain of Sulfation at Y27 (Pr = 0.02 | P = 0.02), ELME000085|ELME000155,-
SLC26A4_HUMAN,C565Y,0.414,-,-,-
SLC26A4_HUMAN,P142R,0.844,Gain of Helix (Pr = 0.30 | P = 7.8e-03); Loss of Strand (Pr = 0.29 | P = 3.4e-03); Gain of ADP-ribosylation at P142 (Pr = 0.24 | P = 0.01), ELME000141|ELME000148|ELME000239,-
SLC26A4_HUMAN,T94I,0.824,Gain of Strand (Pr = 0.26 | P = 0.05); Altered Transmembrane protein (Pr = 0.16 | P = 0.01), ELME000052|ELME000063|ELME000335|PS00008,-
SLC26A4_HUMAN,D661Y,0.938,Altered Ordered interface (Pr = 0.27 | P = 6.7e-03); Altered Metal binding (Pr = 0.14 | P = 0.04); Loss of Catalytic site at D661 (Pr = 0.14 | P = 0.02), ELME000182|ELME000313|ELME000333,-
SLC26A4_HUMAN,V186F,0.781,Altered Transmembrane protein (Pr = 0.24 | P = 2.1e-03), ELME000052|ELME000062|ELME000106|ELME000300,-
SLC26A4_HUMAN,G116S,0.809,Altered Ordered interface (Pr = 0.27 | P = 8.1e-03); Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03), ELME000063|PS00008|PS01130,-
SLC26A4_HUMAN,G197R,0.91,, ELME000052|ELME000149,-
SLC26A4_HUMAN,H723D,0.864,Altered Metal binding (Pr = 0.06 | P = 0.03), ELME000134|ELME000220|ELME000336|PS00006,-
SLC26A4_HUMAN,L676Q,0.826,Gain of ADP-ribosylation at R674 (Pr = 0.20 | P = 0.03), ELME000106|ELME000202|ELME000313|ELME000335|ELME000337|PS00005,-
SLC26A4_HUMAN,K715N,0.467,-,-,-
SLC26A4_HUMAN,F354S,0.929,Altered Transmembrane protein (Pr = 0.26 | P = 7.3e-04), ELME000239|ELME000335|ELME000336,-
SLC26A4_HUMAN,V545A,0.537,Altered Ordered interface (Pr = 0.27 | P = 0.05); Loss of Allosteric site at F550 (Pr = 0.26 | P = 0.01); Altered DNA binding (Pr = 0.15 | P = 0.04); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000137,-
SLC26A4_HUMAN,Y27N,0.709,Loss of Sulfation at Y27 (Pr = 0.02 | P = 0.04), ELME000120|ELME000239,-
SLC26A4_HUMAN,I665V,0.087,-,-,-
SLC26A4_HUMAN,G389W,0.949,Altered Metal binding (Pr = 0.36 | P = 1.8e-03); Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Transmembrane protein (Pr = 0.21 | P = 4.4e-03); Gain of Catalytic site at E384 (Pr = 0.20 | P = 0.01), ELME000053|ELME000328|ELME000336,-
SLC26A4_HUMAN,N324Y,0.778,Loss of Relative solvent accessibility (Pr = 0.31 | P = 6.4e-03); Altered Transmembrane protein (Pr = 0.29 | P = 2.1e-04); Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Strand (Pr = 0.27 | P = 0.03); Loss of Ubiquitylation at K321 (Pr = 0.15 | P = 0.05); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000120,-
SLC26A4_HUMAN,S642P,0.527,, ELME000006|ELME000155,-
SLC26A4_HUMAN,T67S,0.056,-,-,-
SLC26A4_HUMAN,V69L,0.047,-,-,-
SLC26A4_HUMAN,V69M,0.272,-,-,-
SLC26A4_HUMAN,M155V,0.226,-,-,-
SLC26A4_HUMAN,D158N,0.193,-,-,-
SLC26A4_HUMAN,M175V,0.054,-,-,-
SLC26A4_HUMAN,A191T,0.054,-,-,-
SLC26A4_HUMAN,S243F,0.458,-,-,-
SLC26A4_HUMAN,T244Q,0.874,Altered Transmembrane protein (Pr = 0.28 | P = 5.4e-04); Altered Stability (Pr = 0.09 | P = 0.04); Loss of N-linked glycosylation at N241 (Pr = 0.03 | P = 0.03), ELME000070|ELME000202|ELME000333|ELME000336|PS00001|PS00005,-
SLC26A4_HUMAN,I379V,0.29,-,-,-
SLC26A4_HUMAN,I468V,0.042,-,-,-
SLC26A4_HUMAN,Q543R,0.219,-,-,-
SLC26A4_HUMAN,S594N,0.107,-,-,-
SLC26A4_HUMAN,L624P,0.055,-,-,-
SLC26A4_HUMAN,V670I,0.079,-,-,-
SLC26A4_HUMAN,Y698H,0.031,-,-,-
SLC26A4_HUMAN,T747A,0.066,-,-,-
SLC26A4_HUMAN,F572V,0.691,Altered Disordered interface (Pr = 0.24 | P = 0.02); Altered Coiled coil (Pr = 0.12 | P = 0.03), ELME000052|ELME000233|ELME000276,-
SLC26A4_HUMAN,K369E,0.783,Altered Transmembrane protein (Pr = 0.27 | P = 7.9e-04); Loss of Methylation at K369 (Pr = 0.11 | P = 0.03), ELME000064|PS00006,-
SLC26A4_HUMAN,V163I,0.034,-,-,-
SLC26A4_HUMAN,R134G,0.745,Gain of Loop (Pr = 0.32 | P = 1.7e-03); Altered Ordered interface (Pr = 0.31 | P = 3.9e-03), ELME000053|ELME000065|ELME000085|ELME000336|PS00005|PS01130,-
SLC26A4_HUMAN,R581M,0.655,Altered Disordered interface (Pr = 0.34 | P = 9.9e-03); Loss of Acetylation at K580 (Pr = 0.25 | P = 0.01); Altered Coiled coil (Pr = 0.21 | P = 0.02), ELME000100|ELME000103|ELME000108|ELME000120|ELME000146|ELME000276,-
SLC26A4_HUMAN,S166N,0.13,-,-,-
SLC26A4_HUMAN,R409C,0.911,Loss of Intrinsic disorder (Pr = 0.38 | P = 0.03); Loss of ADP-ribosylation at R409 (Pr = 0.23 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q413 (Pr = 0.04 | P = 0.04), ELME000336,-
SLC26A4_HUMAN,G493W,0.765,Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000333|PS00008,-
SLC26A4_HUMAN,V163L,0.085,-,-,-
SLC26A4_HUMAN,E633K,0.455,-,-,-
SLC26A4_HUMAN,Y78H,0.868,Altered Ordered interface (Pr = 0.37 | P = 1.9e-03); Altered Transmembrane protein (Pr = 0.17 | P = 9.0e-03), ELME000080,-
SLC26A4_HUMAN,N558S,0.797,Altered DNA binding (Pr = 0.22 | P = 0.01), ELME000020|ELME000084|ELME000120|PS00008,-
SLC26A4_HUMAN,R714K,0.172,-,-,-
SLC26A4_HUMAN,S28G,0.282,-,-,-
SLC26A4_HUMAN,D661G,0.917,Loss of Strand (Pr = 0.27 | P = 0.03); Altered Metal binding (Pr = 0.14 | P = 0.04); Loss of Catalytic site at D661 (Pr = 0.14 | P = 0.02), ELME000313|ELME000333,-
SLC26A4_HUMAN,A228D,0.932,Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000149|ELME000220|PS00006,-
SLC26A4_HUMAN,V545E,0.842,Altered Ordered interface (Pr = 0.33 | P = 7.0e-03); Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Gain of Allosteric site at F550 (Pr = 0.27 | P = 5.6e-03); Altered DNA binding (Pr = 0.16 | P = 0.04); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000137,-
SLC26A4_HUMAN,H135R,0.846,Loss of Strand (Pr = 0.27 | P = 0.02); Altered Ordered interface (Pr = 0.23 | P = 0.05), ELME000008|ELME000012|ELME000053|ELME000062|ELME000065|ELME000102|ELME000108|ELME000336|PS00004,-
SLC26A4_HUMAN,F335L,0.807,Altered Transmembrane protein (Pr = 0.30 | P = 1.8e-04); Altered Ordered interface (Pr = 0.28 | P = 0.05); Gain of ADP-ribosylation at R333 (Pr = 0.20 | P = 0.04), ELME000106|ELME000146|ELME000155,-
SLC26A4_HUMAN,Q235R,0.875,Loss of Strand (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.16 | P = 0.01), ELME000202|ELME000233,-
SLC26A4_HUMAN,R409P,0.956,Loss of Helix (Pr = 0.28 | P = 0.03); Gain of Strand (Pr = 0.26 | P = 0.04); Loss of ADP-ribosylation at R409 (Pr = 0.23 | P = 0.02); Altered Transmembrane protein (Pr = 0.11 | P = 0.04); Loss of Pyrrolidone carboxylic acid at Q413 (Pr = 0.04 | P = 0.04), ELME000136|ELME000159|ELME000336,-
SLC26A4_HUMAN,D573Y,0.798,Altered Disordered interface (Pr = 0.32 | P = 7.1e-03); Altered Coiled coil (Pr = 0.11 | P = 0.04), ELME000276,-
SLC26A4_HUMAN,G334W,0.919,Altered Transmembrane protein (Pr = 0.31 | P = 9.7e-05); Altered Ordered interface (Pr = 0.30 | P = 0.02); Gain of Allosteric site at G334 (Pr = 0.22 | P = 0.02); Loss of ADP-ribosylation at R333 (Pr = 0.20 | P = 0.04), ELME000146,-
SLC26A4_HUMAN,F550Y,0.354,-,-,-
SLC26A4_HUMAN,P140H,0.615,Gain of Helix (Pr = 0.27 | P = 0.04), ELME000065|ELME000148,-
SLC26A4_HUMAN,P123S,0.773,Gain of Helix (Pr = 0.27 | P = 0.05); Altered Ordered interface (Pr = 0.24 | P = 0.04); Altered Transmembrane protein (Pr = 0.11 | P = 0.04), ELME000053|ELME000063|PS01130,-
SLC26A4_HUMAN,V483E,0.761,Gain of Helix (Pr = 0.32 | P = 2.7e-03); Loss of Strand (Pr = 0.30 | P = 1.8e-03), ELME000052|ELME000053|ELME000233,-
SLC26A4_HUMAN,V659G,0.852,Altered Stability (Pr = 0.35 | P = 4.0e-03); Gain of Strand (Pr = 0.27 | P = 0.02); Gain of Catalytic site at D661 (Pr = 0.24 | P = 6.0e-03); Altered Metal binding (Pr = 0.16 | P = 0.03), ELME000333|ELME000335|PS00008,-
SLC26A4_HUMAN,P516S,0.756,Gain of Pyrrolidone carboxylic acid at Q514 (Pr = 0.06 | P = 0.02); Gain of GPI-anchor amidation at N519 (Pr = 0.04 | P = 5.3e-03), ELME000137|ELME000155,-
SLC26A4_HUMAN,C662Y,0.777,Altered Metal binding (Pr = 0.27 | P = 4.8e-03); Gain of Strand (Pr = 0.27 | P = 0.02); Gain of Catalytic site at D661 (Pr = 0.13 | P = 0.03), ELME000020|ELME000120|ELME000313,-
SLC26A4_HUMAN,N457I,0.928,Altered Transmembrane protein (Pr = 0.11 | P = 0.04), None,-
SLC26A4_HUMAN,G439R,0.78,Gain of Helix (Pr = 0.28 | P = 0.03); Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000045|ELME000102|ELME000106|ELME000146|ELME000231,-
SLC26A4_HUMAN,G209E,0.899,Altered Transmembrane protein (Pr = 0.25 | P = 1.5e-03), PS00008,-
SLC26A4_HUMAN,G672E,0.758,Loss of ADP-ribosylation at R674 (Pr = 0.20 | P = 0.05), ELME000313|ELME000333|ELME000335|ELME000337,-
SLC26A4_HUMAN,H135Y,0.765,Altered Ordered interface (Pr = 0.41 | P = 2.8e-04), ELME000053|ELME000065|ELME000083|ELME000120|ELME000182|ELME000336,-
SLC26A4_HUMAN,T485R,0.826,Gain of Helix (Pr = 0.29 | P = 0.02); Loss of Strand (Pr = 0.29 | P = 3.5e-03); Altered Transmembrane protein (Pr = 0.01 | P = 0.01), ELME000051|ELME000052|ELME000053,-
SLC26A4_HUMAN,N457Y,0.912,Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000182,-
SLC26A4_HUMAN,D697H,0.547,, PS00006,-
SLC26A4_HUMAN,R581S,0.708,Altered Disordered interface (Pr = 0.41 | P = 6.5e-03); Loss of Acetylation at K580 (Pr = 0.26 | P = 0.01); Altered Coiled coil (Pr = 0.13 | P = 0.04); Gain of N-linked glycosylation at N579 (Pr = 0.02 | P = 0.04), ELME000070|ELME000100|ELME000103|ELME000108|ELME000146|ELME000276|ELME000337|PS00001|PS00005,-
SLC26A4_HUMAN,L236P,0.91,Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Transmembrane protein (Pr = 0.28 | P = 5.6e-04); Loss of Helix (Pr = 0.28 | P = 0.02); Gain of Strand (Pr = 0.28 | P = 0.01); Gain of N-linked glycosylation at N241 (Pr = 0.03 | P = 0.03), ELME000155|ELME000202,-
SLC26A4_HUMAN,S657I,0.679,Loss of Strand (Pr = 0.28 | P = 0.01); Loss of Catalytic site at D661 (Pr = 0.14 | P = 0.02); Altered Metal binding (Pr = 0.13 | P = 0.05), ELME000239|ELME000333|ELME000335,-
SLC26A4_HUMAN,G557D,0.772,Loss of Strand (Pr = 0.29 | P = 5.0e-03); Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered DNA binding (Pr = 0.24 | P = 7.8e-03), ELME000020|ELME000081|ELME000084|ELME000120|ELME000321|PS00008,-
SLC26A4_HUMAN,T307A,0.797,Gain of Helix (Pr = 0.27 | P = 0.04), ELME000053|ELME000333,-
MYO7A_HUMAN,A391V,0.788,Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Loss of Allosteric site at D396 (Pr = 0.25 | P = 0.02); Altered Metal binding (Pr = 0.19 | P = 0.04); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Gain of Pyrrolidone carboxylic acid at Q390 (Pr = 0.09 | P = 0.01); Loss of Catalytic site at R395 (Pr = 0.08 | P = 0.05), None,-
MYO7A_HUMAN,R212H,0.871,Altered Disordered interface (Pr = 0.34 | P = 0.01); Loss of Allosteric site at R212 (Pr = 0.32 | P = 2.5e-03); Altered DNA binding (Pr = 0.30 | P = 2.6e-03); Altered Metal binding (Pr = 0.28 | P = 4.8e-03); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered Ordered interface (Pr = 0.25 | P = 0.02); Gain of Catalytic site at S210 (Pr = 0.23 | P = 7.5e-03); Loss of Methylation at K215 (Pr = 0.19 | P = 8.7e-03); Altered Transmembrane protein (Pr = 0.15 | P = 0.02); Gain of N-linked glycosylation at N209 (Pr = 0.03 | P = 0.03), ELME000070|ELME000197|ELME000198|ELME000233|PS00001|PS00005,-
MYO7A_HUMAN,P1183T,0.638,Loss of Loop (Pr = 0.27 | P = 0.05); Gain of N-linked glycosylation at N1182 (Pr = 0.02 | P = 0.03), ELME000070|ELME000239|PS00001|PS00005,-
MYO7A_HUMAN,T193I,0.763,Altered Transmembrane protein (Pr = 0.19 | P = 7.1e-03); Loss of Allosteric site at E197 (Pr = 0.19 | P = 0.05); Altered Metal binding (Pr = 0.10 | P = 0.05), ELME000052|ELME000136|ELME000159|ELME000292|ELME000333,-
MYO7A_HUMAN,A397D,0.946,Altered Ordered interface (Pr = 0.29 | P = 0.02); Altered Metal binding (Pr = 0.28 | P = 0.02); Gain of Allosteric site at D396 (Pr = 0.26 | P = 6.6e-03); Gain of Acetylation at K400 (Pr = 0.25 | P = 0.01); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Gain of Catalytic site at R395 (Pr = 0.09 | P = 0.04), ELME000146|ELME000321,-
MYO7A_HUMAN,L73P,0.966,Loss of Helix (Pr = 0.29 | P = 0.01); Gain of Loop (Pr = 0.27 | P = 0.03); Altered Stability (Pr = 0.11 | P = 0.04), None,-
MYO7A_HUMAN,G1374R,0.909,Altered Transmembrane protein (Pr = 0.09 | P = 0.05), ELME000012|ELME000102|ELME000108|ELME000137|ELME000146|PS00008,-
MYO7A_HUMAN,R88C,0.932,Altered Ordered interface (Pr = 0.30 | P = 4.6e-03); Loss of Allosteric site at Y89 (Pr = 0.22 | P = 0.03); Altered Transmembrane protein (Pr = 0.19 | P = 7.0e-03), PS00007,-
MYO7A_HUMAN,A1492V,0.902,Altered Transmembrane protein (Pr = 0.34 | P = 4.4e-05); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Gain of Strand (Pr = 0.27 | P = 0.03); Loss of N-linked glycosylation at N1494 (Pr = 0.03 | P = 0.03), ELME000335,-
MYO7A_HUMAN,N415S,0.866,Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Disordered interface (Pr = 0.28 | P = 0.04); Altered DNA binding (Pr = 0.24 | P = 0.01); Loss of Relative solvent accessibility (Pr = 0.23 | P = 0.05); Loss of Allosteric site at N415 (Pr = 0.19 | P = 0.05); Gain of Ubiquitylation at K420 (Pr = 0.18 | P = 0.02), ELME000085,-
MYO7A_HUMAN,E442G,0.94,Altered Ordered interface (Pr = 0.28 | P = 0.04); Loss of Allosteric site at D437 (Pr = 0.27 | P = 8.6e-03); Altered Metal binding (Pr = 0.18 | P = 0.03); Altered Transmembrane protein (Pr = 0.15 | P = 0.01); Loss of Catalytic site at D437 (Pr = 0.10 | P = 0.04), ELME000193,-
MYO7A_HUMAN,S583P,0.751,Loss of Helix (Pr = 0.28 | P = 0.03); Altered Coiled coil (Pr = 0.09 | P = 0.05), ELME000336|PS00005,-
MYO7A_HUMAN,Y1017D,0.818,Gain of Intrinsic disorder (Pr = 0.36 | P = 0.02); Gain of Helix (Pr = 0.29 | P = 0.02); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000173|ELME000182|ELME000220|PS00006,-
MYO7A_HUMAN,R1230H,0.749,Altered Metal binding (Pr = 0.72 | P = 1.3e-03); Altered DNA binding (Pr = 0.23 | P = 0.01); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000012|ELME000101,-
MYO7A_HUMAN,R241P,0.968,Loss of Allosteric site at R241 (Pr = 0.37 | P = 9.9e-04); Altered Ordered interface (Pr = 0.31 | P = 0.02); Altered Metal binding (Pr = 0.25 | P = 7.5e-03); Altered DNA binding (Pr = 0.22 | P = 0.01); Gain of Catalytic site at E238 (Pr = 0.09 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q245 (Pr = 0.06 | P = 0.03), ELME000136|ELME000159|ELME000336,-
MYO7A_HUMAN,L1836P,0.951,Loss of Helix (Pr = 0.27 | P = 0.04); Gain of Loop (Pr = 0.27 | P = 0.03); Gain of Allosteric site at W1834 (Pr = 0.23 | P = 0.02), ELME000149|ELME000335,-
MYO7A_HUMAN,E1349K,0.951,Gain of Relative solvent accessibility (Pr = 0.23 | P = 0.05); Altered DNA binding (Pr = 0.19 | P = 0.02); Altered Transmembrane protein (Pr = 0.18 | P = 9.0e-03), ELME000053|ELME000136|ELME000146|ELME000155|ELME000159,-
MYO7A_HUMAN,A2039P,0.936,Gain of Allosteric site at Y2042 (Pr = 0.23 | P = 0.02), ELME000149,-
MYO7A_HUMAN,L1954I,0.034,-,-,-
MYO7A_HUMAN,L16S,0.092,-,-,-
MYO7A_HUMAN,L4V,0.628,Altered Metal binding (Pr = 0.27 | P = 0.03); Gain of N-terminal acetylation at M1 (Pr = 0.23 | P = 3.8e-04); Altered Stability (Pr = 0.16 | P = 0.02), None,-
MYO7A_HUMAN,L4W,0.85,Loss of Intrinsic disorder (Pr = 0.35 | P = 0.04); Altered Metal binding (Pr = 0.32 | P = 0.01); Loss of N-terminal acetylation at M1 (Pr = 0.22 | P = 6.9e-04); Altered Stability (Pr = 0.21 | P = 0.01), None,-
MYO7A_HUMAN,Q6A,0.542,Loss of Intrinsic disorder (Pr = 0.36 | P = 0.04); Altered Metal binding (Pr = 0.26 | P = 0.03); Loss of N-terminal acetylation at M1 (Pr = 0.20 | P = 8.6e-04), None,-
MYO7A_HUMAN,V39M,0.208,-,-,-
MYO7A_HUMAN,N52K,0.307,-,-,-
MYO7A_HUMAN,N52T,0.338,-,-,-
MYO7A_HUMAN,T54M,0.143,-,-,-
MYO7A_HUMAN,T54R,0.294,-,-,-
MYO7A_HUMAN,H55N,0.204,-,-,-
MYO7A_HUMAN,I56V,0.301,-,-,-
MYO7A_HUMAN,H118N,0.633,Altered Ordered interface (Pr = 0.37 | P = 2.4e-03); Altered Metal binding (Pr = 0.34 | P = 9.2e-03); Gain of Relative solvent accessibility (Pr = 0.33 | P = 2.3e-03); Altered Transmembrane protein (Pr = 0.29 | P = 2.9e-04); Gain of Allosteric site at Y114 (Pr = 0.26 | P = 6.5e-03), ELME000063|ELME000159|ELME000334,-
MYO7A_HUMAN,S149N,0.219,-,-,-
MYO7A_HUMAN,I171M,0.651,Altered Ordered interface (Pr = 0.30 | P = 0.03); Loss of Methylation at K169 (Pr = 0.19 | P = 8.7e-03), ELME000052|ELME000146|ELME000149,-
MYO7A_HUMAN,N222T,0.807,Altered Metal binding (Pr = 0.33 | P = 1.8e-03); Altered Ordered interface (Pr = 0.29 | P = 0.03); Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Gain of Acetylation at K223 (Pr = 0.26 | P = 9.8e-03); Loss of Allosteric site at R224 (Pr = 0.25 | P = 0.02); Altered DNA binding (Pr = 0.21 | P = 0.02); Gain of Methylation at K223 (Pr = 0.10 | P = 0.04), PS00005,-
MYO7A_HUMAN,E260A,0.417,-,-,-
MYO7A_HUMAN,E264A,0.127,-,-,-
MYO7A_HUMAN,E264V,0.209,-,-,-
MYO7A_HUMAN,D265E,0.085,-,-,-
MYO7A_HUMAN,D265G,0.397,-,-,-
MYO7A_HUMAN,Q266E,0.162,-,-,-
MYO7A_HUMAN,K268A,0.3,-,-,-
MYO7A_HUMAN,K269Q,0.183,-,-,-
MYO7A_HUMAN,K269R,0.091,-,-,-
MYO7A_HUMAN,V293E,0.249,-,-,-
MYO7A_HUMAN,R302C,0.627,Altered Ordered interface (Pr = 0.43 | P = 6.0e-04); Loss of Relative solvent accessibility (Pr = 0.32 | P = 5.3e-03); Altered Metal binding (Pr = 0.26 | P = 0.03); Gain of Allosteric site at M305 (Pr = 0.23 | P = 0.02); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000079|ELME000085,-
MYO7A_HUMAN,M309L,0.535,Altered Ordered interface (Pr = 0.27 | P = 0.05); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Gain of Allosteric site at M305 (Pr = 0.23 | P = 0.02); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Altered Metal binding (Pr = 0.12 | P = 0.03), ELME000064|ELME000106|ELME000137|ELME000146|ELME000220,-
MYO7A_HUMAN,L328M,0.227,-,-,-
MYO7A_HUMAN,E334K,0.508,Gain of Allosteric site at N330 (Pr = 0.28 | P = 3.6e-03); Altered Metal binding (Pr = 0.27 | P = 1.2e-03); Gain of Catalytic site at N330 (Pr = 0.15 | P = 0.02); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000122|ELME000173,-
MYO7A_HUMAN,T337M,0.202,-,-,-
MYO7A_HUMAN,P350T,0.205,-,-,-
MYO7A_HUMAN,A355T,0.344,-,-,-
MYO7A_HUMAN,D365K,0.268,-,-,-
MYO7A_HUMAN,L366V,0.267,-,-,-
MYO7A_HUMAN,S368T,0.132,-,-,-
MYO7A_HUMAN,A416V,0.393,-,-,-
MYO7A_HUMAN,P422A,0.129,-,-,-
MYO7A_HUMAN,Q424H,0.162,-,-,-
MYO7A_HUMAN,Q424L,0.196,-,-,-
MYO7A_HUMAN,K427Q,0.183,-,-,-
MYO7A_HUMAN,S429C,0.182,-,-,-
MYO7A_HUMAN,R430C,0.637,Loss of Intrinsic disorder (Pr = 0.51 | P = 6.4e-03); Altered Transmembrane protein (Pr = 0.28 | P = 3.9e-04); Altered Ordered interface (Pr = 0.28 | P = 0.05); Gain of Strand (Pr = 0.27 | P = 0.03); Loss of Allosteric site at L435 (Pr = 0.20 | P = 0.04), ELME000062|ELME000063|ELME000079|ELME000102|ELME000108|ELME000233|PS00005,-
MYO7A_HUMAN,K518R,0.185,-,-,-
MYO7A_HUMAN,S530G,0.291,-,-,-
MYO7A_HUMAN,I539V,0.073,-,-,-
MYO7A_HUMAN,E546D,0.358,-,-,-
MYO7A_HUMAN,S607A,0.329,-,-,-
MYO7A_HUMAN,L620Q,0.532,Gain of Intrinsic disorder (Pr = 0.34 | P = 0.02), ELME000106|ELME000125|ELME000149|ELME000335,-
MYO7A_HUMAN,R623P,0.907,Loss of Helix (Pr = 0.27 | P = 0.05), ELME000125|ELME000336,-
MYO7A_HUMAN,G626S,0.334,-,-,-
MYO7A_HUMAN,M708R,0.795,, ELME000102|ELME000108,-
MYO7A_HUMAN,A711V,0.152,-,-,-
MYO7A_HUMAN,T715V,0.388,-,-,-
MYO7A_HUMAN,H716Q,0.336,-,-,-
MYO7A_HUMAN,I721M,0.638,Altered Metal binding (Pr = 0.25 | P = 0.03); Altered DNA binding (Pr = 0.16 | P = 0.04), ELME000336,-
MYO7A_HUMAN,L735M,0.211,-,-,-
MYO7A_HUMAN,D741G,0.873,Altered Coiled coil (Pr = 0.13 | P = 0.03); Altered Stability (Pr = 0.13 | P = 0.03), None,-
MYO7A_HUMAN,I749V,0.165,-,-,-
MYO7A_HUMAN,F764Y,0.452,-,-,-
MYO7A_HUMAN,L792M,0.114,-,-,-
MYO7A_HUMAN,R802H,0.714,Altered Disordered interface (Pr = 0.48 | P = 3.1e-03); Altered DNA binding (Pr = 0.24 | P = 9.9e-03); Altered Coiled coil (Pr = 0.12 | P = 0.04), ELME000336,-
MYO7A_HUMAN,S803T,0.349,-,-,-
MYO7A_HUMAN,Q808F,0.256,-,-,-
MYO7A_HUMAN,Q815W,0.225,-,-,-
MYO7A_HUMAN,R816S,0.359,-,-,-
MYO7A_HUMAN,I818A,0.424,-,-,-
MYO7A_HUMAN,I818V,0.131,-,-,-
MYO7A_HUMAN,Q819G,0.211,-,-,-
MYO7A_HUMAN,Q819V,0.262,-,-,-
MYO7A_HUMAN,V840L,0.507,Altered Disordered interface (Pr = 0.28 | P = 0.02), ELME000045|ELME000134|ELME000149|ELME000231|ELME000233,-
MYO7A_HUMAN,A861V,0.102,-,-,-
MYO7A_HUMAN,L864R,0.178,-,-,-
MYO7A_HUMAN,L864W,0.179,-,-,-
MYO7A_HUMAN,K916R,0.153,-,-,-
MYO7A_HUMAN,E917A,0.204,-,-,-
MYO7A_HUMAN,E935Q,0.238,-,-,-
MYO7A_HUMAN,N938S,0.096,-,-,-
MYO7A_HUMAN,S953T,0.088,-,-,-
MYO7A_HUMAN,G954S,0.081,-,-,-
MYO7A_HUMAN,L956A,0.321,-,-,-
MYO7A_HUMAN,G961D,0.556,Gain of Loop (Pr = 0.40 | P = 9.3e-05); Gain of Helix (Pr = 0.32 | P = 3.1e-03); Gain of Phosphorylation at S965 (Pr = 0.23 | P = 0.05), PS00008,-
MYO7A_HUMAN,K1923R,0.265,-,-,-
MYO7A_HUMAN,K1925A,0.602,Altered Metal binding (Pr = 0.33 | P = 0.01); Altered Ordered interface (Pr = 0.32 | P = 0.01); Altered DNA binding (Pr = 0.19 | P = 0.03), ELME000313,-
MYO7A_HUMAN,D1926E,0.753,Altered Metal binding (Pr = 0.23 | P = 0.04); Altered DNA binding (Pr = 0.19 | P = 0.03), ELME000313,-
MYO7A_HUMAN,I1931V,0.262,-,-,-
MYO7A_HUMAN,T1933A,0.108,-,-,-
MYO7A_HUMAN,T1933G,0.419,-,-,-
MYO7A_HUMAN,T1933L,0.432,-,-,-
MYO7A_HUMAN,K1938P,0.677,Loss of Helix (Pr = 0.28 | P = 0.02), ELME000053|ELME000106|ELME000146|ELME000313,-
MYO7A_HUMAN,S1939L,0.574,, ELME000053|ELME000197|ELME000313|ELME000333,-
MYO7A_HUMAN,S1939T,0.3,-,-,-
MYO7A_HUMAN,F1943R,0.944,, ELME000053|ELME000106|ELME000146|ELME000197,-
MYO7A_HUMAN,L1945D,0.962,Altered Stability (Pr = 0.24 | P = 8.8e-03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), None,-
MYO7A_HUMAN,L1945S,0.937,Altered Stability (Pr = 0.34 | P = 4.2e-03), None,-
MYO7A_HUMAN,K1948E,0.822,Altered Transmembrane protein (Pr = 0.11 | P = 0.03), None,-
MYO7A_HUMAN,K1948Q,0.756,Altered Transmembrane protein (Pr = 0.10 | P = 0.05), None,-
MYO7A_HUMAN,K1952A,0.836,Altered Transmembrane protein (Pr = 0.17 | P = 0.01), ELME000064|ELME000065|ELME000106|ELME000173,-
MYO7A_HUMAN,E1958D,0.588,Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.17 | P = 0.01), ELME000064|ELME000065|ELME000321|PS00006,-
MYO7A_HUMAN,K1980R,0.274,-,-,-
MYO7A_HUMAN,S1986L,0.604,Altered Ordered interface (Pr = 0.26 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.23 | P = 0.05); Altered Transmembrane protein (Pr = 0.15 | P = 0.02); Gain of Proteolytic cleavage at D1981 (Pr = 0.12 | P = 0.04), ELME000052|ELME000233|ELME000333|PS00008,-
MYO7A_HUMAN,R2061W,0.403,-,-,-
MYO7A_HUMAN,Q2119V,0.916,Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Transmembrane protein (Pr = 0.12 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q2119 (Pr = 0.05 | P = 0.03), ELME000173,-
MYO7A_HUMAN,I2128V,0.109,-,-,-
MYO7A_HUMAN,V2138L,0.475,-,-,-
MYO7A_HUMAN,I2141A,0.676,Altered Stability (Pr = 0.64 | P = 7.4e-04); Altered Transmembrane protein (Pr = 0.27 | P = 6.8e-04); Altered Metal binding (Pr = 0.24 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.24 | P = 0.05), ELME000333|PS00006|PS00008,-
MYO7A_HUMAN,D2142E,0.321,-,-,-
MYO7A_HUMAN,P2143S,0.339,-,-,-
MYO7A_HUMAN,T2145S,0.184,-,-,-
MYO7A_HUMAN,D2147R,0.539,Altered Transmembrane protein (Pr = 0.31 | P = 9.7e-05); Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.30 | P = 8.7e-03); Loss of Strand (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.26 | P = 0.01), ELME000052|ELME000100|ELME000108|ELME000146|PS00005,-
MYO7A_HUMAN,T2150I,0.339,-,-,-
MYO7A_HUMAN,T2155A,0.654,Altered Transmembrane protein (Pr = 0.31 | P = 1.2e-04); Gain of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000053,-
MYO7A_HUMAN,W2160L,0.885,Altered Ordered interface (Pr = 0.33 | P = 9.9e-03); Loss of Loop (Pr = 0.28 | P = 0.01); Loss of Strand (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.26 | P = 9.7e-04); Loss of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000053|ELME000063|ELME000070|PS00001,-
MYO7A_HUMAN,S2161E,0.84,Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Loop (Pr = 0.28 | P = 0.01); Altered Transmembrane protein (Pr = 0.21 | P = 4.1e-03); Altered DNA binding (Pr = 0.14 | P = 0.05); Loss of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000053|ELME000063|ELME000064|ELME000070|ELME000085|PS00001|PS00006,-
MYO7A_HUMAN,G2163A,0.57,Altered Ordered interface (Pr = 0.29 | P = 0.03); Loss of Strand (Pr = 0.26 | P = 0.04); Altered Transmembrane protein (Pr = 0.11 | P = 0.03); Gain of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000053|ELME000063|ELME000070|ELME000085,-
MYO7A_HUMAN,H2168D,0.892,Altered Ordered interface (Pr = 0.31 | P = 0.01); Gain of Loop (Pr = 0.28 | P = 0.02); Altered Metal binding (Pr = 0.24 | P = 0.04); Altered Transmembrane protein (Pr = 0.17 | P = 9.4e-03); Altered DNA binding (Pr = 0.17 | P = 0.03), ELME000120|ELME000147|ELME000182|ELME000220|ELME000336|PS00006,-
MYO7A_HUMAN,H2168P,0.918,Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Metal binding (Pr = 0.26 | P = 0.02); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000120|ELME000182|ELME000336,-
MYO7A_HUMAN,I2171P,0.844,Altered Ordered interface (Pr = 0.29 | P = 0.04); Gain of Loop (Pr = 0.27 | P = 0.03); Altered Stability (Pr = 0.19 | P = 0.01); Altered Metal binding (Pr = 0.17 | P = 0.04); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000136|ELME000159|ELME000336,-
MYO7A_HUMAN,G2172S,0.812,Altered Metal binding (Pr = 0.23 | P = 0.05); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000336,-
MYO7A_HUMAN,R2176P,0.88,Gain of Loop (Pr = 0.26 | P = 0.05); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000062|ELME000149,-
MYO7A_HUMAN,K2179T,0.815,Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000062|ELME000149,-
MYO7A_HUMAN,Y2188W,0.688,, ELME000147|ELME000148|ELME000317,-
MYO7A_HUMAN,L2193G,0.873,Altered Stability (Pr = 0.55 | P = 1.3e-03); Altered Disordered interface (Pr = 0.29 | P = 0.03), ELME000052|ELME000053|ELME000148|ELME000317|ELME000336,-
MYO7A_HUMAN,T2195H,0.793,Altered Transmembrane protein (Pr = 0.11 | P = 0.04), ELME000052|ELME000053|ELME000148|ELME000336,-
MYO7A_HUMAN,I2198T,0.853,Gain of Intrinsic disorder (Pr = 0.50 | P = 1.7e-03); Altered Disordered interface (Pr = 0.30 | P = 0.02); Altered Stability (Pr = 0.15 | P = 0.02); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000052|ELME000053|ELME000063|ELME000163|ELME000182|ELME000202|ELME000336,-
MYO7A_HUMAN,Q2200E,0.644,Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000063|ELME000163|ELME000182|ELME000202,-
MYO7A_HUMAN,Q2200F,0.877,Loss of Intrinsic disorder (Pr = 0.48 | P = 8.9e-03); Altered Disordered interface (Pr = 0.34 | P = 0.01); Gain of Allosteric site at Y2197 (Pr = 0.20 | P = 0.04); Altered Transmembrane protein (Pr = 0.10 | P = 0.05), ELME000063|ELME000120|ELME000163|ELME000182|ELME000202|ELME000336,-
MYO7A_HUMAN,M2201P,0.886,Altered Disordered interface (Pr = 0.32 | P = 0.01); Loss of Helix (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.18 | P = 8.4e-03); Altered Stability (Pr = 0.14 | P = 0.02), ELME000063|ELME000202,-
MYO7A_HUMAN,A2204D,0.573,Gain of Intrinsic disorder (Pr = 0.42 | P = 5.6e-03); Altered Disordered interface (Pr = 0.29 | P = 0.01); Altered DNA binding (Pr = 0.15 | P = 0.05); Loss of Methylation at K2207 (Pr = 0.09 | P = 0.05), None,-
MYO7A_HUMAN,G2210N,0.233,-,-,-
MYO7A_HUMAN,S2211P,0.268,-,-,-
MYO7A_HUMAN,R2212Y,0.331,-,-,-
MYO7A_HUMAN,S2213G,0.086,-,-,-
MYO7A_HUMAN,G2214C,0.304,-,-,-
MYO7A_HUMAN,T165A,0.761,Altered Ordered interface (Pr = 0.31 | P = 0.02); Gain of Methylation at K164 (Pr = 0.23 | P = 1.8e-03); Loss of Catalytic site at S160 (Pr = 0.15 | P = 0.02), PS00008|PS00017,-
MYO7A_HUMAN,D1266G,0.907,Loss of Loop (Pr = 0.29 | P = 0.01), ELME000220|ELME000321|ELME000336|PS00006,-
MYO7A_HUMAN,R212C,0.931,Altered Disordered interface (Pr = 0.52 | P = 6.9e-04); Altered DNA binding (Pr = 0.47 | P = 1.2e-04); Altered Metal binding (Pr = 0.39 | P = 2.3e-04); Loss of Relative solvent accessibility (Pr = 0.35 | P = 2.2e-03); Loss of Allosteric site at R212 (Pr = 0.34 | P = 1.7e-03); Gain of Catalytic site at S210 (Pr = 0.30 | P = 1.4e-03); Altered Ordered interface (Pr = 0.26 | P = 0.01); Loss of Methylation at K215 (Pr = 0.19 | P = 8.5e-03); Altered Transmembrane protein (Pr = 0.15 | P = 0.01); Gain of N-linked glycosylation at N209 (Pr = 0.03 | P = 0.03), ELME000070|ELME000197|ELME000198|ELME000233|PS00001|PS00005,-
MYO7A_HUMAN,W2077R,0.874,Gain of Helix (Pr = 0.28 | P = 0.02); Gain of B-factor (Pr = 0.27 | P = 9.5e-03); Loss of Allosteric site at W2077 (Pr = 0.27 | P = 8.6e-03); Gain of Phosphorylation at S2073 (Pr = 0.23 | P = 0.05), ELME000008|ELME000065|ELME000102|PS00004,-
MYO7A_HUMAN,E1812Q,0.822,Altered Ordered interface (Pr = 0.24 | P = 0.04); Altered Metal binding (Pr = 0.22 | P = 0.02), ELME000002|ELME000251,-
MYO7A_HUMAN,H133D,0.93,Altered Metal binding (Pr = 0.59 | P = 4.9e-04); Loss of Allosteric site at H133 (Pr = 0.30 | P = 3.8e-03); Altered Ordered interface (Pr = 0.29 | P = 0.02); Gain of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered DNA binding (Pr = 0.19 | P = 0.03); Loss of Catalytic site at H133 (Pr = 0.10 | P = 0.04), ELME000058,-
MYO7A_HUMAN,L326Q,0.955,Altered Metal binding (Pr = 0.39 | P = 8.6e-03); Gain of Allosteric site at H327 (Pr = 0.27 | P = 5.7e-03); Gain of Catalytic site at H327 (Pr = 0.22 | P = 9.0e-03); Altered Transmembrane protein (Pr = 0.11 | P = 0.04), ELME000193,-
MYO7A_HUMAN,R1347S,0.949,Altered Transmembrane protein (Pr = 0.25 | P = 1.6e-03); Altered DNA binding (Pr = 0.17 | P = 0.04); Altered Stability (Pr = 0.11 | P = 0.04), ELME000102|ELME000137|ELME000146|ELME000155,-
MYO7A_HUMAN,H133P,0.958,Altered Metal binding (Pr = 0.94 | P = 6.3e-05); Loss of Allosteric site at H133 (Pr = 0.37 | P = 1.0e-03); Altered Ordered interface (Pr = 0.30 | P = 0.03); Loss of Helix (Pr = 0.29 | P = 0.02); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered DNA binding (Pr = 0.19 | P = 0.03); Loss of Catalytic site at H133 (Pr = 0.10 | P = 0.04), ELME000058,-
MYO7A_HUMAN,D1689N,0.35,-,-,-
MYO7A_HUMAN,I1045T,0.749,Gain of Allosteric site at F1048 (Pr = 0.22 | P = 0.02), ELME000337|PS00005,-
MYO7A_HUMAN,V67M,0.666,, ELME000148,-
MYO7A_HUMAN,L566P,0.942,Altered Metal binding (Pr = 0.31 | P = 3.5e-03); Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered Ordered interface (Pr = 0.28 | P = 0.04); Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Strand (Pr = 0.26 | P = 0.04); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Gain of Allosteric site at K568 (Pr = 0.20 | P = 0.04); Altered Transmembrane protein (Pr = 0.12 | P = 0.03); Altered Coiled coil (Pr = 0.10 | P = 0.04); Loss of Catalytic site at E567 (Pr = 0.08 | P = 0.05), None,-
MYO7A_HUMAN,G2187D,0.74,Altered Transmembrane protein (Pr = 0.11 | P = 0.04); Gain of Sulfation at Y2188 (Pr = 0.02 | P = 0.04), ELME000147|ELME000148|ELME000220|PS00006,-
MYO7A_HUMAN,L1484F,0.759,Altered Ordered interface (Pr = 0.35 | P = 4.2e-03); Loss of Loop (Pr = 0.27 | P = 0.04); Altered Transmembrane protein (Pr = 0.26 | P = 1.0e-03); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03), ELME000063|ELME000155,-
MYO7A_HUMAN,D1502G,0.884,Altered Transmembrane protein (Pr = 0.17 | P = 0.01), ELME000182,-
MYO7A_HUMAN,R1343S,0.906,Altered Transmembrane protein (Pr = 0.34 | P = 2.4e-05); Altered DNA binding (Pr = 0.19 | P = 0.02); Gain of Catalytic site at R1347 (Pr = 0.10 | P = 0.04), ELME000080|ELME000137|ELME000146|ELME000197|ELME000198,-
MYO7A_HUMAN,R241G,0.95,Loss of Allosteric site at R241 (Pr = 0.39 | P = 7.0e-04); Altered Ordered interface (Pr = 0.33 | P = 0.01); Altered Metal binding (Pr = 0.27 | P = 7.0e-03); Altered DNA binding (Pr = 0.23 | P = 0.01); Gain of Catalytic site at K239 (Pr = 0.09 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q245 (Pr = 0.06 | P = 0.03), ELME000085|ELME000336,-
MYO7A_HUMAN,L435H,0.948,Altered Stability (Pr = 0.57 | P = 1.1e-03); Altered Metal binding (Pr = 0.35 | P = 3.1e-03); Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Strand (Pr = 0.26 | P = 0.04); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.04); Altered Transmembrane protein (Pr = 0.24 | P = 1.6e-03); Gain of Allosteric site at D437 (Pr = 0.24 | P = 0.01); Gain of Catalytic site at D437 (Pr = 0.11 | P = 0.03), ELME000062|ELME000063|ELME000149|ELME000233|ELME000333|ELME000335,-
MYO7A_HUMAN,E450Q,0.855,Altered Metal binding (Pr = 0.24 | P = 0.03); Altered Coiled coil (Pr = 0.24 | P = 0.02), ELME000193,-
MYO7A_HUMAN,S211G,0.886,Altered Disordered interface (Pr = 0.32 | P = 0.01); Loss of Relative solvent accessibility (Pr = 0.32 | P = 4.9e-03); Altered DNA binding (Pr = 0.31 | P = 2.5e-03); Altered Ordered interface (Pr = 0.28 | P = 0.05); Altered Metal binding (Pr = 0.26 | P = 9.4e-03); Loss of Allosteric site at R212 (Pr = 0.26 | P = 0.01); Loss of Catalytic site at R206 (Pr = 0.21 | P = 0.01); Gain of Methylation at K215 (Pr = 0.19 | P = 6.3e-03); Altered Transmembrane protein (Pr = 0.15 | P = 0.01); Loss of N-linked glycosylation at N209 (Pr = 0.03 | P = 0.03), ELME000070|ELME000085|ELME000197|ELME000198|PS00001|PS00005,-
MYO7A_HUMAN,E1248K,0.857,, ELME000064|PS00006,-
MYO7A_HUMAN,R1146Q,0.522,Loss of Helix (Pr = 0.27 | P = 0.05); Altered Transmembrane protein (Pr = 0.24 | P = 2.0e-03), ELME000052|ELME000062|ELME000064,-
MYO7A_HUMAN,C635R,0.972,Altered Metal binding (Pr = 0.46 | P = 4.7e-03); Gain of Catalytic site at C635 (Pr = 0.41 | P = 1.6e-04); Loss of Allosteric site at R634 (Pr = 0.24 | P = 0.02); Altered DNA binding (Pr = 0.19 | P = 0.02); Altered Transmembrane protein (Pr = 0.10 | P = 0.05), ELME000012|ELME000102|ELME000108|ELME000146,-
MYO7A_HUMAN,G1159V,0.881,, ELME000313,-
MYO7A_HUMAN,A1340P,0.945,Altered Transmembrane protein (Pr = 0.29 | P = 2.1e-04); Gain of Pyrrolidone carboxylic acid at Q1336 (Pr = 0.08 | P = 0.02), None,-
MYO7A_HUMAN,R373C,0.85,Altered Ordered interface (Pr = 0.29 | P = 0.02), ELME000063|ELME000106|PS00005,-
MYO7A_HUMAN,R1883Q,0.764,Gain of Acetylation at K1884 (Pr = 0.28 | P = 5.6e-03); Loss of Allosteric site at R1883 (Pr = 0.26 | P = 0.01); Altered DNA binding (Pr = 0.15 | P = 0.05); Altered Coiled coil (Pr = 0.13 | P = 0.04), ELME000070|ELME000102|ELME000134|ELME000202|PS00001|PS00005,-
MYO7A_HUMAN,R1708S,0.397,-,-,-
MYO7A_HUMAN,K2118N,0.686,Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Loop (Pr = 0.29 | P = 9.7e-03); Loss of Strand (Pr = 0.26 | P = 0.05); Altered Transmembrane protein (Pr = 0.12 | P = 0.03); Gain of Pyrrolidone carboxylic acid at Q2119 (Pr = 0.07 | P = 0.02); Gain of N-linked glycosylation at K2118 (Pr = 0.04 | P = 0.02), ELME000070|PS00001,-
MYO7A_HUMAN,G671S,0.9,Altered Ordered interface (Pr = 0.33 | P = 7.5e-03); Gain of Allosteric site at R675 (Pr = 0.27 | P = 6.2e-03); Altered DNA binding (Pr = 0.22 | P = 0.02); Altered Metal binding (Pr = 0.11 | P = 0.04); Gain of Catalytic site at Y672 (Pr = 0.08 | P = 0.05), ELME000008|ELME000048|ELME000061|ELME000062|PS00004,-
MYO7A_HUMAN,Y560S,0.921,Altered Ordered interface (Pr = 0.36 | P = 2.1e-03); Gain of Relative solvent accessibility (Pr = 0.33 | P = 2.4e-03); Altered Transmembrane protein (Pr = 0.15 | P = 0.01); Altered Metal binding (Pr = 0.12 | P = 0.03); Altered Coiled coil (Pr = 0.09 | P = 0.05); Loss of Sulfation at Y559 (Pr = 0.02 | P = 0.04), ELME000163|ELME000202|PS00008,-
MYO7A_HUMAN,R657W,0.936,Gain of Strand (Pr = 0.28 | P = 0.01); Loss of Allosteric site at R657 (Pr = 0.28 | P = 7.3e-03); Altered DNA binding (Pr = 0.25 | P = 8.3e-03); Loss of Catalytic site at R657 (Pr = 0.22 | P = 9.4e-03), ELME000062|ELME000106|ELME000313|ELME000336,-
MYO7A_HUMAN,H2014R,0.912,Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Strand (Pr = 0.27 | P = 0.03); Loss of Allosteric site at Y2015 (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Loss of Catalytic site at Y2015 (Pr = 0.16 | P = 0.02); Altered Metal binding (Pr = 0.12 | P = 6.7e-03); Gain of Sulfation at Y2016 (Pr = 0.03 | P = 0.02), PS00007,-
MYO7A_HUMAN,G1600R,0.772,Gain of Loop (Pr = 0.27 | P = 0.03); Loss of ADP-ribosylation at R1604 (Pr = 0.21 | P = 0.03); Altered Transmembrane protein (Pr = 0.18 | P = 8.9e-03); Altered DNA binding (Pr = 0.15 | P = 0.05), ELME000061|ELME000220|ELME000271,-
MYO7A_HUMAN,T1496K,0.882,Altered Ordered interface (Pr = 0.33 | P = 7.0e-03); Altered Transmembrane protein (Pr = 0.26 | P = 8.8e-04); Loss of N-linked glycosylation at N1494 (Pr = 0.03 | P = 0.03), ELME000070|ELME000080|ELME000137|PS00001,-
MYO7A_HUMAN,K1384N,0.739,Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.15 | P = 0.01), None,-
MYO7A_HUMAN,R83S,0.861,Altered Ordered interface (Pr = 0.25 | P = 0.03); Altered Transmembrane protein (Pr = 0.16 | P = 0.01), ELME000045|ELME000106|ELME000146|PS00008,-
MYO7A_HUMAN,T1841R,0.832,, ELME000106|ELME000146,-
MYO7A_HUMAN,I1157N,0.883,Altered Stability (Pr = 0.10 | P = 0.04), ELME000137|ELME000313,-
MYO7A_HUMAN,C652Y,0.935,Altered Ordered interface (Pr = 0.27 | P = 0.05); Gain of Allosteric site at R657 (Pr = 0.25 | P = 0.01); Loss of Catalytic site at R657 (Pr = 0.20 | P = 0.01); Altered DNA binding (Pr = 0.18 | P = 0.03), ELME000106|ELME000163|ELME000182|ELME000313,-
MYO7A_HUMAN,Y235D,0.957,Altered DNA binding (Pr = 0.32 | P = 8.9e-04); Altered Ordered interface (Pr = 0.31 | P = 0.02); Gain of Helix (Pr = 0.28 | P = 0.02); Loss of Strand (Pr = 0.27 | P = 0.03); Loss of Allosteric site at Y235 (Pr = 0.26 | P = 0.01); Altered Metal binding (Pr = 0.24 | P = 0.01); Loss of Acetylation at K231 (Pr = 0.19 | P = 0.05); Altered Transmembrane protein (Pr = 0.10 | P = 0.05); Gain of Catalytic site at K239 (Pr = 0.10 | P = 0.04), ELME000182,-
MYO7A_HUMAN,V1669I,0.311,-,-,-
MYO7A_HUMAN,R816H,0.209,-,-,-
MYO7A_HUMAN,P1724A,0.259,-,-,-
MYO7A_HUMAN,I1157V,0.181,-,-,-
MYO7A_HUMAN,R1602Q,0.531,Gain of Helix (Pr = 0.27 | P = 0.05); Altered Ordered interface (Pr = 0.24 | P = 0.03); Loss of ADP-ribosylation at R1604 (Pr = 0.21 | P = 0.03); Altered Transmembrane protein (Pr = 0.20 | P = 5.1e-03); Altered DNA binding (Pr = 0.15 | P = 0.04), ELME000008|ELME000012|ELME000102|ELME000134|ELME000233|ELME000271|ELME000278|PS00004,-
SLC26A4_HUMAN,G6S,0.064,-,-,-
SLC26A4_HUMAN,M21V,0.022,-,-,-
SLC26A4_HUMAN,A51T,0.14,-,-,-
SLC26A4_HUMAN,C53G,0.125,-,-,-
SLC26A4_HUMAN,V163I,0.034,-,-,-
SLC26A4_HUMAN,A180T,0.07,-,-,-
SLC26A4_HUMAN,I188V,0.154,-,-,-
SLC26A4_HUMAN,V250I,0.092,-,-,-
SLC26A4_HUMAN,Y255M,0.859,Altered Transmembrane protein (Pr = 0.33 | P = 5.8e-05); Gain of Helix (Pr = 0.28 | P = 0.03); Altered Ordered interface (Pr = 0.23 | P = 0.05), ELME000020|ELME000053|ELME000064|ELME000120|ELME000182|ELME000220,-
SLC26A4_HUMAN,E339A,0.095,-,-,-
SLC26A4_HUMAN,S344G,0.191,-,-,-
SLC26A4_HUMAN,A429G,0.043,-,-,-
SLC26A4_HUMAN,L465V,0.042,-,-,-
SLC26A4_HUMAN,V609G,0.053,-,-,-
SLC26A4_HUMAN,T755P,0.044,-,-,-
SLC26A4_HUMAN,R776G,0.63,Altered Coiled coil (Pr = 0.31 | P = 0.01); Loss of Helix (Pr = 0.30 | P = 7.1e-03), None,-
SLC26A4_HUMAN,P76S,0.534,Gain of Helix (Pr = 0.28 | P = 0.03); Altered Ordered interface (Pr = 0.26 | P = 0.02); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000080,-
SLC26A4_HUMAN,G222D,0.933,Altered Transmembrane protein (Pr = 0.32 | P = 7.8e-05); Gain of Helix (Pr = 0.27 | P = 0.05), PS00008,-
SLC26A4_HUMAN,L727F,0.259,-,-,-
SLC26A4_HUMAN,A372V,0.7,Altered Transmembrane protein (Pr = 0.31 | P = 9.3e-05); Altered Ordered interface (Pr = 0.26 | P = 0.01); Altered Metal binding (Pr = 0.12 | P = 0.03); Loss of Methylation at K369 (Pr = 0.10 | P = 0.04), ELME000182|ELME000220,-
SLC26A4_HUMAN,Y20H,0.546,Loss of Phosphorylation at Y20 (Pr = 0.30 | P = 0.02); Loss of Sulfation at Y16 (Pr = 0.02 | P = 0.02), ELME000053|ELME000155,-
SLC26A4_HUMAN,P469S,0.671,, None,-
SLC26A4_HUMAN,R470H,0.205,-,-,-
SLC26A4_HUMAN,D661E,0.805,Gain of Catalytic site at D661 (Pr = 0.17 | P = 0.02); Altered Metal binding (Pr = 0.13 | P = 0.05), ELME000313|ELME000333,-
SLC26A4_HUMAN,F667L,0.817,Loss of Strand (Pr = 0.27 | P = 0.02), ELME000313|ELME000333|ELME000335|PS00006,-
SLC26A4_HUMAN,G740V,0.264,-,-,-
SLC26A4_HUMAN,D669N,0.879,Gain of ADP-ribosylation at R674 (Pr = 0.20 | P = 0.04), ELME000313|ELME000335|PS00006,-
SLC26A4_HUMAN,S133L,0.824,Gain of Helix (Pr = 0.30 | P = 9.8e-03); Loss of Strand (Pr = 0.29 | P = 3.6e-03), ELME000053|ELME000336|PS00005|PS01130,-
SLC26A4_HUMAN,A411T,0.63,Gain of Intrinsic disorder (Pr = 0.30 | P = 0.05); Loss of Helix (Pr = 0.28 | P = 0.03); Gain of Strand (Pr = 0.26 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q413 (Pr = 0.05 | P = 0.03), ELME000062|ELME000063|ELME000064|ELME000117|ELME000220|ELME000336|PS00006,-
SLC26A4_HUMAN,D697G,0.569,, PS00006,-
SLC26A4_HUMAN,G368R,0.849,Gain of ADP-ribosylation at G368 (Pr = 0.30 | P = 3.2e-03); Altered Transmembrane protein (Pr = 0.24 | P = 1.5e-03); Loss of Methylation at K369 (Pr = 0.10 | P = 0.04), ELME000102|PS00005,-
SLC26A4_HUMAN,N382K,0.914,Altered Ordered interface (Pr = 0.30 | P = 3.0e-03); Altered Transmembrane protein (Pr = 0.29 | P = 2.1e-04); Altered Metal binding (Pr = 0.26 | P = 7.8e-03); Gain of Catalytic site at E384 (Pr = 0.19 | P = 0.01), None,-
SLC26A4_HUMAN,V138F,0.681,Loss of Strand (Pr = 0.27 | P = 0.02), ELME000065|ELME000137,-
SLC26A4_HUMAN,T527P,0.886,Altered Transmembrane protein (Pr = 0.28 | P = 4.1e-04), ELME000053|ELME000063|ELME000136|ELME000159|PS00008,-
SLC26A4_HUMAN,I529S,0.803,Gain of Intrinsic disorder (Pr = 0.60 | P = 4.0e-04); Altered Stability (Pr = 0.46 | P = 2.2e-03); Altered Transmembrane protein (Pr = 0.31 | P = 8.8e-05), ELME000063|PS00005,-
SLC26A4_HUMAN,L445W,0.887,Gain of Helix (Pr = 0.31 | P = 5.3e-03); Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000336,-
SLC26A4_HUMAN,N558K,0.902,Gain of Acetylation at N558 (Pr = 0.51 | P = 5.0e-04); Altered Ordered interface (Pr = 0.32 | P = 0.01); Altered DNA binding (Pr = 0.23 | P = 0.01), ELME000020|ELME000084|ELME000120|PS00008,-
SLC26A4_HUMAN,V659L,0.627,Loss of Strand (Pr = 0.31 | P = 1.3e-03); Altered Metal binding (Pr = 0.15 | P = 0.04); Gain of Catalytic site at D661 (Pr = 0.13 | P = 0.03), ELME000333|ELME000335,-
SLC26A4_HUMAN,P553H,0.806,Altered Ordered interface (Pr = 0.32 | P = 0.01); Loss of Allosteric site at F550 (Pr = 0.30 | P = 4.6e-03); Gain of Helix (Pr = 0.29 | P = 0.01); Altered DNA binding (Pr = 0.29 | P = 2.6e-03), ELME000062|ELME000136|ELME000159|ELME000197|ELME000336,-
SLC26A4_HUMAN,F667S,0.886,Loss of Strand (Pr = 0.26 | P = 0.05), ELME000239|ELME000313|ELME000335|PS00006|PS00008,-
SLC26A4_HUMAN,I490L,0.511,Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000335,-
SLC26A4_HUMAN,T99R,0.804,Altered Transmembrane protein (Pr = 0.29 | P = 3.6e-04), ELME000336,-
SLC26A4_HUMAN,F141L,0.771,Gain of Helix (Pr = 0.31 | P = 5.0e-03); Loss of Strand (Pr = 0.31 | P = 9.6e-04), ELME000148|ELME000333,-
SLC26A4_HUMAN,F683S,0.834,, ELME000202|PS00005,-
SLC26A4_HUMAN,T307M,0.83,, ELME000053|ELME000333,-
SLC26A4_HUMAN,L257P,0.904,Altered Transmembrane protein (Pr = 0.49 | P = 0.0e+00); Altered Ordered interface (Pr = 0.28 | P = 0.04); Loss of Helix (Pr = 0.28 | P = 0.02); Gain of Strand (Pr = 0.27 | P = 0.03), ELME000020|ELME000064|ELME000120|ELME000136|ELME000159|ELME000182|ELME000220|ELME000335|ELME000358|PS00006,-
SLC26A4_HUMAN,W74C,0.936,Altered Ordered interface (Pr = 0.29 | P = 5.6e-03), ELME000080,-
SLC26A4_HUMAN,A360V,0.708,Altered Transmembrane protein (Pr = 0.10 | P = 0.04), None,-
SLC26A4_HUMAN,R24Q,0.508,Gain of Sulfation at Y27 (Pr = 0.02 | P = 0.03), ELME000155|ELME000202,-
SLC26A4_HUMAN,G116D,0.88,Altered Transmembrane protein (Pr = 0.31 | P = 1.1e-04); Altered Ordered interface (Pr = 0.28 | P = 6.9e-03); Gain of Helix (Pr = 0.27 | P = 0.03); Gain of Sulfation at Y115 (Pr = 0.01 | P = 0.04), ELME000193|PS00008|PS01130,-
SLC26A4_HUMAN,L703P,0.867,Altered Transmembrane protein (Pr = 0.18 | P = 7.8e-03); Gain of Sulfation at Y698 (Pr = 0.01 | P = 0.05), None,-
SLC26A4_HUMAN,T508N,0.551,Loss of Strand (Pr = 0.27 | P = 0.03), ELME000052|ELME000335,-
SLC26A4_HUMAN,S252P,0.894,Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03), ELME000053,-
SLC26A4_HUMAN,S552I,0.821,Altered Ordered interface (Pr = 0.34 | P = 6.9e-03); Loss of Allosteric site at F550 (Pr = 0.31 | P = 3.4e-03); Altered DNA binding (Pr = 0.23 | P = 0.01), ELME000062|ELME000136|ELME000159|ELME000197|ELME000233|ELME000300|ELME000336,-
SLC26A4_HUMAN,Y115D,0.849,Altered Ordered interface (Pr = 0.41 | P = 8.6e-04); Altered Transmembrane protein (Pr = 0.29 | P = 3.9e-04), ELME000193|PS01130,-
SLC26A4_HUMAN,G209V,0.932,Loss of Strand (Pr = 0.28 | P = 0.01); Altered Transmembrane protein (Pr = 0.19 | P = 6.1e-03), PS00008,-
SLC26A4_HUMAN,T721M,0.701,Altered Metal binding (Pr = 0.06 | P = 0.03), ELME000052|ELME000053|ELME000220|ELME000233|ELME000336|PS00006,-
SLC26A4_HUMAN,S415G,0.395,-,-,-
SLC26A4_HUMAN,L627R,0.322,-,-,-
SLC26A4_HUMAN,E29D,0.322,-,-,-
SLC26A4_HUMAN,G139V,0.912,Gain of Helix (Pr = 0.28 | P = 0.02); Loss of Strand (Pr = 0.27 | P = 0.02); Altered Ordered interface (Pr = 0.23 | P = 0.05), ELME000065|ELME000155,-
SLC26A4_HUMAN,S137L,0.802,Loss of Strand (Pr = 0.26 | P = 0.03), ELME000053|ELME000065|ELME000146,-
SLC26A4_HUMAN,L624V,0.11,-,-,-
SLC26A4_HUMAN,R24L,0.742,Loss of Intrinsic disorder (Pr = 0.38 | P = 0.03); Loss of Strand (Pr = 0.26 | P = 0.03); Gain of Sulfation at Y27 (Pr = 0.03 | P = 0.02), ELME000155,-
SLC26A4_HUMAN,V422I,0.053,-,-,-
SLC26A4_HUMAN,A227P,0.924,Loss of Helix (Pr = 0.27 | P = 0.04), None,-
SLC26A4_HUMAN,L215S,0.909,Altered Transmembrane protein (Pr = 0.40 | P = 0.0e+00); Gain of Strand (Pr = 0.28 | P = 7.8e-03); Loss of Helix (Pr = 0.27 | P = 0.05), ELME000062|ELME000085|ELME000182|ELME000317,-
SLC26A4_HUMAN,D271H,0.745,Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.03), ELME000052|ELME000147,-
SLC26A4_HUMAN,I300L,0.635,Gain of Helix (Pr = 0.33 | P = 1.7e-03); Altered Ordered interface (Pr = 0.31 | P = 0.02); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000155|ELME000233,-
SLC26A4_HUMAN,S17R,0.142,-,-,-
SLC26A4_HUMAN,A51V,0.162,-,-,-
SLC26A4_HUMAN,A104T,0.749,Altered Transmembrane protein (Pr = 0.26 | P = 9.1e-04); Altered Ordered interface (Pr = 0.24 | P = 0.03), ELME000052|PS00008,-
SLC26A4_HUMAN,V170A,0.054,-,-,-
SLC26A4_HUMAN,T178I,0.093,-,-,-
SLC26A4_HUMAN,V242M,0.438,-,-,-
SLC26A4_HUMAN,A284V,0.259,-,-,-
SLC26A4_HUMAN,R333K,0.195,-,-,-
SLC26A4_HUMAN,T378A,0.061,-,-,-
SLC26A4_HUMAN,I621T,0.088,-,-,-
SLC26A4_HUMAN,I629T,0.087,-,-,-
SLC26A4_HUMAN,R674K,0.158,-,-,-
SLC26A4_HUMAN,E737G,0.091,-,-,-
SLC26A4_HUMAN,C752R,0.306,-,-,-
SLC26A4_HUMAN,S780T,0.148,-,-,-
SLC26A4_HUMAN,D724N,0.761,Altered Metal binding (Pr = 0.06 | P = 0.03), ELME000134|ELME000220|PS00006,-
SLC26A4_HUMAN,T410M,0.782,Gain of Helix (Pr = 0.27 | P = 0.03); Loss of Strand (Pr = 0.27 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q413 (Pr = 0.04 | P = 0.04), ELME000336,-
SLC26A4_HUMAN,C565R,0.493,-,-,-
SLC26A4_HUMAN,V690A,0.649,Altered Stability (Pr = 0.17 | P = 0.02), None,-
SLC26A4_HUMAN,G334V,0.922,Altered Transmembrane protein (Pr = 0.27 | P = 4.9e-04); Gain of ADP-ribosylation at R333 (Pr = 0.20 | P = 0.03), ELME000146|ELME000155,-
SLC26A4_HUMAN,R685I,0.708,, None,-
SLC26A4_HUMAN,D724V,0.908,Altered Metal binding (Pr = 0.06 | P = 0.03), ELME000134|ELME000220|PS00006,-
SLC26A4_HUMAN,G334A,0.856,Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03), ELME000146,-
SLC26A4_HUMAN,Y728H,0.111,-,-,-
SLC26A4_HUMAN,V422D,0.856,Gain of Intrinsic disorder (Pr = 0.37 | P = 0.01); Altered Ordered interface (Pr = 0.30 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q421 (Pr = 0.21 | P = 1.7e-03); Gain of Ubiquitylation at K419 (Pr = 0.18 | P = 0.02); Loss of Methylation at K419 (Pr = 0.15 | P = 0.02), ELME000202,-
SLC26A4_HUMAN,Q413P,0.914,Loss of Pyrrolidone carboxylic acid at Q413 (Pr = 0.05 | P = 0.04), ELME000053|ELME000117,-
SLC26A4_HUMAN,I491T,0.535,Altered Transmembrane protein (Pr = 0.17 | P = 0.01), ELME000333|ELME000335,-
SLC26A4_HUMAN,S391N,0.777,Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000053|ELME000197|ELME000336,-
SLC26A4_HUMAN,L50R,0.719,Gain of Intrinsic disorder (Pr = 0.43 | P = 5.5e-03); Altered Disordered interface (Pr = 0.25 | P = 0.02), ELME000276|ELME000336,-
SLC26A4_HUMAN,P142L,0.765,Gain of Helix (Pr = 0.33 | P = 1.9e-03); Loss of Strand (Pr = 0.32 | P = 4.9e-04), ELME000141|ELME000148|ELME000239|ELME000333|ELME000336,-
MYO7A_HUMAN,I589V,0.104,-,-,-
MYO7A_HUMAN,A595V,0.282,-,-,-
MYO7A_HUMAN,M599C,0.477,-,-,-
MYO7A_HUMAN,K605Q,0.517,Gain of ADP-ribosylation at R604 (Pr = 0.20 | P = 0.03); Loss of SUMOylation at K605 (Pr = 0.19 | P = 0.04); Loss of Ubiquitylation at K605 (Pr = 0.17 | P = 0.02), ELME000053|ELME000061|ELME000100|ELME000102|ELME000108|ELME000136|ELME000159|ELME000278|PS00004|PS00005,-
MYO7A_HUMAN,M622R,0.943,, ELME000012|ELME000062|ELME000102|ELME000108|ELME000125|ELME000331|ELME000336,-
MYO7A_HUMAN,A627S,0.274,-,-,-
MYO7A_HUMAN,E680Q,0.648,Loss of Allosteric site at R675 (Pr = 0.28 | P = 7.8e-03); Altered DNA binding (Pr = 0.21 | P = 0.02); Altered Disordered interface (Pr = 0.16 | P = 0.05), ELME000062|ELME000064|PS00006,-
MYO7A_HUMAN,G699N,0.261,-,-,-
MYO7A_HUMAN,R707H,0.201,-,-,-
MYO7A_HUMAN,M708I,0.234,-,-,-
MYO7A_HUMAN,M708L,0.445,-,-,-
MYO7A_HUMAN,T715A,0.268,-,-,-
MYO7A_HUMAN,D746N,0.529,Altered Disordered interface (Pr = 0.16 | P = 0.05); Altered DNA binding (Pr = 0.15 | P = 0.05), ELME000052|ELME000134|ELME000146|ELME000149|ELME000173|PS00005,-
MYO7A_HUMAN,V754I,0.184,-,-,-
MYO7A_HUMAN,N763H,0.311,-,-,-
MYO7A_HUMAN,N782S,0.219,-,-,-
MYO7A_HUMAN,N782Y,0.516,Altered DNA binding (Pr = 0.32 | P = 1.5e-03); Altered Disordered interface (Pr = 0.25 | P = 0.02); Altered Metal binding (Pr = 0.04 | P = 0.05), ELME000080|ELME000134|ELME000182,-
MYO7A_HUMAN,M790V,0.469,-,-,-
MYO7A_HUMAN,L792V,0.136,-,-,-
MYO7A_HUMAN,G793C,0.922,Altered Disordered interface (Pr = 0.29 | P = 0.01); Altered DNA binding (Pr = 0.26 | P = 6.7e-03), ELME000137,-
MYO7A_HUMAN,H801Q,0.221,-,-,-
MYO7A_HUMAN,R802Q,0.723,Altered Disordered interface (Pr = 0.45 | P = 4.4e-03); Altered DNA binding (Pr = 0.25 | P = 9.6e-03); Altered Coiled coil (Pr = 0.16 | P = 0.02), ELME000336,-
MYO7A_HUMAN,S803G,0.387,-,-,-
MYO7A_HUMAN,Q808E,0.149,-,-,-
MYO7A_HUMAN,Q808L,0.176,-,-,-
MYO7A_HUMAN,A813P,0.512,Altered Disordered interface (Pr = 0.45 | P = 4.6e-03); Altered Coiled coil (Pr = 0.14 | P = 0.03), ELME000012|ELME000233,-
MYO7A_HUMAN,F820L,0.364,-,-,-
MYO7A_HUMAN,L841F,0.275,-,-,-
MYO7A_HUMAN,W865R,0.038,-,-,-
MYO7A_HUMAN,E878Q,0.265,-,-,-
MYO7A_HUMAN,K887R,0.169,-,-,-
MYO7A_HUMAN,E910A,0.458,-,-,-
MYO7A_HUMAN,K914R,0.128,-,-,-
MYO7A_HUMAN,A919S,0.088,-,-,-
MYO7A_HUMAN,R921K,0.145,-,-,-
MYO7A_HUMAN,H934Q,0.077,-,-,-
MYO7A_HUMAN,T952I,0.208,-,-,-
MYO7A_HUMAN,S953P,0.396,-,-,-
MYO7A_HUMAN,R972H,0.083,-,-,-
MYO7A_HUMAN,L982V,0.055,-,-,-
MYO7A_HUMAN,T1018N,0.166,-,-,-
MYO7A_HUMAN,Y1028F,0.094,-,-,-
MYO7A_HUMAN,D1030E,0.133,-,-,-
MYO7A_HUMAN,K1056R,0.213,-,-,-
MYO7A_HUMAN,D1063N,0.347,-,-,-
MYO7A_HUMAN,K1080R,0.304,-,-,-
MYO7A_HUMAN,A1096T,0.071,-,-,-
MYO7A_HUMAN,P1099T,0.158,-,-,-
MYO7A_HUMAN,S1105T,0.087,-,-,-
MYO7A_HUMAN,E1124G,0.655,Altered Disordered interface (Pr = 0.35 | P = 5.5e-03); Loss of Helix (Pr = 0.28 | P = 0.02); Gain of Acetylation at K1128 (Pr = 0.24 | P = 0.01), ELME000052|ELME000053|ELME000063,-
MYO7A_HUMAN,V1137M,0.208,-,-,-
MYO7A_HUMAN,A1166G,0.376,-,-,-
MYO7A_HUMAN,I1171V,0.413,-,-,-
MYO7A_HUMAN,V1195M,0.221,-,-,-
MYO7A_HUMAN,Y1211F,0.369,-,-,-
MYO7A_HUMAN,E1248H,0.855,, ELME000064|PS00006,-
MYO7A_HUMAN,R1296H,0.476,-,-,-
MYO7A_HUMAN,S1356N,0.08,-,-,-
MYO7A_HUMAN,I1405V,0.104,-,-,-
MYO7A_HUMAN,N1411S,0.138,-,-,-
MYO7A_HUMAN,Y1477F,0.155,-,-,-
MYO7A_HUMAN,S1483H,0.471,-,-,-
MYO7A_HUMAN,N1487S,0.272,-,-,-
MYO7A_HUMAN,V1498I,0.537,Altered Transmembrane protein (Pr = 0.17 | P = 9.8e-03); Gain of N-linked glycosylation at N1494 (Pr = 0.03 | P = 0.03), ELME000070|ELME000080,-
MYO7A_HUMAN,M1517T,0.42,-,-,-
MYO7A_HUMAN,V1519M,0.561,Altered Stability (Pr = 0.13 | P = 0.03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000064|ELME000239|ELME000336,-
MYO7A_HUMAN,C1533A,0.704,, ELME000007|ELME000053,-
MYO7A_HUMAN,D1535E,0.488,-,-,-
MYO7A_HUMAN,D1535G,0.628,, ELME000007|ELME000085|ELME000336|PS00008,-
MYO7A_HUMAN,P1541C,0.257,-,-,-
MYO7A_HUMAN,P1541T,0.218,-,-,-
MYO7A_HUMAN,T1549S,0.128,-,-,-
MYO7A_HUMAN,A1551P,0.482,-,-,-
MYO7A_HUMAN,P1556S,0.418,-,-,-
MYO7A_HUMAN,C1560S,0.249,-,-,-
MYO7A_HUMAN,A1563T,0.087,-,-,-
MYO7A_HUMAN,A1563V,0.09,-,-,-
MYO7A_HUMAN,T1565L,0.087,-,-,-
MYO7A_HUMAN,T1566A,0.102,-,-,-
MYO7A_HUMAN,T1566M,0.085,-,-,-
MYO7A_HUMAN,T1574A,0.578,Altered Transmembrane protein (Pr = 0.21 | P = 3.6e-03); Altered Stability (Pr = 0.19 | P = 0.01), PS00005,-
MYO7A_HUMAN,S1585T,0.299,-,-,-
MYO7A_HUMAN,K1603R,0.251,-,-,-
MYO7A_HUMAN,I1634V,0.1,-,-,-
MYO7A_HUMAN,H1637R,0.374,-,-,-
MYO7A_HUMAN,Q1642H,0.252,-,-,-
MYO7A_HUMAN,V1684I,0.133,-,-,-
MYO7A_HUMAN,V1694M,0.15,-,-,-
MYO7A_HUMAN,L1697F,0.173,-,-,-
MYO7A_HUMAN,R1701Q,0.118,-,-,-
MYO7A_HUMAN,A1709T,0.066,-,-,-
MYO7A_HUMAN,F1722V,0.771,Gain of Phosphorylation at Y1721 (Pr = 0.29 | P = 0.02); Loss of Sulfation at Y1721 (Pr = 0.05 | P = 9.2e-03), ELME000081|ELME000083|ELME000120|ELME000155|ELME000182,-
MYO7A_HUMAN,S1731A,0.41,-,-,-
MYO7A_HUMAN,R1732G,0.765,Altered Disordered interface (Pr = 0.52 | P = 2.1e-03); Loss of Helix (Pr = 0.28 | P = 0.03), ELME000085|PS00008,-
MYO7A_HUMAN,V1733A,0.331,-,-,-
MYO7A_HUMAN,M1734G,0.702,Altered Disordered interface (Pr = 0.30 | P = 0.01); Gain of Intrinsic disorder (Pr = 0.30 | P = 0.05); Loss of Helix (Pr = 0.28 | P = 0.03); Altered Stability (Pr = 0.17 | P = 0.02), PS00008,-
MYO7A_HUMAN,S1736R,0.267,-,-,-
MYO7A_HUMAN,K1737E,0.496,-,-,-
MYO7A_HUMAN,D1742A,0.578,Altered Disordered interface (Pr = 0.43 | P = 2.6e-03); Loss of Proteolytic cleavage at W1745 (Pr = 0.12 | P = 0.04), None,-
COL2A1_HUMAN,A1253E,0.432,-,-,-
COL2A1_HUMAN,I1269L,0.302,-,-,-
COL2A1_HUMAN,K1287Q,0.685,Altered Transmembrane protein (Pr = 0.20 | P = 5.9e-03); Loss of Disulfide linkage at C1283 (Pr = 0.14 | P = 0.04), ELME000106|ELME000146,-
COL2A1_HUMAN,W1293F,0.878,Altered Ordered interface (Pr = 0.24 | P = 0.04); Altered Transmembrane protein (Pr = 0.11 | P = 0.03); Loss of Sulfation at Y1298 (Pr = 0.05 | P = 8.8e-03), None,-
COL2A1_HUMAN,S1295T,0.804,Altered Transmembrane protein (Pr = 0.10 | P = 0.05); Loss of Catalytic site at W1299 (Pr = 0.10 | P = 0.04); Gain of Sulfation at Y1298 (Pr = 0.05 | P = 8.1e-03), ELME000085,-
COL2A1_HUMAN,D1301E,0.871,Altered Metal binding (Pr = 0.26 | P = 0.01); Gain of Catalytic site at D1301 (Pr = 0.25 | P = 4.3e-03); Gain of Disulfide linkage at C1306 (Pr = 0.23 | P = 0.01); Altered Transmembrane protein (Pr = 0.15 | P = 0.02); Loss of Sulfation at Y1298 (Pr = 0.05 | P = 8.7e-03), None,-
COL2A1_HUMAN,E1321Q,0.728,Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Transmembrane protein (Pr = 0.27 | P = 6.5e-04); Loss of Disulfide linkage at C1323 (Pr = 0.24 | P = 7.7e-03); Altered Metal binding (Pr = 0.10 | P = 0.05), None,-
COL2A1_HUMAN,S1338G,0.396,-,-,-
COL2A1_HUMAN,K1342Q,0.459,-,-,-
COL2A1_HUMAN,K1344R,0.163,-,-,-
COL2A1_HUMAN,K1345Q,0.555,Loss of B-factor (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.25 | P = 1.6e-03), ELME000137|ELME000233,-
COL2A1_HUMAN,I1353V,0.314,-,-,-
COL2A1_HUMAN,D1364S,0.347,-,-,-
COL2A1_HUMAN,N1365H,0.24,-,-,-
COL2A1_HUMAN,N1395D,0.901,Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Transmembrane protein (Pr = 0.26 | P = 1.0e-03); Altered Metal binding (Pr = 0.19 | P = 0.04); Loss of Disulfide linkage at C1393 (Pr = 0.11 | P = 0.05); Gain of Catalytic site at Y1391 (Pr = 0.10 | P = 0.04), ELME000313,-
COL2A1_HUMAN,I1413L,0.326,-,-,-
COL2A1_HUMAN,A1433V,0.149,-,-,-
COL2A1_HUMAN,K1440R,0.393,-,-,-
COL2A1_HUMAN,K1447N,0.681,Altered Ordered interface (Pr = 0.35 | P = 3.6e-03); Altered Transmembrane protein (Pr = 0.32 | P = 7.8e-05); Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.02); Loss of Acetylation at K1447 (Pr = 0.25 | P = 0.01); Altered Metal binding (Pr = 0.20 | P = 0.04), ELME000064|ELME000220,-
COL2A1_HUMAN,V1449T,0.62,Altered Ordered interface (Pr = 0.36 | P = 3.6e-03); Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.26 | P = 7.3e-04); Altered Stability (Pr = 0.20 | P = 0.01); Loss of Acetylation at K1444 (Pr = 0.19 | P = 0.05), ELME000064|ELME000220|PS00006,-
COL2A1_HUMAN,I1463M,0.51,Altered Disordered interface (Pr = 0.40 | P = 4.5e-03); Loss of Catalytic site at D1464 (Pr = 0.33 | P = 1.2e-03); Altered Metal binding (Pr = 0.31 | P = 2.7e-03); Altered Transmembrane protein (Pr = 0.29 | P = 2.5e-04); Altered Ordered interface (Pr = 0.29 | P = 0.03); Loss of Strand (Pr = 0.27 | P = 0.02); Gain of Allosteric site at D1464 (Pr = 0.27 | P = 6.3e-03); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03), ELME000237|ELME000333,-
COL2A1_HUMAN,I1463V,0.167,-,-,-
COL2A1_HUMAN,G1200D,0.954,Gain of Loop (Pr = 0.29 | P = 0.01); Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of Hydroxylation at P1205 (Pr = 0.01 | P = 2.9e-05), ELME000155,-
COL2A1_HUMAN,G546V,0.958,Altered Disordered interface (Pr = 0.30 | P = 0.03); Loss of B-factor (Pr = 0.30 | P = 8.8e-03); Loss of Methylation at K542 (Pr = 0.29 | P = 7.2e-04); Gain of Acetylation at K542 (Pr = 0.24 | P = 0.01); Gain of SUMOylation at K542 (Pr = 0.19 | P = 0.04); Loss of Ubiquitylation at K542 (Pr = 0.17 | P = 0.02), ELME000155,-
COL2A1_HUMAN,G717S,0.956,Loss of Methylation at R719 (Pr = 0.14 | P = 0.02), ELME000136|ELME000159|PS00005,-
COL2A1_HUMAN,G504C,0.962,Altered Disordered interface (Pr = 0.32 | P = 0.02); Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Methylation at R509 (Pr = 0.12 | P = 0.03), ELME000155,-
COL2A1_HUMAN,G405D,0.958,Gain of Loop (Pr = 0.28 | P = 0.01); Loss of O-linked glycosylation at S407 (Pr = 0.13 | P = 0.04); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000085|ELME000239|ELME000293,-
COL2A1_HUMAN,G870E,0.955,Loss of O-linked glycosylation at S869 (Pr = 0.13 | P = 0.04); Altered Metal binding (Pr = 0.11 | P = 0.04); Altered Transmembrane protein (Pr = 0.10 | P = 0.05), ELME000085,-
COL2A1_HUMAN,Y1298N,0.953,Altered Ordered interface (Pr = 0.34 | P = 5.5e-03); Loss of Loop (Pr = 0.27 | P = 0.04); Altered Metal binding (Pr = 0.23 | P = 0.02); Loss of Catalytic site at D1301 (Pr = 0.17 | P = 0.02); Altered Transmembrane protein (Pr = 0.10 | P = 0.05); Loss of Sulfation at Y1298 (Pr = 0.05 | P = 8.2e-03), None,-
COL2A1_HUMAN,G1008V,0.963,Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Methylation at K1006 (Pr = 0.26 | P = 1.5e-03); Gain of Acetylation at K1006 (Pr = 0.24 | P = 0.01); Gain of O-linked glycosylation at S1013 (Pr = 0.16 | P = 0.03); Gain of Ubiquitylation at K1006 (Pr = 0.15 | P = 0.05), PS00008,-
COL2A1_HUMAN,G936D,0.967,Gain of Loop (Pr = 0.29 | P = 1.0e-02); Gain of B-factor (Pr = 0.25 | P = 0.03); Loss of O-linked glycosylation at S935 (Pr = 0.24 | P = 0.01); Loss of Methylation at R932 (Pr = 0.21 | P = 5.9e-03), ELME000048|ELME000085,-
COL2A1_HUMAN,G609V,0.971,Altered Disordered interface (Pr = 0.30 | P = 0.02); Loss of B-factor (Pr = 0.30 | P = 8.8e-03); Gain of Acetylation at K608 (Pr = 0.24 | P = 0.02); Loss of Methylation at K608 (Pr = 0.23 | P = 3.5e-03); Gain of SUMOylation at K608 (Pr = 0.21 | P = 0.03); Gain of Ubiquitylation at K608 (Pr = 0.16 | P = 0.04), None,-
COL2A1_HUMAN,T1448P,0.924,Gain of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered Transmembrane protein (Pr = 0.28 | P = 6.5e-04); Altered Ordered interface (Pr = 0.28 | P = 0.04); Gain of Acetylation at K1447 (Pr = 0.21 | P = 0.03), ELME000064|ELME000220|PS00006,-
COL2A1_HUMAN,G204A,0.919,Gain of Loop (Pr = 0.30 | P = 4.8e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Methylation at R209 (Pr = 0.25 | P = 1.9e-03), ELME000155,-
COL2A1_HUMAN,G513S,0.962,Altered Disordered interface (Pr = 0.28 | P = 0.03); Loss of Methylation at R515 (Pr = 0.20 | P = 6.3e-03), PS00005|PS00008,-
COL2A1_HUMAN,R1379C,0.865,Altered Ordered interface (Pr = 0.46 | P = 1.9e-04); Altered Transmembrane protein (Pr = 0.19 | P = 6.7e-03), ELME000053|ELME000173|ELME000333,-
COL2A1_HUMAN,G426R,0.969,Altered Disordered interface (Pr = 0.32 | P = 0.01); Gain of Methylation at G426 (Pr = 0.10 | P = 0.04), None,-
COL2A1_HUMAN,T455M,0.176,-,-,-
COL2A1_HUMAN,G375D,0.966,Gain of Loop (Pr = 0.29 | P = 7.2e-03); Loss of Methylation at K374 (Pr = 0.26 | P = 1.5e-03); Loss of Acetylation at K374 (Pr = 0.21 | P = 0.04); Gain of Ubiquitylation at K374 (Pr = 0.21 | P = 5.6e-03); Gain of O-linked glycosylation at T380 (Pr = 0.11 | P = 0.05), ELME000002,-
COL2A1_HUMAN,G438S,0.958,Gain of Loop (Pr = 0.30 | P = 4.7e-03); Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Methylation at R437 (Pr = 0.18 | P = 8.9e-03), ELME000136|ELME000155|ELME000159,-
COL2A1_HUMAN,G303D,0.933,Loss of Methylation at K308 (Pr = 0.29 | P = 7.2e-04); Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Acetylation at K308 (Pr = 0.27 | P = 7.3e-03); Gain of SUMOylation at K308 (Pr = 0.27 | P = 4.6e-03); Gain of Ubiquitylation at K299 (Pr = 0.20 | P = 8.6e-03), ELME000293,-
COL2A1_HUMAN,G537S,0.935,Loss of Methylation at K542 (Pr = 0.27 | P = 1.4e-03); Loss of Acetylation at K542 (Pr = 0.24 | P = 0.02); Loss of SUMOylation at K542 (Pr = 0.19 | P = 0.04); Loss of Ubiquitylation at K542 (Pr = 0.17 | P = 0.02), ELME000051|ELME000085,-
COL2A1_HUMAN,G801S,0.952,Loss of Methylation at K803 (Pr = 0.27 | P = 1.2e-03); Loss of B-factor (Pr = 0.25 | P = 0.05); Loss of Acetylation at K803 (Pr = 0.24 | P = 0.02); Loss of SUMOylation at K803 (Pr = 0.24 | P = 0.01); Altered Metal binding (Pr = 0.20 | P = 9.1e-03); Loss of Ubiquitylation at K803 (Pr = 0.16 | P = 0.03), PS00005,-
COL2A1_HUMAN,G204V,0.954,Loss of Methylation at R209 (Pr = 0.31 | P = 4.7e-04); Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of Loop (Pr = 0.28 | P = 0.02), ELME000155,-
COL2A1_HUMAN,G231D,0.96,Gain of Loop (Pr = 0.30 | P = 4.3e-03); Loss of B-factor (Pr = 0.26 | P = 0.03); Loss of O-linked glycosylation at S236 (Pr = 0.12 | P = 0.05), ELME000133,-
COL2A1_HUMAN,G1170S,0.944,Gain of Phosphorylation at G1170 (Pr = 0.38 | P = 7.0e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of Acetylation at K1174 (Pr = 0.24 | P = 0.01); Loss of Methylation at K1174 (Pr = 0.24 | P = 2.7e-03); Loss of SUMOylation at K1174 (Pr = 0.19 | P = 0.04); Loss of Ubiquitylation at K1174 (Pr = 0.17 | P = 0.02), ELME000136|ELME000159,-
COL2A1_HUMAN,G489D,0.973,Loss of Acetylation at K490 (Pr = 0.34 | P = 2.4e-03); Gain of Loop (Pr = 0.27 | P = 0.03); Gain of SUMOylation at K490 (Pr = 0.27 | P = 4.6e-03); Loss of Methylation at K490 (Pr = 0.26 | P = 1.4e-03); Gain of Ubiquitylation at K490 (Pr = 0.15 | P = 0.04), ELME000093|PS00009,-
COL2A1_HUMAN,G981S,0.962,Altered Disordered interface (Pr = 0.28 | P = 0.04); Gain of Loop (Pr = 0.27 | P = 0.03); Gain of Proteolytic cleavage at R980 (Pr = 0.15 | P = 0.01); Loss of Methylation at R980 (Pr = 0.11 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q979 (Pr = 0.05 | P = 0.04), ELME000155|ELME000335,-
COL2A1_HUMAN,G687D,0.971,Gain of Loop (Pr = 0.27 | P = 0.04); Altered Metal binding (Pr = 0.10 | P = 0.05), None,-
COL2A1_HUMAN,G822C,0.966,Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Methylation at R818 (Pr = 0.20 | P = 7.0e-03), ELME000133,-
COL2A1_HUMAN,G771D,0.972,Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Acetylation at K773 (Pr = 0.25 | P = 0.01); Loss of Methylation at K773 (Pr = 0.25 | P = 1.9e-03); Altered Metal binding (Pr = 0.22 | P = 0.03); Gain of SUMOylation at K773 (Pr = 0.21 | P = 0.03); Gain of Ubiquitylation at K773 (Pr = 0.19 | P = 0.01), None,-
COL2A1_HUMAN,G672S,0.917,Gain of Loop (Pr = 0.29 | P = 0.01); Loss of B-factor (Pr = 0.28 | P = 0.02), ELME000136|ELME000159,-
COL2A1_HUMAN,R1036G,0.729,Gain of B-factor (Pr = 0.32 | P = 8.9e-04); Altered Metal binding (Pr = 0.10 | P = 0.05), ELME000136|ELME000159,-
COL2A1_HUMAN,G1128R,0.962,Gain of SUMOylation at K1130 (Pr = 0.26 | P = 5.7e-03); Loss of Acetylation at K1130 (Pr = 0.19 | P = 0.05); Loss of Methylation at K1130 (Pr = 0.12 | P = 0.03), ELME000012|ELME000102|ELME000108|ELME000146,-
COL2A1_HUMAN,G945S,0.924,Loss of Methylation at R940 (Pr = 0.10 | P = 0.04), ELME000147,-
COL2A1_HUMAN,G1089R,0.961,Altered Disordered interface (Pr = 0.26 | P = 0.05); Loss of Methylation at R1088 (Pr = 0.23 | P = 3.7e-03); Gain of Acetylation at K1084 (Pr = 0.21 | P = 0.03); Loss of SUMOylation at K1084 (Pr = 0.20 | P = 0.04); Loss of Ubiquitylation at K1084 (Pr = 0.16 | P = 0.04), ELME000102|ELME000108,-
COL2A1_HUMAN,G450D,0.966,Gain of Loop (Pr = 0.27 | P = 0.02); Loss of Methylation at K452 (Pr = 0.24 | P = 2.5e-03); Loss of SUMOylation at K452 (Pr = 0.18 | P = 0.05); Gain of Ubiquitylation at K452 (Pr = 0.16 | P = 0.03), ELME000052|ELME000155,-
COL2A1_HUMAN,P329S,0.749,Gain of Loop (Pr = 0.26 | P = 0.05); Loss of Methylation at R326 (Pr = 0.19 | P = 7.3e-03), ELME000085|ELME000106,-
COL2A1_HUMAN,G660E,0.967,Gain of Loop (Pr = 0.29 | P = 7.3e-03); Loss of O-linked glycosylation at S662 (Pr = 0.21 | P = 0.02), ELME000085|ELME000239,-
COL2A1_HUMAN,G453S,0.939,Loss of Methylation at K452 (Pr = 0.24 | P = 3.1e-03); Gain of SUMOylation at K452 (Pr = 0.18 | P = 0.05), ELME000173|ELME000202,-
COL2A1_HUMAN,G732D,0.937,Gain of Loop (Pr = 0.29 | P = 8.7e-03); Loss of Methylation at K731 (Pr = 0.27 | P = 1.4e-03); Loss of Acetylation at K731 (Pr = 0.23 | P = 0.02); Gain of SUMOylation at K731 (Pr = 0.20 | P = 0.03); Gain of Ubiquitylation at K731 (Pr = 0.19 | P = 0.01); Loss of O-linked glycosylation at T727 (Pr = 0.12 | P = 0.05); Altered Metal binding (Pr = 0.10 | P = 0.04), ELME000085|ELME000293,-
COL2A1_HUMAN,G1119R,0.951,Loss of Loop (Pr = 0.30 | P = 6.7e-03); Gain of SUMOylation at K1118 (Pr = 0.28 | P = 4.3e-03); Loss of B-factor (Pr = 0.27 | P = 0.02); Loss of Methylation at K1118 (Pr = 0.21 | P = 5.7e-03); Loss of Ubiquitylation at K1118 (Pr = 0.15 | P = 0.05), ELME000100|ELME000108,-
COL2A1_HUMAN,G492D,0.964,Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Acetylation at K490 (Pr = 0.27 | P = 7.7e-03); Loss of Methylation at K490 (Pr = 0.26 | P = 1.4e-03); Loss of SUMOylation at K490 (Pr = 0.25 | P = 9.6e-03), ELME000100|ELME000108|ELME000293,-
COL2A1_HUMAN,G477V,0.956,Loss of B-factor (Pr = 0.30 | P = 0.01), ELME000155,-
COL2A1_HUMAN,A559G,0.62,Gain of B-factor (Pr = 0.27 | P = 0.01); Gain of Methylation at R560 (Pr = 0.16 | P = 0.01), PS00008,-
COL2A1_HUMAN,G1068E,0.95,Loss of B-factor (Pr = 0.26 | P = 0.04), None,-
COL2A1_HUMAN,G411R,0.97,Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of Loop (Pr = 0.27 | P = 0.03); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of O-linked glycosylation at S407 (Pr = 0.13 | P = 0.04); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000052|PS00008,-
COL2A1_HUMAN,G402E,0.953,Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of O-linked glycosylation at S407 (Pr = 0.14 | P = 0.03), None,-
COL2A1_HUMAN,G447S,0.951,Loss of Methylation at K452 (Pr = 0.24 | P = 2.7e-03); Loss of SUMOylation at K452 (Pr = 0.18 | P = 0.05), ELME000052|ELME000136|ELME000155|ELME000159,-
COL2A1_HUMAN,G600V,0.97,Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of Methylation at R596 (Pr = 0.17 | P = 0.01); Gain of Pyrrolidone carboxylic acid at Q598 (Pr = 0.10 | P = 0.01), None,-
COL2A1_HUMAN,G276D,0.971,Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Methylation at R275 (Pr = 0.14 | P = 0.02), ELME000005|ELME000155,-
COL2A1_HUMAN,G684R,0.962,Loss of Methylation at K679 (Pr = 0.27 | P = 1.3e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of Acetylation at K679 (Pr = 0.26 | P = 9.2e-03); Gain of SUMOylation at K679 (Pr = 0.21 | P = 0.03), ELME000156,-
COL2A1_HUMAN,G657R,0.949,Loss of Loop (Pr = 0.28 | P = 0.02); Loss of B-factor (Pr = 0.26 | P = 0.05); Gain of O-linked glycosylation at S662 (Pr = 0.20 | P = 0.02); Gain of Methylation at R653 (Pr = 0.15 | P = 0.01), None,-
COL2A1_HUMAN,D1469H,0.938,Altered Metal binding (Pr = 0.43 | P = 1.9e-03); Altered Transmembrane protein (Pr = 0.32 | P = 6.3e-05); Altered Disordered interface (Pr = 0.30 | P = 0.02); Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Strand (Pr = 0.27 | P = 0.03); Loss of Catalytic site at D1464 (Pr = 0.27 | P = 3.3e-03); Gain of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Gain of Allosteric site at D1464 (Pr = 0.21 | P = 0.03), None,-
COL2A1_HUMAN,G822S,0.948,Gain of Methylation at R818 (Pr = 0.19 | P = 6.3e-03), ELME000133|PS00005,-
COL2A1_HUMAN,R137C,0.563,Gain of Loop (Pr = 0.32 | P = 2.1e-03); Loss of Acetylation at K140 (Pr = 0.29 | P = 5.3e-03); Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Methylation at K140 (Pr = 0.27 | P = 1.2e-03); Loss of SUMOylation at K140 (Pr = 0.27 | P = 5.6e-03), PS00016,-
COL2A1_HUMAN,G1176S,0.942,Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of Acetylation at K1174 (Pr = 0.26 | P = 9.4e-03); Loss of Methylation at K1174 (Pr = 0.24 | P = 2.7e-03); Loss of SUMOylation at K1174 (Pr = 0.19 | P = 0.04); Gain of Ubiquitylation at K1174 (Pr = 0.18 | P = 0.02), ELME000053|ELME000085|ELME000321,-
COL2A1_HUMAN,G483E,0.961,Gain of Loop (Pr = 0.28 | P = 0.02), None,-
COL2A1_HUMAN,G849S,0.933,Loss of Methylation at K848 (Pr = 0.28 | P = 1.1e-03); Loss of Acetylation at K848 (Pr = 0.25 | P = 0.01); Loss of Ubiquitylation at K848 (Pr = 0.15 | P = 0.04); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000002,-
COL2A1_HUMAN,G1443S,0.731,Altered Ordered interface (Pr = 0.29 | P = 0.02); Gain of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Gain of Disulfide linkage at C1438 (Pr = 0.29 | P = 8.3e-04); Altered Metal binding (Pr = 0.28 | P = 6.1e-03); Altered Transmembrane protein (Pr = 0.28 | P = 5.8e-04); Loss of Acetylation at K1444 (Pr = 0.21 | P = 0.03); Altered DNA binding (Pr = 0.17 | P = 0.03); Gain of Catalytic site at C1438 (Pr = 0.08 | P = 0.05), ELME000053|PS00005,-
COL2A1_HUMAN,M1R,0.96,Loss of N-terminal acetylation at M1 (Pr = 0.08 | P = 2.4e-03); Altered Signal peptide (Pr = 0.07 | P = 2.8e-03), ELME000012|ELME000351|ELME000355,-
COL2A1_HUMAN,I2A,0.66,Altered Stability (Pr = 0.37 | P = 3.5e-03); Gain of Helix (Pr = 0.31 | P = 4.7e-03); Altered Signal peptide (Pr = 0.07 | P = 2.8e-03); Loss of N-terminal acetylation at M1 (Pr = 0.07 | P = 2.5e-03), ELME000285|ELME000355,-
COL2A1_HUMAN,I2V,0.24,-,-,-
COL2A1_HUMAN,A6P,0.453,-,-,-
COL2A1_HUMAN,V17A,0.387,-,-,-
COL2A1_HUMAN,A19T,0.448,-,-,-
COL2A1_HUMAN,Q29E,0.479,-,-,-
COL2A1_HUMAN,E30K,0.138,-,-,-
COL2A1_HUMAN,A31T,0.166,-,-,-
COL2A1_HUMAN,A31V,0.189,-,-,-
COL2A1_HUMAN,S33G,0.27,-,-,-
COL2A1_HUMAN,D37E,0.173,-,-,-
COL2A1_HUMAN,D37G,0.411,-,-,-
COL2A1_HUMAN,Q39K,0.567,Altered Transmembrane protein (Pr = 0.23 | P = 2.4e-03); Gain of Disulfide linkage at C34 (Pr = 0.20 | P = 0.02); Loss of Sulfation at Y41 (Pr = 0.01 | P = 0.05), ELME000093|ELME000100|ELME000108|PS00008|PS00009,-
COL2A1_HUMAN,R40M,0.457,-,-,-
COL2A1_HUMAN,N42D,0.331,-,-,-
COL2A1_HUMAN,D43N,0.723,Loss of Loop (Pr = 0.27 | P = 0.05); Altered Transmembrane protein (Pr = 0.23 | P = 2.8e-03); Loss of SUMOylation at K48 (Pr = 0.20 | P = 0.04); Loss of Sulfation at Y41 (Pr = 0.01 | P = 0.05), ELME000084|ELME000155|PS00008,-
COL2A1_HUMAN,K44N,0.711,Altered Transmembrane protein (Pr = 0.23 | P = 2.3e-03); Loss of SUMOylation at K48 (Pr = 0.20 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q39 (Pr = 0.05 | P = 0.04); Gain of Sulfation at Y41 (Pr = 0.01 | P = 0.05), ELME000155,-
COL2A1_HUMAN,E50T,0.696,Loss of SUMOylation at K48 (Pr = 0.24 | P = 0.01); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000136|ELME000153|ELME000159,-
COL2A1_HUMAN,P51T,0.489,-,-,-
COL4A3_HUMAN,R873K,0.027,-,-,-
COL4A3_HUMAN,D888G,0.318,-,-,-
COL4A3_HUMAN,A963T,0.043,-,-,-
COL4A3_HUMAN,P1008L,0.272,-,-,-
COL4A3_HUMAN,M1020R,0.415,-,-,-
COL4A3_HUMAN,P1132S,0.062,-,-,-
COL4A3_HUMAN,P1142I,0.637,Altered Disordered interface (Pr = 0.32 | P = 0.02); Loss of B-factor (Pr = 0.27 | P = 0.03), ELME000005|ELME000155|ELME000340,-
COL4A3_HUMAN,F1144D,0.388,-,-,-
COL4A3_HUMAN,R1241H,0.12,-,-,-
COL4A3_HUMAN,I1264T,0.079,-,-,-
COL4A3_HUMAN,K1279Q,0.186,-,-,-
COL4A3_HUMAN,V1344I,0.025,-,-,-
COL4A3_HUMAN,Q1480E,0.042,-,-,-
COL4A3_HUMAN,I1575V,0.05,-,-,-
COL4A3_HUMAN,F1586K,0.903,Altered Transmembrane protein (Pr = 0.36 | P = 1.5e-05); Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Stability (Pr = 0.22 | P = 0.01), ELME000053|ELME000336,-
COL4A3_HUMAN,L1614I,0.048,-,-,-
COL4A3_HUMAN,N1627R,0.846,Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Transmembrane protein (Pr = 0.28 | P = 4.5e-04); Altered DNA binding (Pr = 0.27 | P = 6.1e-03); Altered Metal binding (Pr = 0.25 | P = 0.03); Loss of Disulfide linkage at C1622 (Pr = 0.20 | P = 0.02), ELME000053|ELME000084|ELME000197,-
COL4A3_HUMAN,S1628K,0.829,Altered Transmembrane protein (Pr = 0.33 | P = 6.8e-05); Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Helix (Pr = 0.28 | P = 0.03); Loss of Strand (Pr = 0.27 | P = 0.02); Altered DNA binding (Pr = 0.26 | P = 7.3e-03); Altered Metal binding (Pr = 0.25 | P = 0.01); Gain of Acetylation at S1628 (Pr = 0.22 | P = 0.03), ELME000053|ELME000084|ELME000197|PS00005,-
COL4A3_HUMAN,S1630N,0.785,Altered Ordered interface (Pr = 0.31 | P = 0.01); Altered Transmembrane protein (Pr = 0.30 | P = 1.9e-04); Gain of Helix (Pr = 0.28 | P = 0.03); Loss of Strand (Pr = 0.26 | P = 0.04); Altered DNA binding (Pr = 0.26 | P = 6.8e-03); Altered Metal binding (Pr = 0.24 | P = 0.02), ELME000053|ELME000197,-
COL4A3_HUMAN,W1632S,0.952,Altered Transmembrane protein (Pr = 0.33 | P = 4.9e-05); Altered Ordered interface (Pr = 0.31 | P = 0.02); Altered DNA binding (Pr = 0.30 | P = 2.6e-03); Gain of Helix (Pr = 0.29 | P = 0.01); Loss of Strand (Pr = 0.26 | P = 0.05); Altered Metal binding (Pr = 0.25 | P = 0.01); Altered Stability (Pr = 0.15 | P = 0.02), ELME000063,-
COL4A3_HUMAN,N1637H,0.211,-,-,-
COL4A3_HUMAN,R1643K,0.249,-,-,-
COL4A3_HUMAN,K1644L,0.715,Altered Transmembrane protein (Pr = 0.31 | P = 1.2e-04); Altered Ordered interface (Pr = 0.29 | P = 0.03); Loss of SUMOylation at K1644 (Pr = 0.21 | P = 0.03), ELME000102,-
COL4A3_HUMAN,E1656A,0.405,-,-,-
COL4A3_HUMAN,K1657F,0.426,-,-,-
COL4A3_HUMAN,I1658F,0.314,-,-,-
COL4A3_HUMAN,G1412V,0.933,Loss of B-factor (Pr = 0.34 | P = 1.7e-03); Loss of Methylation at K1408 (Pr = 0.28 | P = 1.1e-03); Gain of Acetylation at K1408 (Pr = 0.26 | P = 7.8e-03); Loss of SUMOylation at K1414 (Pr = 0.26 | P = 6.6e-03), ELME000064|PS00008,-
COL4A3_HUMAN,G532C,0.93,Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Acetylation at K537 (Pr = 0.21 | P = 0.03); Loss of Methylation at K537 (Pr = 0.17 | P = 0.01); Gain of Pyrrolidone carboxylic acid at Q531 (Pr = 0.04 | P = 0.05), None,-
COL4A3_HUMAN,G265E,0.898,Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of Loop (Pr = 0.26 | P = 0.05); Loss of Acetylation at K261 (Pr = 0.26 | P = 0.01); Loss of Methylation at K264 (Pr = 0.22 | P = 4.7e-03); Gain of SUMOylation at K264 (Pr = 0.22 | P = 0.02), None,-
COL4A3_HUMAN,G118R,0.923,Loss of Sulfation at Y117 (Pr = 0.01 | P = 0.05), ELME000120|ELME000155,-
COL4A3_HUMAN,G392E,0.795,Gain of Loop (Pr = 0.28 | P = 0.01); Altered Disordered interface (Pr = 0.23 | P = 0.03); Loss of Proteolytic cleavage at R391 (Pr = 0.14 | P = 0.02), ELME000005|ELME000155,-
COL4A3_HUMAN,G1192E,0.944,Gain of Loop (Pr = 0.30 | P = 6.5e-03); Loss of Acetylation at K1191 (Pr = 0.25 | P = 0.01); Loss of Methylation at K1191 (Pr = 0.25 | P = 2.4e-03); Loss of Ubiquitylation at K1191 (Pr = 0.17 | P = 0.03), None,-
COL4A3_HUMAN,G455C,0.909,Altered Disordered interface (Pr = 0.30 | P = 0.02); Loss of Phosphorylation at Y456 (Pr = 0.26 | P = 0.03); Loss of Sulfation at Y456 (Pr = 0.01 | P = 0.05), None,-
COL4A3_HUMAN,G1155D,0.953,Loss of Methylation at R1154 (Pr = 0.13 | P = 0.02), PS00016,-
COL4A3_HUMAN,C1665Y,0.842,Altered Disordered interface (Pr = 0.50 | P = 4.6e-04); Loss of Intrinsic disorder (Pr = 0.38 | P = 0.03); Altered Metal binding (Pr = 0.33 | P = 0.01); Gain of Strand (Pr = 0.29 | P = 4.6e-03); Altered DNA binding (Pr = 0.23 | P = 9.8e-03), None,-
COL4A3_HUMAN,G1219C,0.934,Altered Disordered interface (Pr = 0.32 | P = 0.01); Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Methylation at R1215 (Pr = 0.18 | P = 9.7e-03), ELME000064|ELME000220|PS00006,-
COL4A3_HUMAN,R1661C,0.803,Altered Metal binding (Pr = 0.58 | P = 3.1e-03); Altered Disordered interface (Pr = 0.36 | P = 9.2e-03); Altered DNA binding (Pr = 0.19 | P = 0.03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), None,-
COL4A3_HUMAN,H495Y,0.183,-,-,-
COL4A3_HUMAN,G777D,0.961,Gain of Loop (Pr = 0.27 | P = 0.03), None,-
COL4A3_HUMAN,G836E,0.92,Gain of SUMOylation at K834 (Pr = 0.31 | P = 2.8e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Acetylation at K838 (Pr = 0.23 | P = 0.02); Loss of Methylation at K838 (Pr = 0.20 | P = 7.0e-03), ELME000048,-
COL4A3_HUMAN,G213R,0.938,Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Acetylation at K215 (Pr = 0.19 | P = 0.05); Gain of SUMOylation at K215 (Pr = 0.19 | P = 0.04); Loss of Methylation at R212 (Pr = 0.18 | P = 9.0e-03), ELME000012|ELME000102|ELME000108|ELME000155,-
COL4A3_HUMAN,P1501Q,0.785,Altered Transmembrane protein (Pr = 0.28 | P = 4.0e-04); Loss of Disulfide linkage at C1505 (Pr = 0.21 | P = 0.02), ELME000048|ELME000062,-
COL4A3_HUMAN,G333A,0.908,Altered Disordered interface (Pr = 0.27 | P = 0.04); Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Acetylation at K332 (Pr = 0.25 | P = 0.01); Altered Metal binding (Pr = 0.19 | P = 0.04); Loss of Methylation at K329 (Pr = 0.17 | P = 0.01), None,-
COL4A3_HUMAN,F1475S,0.697,Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03); Altered Stability (Pr = 0.12 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q1480 (Pr = 0.06 | P = 0.03), ELME000063|ELME000197|ELME000328,-
COL4A3_HUMAN,G1277S,0.904,Loss of B-factor (Pr = 0.27 | P = 0.02); Loss of Methylation at K1279 (Pr = 0.24 | P = 2.7e-03); Loss of SUMOylation at K1279 (Pr = 0.19 | P = 0.04), ELME000136|ELME000155|ELME000159|PS00005,-
COL4A3_HUMAN,G1080A,0.91,Loss of B-factor (Pr = 0.29 | P = 0.02); Loss of Acetylation at K1081 (Pr = 0.29 | P = 4.9e-03); Gain of SUMOylation at K1082 (Pr = 0.26 | P = 6.5e-03); Loss of Methylation at K1081 (Pr = 0.23 | P = 3.8e-03), ELME000093|PS00009,-
COL4A3_HUMAN,G631V,0.943,Gain of O-linked glycosylation at T629 (Pr = 0.19 | P = 0.02), ELME000052|ELME000155|ELME000202|ELME000336,-
COL4A3_HUMAN,G1164C,0.956,Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Acetylation at K1169 (Pr = 0.27 | P = 7.5e-03); Loss of SUMOylation at K1169 (Pr = 0.26 | P = 6.2e-03); Loss of Methylation at K1169 (Pr = 0.20 | P = 7.0e-03); Loss of Ubiquitylation at K1169 (Pr = 0.16 | P = 0.03); Gain of Disulfide linkage at G1164 (Pr = 0.10 | P = 0.05), None,-
COL4A3_HUMAN,G91D,0.952,Gain of Acetylation at K90 (Pr = 0.23 | P = 0.02); Loss of Methylation at K90 (Pr = 0.20 | P = 6.8e-03); Gain of SUMOylation at K90 (Pr = 0.18 | P = 0.05); Gain of O-linked glycosylation at S96 (Pr = 0.11 | P = 0.05), ELME000336,-
COL4A3_HUMAN,G856E,0.839,Gain of Loop (Pr = 0.27 | P = 0.03); Gain of O-linked glycosylation at T855 (Pr = 0.15 | P = 0.03), ELME000136|ELME000155|ELME000159,-
COL4A3_HUMAN,G43R,0.84,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of SUMOylation at K48 (Pr = 0.24 | P = 0.01); Loss of Acetylation at K45 (Pr = 0.23 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q38 (Pr = 0.19 | P = 2.5e-03); Loss of Methylation at K45 (Pr = 0.14 | P = 0.02), None,-
COL4A3_HUMAN,H451R,0.072,-,-,-
COL4A3_HUMAN,R408H,0.17,-,-,-
COL4A3_HUMAN,P116T,0.584,Gain of Sulfation at Y117 (Pr = 0.01 | P = 0.04), ELME000052,-
COL4A3_HUMAN,K834R,0.072,-,-,-
COL4A3_HUMAN,A24G,0.114,-,-,-
COL4A3_HUMAN,A26T,0.088,-,-,-
COL4A3_HUMAN,A26V,0.089,-,-,-
COL4A3_HUMAN,K51R,0.083,-,-,-
COL4A3_HUMAN,G73I,0.946,Loss of B-factor (Pr = 0.31 | P = 5.8e-03); Loss of Methylation at K78 (Pr = 0.21 | P = 5.3e-03); Gain of Acetylation at K78 (Pr = 0.20 | P = 0.04), ELME000155,-
COL4A3_HUMAN,S126N,0.067,-,-,-
COL4A3_HUMAN,Q132R,0.219,-,-,-
COL4A3_HUMAN,L141P,0.109,-,-,-
COL4A3_HUMAN,P144Q,0.171,-,-,-
COL4A3_HUMAN,P144R,0.332,-,-,-
COL4A3_HUMAN,E269Q,0.062,-,-,-
COL4A3_HUMAN,S310N,0.152,-,-,-
COL4A3_HUMAN,L322I,0.108,-,-,-
COL4A3_HUMAN,M323A,0.119,-,-,-
COL4A3_HUMAN,D355E,0.072,-,-,-
COL4A3_HUMAN,Q531E,0.123,-,-,-
COL4A3_HUMAN,L544H,0.413,-,-,-
COL4A3_HUMAN,V552A,0.038,-,-,-
COL4A3_HUMAN,K565N,0.38,-,-,-
COL4A3_HUMAN,V632A,0.1,-,-,-
COL4A3_HUMAN,P657L,0.157,-,-,-
COL4A3_HUMAN,P669L,0.134,-,-,-
COL4A3_HUMAN,I675M,0.043,-,-,-
COL4A3_HUMAN,M726L,0.07,-,-,-
COL4A3_HUMAN,P861S,0.244,-,-,-
COL4A3_HUMAN,P884L,0.094,-,-,-
COL4A3_HUMAN,Q926R,0.084,-,-,-
COL4A3_HUMAN,E946Q,0.073,-,-,-
COL4A3_HUMAN,D953H,0.208,-,-,-
COL4A3_HUMAN,L999F,0.124,-,-,-
COL4A3_HUMAN,T1002I,0.043,-,-,-
COL4A3_HUMAN,I1126T,0.125,-,-,-
COL4A3_HUMAN,D1156A,0.162,-,-,-
COL4A3_HUMAN,D1211E,0.138,-,-,-
COL4A3_HUMAN,T1238K,0.055,-,-,-
COL4A3_HUMAN,P1244R,0.388,-,-,-
COL4A3_HUMAN,S1246L,0.062,-,-,-
COL4A3_HUMAN,L1294R,0.522,Loss of Loop (Pr = 0.27 | P = 0.02); Gain of B-factor (Pr = 0.26 | P = 0.01); Gain of ADP-ribosylation at L1294 (Pr = 0.19 | P = 0.04); Gain of Methylation at L1294 (Pr = 0.16 | P = 0.01), ELME000005|ELME000093|ELME000097|ELME000102|ELME000108|ELME000155|PS00009,-
COL4A3_HUMAN,K1318T,0.178,-,-,-
COL4A3_HUMAN,I1330T,0.094,-,-,-
COL4A3_HUMAN,G1553A,0.307,-,-,-
COL4A3_HUMAN,T1587A,0.79,Altered Transmembrane protein (Pr = 0.29 | P = 2.5e-04); Altered Stability (Pr = 0.09 | P = 0.05), ELME000053|ELME000085|ELME000336,-
COL4A3_HUMAN,S1626I,0.781,Altered Ordered interface (Pr = 0.32 | P = 0.01); Altered Disordered interface (Pr = 0.29 | P = 0.03); Altered Transmembrane protein (Pr = 0.28 | P = 4.1e-04); Gain of Strand (Pr = 0.28 | P = 0.01); Altered Metal binding (Pr = 0.25 | P = 0.01); Altered DNA binding (Pr = 0.25 | P = 6.2e-03); Gain of Disulfide linkage at C1622 (Pr = 0.22 | P = 0.01), ELME000053|ELME000081|ELME000084|ELME000182,-
COL4A3_HUMAN,A1634S,0.497,-,-,-
COL4A3_HUMAN,G67S,0.919,Loss of Methylation at K63 (Pr = 0.18 | P = 0.01), ELME000064|ELME000136|ELME000146|ELME000159|ELME000220|PS00006,-
COL4A3_HUMAN,K78L,0.816,Gain of Loop (Pr = 0.29 | P = 9.6e-03); Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Methylation at K78 (Pr = 0.27 | P = 1.2e-03); Loss of Acetylation at K78 (Pr = 0.24 | P = 0.02); Loss of SUMOylation at K78 (Pr = 0.19 | P = 0.05), ELME000005|ELME000155,-
COL4A3_HUMAN,F80S,0.07,-,-,-
COL4A3_HUMAN,T87M,0.114,-,-,-
COL4A3_HUMAN,T87R,0.219,-,-,-
COL4A3_HUMAN,S96T,0.035,-,-,-
COL4A3_HUMAN,E162G,0.083,-,-,-
COL4A3_HUMAN,E228D,0.085,-,-,-
COL4A3_HUMAN,M267I,0.063,-,-,-
COL4A3_HUMAN,V304I,0.06,-,-,-
COL4A3_HUMAN,I335T,0.087,-,-,-
COL4A3_HUMAN,T344I,0.302,-,-,-
COL4A3_HUMAN,P417S,0.529,Gain of Loop (Pr = 0.27 | P = 0.03); Gain of O-linked glycosylation at P417 (Pr = 0.18 | P = 0.02), ELME000085|ELME000136|ELME000155|ELME000159|ELME000336|ELME000358,-
COL4A3_HUMAN,D450G,0.217,-,-,-
COL4A3_HUMAN,P639R,0.405,-,-,-
COL4A3_HUMAN,L737V,0.036,-,-,-
COL4A3_HUMAN,P837S,0.145,-,-,-
COL4A3_HUMAN,P903L,0.204,-,-,-
COL4A3_HUMAN,P905S,0.171,-,-,-
COL4A3_HUMAN,T911M,0.043,-,-,-
COL4A3_HUMAN,S917N,0.154,-,-,-
COL4A3_HUMAN,P918L,0.057,-,-,-
COL4A3_HUMAN,S948F,0.126,-,-,-
COL4A3_HUMAN,S1001R,0.106,-,-,-
COL4A3_HUMAN,R1063T,0.186,-,-,-
COL4A3_HUMAN,H1093Y,0.125,-,-,-
COL4A3_HUMAN,L1129F,0.019,-,-,-
COL4A3_HUMAN,G1143F,0.931,Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of B-factor (Pr = 0.26 | P = 0.05), None,-
COL4A3_HUMAN,R1176G,0.104,-,-,-
COL4A3_HUMAN,K1206R,0.157,-,-,-
COL4A3_HUMAN,M1209K,0.319,-,-,-
COL4A3_HUMAN,R1215Q,0.074,-,-,-
COL4A3_HUMAN,A1285V,0.05,-,-,-
COL4A3_HUMAN,P1305L,0.037,-,-,-
COL4A3_HUMAN,K1339I,0.205,-,-,-
COL4A3_HUMAN,K1352Q,0.196,-,-,-
COL4A3_HUMAN,V1465A,0.109,-,-,-
COL4A3_HUMAN,L1541I,0.122,-,-,-
COL4A3_HUMAN,D1566N,0.15,-,-,-
COL4A3_HUMAN,A1599R,0.669,Gain of ADP-ribosylation at A1599 (Pr = 0.33 | P = 2.0e-03); Altered Transmembrane protein (Pr = 0.29 | P = 2.1e-04); Loss of Loop (Pr = 0.27 | P = 0.03), ELME000136|ELME000159,-
COL4A3_HUMAN,E1615N,0.814,Altered Metal binding (Pr = 0.41 | P = 6.1e-03); Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03); Gain of Disulfide linkage at C1616 (Pr = 0.16 | P = 0.03), None,-
COL4A3_HUMAN,G1618S,0.812,Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Metal binding (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.27 | P = 8.5e-04); Loss of Strand (Pr = 0.26 | P = 0.05); Gain of Disulfide linkage at C1622 (Pr = 0.21 | P = 0.02), ELME000062|ELME000063|ELME000162,-
COL4A3_HUMAN,F1631H,0.82,Altered Ordered interface (Pr = 0.36 | P = 4.4e-03); Altered Transmembrane protein (Pr = 0.31 | P = 1.1e-04); Altered DNA binding (Pr = 0.26 | P = 5.3e-03); Altered Metal binding (Pr = 0.23 | P = 0.02); Altered Stability (Pr = 0.16 | P = 0.02), ELME000197,-
COL4A3_HUMAN,F1631K,0.922,Altered Transmembrane protein (Pr = 0.32 | P = 7.3e-05); Altered Ordered interface (Pr = 0.32 | P = 0.01); Gain of Helix (Pr = 0.29 | P = 0.02); Loss of Strand (Pr = 0.27 | P = 0.02); Altered DNA binding (Pr = 0.27 | P = 3.7e-03); Altered Metal binding (Pr = 0.26 | P = 9.4e-03); Gain of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Altered Stability (Pr = 0.22 | P = 0.01); Gain of Acetylation at F1631 (Pr = 0.19 | P = 0.05), ELME000197,-
COL4A3_HUMAN,S1635G,0.581,Loss of Helix (Pr = 0.30 | P = 9.2e-03); Altered Transmembrane protein (Pr = 0.28 | P = 4.6e-04); Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Metal binding (Pr = 0.25 | P = 0.01); Altered DNA binding (Pr = 0.15 | P = 0.04), None,-
COL4A3_HUMAN,P1647A,0.211,-,-,-
COL4A3_HUMAN,A1652N,0.563,Altered Transmembrane protein (Pr = 0.21 | P = 4.2e-03), None,-
COL4A3_HUMAN,E1656V,0.504,Altered Disordered interface (Pr = 0.21 | P = 0.03); Altered DNA binding (Pr = 0.18 | P = 0.03); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000333|ELME000335,-
COL4A3_HUMAN,K1657H,0.285,-,-,-
COL4A3_HUMAN,M1666T,0.684,Altered Disordered interface (Pr = 0.34 | P = 0.01); Altered Metal binding (Pr = 0.25 | P = 0.03); Altered Stability (Pr = 0.23 | P = 9.5e-03); Altered DNA binding (Pr = 0.18 | P = 0.03), PS00005,-
COL4A3_HUMAN,H1670V,0.283,-,-,-
COL4A3_HUMAN,Q182H,0.411,-,-,-
COL4A3_HUMAN,G1039R,0.937,Loss of Loop (Pr = 0.29 | P = 0.01); Altered Disordered interface (Pr = 0.25 | P = 0.02), ELME000012|ELME000101|ELME000102|ELME000108|ELME000155|ELME000231,-
COL4A3_HUMAN,G407C,0.92,Loss of B-factor (Pr = 0.29 | P = 0.01); Loss of SUMOylation at K403 (Pr = 0.26 | P = 6.5e-03); Loss of Acetylation at K411 (Pr = 0.25 | P = 0.01); Loss of Methylation at K411 (Pr = 0.19 | P = 7.8e-03); Gain of Disulfide linkage at G407 (Pr = 0.11 | P = 0.05), ELME000012,-
COL4A3_HUMAN,G584C,0.904,Loss of Acetylation at K583 (Pr = 0.32 | P = 3.0e-03); Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Methylation at K583 (Pr = 0.24 | P = 3.0e-03), ELME000002,-
COL4A3_HUMAN,G49R,0.951,Loss of B-factor (Pr = 0.30 | P = 0.01); Gain of SUMOylation at K48 (Pr = 0.27 | P = 4.6e-03); Loss of Acetylation at K45 (Pr = 0.22 | P = 0.03); Loss of Methylation at K51 (Pr = 0.16 | P = 0.01), ELME000100|ELME000108,-
COL4A3_HUMAN,G634E,0.911,Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of O-linked glycosylation at T629 (Pr = 0.15 | P = 0.04), ELME000155,-
COL4A3_HUMAN,G662E,0.927,Gain of Loop (Pr = 0.34 | P = 9.3e-04); Loss of B-factor (Pr = 0.27 | P = 0.03), ELME000155,-
COL4A3_HUMAN,G1242D,0.918,Gain of Loop (Pr = 0.29 | P = 9.2e-03); Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of Methylation at R1247 (Pr = 0.19 | P = 8.6e-03); Loss of O-linked glycosylation at S1246 (Pr = 0.14 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q1237 (Pr = 0.04 | P = 0.04), None,-
COL4A3_HUMAN,G1406E,0.929,Gain of Loop (Pr = 0.29 | P = 8.5e-03); Loss of Methylation at K1408 (Pr = 0.27 | P = 1.3e-03); Loss of Acetylation at K1408 (Pr = 0.26 | P = 9.5e-03); Gain of SUMOylation at K1408 (Pr = 0.26 | P = 6.7e-03); Gain of B-factor (Pr = 0.25 | P = 0.03), ELME000117,-
COL4A3_HUMAN,G608R,0.915,Loss of B-factor (Pr = 0.30 | P = 0.01); Gain of Methylation at G608 (Pr = 0.15 | P = 0.01), ELME000063|ELME000155|PS00005,-
COL4A3_HUMAN,G148V,0.936,Loss of Intrinsic disorder (Pr = 0.45 | P = 0.01); Gain of Loop (Pr = 0.27 | P = 0.02); Loss of Methylation at K153 (Pr = 0.17 | P = 0.01); Loss of Ubiquitylation at K153 (Pr = 0.17 | P = 0.02); Loss of Sulfation at Y143 (Pr = 0.01 | P = 0.05), PS00008,-
COL4A3_HUMAN,S1452C,0.692,Loss of O-linked glycosylation at T1455 (Pr = 0.23 | P = 0.02); Altered Transmembrane protein (Pr = 0.11 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q1453 (Pr = 0.11 | P = 8.2e-03), ELME000052|ELME000053|ELME000062|ELME000063|ELME000202,-
COL4A3_HUMAN,G1470W,0.91,Altered Transmembrane protein (Pr = 0.21 | P = 4.0e-03), ELME000063|ELME000085|ELME000120,-
COL4A3_HUMAN,G1334E,0.896,Gain of Loop (Pr = 0.29 | P = 9.7e-03); Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of Acetylation at K1339 (Pr = 0.22 | P = 0.03); Loss of Methylation at K1339 (Pr = 0.20 | P = 6.0e-03); Gain of SUMOylation at K1339 (Pr = 0.20 | P = 0.03), ELME000155,-
COL4A3_HUMAN,G795V,0.951,Loss of B-factor (Pr = 0.33 | P = 2.3e-03); Loss of Methylation at R791 (Pr = 0.10 | P = 0.04), ELME000005|ELME000155,-
COL4A3_HUMAN,P879L,0.44,-,-,-
COL4A3_HUMAN,G91V,0.955,Loss of Acetylation at K90 (Pr = 0.25 | P = 0.01); Loss of Methylation at K90 (Pr = 0.20 | P = 6.8e-03); Gain of SUMOylation at K90 (Pr = 0.19 | P = 0.04); Gain of O-linked glycosylation at S96 (Pr = 0.13 | P = 0.04), ELME000336,-
COL4A3_HUMAN,G566A,0.936,Altered Disordered interface (Pr = 0.27 | P = 0.05); Gain of SUMOylation at K565 (Pr = 0.21 | P = 0.03); Gain of Methylation at K565 (Pr = 0.17 | P = 9.1e-03), ELME000146|ELME000231,-
COL4A3_HUMAN,G1251S,0.884,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Loop (Pr = 0.26 | P = 0.05); Loss of Methylation at R1247 (Pr = 0.18 | P = 9.3e-03); Gain of O-linked glycosylation at S1246 (Pr = 0.15 | P = 0.03), ELME000005|ELME000063|ELME000085|ELME000099|ELME000136|ELME000155|ELME000159,-
COL4A3_HUMAN,G1403R,0.914,Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Loop (Pr = 0.28 | P = 0.01); Loss of Methylation at K1408 (Pr = 0.28 | P = 9.2e-04); Loss of Acetylation at K1408 (Pr = 0.27 | P = 7.2e-03); Gain of SUMOylation at K1408 (Pr = 0.20 | P = 0.03), ELME000136|ELME000159|ELME000358|PS00005,-
COL4A3_HUMAN,G801R,0.937,Loss of B-factor (Pr = 0.30 | P = 8.8e-03), ELME000135,-
COL4A3_HUMAN,G1319R,0.921,Gain of SUMOylation at K1318 (Pr = 0.32 | P = 2.5e-03); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Acetylation at K1321 (Pr = 0.27 | P = 7.8e-03); Loss of Methylation at K1318 (Pr = 0.15 | P = 0.01), ELME000002|ELME000100|ELME000108,-
COL4A3_HUMAN,G1488R,0.771,Altered Transmembrane protein (Pr = 0.12 | P = 0.03), PS00008,-
COL4A3_HUMAN,G631R,0.932,Loss of O-linked glycosylation at T629 (Pr = 0.15 | P = 0.03), ELME000052|ELME000155|ELME000202|ELME000336|PS00005,-
COL4A3_HUMAN,G520R,0.945,Loss of B-factor (Pr = 0.25 | P = 0.05); Gain of O-linked glycosylation at T519 (Pr = 0.13 | P = 0.03), ELME000155,-
COL4A3_HUMAN,G695R,0.917,Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of B-factor (Pr = 0.27 | P = 0.03), ELME000097|ELME000155,-
COL4A3_HUMAN,P574L,0.475,-,-,-
COL4A3_HUMAN,R1011C,0.187,-,-,-
COL4A3_HUMAN,R8G,0.127,-,-,-
COL4A3_HUMAN,L12F,0.078,-,-,-
COL4A3_HUMAN,P72L,0.305,-,-,-
COL4A3_HUMAN,G76W,0.944,Loss of B-factor (Pr = 0.32 | P = 3.6e-03); Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Methylation at K78 (Pr = 0.23 | P = 3.4e-03), ELME000080|ELME000155,-
COL4A3_HUMAN,V92A,0.141,-,-,-
COL4A3_HUMAN,G284R,0.299,-,-,-
COL4A3_HUMAN,Y350H,0.091,-,-,-
COL4A3_HUMAN,T358I,0.039,-,-,-
COL4A3_HUMAN,R365K,0.029,-,-,-
COL4A3_HUMAN,S382G,0.141,-,-,-
COL4A3_HUMAN,P394S,0.248,-,-,-
COL4A3_HUMAN,S402T,0.12,-,-,-
COL4A3_HUMAN,A423P,0.075,-,-,-
COL4A3_HUMAN,L428P,0.071,-,-,-
COL4A3_HUMAN,T519A,0.039,-,-,-
COL4A3_HUMAN,A610T,0.096,-,-,-
COL4A3_HUMAN,A635D,0.139,-,-,-
COL4A3_HUMAN,K681R,0.048,-,-,-
COL4A3_HUMAN,R832I,0.247,-,-,-
COL4A3_HUMAN,T835M,0.059,-,-,-
COL4A3_HUMAN,I860M,0.029,-,-,-
COL4A5_HUMAN,G156D,0.962,Gain of Loop (Pr = 0.31 | P = 3.3e-03); Loss of Methylation at K155 (Pr = 0.22 | P = 4.5e-03); Gain of SUMOylation at K155 (Pr = 0.21 | P = 0.03), ELME000002,-
COL4A5_HUMAN,G632D,0.936,Loss of Acetylation at K634 (Pr = 0.26 | P = 9.5e-03); Loss of Methylation at K634 (Pr = 0.20 | P = 6.3e-03), None,-
COL4A5_HUMAN,G1158R,0.942,Loss of B-factor (Pr = 0.29 | P = 0.02); Loss of Loop (Pr = 0.27 | P = 0.03); Altered Metal binding (Pr = 0.12 | P = 0.03), ELME000155|PS00008,-
COL4A5_HUMAN,G699R,0.94,Gain of SUMOylation at K698 (Pr = 0.29 | P = 3.6e-03); Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Loop (Pr = 0.27 | P = 0.03); Gain of Acetylation at K698 (Pr = 0.20 | P = 0.04); Loss of Methylation at K698 (Pr = 0.18 | P = 8.8e-03), ELME000005|ELME000064|ELME000100|ELME000108|ELME000155|PS00005|PS00006,-
COL4A5_HUMAN,G579E,0.962,, ELME000136|ELME000159|ELME000358,-
COL4A5_HUMAN,G374V,0.945,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of SUMOylation at K370 (Pr = 0.25 | P = 7.4e-03); Loss of Acetylation at K370 (Pr = 0.21 | P = 0.03); Loss of Methylation at K370 (Pr = 0.16 | P = 0.01), ELME000259,-
COL4A5_HUMAN,G837S,0.912,Altered Disordered interface (Pr = 0.28 | P = 0.04), None,-
COL4A5_HUMAN,G1385V,0.959,Loss of B-factor (Pr = 0.25 | P = 0.05); Gain of Methylation at K1387 (Pr = 0.16 | P = 0.01), None,-
COL4A5_HUMAN,G420V,0.871,Altered Disordered interface (Pr = 0.28 | P = 0.04); Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of O-linked glycosylation at S417 (Pr = 0.14 | P = 0.04), ELME000155,-
COL4A5_HUMAN,G359R,0.953,Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of Acetylation at K358 (Pr = 0.25 | P = 0.01); Gain of SUMOylation at K358 (Pr = 0.21 | P = 0.03); Loss of Methylation at K358 (Pr = 0.18 | P = 9.7e-03); Gain of O-linked glycosylation at T354 (Pr = 0.14 | P = 0.03), ELME000100|ELME000108,-
COL4A5_HUMAN,G313V,0.956,Altered Disordered interface (Pr = 0.33 | P = 0.02); Loss of B-factor (Pr = 0.27 | P = 0.03), None,-
COL4A5_HUMAN,G1161E,0.941,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Loop (Pr = 0.26 | P = 0.05); Gain of SUMOylation at K1166 (Pr = 0.23 | P = 0.02); Loss of Acetylation at K1166 (Pr = 0.22 | P = 0.03); Loss of Methylation at K1166 (Pr = 0.21 | P = 5.3e-03); Altered Metal binding (Pr = 0.10 | P = 0.05), None,-
COL4A5_HUMAN,G1279C,0.741,Loss of Methylation at K1281 (Pr = 0.32 | P = 4.1e-04); Loss of Acetylation at K1281 (Pr = 0.29 | P = 5.1e-03); Gain of SUMOylation at K1281 (Pr = 0.27 | P = 4.7e-03); Loss of B-factor (Pr = 0.26 | P = 0.03), ELME000079,-
COL4A5_HUMAN,G612D,0.957,Gain of Loop (Pr = 0.31 | P = 4.2e-03); Altered Disordered interface (Pr = 0.29 | P = 0.03), PS00008,-
COL4A5_HUMAN,G239R,0.921,Loss of B-factor (Pr = 0.31 | P = 5.5e-03), ELME000135|ELME000155,-
COL4A5_HUMAN,G227D,0.925,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Loop (Pr = 0.27 | P = 0.04); Loss of SUMOylation at K229 (Pr = 0.26 | P = 7.5e-03); Loss of Acetylation at K226 (Pr = 0.24 | P = 0.02); Loss of Methylation at K229 (Pr = 0.21 | P = 5.7e-03), ELME000002,-
COL4A5_HUMAN,G626A,0.462,-,-,-
COL4A5_HUMAN,G177C,0.965,Altered Disordered interface (Pr = 0.40 | P = 4.2e-03); Loss of B-factor (Pr = 0.31 | P = 6.8e-03); Loss of Phosphorylation at Y175 (Pr = 0.24 | P = 0.05); Loss of Sulfation at Y175 (Pr = 0.02 | P = 0.03), ELME000057,-
COL4A5_HUMAN,G397V,0.924,Loss of B-factor (Pr = 0.35 | P = 9.7e-04), ELME000155,-
COL4A5_HUMAN,P628L,0.42,-,-,-
COL4A5_HUMAN,G233V,0.937,Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of SUMOylation at K229 (Pr = 0.26 | P = 5.7e-03); Gain of Acetylation at K229 (Pr = 0.22 | P = 0.02); Loss of Methylation at K229 (Pr = 0.21 | P = 5.7e-03); Gain of Pyrrolidone carboxylic acid at Q235 (Pr = 0.05 | P = 0.04), None,-
COL4A5_HUMAN,G503R,0.959,Loss of B-factor (Pr = 0.30 | P = 0.01); Loss of Loop (Pr = 0.27 | P = 0.03); Gain of O-linked glycosylation at S507 (Pr = 0.12 | P = 0.04), ELME000051|ELME000057|ELME000155,-
COL4A5_HUMAN,G899D,0.958,Loss of SUMOylation at K895 (Pr = 0.25 | P = 8.8e-03); Loss of Acetylation at K895 (Pr = 0.24 | P = 0.01); Loss of Methylation at K895 (Pr = 0.19 | P = 7.4e-03), None,-
COL4A5_HUMAN,G129E,0.966,Gain of SUMOylation at K128 (Pr = 0.31 | P = 3.0e-03); Loss of Methylation at K128 (Pr = 0.15 | P = 0.02); Loss of N-linked glycosylation at N125 (Pr = 0.02 | P = 0.03), ELME000064|ELME000070|ELME000117|ELME000220|PS00006,-
COL4A5_HUMAN,G1125R,0.958,Loss of Loop (Pr = 0.32 | P = 3.3e-03); Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of O-linked glycosylation at T1126 (Pr = 0.17 | P = 0.03), ELME000136|ELME000155|ELME000159|ELME000358,-
COL4A5_HUMAN,G1415V,0.962,Gain of ADP-ribosylation at R1410 (Pr = 0.19 | P = 0.04); Gain of Proteolytic cleavage at D1417 (Pr = 0.12 | P = 0.03), None,-
COL4A5_HUMAN,G138S,0.941,, ELME000136|ELME000159|ELME000197,-
COL4A5_HUMAN,G1128D,0.944,Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Methylation at K1133 (Pr = 0.22 | P = 4.7e-03); Loss of Acetylation at K1133 (Pr = 0.21 | P = 0.03); Loss of SUMOylation at K1133 (Pr = 0.18 | P = 0.05); Loss of O-linked glycosylation at T1126 (Pr = 0.17 | P = 0.03), ELME000136|ELME000155|ELME000159|ELME000358,-
COL4A5_HUMAN,G1264S,0.94,Gain of Loop (Pr = 0.33 | P = 1.2e-03); Loss of B-factor (Pr = 0.26 | P = 0.04), ELME000062|ELME000155,-
COL4A5_HUMAN,G905D,0.953,Loss of B-factor (Pr = 0.27 | P = 0.03), ELME000155,-
COL4A5_HUMAN,G953V,0.851,Loss of B-factor (Pr = 0.33 | P = 2.4e-03); Altered Disordered interface (Pr = 0.27 | P = 0.05), ELME000155,-
COL4A5_HUMAN,L933F,0.07,-,-,-
COL4A5_HUMAN,R788H,0.095,-,-,-
COL4A5_HUMAN,N1010S,0.107,-,-,-
COL2A1_HUMAN,K1408R,0.414,-,-,-
COL2A1_HUMAN,I1421M,0.555,Altered Metal binding (Pr = 0.27 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered Transmembrane protein (Pr = 0.17 | P = 9.3e-03); Altered Stability (Pr = 0.16 | P = 0.02); Loss of Catalytic site at E1420 (Pr = 0.11 | P = 0.03), None,-
COL2A1_HUMAN,T1432S,0.11,-,-,-
COL2A1_HUMAN,A1433T,0.364,-,-,-
COL2A1_HUMAN,I1462V,0.59,Altered Disordered interface (Pr = 0.41 | P = 3.9e-03); Altered Metal binding (Pr = 0.29 | P = 4.2e-03); Gain of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Gain of Allosteric site at D1464 (Pr = 0.28 | P = 3.6e-03); Loss of Catalytic site at D1464 (Pr = 0.26 | P = 3.8e-03); Altered Transmembrane protein (Pr = 0.25 | P = 1.5e-03), ELME000233|ELME000237|ELME000333,-
COL2A1_HUMAN,I1463T,0.689,Altered Stability (Pr = 0.60 | P = 9.8e-04); Altered Disordered interface (Pr = 0.40 | P = 4.1e-03); Loss of Catalytic site at D1464 (Pr = 0.34 | P = 8.9e-04); Altered Metal binding (Pr = 0.28 | P = 6.6e-03); Altered Ordered interface (Pr = 0.28 | P = 0.05); Gain of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Gain of Allosteric site at D1464 (Pr = 0.28 | P = 4.3e-03); Altered Transmembrane protein (Pr = 0.27 | P = 7.1e-04); Loss of Strand (Pr = 0.26 | P = 0.03), ELME000237|ELME000333,-
COL2A1_HUMAN,I1465F,0.885,Altered Transmembrane protein (Pr = 0.32 | P = 1.0e-04); Altered Disordered interface (Pr = 0.32 | P = 0.01); Altered Metal binding (Pr = 0.30 | P = 3.9e-03); Gain of Allosteric site at D1464 (Pr = 0.29 | P = 2.8e-03); Altered Ordered interface (Pr = 0.27 | P = 0.05); Gain of Catalytic site at D1464 (Pr = 0.26 | P = 4.0e-03), ELME000237,-
COL2A1_HUMAN,M1468V,0.518,Altered Disordered interface (Pr = 0.30 | P = 0.02); Altered Metal binding (Pr = 0.27 | P = 7.2e-03); Altered Transmembrane protein (Pr = 0.26 | P = 9.8e-04); Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Loss of Catalytic site at D1464 (Pr = 0.26 | P = 4.5e-03); Loss of Allosteric site at D1464 (Pr = 0.21 | P = 0.04), None,-
COL2A1_HUMAN,P1473A,0.345,-,-,-
COL2A1_HUMAN,V1479A,0.723,Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Metal binding (Pr = 0.27 | P = 7.1e-03); Altered Transmembrane protein (Pr = 0.27 | P = 7.3e-04); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q1475 (Pr = 0.14 | P = 5.3e-03); Loss of Catalytic site at E1476 (Pr = 0.10 | P = 0.04), None,-
COL2A1_HUMAN,V1484A,0.727,Altered Metal binding (Pr = 0.25 | P = 0.03); Altered Transmembrane protein (Pr = 0.22 | P = 3.1e-03), None,-
COL2A1_HUMAN,G846E,0.945,Gain of Loop (Pr = 0.28 | P = 0.02); Loss of Methylation at K848 (Pr = 0.28 | P = 1.0e-03); Loss of Acetylation at K848 (Pr = 0.23 | P = 0.02); Loss of Ubiquitylation at K848 (Pr = 0.15 | P = 0.04), PS00008,-
COL2A1_HUMAN,G384S,0.945,Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Methylation at R383 (Pr = 0.26 | P = 1.8e-03); Gain of O-linked glycosylation at T380 (Pr = 0.11 | P = 0.05), ELME000053|ELME000136|ELME000159,-
COL2A1_HUMAN,G315V,0.97,Loss of B-factor (Pr = 0.33 | P = 2.7e-03); Altered Metal binding (Pr = 0.19 | P = 0.05), ELME000064|ELME000136|ELME000159|PS00006,-
COL2A1_HUMAN,G1101R,0.953,Loss of Loop (Pr = 0.29 | P = 0.01); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Methylation at R1106 (Pr = 0.19 | P = 8.7e-03), ELME000006|ELME000085,-
COL2A1_HUMAN,G495E,0.961,Loss of Acetylation at K490 (Pr = 0.28 | P = 6.4e-03); Gain of SUMOylation at K490 (Pr = 0.27 | P = 4.9e-03); Loss of Methylation at K490 (Pr = 0.26 | P = 1.6e-03), ELME000117,-
COL2A1_HUMAN,G504A,0.943,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Methylation at R509 (Pr = 0.12 | P = 0.02), ELME000155,-
COL2A1_HUMAN,G1086V,0.971,Loss of B-factor (Pr = 0.29 | P = 0.01); Gain of Acetylation at K1084 (Pr = 0.22 | P = 0.03); Loss of Methylation at K1084 (Pr = 0.21 | P = 5.0e-03); Loss of SUMOylation at K1084 (Pr = 0.20 | P = 0.03); Gain of Ubiquitylation at K1084 (Pr = 0.15 | P = 0.04), None,-
COL2A1_HUMAN,T1028M,0.429,-,-,-
COL2A1_HUMAN,G1110S,0.925,Gain of Phosphorylation at G1110 (Pr = 0.29 | P = 0.02); Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Methylation at R1106 (Pr = 0.18 | P = 9.0e-03), ELME000136|ELME000155|ELME000159,-
COL2A1_HUMAN,G711R,0.963,Gain of Methylation at R707 (Pr = 0.12 | P = 0.03), ELME000136|ELME000159|PS00005|PS00008,-
COL2A1_HUMAN,G282D,0.962,Loss of Acetylation at K287 (Pr = 0.26 | P = 9.1e-03); Loss of SUMOylation at K287 (Pr = 0.19 | P = 0.04); Loss of Methylation at K287 (Pr = 0.16 | P = 0.01), ELME000052|ELME000136|ELME000159|ELME000358,-
COL2A1_HUMAN,G684V,0.969,Loss of B-factor (Pr = 0.27 | P = 0.02); Loss of Methylation at K679 (Pr = 0.26 | P = 1.7e-03); Loss of Acetylation at K679 (Pr = 0.23 | P = 0.02); Gain of SUMOylation at K679 (Pr = 0.20 | P = 0.03), ELME000156,-
COL2A1_HUMAN,G966A,0.885,Loss of B-factor (Pr = 0.28 | P = 0.02); Altered Metal binding (Pr = 0.20 | P = 0.04), ELME000064|ELME000085|PS00006,-
COL2A1_HUMAN,G759D,0.966,Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of Acetylation at K764 (Pr = 0.27 | P = 8.3e-03); Loss of Methylation at K764 (Pr = 0.25 | P = 1.9e-03); Gain of Ubiquitylation at K764 (Pr = 0.20 | P = 9.4e-03), None,-
COL2A1_HUMAN,G369D,0.955,Gain of Loop (Pr = 0.29 | P = 0.01); Loss of Methylation at K374 (Pr = 0.27 | P = 1.2e-03); Gain of Ubiquitylation at K374 (Pr = 0.22 | P = 4.5e-03); Loss of Acetylation at K374 (Pr = 0.21 | P = 0.03), ELME000293|PS00008,-
COL2A1_HUMAN,G948D,0.966,Gain of Loop (Pr = 0.28 | P = 0.01); Loss of B-factor (Pr = 0.25 | P = 0.05), ELME000155,-
COL2A1_HUMAN,G369R,0.955,Loss of Loop (Pr = 0.29 | P = 0.01); Loss of Methylation at K374 (Pr = 0.28 | P = 8.9e-04); Gain of Acetylation at K374 (Pr = 0.25 | P = 0.01); Loss of Ubiquitylation at K374 (Pr = 0.21 | P = 5.6e-03), PS00008,-
COL2A1_HUMAN,G672C,0.949,Loss of B-factor (Pr = 0.36 | P = 6.0e-04); Gain of Loop (Pr = 0.27 | P = 0.02), None,-
COL2A1_HUMAN,R992G,0.875,Altered Disordered interface (Pr = 0.29 | P = 0.03); Gain of B-factor (Pr = 0.26 | P = 0.02); Gain of Methylation at R989 (Pr = 0.11 | P = 0.03), ELME000005|ELME000155|PS00008,-
COL2A1_HUMAN,G861D,0.959,Loss of Methylation at K857 (Pr = 0.28 | P = 1.0e-03); Loss of Acetylation at K857 (Pr = 0.25 | P = 0.01); Loss of SUMOylation at K857 (Pr = 0.23 | P = 0.02); Gain of Ubiquitylation at K857 (Pr = 0.19 | P = 0.01); Altered Metal binding (Pr = 0.11 | P = 0.04); Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000293,-
COL2A1_HUMAN,G873W,0.963,Loss of B-factor (Pr = 0.33 | P = 3.0e-03); Altered Disordered interface (Pr = 0.29 | P = 0.03); Gain of O-linked glycosylation at S869 (Pr = 0.16 | P = 0.03); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000155,-
COL2A1_HUMAN,G1158A,0.936,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of O-linked glycosylation at S1154 (Pr = 0.14 | P = 0.03); Gain of Methylation at R1163 (Pr = 0.13 | P = 0.02), ELME000155|ELME000239,-
COL2A1_HUMAN,G744S,0.922,Altered Metal binding (Pr = 0.10 | P = 0.04), ELME000136|ELME000159,-
COL2A1_HUMAN,G1140D,0.959,Loss of B-factor (Pr = 0.26 | P = 0.05), ELME000155,-
COL2A1_HUMAN,G813R,0.956,Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Methylation at R818 (Pr = 0.19 | P = 8.1e-03); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000006|ELME000085|ELME000239|PS00008,-
COL2A1_HUMAN,G1083D,0.965,Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Acetylation at K1084 (Pr = 0.22 | P = 0.03); Loss of Methylation at K1084 (Pr = 0.21 | P = 5.1e-03); Gain of SUMOylation at K1084 (Pr = 0.20 | P = 0.03); Gain of Ubiquitylation at K1084 (Pr = 0.17 | P = 0.03), PS00005,-
COL2A1_HUMAN,G522V,0.971,Altered Disordered interface (Pr = 0.30 | P = 0.02); Loss of Methylation at K527 (Pr = 0.23 | P = 3.3e-03); Loss of Acetylation at K527 (Pr = 0.22 | P = 0.03); Loss of SUMOylation at K527 (Pr = 0.19 | P = 0.04); Loss of Ubiquitylation at K527 (Pr = 0.16 | P = 0.04), None,-
COL2A1_HUMAN,G726D,0.97,Loss of Methylation at K731 (Pr = 0.27 | P = 1.3e-03); Gain of B-factor (Pr = 0.25 | P = 0.03); Loss of Acetylation at K731 (Pr = 0.23 | P = 0.02); Gain of Ubiquitylation at K731 (Pr = 0.19 | P = 0.01); Loss of SUMOylation at K731 (Pr = 0.18 | P = 0.05); Loss of O-linked glycosylation at T727 (Pr = 0.13 | P = 0.04); Altered Metal binding (Pr = 0.10 | P = 0.05), ELME000136|ELME000159|ELME000358|PS00008,-
COL2A1_HUMAN,G846R,0.951,Loss of Methylation at K848 (Pr = 0.30 | P = 5.9e-04); Loss of Loop (Pr = 0.27 | P = 0.04); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Acetylation at K848 (Pr = 0.26 | P = 9.7e-03); Loss of Ubiquitylation at K848 (Pr = 0.16 | P = 0.04), PS00008,-
COL2A1_HUMAN,G270R,0.966,Loss of B-factor (Pr = 0.30 | P = 0.01); Loss of Loop (Pr = 0.29 | P = 8.8e-03); Loss of Methylation at R266 (Pr = 0.19 | P = 7.9e-03), ELME000135|ELME000155,-
COL2A1_HUMAN,P986L,0.89,Altered Disordered interface (Pr = 0.35 | P = 0.01); Loss of Methylation at R989 (Pr = 0.10 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q988 (Pr = 0.05 | P = 0.04), ELME000155,-
COL2A1_HUMAN,G894E,0.964,Gain of O-linked glycosylation at T896 (Pr = 0.23 | P = 0.01), None,-
COL2A1_HUMAN,C57Y,0.941,Loss of Disulfide linkage at C57 (Pr = 0.26 | P = 3.8e-03), ELME000052|PS01208,-
COL2A1_HUMAN,R989C,0.827,Altered Disordered interface (Pr = 0.37 | P = 7.0e-03); Gain of Loop (Pr = 0.30 | P = 4.4e-03); Loss of Methylation at R989 (Pr = 0.11 | P = 0.03), None,-
COL2A1_HUMAN,G516S,0.965,Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of Methylation at R515 (Pr = 0.23 | P = 3.6e-03); Gain of N-linked glycosylation at N514 (Pr = 0.02 | P = 0.04), ELME000070|PS00001,-
COL2A1_HUMAN,G240C,0.957,Loss of B-factor (Pr = 0.29 | P = 0.01); Gain of Loop (Pr = 0.29 | P = 1.0e-02); Loss of Methylation at R242 (Pr = 0.16 | P = 0.01); Loss of O-linked glycosylation at S236 (Pr = 0.12 | P = 0.05), None,-
COL2A1_HUMAN,Y1399C,0.921,Altered Metal binding (Pr = 0.52 | P = 4.3e-03); Altered Ordered interface (Pr = 0.37 | P = 1.7e-03); Altered Transmembrane protein (Pr = 0.34 | P = 4.4e-05); Gain of Helix (Pr = 0.27 | P = 0.04); Gain of Disulfide linkage at Y1399 (Pr = 0.19 | P = 0.02), ELME000007|ELME000182|ELME000313,-
COL2A1_HUMAN,G207R,0.958,Loss of Loop (Pr = 0.27 | P = 0.03); Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of Methylation at R209 (Pr = 0.26 | P = 6.7e-04), ELME000006|ELME000012,-
COL2A1_HUMAN,G1062A,0.938,Altered Disordered interface (Pr = 0.28 | P = 0.04); Loss of Methylation at R1058 (Pr = 0.13 | P = 0.02), ELME000052|ELME000155,-
COL2A1_HUMAN,G753D,0.974,Loss of Methylation at R755 (Pr = 0.12 | P = 0.03), None,-
COL2A1_HUMAN,G474S,0.88,Loss of B-factor (Pr = 0.27 | P = 0.02); Gain of Loop (Pr = 0.26 | P = 0.05); Loss of Methylation at K470 (Pr = 0.23 | P = 3.8e-03); Loss of Acetylation at K470 (Pr = 0.20 | P = 0.04), ELME000136|ELME000155|ELME000159,-
COL2A1_HUMAN,R275C,0.867,Gain of Loop (Pr = 0.30 | P = 5.2e-03); Loss of Methylation at R275 (Pr = 0.15 | P = 0.02), ELME000005|ELME000155,-
COL2A1_HUMAN,G1041S,0.962,Loss of B-factor (Pr = 0.26 | P = 0.04); Altered Metal binding (Pr = 0.10 | P = 0.05), ELME000085|ELME000136|ELME000159|PS00008,-
COL2A1_HUMAN,G804A,0.947,Loss of B-factor (Pr = 0.26 | P = 0.03); Gain of SUMOylation at K803 (Pr = 0.26 | P = 6.5e-03); Loss of Acetylation at K803 (Pr = 0.25 | P = 0.01); Gain of Methylation at K803 (Pr = 0.24 | P = 1.0e-03); Gain of Ubiquitylation at K803 (Pr = 0.18 | P = 0.02); Altered Metal binding (Pr = 0.15 | P = 0.02), ELME000155,-
COL2A1_HUMAN,D1285Y,0.957,Altered Ordered interface (Pr = 0.37 | P = 2.3e-03); Altered Transmembrane protein (Pr = 0.23 | P = 2.2e-03); Loss of Disulfide linkage at C1283 (Pr = 0.14 | P = 0.04), ELME000106|ELME000120|ELME000146|ELME000182|ELME000220|PS00006,-
COL2A1_HUMAN,R550C,0.776,Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of ADP-ribosylation at R550 (Pr = 0.20 | P = 0.04); Loss of Methylation at R550 (Pr = 0.11 | P = 0.03), ELME000155,-
COL2A1_HUMAN,G1188R,0.96,Altered Disordered interface (Pr = 0.30 | P = 0.02); Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Loop (Pr = 0.27 | P = 0.02); Gain of Methylation at R1190 (Pr = 0.24 | P = 1.3e-03); Loss of ADP-ribosylation at R1192 (Pr = 0.20 | P = 0.05), ELME000006|ELME000012|ELME000061|ELME000135,-
COL2A1_HUMAN,P458L,0.662,Altered Disordered interface (Pr = 0.35 | P = 0.01), ELME000052,-
COL2A1_HUMAN,G219R,0.969,Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Methylation at G219 (Pr = 0.14 | P = 0.02), None,-
COL2A1_HUMAN,G462V,0.961,Altered Disordered interface (Pr = 0.27 | P = 0.05); Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Acetylation at K464 (Pr = 0.27 | P = 7.8e-03); Gain of SUMOylation at K464 (Pr = 0.27 | P = 4.9e-03); Loss of Methylation at K464 (Pr = 0.25 | P = 1.9e-03), ELME000237,-
COL2A1_HUMAN,G327D,0.971,Gain of Loop (Pr = 0.29 | P = 7.0e-03); Loss of Methylation at R326 (Pr = 0.23 | P = 3.9e-03), ELME000106,-
COL2A1_HUMAN,G1053V,0.969,Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of Acetylation at K1055 (Pr = 0.24 | P = 0.02); Loss of Methylation at K1055 (Pr = 0.23 | P = 3.7e-03); Loss of Ubiquitylation at K1055 (Pr = 0.19 | P = 0.01), None,-
COL2A1_HUMAN,G1143S,0.936,Gain of Phosphorylation at G1143 (Pr = 0.35 | P = 8.7e-03); Loss of B-factor (Pr = 0.27 | P = 0.02); Gain of Loop (Pr = 0.27 | P = 0.03), ELME000057|ELME000136|ELME000155|ELME000159,-
COL2A1_HUMAN,G687S,0.955,Gain of Loop (Pr = 0.27 | P = 0.04); Altered Metal binding (Pr = 0.11 | P = 0.04), None,-
COL2A1_HUMAN,R904C,0.715,Altered Disordered interface (Pr = 0.28 | P = 0.03); Gain of Loop (Pr = 0.27 | P = 0.03); Gain of B-factor (Pr = 0.25 | P = 0.04); Loss of ADP-ribosylation at R904 (Pr = 0.23 | P = 0.02); Loss of Methylation at R904 (Pr = 0.14 | P = 0.02), ELME000097|ELME000155|ELME000259|PS00008,-
COL2A1_HUMAN,G498V,0.969,Loss of B-factor (Pr = 0.30 | P = 9.5e-03); Gain of Loop (Pr = 0.26 | P = 0.04); Loss of Methylation at R494 (Pr = 0.16 | P = 0.01), ELME000233,-
COL2A1_HUMAN,G822D,0.967,Loss of Methylation at R818 (Pr = 0.19 | P = 7.6e-03), ELME000133,-
COL2A1_HUMAN,T638I,0.54,Altered Disordered interface (Pr = 0.45 | P = 1.8e-03); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Acetylation at K634 (Pr = 0.25 | P = 0.01); Loss of Methylation at K634 (Pr = 0.22 | P = 4.3e-03); Gain of SUMOylation at K634 (Pr = 0.21 | P = 0.03); Loss of Ubiquitylation at K634 (Pr = 0.15 | P = 0.05), None,-
COL2A1_HUMAN,I2L,0.319,-,-,-
COL2A1_HUMAN,I2T,0.568,Altered Stability (Pr = 0.32 | P = 4.9e-03); Gain of N-terminal acetylation at M1 (Pr = 0.08 | P = 2.1e-03); Altered Signal peptide (Pr = 0.07 | P = 2.8e-03), ELME000355,-
COL2A1_HUMAN,R3L,0.482,-,-,-
COL2A1_HUMAN,G5R,0.731,Gain of Helix (Pr = 0.32 | P = 2.1e-03); Altered Signal peptide (Pr = 0.18 | P = 1.2e-03); Loss of N-terminal acetylation at M1 (Pr = 0.07 | P = 2.5e-03), ELME000012|ELME000051|ELME000233|PS00008,-
COL2A1_HUMAN,T9M,0.17,-,-,-
COL2A1_HUMAN,L10W,0.648,Altered Signal peptide (Pr = 0.25 | P = 5.7e-04), ELME000052|ELME000149|ELME000333|ELME000335|PS00008,-
COL2A1_HUMAN,V17I,0.119,-,-,-
COL2A1_HUMAN,V28I,0.086,-,-,-
COL2A1_HUMAN,Q29I,0.657,Loss of Pyrrolidone carboxylic acid at Q24 (Pr = 0.25 | P = 7.1e-04); Gain of Disulfide linkage at C34 (Pr = 0.21 | P = 0.02); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Altered Signal peptide (Pr = 0.01 | P = 5.1e-03), None,-
COL2A1_HUMAN,E30Q,0.178,-,-,-
COL2A1_HUMAN,A31E,0.386,-,-,-
COL2A1_HUMAN,N42K,0.349,-,-,-
COL2A1_HUMAN,W47R,0.864,Gain of Intrinsic disorder (Pr = 0.38 | P = 0.01); Gain of SUMOylation at K48 (Pr = 0.22 | P = 0.02); Altered Transmembrane protein (Pr = 0.16 | P = 0.01), ELME000102|ELME000155,-
COL2A1_HUMAN,T59D,0.503,Gain of Disulfide linkage at C57 (Pr = 0.20 | P = 0.02), ELME000052|ELME000147|PS01208,-
COL2A1_HUMAN,V62I,0.286,-,-,-
COL2A1_HUMAN,E79H,0.348,-,-,-
COL2A1_HUMAN,I88V,0.14,-,-,-
COL2A1_HUMAN,T91A,0.132,-,-,-
COL2A1_HUMAN,L93R,0.617,Gain of Intrinsic disorder (Pr = 0.32 | P = 0.03); Gain of O-linked glycosylation at S97 (Pr = 0.22 | P = 0.01); Gain of Proteolytic cleavage at L93 (Pr = 0.21 | P = 1.7e-03); Gain of ADP-ribosylation at L93 (Pr = 0.20 | P = 0.03), ELME000053|ELME000062|PS00005,-
COL2A1_HUMAN,S97G,0.404,-,-,-
COL2A1_HUMAN,G98S,0.849,Gain of O-linked glycosylation at T95 (Pr = 0.27 | P = 7.0e-03); Loss of B-factor (Pr = 0.25 | P = 0.05); Gain of Proteolytic cleavage at S97 (Pr = 0.21 | P = 1.7e-03); Loss of Methylation at K103 (Pr = 0.16 | P = 0.01), ELME000085|ELME000202|ELME000239,-
COL2A1_HUMAN,Q99N,0.241,-,-,-
COL2A1_HUMAN,P100S,0.4,-,-,-
COL2A1_HUMAN,P100W,0.7,Loss of Intrinsic disorder (Pr = 0.43 | P = 0.02); Loss of B-factor (Pr = 0.33 | P = 2.4e-03); Loss of O-linked glycosylation at T95 (Pr = 0.22 | P = 0.02); Gain of Proteolytic cleavage at A96 (Pr = 0.18 | P = 4.9e-03); Loss of Methylation at K103 (Pr = 0.17 | P = 0.01); Gain of Pyrrolidone carboxylic acid at Q105 (Pr = 0.08 | P = 0.02), None,-
COL2A1_HUMAN,G104L,0.956,Loss of B-factor (Pr = 0.32 | P = 3.7e-03); Gain of SUMOylation at K106 (Pr = 0.23 | P = 0.02); Gain of Acetylation at K106 (Pr = 0.22 | P = 0.03); Loss of Methylation at K106 (Pr = 0.18 | P = 9.9e-03); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), None,-
COL2A1_HUMAN,G104W,0.951,Loss of B-factor (Pr = 0.35 | P = 1.4e-03); Loss of SUMOylation at K106 (Pr = 0.22 | P = 0.02); Gain of Acetylation at K106 (Pr = 0.19 | P = 0.05); Loss of Methylation at K106 (Pr = 0.19 | P = 8.2e-03); Gain of Pyrrolidone carboxylic acid at Q105 (Pr = 0.08 | P = 0.02), None,-
COL2A1_HUMAN,Q105A,0.76,Loss of SUMOylation at K106 (Pr = 0.31 | P = 2.5e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of Acetylation at K106 (Pr = 0.20 | P = 0.04); Gain of Methylation at K106 (Pr = 0.19 | P = 6.3e-03); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), ELME000002|ELME000146,-
COL2A1_HUMAN,Q105E,0.616,Gain of B-factor (Pr = 0.29 | P = 4.8e-03); Gain of SUMOylation at K106 (Pr = 0.28 | P = 4.2e-03); Gain of Acetylation at K106 (Pr = 0.19 | P = 0.04); Gain of Methylation at K106 (Pr = 0.17 | P = 8.2e-03); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), ELME000002,-
COL2A1_HUMAN,K106P,0.808,Loss of SUMOylation at K106 (Pr = 0.32 | P = 2.3e-03); Gain of B-factor (Pr = 0.25 | P = 0.02); Loss of Acetylation at K106 (Pr = 0.23 | P = 0.02); Loss of Methylation at K106 (Pr = 0.21 | P = 5.3e-03); Gain of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), ELME000005|ELME000133|ELME000155,-
COL2A1_HUMAN,E108P,0.759,Gain of B-factor (Pr = 0.27 | P = 0.01); Loss of SUMOylation at K106 (Pr = 0.27 | P = 5.5e-03); Gain of Acetylation at K113 (Pr = 0.25 | P = 0.01); Gain of Methylation at K113 (Pr = 0.20 | P = 4.5e-03); Gain of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), None,-
COL2A1_HUMAN,G110S,0.848,Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Acetylation at K113 (Pr = 0.25 | P = 0.01); Gain of Phosphorylation at G110 (Pr = 0.24 | P = 0.04); Loss of SUMOylation at K106 (Pr = 0.22 | P = 0.02); Loss of Methylation at K113 (Pr = 0.19 | P = 8.1e-03); Gain of Proteolytic cleavage at D114 (Pr = 0.14 | P = 0.01); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), None,-
MYO7A_HUMAN,S1106T,0.142,-,-,-
MYO7A_HUMAN,R1108K,0.257,-,-,-
MYO7A_HUMAN,V1126D,0.753,Gain of B-factor (Pr = 0.25 | P = 0.03); Loss of Acetylation at K1128 (Pr = 0.22 | P = 0.03); Altered Disordered interface (Pr = 0.18 | P = 0.05), ELME000052|ELME000053|ELME000063|ELME000220|PS00006,-
MYO7A_HUMAN,T1127S,0.213,-,-,-
MYO7A_HUMAN,Q1138R,0.238,-,-,-
MYO7A_HUMAN,I1157V,0.181,-,-,-
MYO7A_HUMAN,A1166T,0.336,-,-,-
MYO7A_HUMAN,K1281R,0.099,-,-,-
MYO7A_HUMAN,I1323V,0.223,-,-,-
MYO7A_HUMAN,S1358F,0.383,-,-,-
MYO7A_HUMAN,E1359D,0.249,-,-,-
MYO7A_HUMAN,N1365H,0.584,Altered Ordered interface (Pr = 0.31 | P = 0.02); Altered Metal binding (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.24 | P = 1.6e-03); Loss of Allosteric site at Y1368 (Pr = 0.21 | P = 0.04), ELME000052,-
MYO7A_HUMAN,S1402C,0.592,Altered Transmembrane protein (Pr = 0.11 | P = 0.03); Loss of Sulfation at Y1400 (Pr = 0.03 | P = 0.02), None,-
MYO7A_HUMAN,Y1416S,0.815,Altered Transmembrane protein (Pr = 0.15 | P = 0.01); Gain of O-linked glycosylation at T1415 (Pr = 0.11 | P = 0.05), ELME000182|PS00006,-
MYO7A_HUMAN,T1427N,0.25,-,-,-
MYO7A_HUMAN,A1445T,0.249,-,-,-
MYO7A_HUMAN,A1451S,0.087,-,-,-
MYO7A_HUMAN,G1481V,0.859,Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Strand (Pr = 0.28 | P = 0.01); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered Transmembrane protein (Pr = 0.25 | P = 1.1e-03); Loss of Sulfation at Y1477 (Pr = 0.01 | P = 0.04), ELME000063|ELME000085|ELME000155,-
MYO7A_HUMAN,A1540G,0.15,-,-,-
MYO7A_HUMAN,P1541S,0.183,-,-,-
MYO7A_HUMAN,H1542Q,0.157,-,-,-
MYO7A_HUMAN,H1542R,0.173,-,-,-
MYO7A_HUMAN,S1543L,0.139,-,-,-
MYO7A_HUMAN,L1548V,0.253,-,-,-
MYO7A_HUMAN,T1549I,0.205,-,-,-
MYO7A_HUMAN,P1553S,0.37,-,-,-
MYO7A_HUMAN,P1556L,0.425,-,-,-
MYO7A_HUMAN,C1557Y,0.591,Altered Ordered interface (Pr = 0.31 | P = 2.4e-03); Gain of Strand (Pr = 0.28 | P = 8.7e-03); Loss of Loop (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.10 | P = 0.05); Gain of Disulfide linkage at C1560 (Pr = 0.10 | P = 0.05), ELME000053|ELME000136|ELME000162|ELME000337,-
MYO7A_HUMAN,T1566V,0.125,-,-,-
MYO7A_HUMAN,A1567V,0.206,-,-,-
MYO7A_HUMAN,I1575L,0.374,-,-,-
MYO7A_HUMAN,I1575M,0.45,-,-,-
MYO7A_HUMAN,A1618V,0.113,-,-,-
MYO7A_HUMAN,N1645T,0.616,Altered Transmembrane protein (Pr = 0.15 | P = 0.02); Altered DNA binding (Pr = 0.14 | P = 0.05), ELME000085,-
MYO7A_HUMAN,T1656N,0.76,Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03); Altered DNA binding (Pr = 0.18 | P = 0.03), None,-
MYO7A_HUMAN,Q1658H,0.478,-,-,-
MYO7A_HUMAN,T1664M,0.324,-,-,-
MYO7A_HUMAN,M1686L,0.254,-,-,-
MYO7A_HUMAN,D1689A,0.383,-,-,-
MYO7A_HUMAN,V1695A,0.156,-,-,-
MYO7A_HUMAN,R1701H,0.131,-,-,-
MYO7A_HUMAN,A1703P,0.228,-,-,-
MYO7A_HUMAN,A1703T,0.081,-,-,-
MYO7A_HUMAN,Y1719L,0.762,Loss of Phosphorylation at Y1719 (Pr = 0.47 | P = 5.0e-03); Gain of Helix (Pr = 0.28 | P = 0.03); Loss of Sulfation at Y1721 (Pr = 0.05 | P = 9.1e-03), ELME000120|ELME000147,-
MYO7A_HUMAN,Y1721R,0.732,Loss of Phosphorylation at Y1721 (Pr = 0.46 | P = 5.2e-03); Gain of Intrinsic disorder (Pr = 0.43 | P = 4.9e-03); Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of Sulfation at Y1721 (Pr = 0.05 | P = 8.7e-03), ELME000120|ELME000182,-
MYO7A_HUMAN,P1725Q,0.779,Gain of Phosphorylation at Y1721 (Pr = 0.25 | P = 0.03); Loss of Sulfation at Y1721 (Pr = 0.05 | P = 9.3e-03), None,-
MYO7A_HUMAN,K1727A,0.82,Altered Disordered interface (Pr = 0.17 | P = 0.05), None,-
MYO7A_HUMAN,M1734E,0.659,Altered Disordered interface (Pr = 0.48 | P = 3.3e-03); Gain of Intrinsic disorder (Pr = 0.38 | P = 0.01), ELME000064|PS00006,-
MYO7A_HUMAN,A1738V,0.145,-,-,-
MYO7A_HUMAN,R1739D,0.833,Altered Disordered interface (Pr = 0.61 | P = 6.0e-04); Gain of B-factor (Pr = 0.24 | P = 0.04), ELME000321|PS00006,-
MYO7A_HUMAN,K1741R,0.302,-,-,-
MYO7A_HUMAN,T1748F,0.737,Altered Disordered interface (Pr = 0.26 | P = 0.01); Gain of Proteolytic cleavage at W1745 (Pr = 0.12 | P = 0.03), ELME000173,-
MYO7A_HUMAN,R1749V,0.707,Altered Disordered interface (Pr = 0.31 | P = 0.01); Altered DNA binding (Pr = 0.15 | P = 0.04); Gain of Proteolytic cleavage at W1745 (Pr = 0.13 | P = 0.02), None,-
MYO7A_HUMAN,K1753E,0.543,Altered Disordered interface (Pr = 0.18 | P = 0.05), ELME000146,-
MYO7A_HUMAN,K1753P,0.694,Altered Disordered interface (Pr = 0.18 | P = 0.05), ELME000146,-
MYO7A_HUMAN,A1755G,0.278,-,-,-
MYO7A_HUMAN,L1760Q,0.44,-,-,-
MYO7A_HUMAN,L1761A,0.35,-,-,-
MYO7A_HUMAN,G1762L,0.48,-,-,-
MYO7A_HUMAN,S1763N,0.133,-,-,-
MYO7A_HUMAN,S1767R,0.373,-,-,-
MYO7A_HUMAN,C1771S,0.88,, ELME000147|ELME000197,-
MYO7A_HUMAN,I1775T,0.373,-,-,-
MYO7A_HUMAN,K1779H,0.862,Altered Ordered interface (Pr = 0.27 | P = 0.05); Loss of Acetylation at K1779 (Pr = 0.25 | P = 0.01); Loss of Allosteric site at Y1780 (Pr = 0.23 | P = 0.02); Gain of Proteolytic cleavage at D1783 (Pr = 0.11 | P = 0.04), ELME000041,-
MYO7A_HUMAN,Y1780T,0.932,Altered Ordered interface (Pr = 0.29 | P = 0.03); Loss of Allosteric site at Y1780 (Pr = 0.28 | P = 7.1e-03); Loss of Acetylation at K1779 (Pr = 0.22 | P = 0.03); Loss of Proteolytic cleavage at D1783 (Pr = 0.11 | P = 0.05), ELME000041|ELME000220|PS00006,-
MYO7A_HUMAN,T1789V,0.325,-,-,-
MYO7A_HUMAN,P1808A,0.481,-,-,-
MYO7A_HUMAN,Q1816H,0.856,Altered Disordered interface (Pr = 0.29 | P = 0.03); Altered Metal binding (Pr = 0.19 | P = 0.02); Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000081|ELME000083|ELME000120|ELME000182,-
MYO7A_HUMAN,F1844Y,0.462,-,-,-
MYO7A_HUMAN,I1849V,0.071,-,-,-
MYO7A_HUMAN,L1851V,0.602,, None,-
MYO7A_HUMAN,Q1855S,0.728,, ELME000239,-
MYO7A_HUMAN,S1860P,0.699,, ELME000102|ELME000106|ELME000336|PS00005,-
MYO7A_HUMAN,R1861W,0.534,, ELME000102|ELME000233|ELME000328|ELME000336|PS00005,-
MYO7A_HUMAN,V1918A,0.854,Gain of Intrinsic disorder (Pr = 0.35 | P = 0.02); Altered Metal binding (Pr = 0.31 | P = 0.01); Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Loss of Strand (Pr = 0.26 | P = 0.03); Altered DNA binding (Pr = 0.19 | P = 0.03); Altered Stability (Pr = 0.11 | P = 0.04), ELME000239,-
MYO7A_HUMAN,V1918E,0.952,Gain of Intrinsic disorder (Pr = 0.45 | P = 3.8e-03); Altered Metal binding (Pr = 0.33 | P = 0.01); Altered Ordered interface (Pr = 0.31 | P = 0.02); Gain of B-factor (Pr = 0.29 | P = 4.0e-03); Loss of Strand (Pr = 0.26 | P = 0.03); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Altered DNA binding (Pr = 0.19 | P = 0.03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000117,-
MYO7A_HUMAN,K1923P,0.713,Altered Ordered interface (Pr = 0.36 | P = 3.2e-03); Loss of Helix (Pr = 0.27 | P = 0.04); Altered Metal binding (Pr = 0.25 | P = 0.01); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.04); Altered DNA binding (Pr = 0.20 | P = 0.02), ELME000136|ELME000153|ELME000159|PS00005,-
MYO7A_HUMAN,N1930G,0.366,-,-,-
MYO7A_HUMAN,N1930S,0.139,-,-,-
MYO7A_HUMAN,I1931H,0.85,Altered Metal binding (Pr = 0.23 | P = 0.04), ELME000052|ELME000313,-
MYO7A_HUMAN,T1933S,0.1,-,-,-
MYO7A_HUMAN,R1934G,0.724,, ELME000052|ELME000106|ELME000146|ELME000313,-
MYO7A_HUMAN,R1934S,0.664,, ELME000052|ELME000106|ELME000146|ELME000313|ELME000335,-
MYO7A_HUMAN,L1936V,0.304,-,-,-
MYO7A_HUMAN,F1946L,0.924,Altered Stability (Pr = 0.10 | P = 0.04), ELME000041|ELME000149|ELME000335,-
MYO7A_HUMAN,F1946S,0.944,Altered Stability (Pr = 0.40 | P = 2.9e-03); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.04); Altered Transmembrane protein (Pr = 0.09 | P = 0.05), ELME000336|PS00005,-
MYO7A_HUMAN,I1949V,0.48,-,-,-
MYO7A_HUMAN,A1950I,0.445,-,-,-
MYO7A_HUMAN,A1950L,0.594,Altered Transmembrane protein (Pr = 0.16 | P = 0.01), ELME000333,-
MYO7A_HUMAN,V1984L,0.335,-,-,-
MYO7A_HUMAN,V1984M,0.401,-,-,-
MYO7A_HUMAN,T2000S,0.219,-,-,-
MYO7A_HUMAN,R2061Q,0.236,-,-,-
MYO7A_HUMAN,V2072I,0.041,-,-,-
MYO7A_HUMAN,N2124H,0.348,-,-,-
MYO7A_HUMAN,K2135H,0.859,Altered Transmembrane protein (Pr = 0.21 | P = 4.3e-03); Altered Metal binding (Pr = 0.19 | P = 0.02), None,-
MYO7A_HUMAN,K2156S,0.861,Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Transmembrane protein (Pr = 0.28 | P = 3.6e-04); Loss of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000239,-
MYO7A_HUMAN,N2159L,0.864,Altered Ordered interface (Pr = 0.44 | P = 4.0e-04); Altered Transmembrane protein (Pr = 0.29 | P = 2.1e-04); Gain of Loop (Pr = 0.29 | P = 8.4e-03); Loss of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000053|ELME000063|ELME000070|ELME000336|PS00001,-
MYO7A_HUMAN,Y2166V,0.881,Altered Ordered interface (Pr = 0.35 | P = 4.8e-03); Loss of Loop (Pr = 0.28 | P = 0.02); Altered Metal binding (Pr = 0.26 | P = 0.03); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000120|ELME000182,-
COL2A1_HUMAN,Q29D,0.567,Loss of Pyrrolidone carboxylic acid at Q24 (Pr = 0.25 | P = 7.5e-04); Gain of Disulfide linkage at C34 (Pr = 0.19 | P = 0.02); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), None,-
COL2A1_HUMAN,S33N,0.281,-,-,-
COL2A1_HUMAN,V35L,0.168,-,-,-
COL2A1_HUMAN,V35M,0.224,-,-,-
COL2A1_HUMAN,D37S,0.341,-,-,-
COL2A1_HUMAN,R40S,0.555,Gain of Loop (Pr = 0.27 | P = 0.04); Altered Transmembrane protein (Pr = 0.25 | P = 1.6e-03); Gain of Sulfation at Y41 (Pr = 0.01 | P = 0.04), PS00006|PS00008,-
COL2A1_HUMAN,E50S,0.623,Loss of SUMOylation at K48 (Pr = 0.24 | P = 0.01); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000136|ELME000153|ELME000159,-
COL2A1_HUMAN,R53K,0.438,-,-,-
COL2A1_HUMAN,T61A,0.256,-,-,-
COL2A1_HUMAN,I68V,0.123,-,-,-
COL2A1_HUMAN,V72M,0.058,-,-,-
COL2A1_HUMAN,C75I,0.75,Loss of Disulfide linkage at C75 (Pr = 0.15 | P = 0.03), ELME000136|ELME000146|ELME000155|ELME000159|PS01208,-
COL2A1_HUMAN,C75V,0.762,Gain of Loop (Pr = 0.28 | P = 0.01); Loss of Disulfide linkage at C75 (Pr = 0.15 | P = 0.03), ELME000136|ELME000146|ELME000155|ELME000159|PS01208,-
COL2A1_HUMAN,S77N,0.099,-,-,-
COL2A1_HUMAN,S77R,0.21,-,-,-
COL2A1_HUMAN,I80T,0.352,-,-,-
COL2A1_HUMAN,I80V,0.196,-,-,-
COL2A1_HUMAN,D92E,0.469,-,-,-
COL2A1_HUMAN,T95P,0.634,Gain of Intrinsic disorder (Pr = 0.33 | P = 0.03); Gain of O-linked glycosylation at S97 (Pr = 0.27 | P = 7.4e-03); Loss of Proteolytic cleavage at A96 (Pr = 0.18 | P = 4.6e-03), ELME000053|ELME000239,-
COL2A1_HUMAN,Q99K,0.172,-,-,-
COL2A1_HUMAN,G101L,0.918,Loss of B-factor (Pr = 0.32 | P = 3.7e-03); Loss of SUMOylation at K106 (Pr = 0.22 | P = 0.02); Gain of Acetylation at K106 (Pr = 0.20 | P = 0.04); Gain of O-linked glycosylation at S97 (Pr = 0.19 | P = 0.02); Loss of Methylation at K106 (Pr = 0.17 | P = 0.01); Gain of Proteolytic cleavage at A96 (Pr = 0.17 | P = 7.3e-03); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), None,-
COL2A1_HUMAN,K103L,0.626,Loss of B-factor (Pr = 0.32 | P = 4.4e-03); Gain of Loop (Pr = 0.29 | P = 8.8e-03); Gain of SUMOylation at K106 (Pr = 0.22 | P = 0.02); Loss of Methylation at K103 (Pr = 0.19 | P = 8.2e-03); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), None,-
COL2A1_HUMAN,Q105R,0.665,Loss of Loop (Pr = 0.31 | P = 4.5e-03); Loss of B-factor (Pr = 0.25 | P = 0.05); Gain of SUMOylation at K106 (Pr = 0.24 | P = 0.01); Loss of Acetylation at K106 (Pr = 0.20 | P = 0.04); Loss of Methylation at K106 (Pr = 0.17 | P = 0.01); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), ELME000093|ELME000102|PS00009,-
COL2A1_HUMAN,G107A,0.92,Loss of B-factor (Pr = 0.30 | P = 9.5e-03); Gain of SUMOylation at K106 (Pr = 0.26 | P = 7.2e-03); Gain of Methylation at K106 (Pr = 0.17 | P = 8.4e-03); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), None,-
COL2A1_HUMAN,P109C,0.808,Loss of B-factor (Pr = 0.29 | P = 0.01); Loss of Acetylation at K113 (Pr = 0.27 | P = 7.5e-03); Loss of SUMOylation at K106 (Pr = 0.23 | P = 0.02); Loss of Methylation at K113 (Pr = 0.21 | P = 5.6e-03); Loss of Proteolytic cleavage at D114 (Pr = 0.14 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.02), None,-
COL2A1_HUMAN,G110D,0.912,Loss of Acetylation at K113 (Pr = 0.26 | P = 9.8e-03); Loss of SUMOylation at K106 (Pr = 0.22 | P = 0.02); Loss of Methylation at K113 (Pr = 0.19 | P = 8.3e-03); Gain of Proteolytic cleavage at D114 (Pr = 0.15 | P = 0.01); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), None,-
COL2A1_HUMAN,D111R,0.711,Loss of Acetylation at K113 (Pr = 0.32 | P = 2.9e-03); Gain of SUMOylation at K106 (Pr = 0.22 | P = 0.02); Loss of Methylation at K113 (Pr = 0.19 | P = 8.1e-03); Loss of Proteolytic cleavage at D114 (Pr = 0.14 | P = 0.02), None,-
COL2A1_HUMAN,D114G,0.775,Gain of Acetylation at K113 (Pr = 0.27 | P = 6.3e-03); Gain of Methylation at K119 (Pr = 0.23 | P = 2.0e-03); Loss of SUMOylation at K113 (Pr = 0.21 | P = 0.03); Loss of Proteolytic cleavage at D114 (Pr = 0.15 | P = 0.01), None,-
COL2A1_HUMAN,I115V,0.079,-,-,-
COL2A1_HUMAN,V116K,0.529,Gain of Acetylation at K113 (Pr = 0.35 | P = 1.9e-03); Gain of B-factor (Pr = 0.30 | P = 2.3e-03); Altered Disordered interface (Pr = 0.28 | P = 0.03); Gain of SUMOylation at V116 (Pr = 0.28 | P = 4.4e-03); Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Methylation at K119 (Pr = 0.21 | P = 5.5e-03); Loss of Proteolytic cleavage at D114 (Pr = 0.15 | P = 0.01), ELME000146|ELME000155,-
COL2A1_HUMAN,K119Q,0.4,-,-,-
COL2A1_HUMAN,D139E,0.237,-,-,-
COL2A1_HUMAN,P163L,0.613,Loss of B-factor (Pr = 0.38 | P = 2.6e-04); Gain of Loop (Pr = 0.28 | P = 0.01), ELME000057|ELME000155,-
COL2A1_HUMAN,G165A,0.934,Loss of B-factor (Pr = 0.32 | P = 4.2e-03), ELME000155,-
COL2A1_HUMAN,P167A,0.665,Loss of B-factor (Pr = 0.35 | P = 1.1e-03); Gain of Loop (Pr = 0.27 | P = 0.03), ELME000155,-
COL2A1_HUMAN,G168Y,0.965,Altered Disordered interface (Pr = 0.37 | P = 7.0e-03); Loss of B-factor (Pr = 0.36 | P = 5.9e-04); Gain of Loop (Pr = 0.29 | P = 7.8e-03); Gain of Sulfation at G168 (Pr = 0.02 | P = 0.03), ELME000155,-
COL2A1_HUMAN,P173H,0.549,Loss of B-factor (Pr = 0.32 | P = 4.7e-03); Gain of Loop (Pr = 0.29 | P = 8.8e-03); Altered Disordered interface (Pr = 0.28 | P = 0.03), ELME000155,-
COL2A1_HUMAN,P173S,0.449,-,-,-
COL2A1_HUMAN,G176I,0.753,Altered Disordered interface (Pr = 0.43 | P = 2.5e-03); Loss of B-factor (Pr = 0.32 | P = 5.1e-03); Gain of Loop (Pr = 0.27 | P = 0.02), ELME000340|PS00008,-
COL2A1_HUMAN,G176T,0.703,Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of Loop (Pr = 0.28 | P = 0.01), PS00008,-
COL2A1_HUMAN,A217S,0.182,-,-,-
COL2A1_HUMAN,P245A,0.263,-,-,-
COL2A1_HUMAN,P245S,0.303,-,-,-
COL2A1_HUMAN,P260A,0.505,Loss of B-factor (Pr = 0.26 | P = 0.05); Gain of Methylation at K262 (Pr = 0.26 | P = 6.3e-04); Loss of Acetylation at K262 (Pr = 0.25 | P = 0.01); Gain of SUMOylation at K259 (Pr = 0.22 | P = 0.02); Gain of Ubiquitylation at K259 (Pr = 0.20 | P = 8.9e-03), None,-
COL2A1_HUMAN,P268L,0.257,-,-,-
COL2A1_HUMAN,S311N,0.234,-,-,-
COL2A1_HUMAN,N317S,0.313,-,-,-
COL2A1_HUMAN,A388G,0.295,-,-,-
COL2A1_HUMAN,P391A,0.33,-,-,-
COL2A1_HUMAN,T455A,0.144,-,-,-
COL2A1_HUMAN,I460V,0.096,-,-,-
COL2A1_HUMAN,G474D,0.913,Gain of Loop (Pr = 0.29 | P = 9.8e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Methylation at K470 (Pr = 0.23 | P = 3.6e-03); Loss of Acetylation at K470 (Pr = 0.20 | P = 0.04), ELME000155,-
COL2A1_HUMAN,I503V,0.068,-,-,-
COL2A1_HUMAN,F517V,0.799,Altered Disordered interface (Pr = 0.39 | P = 4.7e-03); Gain of Methylation at R515 (Pr = 0.19 | P = 5.4e-03), None,-
COL2A1_HUMAN,S536N,0.255,-,-,-
COL2A1_HUMAN,A544P,0.425,-,-,-
COL2A1_HUMAN,P548N,0.81,Loss of B-factor (Pr = 0.26 | P = 0.04); Altered Metal binding (Pr = 0.10 | P = 0.05); Loss of Methylation at R550 (Pr = 0.10 | P = 0.04), ELME000155|ELME000316,-
COL2A1_HUMAN,V575L,0.129,-,-,-
COL2A1_HUMAN,A595T,0.375,-,-,-
COL2A1_HUMAN,P623A,0.252,-,-,-
COL2A1_HUMAN,A650S,0.179,-,-,-
COL2A1_HUMAN,P673A,0.229,-,-,-
COL2A1_HUMAN,P680A,0.252,-,-,-
COL2A1_HUMAN,P736S,0.582,Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Methylation at K731 (Pr = 0.26 | P = 1.6e-03); Gain of Acetylation at K731 (Pr = 0.23 | P = 0.02); Loss of SUMOylation at K731 (Pr = 0.19 | P = 0.05); Gain of Ubiquitylation at K731 (Pr = 0.17 | P = 0.02); Gain of O-linked glycosylation at S734 (Pr = 0.14 | P = 0.03); Altered Metal binding (Pr = 0.12 | P = 0.04), ELME000085|ELME000155|ELME000239|PS00008,-
COL2A1_HUMAN,A737T,0.141,-,-,-
COL2A1_HUMAN,A761S,0.137,-,-,-
COL2A1_HUMAN,G784A,0.21,-,-,-
COL2A1_HUMAN,G784V,0.381,-,-,-
COL2A1_HUMAN,P808L,0.423,-,-,-
COL2A1_HUMAN,A812T,0.149,-,-,-
COL2A1_HUMAN,P830W,0.684,Loss of B-factor (Pr = 0.37 | P = 4.7e-04); Altered Disordered interface (Pr = 0.30 | P = 0.02); Altered Metal binding (Pr = 0.10 | P = 0.05), ELME000155,-
COL2A1_HUMAN,G831T,0.959,Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of O-linked glycosylation at G831 (Pr = 0.22 | P = 0.01); Altered Metal binding (Pr = 0.10 | P = 0.05), ELME000053|ELME000136|ELME000155|ELME000159|ELME000358,-
COL2A1_HUMAN,A833C,0.428,-,-,-
COL2A1_HUMAN,A836S,0.343,-,-,-
COL2A1_HUMAN,P839Q,0.749,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Pyrrolidone carboxylic acid at P839 (Pr = 0.04 | P = 0.05), None,-
COL2A1_HUMAN,A862N,0.417,-,-,-
COL2A1_HUMAN,A862V,0.238,-,-,-
COL2A1_HUMAN,P868L,0.605,Loss of B-factor (Pr = 0.30 | P = 8.5e-03); Loss of O-linked glycosylation at S869 (Pr = 0.12 | P = 0.05); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000085|ELME000155,-
COL2A1_HUMAN,S869Q,0.652,Gain of B-factor (Pr = 0.25 | P = 0.03); Loss of O-linked glycosylation at S869 (Pr = 0.13 | P = 0.04); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000085,-
COL2A1_HUMAN,N913S,0.495,-,-,-
COL2A1_HUMAN,P917T,0.421,-,-,-
COL2A1_HUMAN,P937S,0.442,-,-,-
COL2A1_HUMAN,P938S,0.482,-,-,-
COL2A1_HUMAN,D962S,0.383,-,-,-
COL2A1_HUMAN,P964A,0.233,-,-,-
COL2A1_HUMAN,S1001T,0.528,Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Methylation at K1006 (Pr = 0.26 | P = 1.4e-03); Loss of Acetylation at K1006 (Pr = 0.24 | P = 0.02); Loss of O-linked glycosylation at S1001 (Pr = 0.18 | P = 0.03); Loss of Ubiquitylation at K1006 (Pr = 0.15 | P = 0.05), ELME000085|ELME000239,-
COL2A1_HUMAN,T1028S,0.267,-,-,-
COL2A1_HUMAN,A1031S,0.108,-,-,-
COL2A1_HUMAN,P1046S,0.85,Loss of B-factor (Pr = 0.28 | P = 0.02); Altered Metal binding (Pr = 0.13 | P = 0.03); Loss of Methylation at R1048 (Pr = 0.10 | P = 0.04), ELME000085|ELME000321|PS00005|PS00006,-
COL2A1_HUMAN,A1051V,0.363,-,-,-
COL2A1_HUMAN,T1061A,0.229,-,-,-
COL2A1_HUMAN,A1069T,0.226,-,-,-
COL2A1_HUMAN,P1076S,0.69,Gain of Loop (Pr = 0.32 | P = 2.4e-03); Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of O-linked glycosylation at P1076 (Pr = 0.15 | P = 0.03), ELME000085|ELME000136|ELME000155|ELME000159|ELME000239,-
COL2A1_HUMAN,T1082V,0.267,-,-,-
COL2A1_HUMAN,P1124Q,0.346,-,-,-
COL2A1_HUMAN,A1153T,0.179,-,-,-
COL2A1_HUMAN,N1204S,0.211,-,-,-
COL2A1_HUMAN,P1228Q,0.043,-,-,-
COL2A1_HUMAN,G1247D,0.296,-,-,-
COL2A1_HUMAN,G1247N,0.102,-,-,-
FGFR1_HUMAN,M1T,0.949,Altered Disordered interface (Pr = 0.20 | P = 0.04); Altered Signal peptide (Pr = 0.12 | P = 1.6e-03); Loss of N-terminal acetylation at M1 (Pr = 0.02 | P = 6.1e-03), ELME000355,-
FGFR1_HUMAN,W2K,0.89,Gain of Intrinsic disorder (Pr = 0.37 | P = 0.01); Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Disordered interface (Pr = 0.21 | P = 0.03); Altered Signal peptide (Pr = 0.19 | P = 7.3e-04); Loss of N-terminal acetylation at M1 (Pr = 0.02 | P = 6.1e-03), ELME000351|ELME000355,-
FGFR1_HUMAN,S3G,0.459,-,-,-
FGFR1_HUMAN,W4F,0.859,Altered Disordered interface (Pr = 0.23 | P = 0.03); Altered Signal peptide (Pr = 0.11 | P = 1.6e-03); Loss of N-terminal acetylation at M1 (Pr = 0.02 | P = 6.1e-03), ELME000137|PS00005,-
FGFR1_HUMAN,L7R,0.93,Altered Disordered interface (Pr = 0.76 | P = 1.5e-05); Altered Signal peptide (Pr = 0.13 | P = 1.3e-03), ELME000106|ELME000137|ELME000146|ELME000233,-
FGFR1_HUMAN,F9L,0.731,Altered Signal peptide (Pr = 0.17 | P = 1.1e-03); Altered Disordered interface (Pr = 0.17 | P = 0.04), ELME000041|ELME000106|ELME000137|ELME000146,-
FGFR1_HUMAN,F9V,0.758,Altered Disordered interface (Pr = 0.21 | P = 0.03); Altered Signal peptide (Pr = 0.16 | P = 1.2e-03), ELME000041|ELME000106|ELME000137|ELME000146,-
FGFR1_HUMAN,A11G,0.714,Altered Signal peptide (Pr = 0.15 | P = 1.6e-03), ELME000041|PS00008,-
FGFR1_HUMAN,A11N,0.822,Altered Signal peptide (Pr = 0.15 | P = 1.6e-03); Gain of GPI-anchor amidation at A11 (Pr = 0.02 | P = 0.01), ELME000041,-
FGFR1_HUMAN,L13G,0.941,Altered Signal peptide (Pr = 0.16 | P = 4.9e-04), ELME000041|ELME000052|ELME000333|PS00008,-
FGFR1_HUMAN,V14G,0.896,Altered Signal peptide (Pr = 0.18 | P = 4.1e-04); Altered Stability (Pr = 0.09 | P = 0.05), ELME000041|ELME000052|ELME000333,-
FGFR1_HUMAN,V14R,0.919,Altered Disordered interface (Pr = 0.21 | P = 0.03); Altered Signal peptide (Pr = 0.20 | P = 2.9e-04), ELME000041|ELME000052|ELME000146|ELME000333,-
FGFR1_HUMAN,V14Y,0.925,Altered Signal peptide (Pr = 0.19 | P = 3.3e-04), ELME000041|ELME000052|ELME000080|ELME000182|ELME000333,-
FGFR1_HUMAN,T17A,0.641,Altered Signal peptide (Pr = 0.22 | P = 5.7e-04); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.05), ELME000052|ELME000053,-
FGFR1_HUMAN,L18E,0.902,Altered Signal peptide (Pr = 0.21 | P = 2.7e-04); Gain of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.03), ELME000052|ELME000053|ELME000064|ELME000147|ELME000220|PS00006,-
FGFR1_HUMAN,L18P,0.941,Altered Signal peptide (Pr = 0.21 | P = 2.6e-04); Gain of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.03), ELME000052|ELME000053|ELME000136|ELME000159,-
FGFR1_HUMAN,R22H,0.433,-,-,-
FGFR1_HUMAN,R22K,0.412,-,-,-
FGFR1_HUMAN,P23I,0.721,Altered Signal peptide (Pr = 0.37 | P = 2.4e-05); Loss of Intrinsic disorder (Pr = 0.35 | P = 0.04); Loss of Loop (Pr = 0.27 | P = 0.04); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.05); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000005|ELME000053|ELME000064|ELME000136|ELME000155|ELME000159,-
FGFR1_HUMAN,P25R,0.663,Gain of ADP-ribosylation at P25 (Pr = 0.31 | P = 3.1e-03); Loss of Loop (Pr = 0.27 | P = 0.03); Altered Signal peptide (Pr = 0.21 | P = 2.4e-04); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q30 (Pr = 0.07 | P = 0.02), ELME000005|ELME000051|ELME000062|ELME000064|ELME000106|ELME000136|ELME000155|ELME000159|ELME000220|ELME000239,-
FGFR1_HUMAN,L27T,0.827,Gain of Intrinsic disorder (Pr = 0.40 | P = 8.8e-03); Gain of B-factor (Pr = 0.26 | P = 0.02); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.05); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q30 (Pr = 0.08 | P = 0.01); Altered Signal peptide (Pr = 0.04 | P = 2.5e-03), ELME000005|ELME000063|ELME000064|ELME000155|ELME000159|ELME000220|ELME000358|PS00006,-
FGFR1_HUMAN,P28S,0.533,Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q32 (Pr = 0.07 | P = 0.02); Altered Signal peptide (Pr = 0.01 | P = 5.1e-03), ELME000005|ELME000064|ELME000155|ELME000220|PS00006,-
FGFR1_HUMAN,Q32K,0.285,-,-,-
FGFR1_HUMAN,G35K,0.376,-,-,-
FGFR1_HUMAN,V38E,0.456,-,-,-
FGFR1_HUMAN,S42A,0.215,-,-,-
FGFR1_HUMAN,R58Q,0.506,Altered Transmembrane protein (Pr = 0.30 | P = 1.4e-04); Altered Metal binding (Pr = 0.27 | P = 0.02); Gain of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Gain of Disulfide linkage at C55 (Pr = 0.22 | P = 0.01), None,-
FGFR1_HUMAN,N65D,0.292,-,-,-
FGFR1_HUMAN,Q72K,0.284,-,-,-
FGFR1_HUMAN,D90E,0.223,-,-,-
FGFR1_HUMAN,V92N,0.335,-,-,-
FGFR1_HUMAN,V92T,0.213,-,-,-
FGFR1_HUMAN,A94G,0.186,-,-,-
FGFR1_HUMAN,A100T,0.397,-,-,-
FGFR1_HUMAN,T141S,0.096,-,-,-
FGFR1_HUMAN,N143S,0.291,-,-,-
FGFR1_HUMAN,L245F,0.878,Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Transmembrane protein (Pr = 0.28 | P = 4.9e-04); Loss of Relative solvent accessibility (Pr = 0.23 | P = 0.05); Altered Stability (Pr = 0.19 | P = 0.01); Loss of N-linked glycosylation at N240 (Pr = 0.13 | P = 8.1e-03); Gain of Sulfation at Y243 (Pr = 0.02 | P = 0.03), ELME000052|ELME000333,-
FGFR1_HUMAN,T318S,0.466,-,-,-
FGFR1_HUMAN,L328A,0.892,Altered Stability (Pr = 0.57 | P = 1.2e-03); Altered Transmembrane protein (Pr = 0.29 | P = 4.0e-04); Gain of N-linked glycosylation at N330 (Pr = 0.11 | P = 0.01), ELME000122|ELME000137|ELME000334|ELME000335,-
FGFR1_HUMAN,R329Q,0.472,-,-,-
FGFR1_HUMAN,F333E,0.891,Altered Transmembrane protein (Pr = 0.34 | P = 4.4e-05); Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Gain of B-factor (Pr = 0.27 | P = 0.01); Altered Metal binding (Pr = 0.17 | P = 0.05); Loss of N-linked glycosylation at N330 (Pr = 0.10 | P = 0.01), ELME000070|ELME000122|ELME000137|ELME000334|PS00001|PS00006,-
FGFR1_HUMAN,D335Q,0.922,Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Metal binding (Pr = 0.19 | P = 0.03); Loss of N-linked glycosylation at N330 (Pr = 0.10 | P = 0.01); Gain of Pyrrolidone carboxylic acid at D335 (Pr = 0.05 | P = 0.04), PS00006,-
FGFR1_HUMAN,A336S,0.548,Altered Metal binding (Pr = 0.32 | P = 0.01); Altered Transmembrane protein (Pr = 0.31 | P = 9.7e-05); Altered Ordered interface (Pr = 0.25 | P = 0.02); Loss of Disulfide linkage at C341 (Pr = 0.18 | P = 0.03), ELME000053|ELME000085|ELME000269,-
FGFR1_HUMAN,A336T,0.729,Altered Transmembrane protein (Pr = 0.31 | P = 1.1e-04); Altered Metal binding (Pr = 0.30 | P = 0.02); Altered Ordered interface (Pr = 0.25 | P = 0.02); Loss of Disulfide linkage at C341 (Pr = 0.18 | P = 0.03), ELME000053,-
FGFR1_HUMAN,L342K,0.943,Altered Metal binding (Pr = 0.30 | P = 0.01); Gain of Strand (Pr = 0.27 | P = 0.03); Altered Transmembrane protein (Pr = 0.26 | P = 9.9e-04); Altered Ordered interface (Pr = 0.26 | P = 0.02); Gain of Disulfide linkage at C341 (Pr = 0.20 | P = 0.02); Altered Stability (Pr = 0.16 | P = 0.02), ELME000120|ELME000182|ELME000337|PS00005,-
FGFR1_HUMAN,L349I,0.12,-,-,-
FGFR1_HUMAN,H351N,0.662,Altered Transmembrane protein (Pr = 0.30 | P = 1.8e-04); Loss of Strand (Pr = 0.26 | P = 0.04); Gain of N-linked glycosylation at H351 (Pr = 0.12 | P = 8.3e-03), ELME000063|ELME000070|PS00001,-
FGFR1_HUMAN,W355L,0.802,Altered Ordered interface (Pr = 0.30 | P = 4.7e-03); Loss of Strand (Pr = 0.28 | P = 0.01); Altered Transmembrane protein (Pr = 0.26 | P = 1.0e-03); Altered Stability (Pr = 0.10 | P = 0.04), ELME000063|ELME000064|ELME000085|ELME000220,-
FGFR1_HUMAN,L356R,0.969,Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Gain of Strand (Pr = 0.28 | P = 7.5e-03); Altered Stability (Pr = 0.15 | P = 0.02), ELME000063|ELME000064|ELME000146|ELME000220|ELME000231|ELME000333,-
FGFR1_HUMAN,M369I,0.286,-,-,-
FGFR1_HUMAN,T370A,0.237,-,-,-
FGFR1_HUMAN,T370P,0.66,Altered Transmembrane protein (Pr = 0.22 | P = 2.7e-03), ELME000052|ELME000136|ELME000159,-
FGFR1_HUMAN,I377V,0.201,-,-,-
FGFR1_HUMAN,V394A,0.21,-,-,-
FGFR1_HUMAN,V396T,0.27,-,-,-
FGFR1_HUMAN,Y397C,0.315,-,-,-
FGFR1_HUMAN,M399T,0.358,-,-,-
FGFR1_HUMAN,G402S,0.1,-,-,-
FGFR1_HUMAN,D554E,0.42,-,-,-
FGFR1_HUMAN,S588T,0.101,-,-,-
FGFR1_HUMAN,H589R,0.177,-,-,-
FGFR1_HUMAN,N590A,0.135,-,-,-
FGFR1_HUMAN,N590S,0.073,-,-,-
FGFR1_HUMAN,K598R,0.301,-,-,-
FGFR1_HUMAN,G660D,0.938,Loss of Acetylation at K655 (Pr = 0.26 | P = 9.7e-03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000008|ELME000220|ELME000316|PS00006,-
FGFR1_HUMAN,T678S,0.67,Altered Ordered interface (Pr = 0.31 | P = 0.01); Altered Transmembrane protein (Pr = 0.23 | P = 2.6e-03); Altered Metal binding (Pr = 0.18 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q680 (Pr = 0.07 | P = 0.02), ELME000053|ELME000063|ELME000163|ELME000182,-
FGFR1_HUMAN,H679P,0.854,Altered Ordered interface (Pr = 0.31 | P = 0.02); Loss of Strand (Pr = 0.26 | P = 0.03); Altered Transmembrane protein (Pr = 0.22 | P = 3.1e-03); Altered Metal binding (Pr = 0.18 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q680 (Pr = 0.07 | P = 0.02), ELME000053|ELME000136|ELME000159|ELME000163|ELME000182|ELME000358,-
FGFR1_HUMAN,S723T,0.323,-,-,-
FGFR1_HUMAN,N727H,0.42,-,-,-
FGFR1_HUMAN,V740I,0.136,-,-,-
FGFR1_HUMAN,Q813P,0.571,Loss of Helix (Pr = 0.29 | P = 0.01), None,-
FGFR1_HUMAN,G817S,0.297,-,-,-
FGFR1_HUMAN,H253P,0.932,Altered Metal binding (Pr = 0.30 | P = 0.01); Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Transmembrane protein (Pr = 0.28 | P = 3.5e-04); Gain of Strand (Pr = 0.26 | P = 0.04); Gain of B-factor (Pr = 0.25 | P = 0.03), ELME000135|ELME000136|ELME000153|ELME000155|ELME000159,-
FGFR1_HUMAN,R254Q,0.858,Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Gain of Strand (Pr = 0.27 | P = 0.02); Gain of Loop (Pr = 0.26 | P = 0.05); Altered Metal binding (Pr = 0.24 | P = 0.02), ELME000146|ELME000153|ELME000155|ELME000159,-
FGFR1_HUMAN,K656E,0.842,Loss of Helix (Pr = 0.28 | P = 0.03); Altered Ordered interface (Pr = 0.25 | P = 0.02); Loss of Acetylation at K655 (Pr = 0.24 | P = 0.02); Altered Transmembrane protein (Pr = 0.20 | P = 5.7e-03), ELME000008|PS00004,-
FGFR1_HUMAN,A608D,0.93,Gain of Helix (Pr = 0.28 | P = 0.03); Altered Ordered interface (Pr = 0.25 | P = 0.02); Gain of Allosteric site at Y613 (Pr = 0.24 | P = 0.01), None,-
FGFR1_HUMAN,M535K,0.914,Altered Coiled coil (Pr = 0.50 | P = 7.1e-03); Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered Stability (Pr = 0.12 | P = 0.03), None,-
FGFR1_HUMAN,S96C,0.641,Loss of Intrinsic disorder (Pr = 0.36 | P = 0.04); Altered Metal binding (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.27 | P = 6.0e-04); Gain of Disulfide linkage at C101 (Pr = 0.25 | P = 7.2e-03); Loss of Proteolytic cleavage at D95 (Pr = 0.13 | P = 0.02), ELME000085|ELME000239,-
FGFR1_HUMAN,I239T,0.741,Altered Transmembrane protein (Pr = 0.35 | P = 2.4e-05); Altered Ordered interface (Pr = 0.33 | P = 8.8e-03); Altered Metal binding (Pr = 0.24 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Altered Stability (Pr = 0.15 | P = 0.02); Loss of N-linked glycosylation at N240 (Pr = 0.14 | P = 7.9e-03); Gain of Sulfation at Y236 (Pr = 0.02 | P = 0.03), ELME000053|ELME000070|ELME000120,-
FGFR1_HUMAN,P28L,0.557,Loss of Intrinsic disorder (Pr = 0.37 | P = 0.04); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q32 (Pr = 0.07 | P = 0.02); Altered Signal peptide (Pr = 0.01 | P = 5.2e-03), ELME000005|ELME000064|ELME000155|ELME000220|PS00006,-
FGFR1_HUMAN,R756H,0.626,Altered Metal binding (Pr = 0.44 | P = 6.6e-03), None,-
FGFR1_HUMAN,N264H,0.888,Loss of Relative solvent accessibility (Pr = 0.34 | P = 3.5e-03); Altered Metal binding (Pr = 0.31 | P = 4.5e-03); Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Transmembrane protein (Pr = 0.28 | P = 3.8e-04); Loss of N-linked glycosylation at N264 (Pr = 0.21 | P = 2.5e-03); Altered Stability (Pr = 0.16 | P = 0.02), ELME000052|ELME000070|PS00001|PS00008,-
FGFR1_HUMAN,T340A,0.829,Altered Metal binding (Pr = 0.29 | P = 0.02); Altered Transmembrane protein (Pr = 0.25 | P = 1.3e-03); Altered Ordered interface (Pr = 0.25 | P = 0.02); Loss of Disulfide linkage at C341 (Pr = 0.18 | P = 0.03), ELME000120|ELME000182,-
FGFR1_HUMAN,P366L,0.595,Altered Transmembrane protein (Pr = 0.28 | P = 4.8e-04); Altered Coiled coil (Pr = 0.08 | P = 0.04), None,-
FGFR1_HUMAN,D224E,0.87,Altered Metal binding (Pr = 0.28 | P = 6.7e-03); Altered Transmembrane protein (Pr = 0.27 | P = 7.1e-04); Altered Ordered interface (Pr = 0.23 | P = 0.05); Loss of N-linked glycosylation at N227 (Pr = 0.16 | P = 5.6e-03), PS00005,-
FGFR1_HUMAN,R627S,0.964,Altered DNA binding (Pr = 0.37 | P = 7.2e-04); Loss of Allosteric site at R627 (Pr = 0.30 | P = 4.1e-03); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.22 | P = 3.6e-03); Altered Metal binding (Pr = 0.19 | P = 0.04); Loss of Catalytic site at R627 (Pr = 0.13 | P = 0.03), ELME000146|ELME000336|PS00109,-
FGFR1_HUMAN,H621R,0.917,Gain of Allosteric site at H621 (Pr = 0.21 | P = 0.03); Altered Transmembrane protein (Pr = 0.17 | P = 9.3e-03), ELME000012|ELME000102|ELME000108|PS00109,-
FGFR1_HUMAN,P663S,0.885,Gain of Strand (Pr = 0.27 | P = 0.02); Loss of Loop (Pr = 0.27 | P = 0.03); Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.10 | P = 0.05), ELME000062|ELME000337|PS00005,-
FGFR1_HUMAN,P252R,0.9,Altered Transmembrane protein (Pr = 0.31 | P = 1.1e-04); Altered Metal binding (Pr = 0.26 | P = 0.03); Gain of ADP-ribosylation at P252 (Pr = 0.23 | P = 0.01), ELME000012|ELME000136|ELME000153|ELME000155|ELME000159,-
FGFR1_HUMAN,K618N,0.89,Loss of Allosteric site at Y613 (Pr = 0.21 | P = 0.04), PS00005,-
FGFR1_HUMAN,P169L,0.795,Loss of Intrinsic disorder (Pr = 0.49 | P = 7.4e-03); Gain of Strand (Pr = 0.26 | P = 0.05); Loss of Acetylation at K172 (Pr = 0.20 | P = 0.04); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), None,-
FGFR1_HUMAN,Y339C,0.952,Altered Metal binding (Pr = 0.38 | P = 9.4e-03); Altered Transmembrane protein (Pr = 0.37 | P = 1.9e-05); Altered Ordered interface (Pr = 0.36 | P = 2.1e-03); Loss of Loop (Pr = 0.27 | P = 0.03); Gain of Disulfide linkage at C341 (Pr = 0.19 | P = 0.02), ELME000120|ELME000182,-
FGFR1_HUMAN,G270A,0.867,Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.01); Altered Transmembrane protein (Pr = 0.24 | P = 1.5e-03); Altered Metal binding (Pr = 0.18 | P = 0.01), ELME000052|ELME000064|ELME000239,-
FGFR1_HUMAN,R744T,0.915,Gain of Loop (Pr = 0.30 | P = 5.1e-03), ELME000053|ELME000062|ELME000136|ELME000159|ELME000202|PS00005,-
FGFR1_HUMAN,T695I,0.906,Altered Ordered interface (Pr = 0.26 | P = 0.02); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000053|ELME000235|ELME000335,-
FGFR1_HUMAN,L712P,0.927,Altered Stability (Pr = 0.43 | P = 2.6e-03); Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Gain of Acetylation at K711 (Pr = 0.20 | P = 0.04), ELME000045|ELME000146|ELME000149,-
FGFR1_HUMAN,C736Y,0.959,Altered Metal binding (Pr = 0.43 | P = 5.5e-03); Altered Ordered interface (Pr = 0.31 | P = 0.01); Gain of Allosteric site at R734 (Pr = 0.22 | P = 0.03); Altered Transmembrane protein (Pr = 0.11 | P = 0.04); Loss of Disulfide linkage at C736 (Pr = 0.11 | P = 0.04); Gain of Sulfation at C736 (Pr = 0.03 | P = 0.02); Loss of N-terminal acetylation at M732 (Pr = 0.02 | P = 8.0e-03), None,-
FGFR1_HUMAN,W4L,0.789,Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Disordered interface (Pr = 0.23 | P = 0.03); Altered Signal peptide (Pr = 0.11 | P = 1.6e-03); Loss of N-terminal acetylation at M1 (Pr = 0.02 | P = 6.1e-03), ELME000045|ELME000137|PS00005,-
FGFR1_HUMAN,K5E,0.513,Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Disordered interface (Pr = 0.25 | P = 0.02); Altered Signal peptide (Pr = 0.12 | P = 1.6e-03); Gain of N-terminal acetylation at M1 (Pr = 0.02 | P = 5.1e-03), ELME000106|ELME000137|ELME000146|PS00005,-
COL4A5_HUMAN,N804S,0.061,-,-,-
COL4A5_HUMAN,M810V,0.095,-,-,-
COL4A5_HUMAN,L853F,0.038,-,-,-
COL4A5_HUMAN,P865R,0.57,Gain of Methylation at P865 (Pr = 0.11 | P = 0.03), ELME000005|ELME000062|ELME000136|ELME000155|ELME000159|ELME000240,-
COL4A5_HUMAN,P873S,0.097,-,-,-
COL4A5_HUMAN,T937A,0.034,-,-,-
COL4A5_HUMAN,P946R,0.508,Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Loop (Pr = 0.27 | P = 0.03); Gain of Acetylation at K943 (Pr = 0.25 | P = 0.01); Gain of SUMOylation at K943 (Pr = 0.25 | P = 9.1e-03); Loss of Methylation at K943 (Pr = 0.24 | P = 2.5e-03), ELME000005|ELME000106|ELME000155,-
COL4A5_HUMAN,E968D,0.111,-,-,-
COL4A5_HUMAN,P999H,0.455,-,-,-
COL4A5_HUMAN,N1010D,0.083,-,-,-
COL4A5_HUMAN,T1028A,0.075,-,-,-
COL4A5_HUMAN,E1041K,0.071,-,-,-
COL4A5_HUMAN,D1064G,0.332,-,-,-
COL4A5_HUMAN,V1100M,0.061,-,-,-
COL4A5_HUMAN,P1129L,0.073,-,-,-
COL4A5_HUMAN,S1136N,0.065,-,-,-
COL4A5_HUMAN,E1147Q,0.147,-,-,-
COL4A5_HUMAN,N1191T,0.158,-,-,-
COL4A5_HUMAN,P1323R,0.332,-,-,-
COL4A5_HUMAN,L1389P,0.291,-,-,-
COL4A5_HUMAN,T1402I,0.048,-,-,-
COL4A5_HUMAN,S1456T,0.076,-,-,-
COL4A5_HUMAN,T1470S,0.163,-,-,-
COL4A5_HUMAN,V1483I,0.028,-,-,-
COL4A5_HUMAN,Q1550E,0.059,-,-,-
COL4A5_HUMAN,G603C,0.941,Loss of B-factor (Pr = 0.32 | P = 4.0e-03); Loss of Acetylation at K599 (Pr = 0.27 | P = 8.2e-03); Loss of Methylation at K599 (Pr = 0.22 | P = 4.8e-03), ELME000005|ELME000155,-
COL4A5_HUMAN,G295D,0.952,Loss of Acetylation at K296 (Pr = 0.31 | P = 3.8e-03); Gain of Loop (Pr = 0.28 | P = 0.01); Loss of Methylation at K296 (Pr = 0.25 | P = 2.1e-03); Gain of SUMOylation at K299 (Pr = 0.23 | P = 0.02), ELME000093|ELME000271|ELME000278|PS00009,-
COL4A5_HUMAN,G198V,0.946,Loss of B-factor (Pr = 0.35 | P = 1.2e-03); Gain of Loop (Pr = 0.28 | P = 0.02); Altered Disordered interface (Pr = 0.27 | P = 0.04), None,-
COL4A5_HUMAN,G1161R,0.946,Loss of B-factor (Pr = 0.31 | P = 6.2e-03); Loss of Loop (Pr = 0.27 | P = 0.03); Loss of Methylation at K1166 (Pr = 0.22 | P = 4.6e-03); Loss of Acetylation at K1166 (Pr = 0.21 | P = 0.04); Gain of SUMOylation at K1166 (Pr = 0.21 | P = 0.03), None,-
COL4A5_HUMAN,G719E,0.953,Altered Disordered interface (Pr = 0.30 | P = 0.02); Gain of Loop (Pr = 0.29 | P = 7.9e-03); Gain of SUMOylation at K715 (Pr = 0.23 | P = 0.02); Loss of Methylation at K715 (Pr = 0.22 | P = 4.6e-03); Loss of Acetylation at K715 (Pr = 0.21 | P = 0.04), ELME000005|ELME000155,-
COL4A5_HUMAN,G301R,0.935,Loss of Acetylation at K302 (Pr = 0.53 | P = 4.6e-04); Loss of B-factor (Pr = 0.30 | P = 0.01); Loss of Methylation at K296 (Pr = 0.26 | P = 1.7e-03); Gain of SUMOylation at K302 (Pr = 0.25 | P = 8.6e-03), ELME000102,-
COL4A5_HUMAN,G1149V,0.956,Loss of B-factor (Pr = 0.30 | P = 7.9e-03); Altered Metal binding (Pr = 0.13 | P = 0.03), None,-
COL4A5_HUMAN,G860R,0.955,Loss of B-factor (Pr = 0.28 | P = 0.02), ELME000135,-
COL4A5_HUMAN,G292R,0.947,Loss of B-factor (Pr = 0.29 | P = 0.01); Loss of Methylation at K288 (Pr = 0.28 | P = 9.0e-04); Loss of Loop (Pr = 0.27 | P = 0.03); Gain of SUMOylation at K288 (Pr = 0.26 | P = 7.2e-03); Gain of Acetylation at K288 (Pr = 0.25 | P = 0.01), ELME000103,-
COL4A5_HUMAN,G849E,0.946,Loss of B-factor (Pr = 0.27 | P = 0.02); Gain of Loop (Pr = 0.27 | P = 0.02); Loss of Acetylation at K845 (Pr = 0.22 | P = 0.03); Gain of SUMOylation at K845 (Pr = 0.22 | P = 0.02); Loss of Methylation at K845 (Pr = 0.19 | P = 7.6e-03), ELME000005|ELME000155,-
COL4A5_HUMAN,G772A,0.922,Altered Disordered interface (Pr = 0.28 | P = 0.04); Loss of Acetylation at K768 (Pr = 0.27 | P = 8.0e-03); Gain of SUMOylation at K768 (Pr = 0.18 | P = 0.04); Gain of Methylation at K774 (Pr = 0.17 | P = 9.6e-03), ELME000146,-
COL4A5_HUMAN,G144R,0.948,Loss of B-factor (Pr = 0.29 | P = 0.02); Loss of Loop (Pr = 0.29 | P = 0.01), ELME000155,-
COL4A5_HUMAN,G129R,0.967,Gain of SUMOylation at K128 (Pr = 0.28 | P = 4.2e-03); Loss of Loop (Pr = 0.27 | P = 0.04); Gain of Acetylation at K128 (Pr = 0.20 | P = 0.04); Loss of Methylation at K128 (Pr = 0.15 | P = 0.02); Loss of N-linked glycosylation at N125 (Pr = 0.02 | P = 0.03), ELME000064|ELME000070|ELME000100|ELME000108|ELME000220|PS00005|PS00006,-
COL4A5_HUMAN,G292V,0.955,Loss of B-factor (Pr = 0.33 | P = 2.9e-03); Gain of Loop (Pr = 0.27 | P = 0.03); Gain of Acetylation at K288 (Pr = 0.27 | P = 7.2e-03); Loss of Methylation at K288 (Pr = 0.27 | P = 1.2e-03); Loss of SUMOylation at K288 (Pr = 0.25 | P = 9.0e-03); Gain of Amidation at P294 (Pr = 0.01 | P = 1.0e-03), None,-
COL4A5_HUMAN,G1217D,0.946,Gain of Loop (Pr = 0.30 | P = 6.8e-03); Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of Methylation at K1222 (Pr = 0.18 | P = 0.01), None,-
COL4A5_HUMAN,G469E,0.915,Gain of Loop (Pr = 0.30 | P = 5.5e-03); Loss of Acetylation at K465 (Pr = 0.21 | P = 0.04); Loss of Methylation at K465 (Pr = 0.19 | P = 8.4e-03), None,-
COL4A5_HUMAN,G893A,0.94,Gain of Loop (Pr = 0.26 | P = 0.05); Gain of SUMOylation at K895 (Pr = 0.26 | P = 5.9e-03); Loss of Acetylation at K895 (Pr = 0.24 | P = 0.02); Gain of Methylation at K895 (Pr = 0.20 | P = 4.5e-03), ELME000064|ELME000220,-
COL4A5_HUMAN,G1427W,0.955,Loss of B-factor (Pr = 0.30 | P = 0.01); Loss of Methylation at K1423 (Pr = 0.24 | P = 2.7e-03), ELME000005|ELME000155|ELME000190,-
COL4A5_HUMAN,G500R,0.944,Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Loop (Pr = 0.28 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q495 (Pr = 0.07 | P = 0.02), ELME000155,-
COL4A5_HUMAN,G594S,0.745,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Acetylation at K599 (Pr = 0.25 | P = 0.01); Loss of Methylation at K599 (Pr = 0.19 | P = 7.7e-03); Gain of SUMOylation at K599 (Pr = 0.19 | P = 0.04), ELME000063|ELME000085|ELME000337,-
COL4A5_HUMAN,G875R,0.937,Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of O-linked glycosylation at S879 (Pr = 0.11 | P = 0.05); Gain of Methylation at G875 (Pr = 0.10 | P = 0.04), ELME000155,-
COL4A5_HUMAN,G475S,0.926,Gain of Loop (Pr = 0.27 | P = 0.03); Loss of B-factor (Pr = 0.26 | P = 0.05), PS00005,-
COL4A5_HUMAN,G869E,0.911,Gain of Loop (Pr = 0.28 | P = 0.02), None,-
COL4A5_HUMAN,G545S,0.901,Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of SUMOylation at K544 (Pr = 0.26 | P = 6.2e-03); Loss of Methylation at K544 (Pr = 0.19 | P = 8.4e-03); Loss of Ubiquitylation at K544 (Pr = 0.15 | P = 0.04); Gain of Proteolytic cleavage at D549 (Pr = 0.13 | P = 0.02), ELME000064|PS00006,-
COL4A5_HUMAN,G769V,0.959,Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of Acetylation at K768 (Pr = 0.28 | P = 6.2e-03); Gain of SUMOylation at K768 (Pr = 0.21 | P = 0.03); Loss of Methylation at K768 (Pr = 0.17 | P = 0.01), ELME000146,-
COL4A5_HUMAN,G595R,0.207,-,-,-
COL4A5_HUMAN,G1196R,0.924,Loss of B-factor (Pr = 0.29 | P = 0.01); Loss of Loop (Pr = 0.29 | P = 8.3e-03); Gain of O-linked glycosylation at S1201 (Pr = 0.13 | P = 0.04), ELME000135,-
COL4A5_HUMAN,G653R,0.921,Loss of B-factor (Pr = 0.30 | P = 7.8e-03); Loss of Methylation at K652 (Pr = 0.25 | P = 1.9e-03); Gain of O-linked glycosylation at T658 (Pr = 0.12 | P = 0.04), ELME000100|ELME000108,-
COL4A5_HUMAN,G491E,0.904,Gain of Loop (Pr = 0.27 | P = 0.02); Loss of B-factor (Pr = 0.25 | P = 0.05); Loss of O-linked glycosylation at S490 (Pr = 0.19 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q495 (Pr = 0.07 | P = 0.02), ELME000085|ELME000155|PS00008,-
COL4A5_HUMAN,G869V,0.941,, None,-
COL4A5_HUMAN,G769R,0.958,Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of Loop (Pr = 0.29 | P = 0.01); Gain of Acetylation at K774 (Pr = 0.27 | P = 6.6e-03); Gain of SUMOylation at K768 (Pr = 0.21 | P = 0.03); Loss of Methylation at K768 (Pr = 0.17 | P = 0.01), ELME000100|ELME000106|ELME000108|ELME000146,-
COL4A5_HUMAN,G1229C,0.957,Altered Disordered interface (Pr = 0.29 | P = 0.03), None,-
COL4A5_HUMAN,G887V,0.952,Gain of Acetylation at K885 (Pr = 0.22 | P = 0.02); Loss of Methylation at K885 (Pr = 0.20 | P = 6.2e-03); Gain of SUMOylation at K885 (Pr = 0.18 | P = 0.05); Gain of Ubiquitylation at K885 (Pr = 0.16 | P = 0.04), ELME000239,-
COL4A5_HUMAN,G138D,0.96,Gain of Loop (Pr = 0.27 | P = 0.04), ELME000136|ELME000159|ELME000197,-
COL4A5_HUMAN,G264D,0.963,Gain of Loop (Pr = 0.30 | P = 6.7e-03); Gain of B-factor (Pr = 0.25 | P = 0.03); Loss of Methylation at R266 (Pr = 0.11 | P = 0.03), None,-
COL4A5_HUMAN,G1066R,0.939,Loss of B-factor (Pr = 0.29 | P = 0.01); Gain of Acetylation at K1062 (Pr = 0.23 | P = 0.02); Loss of Methylation at K1062 (Pr = 0.19 | P = 7.6e-03); Gain of SUMOylation at K1065 (Pr = 0.19 | P = 0.04); Loss of O-linked glycosylation at S1071 (Pr = 0.12 | P = 0.05), ELME000100|ELME000108,-
COL4A5_HUMAN,G1235A,0.849,Loss of B-factor (Pr = 0.29 | P = 0.01); Gain of Loop (Pr = 0.27 | P = 0.04), ELME000155,-
COL4A5_HUMAN,C451R,0.798,Gain of B-factor (Pr = 0.26 | P = 0.02); Gain of O-linked glycosylation at S447 (Pr = 0.13 | P = 0.03), ELME000155,-
COL4A5_HUMAN,G180R,0.955,Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of Phosphorylation at Y175 (Pr = 0.25 | P = 0.03); Loss of Sulfation at Y175 (Pr = 0.02 | P = 0.03), ELME000135,-
COL4A5_HUMAN,G233S,0.882,Loss of B-factor (Pr = 0.26 | P = 0.05); Loss of SUMOylation at K229 (Pr = 0.25 | P = 8.2e-03); Loss of Acetylation at K229 (Pr = 0.21 | P = 0.03); Loss of Methylation at K229 (Pr = 0.21 | P = 6.0e-03), ELME000147,-
COL4A5_HUMAN,G1363S,0.895,Gain of Phosphorylation at G1363 (Pr = 0.34 | P = 9.4e-03); Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of O-linked glycosylation at S1365 (Pr = 0.16 | P = 0.03), ELME000136|ELME000159|ELME000239,-
COL4A5_HUMAN,G365V,0.941,Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Loop (Pr = 0.27 | P = 0.03); Gain of SUMOylation at K370 (Pr = 0.25 | P = 9.0e-03); Loss of Acetylation at K370 (Pr = 0.21 | P = 0.03); Loss of Methylation at K370 (Pr = 0.16 | P = 0.01), ELME000133|ELME000155,-
COL4A5_HUMAN,G1066S,0.891,Loss of B-factor (Pr = 0.27 | P = 0.02); Loss of Acetylation at K1062 (Pr = 0.23 | P = 0.02); Loss of Methylation at K1062 (Pr = 0.19 | P = 8.7e-03); Gain of O-linked glycosylation at S1071 (Pr = 0.12 | P = 0.04), None,-
COL4A5_HUMAN,G1179R,0.963,Loss of Loop (Pr = 0.30 | P = 6.7e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of SUMOylation at K1181 (Pr = 0.26 | P = 7.1e-03); Loss of Acetylation at K1181 (Pr = 0.22 | P = 0.03); Loss of Methylation at K1181 (Pr = 0.19 | P = 7.5e-03); Gain of Pyrrolidone carboxylic acid at Q1180 (Pr = 0.05 | P = 0.04), None,-
COL4A5_HUMAN,G594R,0.851,Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of Acetylation at K599 (Pr = 0.24 | P = 0.01); Loss of Methylation at K599 (Pr = 0.19 | P = 7.4e-03), ELME000137|ELME000146|ELME000337,-
COL4A5_HUMAN,G893S,0.948,Gain of Loop (Pr = 0.26 | P = 0.05); Loss of SUMOylation at K895 (Pr = 0.25 | P = 8.3e-03); Gain of Acetylation at K895 (Pr = 0.24 | P = 0.02); Loss of Methylation at K895 (Pr = 0.19 | P = 7.7e-03), ELME000053|ELME000064|ELME000220|PS00005,-
COL4A5_HUMAN,A28S,0.364,-,-,-
COL4A5_HUMAN,G289R,0.959,Loss of B-factor (Pr = 0.30 | P = 9.5e-03); Loss of Methylation at K288 (Pr = 0.28 | P = 9.1e-04); Loss of Loop (Pr = 0.27 | P = 0.04); Gain of Acetylation at K285 (Pr = 0.27 | P = 7.1e-03); Gain of SUMOylation at K288 (Pr = 0.27 | P = 5.1e-03), ELME000100|ELME000108,-
COL4A5_HUMAN,G144D,0.95,Loss of B-factor (Pr = 0.26 | P = 0.04), ELME000155,-
COL4A5_HUMAN,G298S,0.928,Loss of Acetylation at K299 (Pr = 0.30 | P = 4.3e-03); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Methylation at K296 (Pr = 0.25 | P = 2.2e-03); Loss of SUMOylation at K299 (Pr = 0.22 | P = 0.02), ELME000100|ELME000108|ELME000271|ELME000278,-
COL4A5_HUMAN,G775D,0.961,Gain of Loop (Pr = 0.28 | P = 0.02); Loss of Acetylation at K774 (Pr = 0.25 | P = 0.01); Loss of Methylation at K774 (Pr = 0.15 | P = 0.02), None,-
COL4A5_HUMAN,G322V,0.958,Altered Disordered interface (Pr = 0.31 | P = 0.02); Loss of B-factor (Pr = 0.30 | P = 9.2e-03); Gain of Phosphorylation at Y320 (Pr = 0.29 | P = 0.02); Loss of Sulfation at Y320 (Pr = 0.04 | P = 0.01), ELME000006,-
COL4A5_HUMAN,G1232S,0.918,Gain of Loop (Pr = 0.27 | P = 0.02), ELME000155,-
COL4A5_HUMAN,G902E,0.941,Loss of B-factor (Pr = 0.26 | P = 0.04), ELME000155,-
COL4A5_HUMAN,G334S,0.851,Gain of Loop (Pr = 0.27 | P = 0.04); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Acetylation at K330 (Pr = 0.25 | P = 0.01); Loss of Methylation at K330 (Pr = 0.24 | P = 2.8e-03); Loss of SUMOylation at K333 (Pr = 0.19 | P = 0.04), ELME000173,-
COL4A5_HUMAN,G811R,0.93,Loss of B-factor (Pr = 0.29 | P = 0.01); Loss of Loop (Pr = 0.27 | P = 0.03), ELME000155,-
COL4A5_HUMAN,G766D,0.953,Gain of Loop (Pr = 0.28 | P = 0.01); Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of B-factor (Pr = 0.25 | P = 0.05); Gain of Acetylation at K768 (Pr = 0.25 | P = 0.01); Gain of SUMOylation at K768 (Pr = 0.19 | P = 0.04); Loss of Methylation at K768 (Pr = 0.17 | P = 0.01), None,-
COL4A5_HUMAN,G567A,0.924,, ELME000136|ELME000155|ELME000159,-
COL4A5_HUMAN,G624D,0.775,, ELME000155,-
COL4A5_HUMAN,G719V,0.962,Altered Disordered interface (Pr = 0.28 | P = 0.04); Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of Loop (Pr = 0.28 | P = 0.01); Loss of Methylation at K715 (Pr = 0.22 | P = 4.8e-03); Loss of Acetylation at K715 (Pr = 0.21 | P = 0.04); Loss of SUMOylation at K715 (Pr = 0.19 | P = 0.04), ELME000005|ELME000155,-
COL4A5_HUMAN,G1182V,0.965,Loss of B-factor (Pr = 0.31 | P = 6.8e-03); Gain of SUMOylation at K1181 (Pr = 0.27 | P = 5.0e-03); Loss of Acetylation at K1181 (Pr = 0.20 | P = 0.04); Loss of Methylation at K1181 (Pr = 0.19 | P = 7.2e-03), ELME000005|ELME000155,-
COL4A5_HUMAN,G298D,0.952,Loss of Acetylation at K302 (Pr = 0.32 | P = 2.9e-03); Gain of Loop (Pr = 0.27 | P = 0.02); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Methylation at K296 (Pr = 0.25 | P = 2.2e-03); Loss of SUMOylation at K299 (Pr = 0.22 | P = 0.02), ELME000100|ELME000108|ELME000271|ELME000278,-
COL4A5_HUMAN,C1638S,0.916,Altered Metal binding (Pr = 0.71 | P = 9.3e-04); Loss of Disulfide linkage at C1638 (Pr = 0.36 | P = 6.8e-04); Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Transmembrane protein (Pr = 0.28 | P = 4.6e-04), ELME000062|ELME000162|ELME000334,-
COL4A5_HUMAN,G1205C,0.953,Loss of B-factor (Pr = 0.33 | P = 3.1e-03); Loss of Methylation at K1204 (Pr = 0.32 | P = 4.4e-04); Altered Disordered interface (Pr = 0.31 | P = 0.02); Loss of Acetylation at K1204 (Pr = 0.23 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q1203 (Pr = 0.05 | P = 0.04), None,-
COL4A5_HUMAN,G722E,0.952,Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of B-factor (Pr = 0.26 | P = 0.05), None,-
COL4A5_HUMAN,G1223V,0.956,Loss of B-factor (Pr = 0.33 | P = 3.1e-03); Loss of Methylation at K1222 (Pr = 0.18 | P = 9.6e-03), ELME000002,-
COL4A5_HUMAN,G1176R,0.972,Loss of SUMOylation at K1181 (Pr = 0.25 | P = 9.6e-03); Gain of Acetylation at K1181 (Pr = 0.22 | P = 0.03); Loss of Methylation at K1181 (Pr = 0.19 | P = 7.6e-03), None,-
COL4A5_HUMAN,G1448R,0.957,Loss of B-factor (Pr = 0.29 | P = 0.02), ELME000155,-
COL4A5_HUMAN,G1066D,0.937,Gain of Loop (Pr = 0.28 | P = 0.02); Gain of B-factor (Pr = 0.27 | P = 0.01); Loss of Acetylation at K1062 (Pr = 0.24 | P = 0.01); Loss of Methylation at K1065 (Pr = 0.18 | P = 8.9e-03); Loss of O-linked glycosylation at S1071 (Pr = 0.12 | P = 0.05), None,-
COL4A5_HUMAN,G180E,0.947,Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of Sulfation at Y175 (Pr = 0.02 | P = 0.03), None,-
COL4A5_HUMAN,G316D,0.949,Altered Disordered interface (Pr = 0.28 | P = 0.03); Gain of Loop (Pr = 0.27 | P = 0.04); Gain of Phosphorylation at Y320 (Pr = 0.27 | P = 0.02); Gain of B-factor (Pr = 0.24 | P = 0.04); Altered Metal binding (Pr = 0.13 | P = 0.03); Gain of Sulfation at Y320 (Pr = 0.04 | P = 9.4e-03), ELME000155,-
COL4A5_HUMAN,G383R,0.919,Loss of B-factor (Pr = 0.28 | P = 0.02); Altered Disordered interface (Pr = 0.26 | P = 0.05), ELME000135|ELME000155,-
COL4A5_HUMAN,G1006V,0.947,Loss of B-factor (Pr = 0.37 | P = 4.4e-04); Gain of Loop (Pr = 0.29 | P = 0.01); Loss of Methylation at K1008 (Pr = 0.25 | P = 1.9e-03), None,-
COL4A5_HUMAN,G973D,0.968,Gain of Loop (Pr = 0.30 | P = 4.7e-03); Gain of O-linked glycosylation at S978 (Pr = 0.14 | P = 0.03), None,-
COL4A5_HUMAN,G561R,0.944,Gain of SUMOylation at K560 (Pr = 0.28 | P = 4.1e-03); Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Acetylation at K557 (Pr = 0.23 | P = 0.02); Loss of Methylation at K557 (Pr = 0.18 | P = 9.6e-03), ELME000100|ELME000108,-
MYO7A_HUMAN,E1750L,0.827,Altered Disordered interface (Pr = 0.32 | P = 6.9e-03); Loss of Helix (Pr = 0.31 | P = 2.9e-03); Gain of Proteolytic cleavage at W1745 (Pr = 0.13 | P = 0.03), None,-
MYO7A_HUMAN,E1750S,0.696,Altered Disordered interface (Pr = 0.38 | P = 4.5e-03); Gain of Proteolytic cleavage at W1745 (Pr = 0.12 | P = 0.03), ELME000053|ELME000136|ELME000153|ELME000159,-
MYO7A_HUMAN,Q1754S,0.671,, ELME000085|ELME000146|ELME000239,-
MYO7A_HUMAN,K1759P,0.608,Loss of Helix (Pr = 0.27 | P = 0.03), ELME000045|ELME000106|ELME000146,-
MYO7A_HUMAN,L1760I,0.038,-,-,-
MYO7A_HUMAN,S1763A,0.155,-,-,-
MYO7A_HUMAN,E1765L,0.66,, ELME000053|ELME000202,-
MYO7A_HUMAN,L1766Q,0.816,Gain of B-factor (Pr = 0.27 | P = 0.01), ELME000053|ELME000202,-
MYO7A_HUMAN,S1767V,0.381,-,-,-
MYO7A_HUMAN,Q1768P,0.844,, ELME000136|ELME000159|ELME000202,-
MYO7A_HUMAN,E1769S,0.479,-,-,-
MYO7A_HUMAN,L1772M,0.055,-,-,-
MYO7A_HUMAN,L1772W,0.615,, None,-
MYO7A_HUMAN,A1773G,0.553,, None,-
MYO7A_HUMAN,A1776T,0.652,Gain of Allosteric site at Y1780 (Pr = 0.25 | P = 0.01); Gain of Acetylation at K1779 (Pr = 0.20 | P = 0.04), ELME000041,-
MYO7A_HUMAN,V1777I,0.19,-,-,-
MYO7A_HUMAN,V1777M,0.2,-,-,-
MYO7A_HUMAN,R1788G,0.832,Altered Ordered interface (Pr = 0.32 | P = 0.01); Gain of Ubiquitylation at K1787 (Pr = 0.16 | P = 0.04); Altered Transmembrane protein (Pr = 0.11 | P = 0.03); Gain of Proteolytic cleavage at D1783 (Pr = 0.11 | P = 0.04); Gain of Sulfation at Y1784 (Pr = 0.01 | P = 0.05), ELME000052|ELME000063|ELME000064|ELME000065|ELME000100|ELME000108|ELME000271|PS00005,-
MYO7A_HUMAN,P1803S,0.645,Gain of Helix (Pr = 0.27 | P = 0.05); Loss of Allosteric site at F1800 (Pr = 0.24 | P = 0.02); Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000147|ELME000336|PS00005|PS00008,-
MYO7A_HUMAN,L1804V,0.433,-,-,-
MYO7A_HUMAN,L1837F,0.876,Gain of Allosteric site at W1834 (Pr = 0.19 | P = 0.05), ELME000149|ELME000335,-
MYO7A_HUMAN,C1840N,0.934,, None,-
MYO7A_HUMAN,N1848S,0.258,-,-,-
MYO7A_HUMAN,N1848T,0.44,-,-,-
MYO7A_HUMAN,L1858V,0.386,-,-,-
MYO7A_HUMAN,K1862P,0.674,Loss of Helix (Pr = 0.27 | P = 0.04), ELME000102|ELME000155|ELME000233|ELME000336|PS00005,-
MYO7A_HUMAN,P1865L,0.473,-,-,-
MYO7A_HUMAN,A1867S,0.279,-,-,-
MYO7A_HUMAN,I1868V,0.055,-,-,-
MYO7A_HUMAN,Q1875H,0.536,Altered Metal binding (Pr = 0.24 | P = 0.04); Gain of Acetylation at K1876 (Pr = 0.20 | P = 0.04); Altered DNA binding (Pr = 0.17 | P = 0.04); Altered Coiled coil (Pr = 0.15 | P = 0.03), ELME000134|ELME000313,-
MYO7A_HUMAN,A1877V,0.46,-,-,-
MYO7A_HUMAN,L1878F,0.591,Gain of Loop (Pr = 0.29 | P = 9.6e-03); Gain of Allosteric site at R1883 (Pr = 0.23 | P = 0.02); Gain of Acetylation at K1876 (Pr = 0.23 | P = 0.02); Altered DNA binding (Pr = 0.19 | P = 0.02); Altered Coiled coil (Pr = 0.14 | P = 0.03); Altered Stability (Pr = 0.10 | P = 0.04), ELME000134|ELME000313,-
MYO7A_HUMAN,S1882A,0.187,-,-,-
MYO7A_HUMAN,F1916V,0.871,Altered Metal binding (Pr = 0.27 | P = 0.03); Altered Ordered interface (Pr = 0.27 | P = 0.05); Gain of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Altered Stability (Pr = 0.18 | P = 0.01), None,-
MYO7A_HUMAN,S1921D,0.64,Altered Metal binding (Pr = 0.34 | P = 6.7e-04); Altered Ordered interface (Pr = 0.28 | P = 0.04); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered DNA binding (Pr = 0.19 | P = 0.03), PS00005,-
MYO7A_HUMAN,I1931Q,0.843,Altered Metal binding (Pr = 0.25 | P = 0.03), ELME000052|ELME000149|ELME000313,-
MYO7A_HUMAN,A1932F,0.695,, ELME000052|ELME000313,-
MYO7A_HUMAN,L1936P,0.812,Altered Stability (Pr = 0.27 | P = 6.7e-03), ELME000052|ELME000106|ELME000146|ELME000239|ELME000313,-
MYO7A_HUMAN,L1937V,0.636,, ELME000052|ELME000053|ELME000106|ELME000146|ELME000313,-
MYO7A_HUMAN,K1938S,0.594,, ELME000053|ELME000064|ELME000146|ELME000313|ELME000333|ELME000336|PS00006,-
MYO7A_HUMAN,E1941D,0.336,-,-,-
MYO7A_HUMAN,E1941G,0.765,, ELME000053|ELME000085|ELME000197|ELME000336|ELME000337,-
MYO7A_HUMAN,G1942T,0.918,, ELME000052|ELME000053|ELME000063|ELME000197,-
MYO7A_HUMAN,V1947S,0.903,Altered Stability (Pr = 0.33 | P = 4.4e-03); Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000063,-
MYO7A_HUMAN,I1949Q,0.9,Altered Transmembrane protein (Pr = 0.14 | P = 0.02), None,-
MYO7A_HUMAN,V1956I,0.227,-,-,-
MYO7A_HUMAN,I1979V,0.063,-,-,-
MYO7A_HUMAN,I1983V,0.131,-,-,-
MYO7A_HUMAN,L2059M,0.104,-,-,-
MYO7A_HUMAN,S2073A,0.281,-,-,-
MYO7A_HUMAN,L2103V,0.149,-,-,-
MYO7A_HUMAN,D2142V,0.589,Loss of Relative solvent accessibility (Pr = 0.43 | P = 4.9e-04); Altered Metal binding (Pr = 0.30 | P = 4.0e-03); Altered Ordered interface (Pr = 0.30 | P = 0.03); Altered Transmembrane protein (Pr = 0.28 | P = 4.7e-04), ELME000148|ELME000333|ELME000335|PS00006,-
MYO7A_HUMAN,D2147A,0.462,-,-,-
MYO7A_HUMAN,P2153R,0.842,Altered Ordered interface (Pr = 0.31 | P = 0.02); Altered Transmembrane protein (Pr = 0.27 | P = 5.1e-04); Gain of Strand (Pr = 0.27 | P = 0.03); Loss of Relative solvent accessibility (Pr = 0.23 | P = 0.05), ELME000053|ELME000062|PS00005,-
MYO7A_HUMAN,F2154D,0.968,Gain of Intrinsic disorder (Pr = 0.33 | P = 0.03); Altered Ordered interface (Pr = 0.31 | P = 0.02); Altered Transmembrane protein (Pr = 0.28 | P = 3.7e-04); Loss of Strand (Pr = 0.27 | P = 0.02); Altered Stability (Pr = 0.11 | P = 0.03); Gain of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000053|ELME000220|PS00006,-
MYO7A_HUMAN,F2154W,0.909,Altered Ordered interface (Pr = 0.33 | P = 7.9e-03); Altered Transmembrane protein (Pr = 0.29 | P = 3.0e-04); Gain of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000053,-
MYO7A_HUMAN,I2157L,0.724,Altered Ordered interface (Pr = 0.34 | P = 7.8e-03); Altered Transmembrane protein (Pr = 0.27 | P = 7.1e-04); Loss of Strand (Pr = 0.27 | P = 0.02); Loss of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), None,-
MYO7A_HUMAN,S2158G,0.688,Altered Stability (Pr = 0.34 | P = 4.1e-03); Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Transmembrane protein (Pr = 0.29 | P = 2.1e-04); Loss of Strand (Pr = 0.26 | P = 0.04); Gain of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000053|ELME000063|ELME000070|PS00008,-
MYO7A_HUMAN,N2159S,0.593,Altered Transmembrane protein (Pr = 0.27 | P = 4.9e-04); Gain of Strand (Pr = 0.26 | P = 0.04); Altered Stability (Pr = 0.15 | P = 0.02); Loss of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000053|ELME000063|ELME000070|PS00001,-
MYO7A_HUMAN,G2163R,0.731,Loss of Loop (Pr = 0.31 | P = 5.7e-03); Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Strand (Pr = 0.26 | P = 0.03); Altered Metal binding (Pr = 0.23 | P = 0.05); Altered DNA binding (Pr = 0.17 | P = 0.03); Gain of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000053|ELME000062|ELME000063|ELME000070|ELME000085|PS00005,-
MYO7A_HUMAN,T2165A,0.77,Altered Ordered interface (Pr = 0.27 | P = 0.05); Gain of Loop (Pr = 0.27 | P = 0.03); Altered Transmembrane protein (Pr = 0.13 | P = 0.03), ELME000053,-
MYO7A_HUMAN,I2169K,0.971,Gain of Loop (Pr = 0.27 | P = 0.02); Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Metal binding (Pr = 0.23 | P = 0.04); Altered Stability (Pr = 0.17 | P = 0.02); Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000120|ELME000182|ELME000336,-
MYO7A_HUMAN,I2169T,0.938,Altered Ordered interface (Pr = 0.27 | P = 0.05); Altered Stability (Pr = 0.21 | P = 0.01); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000120|ELME000182|ELME000336,-
MYO7A_HUMAN,L2186P,0.922,Loss of Helix (Pr = 0.31 | P = 3.0e-03); Gain of Strand (Pr = 0.26 | P = 0.04); Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000136|ELME000147|ELME000159|ELME000336,-
MYO7A_HUMAN,Y2188S,0.819,Loss of Strand (Pr = 0.26 | P = 0.03); Altered Stability (Pr = 0.16 | P = 0.02); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000053|ELME000063|ELME000147|ELME000148|ELME000317|PS00006,-
MYO7A_HUMAN,K2189A,0.774,Altered Disordered interface (Pr = 0.27 | P = 0.04), ELME000148|ELME000317,-
MYO7A_HUMAN,D2191E,0.311,-,-,-
MYO7A_HUMAN,T2195C,0.723,Altered Disordered interface (Pr = 0.56 | P = 3.8e-04); Altered Transmembrane protein (Pr = 0.09 | P = 0.05), ELME000052|ELME000053|ELME000148|ELME000336,-
MYO7A_HUMAN,Y2197D,0.921,Gain of Intrinsic disorder (Pr = 0.44 | P = 4.7e-03); Altered Disordered interface (Pr = 0.36 | P = 7.6e-03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000052|ELME000053|ELME000063|ELME000163|ELME000182|ELME000202|ELME000336,-
MYO7A_HUMAN,T2203P,0.768,Altered Disordered interface (Pr = 0.27 | P = 0.05); Altered DNA binding (Pr = 0.17 | P = 0.03); Gain of Methylation at K2207 (Pr = 0.09 | P = 0.04), ELME000239,-
MYO7A_HUMAN,A2204T,0.232,-,-,-
MYO7A_HUMAN,M2205W,0.717,Loss of Intrinsic disorder (Pr = 0.59 | P = 1.9e-03); Altered Disordered interface (Pr = 0.33 | P = 6.1e-03); Altered DNA binding (Pr = 0.17 | P = 0.03); Loss of Methylation at K2207 (Pr = 0.10 | P = 0.05), None,-
MYO7A_HUMAN,Q2208S,0.718,Gain of Intrinsic disorder (Pr = 0.33 | P = 0.03); Altered DNA binding (Pr = 0.29 | P = 2.2e-03); Altered Disordered interface (Pr = 0.27 | P = 0.02); Gain of B-factor (Pr = 0.25 | P = 0.04); Gain of Methylation at K2207 (Pr = 0.10 | P = 0.04), ELME000062|ELME000063|ELME000336,-
MYO7A_HUMAN,G2210S,0.153,-,-,-
MYO7A_HUMAN,G2214K,0.268,-,-,-
MYO7A_HUMAN,G2214N,0.195,-,-,-
MYO7A_HUMAN,V1372G,0.887,Gain of Allosteric site at Y1368 (Pr = 0.20 | P = 0.04); Altered Transmembrane protein (Pr = 0.15 | P = 0.01); Altered Stability (Pr = 0.12 | P = 0.03), ELME000137,-
MYO7A_HUMAN,L728P,0.972,Altered Stability (Pr = 0.61 | P = 9.6e-04); Loss of Helix (Pr = 0.28 | P = 0.03); Gain of Strand (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.26 | P = 0.01); Altered Coiled coil (Pr = 0.21 | P = 0.02); Altered DNA binding (Pr = 0.16 | P = 0.04), ELME000146,-
MYO7A_HUMAN,K400N,0.897,Loss of Acetylation at K400 (Pr = 0.40 | P = 1.3e-03); Altered Ordered interface (Pr = 0.31 | P = 0.01); Loss of Allosteric site at D396 (Pr = 0.25 | P = 0.01); Loss of Catalytic site at R395 (Pr = 0.08 | P = 0.05), ELME000095|ELME000122,-
MYO7A_HUMAN,P1225L,0.519,Loss of Loop (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.22 | P = 0.04); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000007,-
MYO7A_HUMAN,S1176N,0.508,Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.12 | P = 0.03); Loss of Disulfide linkage at C1173 (Pr = 0.12 | P = 0.04), ELME000053,-
MYO7A_HUMAN,P503L,0.725,Gain of Helix (Pr = 0.29 | P = 0.02); Gain of Allosteric site at K502 (Pr = 0.19 | P = 0.04), None,-
MYO7A_HUMAN,A230V,0.873,Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered DNA binding (Pr = 0.28 | P = 2.9e-03); Gain of Strand (Pr = 0.27 | P = 0.02); Gain of Allosteric site at I227 (Pr = 0.27 | P = 5.8e-03); Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.03), ELME000002|PS00008,-
MYO7A_HUMAN,Q1369H,0.805,Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Metal binding (Pr = 0.25 | P = 0.04); Gain of Allosteric site at Y1368 (Pr = 0.21 | P = 0.03); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000020|ELME000120,-
MYO7A_HUMAN,G163R,0.937,Altered Metal binding (Pr = 0.26 | P = 0.03); Loss of B-factor (Pr = 0.26 | P = 0.05); Gain of Allosteric site at E159 (Pr = 0.26 | P = 7.7e-03); Loss of Methylation at K164 (Pr = 0.22 | P = 4.6e-03); Loss of Catalytic site at S160 (Pr = 0.16 | P = 0.02), ELME000062|ELME000063|ELME000102|PS00008|PS00017,-
MYO7A_HUMAN,R666Q,0.869,Altered Metal binding (Pr = 0.33 | P = 1.7e-03); Gain of Strand (Pr = 0.28 | P = 0.01); Altered DNA binding (Pr = 0.24 | P = 0.01); Gain of Catalytic site at E663 (Pr = 0.13 | P = 0.03), ELME000012|ELME000052|ELME000101|PS00005,-
MYO7A_HUMAN,G1497R,0.957,Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Transmembrane protein (Pr = 0.23 | P = 2.2e-03); Loss of N-linked glycosylation at N1494 (Pr = 0.03 | P = 0.03), ELME000070|ELME000080|ELME000137|PS00001,-
MYO7A_HUMAN,T165M,0.776,Altered Ordered interface (Pr = 0.32 | P = 0.01); Loss of Methylation at K164 (Pr = 0.21 | P = 5.6e-03); Loss of Catalytic site at S160 (Pr = 0.15 | P = 0.02), ELME000336|PS00008|PS00017,-
MYO7A_HUMAN,S617P,0.895,Loss of Helix (Pr = 0.28 | P = 0.03), ELME000100|ELME000106|ELME000108|ELME000149|ELME000335,-
MYO7A_HUMAN,A2113P,0.946,Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Strand (Pr = 0.26 | P = 0.04), ELME000085|ELME000136|ELME000159|ELME000197|ELME000328,-
MYO7A_HUMAN,L1122I,0.1,-,-,-
MYO7A_HUMAN,L236Q,0.919,Altered Ordered interface (Pr = 0.28 | P = 0.03); Altered DNA binding (Pr = 0.28 | P = 4.3e-03); Altered Metal binding (Pr = 0.27 | P = 6.3e-03); Gain of Strand (Pr = 0.27 | P = 0.03); Loss of Allosteric site at R241 (Pr = 0.26 | P = 0.01); Loss of Acetylation at K231 (Pr = 0.19 | P = 0.05); Altered Transmembrane protein (Pr = 0.10 | P = 0.05); Gain of Catalytic site at K239 (Pr = 0.09 | P = 0.05), ELME000182,-
MYO7A_HUMAN,R1240Q,0.771,Gain of N-linked glycosylation at N1237 (Pr = 0.02 | P = 0.03), ELME000053|ELME000070|ELME000202|PS00001,-
MYO7A_HUMAN,G519V,0.818,, PS00008,-
MYO7A_HUMAN,L651P,0.952,Gain of Allosteric site at F647 (Pr = 0.21 | P = 0.03), ELME000106|ELME000313,-
MYO7A_HUMAN,Y95C,0.914,Altered Ordered interface (Pr = 0.44 | P = 5.7e-04); Altered Transmembrane protein (Pr = 0.31 | P = 9.7e-05); Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of Allosteric site at Y97 (Pr = 0.27 | P = 8.5e-03); Loss of Strand (Pr = 0.26 | P = 0.05); Altered DNA binding (Pr = 0.25 | P = 8.3e-03); Altered Metal binding (Pr = 0.18 | P = 0.01), ELME000053|ELME000182|ELME000336|PS00007,-
MYO7A_HUMAN,R378S,0.788,Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000053|ELME000063|ELME000064|ELME000085|ELME000220|PS00006,-
MYO7A_HUMAN,L1167H,0.924,Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Stability (Pr = 0.13 | P = 0.03), ELME000146,-
MYO7A_HUMAN,M283I,0.6,Altered Ordered interface (Pr = 0.28 | P = 0.03); Gain of Relative solvent accessibility (Pr = 0.28 | P = 0.01); Gain of Disulfide linkage at C286 (Pr = 0.15 | P = 0.03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04); Gain of Sulfation at Y278 (Pr = 0.02 | P = 0.04), ELME000182,-
MYO7A_HUMAN,P1467L,0.894,Altered Ordered interface (Pr = 0.30 | P = 0.02); Gain of Helix (Pr = 0.27 | P = 0.05); Loss of Allosteric site at W1466 (Pr = 0.21 | P = 0.03); Altered Transmembrane protein (Pr = 0.11 | P = 0.04), ELME000080|ELME000106|ELME000146|ELME000149|ELME000233,-
MYO7A_HUMAN,L247P,0.142,-,-,-
MYO7A_HUMAN,D248S,0.66,Gain of Allosteric site at R250 (Pr = 0.28 | P = 3.7e-03); Altered Metal binding (Pr = 0.27 | P = 7.7e-03); Gain of Pyrrolidone carboxylic acid at Q245 (Pr = 0.06 | P = 0.02), ELME000146|PS00005|PS00007,-
MYO7A_HUMAN,R250A,0.938,Loss of Allosteric site at R250 (Pr = 0.32 | P = 2.4e-03); Altered Metal binding (Pr = 0.30 | P = 5.3e-03); Loss of Pyrrolidone carboxylic acid at Q245 (Pr = 0.06 | P = 0.03), PS00007,-
MYO7A_HUMAN,V254I,0.299,-,-,-
MYO7A_HUMAN,V254L,0.608,Altered Metal binding (Pr = 0.28 | P = 5.9e-03); Loss of Allosteric site at Y256 (Pr = 0.26 | P = 0.01); Loss of Catalytic site at Y256 (Pr = 0.09 | P = 0.04), ELME000020|ELME000120,-
MYO7A_HUMAN,M258G,0.903,Altered Metal binding (Pr = 0.29 | P = 6.1e-03); Gain of Allosteric site at F255 (Pr = 0.29 | P = 2.4e-03); Gain of Catalytic site at Y256 (Pr = 0.15 | P = 0.02), ELME000020|ELME000120|ELME000182,-
MYO7A_HUMAN,E260P,0.533,Loss of Helix (Pr = 0.27 | P = 0.03); Gain of Allosteric site at Y256 (Pr = 0.27 | P = 4.5e-03); Gain of Catalytic site at Y256 (Pr = 0.10 | P = 0.04); Altered Metal binding (Pr = 0.08 | P = 0.02), ELME000239,-
MYO7A_HUMAN,G261S,0.598,Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Allosteric site at Y256 (Pr = 0.25 | P = 0.01); Gain of Catalytic site at Y256 (Pr = 0.10 | P = 0.04); Altered Metal binding (Pr = 0.09 | P = 0.01), ELME000064|ELME000336|PS00006,-
MYO7A_HUMAN,S263G,0.181,-,-,-
MYO7A_HUMAN,E264Q,0.114,-,-,-
MYO7A_HUMAN,D265Q,0.293,-,-,-
MYO7A_HUMAN,K267L,0.517,Loss of B-factor (Pr = 0.30 | P = 7.7e-03); Loss of Methylation at K268 (Pr = 0.10 | P = 0.05), None,-
MYO7A_HUMAN,K268Q,0.236,-,-,-
MYO7A_HUMAN,Q274E,0.092,-,-,-
MYO7A_HUMAN,D277E,0.328,-,-,-
MYO7A_HUMAN,T288I,0.278,-,-,-
MYO7A_HUMAN,N300S,0.181,-,-,-
MYO7A_HUMAN,S351C,0.384,-,-,-
MYO7A_HUMAN,S357T,0.135,-,-,-
MYO7A_HUMAN,P364R,0.182,-,-,-
MYO7A_HUMAN,S423P,0.4,-,-,-
MYO7A_HUMAN,N443K,0.896,Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Allosteric site at F439 (Pr = 0.25 | P = 9.7e-03); Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000193,-
MYO7A_HUMAN,A445S,0.171,-,-,-
MYO7A_HUMAN,S481T,0.18,-,-,-
MYO7A_HUMAN,A495T,0.69,Altered Metal binding (Pr = 0.26 | P = 7.9e-03); Loss of Allosteric site at N492 (Pr = 0.26 | P = 0.01); Gain of Catalytic site at N492 (Pr = 0.14 | P = 0.02); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), None,-
MYO7A_HUMAN,N501S,0.257,-,-,-
MYO7A_HUMAN,I510L,0.559,Loss of Strand (Pr = 0.26 | P = 0.04); Gain of Allosteric site at E513 (Pr = 0.19 | P = 0.05); Altered Metal binding (Pr = 0.17 | P = 0.03), ELME000333|PS00006,-
MYO7A_HUMAN,N529W,0.756,, ELME000202,-
MYO7A_HUMAN,L534V,0.114,-,-,-
MYO7A_HUMAN,L534Y,0.28,-,-,-
MYO7A_HUMAN,A536M,0.21,-,-,-
MYO7A_HUMAN,A536T,0.08,-,-,-
MYO7A_HUMAN,Y538S,0.773,Gain of Intrinsic disorder (Pr = 0.37 | P = 0.01); Altered Ordered interface (Pr = 0.34 | P = 2.8e-03); Altered DNA binding (Pr = 0.21 | P = 0.02); Gain of GPI-anchor amidation at N543 (Pr = 0.01 | P = 0.03), ELME000081|ELME000083|ELME000182,-
MYO7A_HUMAN,T562S,0.15,-,-,-
MYO7A_HUMAN,R585W,0.338,-,-,-
MYO7A_HUMAN,T603R,0.728,Gain of ADP-ribosylation at T603 (Pr = 0.24 | P = 0.01); Gain of Phosphorylation at S607 (Pr = 0.23 | P = 0.05), ELME000012|ELME000053|ELME000101|ELME000102|ELME000108|ELME000271|ELME000278|PS00005,-
MYO7A_HUMAN,L610M,0.387,-,-,-
MYO7A_HUMAN,A627G,0.322,-,-,-
MYO7A_HUMAN,R669H,0.605,Altered Ordered interface (Pr = 0.35 | P = 5.0e-03); Gain of Strand (Pr = 0.27 | P = 0.02); Altered DNA binding (Pr = 0.24 | P = 1.0e-02); Altered Metal binding (Pr = 0.10 | P = 0.05); Gain of Catalytic site at Y672 (Pr = 0.09 | P = 0.05), ELME000101|ELME000102|ELME000108,-
MYO7A_HUMAN,L689Q,0.84,Gain of Strand (Pr = 0.27 | P = 0.02); Loss of Allosteric site at Y685 (Pr = 0.22 | P = 0.03), ELME000106|ELME000146|ELME000149|ELME000155|ELME000167|ELME000231,-
MYO7A_HUMAN,A695V,0.439,-,-,-
MYO7A_HUMAN,K697Q,0.365,-,-,-
MYO7A_HUMAN,G699E,0.228,-,-,-
MYO7A_HUMAN,L701V,0.407,-,-,-
MYO7A_HUMAN,R707P,0.673,, ELME000062,-
MYO7A_HUMAN,A711T,0.135,-,-,-
MYO7A_HUMAN,H716Y,0.429,-,-,-
MYO7A_HUMAN,I726V,0.57,Gain of Strand (Pr = 0.27 | P = 0.03); Altered Metal binding (Pr = 0.23 | P = 0.02); Altered DNA binding (Pr = 0.19 | P = 0.02), ELME000146,-
MYO7A_HUMAN,D730R,0.944,Altered Metal binding (Pr = 0.30 | P = 4.3e-03); Gain of Helix (Pr = 0.27 | P = 0.05); Altered DNA binding (Pr = 0.16 | P = 0.04), ELME000100|ELME000108|ELME000233|ELME000326,-
MYO7A_HUMAN,H731R,0.798,Altered Metal binding (Pr = 0.36 | P = 1.9e-03); Altered DNA binding (Pr = 0.15 | P = 0.04), ELME000149|ELME000233,-
MYO7A_HUMAN,D733G,0.86,Altered Metal binding (Pr = 0.30 | P = 4.1e-03), None,-
MYO7A_HUMAN,M734T,0.628,Altered Metal binding (Pr = 0.26 | P = 0.01); Gain of Relative solvent accessibility (Pr = 0.23 | P = 0.05); Altered Stability (Pr = 0.14 | P = 0.02), ELME000064|ELME000220|ELME000335|PS00006,-
MYO7A_HUMAN,L736A,0.898,Altered Metal binding (Pr = 0.27 | P = 8.9e-03); Altered Stability (Pr = 0.11 | P = 0.03), ELME000047|ELME000333,-
MYO7A_HUMAN,V738C,0.352,-,-,-
MYO7A_HUMAN,K742P,0.77,Gain of Allosteric site at R740 (Pr = 0.19 | P = 0.05), ELME000146|ELME000173,-
MYO7A_HUMAN,K766R,0.174,-,-,-
MYO7A_HUMAN,N769S,0.099,-,-,-
MYO7A_HUMAN,A770S,0.291,-,-,-
MYO7A_HUMAN,L773V,0.125,-,-,-
MYO7A_HUMAN,R776K,0.378,-,-,-
MYO7A_HUMAN,H781Y,0.41,-,-,-
MYO7A_HUMAN,H801F,0.387,-,-,-
MYO7A_HUMAN,R802S,0.869,Altered Disordered interface (Pr = 0.46 | P = 4.1e-03); Altered DNA binding (Pr = 0.27 | P = 6.5e-03); Altered Coiled coil (Pr = 0.12 | P = 0.04), ELME000239|ELME000336|PS00005,-
MYO7A_HUMAN,R804Q,0.278,-,-,-
MYO7A_HUMAN,Q808K,0.112,-,-,-
MYO7A_HUMAN,Q809H,0.169,-,-,-
MYO7A_HUMAN,Q809K,0.174,-,-,-
MYO7A_HUMAN,Q809R,0.176,-,-,-
MYO7A_HUMAN,R811C,0.123,-,-,-
MYO7A_HUMAN,R814S,0.533,Altered Disordered interface (Pr = 0.47 | P = 3.8e-03); Altered DNA binding (Pr = 0.15 | P = 0.04); Altered Coiled coil (Pr = 0.13 | P = 0.04), ELME000012|ELME000134|ELME000137|ELME000173|ELME000202|ELME000233|PS00005,-
MYO7A_HUMAN,Q815G,0.182,-,-,-
MYO7A_HUMAN,Q815R,0.051,-,-,-
MYO7A_HUMAN,I817M,0.252,-,-,-
MYO7A_HUMAN,I817V,0.116,-,-,-
MYO7A_HUMAN,I818T,0.363,-,-,-
MYO7A_HUMAN,V843L,0.295,-,-,-
MYO7A_HUMAN,L855V,0.197,-,-,-
MYO7A_HUMAN,H856Y,0.221,-,-,-
MYO7A_HUMAN,Q857R,0.056,-,-,-
MYO7A_HUMAN,R860K,0.144,-,-,-
MYO7A_HUMAN,A861G,0.075,-,-,-
MYO7A_HUMAN,A918E,0.057,-,-,-
MYO7A_HUMAN,A918K,0.221,-,-,-
MYO7A_HUMAN,R921P,0.624,Altered Coiled coil (Pr = 0.53 | P = 6.5e-03); Loss of SUMOylation at K922 (Pr = 0.47 | P = 5.5e-04); Gain of Acetylation at K916 (Pr = 0.24 | P = 0.02), ELME000002|ELME000102|ELME000108|ELME000149,-
MYO7A_HUMAN,Q928R,0.167,-,-,-
MYO7A_HUMAN,V937I,0.03,-,-,-
MYO7A_HUMAN,G954A,0.09,-,-,-
MYO7A_HUMAN,R974Q,0.074,-,-,-
MYO7A_HUMAN,R975M,0.183,-,-,-
MYO7A_HUMAN,R975T,0.215,-,-,-
MYO7A_HUMAN,A984T,0.1,-,-,-
MYO7A_HUMAN,A1005S,0.228,-,-,-
MYO7A_HUMAN,H1029Q,0.584,Altered Transmembrane protein (Pr = 0.15 | P = 0.02); Gain of Sulfation at Y1028 (Pr = 0.03 | P = 0.02), None,-
MYO7A_HUMAN,D1034N,0.723,, PS00008,-
MYO7A_HUMAN,I1045V,0.253,-,-,-
MYO7A_HUMAN,M1061I,0.185,-,-,-
MYO7A_HUMAN,K1067N,0.667,Altered Disordered interface (Pr = 0.31 | P = 0.02); Gain of Loop (Pr = 0.28 | P = 0.02); Loss of Ubiquitylation at K1067 (Pr = 0.22 | P = 2.9e-03); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000063|PS00005,-
MYO7A_HUMAN,Q1097P,0.386,-,-,-
MYO7A_HUMAN,P1099S,0.122,-,-,-
MYO7A_HUMAN,K1104R,0.085,-,-,-
MYO7A_HUMAN,D483G,0.443,-,-,-
MYO7A_HUMAN,D483N,0.211,-,-,-
MYO7A_HUMAN,T520L,0.798,Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Metal binding (Pr = 0.16 | P = 0.05), ELME000052|ELME000147|ELME000336|PS00008,-
MYO7A_HUMAN,T522A,0.09,-,-,-
MYO7A_HUMAN,T523H,0.824,Altered Metal binding (Pr = 0.20 | P = 0.03), ELME000052|ELME000147|PS00008,-
MYO7A_HUMAN,K533R,0.189,-,-,-
MYO7A_HUMAN,A536R,0.243,-,-,-
MYO7A_HUMAN,A536S,0.071,-,-,-
MYO7A_HUMAN,I539F,0.454,-,-,-
MYO7A_HUMAN,N544S,0.157,-,-,-
MYO7A_HUMAN,I551H,0.936,Altered Metal binding (Pr = 0.79 | P = 7.3e-04); Altered Stability (Pr = 0.31 | P = 5.0e-03); Altered Ordered interface (Pr = 0.27 | P = 0.05); Gain of Allosteric site at H553 (Pr = 0.22 | P = 0.02); Altered Transmembrane protein (Pr = 0.16 | P = 0.01), None,-
MYO7A_HUMAN,N552Q,0.288,-,-,-
MYO7A_HUMAN,H582Y,0.418,-,-,-
MYO7A_HUMAN,I592L,0.279,-,-,-
MYO7A_HUMAN,A595T,0.217,-,-,-
MYO7A_HUMAN,A601S,0.164,-,-,-
MYO7A_HUMAN,S607W,0.629,Loss of Phosphorylation at S607 (Pr = 0.70 | P = 1.2e-03); Loss of Intrinsic disorder (Pr = 0.51 | P = 5.8e-03); Loss of ADP-ribosylation at R604 (Pr = 0.21 | P = 0.03); Loss of Ubiquitylation at K605 (Pr = 0.15 | P = 0.05), ELME000012|ELME000053|ELME000061|ELME000100|ELME000108|ELME000136|ELME000159|ELME000173|ELME000278|PS00004,-
MYO7A_HUMAN,S612C,0.394,-,-,-
MYO7A_HUMAN,L646R,0.732,Gain of Acetylation at K642 (Pr = 0.29 | P = 4.6e-03); Gain of Allosteric site at F647 (Pr = 0.23 | P = 0.02), ELME000146|ELME000233|ELME000313,-
MYO7A_HUMAN,H650P,0.68,Gain of Allosteric site at F647 (Pr = 0.26 | P = 7.5e-03); Altered Transmembrane protein (Pr = 0.09 | P = 0.05), ELME000106|ELME000313,-
MYO7A_HUMAN,V653I,0.35,-,-,-
MYO7A_HUMAN,E663K,0.929,Altered Disordered interface (Pr = 0.45 | P = 2.1e-03); Altered Metal binding (Pr = 0.35 | P = 2.1e-03); Gain of Strand (Pr = 0.27 | P = 0.03); Altered DNA binding (Pr = 0.25 | P = 6.4e-03); Gain of Acetylation at E663 (Pr = 0.22 | P = 0.02); Loss of Allosteric site at Y658 (Pr = 0.20 | P = 0.04), ELME000052|PS00008,-
MYO7A_HUMAN,D700N,0.606,, ELME000156|PS00008,-
MYO7A_HUMAN,T704P,0.843,, ELME000062|ELME000336,-
MYO7A_HUMAN,Q706R,0.451,-,-,-
MYO7A_HUMAN,K723R,0.33,-,-,-
MYO7A_HUMAN,E739K,0.602,, ELME000047|ELME000100|ELME000108|ELME000333,-
MYO7A_HUMAN,A743E,0.721,Altered Coiled coil (Pr = 0.24 | P = 0.01); Altered DNA binding (Pr = 0.15 | P = 0.04), ELME000052|ELME000146|ELME000173,-
MYO7A_HUMAN,N763S,0.3,-,-,-
MYO7A_HUMAN,Y787C,0.809,Altered Disordered interface (Pr = 0.26 | P = 0.02), ELME000120|ELME000134|ELME000233,-
MYO7A_HUMAN,Y787F,0.399,-,-,-
MYO7A_HUMAN,G788E,0.154,-,-,-
MYO7A_HUMAN,M790I,0.387,-,-,-
MYO7A_HUMAN,R791Q,0.468,-,-,-
MYO7A_HUMAN,A799V,0.654,Altered Coiled coil (Pr = 0.32 | P = 9.7e-03); Altered DNA binding (Pr = 0.27 | P = 4.0e-03); Altered Disordered interface (Pr = 0.26 | P = 0.01), None,-
MYO7A_HUMAN,L800W,0.634,Altered Disordered interface (Pr = 0.49 | P = 1.5e-03); Altered Stability (Pr = 0.26 | P = 7.5e-03); Altered DNA binding (Pr = 0.25 | P = 8.9e-03), ELME000336,-
MYO7A_HUMAN,S803A,0.257,-,-,-
MYO7A_HUMAN,R804G,0.53,Altered Disordered interface (Pr = 0.49 | P = 3.0e-03); Altered DNA binding (Pr = 0.30 | P = 1.8e-03); Altered Stability (Pr = 0.15 | P = 0.02); Altered Coiled coil (Pr = 0.13 | P = 0.04), ELME000085|ELME000102|ELME000336|PS00005,-
MYO7A_HUMAN,K805G,0.498,-,-,-
MYO7A_HUMAN,L806M,0.25,-,-,-
MYO7A_HUMAN,Y810P,0.908,Altered Disordered interface (Pr = 0.37 | P = 8.2e-03); Gain of Intrinsic disorder (Pr = 0.37 | P = 0.01); Altered DNA binding (Pr = 0.17 | P = 0.03); Altered Coiled coil (Pr = 0.14 | P = 0.03), None,-
MYO7A_HUMAN,Y810S,0.83,Gain of Intrinsic disorder (Pr = 0.44 | P = 4.6e-03); Altered Disordered interface (Pr = 0.23 | P = 0.02); Altered DNA binding (Pr = 0.18 | P = 0.03); Altered Coiled coil (Pr = 0.13 | P = 0.04), None,-
MYO7A_HUMAN,R811G,0.239,-,-,-
MYO7A_HUMAN,R816H,0.209,-,-,-
MYO7A_HUMAN,R816L,0.428,-,-,-
MYO7A_HUMAN,I817L,0.212,-,-,-
MYO7A_HUMAN,Q819E,0.084,-,-,-
MYO7A_HUMAN,Q821R,0.782,Altered Coiled coil (Pr = 0.19 | P = 0.02), ELME000012|ELME000134|ELME000137,-
MYO7A_HUMAN,K831R,0.116,-,-,-
MYO7A_HUMAN,L864Q,0.166,-,-,-
MYO7A_HUMAN,R866S,0.547,Altered Disordered interface (Pr = 0.49 | P = 2.9e-03); Altered Coiled coil (Pr = 0.21 | P = 0.02), ELME000182,-
MYO7A_HUMAN,K871R,0.205,-,-,-
MYO7A_HUMAN,M872L,0.108,-,-,-
MYO7A_HUMAN,K888R,0.15,-,-,-
MYO7A_HUMAN,D908S,0.361,-,-,-
MYO7A_HUMAN,R921Q,0.139,-,-,-
MYO7A_HUMAN,H934R,0.115,-,-,-
MYO7A_HUMAN,K945R,0.135,-,-,-
MYO7A_HUMAN,R972Q,0.085,-,-,-
MYO7A_HUMAN,V978L,0.09,-,-,-
MYO7A_HUMAN,E998D,0.302,-,-,-
MYO7A_HUMAN,S1016T,0.065,-,-,-
MYO7A_HUMAN,D1030S,0.319,-,-,-
MYO7A_HUMAN,A1089T,0.381,-,-,-
MYO7A_HUMAN,G1092C,0.412,-,-,-
MYO7A_HUMAN,G1094S,0.197,-,-,-
MYO7A_HUMAN,L1098V,0.081,-,-,-
MYO7A_HUMAN,K1128V,0.604,Loss of Intrinsic disorder (Pr = 0.47 | P = 0.01); Loss of Acetylation at K1128 (Pr = 0.29 | P = 4.6e-03), ELME000100|ELME000108|ELME000147|ELME000233|PS00005,-
MYO7A_HUMAN,D1132Q,0.365,-,-,-
MYO7A_HUMAN,G1133A,0.389,-,-,-
MYO7A_HUMAN,I1158V,0.349,-,-,-
MYO7A_HUMAN,A1203S,0.313,-,-,-
MYO7A_HUMAN,F1235S,0.662,Gain of Intrinsic disorder (Pr = 0.37 | P = 0.01); Altered DNA binding (Pr = 0.26 | P = 5.7e-03); Altered Stability (Pr = 0.25 | P = 8.0e-03); Altered Transmembrane protein (Pr = 0.09 | P = 0.05); Gain of N-linked glycosylation at N1237 (Pr = 0.03 | P = 0.03), ELME000008|ELME000053|ELME000061|ELME000062|ELME000065|ELME000336|PS00004,-
MYO7A_HUMAN,N1285D,0.259,-,-,-
MYO7A_HUMAN,K1294R,0.215,-,-,-
MYO7A_HUMAN,I1303V,0.525,Altered Transmembrane protein (Pr = 0.10 | P = 0.05), ELME000083|ELME000120|ELME000182|ELME000233,-
MYO7A_HUMAN,A1340T,0.811,Altered Transmembrane protein (Pr = 0.29 | P = 2.1e-04); Gain of Pyrrolidone carboxylic acid at Q1336 (Pr = 0.08 | P = 0.02), ELME000136|ELME000153|ELME000159,-
MYO7A_HUMAN,T1352A,0.712,Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Metal binding (Pr = 0.27 | P = 0.03); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered Transmembrane protein (Pr = 0.19 | P = 6.7e-03); Altered DNA binding (Pr = 0.16 | P = 0.04), ELME000053|ELME000136|ELME000146|ELME000155|ELME000159|ELME000289|ELME000358,-
MYO7A_HUMAN,P1357S,0.711,Gain of Relative solvent accessibility (Pr = 0.38 | P = 5.7e-04); Altered Metal binding (Pr = 0.29 | P = 0.02); Altered Ordered interface (Pr = 0.28 | P = 0.05); Altered Transmembrane protein (Pr = 0.25 | P = 1.5e-03), ELME000064|ELME000173|ELME000239|PS00006,-
MYO7A_HUMAN,S1358A,0.135,-,-,-
MYO7A_HUMAN,I1417V,0.336,-,-,-
MYO7A_HUMAN,D1419A,0.703,Altered Transmembrane protein (Pr = 0.15 | P = 0.02), ELME000081|ELME000182|ELME000254|ELME000322,-
MYO7A_HUMAN,K1426R,0.217,-,-,-
MYO7A_HUMAN,D1450E,0.23,-,-,-
MYO7A_HUMAN,S1460N,0.049,-,-,-
MYO7A_HUMAN,F1479C,0.673,Loss of Strand (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Loss of Sulfation at Y1477 (Pr = 0.01 | P = 0.04), ELME000085|ELME000155,-
MYO7A_HUMAN,S1483T,0.265,-,-,-
MYO7A_HUMAN,M1517L,0.352,-,-,-
MYO7A_HUMAN,C1525F,0.846,Gain of Strand (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Loss of Disulfide linkage at C1525 (Pr = 0.10 | P = 0.05), ELME000197|ELME000233,-
MYO7A_HUMAN,W1528S,0.378,-,-,-
MYO7A_HUMAN,G1537D,0.615,, PS00006,-
MYO7A_HUMAN,A1540E,0.282,-,-,-
MYO7A_HUMAN,A1540V,0.135,-,-,-
MYO7A_HUMAN,A1551D,0.364,-,-,-
MYO7A_HUMAN,A1551S,0.12,-,-,-
MYO7A_HUMAN,T1565M,0.103,-,-,-
MYO7A_HUMAN,A1587S,0.524,Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.23 | P = 0.02); Altered Transmembrane protein (Pr = 0.17 | P = 0.01); Gain of GPI-anchor amidation at N1586 (Pr = 0.02 | P = 0.02), ELME000063|ELME000064|ELME000336|PS00006,-
MYO7A_HUMAN,P1615S,0.341,-,-,-
MYO7A_HUMAN,E1621D,0.338,-,-,-
MYO7A_HUMAN,S1626G,0.443,-,-,-
FGFR1_HUMAN,T15D,0.847,Gain of Loop (Pr = 0.27 | P = 0.03); Altered Signal peptide (Pr = 0.18 | P = 3.8e-04), ELME000041|ELME000052|ELME000147|ELME000333,-
FGFR1_HUMAN,T15R,0.892,Altered Disordered interface (Pr = 0.21 | P = 0.03); Altered Signal peptide (Pr = 0.20 | P = 2.9e-04), ELME000041|ELME000052|ELME000062|ELME000333,-
FGFR1_HUMAN,T15V,0.803,Altered Signal peptide (Pr = 0.18 | P = 3.5e-04), ELME000041|ELME000052|ELME000333,-
FGFR1_HUMAN,T17S,0.561,Gain of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.03); Altered Signal peptide (Pr = 0.19 | P = 3.3e-04), ELME000052|ELME000053|ELME000063,-
FGFR1_HUMAN,T20G,0.752,Gain of Loop (Pr = 0.27 | P = 0.03); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.05); Altered Signal peptide (Pr = 0.19 | P = 3.6e-04); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000053|PS00005,-
FGFR1_HUMAN,T20L,0.727,Altered Signal peptide (Pr = 0.24 | P = 1.5e-04); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.05); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000053|PS00005,-
FGFR1_HUMAN,P23A,0.488,-,-,-
FGFR1_HUMAN,S24P,0.645,Loss of Loop (Pr = 0.27 | P = 0.03); Gain of B-factor (Pr = 0.26 | P = 0.02); Altered Signal peptide (Pr = 0.20 | P = 3.0e-04); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.05); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000005|ELME000053|ELME000064|ELME000136|ELME000155|ELME000159|ELME000220,-
FGFR1_HUMAN,P25L,0.601,Altered Signal peptide (Pr = 0.36 | P = 3.4e-05); Loss of Intrinsic disorder (Pr = 0.35 | P = 0.04); Loss of Loop (Pr = 0.27 | P = 0.04); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.04); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Loss of Pyrrolidone carboxylic acid at Q30 (Pr = 0.07 | P = 0.02), ELME000005|ELME000051|ELME000062|ELME000064|ELME000136|ELME000155|ELME000159|ELME000220|ELME000239,-
FGFR1_HUMAN,T26S,0.521,Gain of Intrinsic disorder (Pr = 0.35 | P = 0.02); Gain of B-factor (Pr = 0.25 | P = 0.03); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.05); Altered Signal peptide (Pr = 0.18 | P = 4.0e-04); Altered Transmembrane protein (Pr = 0.14 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q30 (Pr = 0.06 | P = 0.02), ELME000005|ELME000064|ELME000136|ELME000155|ELME000159|ELME000220|ELME000239|PS00006,-
FGFR1_HUMAN,E29P,0.823,Gain of O-linked glycosylation at T26 (Pr = 0.17 | P = 0.02); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q30 (Pr = 0.08 | P = 0.02), ELME000064|ELME000145|ELME000220|PS00006,-
FGFR1_HUMAN,Q30A,0.398,-,-,-
FGFR1_HUMAN,A31G,0.335,-,-,-
FGFR1_HUMAN,A31L,0.534,Altered Transmembrane protein (Pr = 0.14 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q32 (Pr = 0.08 | P = 0.02), None,-
FGFR1_HUMAN,A36T,0.14,-,-,-
FGFR1_HUMAN,V45A,0.256,-,-,-
FGFR1_HUMAN,P47S,0.302,-,-,-
FGFR1_HUMAN,S63I,0.572,Altered Transmembrane protein (Pr = 0.34 | P = 4.4e-05); Altered Metal binding (Pr = 0.24 | P = 0.02), ELME000193|ELME000233|ELME000335,-
FGFR1_HUMAN,D69G,0.821,Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Gain of Strand (Pr = 0.27 | P = 0.03); Altered Metal binding (Pr = 0.21 | P = 0.03); Loss of Proteolytic cleavage at D69 (Pr = 0.12 | P = 0.03), ELME000193,-
FGFR1_HUMAN,V71A,0.357,-,-,-
FGFR1_HUMAN,S76G,0.34,-,-,-
FGFR1_HUMAN,Q89R,0.05,-,-,-
FGFR1_HUMAN,Q89W,0.261,-,-,-
FGFR1_HUMAN,V92G,0.326,-,-,-
FGFR1_HUMAN,V102M,0.187,-,-,-
FGFR1_HUMAN,D128E,0.458,-,-,-
FGFR1_HUMAN,T141A,0.159,-,-,-
FGFR1_HUMAN,T141M,0.165,-,-,-
FGFR1_HUMAN,M149R,0.394,-,-,-
FGFR1_HUMAN,S181N,0.334,-,-,-
FGFR1_HUMAN,N185S,0.227,-,-,-
FGFR1_HUMAN,M276V,0.277,-,-,-
FGFR1_HUMAN,V308D,0.897,Loss of Strand (Pr = 0.26 | P = 0.05); Altered Transmembrane protein (Pr = 0.20 | P = 5.7e-03); Altered Stability (Pr = 0.10 | P = 0.04), ELME000020|ELME000083|ELME000120|ELME000182,-
FGFR1_HUMAN,E324S,0.8,Altered Transmembrane protein (Pr = 0.28 | P = 4.3e-04); Gain of Ubiquitylation at K321 (Pr = 0.15 | P = 0.05), ELME000065|ELME000147|ELME000335,-
FGFR1_HUMAN,H327T,0.701,Altered Transmembrane protein (Pr = 0.26 | P = 1.0e-03); Gain of N-linked glycosylation at N330 (Pr = 0.10 | P = 0.01), ELME000122|ELME000137|ELME000334|ELME000335|PS00005,-
FGFR1_HUMAN,V331I,0.763,Altered Transmembrane protein (Pr = 0.28 | P = 3.6e-04); Gain of Strand (Pr = 0.26 | P = 0.03); Altered Metal binding (Pr = 0.17 | P = 0.04); Gain of N-linked glycosylation at N330 (Pr = 0.10 | P = 0.01), ELME000070|ELME000122|ELME000137|ELME000334|PS00001,-
FGFR1_HUMAN,T340M,0.834,Altered Metal binding (Pr = 0.30 | P = 0.01); Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Altered Ordered interface (Pr = 0.26 | P = 0.02); Loss of Disulfide linkage at C341 (Pr = 0.18 | P = 0.03), ELME000120|ELME000182,-
FGFR1_HUMAN,L342F,0.807,Altered Metal binding (Pr = 0.27 | P = 0.03); Gain of Strand (Pr = 0.27 | P = 0.03); Gain of Loop (Pr = 0.26 | P = 0.05); Altered Transmembrane protein (Pr = 0.25 | P = 1.6e-03); Altered Ordered interface (Pr = 0.25 | P = 0.03); Loss of Disulfide linkage at C341 (Pr = 0.18 | P = 0.03), ELME000120|ELME000182|ELME000337,-
FGFR1_HUMAN,A343S,0.772,Altered Metal binding (Pr = 0.31 | P = 0.02); Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.24 | P = 1.5e-03); Gain of Disulfide linkage at C341 (Pr = 0.19 | P = 0.02); Gain of Catalytic site at N345 (Pr = 0.10 | P = 0.04), ELME000053|ELME000063|ELME000085|ELME000239,-
FGFR1_HUMAN,S346G,0.811,Altered Metal binding (Pr = 0.34 | P = 9.6e-03); Altered Transmembrane protein (Pr = 0.26 | P = 8.7e-04); Loss of Strand (Pr = 0.26 | P = 0.05); Loss of Disulfide linkage at C341 (Pr = 0.19 | P = 0.02); Gain of Catalytic site at N345 (Pr = 0.08 | P = 0.05), ELME000053|ELME000239|PS00008,-
FGFR1_HUMAN,S350A,0.516,Altered Transmembrane protein (Pr = 0.27 | P = 5.5e-04); Loss of Strand (Pr = 0.26 | P = 0.04); Altered Ordered interface (Pr = 0.23 | P = 0.05), ELME000053|ELME000063|ELME000239,-
FGFR1_HUMAN,E360P,0.715,Altered Transmembrane protein (Pr = 0.29 | P = 2.9e-04), ELME000064|ELME000220|ELME000333|ELME000341|PS00006,-
FGFR1_HUMAN,E364D,0.199,-,-,-
FGFR1_HUMAN,V368G,0.38,-,-,-
FGFR1_HUMAN,T382A,0.375,-,-,-
FGFR1_HUMAN,V391A,0.257,-,-,-
FGFR1_HUMAN,V391L,0.191,-,-,-
FGFR1_HUMAN,T428Q,0.822,Gain of Intrinsic disorder (Pr = 0.32 | P = 0.03); Loss of Phosphorylation at T428 (Pr = 0.30 | P = 0.02); Loss of O-linked glycosylation at T428 (Pr = 0.20 | P = 0.02); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Loss of Proteolytic cleavage at D432 (Pr = 0.13 | P = 0.02), ELME000051|ELME000053|ELME000146,-
FGFR1_HUMAN,A435T,0.147,-,-,-
FGFR1_HUMAN,R477K,0.562,, ELME000146,-
FGFR1_HUMAN,K504R,0.328,-,-,-
FGFR1_HUMAN,S518A,0.295,-,-,-
FGFR1_HUMAN,D554G,0.648,Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Altered Metal binding (Pr = 0.21 | P = 0.03); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Gain of Catalytic site at C551 (Pr = 0.13 | P = 0.03), ELME000202,-
FGFR1_HUMAN,S588G,0.138,-,-,-
FGFR1_HUMAN,Q594L,0.503,Loss of Loop (Pr = 0.27 | P = 0.03), ELME000240,-
FGFR1_HUMAN,V601I,0.254,-,-,-
FGFR1_HUMAN,N635S,0.471,-,-,-
FGFR1_HUMAN,L662A,0.899,Altered Stability (Pr = 0.55 | P = 1.4e-03); Altered Ordered interface (Pr = 0.28 | P = 0.03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), None,-
FGFR1_HUMAN,A671G,0.762,Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Altered Stability (Pr = 0.09 | P = 0.05), None,-
FGFR1_HUMAN,E728D,0.615,Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Allosteric site at Y730 (Pr = 0.23 | P = 0.02); Altered Metal binding (Pr = 0.06 | P = 0.03); Loss of N-linked glycosylation at N724 (Pr = 0.02 | P = 0.03); Loss of N-terminal acetylation at M732 (Pr = 0.02 | P = 8.1e-03), ELME000052|ELME000063|ELME000070,-
FGFR1_HUMAN,H738N,0.704,Altered Metal binding (Pr = 0.28 | P = 0.02); Gain of Allosteric site at W737 (Pr = 0.25 | P = 0.01); Gain of Disulfide linkage at C736 (Pr = 0.12 | P = 0.04), None,-
FGFR1_HUMAN,M771V,0.068,-,-,-
FGFR1_HUMAN,T783A,0.197,-,-,-
FGFR1_HUMAN,A812I,0.139,-,-,-
FGFR1_HUMAN,R821P,0.496,-,-,-
FGFR1_HUMAN,E294K,0.856,Loss of Strand (Pr = 0.27 | P = 0.03); Altered DNA binding (Pr = 0.17 | P = 0.03); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Altered Stability (Pr = 0.11 | P = 0.03); Loss of N-linked glycosylation at N296 (Pr = 0.08 | P = 0.02), ELME000146,-
FGFR1_HUMAN,L624P,0.954,Altered Transmembrane protein (Pr = 0.31 | P = 1.2e-04); Gain of Allosteric site at R627 (Pr = 0.29 | P = 3.1e-03); Loss of Helix (Pr = 0.28 | P = 0.02); Altered DNA binding (Pr = 0.28 | P = 2.7e-03); Altered Metal binding (Pr = 0.15 | P = 0.02); Gain of Catalytic site at R627 (Pr = 0.12 | P = 0.03), PS00109,-
FGFR1_HUMAN,C341W,0.973,Altered Metal binding (Pr = 0.53 | P = 3.4e-03); Altered Ordered interface (Pr = 0.30 | P = 3.2e-03); Altered Transmembrane protein (Pr = 0.27 | P = 9.5e-04); Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Disulfide linkage at C341 (Pr = 0.24 | P = 9.7e-03); Altered Stability (Pr = 0.09 | P = 0.04), ELME000120|ELME000147|ELME000182,-
FGFR1_HUMAN,D623Y,0.907,Altered DNA binding (Pr = 0.36 | P = 7.9e-04); Altered Disordered interface (Pr = 0.34 | P = 0.01); Altered Ordered interface (Pr = 0.30 | P = 3.0e-03); Gain of Allosteric site at R627 (Pr = 0.23 | P = 0.02); Altered Transmembrane protein (Pr = 0.22 | P = 2.8e-03); Altered Metal binding (Pr = 0.12 | P = 0.03); Loss of Catalytic site at R627 (Pr = 0.12 | P = 0.03), ELME000182|PS00109,-
FGFR1_HUMAN,M161T,0.829,Loss of SUMOylation at K160 (Pr = 0.27 | P = 5.1e-03); Gain of B-factor (Pr = 0.25 | P = 0.03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000053|PS00005,-
FGFR1_HUMAN,C101F,0.963,Altered Metal binding (Pr = 0.33 | P = 0.01); Altered Stability (Pr = 0.26 | P = 7.2e-03); Altered Transmembrane protein (Pr = 0.24 | P = 2.0e-03); Loss of Disulfide linkage at C101 (Pr = 0.23 | P = 0.01); Gain of O-linked glycosylation at T103 (Pr = 0.19 | P = 0.02), ELME000053|ELME000120|ELME000336|PS00008,-
FGFR1_HUMAN,L342S,0.901,Altered Metal binding (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.27 | P = 5.5e-04); Altered Ordered interface (Pr = 0.27 | P = 0.05); Gain of Strand (Pr = 0.26 | P = 0.04); Gain of Disulfide linkage at C341 (Pr = 0.20 | P = 0.02); Altered Stability (Pr = 0.17 | P = 0.02); Gain of Catalytic site at N345 (Pr = 0.09 | P = 0.05); Gain of GPI-anchor amidation at N345 (Pr = 0.01 | P = 0.03), ELME000053|ELME000085|ELME000120|ELME000182,-
FGFR1_HUMAN,D129A,0.512,Loss of B-factor (Pr = 0.34 | P = 1.6e-03); Loss of Loop (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.23 | P = 2.7e-03); Gain of Proteolytic cleavage at D133 (Pr = 0.20 | P = 2.1e-03); Altered Metal binding (Pr = 0.13 | P = 0.03), None,-
FGFR1_HUMAN,I216V,0.215,-,-,-
FGFR1_HUMAN,S450F,0.795,Loss of Intrinsic disorder (Pr = 0.62 | P = 1.1e-03); Gain of Strand (Pr = 0.30 | P = 2.9e-03); Loss of Phosphorylation at T454 (Pr = 0.28 | P = 0.02); Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of ADP-ribosylation at R448 (Pr = 0.20 | P = 0.04), ELME000053|ELME000062|ELME000063|ELME000197|ELME000336,-
FGFR1_HUMAN,G260E,0.848,Gain of Relative solvent accessibility (Pr = 0.34 | P = 1.8e-03); Altered Ordered interface (Pr = 0.31 | P = 0.01); Altered Metal binding (Pr = 0.30 | P = 2.9e-03); Altered Transmembrane protein (Pr = 0.26 | P = 7.9e-04); Gain of N-linked glycosylation at N264 (Pr = 0.17 | P = 4.3e-03), PS00008,-
FGFR1_HUMAN,G97S,0.874,Gain of Intrinsic disorder (Pr = 0.36 | P = 0.02); Altered Transmembrane protein (Pr = 0.26 | P = 1.0e-03); Altered Metal binding (Pr = 0.23 | P = 0.05); Loss of Disulfide linkage at C101 (Pr = 0.18 | P = 0.03); Loss of Proteolytic cleavage at D95 (Pr = 0.12 | P = 0.03), ELME000085|ELME000147|ELME000239|ELME000337|PS00008,-
FGFR1_HUMAN,S346C,0.851,Altered Transmembrane protein (Pr = 0.33 | P = 5.4e-05); Altered Metal binding (Pr = 0.28 | P = 0.02); Loss of Loop (Pr = 0.27 | P = 0.04); Loss of Strand (Pr = 0.26 | P = 0.04); Gain of Disulfide linkage at C341 (Pr = 0.22 | P = 0.01), ELME000053|ELME000239|PS00008,-
FGFR1_HUMAN,I538V,0.505,Altered Coiled coil (Pr = 0.27 | P = 0.01), None,-
FGFR1_HUMAN,V688L,0.59,Loss of Strand (Pr = 0.27 | P = 0.02); Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.22 | P = 2.9e-03), None,-
FGFR1_HUMAN,C178S,0.96,Altered Metal binding (Pr = 0.57 | P = 2.5e-03); Gain of Intrinsic disorder (Pr = 0.49 | P = 1.9e-03); Loss of Disulfide linkage at C178 (Pr = 0.42 | P = 5.1e-04); Altered Ordered interface (Pr = 0.30 | P = 0.02); Gain of B-factor (Pr = 0.28 | P = 8.3e-03); Altered Transmembrane protein (Pr = 0.27 | P = 8.8e-04); Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Gain of O-linked glycosylation at S181 (Pr = 0.26 | P = 7.9e-03), ELME000063|ELME000136|ELME000159,-
FGFR1_HUMAN,F747L,0.857,Loss of Loop (Pr = 0.26 | P = 0.05); Altered DNA binding (Pr = 0.15 | P = 0.04), ELME000062|ELME000231|PS00005,-
FGFR1_HUMAN,S96P,0.816,Altered Transmembrane protein (Pr = 0.26 | P = 1.0e-03); Altered Metal binding (Pr = 0.25 | P = 0.03); Loss of Disulfide linkage at C101 (Pr = 0.18 | P = 0.03); Loss of Proteolytic cleavage at D95 (Pr = 0.14 | P = 0.02), ELME000085|ELME000155|ELME000239,-
FGFR1_HUMAN,R448W,0.678,Loss of Intrinsic disorder (Pr = 0.64 | P = 6.0e-04); Gain of Strand (Pr = 0.30 | P = 1.9e-03); Loss of ADP-ribosylation at R448 (Pr = 0.27 | P = 7.8e-03), ELME000053|ELME000062|ELME000063,-
FGFR1_HUMAN,A167S,0.522,Gain of Strand (Pr = 0.29 | P = 5.4e-03); Gain of Acetylation at K172 (Pr = 0.20 | P = 0.04); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000065|ELME000173,-
FGFR1_HUMAN,P722S,0.866,Altered DNA binding (Pr = 0.22 | P = 0.01); Gain of Disulfide linkage at C725 (Pr = 0.09 | P = 0.05); Gain of N-linked glycosylation at N724 (Pr = 0.02 | P = 0.03), ELME000053|ELME000336,-
FGFR1_HUMAN,P700L,0.91,Altered Ordered interface (Pr = 0.28 | P = 5.2e-03); Altered Transmembrane protein (Pr = 0.14 | P = 0.02); Loss of Catalytic site at Y701 (Pr = 0.12 | P = 0.03), ELME000136|ELME000155|ELME000159|ELME000336,-
FGFR1_HUMAN,G487D,0.921,Gain of Helix (Pr = 0.30 | P = 6.1e-03); Loss of Strand (Pr = 0.27 | P = 0.01), PS00107,-
FGFR1_HUMAN,V116I,0.284,-,-,-
FGFR1_HUMAN,I639T,0.91,Gain of Relative solvent accessibility (Pr = 0.31 | P = 6.3e-03); Gain of Allosteric site at F642 (Pr = 0.27 | P = 6.1e-03); Altered Metal binding (Pr = 0.20 | P = 0.04); Altered DNA binding (Pr = 0.20 | P = 0.02); Gain of Ubiquitylation at K638 (Pr = 0.15 | P = 0.04), None,-
FGFR1_HUMAN,R646W,0.929,Altered Metal binding (Pr = 0.27 | P = 0.02); Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of Helix (Pr = 0.27 | P = 0.05); Loss of Allosteric site at F642 (Pr = 0.23 | P = 0.02); Altered DNA binding (Pr = 0.19 | P = 0.03); Altered Transmembrane protein (Pr = 0.17 | P = 9.8e-03), ELME000328,-
FGFR1_HUMAN,D224H,0.925,Altered Metal binding (Pr = 0.47 | P = 5.7e-03); Altered Transmembrane protein (Pr = 0.32 | P = 5.8e-05); Altered Ordered interface (Pr = 0.31 | P = 0.02); Gain of N-linked glycosylation at N227 (Pr = 0.17 | P = 4.7e-03), PS00005,-
FGFR1_HUMAN,S3A,0.462,-,-,-
FGFR1_HUMAN,W4R,0.846,Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Disordered interface (Pr = 0.23 | P = 0.02); Altered Signal peptide (Pr = 0.21 | P = 5.1e-04); Loss of N-terminal acetylation at M1 (Pr = 0.02 | P = 6.1e-03), ELME000102|ELME000137|PS00005,-
FGFR1_HUMAN,K5R,0.309,-,-,-
FGFR1_HUMAN,K5S,0.48,-,-,-
FGFR1_HUMAN,C6I,0.483,-,-,-
FGFR1_HUMAN,C6L,0.631,Altered Disordered interface (Pr = 0.26 | P = 0.01); Altered Signal peptide (Pr = 0.20 | P = 6.2e-04); Loss of N-terminal acetylation at M1 (Pr = 0.02 | P = 6.2e-03), ELME000106|ELME000137|ELME000146,-
FGFR1_HUMAN,C6S,0.371,-,-,-
FGFR1_HUMAN,C6T,0.511,Altered Disordered interface (Pr = 0.29 | P = 9.2e-03); Altered Signal peptide (Pr = 0.18 | P = 7.7e-04); Gain of N-terminal acetylation at M1 (Pr = 0.03 | P = 4.7e-03), ELME000063|ELME000106|ELME000137|ELME000146,-
MYO7A_HUMAN,A984S,0.072,-,-,-
MYO7A_HUMAN,A984V,0.106,-,-,-
MYO7A_HUMAN,T1014M,0.264,-,-,-
MYO7A_HUMAN,K1023R,0.263,-,-,-
MYO7A_HUMAN,E1032A,0.688,Loss of B-factor (Pr = 0.25 | P = 0.05); Loss of Sulfation at Y1028 (Pr = 0.03 | P = 0.02), None,-
MYO7A_HUMAN,I1068V,0.144,-,-,-
MYO7A_HUMAN,L1098I,0.066,-,-,-
MYO7A_HUMAN,K1103R,0.17,-,-,-
MYO7A_HUMAN,V1107I,0.072,-,-,-
MYO7A_HUMAN,T1127R,0.569,Gain of Helix (Pr = 0.27 | P = 0.05); Altered Disordered interface (Pr = 0.26 | P = 0.01); Loss of Acetylation at K1128 (Pr = 0.25 | P = 0.01); Gain of SUMOylation at K1128 (Pr = 0.18 | P = 0.05); Altered Coiled coil (Pr = 0.16 | P = 0.02), ELME000012|ELME000052|ELME000053|ELME000102|ELME000278|PS00005,-
MYO7A_HUMAN,K1128A,0.558,Loss of Intrinsic disorder (Pr = 0.43 | P = 0.02); Loss of Acetylation at K1128 (Pr = 0.29 | P = 4.6e-03), ELME000100|ELME000108|ELME000147|PS00005,-
MYO7A_HUMAN,L1130C,0.865,Loss of Acetylation at K1128 (Pr = 0.23 | P = 0.02); Altered Stability (Pr = 0.09 | P = 0.04), ELME000100|ELME000108,-
MYO7A_HUMAN,H1131N,0.192,-,-,-
MYO7A_HUMAN,G1133P,0.546,Loss of Acetylation at K1128 (Pr = 0.22 | P = 0.03); Altered Transmembrane protein (Pr = 0.16 | P = 0.01), ELME000147,-
MYO7A_HUMAN,T1136M,0.153,-,-,-
MYO7A_HUMAN,I1175L,0.282,-,-,-
MYO7A_HUMAN,H1181Y,0.266,-,-,-
MYO7A_HUMAN,T1274A,0.463,-,-,-
MYO7A_HUMAN,N1285K,0.331,-,-,-
MYO7A_HUMAN,A1286T,0.202,-,-,-
MYO7A_HUMAN,G1315S,0.766,Gain of Intrinsic disorder (Pr = 0.30 | P = 0.04); Altered Metal binding (Pr = 0.19 | P = 0.04), ELME000063|ELME000085|PS00006,-
MYO7A_HUMAN,R1381K,0.665,, None,-
MYO7A_HUMAN,P1424S,0.207,-,-,-
MYO7A_HUMAN,K1426T,0.519,Loss of Helix (Pr = 0.27 | P = 0.03); Altered Transmembrane protein (Pr = 0.16 | P = 0.01), ELME000053|ELME000064|ELME000153|ELME000159|ELME000220|ELME000289|ELME000322|PS00006,-
MYO7A_HUMAN,E1456Q,0.449,-,-,-
MYO7A_HUMAN,A1476V,0.871,Gain of Strand (Pr = 0.26 | P = 0.04); Altered Transmembrane protein (Pr = 0.12 | P = 0.03); Loss of Sulfation at Y1477 (Pr = 0.01 | P = 0.04), None,-
MYO7A_HUMAN,W1528L,0.169,-,-,-
MYO7A_HUMAN,L1536W,0.507,Gain of Strand (Pr = 0.27 | P = 0.02), None,-
MYO7A_HUMAN,G1537T,0.535,, ELME000063|ELME000162,-
MYO7A_HUMAN,C1538W,0.717,, None,-
MYO7A_HUMAN,A1539V,0.277,-,-,-
MYO7A_HUMAN,A1540T,0.128,-,-,-
MYO7A_HUMAN,P1541D,0.296,-,-,-
MYO7A_HUMAN,H1542P,0.444,-,-,-
MYO7A_HUMAN,S1543P,0.304,-,-,-
MYO7A_HUMAN,W1545R,0.185,-,-,-
MYO7A_HUMAN,C1554S,0.451,-,-,-
MYO7A_HUMAN,K1564N,0.474,-,-,-
MYO7A_HUMAN,P1568S,0.214,-,-,-
MYO7A_HUMAN,S1585N,0.247,-,-,-
MYO7A_HUMAN,I1633L,0.409,-,-,-
MYO7A_HUMAN,S1646A,0.36,-,-,-
MYO7A_HUMAN,R1659H,0.377,-,-,-
MYO7A_HUMAN,M1675L,0.117,-,-,-
MYO7A_HUMAN,R1678Q,0.11,-,-,-
MYO7A_HUMAN,E1679D,0.199,-,-,-
MYO7A_HUMAN,V1681A,0.207,-,-,-
MYO7A_HUMAN,V1695L,0.116,-,-,-
MYO7A_HUMAN,R1701S,0.201,-,-,-
MYO7A_HUMAN,T1702S,0.103,-,-,-
MYO7A_HUMAN,A1703V,0.095,-,-,-
MYO7A_HUMAN,R1708C,0.451,-,-,-
MYO7A_HUMAN,F1717G,0.896,Gain of Phosphorylation at Y1719 (Pr = 0.37 | P = 7.9e-03); Altered Stability (Pr = 0.33 | P = 4.6e-03); Loss of Helix (Pr = 0.28 | P = 0.03); Altered Disordered interface (Pr = 0.26 | P = 0.05); Loss of Sulfation at Y1721 (Pr = 0.05 | P = 9.2e-03), ELME000220,-
MYO7A_HUMAN,P1724R,0.432,-,-,-
MYO7A_HUMAN,H1728W,0.396,-,-,-
MYO7A_HUMAN,L1730K,0.627,Gain of Intrinsic disorder (Pr = 0.45 | P = 4.0e-03); Altered Disordered interface (Pr = 0.39 | P = 3.9e-03); Gain of B-factor (Pr = 0.27 | P = 0.01), ELME000233,-
MYO7A_HUMAN,R1732K,0.428,-,-,-
MYO7A_HUMAN,V1735K,0.507,Gain of Intrinsic disorder (Pr = 0.52 | P = 1.3e-03); Altered Disordered interface (Pr = 0.45 | P = 2.1e-03), ELME000146,-
MYO7A_HUMAN,S1736A,0.185,-,-,-
MYO7A_HUMAN,S1746N,0.368,-,-,-
MYO7A_HUMAN,R1749Q,0.379,-,-,-
MYO7A_HUMAN,E1750A,0.655,Altered Disordered interface (Pr = 0.36 | P = 5.0e-03); Gain of Proteolytic cleavage at W1745 (Pr = 0.12 | P = 0.03), None,-
MYO7A_HUMAN,L1757S,0.788,Gain of Intrinsic disorder (Pr = 0.33 | P = 0.03); Altered Stability (Pr = 0.27 | P = 6.8e-03), ELME000045|ELME000146|PS00005,-
MYO7A_HUMAN,L1760T,0.373,-,-,-
MYO7A_HUMAN,G1762S,0.215,-,-,-
MYO7A_HUMAN,L1766T,0.741,Gain of B-factor (Pr = 0.24 | P = 0.05); Altered Stability (Pr = 0.17 | P = 0.02), ELME000053|ELME000063|ELME000064|ELME000117|ELME000202|ELME000220|PS00006|PS00008,-
MYO7A_HUMAN,E1769Q,0.369,-,-,-
MYO7A_HUMAN,L1772T,0.541,, ELME000052,-
MYO7A_HUMAN,A1773S,0.4,-,-,-
MYO7A_HUMAN,A1776G,0.633,Gain of Allosteric site at Y1780 (Pr = 0.23 | P = 0.02); Gain of Acetylation at K1779 (Pr = 0.22 | P = 0.03), ELME000041,-
MYO7A_HUMAN,V1777D,0.843,Loss of Allosteric site at Y1780 (Pr = 0.23 | P = 0.02); Gain of Acetylation at K1779 (Pr = 0.22 | P = 0.03), ELME000041,-
MYO7A_HUMAN,M1781L,0.784,Altered Ordered interface (Pr = 0.28 | P = 0.04); Loss of Allosteric site at Y1780 (Pr = 0.23 | P = 0.03); Loss of Acetylation at K1779 (Pr = 0.19 | P = 0.05); Gain of Proteolytic cleavage at D1783 (Pr = 0.11 | P = 0.04), ELME000041|ELME000182,-
MYO7A_HUMAN,Y1784G,0.891,Altered Ordered interface (Pr = 0.36 | P = 3.9e-03); Gain of B-factor (Pr = 0.27 | P = 0.01); Loss of Allosteric site at Y1780 (Pr = 0.26 | P = 0.01); Gain of Acetylation at K1779 (Pr = 0.21 | P = 0.04); Gain of Ubiquitylation at K1787 (Pr = 0.15 | P = 0.04); Loss of Proteolytic cleavage at D1783 (Pr = 0.11 | P = 0.05), None,-
MYO7A_HUMAN,K1787R,0.522,Gain of ADP-ribosylation at K1787 (Pr = 0.23 | P = 0.01); Loss of Ubiquitylation at K1787 (Pr = 0.18 | P = 0.02); Altered Transmembrane protein (Pr = 0.11 | P = 0.03); Loss of Proteolytic cleavage at D1783 (Pr = 0.11 | P = 0.05), ELME000012|ELME000051|ELME000052|ELME000062|ELME000063|ELME000100|ELME000102|ELME000108|ELME000271|PS00005,-
MYO7A_HUMAN,N1793S,0.524,Gain of ADP-ribosylation at R1790 (Pr = 0.19 | P = 0.05); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000052|ELME000053|ELME000061|ELME000063|ELME000064|ELME000065|ELME000173|PS00006,-
MYO7A_HUMAN,G1802W,0.629,Gain of Allosteric site at F1800 (Pr = 0.26 | P = 7.1e-03); Loss of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), None,-
MYO7A_HUMAN,P1803A,0.108,-,-,-
MYO7A_HUMAN,L1818V,0.513,Altered Disordered interface (Pr = 0.33 | P = 0.01); Altered Transmembrane protein (Pr = 0.11 | P = 0.03), None,-
MYO7A_HUMAN,L1836K,0.931,Gain of Allosteric site at W1834 (Pr = 0.21 | P = 0.03), ELME000149|ELME000335,-
MYO7A_HUMAN,T1841A,0.594,, None,-
MYO7A_HUMAN,F1844E,0.909,Gain of B-factor (Pr = 0.24 | P = 0.04), ELME000064|ELME000220|PS00006,-
MYO7A_HUMAN,P1846G,0.936,, PS00008,-
MYO7A_HUMAN,L1850Q,0.907,Altered Stability (Pr = 0.15 | P = 0.02), None,-
MYO7A_HUMAN,V1854L,0.438,-,-,-
MYO7A_HUMAN,Q1859S,0.52,, ELME000336|PS00005,-
MYO7A_HUMAN,K1862R,0.246,-,-,-
MYO7A_HUMAN,C1864E,0.553,Altered Coiled coil (Pr = 0.13 | P = 0.03), ELME000233|ELME000313,-
MYO7A_HUMAN,C1864N,0.468,-,-,-
MYO7A_HUMAN,C1864Y,0.291,-,-,-
MYO7A_HUMAN,P1865A,0.327,-,-,-
MYO7A_HUMAN,I1868L,0.102,-,-,-
MYO7A_HUMAN,I1868P,0.225,-,-,-
MYO7A_HUMAN,I1868T,0.097,-,-,-
MYO7A_HUMAN,R1873T,0.841,Loss of Acetylation at K1876 (Pr = 0.20 | P = 0.04); Altered DNA binding (Pr = 0.18 | P = 0.03); Altered Coiled coil (Pr = 0.14 | P = 0.03), ELME000134|ELME000313,-
MYO7A_HUMAN,A1877F,0.657,Gain of Acetylation at K1876 (Pr = 0.24 | P = 0.02); Altered DNA binding (Pr = 0.17 | P = 0.04); Altered Coiled coil (Pr = 0.15 | P = 0.03), ELME000134|ELME000313,-
MYO7A_HUMAN,S1882T,0.21,-,-,-
MYO7A_HUMAN,D1911I,0.811,Altered Ordered interface (Pr = 0.36 | P = 3.3e-03); Loss of B-factor (Pr = 0.28 | P = 0.02); Altered Metal binding (Pr = 0.25 | P = 0.03), None,-
MYO7A_HUMAN,T1912S,0.261,-,-,-
MYO7A_HUMAN,F1916L,0.883,Altered Metal binding (Pr = 0.28 | P = 0.02); Altered Ordered interface (Pr = 0.28 | P = 0.04); Loss of Relative solvent accessibility (Pr = 0.24 | P = 0.05); Altered Stability (Pr = 0.10 | P = 0.04), None,-
MYO7A_HUMAN,S1920Q,0.875,Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered Metal binding (Pr = 0.24 | P = 0.02); Altered DNA binding (Pr = 0.18 | P = 0.03), None,-
MYO7A_HUMAN,M1T,0.967,Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Loss of N-terminal acetylation at M1 (Pr = 0.24 | P = 5.7e-04); Altered Metal binding (Pr = 0.06 | P = 0.03), ELME000335,-
MYO7A_HUMAN,V2G,0.927,Gain of Intrinsic disorder (Pr = 0.43 | P = 5.4e-03); Loss of N-terminal acetylation at M1 (Pr = 0.23 | P = 6.7e-04); Altered Stability (Pr = 0.12 | P = 0.03); Altered Metal binding (Pr = 0.04 | P = 0.04), None,-
MYO7A_HUMAN,I3R,0.878,Gain of Intrinsic disorder (Pr = 0.46 | P = 3.4e-03); Altered Metal binding (Pr = 0.25 | P = 0.03); Loss of N-terminal acetylation at M1 (Pr = 0.20 | P = 8.1e-04); Altered Transmembrane protein (Pr = 0.11 | P = 0.04); Altered Stability (Pr = 0.11 | P = 0.04), None,-
MYO7A_HUMAN,L4S,0.847,Gain of Intrinsic disorder (Pr = 0.58 | P = 5.1e-04); Altered Metal binding (Pr = 0.29 | P = 0.02); Altered Stability (Pr = 0.24 | P = 8.6e-03); Gain of N-terminal acetylation at M1 (Pr = 0.19 | P = 6.6e-04), ELME000202|ELME000336,-
MYO7A_HUMAN,Q5G,0.882,Altered Metal binding (Pr = 0.27 | P = 0.02); Altered Stability (Pr = 0.20 | P = 0.01); Loss of N-terminal acetylation at M1 (Pr = 0.19 | P = 9.4e-04), None,-
MYO7A_HUMAN,Q5L,0.854,Loss of Intrinsic disorder (Pr = 0.51 | P = 5.9e-03); Altered Metal binding (Pr = 0.40 | P = 6.3e-03); Loss of N-terminal acetylation at M1 (Pr = 0.19 | P = 8.8e-04), None,-
MYO7A_HUMAN,V27M,0.356,-,-,-
MYO7A_HUMAN,V36I,0.034,-,-,-
MYO7A_HUMAN,Q37L,0.668,Altered Metal binding (Pr = 0.31 | P = 0.01); Altered Transmembrane protein (Pr = 0.31 | P = 1.1e-04); Loss of Relative solvent accessibility (Pr = 0.23 | P = 0.05), ELME000333,-
MYO7A_HUMAN,N44H,0.204,-,-,-
MYO7A_HUMAN,D91E,0.362,-,-,-
MYO7A_HUMAN,S112T,0.285,-,-,-
MYO7A_HUMAN,E117K,0.751,Altered Metal binding (Pr = 0.34 | P = 9.0e-03); Altered Transmembrane protein (Pr = 0.32 | P = 5.8e-05); Gain of Relative solvent accessibility (Pr = 0.28 | P = 0.01); Altered Ordered interface (Pr = 0.25 | P = 0.02); Gain of Acetylation at E117 (Pr = 0.25 | P = 0.01); Gain of Allosteric site at Y114 (Pr = 0.24 | P = 0.02), ELME000063|ELME000136|ELME000159|PS00005,-
MYO7A_HUMAN,I178V,0.264,-,-,-
MYO7A_HUMAN,N222S,0.566,Altered Ordered interface (Pr = 0.31 | P = 0.02); Altered Metal binding (Pr = 0.28 | P = 5.7e-03); Gain of Acetylation at K223 (Pr = 0.27 | P = 6.3e-03); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Gain of Allosteric site at I227 (Pr = 0.24 | P = 0.01); Altered DNA binding (Pr = 0.22 | P = 0.01); Gain of Methylation at K223 (Pr = 0.10 | P = 0.04), PS00005,-
MYO7A_HUMAN,K223T,0.703,Loss of Acetylation at K223 (Pr = 0.45 | P = 7.9e-04); Altered Metal binding (Pr = 0.29 | P = 4.3e-03); Altered Ordered interface (Pr = 0.29 | P = 0.02); Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Loss of Allosteric site at R224 (Pr = 0.26 | P = 0.01); Altered DNA binding (Pr = 0.21 | P = 0.02); Loss of Methylation at K223 (Pr = 0.10 | P = 0.04), ELME000100|ELME000108,-
MYO7A_HUMAN,K231R,0.34,-,-,-
MYO7A_HUMAN,E233Q,0.603,Altered DNA binding (Pr = 0.30 | P = 1.6e-03); Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Metal binding (Pr = 0.25 | P = 9.9e-03); Loss of Relative solvent accessibility (Pr = 0.23 | P = 0.05); Gain of Allosteric site at Y235 (Pr = 0.22 | P = 0.03); Loss of Acetylation at K231 (Pr = 0.19 | P = 0.05); Loss of Catalytic site at E238 (Pr = 0.08 | P = 0.05), ELME000002,-
MYO7A_HUMAN,A246C,0.845,Altered Metal binding (Pr = 0.36 | P = 0.01); Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Allosteric site at R250 (Pr = 0.28 | P = 3.6e-03); Altered DNA binding (Pr = 0.17 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q245 (Pr = 0.07 | P = 0.02), ELME000146|PS00007,-
MYO7A_HUMAN,E249L,0.945,Altered Metal binding (Pr = 0.28 | P = 5.3e-03); Altered Ordered interface (Pr = 0.27 | P = 0.05); Loss of Allosteric site at H253 (Pr = 0.27 | P = 8.6e-03); Loss of Pyrrolidone carboxylic acid at Q245 (Pr = 0.06 | P = 0.03), ELME000233|PS00007,-
MYO7A_HUMAN,Y252A,0.958,Loss of Allosteric site at Y256 (Pr = 0.29 | P = 5.9e-03); Altered Metal binding (Pr = 0.25 | P = 0.01); Altered Ordered interface (Pr = 0.25 | P = 0.03); Gain of Catalytic site at Y256 (Pr = 0.10 | P = 0.04), ELME000120|PS00007,-
MYO7A_HUMAN,F255L,0.889,Altered Metal binding (Pr = 0.27 | P = 7.1e-03); Gain of Allosteric site at Y256 (Pr = 0.27 | P = 4.6e-03); Loss of Catalytic site at Y256 (Pr = 0.09 | P = 0.04), ELME000020|ELME000120,-
MYO7A_HUMAN,S263N,0.137,-,-,-
MYO7A_HUMAN,E264K,0.167,-,-,-
MYO7A_HUMAN,K267R,0.205,-,-,-
MYO7A_HUMAN,Q274R,0.071,-,-,-
MYO7A_HUMAN,S276A,0.1,-,-,-
MYO7A_HUMAN,S276N,0.217,-,-,-
MYO7A_HUMAN,S319L,0.676,Altered Ordered interface (Pr = 0.30 | P = 0.03); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered Metal binding (Pr = 0.10 | P = 0.04), ELME000149|ELME000193|ELME000335,-
MYO7A_HUMAN,Q332N,0.392,-,-,-
MYO7A_HUMAN,A335D,0.557,Altered Metal binding (Pr = 0.31 | P = 4.1e-04); Altered Ordered interface (Pr = 0.28 | P = 0.04); Gain of Loop (Pr = 0.27 | P = 0.03); Gain of Allosteric site at N330 (Pr = 0.26 | P = 8.1e-03); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Loss of Catalytic site at N330 (Pr = 0.13 | P = 0.03), ELME000147,-
MYO7A_HUMAN,A343S,0.181,-,-,-
MYO7A_HUMAN,A355V,0.365,-,-,-
MYO7A_HUMAN,L358H,0.805,Altered Stability (Pr = 0.14 | P = 0.02), ELME000064|ELME000155|ELME000335|PS00006,-
MYO7A_HUMAN,P364S,0.138,-,-,-
MYO7A_HUMAN,R388K,0.157,-,-,-
MYO7A_HUMAN,I414V,0.572,Altered Disordered interface (Pr = 0.42 | P = 3.1e-03); Gain of Allosteric site at W409 (Pr = 0.30 | P = 2.1e-03); Altered DNA binding (Pr = 0.24 | P = 0.01); Loss of Relative solvent accessibility (Pr = 0.23 | P = 0.05), None,-
MYO7A_HUMAN,Y419H,0.346,-,-,-
MYO7A_HUMAN,D494E,0.336,-,-,-
MYO7A_HUMAN,K502R,0.486,-,-,-
MYO7A_HUMAN,H526R,0.33,-,-,-
MYO7A_HUMAN,K527W,0.886,, ELME000202,-
MYO7A_HUMAN,Q531K,0.471,-,-,-
MYO7A_HUMAN,H532F,0.665,Gain of Relative solvent accessibility (Pr = 0.28 | P = 0.01); Gain of Acetylation at K533 (Pr = 0.19 | P = 0.05), ELME000173|ELME000202,-
MYO7A_HUMAN,N535T,0.517,Altered Ordered interface (Pr = 0.24 | P = 0.04), None,-
MYO7A_HUMAN,A536P,0.315,-,-,-
MYO7A_HUMAN,N544A,0.437,-,-,-
MYO7A_HUMAN,H545Y,0.288,-,-,-
MYO7A_HUMAN,G550W,0.842,Altered Ordered interface (Pr = 0.30 | P = 0.03); Altered Metal binding (Pr = 0.25 | P = 0.01); Loss of Allosteric site at H553 (Pr = 0.21 | P = 0.03); Altered Transmembrane protein (Pr = 0.15 | P = 0.02), ELME000080|ELME000202,-
MYO7A_HUMAN,N552I,0.589,Altered Metal binding (Pr = 0.43 | P = 9.1e-04); Altered Ordered interface (Pr = 0.36 | P = 3.8e-03); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Loss of Allosteric site at H553 (Pr = 0.24 | P = 0.02); Altered Transmembrane protein (Pr = 0.15 | P = 0.01), None,-
MYO7A_HUMAN,H553P,0.958,Altered Metal binding (Pr = 0.90 | P = 1.6e-04); Altered Ordered interface (Pr = 0.32 | P = 1.0e-02); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Loss of Allosteric site at H553 (Pr = 0.24 | P = 0.02); Altered Transmembrane protein (Pr = 0.15 | P = 0.02), ELME000056,-
MYO7A_HUMAN,A601V,0.186,-,-,-
MYO7A_HUMAN,E602P,0.636,Loss of Loop (Pr = 0.31 | P = 4.8e-03); Gain of ADP-ribosylation at R604 (Pr = 0.25 | P = 9.2e-03), ELME000053|ELME000271,-
MYO7A_HUMAN,R606A,0.767,Loss of ADP-ribosylation at R606 (Pr = 0.21 | P = 0.04); Gain of Ubiquitylation at K605 (Pr = 0.18 | P = 0.02), ELME000053|ELME000061|ELME000100|ELME000108|ELME000136|ELME000159|ELME000173|ELME000278|PS00004,-
MYO7A_HUMAN,T609W,0.896,Loss of Phosphorylation at S607 (Pr = 0.52 | P = 3.6e-03); Loss of Intrinsic disorder (Pr = 0.43 | P = 0.02); Loss of ADP-ribosylation at R604 (Pr = 0.21 | P = 0.04); Loss of Ubiquitylation at K605 (Pr = 0.15 | P = 0.05), ELME000061|ELME000136|ELME000159|ELME000173|ELME000202,-
MYO7A_HUMAN,H650Y,0.362,-,-,-
MYO7A_HUMAN,G699D,0.189,-,-,-
MYO7A_HUMAN,R702Q,0.301,-,-,-
MYO7A_HUMAN,G703R,0.742,, ELME000012|ELME000062|ELME000102|ELME000108|ELME000336,-
MYO7A_HUMAN,C705R,0.955,, ELME000012|ELME000062|ELME000336,-
MYO7A_HUMAN,Q706E,0.403,-,-,-
MYO7A_HUMAN,H732E,0.905,Altered Metal binding (Pr = 0.33 | P = 2.7e-03); Gain of Strand (Pr = 0.26 | P = 0.05); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03), None,-
MYO7A_HUMAN,M734L,0.432,-,-,-
MYO7A_HUMAN,M734S,0.738,Gain of Relative solvent accessibility (Pr = 0.33 | P = 2.7e-03); Altered Metal binding (Pr = 0.26 | P = 9.8e-03); Altered Stability (Pr = 0.12 | P = 0.03); Altered Transmembrane protein (Pr = 0.09 | P = 0.05), ELME000064|ELME000335|PS00006,-
MYO7A_HUMAN,V738M,0.205,-,-,-
MYO7A_HUMAN,R740G,0.94,Altered Stability (Pr = 0.32 | P = 4.8e-03), None,-
MYO7A_HUMAN,T772M,0.361,-,-,-
MYO7A_HUMAN,H777Y,0.354,-,-,-
MYO7A_HUMAN,N782H,0.2,-,-,-
MYO7A_HUMAN,N782T,0.305,-,-,-
MYO7A_HUMAN,K785R,0.118,-,-,-
MYO7A_HUMAN,N786S,0.246,-,-,-
MYO7A_HUMAN,L789M,0.134,-,-,-
MYO7A_HUMAN,K805M,0.296,-,-,-
MYO7A_HUMAN,H807Q,0.248,-,-,-
MYO7A_HUMAN,R811H,0.098,-,-,-
MYO7A_HUMAN,Q815E,0.155,-,-,-
MYO7A_HUMAN,Q819K,0.146,-,-,-
MYO7A_HUMAN,Q819N,0.159,-,-,-
MYO7A_HUMAN,A826G,0.166,-,-,-
MYO7A_HUMAN,L841I,0.095,-,-,-
MYO7A_HUMAN,M850L,0.246,-,-,-
MYO7A_HUMAN,R906C,0.287,-,-,-
MYO7A_HUMAN,E927Q,0.19,-,-,-
MYO7A_HUMAN,R931K,0.131,-,-,-
MYO7A_HUMAN,G958D,0.413,-,-,-
MYO7A_HUMAN,Q959R,0.248,-,-,-
MYO7A_HUMAN,S965R,0.163,-,-,-
MYO7A_HUMAN,E976D,0.116,-,-,-
MYO7A_HUMAN,E991D,0.246,-,-,-
MYO7A_HUMAN,D992E,0.13,-,-,-
MYO7A_HUMAN,A1005G,0.32,-,-,-
MYO7A_HUMAN,I1043V,0.185,-,-,-
MYO7A_HUMAN,T1059M,0.19,-,-,-
MYO7A_HUMAN,T1082M,0.424,-,-,-
MYO7A_HUMAN,K1084R,0.336,-,-,-
MYO7A_HUMAN,P1099A,0.143,-,-,-
MYO7A_HUMAN,E1100D,0.115,-,-,-
MYO7A_HUMAN,Q1102L,0.235,-,-,-
MYO7A_HUMAN,Q1102P,0.43,-,-,-
FGFR1_HUMAN,C6G,0.467,-,-,-
FGFR1_HUMAN,C6Y,0.404,-,-,-
FGFR1_HUMAN,F9M,0.759,Altered Disordered interface (Pr = 0.25 | P = 0.02); Altered Ordered interface (Pr = 0.24 | P = 0.04); Altered Signal peptide (Pr = 0.19 | P = 7.5e-04), ELME000041|ELME000106|ELME000137|ELME000146,-
FGFR1_HUMAN,A11E,0.879,Altered Signal peptide (Pr = 0.15 | P = 1.6e-03), ELME000041|ELME000335,-
FGFR1_HUMAN,V12L,0.71,Altered Signal peptide (Pr = 0.21 | P = 2.4e-04), ELME000041|ELME000333|ELME000336,-
FGFR1_HUMAN,V12Q,0.886,Altered Signal peptide (Pr = 0.18 | P = 4.2e-04); Altered Disordered interface (Pr = 0.17 | P = 0.04); Gain of Pyrrolidone carboxylic acid at V12 (Pr = 0.04 | P = 0.04), ELME000041|ELME000333,-
FGFR1_HUMAN,A16E,0.919,Altered Signal peptide (Pr = 0.19 | P = 3.3e-04), ELME000041|ELME000052|ELME000333,-
FGFR1_HUMAN,T17G,0.832,Gain of Loop (Pr = 0.27 | P = 0.04); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.05); Altered Signal peptide (Pr = 0.19 | P = 3.3e-04), ELME000052|ELME000053|PS00008,-
FGFR1_HUMAN,C19G,0.832,Gain of Intrinsic disorder (Pr = 0.38 | P = 0.01); Altered Signal peptide (Pr = 0.25 | P = 4.0e-04); Gain of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.03), ELME000052|ELME000053,-
FGFR1_HUMAN,C19K,0.927,Gain of Intrinsic disorder (Pr = 0.37 | P = 0.01); Gain of ADP-ribosylation at R22 (Pr = 0.21 | P = 0.02); Altered Signal peptide (Pr = 0.18 | P = 4.0e-04), ELME000052|ELME000053|ELME000313|PS00005,-
FGFR1_HUMAN,C19L,0.914,Altered Signal peptide (Pr = 0.28 | P = 9.3e-05); Gain of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.04), ELME000052|ELME000053,-
FGFR1_HUMAN,T20K,0.751,Altered Signal peptide (Pr = 0.21 | P = 2.3e-04); Gain of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.03); Altered Transmembrane protein (Pr = 0.11 | P = 0.04), ELME000053|PS00005,-
FGFR1_HUMAN,A21W,0.929,Gain of Loop (Pr = 0.27 | P = 0.03); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.04); Altered Signal peptide (Pr = 0.19 | P = 3.3e-04); Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000053|ELME000136|ELME000159|PS00005,-
FGFR1_HUMAN,P23V,0.721,Altered Signal peptide (Pr = 0.36 | P = 3.4e-05); Gain of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000005|ELME000053|ELME000064|ELME000136|ELME000155|ELME000159|ELME000259,-
FGFR1_HUMAN,P25A,0.404,-,-,-
FGFR1_HUMAN,T26A,0.636,Altered Signal peptide (Pr = 0.20 | P = 3.1e-04); Gain of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.04); Altered Transmembrane protein (Pr = 0.14 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q30 (Pr = 0.07 | P = 0.02), ELME000005|ELME000064|ELME000136|ELME000155|ELME000159|ELME000220|PS00006,-
FGFR1_HUMAN,T26V,0.697,Altered Signal peptide (Pr = 0.26 | P = 1.2e-04); Gain of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.03); Altered Transmembrane protein (Pr = 0.14 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q30 (Pr = 0.07 | P = 0.02), ELME000005|ELME000064|ELME000136|ELME000155|ELME000159|ELME000220|PS00006,-
FGFR1_HUMAN,L27S,0.811,Gain of Intrinsic disorder (Pr = 0.50 | P = 1.7e-03); Gain of B-factor (Pr = 0.27 | P = 0.01); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.05); Altered Transmembrane protein (Pr = 0.14 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q32 (Pr = 0.08 | P = 0.02); Altered Signal peptide (Pr = 0.04 | P = 2.4e-03), ELME000005|ELME000063|ELME000064|ELME000155|ELME000159|ELME000220|PS00006,-
FGFR1_HUMAN,P28T,0.555,Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q32 (Pr = 0.07 | P = 0.02); Altered Signal peptide (Pr = 0.01 | P = 4.9e-03), ELME000005|ELME000064|ELME000155|ELME000220|PS00006,-
FGFR1_HUMAN,E29G,0.836,Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q30 (Pr = 0.08 | P = 0.02); Altered Signal peptide (Pr = 0.01 | P = 5.3e-03), ELME000064|ELME000220|PS00006,-
FGFR1_HUMAN,Q30K,0.36,-,-,-
FGFR1_HUMAN,Q32R,0.225,-,-,-
FGFR1_HUMAN,P33S,0.365,-,-,-
FGFR1_HUMAN,A36D,0.314,-,-,-
FGFR1_HUMAN,A36G,0.163,-,-,-
FGFR1_HUMAN,A36V,0.145,-,-,-
FGFR1_HUMAN,D59E,0.521,Altered Transmembrane protein (Pr = 0.30 | P = 1.7e-04); Altered Metal binding (Pr = 0.26 | P = 0.01); Loss of Relative solvent accessibility (Pr = 0.23 | P = 0.05); Gain of Disulfide linkage at C55 (Pr = 0.22 | P = 0.01), None,-
FGFR1_HUMAN,A74V,0.12,-,-,-
FGFR1_HUMAN,E75D,0.32,-,-,-
FGFR1_HUMAN,D90A,0.393,-,-,-
FGFR1_HUMAN,S91A,0.261,-,-,-
FGFR1_HUMAN,V92I,0.063,-,-,-
FGFR1_HUMAN,A94T,0.161,-,-,-
FGFR1_HUMAN,S104T,0.195,-,-,-
FGFR1_HUMAN,T111I,0.251,-,-,-
FGFR1_HUMAN,T141N,0.212,-,-,-
FGFR1_HUMAN,P150A,0.337,-,-,-
FGFR1_HUMAN,N185Y,0.513,Altered Ordered interface (Pr = 0.31 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Gain of Strand (Pr = 0.28 | P = 0.01); Altered Transmembrane protein (Pr = 0.27 | P = 6.8e-04); Gain of Allosteric site at W190 (Pr = 0.27 | P = 4.8e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Altered DNA binding (Pr = 0.23 | P = 0.01); Altered Metal binding (Pr = 0.22 | P = 0.03); Gain of O-linked glycosylation at S181 (Pr = 0.20 | P = 0.02), ELME000053|ELME000063|ELME000120|ELME000136|ELME000159,-
FGFR1_HUMAN,D246F,0.91,Altered Transmembrane protein (Pr = 0.29 | P = 1.9e-04); Loss of Sulfation at Y243 (Pr = 0.02 | P = 0.04), ELME000047|ELME000052|ELME000120|ELME000333,-
FGFR1_HUMAN,E294K,0.856,Loss of Strand (Pr = 0.27 | P = 0.03); Altered DNA binding (Pr = 0.17 | P = 0.03); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Altered Stability (Pr = 0.11 | P = 0.03); Loss of N-linked glycosylation at N296 (Pr = 0.08 | P = 0.02), ELME000146,-
FGFR1_HUMAN,G315P,0.802,Altered Transmembrane protein (Pr = 0.26 | P = 1.2e-03); Loss of N-linked glycosylation at N317 (Pr = 0.19 | P = 4.0e-03), ELME000052|PS00008,-
FGFR1_HUMAN,V316I,0.177,-,-,-
FGFR1_HUMAN,T319S,0.372,-,-,-
FGFR1_HUMAN,K321A,0.845,Altered Transmembrane protein (Pr = 0.29 | P = 2.9e-04); Gain of N-linked glycosylation at N317 (Pr = 0.23 | P = 1.3e-03); Loss of Ubiquitylation at K321 (Pr = 0.17 | P = 0.03), ELME000064|ELME000070|ELME000220|PS00005|PS00006,-
FGFR1_HUMAN,L326S,0.921,Altered Transmembrane protein (Pr = 0.31 | P = 1.2e-04); Gain of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Altered Stability (Pr = 0.21 | P = 0.01); Gain of Ubiquitylation at K321 (Pr = 0.15 | P = 0.04); Gain of N-linked glycosylation at N330 (Pr = 0.10 | P = 0.01), ELME000335|ELME000336,-
FGFR1_HUMAN,S332P,0.936,Altered Transmembrane protein (Pr = 0.28 | P = 4.6e-04); Loss of Strand (Pr = 0.27 | P = 0.03); Altered Metal binding (Pr = 0.17 | P = 0.04); Loss of N-linked glycosylation at N330 (Pr = 0.11 | P = 0.01); Altered Stability (Pr = 0.11 | P = 0.04), ELME000070|ELME000122|ELME000137|ELME000334|PS00001|PS00006,-
FGFR1_HUMAN,Y339R,0.97,Altered Ordered interface (Pr = 0.34 | P = 2.9e-03); Altered Metal binding (Pr = 0.29 | P = 0.01); Altered Transmembrane protein (Pr = 0.28 | P = 3.9e-04); Loss of Loop (Pr = 0.27 | P = 0.02); Gain of Disulfide linkage at C341 (Pr = 0.19 | P = 0.02), ELME000120|ELME000182,-
FGFR1_HUMAN,T340V,0.877,Altered Transmembrane protein (Pr = 0.31 | P = 9.7e-05); Altered Metal binding (Pr = 0.26 | P = 0.03); Altered Ordered interface (Pr = 0.25 | P = 0.02); Loss of Disulfide linkage at C341 (Pr = 0.19 | P = 0.02), ELME000083|ELME000120|ELME000182,-
FGFR1_HUMAN,G344S,0.797,Altered Metal binding (Pr = 0.31 | P = 0.02); Altered Transmembrane protein (Pr = 0.27 | P = 9.5e-04); Altered Ordered interface (Pr = 0.25 | P = 0.03); Gain of Disulfide linkage at C341 (Pr = 0.20 | P = 0.02); Gain of Catalytic site at N345 (Pr = 0.11 | P = 0.03), ELME000053|ELME000239|PS00008,-
FGFR1_HUMAN,L349E,0.628,Altered Stability (Pr = 0.40 | P = 3.0e-03); Altered Transmembrane protein (Pr = 0.29 | P = 2.4e-04); Gain of Loop (Pr = 0.27 | P = 0.02); Gain of Strand (Pr = 0.26 | P = 0.04); Altered Metal binding (Pr = 0.05 | P = 0.05); Gain of GPI-anchor amidation at N345 (Pr = 0.01 | P = 0.03), ELME000053|ELME000064|PS00006|PS00008,-
FGFR1_HUMAN,L349P,0.758,Altered Stability (Pr = 0.67 | P = 6.3e-04); Altered Transmembrane protein (Pr = 0.30 | P = 1.3e-04); Gain of Loop (Pr = 0.28 | P = 0.02); Gain of Strand (Pr = 0.27 | P = 0.03); Gain of Catalytic site at N345 (Pr = 0.09 | P = 0.05), ELME000053|PS00008,-
FGFR1_HUMAN,H351M,0.781,Altered Transmembrane protein (Pr = 0.31 | P = 1.1e-04); Loss of Strand (Pr = 0.26 | P = 0.03), ELME000063,-
FGFR1_HUMAN,S353G,0.736,Altered Transmembrane protein (Pr = 0.28 | P = 4.9e-04), ELME000063|ELME000085|PS00008,-
FGFR1_HUMAN,E360K,0.748,Altered Transmembrane protein (Pr = 0.31 | P = 8.3e-05); Gain of Strand (Pr = 0.27 | P = 0.02), ELME000064|ELME000220|ELME000333|PS00006,-
FGFR1_HUMAN,V368A,0.181,-,-,-
FGFR1_HUMAN,S393T,0.178,-,-,-
FGFR1_HUMAN,I395V,0.122,-,-,-
FGFR1_HUMAN,V396I,0.025,-,-,-
FGFR1_HUMAN,S588R,0.168,-,-,-
FGFR1_HUMAN,N590D,0.093,-,-,-
FGFR1_HUMAN,K598Q,0.542,, ELME000106|ELME000202|PS00005|PS00006,-
FGFR1_HUMAN,R661G,0.9,Altered Ordered interface (Pr = 0.27 | P = 7.3e-03); Gain of Loop (Pr = 0.27 | P = 0.03); Altered Stability (Pr = 0.12 | P = 0.03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04); Gain of GPI-anchor amidation at N659 (Pr = 0.01 | P = 0.03), ELME000008|ELME000316,-
FGFR1_HUMAN,K665C,0.93,Altered Ordered interface (Pr = 0.26 | P = 0.01); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), None,-
FGFR1_HUMAN,H810P,0.353,-,-,-
FGFR1_HUMAN,H810R,0.143,-,-,-
FGFR1_HUMAN,P811Q,0.311,-,-,-
FGFR1_HUMAN,A812P,0.181,-,-,-
FGFR1_HUMAN,K820N,0.599,Altered Disordered interface (Pr = 0.35 | P = 9.8e-03); Altered DNA binding (Pr = 0.26 | P = 5.9e-03); Loss of Acetylation at K820 (Pr = 0.20 | P = 0.04); Loss of Methylation at K820 (Pr = 0.13 | P = 0.03); Loss of Proteolytic cleavage at R822 (Pr = 0.12 | P = 0.03), ELME000100|ELME000108,-
FGFR1_HUMAN,N296I,0.92,Gain of Strand (Pr = 0.27 | P = 0.03); Loss of N-linked glycosylation at N296 (Pr = 0.08 | P = 0.01), ELME000070|PS00001,-
FGFR1_HUMAN,S353C,0.747,Altered Transmembrane protein (Pr = 0.34 | P = 4.9e-05), ELME000063|ELME000085,-
FGFR1_HUMAN,L191S,0.891,Altered Stability (Pr = 0.68 | P = 6.3e-04); Altered Ordered interface (Pr = 0.33 | P = 9.5e-03); Gain of Intrinsic disorder (Pr = 0.33 | P = 0.02); Altered Transmembrane protein (Pr = 0.25 | P = 1.4e-03); Loss of Allosteric site at W190 (Pr = 0.25 | P = 0.02); Gain of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Altered DNA binding (Pr = 0.23 | P = 0.01); Loss of Acetylation at K195 (Pr = 0.20 | P = 0.04); Altered Metal binding (Pr = 0.13 | P = 0.05), ELME000062|ELME000146|ELME000336,-
FGFR1_HUMAN,A512V,0.897,Loss of Strand (Pr = 0.29 | P = 4.8e-03); Altered DNA binding (Pr = 0.26 | P = 6.6e-03); Loss of Acetylation at K514 (Pr = 0.26 | P = 8.6e-03); Gain of ADP-ribosylation at R507 (Pr = 0.25 | P = 8.2e-03); Loss of Methylation at K517 (Pr = 0.21 | P = 5.7e-03); Altered Coiled coil (Pr = 0.11 | P = 0.03), ELME000052|ELME000062|ELME000233|PS00107,-
FGFR1_HUMAN,M217T,0.82,Altered Stability (Pr = 0.50 | P = 1.7e-03); Altered Transmembrane protein (Pr = 0.31 | P = 1.2e-04), ELME000053|ELME000063,-
FGFR1_HUMAN,I693F,0.918,Altered Ordered interface (Pr = 0.25 | P = 0.02); Gain of Allosteric site at W691 (Pr = 0.19 | P = 0.05); Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000053,-
FGFR1_HUMAN,G48S,0.831,Loss of Strand (Pr = 0.29 | P = 3.6e-03); Altered Transmembrane protein (Pr = 0.11 | P = 0.04), ELME000134|ELME000335|PS00430,-
FGFR1_HUMAN,A645V,0.906,Altered Metal binding (Pr = 0.27 | P = 0.02); Loss of Allosteric site at F642 (Pr = 0.22 | P = 0.03); Altered DNA binding (Pr = 0.17 | P = 0.03); Altered Transmembrane protein (Pr = 0.11 | P = 0.03), None,-
FGFR1_HUMAN,R622Q,0.733,Altered DNA binding (Pr = 0.25 | P = 6.1e-03); Altered Transmembrane protein (Pr = 0.23 | P = 2.4e-03); Loss of Allosteric site at R627 (Pr = 0.23 | P = 0.02); Gain of Catalytic site at R627 (Pr = 0.13 | P = 0.03), PS00109,-
FGFR1_HUMAN,C341Y,0.967,Altered Metal binding (Pr = 0.48 | P = 4.2e-03); Altered Ordered interface (Pr = 0.27 | P = 6.9e-03); Gain of Loop (Pr = 0.27 | P = 0.03); Altered Transmembrane protein (Pr = 0.24 | P = 2.0e-03); Loss of Disulfide linkage at C341 (Pr = 0.24 | P = 9.7e-03); Gain of Catalytic site at C341 (Pr = 0.10 | P = 0.04), ELME000120|ELME000182,-
FGFR1_HUMAN,Y228D,0.967,Altered Metal binding (Pr = 0.38 | P = 2.8e-04); Altered Ordered interface (Pr = 0.32 | P = 0.01); Gain of Disulfide linkage at C230 (Pr = 0.29 | P = 9.6e-04); Gain of B-factor (Pr = 0.26 | P = 0.02); Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered Transmembrane protein (Pr = 0.25 | P = 1.2e-03); Gain of N-linked glycosylation at N227 (Pr = 0.17 | P = 4.7e-03), ELME000052|ELME000070|ELME000120|ELME000182|PS00001|PS00008,-
FGFR1_HUMAN,Q764H,0.496,-,-,-
FGFR1_HUMAN,V174A,0.808,Gain of Intrinsic disorder (Pr = 0.35 | P = 0.02); Loss of Strand (Pr = 0.27 | P = 0.02); Loss of Disulfide linkage at C178 (Pr = 0.25 | P = 6.3e-03); Altered Metal binding (Pr = 0.24 | P = 0.03); Altered Transmembrane protein (Pr = 0.23 | P = 2.3e-03); Altered Stability (Pr = 0.22 | P = 0.01); Loss of Acetylation at K172 (Pr = 0.20 | P = 0.04), ELME000137|ELME000146|ELME000337|PS00005,-
FGFR1_HUMAN,G237D,0.93,Altered Transmembrane protein (Pr = 0.31 | P = 1.3e-04); Altered Ordered interface (Pr = 0.29 | P = 0.02); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.26 | P = 9.5e-03); Gain of N-linked glycosylation at N240 (Pr = 0.14 | P = 7.1e-03); Gain of Sulfation at Y236 (Pr = 0.02 | P = 0.03), ELME000053|ELME000120,-
FGFR1_HUMAN,D623E,0.699,Altered DNA binding (Pr = 0.29 | P = 4.1e-03); Gain of Allosteric site at R627 (Pr = 0.23 | P = 0.02); Altered Transmembrane protein (Pr = 0.21 | P = 4.0e-03); Altered Metal binding (Pr = 0.12 | P = 0.03); Gain of Catalytic site at R627 (Pr = 0.12 | P = 0.03), PS00109,-
FGFR1_HUMAN,P800L,0.256,-,-,-
FGFR1_HUMAN,D335V,0.945,Altered Transmembrane protein (Pr = 0.37 | P = 1.9e-05); Altered Ordered interface (Pr = 0.26 | P = 0.01); Altered Metal binding (Pr = 0.20 | P = 0.03); Gain of N-linked glycosylation at N330 (Pr = 0.10 | P = 0.01), PS00006,-
FGFR1_HUMAN,S685F,0.913,Altered Ordered interface (Pr = 0.33 | P = 9.6e-03); Altered Transmembrane protein (Pr = 0.24 | P = 1.7e-03); Altered Metal binding (Pr = 0.17 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q680 (Pr = 0.05 | P = 0.03), ELME000053,-
FGFR1_HUMAN,N628S,0.909,Altered DNA binding (Pr = 0.28 | P = 5.0e-03); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Gain of Strand (Pr = 0.27 | P = 0.03); Altered Metal binding (Pr = 0.26 | P = 0.01); Loss of Allosteric site at R627 (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.22 | P = 2.9e-03); Gain of Proteolytic cleavage at R627 (Pr = 0.14 | P = 0.01); Gain of Catalytic site at R627 (Pr = 0.12 | P = 0.03), ELME000053|ELME000146|ELME000239|ELME000335|PS00109,-
FGFR1_HUMAN,R250Q,0.825,Altered Transmembrane protein (Pr = 0.32 | P = 7.8e-05); Altered Metal binding (Pr = 0.24 | P = 0.04), ELME000136|ELME000153|ELME000155|ELME000159,-
FGFR1_HUMAN,G70R,0.744,Altered Transmembrane protein (Pr = 0.33 | P = 5.8e-05); Loss of Strand (Pr = 0.31 | P = 1.3e-03); Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Altered Metal binding (Pr = 0.19 | P = 0.05); Gain of Proteolytic cleavage at D69 (Pr = 0.12 | P = 0.03), ELME000193|PS00008,-
FGFR1_HUMAN,W4C,0.875,Altered Ordered interface (Pr = 0.25 | P = 0.03); Altered Disordered interface (Pr = 0.24 | P = 0.02); Altered Signal peptide (Pr = 0.12 | P = 1.5e-03); Loss of N-terminal acetylation at M1 (Pr = 0.02 | P = 6.1e-03), ELME000137|PS00005,-
FGFR1_HUMAN,N546K,0.903,Gain of Acetylation at K542 (Pr = 0.19 | P = 0.05); Gain of Catalytic site at C551 (Pr = 0.13 | P = 0.03), ELME000233,-
FGFR1_HUMAN,C277Y,0.966,Loss of Disulfide linkage at C277 (Pr = 0.58 | P = 2.9e-04); Altered Metal binding (Pr = 0.57 | P = 2.6e-03); Gain of Relative solvent accessibility (Pr = 0.30 | P = 9.0e-03); Altered Ordered interface (Pr = 0.28 | P = 0.03); Altered Transmembrane protein (Pr = 0.25 | P = 1.5e-03); Gain of Catalytic site at C277 (Pr = 0.14 | P = 0.03); Altered Stability (Pr = 0.13 | P = 0.03), None,-
FGFR1_HUMAN,L245P,0.969,Altered Stability (Pr = 0.63 | P = 7.9e-04); Altered Transmembrane protein (Pr = 0.32 | P = 8.3e-05); Altered Ordered interface (Pr = 0.31 | P = 0.01); Gain of N-linked glycosylation at N240 (Pr = 0.13 | P = 7.3e-03); Gain of Sulfation at Y243 (Pr = 0.03 | P = 0.01), ELME000052|ELME000333,-
FGFR1_HUMAN,Y374C,0.666,Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000052|ELME000081|ELME000120|ELME000159|ELME000182,-
FGFR1_HUMAN,N628K,0.95,Altered DNA binding (Pr = 0.27 | P = 4.4e-03); Altered Metal binding (Pr = 0.26 | P = 6.0e-03); Gain of Strand (Pr = 0.26 | P = 0.05); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Loss of Allosteric site at R627 (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.21 | P = 4.2e-03); Loss of Catalytic site at R627 (Pr = 0.13 | P = 0.03), ELME000102|ELME000106|ELME000146|PS00109,-
FGFR1_HUMAN,P772S,0.366,-,-,-
FGFR1_HUMAN,W2E,0.872,Gain of Intrinsic disorder (Pr = 0.38 | P = 0.01); Altered Ordered interface (Pr = 0.25 | P = 0.03); Altered Disordered interface (Pr = 0.25 | P = 0.02); Altered Signal peptide (Pr = 0.12 | P = 1.6e-03); Gain of N-terminal acetylation at M1 (Pr = 0.03 | P = 4.3e-03), ELME000352|ELME000355,-
FGFR1_HUMAN,K5N,0.395,-,-,-
FGFR1_HUMAN,C6N,0.593,Altered Disordered interface (Pr = 0.30 | P = 7.8e-03); Altered Signal peptide (Pr = 0.17 | P = 9.2e-04); Gain of N-terminal acetylation at M1 (Pr = 0.03 | P = 4.6e-03); Gain of GPI-anchor amidation at C6 (Pr = 0.02 | P = 0.02), ELME000106|ELME000137|ELME000146,-
FGFR1_HUMAN,L8G,0.909,Altered Disordered interface (Pr = 0.20 | P = 0.03); Altered Signal peptide (Pr = 0.12 | P = 1.6e-03), ELME000106|ELME000137|ELME000146,-
COL4A5_HUMAN,G612V,0.954,Altered Disordered interface (Pr = 0.28 | P = 0.04); Loss of B-factor (Pr = 0.26 | P = 0.04), PS00008,-
COL4A5_HUMAN,G799D,0.959,Gain of Loop (Pr = 0.29 | P = 8.0e-03); Gain of B-factor (Pr = 0.24 | P = 0.04); Loss of Acetylation at K798 (Pr = 0.20 | P = 0.04); Loss of Methylation at K798 (Pr = 0.18 | P = 9.0e-03); Altered Metal binding (Pr = 0.15 | P = 0.02), None,-
COL4A5_HUMAN,G322D,0.947,Altered Disordered interface (Pr = 0.27 | P = 0.04); Gain of Phosphorylation at Y320 (Pr = 0.26 | P = 0.03); Altered Metal binding (Pr = 0.18 | P = 0.05); Gain of Sulfation at Y320 (Pr = 0.05 | P = 6.8e-03), ELME000006,-
COL4A5_HUMAN,G828R,0.951,Gain of Loop (Pr = 0.30 | P = 5.1e-03); Loss of B-factor (Pr = 0.29 | P = 0.02); Altered Disordered interface (Pr = 0.28 | P = 0.03), ELME000006|ELME000135|ELME000155,-
COL4A5_HUMAN,M901V,0.351,-,-,-
COL4A5_HUMAN,G527E,0.902,Loss of Methylation at K526 (Pr = 0.22 | P = 4.1e-03); Gain of SUMOylation at K526 (Pr = 0.20 | P = 0.03); Loss of Acetylation at K526 (Pr = 0.19 | P = 0.05), ELME000005|ELME000106|ELME000155,-
COL4A5_HUMAN,G1069V,0.813,Loss of B-factor (Pr = 0.30 | P = 0.01); Gain of Acetylation at K1065 (Pr = 0.21 | P = 0.03); Loss of Methylation at K1065 (Pr = 0.18 | P = 8.8e-03); Gain of O-linked glycosylation at S1071 (Pr = 0.12 | P = 0.04), None,-
COL4A5_HUMAN,G1137D,0.961,Loss of B-factor (Pr = 0.26 | P = 0.05); Loss of Acetylation at K1133 (Pr = 0.22 | P = 0.03); Loss of Methylation at K1133 (Pr = 0.22 | P = 4.6e-03); Loss of SUMOylation at K1133 (Pr = 0.19 | P = 0.05); Altered Metal binding (Pr = 0.17 | P = 0.01), ELME000085|ELME000155,-
COL4A5_HUMAN,G545D,0.943,Gain of Loop (Pr = 0.27 | P = 0.03); Gain of SUMOylation at K544 (Pr = 0.27 | P = 4.9e-03); Loss of B-factor (Pr = 0.26 | P = 0.05); Loss of Methylation at K544 (Pr = 0.19 | P = 8.0e-03); Gain of Ubiquitylation at K544 (Pr = 0.17 | P = 0.03); Gain of Proteolytic cleavage at D549 (Pr = 0.14 | P = 0.02), ELME000064|PS00006,-
COL4A5_HUMAN,S916G,0.283,-,-,-
COL4A5_HUMAN,G371E,0.957,Gain of SUMOylation at K370 (Pr = 0.32 | P = 2.6e-03); Gain of Loop (Pr = 0.28 | P = 0.02); Gain of B-factor (Pr = 0.25 | P = 0.03); Loss of Acetylation at K370 (Pr = 0.22 | P = 0.03); Loss of Methylation at K370 (Pr = 0.16 | P = 0.01), ELME000133,-
COL4A5_HUMAN,G412V,0.872,Loss of B-factor (Pr = 0.34 | P = 2.2e-03); Altered Disordered interface (Pr = 0.28 | P = 0.04); Gain of Acetylation at K408 (Pr = 0.22 | P = 0.03); Loss of Methylation at K408 (Pr = 0.20 | P = 7.1e-03); Gain of SUMOylation at K408 (Pr = 0.20 | P = 0.03); Gain of O-linked glycosylation at S417 (Pr = 0.15 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q407 (Pr = 0.05 | P = 0.03), None,-
COL4A5_HUMAN,G319V,0.952,Altered Disordered interface (Pr = 0.30 | P = 0.02); Loss of B-factor (Pr = 0.29 | P = 0.01); Gain of Phosphorylation at Y320 (Pr = 0.28 | P = 0.02); Gain of Sulfation at Y320 (Pr = 0.04 | P = 0.01), ELME000155,-
COL4A5_HUMAN,G201V,0.959,Loss of B-factor (Pr = 0.31 | P = 5.7e-03); Gain of Loop (Pr = 0.28 | P = 0.02); Altered Disordered interface (Pr = 0.27 | P = 0.04), None,-
COL4A5_HUMAN,G1241C,0.925,Loss of B-factor (Pr = 0.36 | P = 9.1e-04); Loss of O-linked glycosylation at S1242 (Pr = 0.17 | P = 0.03), ELME000136|ELME000155|ELME000159,-
COL4A5_HUMAN,G822R,0.934,Gain of Loop (Pr = 0.31 | P = 4.2e-03); Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of B-factor (Pr = 0.28 | P = 0.02), ELME000155,-
COL4A5_HUMAN,G1196E,0.891,Gain of Loop (Pr = 0.32 | P = 2.6e-03); Loss of B-factor (Pr = 0.26 | P = 0.03), None,-
COL4A5_HUMAN,G669A,0.868,Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Acetylation at K664 (Pr = 0.22 | P = 0.03); Loss of Methylation at K664 (Pr = 0.14 | P = 0.02), ELME000006,-
COL4A5_HUMAN,G524C,0.94,Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Methylation at K526 (Pr = 0.26 | P = 1.4e-03); Loss of Acetylation at K526 (Pr = 0.21 | P = 0.03), None,-
COL4A5_HUMAN,G1063V,0.945,Loss of B-factor (Pr = 0.34 | P = 1.6e-03); Gain of Acetylation at K1065 (Pr = 0.24 | P = 0.02); Loss of Methylation at K1065 (Pr = 0.19 | P = 7.6e-03); Gain of SUMOylation at K1065 (Pr = 0.18 | P = 0.04), ELME000118,-
COL4A5_HUMAN,G409D,0.952,Gain of B-factor (Pr = 0.26 | P = 0.02); Loss of Acetylation at K408 (Pr = 0.21 | P = 0.03); Gain of SUMOylation at K408 (Pr = 0.20 | P = 0.03); Loss of Methylation at K408 (Pr = 0.19 | P = 7.6e-03); Gain of Pyrrolidone carboxylic acid at Q407 (Pr = 0.05 | P = 0.03), None,-
COL4A5_HUMAN,G420E,0.841,Altered Disordered interface (Pr = 0.27 | P = 0.04); Gain of Loop (Pr = 0.27 | P = 0.03); Loss of O-linked glycosylation at S417 (Pr = 0.15 | P = 0.04), ELME000064|ELME000155|PS00006,-
COL4A5_HUMAN,G423E,0.863,Gain of Loop (Pr = 0.27 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q427 (Pr = 0.04 | P = 0.04), None,-
COL4A5_HUMAN,G796R,0.961,Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Loop (Pr = 0.28 | P = 0.02); Loss of Acetylation at K798 (Pr = 0.21 | P = 0.04); Loss of Methylation at K798 (Pr = 0.19 | P = 8.1e-03); Altered Metal binding (Pr = 0.10 | P = 0.05), None,-
COL4A5_HUMAN,G1143S,0.948,Loss of B-factor (Pr = 0.27 | P = 0.03); Altered Metal binding (Pr = 0.17 | P = 0.01), None,-
COL4A5_HUMAN,Q260R,0.38,-,-,-
COL4A5_HUMAN,I444S,0.549,Gain of B-factor (Pr = 0.32 | P = 7.5e-04), ELME000063|ELME000136|ELME000159,-
COL4A5_HUMAN,A28T,0.374,-,-,-
COL4A5_HUMAN,I181L,0.106,-,-,-
COL4A5_HUMAN,I181V,0.062,-,-,-
COL4A5_HUMAN,R275H,0.127,-,-,-
COL4A5_HUMAN,G350E,0.553,Gain of O-linked glycosylation at T354 (Pr = 0.15 | P = 0.03); Loss of Proteolytic cleavage at P349 (Pr = 0.12 | P = 0.03), PS00008,-
COL4A5_HUMAN,G352S,0.384,-,-,-
COL4A5_HUMAN,M393I,0.084,-,-,-
COL4A5_HUMAN,P421S,0.058,-,-,-
COL4A5_HUMAN,H443Y,0.104,-,-,-
COL4A5_HUMAN,S447G,0.138,-,-,-
COL4A5_HUMAN,P529A,0.206,-,-,-
COL4A5_HUMAN,L613H,0.244,-,-,-
COL4A5_HUMAN,M620S,0.215,-,-,-
COL4A5_HUMAN,N642S,0.073,-,-,-
COL4A5_HUMAN,A754G,0.052,-,-,-
COL4A5_HUMAN,A770T,0.023,-,-,-
COL4A5_HUMAN,L791V,0.082,-,-,-
COL4A5_HUMAN,I833T,0.177,-,-,-
COL4A5_HUMAN,H839P,0.384,-,-,-
COL4A5_HUMAN,I874M,0.051,-,-,-
COL4A5_HUMAN,S879P,0.134,-,-,-
COL4A5_HUMAN,P907Q,0.17,-,-,-
COL4A5_HUMAN,T1028N,0.042,-,-,-
COL4A5_HUMAN,P1043S,0.065,-,-,-
COL4A5_HUMAN,V1049A,0.065,-,-,-
COL4A5_HUMAN,P1103T,0.068,-,-,-
COL4A5_HUMAN,L1120F,0.304,-,-,-
COL4A5_HUMAN,H1156R,0.075,-,-,-
COL4A5_HUMAN,H1228P,0.413,-,-,-
COL4A5_HUMAN,V1233L,0.05,-,-,-
COL4A5_HUMAN,L1265S,0.281,-,-,-
COL4A5_HUMAN,P1271S,0.282,-,-,-
COL4A5_HUMAN,G1279A,0.473,-,-,-
COL4A5_HUMAN,Q1302H,0.255,-,-,-
COL4A5_HUMAN,P1332S,0.48,-,-,-
COL4A5_HUMAN,I1353T,0.069,-,-,-
COL4A5_HUMAN,L1361I,0.08,-,-,-
COL4A5_HUMAN,K1387Q,0.31,-,-,-
COL4A5_HUMAN,T1402V,0.11,-,-,-
COL4A5_HUMAN,P1404S,0.139,-,-,-
COL4A5_HUMAN,R1410H,0.169,-,-,-
COL4A5_HUMAN,T1455M,0.102,-,-,-
COL4A5_HUMAN,L1481V,0.032,-,-,-
COL4A5_HUMAN,H1585R,0.087,-,-,-
COL4A5_HUMAN,G1433C,0.962,Loss of B-factor (Pr = 0.26 | P = 0.05), ELME000052|PS00008,-
COL4A5_HUMAN,G1143D,0.96,Loss of B-factor (Pr = 0.26 | P = 0.04); Altered Metal binding (Pr = 0.18 | P = 0.01), None,-
COL4A5_HUMAN,G1042V,0.956,Loss of B-factor (Pr = 0.31 | P = 6.8e-03); Altered Disordered interface (Pr = 0.27 | P = 0.05); Gain of O-linked glycosylation at S1047 (Pr = 0.21 | P = 0.01), ELME000155,-
COL4A5_HUMAN,G177R,0.966,Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Sulfation at Y175 (Pr = 0.02 | P = 0.03), ELME000057,-
COL4A5_HUMAN,G460R,0.923,Loss of B-factor (Pr = 0.31 | P = 6.0e-03); Loss of Loop (Pr = 0.29 | P = 9.2e-03); Gain of Acetylation at K465 (Pr = 0.24 | P = 0.02); Loss of Methylation at K465 (Pr = 0.19 | P = 7.4e-03), ELME000006|ELME000135|ELME000136|ELME000159,-
COL4A5_HUMAN,G872R,0.941,Gain of Methylation at G872 (Pr = 0.09 | P = 0.05), ELME000155,-
COL4A5_HUMAN,G1170V,0.965,Loss of B-factor (Pr = 0.32 | P = 4.4e-03); Loss of Methylation at K1168 (Pr = 0.24 | P = 2.7e-03); Gain of Acetylation at K1168 (Pr = 0.22 | P = 0.03); Gain of SUMOylation at K1166 (Pr = 0.20 | P = 0.03), None,-
COL4A5_HUMAN,G831R,0.96,Altered Disordered interface (Pr = 0.28 | P = 0.03); Loss of B-factor (Pr = 0.26 | P = 0.04), None,-
COL4A5_HUMAN,G1027V,0.964,Altered Disordered interface (Pr = 0.29 | P = 0.03); Gain of SUMOylation at K1026 (Pr = 0.22 | P = 0.02); Loss of Acetylation at K1026 (Pr = 0.19 | P = 0.05); Loss of Methylation at K1026 (Pr = 0.16 | P = 0.01), ELME000220|ELME000336|PS00008,-
COL4A5_HUMAN,G1167S,0.948,Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Methylation at K1168 (Pr = 0.24 | P = 2.9e-03); Loss of Acetylation at K1166 (Pr = 0.22 | P = 0.03); Gain of SUMOylation at K1166 (Pr = 0.20 | P = 0.03), None,-
COL4A5_HUMAN,G1454S,0.863,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of O-linked glycosylation at T1455 (Pr = 0.24 | P = 9.7e-03), ELME000052|ELME000063|ELME000239,-
COL4A5_HUMAN,G1229S,0.935,, None,-
COL4A5_HUMAN,G594D,0.853,Gain of Loop (Pr = 0.30 | P = 6.4e-03); Loss of Acetylation at K599 (Pr = 0.28 | P = 5.6e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of SUMOylation at K599 (Pr = 0.20 | P = 0.03); Loss of Methylation at K599 (Pr = 0.19 | P = 7.5e-03), ELME000337,-
COL4A5_HUMAN,G615E,0.938,Gain of Loop (Pr = 0.30 | P = 4.4e-03); Altered Disordered interface (Pr = 0.27 | P = 0.04), PS00008,-
COL4A5_HUMAN,G834R,0.943,Altered Disordered interface (Pr = 0.29 | P = 0.03); Gain of Pyrrolidone carboxylic acid at Q835 (Pr = 0.04 | P = 0.05), None,-
COL4A5_HUMAN,G144S,0.929,Loss of B-factor (Pr = 0.27 | P = 0.03), ELME000136|ELME000155|ELME000159,-
COL4A5_HUMAN,G429E,0.922,Loss of Pyrrolidone carboxylic acid at Q427 (Pr = 0.04 | P = 0.04), ELME000155,-
COL4A5_HUMAN,G51V,0.955,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of SUMOylation at K47 (Pr = 0.24 | P = 0.01), ELME000259,-
COL4A5_HUMAN,G1030S,0.933,Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of SUMOylation at K1026 (Pr = 0.19 | P = 0.04); Loss of Methylation at K1026 (Pr = 0.16 | P = 0.01), ELME000220|ELME000336|PS00006,-
COL4A5_HUMAN,G264R,0.959,Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Methylation at R266 (Pr = 0.11 | P = 0.03); Gain of Proteolytic cleavage at D265 (Pr = 0.10 | P = 0.05), None,-
COL4A5_HUMAN,G716R,0.945,Altered Disordered interface (Pr = 0.28 | P = 0.03); Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of Loop (Pr = 0.27 | P = 0.03); Gain of Acetylation at K715 (Pr = 0.23 | P = 0.02); Loss of Methylation at K715 (Pr = 0.22 | P = 4.7e-03); Gain of SUMOylation at K715 (Pr = 0.22 | P = 0.02), ELME000005|ELME000006|ELME000100|ELME000108|ELME000155,-
COL4A5_HUMAN,E633K,0.414,-,-,-
COL4A5_HUMAN,G852E,0.889,Gain of Loop (Pr = 0.27 | P = 0.02); Loss of B-factor (Pr = 0.26 | P = 0.04), ELME000155,-
COL4A5_HUMAN,G1045E,0.914,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Loop (Pr = 0.27 | P = 0.03); Loss of O-linked glycosylation at S1047 (Pr = 0.17 | P = 0.03), ELME000085|ELME000239,-
COL4A5_HUMAN,G579R,0.967,Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of O-linked glycosylation at T577 (Pr = 0.11 | P = 0.05), ELME000136|ELME000159|ELME000358|PS00005,-
COL4A5_HUMAN,G710E,0.901,Altered Disordered interface (Pr = 0.30 | P = 0.02); Gain of Loop (Pr = 0.30 | P = 6.4e-03); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Methylation at K715 (Pr = 0.22 | P = 4.8e-03); Gain of SUMOylation at K715 (Pr = 0.22 | P = 0.02); Loss of Acetylation at K715 (Pr = 0.21 | P = 0.04), ELME000057|ELME000155,-
COL4A5_HUMAN,G1104V,0.964,Loss of B-factor (Pr = 0.26 | P = 0.03), None,-
COL4A5_HUMAN,G941C,0.954,Loss of B-factor (Pr = 0.33 | P = 3.2e-03); Loss of Methylation at K943 (Pr = 0.28 | P = 9.1e-04); Gain of SUMOylation at K943 (Pr = 0.25 | P = 8.8e-03); Loss of Acetylation at K943 (Pr = 0.23 | P = 0.02), ELME000064,-
COL4A5_HUMAN,G362V,0.946,Altered Disordered interface (Pr = 0.32 | P = 0.01); Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Acetylation at K358 (Pr = 0.25 | P = 0.01); Loss of Methylation at K358 (Pr = 0.18 | P = 0.01), ELME000155,-
MYO7A_HUMAN,N2173S,0.492,-,-,-
MYO7A_HUMAN,L2174C,0.912,Loss of Loop (Pr = 0.27 | P = 0.03); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), None,-
MYO7A_HUMAN,L2174G,0.945,Altered Stability (Pr = 0.17 | P = 0.02); Altered Transmembrane protein (Pr = 0.16 | P = 0.01), PS00008,-
MYO7A_HUMAN,V2175L,0.734,Gain of Loop (Pr = 0.27 | P = 0.03); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000062|ELME000336,-
MYO7A_HUMAN,E2183G,0.863,Loss of Strand (Pr = 0.26 | P = 0.04); Altered Stability (Pr = 0.12 | P = 0.03); Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000147|ELME000336|PS00008,-
MYO7A_HUMAN,M2190L,0.576,, ELME000045|ELME000148|ELME000317,-
MYO7A_HUMAN,D2192H,0.778,Altered Disordered interface (Pr = 0.27 | P = 0.04), ELME000053|ELME000148|ELME000317,-
MYO7A_HUMAN,L2194I,0.285,-,-,-
MYO7A_HUMAN,T2195E,0.751,Altered Disordered interface (Pr = 0.28 | P = 0.04); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000052|ELME000053|ELME000148|ELME000336,-
MYO7A_HUMAN,Y2197F,0.519,Altered Disordered interface (Pr = 0.37 | P = 7.0e-03); Altered Transmembrane protein (Pr = 0.09 | P = 0.05), ELME000052|ELME000053|ELME000063|ELME000163|ELME000182|ELME000202|ELME000336,-
MYO7A_HUMAN,S2206N,0.237,-,-,-
MYO7A_HUMAN,K2207Q,0.491,-,-,-
MYO7A_HUMAN,K2207S,0.649,Altered Disordered interface (Pr = 0.38 | P = 8.0e-03); Gain of Intrinsic disorder (Pr = 0.30 | P = 0.04); Loss of Helix (Pr = 0.27 | P = 0.04); Altered DNA binding (Pr = 0.25 | P = 8.9e-03); Loss of Ubiquitylation at K2207 (Pr = 0.16 | P = 0.03); Loss of Methylation at K2207 (Pr = 0.10 | P = 0.04), ELME000053|ELME000202|ELME000239|PS00005,-
MYO7A_HUMAN,G2214D,0.286,-,-,-
MYO7A_HUMAN,K2215R,0.062,-,-,-
MYO7A_HUMAN,K2215S,0.149,-,-,-
MYO7A_HUMAN,P541L,0.776,Altered Ordered interface (Pr = 0.26 | P = 0.01); Loss of B-factor (Pr = 0.26 | P = 0.04); Altered DNA binding (Pr = 0.14 | P = 0.05); Altered Transmembrane protein (Pr = 0.12 | P = 0.03); Loss of GPI-anchor amidation at N543 (Pr = 0.01 | P = 0.03), ELME000081|ELME000083|ELME000120|ELME000182,-
MYO7A_HUMAN,C652R,0.954,Loss of Allosteric site at R657 (Pr = 0.32 | P = 2.9e-03); Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Disordered interface (Pr = 0.22 | P = 0.02); Loss of Catalytic site at R657 (Pr = 0.19 | P = 0.01); Altered DNA binding (Pr = 0.19 | P = 0.03), ELME000012|ELME000106|ELME000313,-
MYO7A_HUMAN,Q493P,0.941,Altered Metal binding (Pr = 0.34 | P = 2.3e-03); Altered Ordered interface (Pr = 0.29 | P = 0.02); Gain of Allosteric site at F489 (Pr = 0.29 | P = 2.3e-03); Gain of Loop (Pr = 0.27 | P = 0.03); Altered Transmembrane protein (Pr = 0.23 | P = 2.4e-03); Loss of Catalytic site at N492 (Pr = 0.12 | P = 0.03), None,-
MYO7A_HUMAN,A1628S,0.165,-,-,-
MYO7A_HUMAN,T1639M,0.31,-,-,-
MYO7A_HUMAN,M599I,0.262,-,-,-
MYO7A_HUMAN,L452P,0.944,Altered Coiled coil (Pr = 0.38 | P = 0.01); Altered Metal binding (Pr = 0.28 | P = 0.02); Altered Ordered interface (Pr = 0.28 | P = 0.04); Loss of Helix (Pr = 0.28 | P = 0.03); Gain of Allosteric site at F449 (Pr = 0.26 | P = 7.3e-03), None,-
MYO7A_HUMAN,R756W,0.863,Altered DNA binding (Pr = 0.41 | P = 3.0e-04); Loss of Acetylation at K753 (Pr = 0.24 | P = 0.02); Altered Disordered interface (Pr = 0.22 | P = 0.03), ELME000134|ELME000137|ELME000146,-
MYO7A_HUMAN,R1240W,0.823,Altered Ordered interface (Pr = 0.39 | P = 1.1e-03); Gain of N-linked glycosylation at N1237 (Pr = 0.04 | P = 0.02), ELME000053|ELME000070|ELME000202|PS00001,-
MYO7A_HUMAN,A1251P,0.924,Gain of Intrinsic disorder (Pr = 0.37 | P = 0.01); Gain of Loop (Pr = 0.29 | P = 0.01); Loss of Helix (Pr = 0.28 | P = 0.03); Gain of B-factor (Pr = 0.25 | P = 0.04), ELME000239|ELME000336,-
MYO7A_HUMAN,G1782A,0.844,Loss of Allosteric site at Y1780 (Pr = 0.24 | P = 0.02); Loss of Acetylation at K1779 (Pr = 0.19 | P = 0.05); Gain of Ubiquitylation at K1787 (Pr = 0.16 | P = 0.03); Gain of Proteolytic cleavage at D1783 (Pr = 0.12 | P = 0.03), None,-
MYO7A_HUMAN,L1027P,0.898,Altered Stability (Pr = 0.38 | P = 3.3e-03); Gain of Intrinsic disorder (Pr = 0.30 | P = 0.05); Loss of Helix (Pr = 0.28 | P = 0.02); Gain of B-factor (Pr = 0.24 | P = 0.04); Altered Transmembrane protein (Pr = 0.15 | P = 0.02); Loss of Sulfation at Y1028 (Pr = 0.03 | P = 0.02), None,-
MYO7A_HUMAN,R668C,0.922,Altered Ordered interface (Pr = 0.40 | P = 1.4e-03); Altered Metal binding (Pr = 0.29 | P = 4.9e-03); Altered DNA binding (Pr = 0.23 | P = 0.01); Gain of Allosteric site at E663 (Pr = 0.23 | P = 0.02); Loss of Catalytic site at Y672 (Pr = 0.08 | P = 0.05), ELME000012|ELME000052|ELME000101|ELME000102|ELME000108,-
MYO7A_HUMAN,L1154P,0.963,Altered Stability (Pr = 0.34 | P = 4.2e-03); Loss of Helix (Pr = 0.28 | P = 0.02), ELME000137|ELME000313,-
MYO7A_HUMAN,I665V,0.704,Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Metal binding (Pr = 0.24 | P = 0.01); Altered DNA binding (Pr = 0.24 | P = 0.01); Gain of Allosteric site at E663 (Pr = 0.22 | P = 0.03); Gain of ADP-ribosylation at R669 (Pr = 0.19 | P = 0.05); Altered Disordered interface (Pr = 0.16 | P = 0.04), ELME000012|ELME000052|PS00005|PS00008,-
MYO7A_HUMAN,R675C,0.896,Altered Ordered interface (Pr = 0.42 | P = 6.9e-04); Loss of Allosteric site at R675 (Pr = 0.36 | P = 1.1e-03); Altered DNA binding (Pr = 0.26 | P = 7.0e-03); Altered Metal binding (Pr = 0.10 | P = 0.05); Loss of Catalytic site at Y672 (Pr = 0.08 | P = 0.05), ELME000020|ELME000062|ELME000064,-
MYO7A_HUMAN,R1873Q,0.776,Altered Metal binding (Pr = 0.24 | P = 0.04); Loss of Acetylation at K1876 (Pr = 0.20 | P = 0.04); Altered Coiled coil (Pr = 0.17 | P = 0.02); Altered DNA binding (Pr = 0.17 | P = 0.04), ELME000134|ELME000313,-
MYO7A_HUMAN,L237R,0.963,Altered Metal binding (Pr = 0.29 | P = 5.0e-03); Altered Ordered interface (Pr = 0.29 | P = 0.02); Gain of Allosteric site at R241 (Pr = 0.25 | P = 0.01); Altered DNA binding (Pr = 0.24 | P = 0.01); Loss of Relative solvent accessibility (Pr = 0.23 | P = 0.05); Altered Stability (Pr = 0.14 | P = 0.02); Loss of Catalytic site at E238 (Pr = 0.09 | P = 0.05), ELME000182|ELME000336,-
MYO7A_HUMAN,G519D,0.821,Gain of Intrinsic disorder (Pr = 0.32 | P = 0.03), PS00008,-
MYO7A_HUMAN,G1982E,0.86,Loss of Loop (Pr = 0.27 | P = 0.04); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Altered Transmembrane protein (Pr = 0.21 | P = 4.1e-03); Loss of Proteolytic cleavage at D1981 (Pr = 0.11 | P = 0.04), ELME000002|PS00008,-
MYO7A_HUMAN,A771S,0.379,-,-,-
MYO7A_HUMAN,G1159S,0.819,, ELME000313|ELME000336,-
MYO7A_HUMAN,R1873W,0.795,Altered Metal binding (Pr = 0.22 | P = 0.05); Loss of Acetylation at K1876 (Pr = 0.20 | P = 0.04); Altered DNA binding (Pr = 0.19 | P = 0.03); Altered Coiled coil (Pr = 0.15 | P = 0.03), ELME000134|ELME000313,-
MYO7A_HUMAN,R206C,0.917,Altered Disordered interface (Pr = 0.51 | P = 8.8e-04); Loss of Relative solvent accessibility (Pr = 0.40 | P = 7.5e-04); Altered DNA binding (Pr = 0.39 | P = 4.2e-04); Altered Metal binding (Pr = 0.29 | P = 3.9e-03); Gain of Allosteric site at N201 (Pr = 0.26 | P = 9.1e-03); Loss of Methylation at K203 (Pr = 0.26 | P = 1.4e-03); Loss of Catalytic site at R206 (Pr = 0.24 | P = 6.6e-03); Altered Transmembrane protein (Pr = 0.20 | P = 5.1e-03); Gain of N-linked glycosylation at N209 (Pr = 0.03 | P = 0.03); Loss of GPI-anchor amidation at N201 (Pr = 0.01 | P = 0.03), PS00005,-
MYO7A_HUMAN,A1224T,0.577,Altered Metal binding (Pr = 0.24 | P = 0.03); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000136|ELME000159|ELME000182|ELME000292,-
MYO7A_HUMAN,P1244R,0.807,Altered Disordered interface (Pr = 0.19 | P = 0.04); Altered DNA binding (Pr = 0.14 | P = 0.05), ELME000053|ELME000064|ELME000202,-
MYO7A_HUMAN,R241S,0.939,Loss of Allosteric site at R241 (Pr = 0.37 | P = 9.7e-04); Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered DNA binding (Pr = 0.26 | P = 4.6e-03); Altered Metal binding (Pr = 0.24 | P = 0.01); Gain of Catalytic site at E238 (Pr = 0.10 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q245 (Pr = 0.07 | P = 0.02), ELME000336,-
MYO7A_HUMAN,L326P,0.975,Altered Metal binding (Pr = 0.34 | P = 0.01); Gain of Allosteric site at N330 (Pr = 0.29 | P = 2.9e-03); Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Catalytic site at H327 (Pr = 0.21 | P = 0.01); Altered Transmembrane protein (Pr = 0.10 | P = 0.04); Altered Stability (Pr = 0.10 | P = 0.04), ELME000193,-
MYO7A_HUMAN,L1937P,0.937,Altered Stability (Pr = 0.15 | P = 0.02), ELME000052|ELME000053|ELME000106|ELME000146|ELME000239|ELME000313,-
MYO7A_HUMAN,K164R,0.733,Loss of Methylation at K164 (Pr = 0.29 | P = 7.1e-04); Loss of Catalytic site at E159 (Pr = 0.28 | P = 2.7e-03); Altered Metal binding (Pr = 0.27 | P = 9.1e-03); Gain of Allosteric site at E159 (Pr = 0.22 | P = 0.03), PS00008|PS00017,-
MYO7A_HUMAN,M283T,0.807,Gain of Relative solvent accessibility (Pr = 0.33 | P = 3.2e-03); Altered Ordered interface (Pr = 0.31 | P = 0.01); Altered Metal binding (Pr = 0.20 | P = 0.04); Gain of Disulfide linkage at C286 (Pr = 0.16 | P = 0.03); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Gain of Sulfation at Y278 (Pr = 0.02 | P = 0.04), ELME000182,-
MYO7A_HUMAN,D365N,0.182,-,-,-
MYO7A_HUMAN,T193P,0.851,Altered Ordered interface (Pr = 0.30 | P = 0.02); Gain of Allosteric site at E197 (Pr = 0.21 | P = 0.03); Altered Transmembrane protein (Pr = 0.19 | P = 6.7e-03); Altered Metal binding (Pr = 0.10 | P = 0.05), ELME000052|ELME000136|ELME000159|ELME000292,-
MYO7A_HUMAN,P132L,0.913,Altered Ordered interface (Pr = 0.42 | P = 7.3e-04); Altered Metal binding (Pr = 0.37 | P = 1.9e-03); Loss of Allosteric site at F135 (Pr = 0.32 | P = 2.7e-03); Gain of Helix (Pr = 0.30 | P = 8.3e-03); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered DNA binding (Pr = 0.20 | P = 0.02); Loss of Catalytic site at H133 (Pr = 0.10 | P = 0.04), ELME000058|ELME000233,-
MYO7A_HUMAN,Y2015H,0.881,Altered Metal binding (Pr = 0.38 | P = 2.8e-03); Altered Ordered interface (Pr = 0.34 | P = 6.7e-03); Loss of Allosteric site at Y2015 (Pr = 0.27 | P = 9.1e-03); Gain of Catalytic site at Y2015 (Pr = 0.15 | P = 0.02); Loss of Sulfation at Y2016 (Pr = 0.02 | P = 0.03), None,-
MYO7A_HUMAN,E1641K,0.628,Loss of Loop (Pr = 0.28 | P = 0.02); Gain of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Altered Transmembrane protein (Pr = 0.15 | P = 0.02), PS00005,-
MYO7A_HUMAN,S1605Y,0.891,Altered Ordered interface (Pr = 0.27 | P = 7.5e-03); Gain of Loop (Pr = 0.27 | P = 0.04); Loss of ADP-ribosylation at R1604 (Pr = 0.22 | P = 0.03); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Altered DNA binding (Pr = 0.15 | P = 0.04), ELME000008|ELME000100|ELME000108|ELME000120|ELME000233|ELME000271|ELME000278|PS00004,-
MYO7A_HUMAN,R244P,0.887,Altered Ordered interface (Pr = 0.32 | P = 0.01); Gain of Allosteric site at R241 (Pr = 0.31 | P = 1.3e-03); Altered DNA binding (Pr = 0.23 | P = 0.01); Gain of Catalytic site at R241 (Pr = 0.09 | P = 0.04); Loss of Pyrrolidone carboxylic acid at Q245 (Pr = 0.06 | P = 0.03), ELME000146|ELME000259|PS00007,-
MYO7A_HUMAN,R668H,0.862,Altered Ordered interface (Pr = 0.37 | P = 3.0e-03); Altered DNA binding (Pr = 0.30 | P = 1.6e-03); Gain of Strand (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.24 | P = 0.01); Gain of Allosteric site at Y672 (Pr = 0.19 | P = 0.05); Gain of Catalytic site at Y672 (Pr = 0.08 | P = 0.05), ELME000012|ELME000052|ELME000101|ELME000102|ELME000108,-
MYO7A_HUMAN,G2137E,0.917,Altered Transmembrane protein (Pr = 0.28 | P = 4.6e-04); Altered Ordered interface (Pr = 0.27 | P = 0.04); Loss of Strand (Pr = 0.26 | P = 0.04); Altered Metal binding (Pr = 0.24 | P = 0.02); Gain of Relative solvent accessibility (Pr = 0.23 | P = 0.05), ELME000147|ELME000335,-
MYO7A_HUMAN,T204A,0.742,Altered Disordered interface (Pr = 0.28 | P = 0.03); Altered Transmembrane protein (Pr = 0.26 | P = 9.5e-04); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered DNA binding (Pr = 0.26 | P = 7.0e-03); Loss of Allosteric site at F199 (Pr = 0.26 | P = 0.01); Gain of Methylation at K203 (Pr = 0.25 | P = 9.5e-04); Altered Metal binding (Pr = 0.24 | P = 0.02); Gain of Catalytic site at N201 (Pr = 0.22 | P = 9.2e-03); Gain of Ubiquitylation at K203 (Pr = 0.15 | P = 0.04); Gain of N-linked glycosylation at N209 (Pr = 0.03 | P = 0.03); Loss of GPI-anchor amidation at N201 (Pr = 0.01 | P = 0.03), PS00005|PS00008,-
MYO7A_HUMAN,R90P,0.875,Altered Ordered interface (Pr = 0.30 | P = 4.6e-03); Loss of Helix (Pr = 0.28 | P = 0.03); Gain of Loop (Pr = 0.28 | P = 0.02); Gain of Strand (Pr = 0.27 | P = 0.02); Loss of Allosteric site at Y89 (Pr = 0.23 | P = 0.03); Altered Transmembrane protein (Pr = 0.18 | P = 7.7e-03); Altered Metal binding (Pr = 0.13 | P = 0.03), PS00007,-
MYO7A_HUMAN,S1530L,0.421,-,-,-
MYO7A_HUMAN,V679I,0.152,-,-,-
MYO7A_HUMAN,D2142N,0.349,-,-,-
MYO7A_HUMAN,M1W,0.977,Loss of Intrinsic disorder (Pr = 0.52 | P = 5.2e-03); Loss of N-terminal acetylation at M1 (Pr = 0.24 | P = 5.6e-04); Altered Metal binding (Pr = 0.05 | P = 0.04), ELME000355,-
MYO7A_HUMAN,V2A,0.889,Gain of Intrinsic disorder (Pr = 0.35 | P = 0.02); Loss of N-terminal acetylation at M1 (Pr = 0.23 | P = 6.3e-04); Altered Metal binding (Pr = 0.04 | P = 0.04), ELME000285,-
MYO7A_HUMAN,V2P,0.932,Gain of Intrinsic disorder (Pr = 0.42 | P = 6.5e-03); Loss of N-terminal acetylation at M1 (Pr = 0.22 | P = 7.4e-04); Altered Metal binding (Pr = 0.05 | P = 0.04), None,-
MYO7A_HUMAN,V2Y,0.92,Gain of Strand (Pr = 0.27 | P = 0.03); Loss of N-terminal acetylation at M1 (Pr = 0.22 | P = 6.7e-04); Altered Metal binding (Pr = 0.04 | P = 0.04); Gain of Sulfation at V2 (Pr = 0.02 | P = 0.03), ELME000163|ELME000182|ELME000355,-
MYO7A_HUMAN,I3L,0.536,Gain of Intrinsic disorder (Pr = 0.30 | P = 0.05); Altered Metal binding (Pr = 0.27 | P = 0.02); Gain of Loop (Pr = 0.27 | P = 0.03); Gain of N-terminal acetylation at M1 (Pr = 0.27 | P = 1.8e-04), None,-
MYO7A_HUMAN,I3S,0.902,Gain of Intrinsic disorder (Pr = 0.59 | P = 4.5e-04); Altered Metal binding (Pr = 0.27 | P = 0.02); Loss of N-terminal acetylation at M1 (Pr = 0.19 | P = 9.5e-04); Altered Stability (Pr = 0.17 | P = 0.02), None,-
MYO7A_HUMAN,Q5P,0.907,Altered Metal binding (Pr = 0.24 | P = 0.04); Gain of N-terminal acetylation at M1 (Pr = 0.19 | P = 7.0e-04); Altered Stability (Pr = 0.19 | P = 0.01), None,-
MYO7A_HUMAN,R15K,0.135,-,-,-
MYO7A_HUMAN,E45D,0.207,-,-,-
MYO7A_HUMAN,K125R,0.363,-,-,-
MYO7A_HUMAN,N148H,0.541,Altered Ordered interface (Pr = 0.31 | P = 0.02); Altered Metal binding (Pr = 0.30 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Altered DNA binding (Pr = 0.20 | P = 0.02); Altered Transmembrane protein (Pr = 0.11 | P = 0.04), ELME000008|ELME000062|ELME000100|ELME000108|PS00004,-
MYO7A_HUMAN,N148S,0.386,-,-,-
MYO7A_HUMAN,S149I,0.548,Altered Ordered interface (Pr = 0.33 | P = 6.8e-03); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.04); Altered Metal binding (Pr = 0.22 | P = 0.05); Altered DNA binding (Pr = 0.17 | P = 0.03); Altered Transmembrane protein (Pr = 0.11 | P = 0.04), ELME000008|ELME000062|PS00004,-
MYO7A_HUMAN,I217V,0.452,-,-,-
MYO7A_HUMAN,L247S,0.503,Altered Ordered interface (Pr = 0.29 | P = 0.03); Loss of Allosteric site at R250 (Pr = 0.27 | P = 0.01); Altered Stability (Pr = 0.11 | P = 0.03); Altered Metal binding (Pr = 0.06 | P = 0.03); Gain of Pyrrolidone carboxylic acid at Q245 (Pr = 0.06 | P = 0.03), ELME000146|PS00007,-
MYO7A_HUMAN,L247T,0.424,-,-,-
MYO7A_HUMAN,Y256H,0.892,Altered Metal binding (Pr = 0.52 | P = 1.1e-03); Loss of Allosteric site at Y256 (Pr = 0.30 | P = 4.1e-03); Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered DNA binding (Pr = 0.14 | P = 0.05); Gain of Catalytic site at Y256 (Pr = 0.10 | P = 0.04), ELME000020|ELME000120|ELME000182,-
MYO7A_HUMAN,L259S,0.921,Altered Ordered interface (Pr = 0.34 | P = 5.6e-03); Gain of Intrinsic disorder (Pr = 0.32 | P = 0.03); Gain of Allosteric site at Y256 (Pr = 0.29 | P = 3.1e-03); Gain of Catalytic site at Y256 (Pr = 0.13 | P = 0.03); Altered Metal binding (Pr = 0.09 | P = 0.01), ELME000020|ELME000053|ELME000120|ELME000182,-
MYO7A_HUMAN,D265A,0.303,-,-,-
MYO7A_HUMAN,L270I,0.338,-,-,-
MYO7A_HUMAN,Q274H,0.087,-,-,-
MYO7A_HUMAN,N285S,0.378,-,-,-
MYO7A_HUMAN,T288V,0.246,-,-,-
MYO7A_HUMAN,E290D,0.24,-,-,-
MYO7A_HUMAN,A353T,0.099,-,-,-
MYO7A_HUMAN,P363S,0.131,-,-,-
MYO7A_HUMAN,P364Q,0.112,-,-,-
MYO7A_HUMAN,S368G,0.179,-,-,-
MYO7A_HUMAN,R373H,0.655,Altered Stability (Pr = 0.13 | P = 0.03), ELME000063|ELME000106|PS00005,-
MYO7A_HUMAN,L375I,0.245,-,-,-
MYO7A_HUMAN,E389D,0.253,-,-,-
MYO7A_HUMAN,D425E,0.048,-,-,-
MYO7A_HUMAN,V426T,0.115,-,-,-
MYO7A_HUMAN,K427E,0.24,-,-,-
MYO7A_HUMAN,K427N,0.208,-,-,-
MYO7A_HUMAN,K427R,0.117,-,-,-
MYO7A_HUMAN,S429P,0.361,-,-,-
MYO7A_HUMAN,F456L,0.802,Altered Coiled coil (Pr = 0.34 | P = 8.9e-03); Altered Metal binding (Pr = 0.30 | P = 0.01); Altered Ordered interface (Pr = 0.24 | P = 0.04), None,-
FGFR1_HUMAN,L8V,0.708,Altered Disordered interface (Pr = 0.21 | P = 0.03); Altered Signal peptide (Pr = 0.11 | P = 1.6e-03), ELME000106|ELME000137|ELME000146,-
FGFR1_HUMAN,W10A,0.903,Altered Ordered interface (Pr = 0.24 | P = 0.04); Altered Signal peptide (Pr = 0.12 | P = 2.0e-03), ELME000041|ELME000137,-
FGFR1_HUMAN,L13S,0.918,Altered Signal peptide (Pr = 0.16 | P = 4.9e-04), ELME000041|ELME000052|ELME000053|ELME000333,-
FGFR1_HUMAN,L13T,0.906,Altered Signal peptide (Pr = 0.16 | P = 4.8e-04), ELME000041|ELME000052|ELME000053|ELME000333,-
FGFR1_HUMAN,V14A,0.811,Altered Signal peptide (Pr = 0.24 | P = 1.5e-04), ELME000041|ELME000052|ELME000333,-
FGFR1_HUMAN,T15P,0.871,Altered Signal peptide (Pr = 0.18 | P = 3.8e-04), ELME000041|ELME000052|ELME000155|ELME000333,-
FGFR1_HUMAN,A16F,0.917,Altered Signal peptide (Pr = 0.20 | P = 3.2e-04), ELME000041|ELME000052,-
FGFR1_HUMAN,A16S,0.769,Altered Signal peptide (Pr = 0.19 | P = 3.7e-04), ELME000041|ELME000052|ELME000053|ELME000333|ELME000336,-
FGFR1_HUMAN,C19M,0.88,Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered Signal peptide (Pr = 0.23 | P = 5.4e-04); Gain of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.04), ELME000052|ELME000053,-
FGFR1_HUMAN,T20P,0.769,Gain of ADP-ribosylation at R22 (Pr = 0.22 | P = 0.02); Altered Signal peptide (Pr = 0.21 | P = 2.7e-04); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000053|ELME000155|PS00005,-
FGFR1_HUMAN,T20S,0.442,-,-,-
FGFR1_HUMAN,R22A,0.636,Loss of ADP-ribosylation at R22 (Pr = 0.27 | P = 7.2e-03); Altered Signal peptide (Pr = 0.21 | P = 7.3e-04); Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000005|ELME000053|ELME000136|ELME000155|ELME000159|PS00005,-
FGFR1_HUMAN,S24A,0.081,-,-,-
FGFR1_HUMAN,S24G,0.45,-,-,-
FGFR1_HUMAN,L27M,0.473,-,-,-
FGFR1_HUMAN,E29A,0.781,Altered Transmembrane protein (Pr = 0.15 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q30 (Pr = 0.12 | P = 7.8e-03); Altered Signal peptide (Pr = 0.02 | P = 4.3e-03), ELME000064|ELME000220|PS00006,-
FGFR1_HUMAN,E29V,0.79,Loss of Intrinsic disorder (Pr = 0.39 | P = 0.03); Altered Transmembrane protein (Pr = 0.15 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q32 (Pr = 0.07 | P = 0.02); Altered Signal peptide (Pr = 0.02 | P = 4.2e-03), ELME000052|ELME000064|ELME000220|PS00006,-
FGFR1_HUMAN,Q30E,0.283,-,-,-
FGFR1_HUMAN,L50A,0.417,-,-,-
FGFR1_HUMAN,A74M,0.439,-,-,-
FGFR1_HUMAN,S76N,0.38,-,-,-
FGFR1_HUMAN,D90G,0.383,-,-,-
FGFR1_HUMAN,T111V,0.266,-,-,-
FGFR1_HUMAN,V118I,0.347,-,-,-
FGFR1_HUMAN,D120N,0.629,Loss of Loop (Pr = 0.27 | P = 0.02); Loss of Proteolytic cleavage at D120 (Pr = 0.15 | P = 0.01); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Loss of N-linked glycosylation at N117 (Pr = 0.04 | P = 0.02), ELME000070|ELME000287|PS00001,-
FGFR1_HUMAN,S125A,0.179,-,-,-
FGFR1_HUMAN,M149T,0.232,-,-,-
FGFR1_HUMAN,T187S,0.327,-,-,-
FGFR1_HUMAN,W190C,0.962,Loss of Allosteric site at W190 (Pr = 0.32 | P = 2.4e-03); Loss of Strand (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.26 | P = 7.3e-04); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Altered DNA binding (Pr = 0.25 | P = 8.5e-03); Gain of Disulfide linkage at W190 (Pr = 0.24 | P = 8.4e-03); Altered Metal binding (Pr = 0.20 | P = 0.04); Gain of Acetylation at K195 (Pr = 0.19 | P = 0.05); Altered Stability (Pr = 0.19 | P = 0.01), ELME000146,-
FGFR1_HUMAN,I231V,0.145,-,-,-
FGFR1_HUMAN,E235A,0.307,-,-,-
FGFR1_HUMAN,H241F,0.904,Altered Ordered interface (Pr = 0.33 | P = 6.4e-03); Altered Transmembrane protein (Pr = 0.28 | P = 4.0e-04); Loss of N-linked glycosylation at N240 (Pr = 0.13 | P = 8.1e-03); Loss of Sulfation at Y243 (Pr = 0.01 | P = 0.04), ELME000052|ELME000053|ELME000070|ELME000197|PS00001,-
FGFR1_HUMAN,T242S,0.505,Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Transmembrane protein (Pr = 0.27 | P = 7.2e-04); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.04); Loss of N-linked glycosylation at N240 (Pr = 0.14 | P = 7.6e-03); Altered Stability (Pr = 0.11 | P = 0.04); Gain of Sulfation at Y243 (Pr = 0.02 | P = 0.04), ELME000052|ELME000053|ELME000070|PS00001,-
FGFR1_HUMAN,Q244P,0.915,Altered Transmembrane protein (Pr = 0.29 | P = 2.7e-04); Altered Ordered interface (Pr = 0.27 | P = 0.04); Gain of Relative solvent accessibility (Pr = 0.23 | P = 0.05); Gain of N-linked glycosylation at N240 (Pr = 0.13 | P = 7.3e-03); Altered Stability (Pr = 0.11 | P = 0.03); Gain of Sulfation at Y243 (Pr = 0.02 | P = 0.04), ELME000052|ELME000070,-
FGFR1_HUMAN,A314S,0.509,Altered Transmembrane protein (Pr = 0.25 | P = 1.3e-03); Loss of N-linked glycosylation at N317 (Pr = 0.18 | P = 4.0e-03), ELME000052|ELME000053|ELME000085|ELME000336,-
FGFR1_HUMAN,N317Q,0.82,Altered Transmembrane protein (Pr = 0.27 | P = 5.6e-04); Loss of N-linked glycosylation at N317 (Pr = 0.24 | P = 1.2e-03), ELME000052|ELME000064|ELME000070|ELME000220|PS00001|PS00008,-
FGFR1_HUMAN,D320G,0.84,Altered Transmembrane protein (Pr = 0.31 | P = 1.1e-04); Loss of Strand (Pr = 0.26 | P = 0.05); Loss of N-linked glycosylation at N317 (Pr = 0.19 | P = 3.9e-03), ELME000064|ELME000070|ELME000220|PS00001|PS00005|PS00006|PS00008,-
FGFR1_HUMAN,R329F,0.798,Altered Transmembrane protein (Pr = 0.38 | P = 1.5e-05); Loss of Strand (Pr = 0.26 | P = 0.04); Loss of N-linked glycosylation at N330 (Pr = 0.10 | P = 0.01), ELME000070|ELME000122|ELME000137|ELME000193|ELME000328|ELME000334,-
FGFR1_HUMAN,H352Q,0.791,Altered Transmembrane protein (Pr = 0.29 | P = 2.7e-04); Gain of Strand (Pr = 0.26 | P = 0.04), ELME000063|ELME000085,-
FGFR1_HUMAN,A354V,0.827,Altered Transmembrane protein (Pr = 0.28 | P = 3.9e-04), ELME000063|ELME000064|ELME000085,-
FGFR1_HUMAN,T357A,0.542,Altered Transmembrane protein (Pr = 0.25 | P = 1.1e-03); Altered Ordered interface (Pr = 0.23 | P = 0.05), ELME000064|ELME000220|ELME000333|PS00006,-
FGFR1_HUMAN,V358C,0.902,Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04), ELME000007|ELME000064|ELME000220|ELME000333|PS00006,-
FGFR1_HUMAN,L359T,0.769,Altered Transmembrane protein (Pr = 0.30 | P = 2.1e-04), ELME000052|ELME000064|ELME000220|ELME000333|PS00006,-
FGFR1_HUMAN,E363D,0.267,-,-,-
FGFR1_HUMAN,L373V,0.172,-,-,-
FGFR1_HUMAN,S393A,0.252,-,-,-
FGFR1_HUMAN,V427L,0.462,-,-,-
FGFR1_HUMAN,V427W,0.839,Loss of Intrinsic disorder (Pr = 0.41 | P = 0.02); Gain of Strand (Pr = 0.27 | P = 0.03); Loss of Phosphorylation at T428 (Pr = 0.26 | P = 0.03); Loss of O-linked glycosylation at T428 (Pr = 0.19 | P = 0.02); Altered Transmembrane protein (Pr = 0.17 | P = 0.01); Altered Disordered interface (Pr = 0.16 | P = 0.05); Loss of Proteolytic cleavage at D432 (Pr = 0.13 | P = 0.02), ELME000051|ELME000053|ELME000146,-
FGFR1_HUMAN,L457P,0.875,Gain of Intrinsic disorder (Pr = 0.37 | P = 0.01); Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Phosphorylation at T454 (Pr = 0.25 | P = 0.04), ELME000052|ELME000159,-
FGFR1_HUMAN,I498V,0.117,-,-,-
FGFR1_HUMAN,N506H,0.387,-,-,-
FGFR1_HUMAN,N506S,0.286,-,-,-
FGFR1_HUMAN,V664L,0.786,Loss of Strand (Pr = 0.26 | P = 0.03); Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.10 | P = 0.05), ELME000231,-
FGFR1_HUMAN,M667L,0.861,Altered Ordered interface (Pr = 0.26 | P = 0.01); Loss of Strand (Pr = 0.26 | P = 0.05); Altered Transmembrane protein (Pr = 0.11 | P = 0.04), ELME000106,-
FGFR1_HUMAN,A668T,0.863,Altered Ordered interface (Pr = 0.26 | P = 0.02); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000136|ELME000146|ELME000159|ELME000358,-
FGFR1_HUMAN,E670C,0.947,Altered Ordered interface (Pr = 0.26 | P = 0.01); Altered Transmembrane protein (Pr = 0.11 | P = 0.04), None,-
FGFR1_HUMAN,D682C,0.905,Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03); Altered Metal binding (Pr = 0.20 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q680 (Pr = 0.05 | P = 0.03), ELME000053,-
FGFR1_HUMAN,N763S,0.279,-,-,-
FGFR1_HUMAN,S779G,0.125,-,-,-
FGFR1_HUMAN,E799D,0.149,-,-,-
FGFR1_HUMAN,P811S,0.25,-,-,-
FGFR1_HUMAN,A812T,0.072,-,-,-
FGFR1_HUMAN,I300T,0.392,-,-,-
FGFR1_HUMAN,C725Y,0.938,Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Metal binding (Pr = 0.22 | P = 0.05); Gain of Allosteric site at Y730 (Pr = 0.20 | P = 0.04); Altered DNA binding (Pr = 0.18 | P = 0.03); Gain of N-linked glycosylation at N724 (Pr = 0.03 | P = 0.03); Gain of Sulfation at C725 (Pr = 0.01 | P = 0.04), ELME000052|ELME000063|ELME000070|ELME000084|ELME000095|ELME000122|ELME000182|PS00001,-
FGFR1_HUMAN,L165S,0.847,Gain of B-factor (Pr = 0.26 | P = 0.02); Loss of SUMOylation at K160 (Pr = 0.25 | P = 9.3e-03); Altered Stability (Pr = 0.17 | P = 0.02); Altered Transmembrane protein (Pr = 0.12 | P = 0.03), None,-
FGFR1_HUMAN,D623G,0.868,Altered DNA binding (Pr = 0.32 | P = 1.9e-03); Loss of Helix (Pr = 0.27 | P = 0.04); Loss of Allosteric site at R627 (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.22 | P = 3.7e-03); Altered Metal binding (Pr = 0.13 | P = 0.03); Gain of Catalytic site at R627 (Pr = 0.12 | P = 0.03), PS00109,-
FGFR1_HUMAN,P285R,0.903,Altered Metal binding (Pr = 0.23 | P = 0.04); Altered Transmembrane protein (Pr = 0.23 | P = 2.7e-03); Altered DNA binding (Pr = 0.18 | P = 0.03), ELME000137,-
FGFR1_HUMAN,G270D,0.924,Gain of Relative solvent accessibility (Pr = 0.30 | P = 8.5e-03); Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Metal binding (Pr = 0.24 | P = 3.7e-03); Altered Transmembrane protein (Pr = 0.21 | P = 4.4e-03), ELME000052|ELME000064|ELME000239,-
FGFR1_HUMAN,S332C,0.842,Altered Metal binding (Pr = 0.49 | P = 5.3e-03); Altered Transmembrane protein (Pr = 0.43 | P = 4.9e-06); Loss of Strand (Pr = 0.27 | P = 0.03); Loss of N-linked glycosylation at N330 (Pr = 0.11 | P = 0.01), ELME000070|ELME000079|ELME000122|ELME000137|ELME000334|PS00001|PS00006,-
FGFR1_HUMAN,S616P,0.954,Loss of Helix (Pr = 0.29 | P = 0.02); Gain of Allosteric site at Y613 (Pr = 0.22 | P = 0.02), ELME000182|PS00005,-
FGFR1_HUMAN,D641N,0.865,Gain of Relative solvent accessibility (Pr = 0.35 | P = 1.5e-03); Altered Metal binding (Pr = 0.23 | P = 0.02); Gain of Allosteric site at F642 (Pr = 0.22 | P = 0.02); Altered DNA binding (Pr = 0.17 | P = 0.03), None,-
FGFR1_HUMAN,R627T,0.965,Altered DNA binding (Pr = 0.38 | P = 5.1e-04); Loss of Allosteric site at R627 (Pr = 0.29 | P = 4.8e-03); Altered Transmembrane protein (Pr = 0.21 | P = 3.5e-03); Altered Metal binding (Pr = 0.15 | P = 0.02); Loss of Catalytic site at R627 (Pr = 0.13 | P = 0.03), ELME000052|ELME000146|ELME000336|PS00109,-
FGFR1_HUMAN,Y339H,0.925,Altered Metal binding (Pr = 0.34 | P = 0.01); Altered Ordered interface (Pr = 0.34 | P = 2.8e-03); Altered Transmembrane protein (Pr = 0.29 | P = 2.5e-04); Loss of Disulfide linkage at C341 (Pr = 0.18 | P = 0.03), ELME000120|ELME000182,-
FGFR1_HUMAN,G97D,0.94,Altered Transmembrane protein (Pr = 0.31 | P = 1.2e-04); Gain of Intrinsic disorder (Pr = 0.30 | P = 0.04); Altered Metal binding (Pr = 0.27 | P = 0.03); Gain of Disulfide linkage at C101 (Pr = 0.19 | P = 0.02); Loss of Proteolytic cleavage at D95 (Pr = 0.13 | P = 0.03), ELME000085|ELME000239|PS00008,-
FGFR1_HUMAN,V429E,0.857,Gain of Intrinsic disorder (Pr = 0.32 | P = 0.03); Gain of B-factor (Pr = 0.25 | P = 0.04); Altered Transmembrane protein (Pr = 0.19 | P = 7.0e-03); Loss of O-linked glycosylation at T428 (Pr = 0.19 | P = 0.02); Loss of Proteolytic cleavage at D432 (Pr = 0.13 | P = 0.02), ELME000051|ELME000053|ELME000085|ELME000146|ELME000321,-
FGFR1_HUMAN,D768H,0.645,Altered Disordered interface (Pr = 0.30 | P = 0.02); Gain of Helix (Pr = 0.28 | P = 0.03), ELME000120|ELME000147|ELME000182|ELME000336,-
FGFR1_HUMAN,G237S,0.862,Altered Ordered interface (Pr = 0.31 | P = 0.01); Altered Transmembrane protein (Pr = 0.27 | P = 9.4e-04); Altered Metal binding (Pr = 0.25 | P = 0.01); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Loss of N-linked glycosylation at N240 (Pr = 0.13 | P = 8.1e-03); Loss of Sulfation at Y236 (Pr = 0.01 | P = 0.05), ELME000053|ELME000120,-
FGFR1_HUMAN,R78C,0.846,Altered Transmembrane protein (Pr = 0.24 | P = 1.6e-03); Loss of N-linked glycosylation at N77 (Pr = 0.20 | P = 3.1e-03), ELME000012|ELME000063|ELME000070|ELME000336|PS00001|PS00005,-
FGFR1_HUMAN,Y99C,0.923,Altered Metal binding (Pr = 0.38 | P = 9.2e-03); Gain of Intrinsic disorder (Pr = 0.34 | P = 0.02); Loss of Loop (Pr = 0.27 | P = 0.04); Altered Transmembrane protein (Pr = 0.25 | P = 1.2e-03); Gain of Disulfide linkage at C101 (Pr = 0.18 | P = 0.03); Loss of O-linked glycosylation at T103 (Pr = 0.17 | P = 0.03); Loss of Proteolytic cleavage at D95 (Pr = 0.12 | P = 0.03), ELME000120|PS00008,-
FGFR1_HUMAN,A343V,0.88,Altered Transmembrane protein (Pr = 0.29 | P = 2.2e-04); Altered Metal binding (Pr = 0.28 | P = 0.02); Gain of Strand (Pr = 0.26 | P = 0.05); Altered Ordered interface (Pr = 0.24 | P = 0.03); Loss of Disulfide linkage at C341 (Pr = 0.18 | P = 0.03), ELME000052|ELME000053|ELME000149|ELME000239,-
FGFR1_HUMAN,D476E,0.482,-,-,-
FGFR1_HUMAN,G687R,0.935,Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Transmembrane protein (Pr = 0.24 | P = 1.9e-03); Altered Metal binding (Pr = 0.17 | P = 0.04), ELME000106|ELME000137|ELME000146|ELME000231|PS00005,-
FGFR1_HUMAN,W666R,0.955,Altered Ordered interface (Pr = 0.31 | P = 3.8e-03); Loss of Strand (Pr = 0.27 | P = 0.03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000100|ELME000103|ELME000108,-
FGFR1_HUMAN,G348R,0.95,Gain of Strand (Pr = 0.28 | P = 0.01); Altered Transmembrane protein (Pr = 0.27 | P = 9.0e-04); Altered Stability (Pr = 0.10 | P = 0.04), ELME000053|ELME000062|ELME000337|PS00005|PS00008,-
FGFR1_HUMAN,D682G,0.916,Altered Ordered interface (Pr = 0.28 | P = 0.05); Altered Transmembrane protein (Pr = 0.24 | P = 1.9e-03); Altered Metal binding (Pr = 0.19 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q680 (Pr = 0.05 | P = 0.03), ELME000053|ELME000085,-
FGFR1_HUMAN,A671P,0.945,Altered Ordered interface (Pr = 0.26 | P = 0.01); Gain of Allosteric site at W666 (Pr = 0.21 | P = 0.03); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), None,-
FGFR1_HUMAN,R189C,0.745,Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Gain of Allosteric site at W190 (Pr = 0.29 | P = 2.9e-03); Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Altered DNA binding (Pr = 0.28 | P = 5.2e-03); Altered Ordered interface (Pr = 0.27 | P = 0.05); Altered Metal binding (Pr = 0.20 | P = 0.04), ELME000146|PS00005,-
FGFR1_HUMAN,A520T,0.698,Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Loss of Acetylation at K517 (Pr = 0.21 | P = 0.03); Loss of Ubiquitylation at K523 (Pr = 0.21 | P = 4.4e-03); Loss of Methylation at K517 (Pr = 0.20 | P = 6.3e-03); Altered Metal binding (Pr = 0.18 | P = 0.05); Altered DNA binding (Pr = 0.17 | P = 0.04); Altered Coiled coil (Pr = 0.09 | P = 0.05), ELME000063|ELME000173|ELME000220,-
COL2A1_HUMAN,L4Q,0.55,Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered Signal peptide (Pr = 0.08 | P = 2.1e-03); Gain of N-terminal acetylation at M1 (Pr = 0.07 | P = 2.2e-03); Gain of Pyrrolidone carboxylic acid at L4 (Pr = 0.05 | P = 0.04), None,-
COL2A1_HUMAN,L4R,0.653,Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered Signal peptide (Pr = 0.15 | P = 1.1e-03); Gain of N-terminal acetylation at M1 (Pr = 0.09 | P = 1.9e-03), ELME000012|ELME000102|ELME000108,-
COL2A1_HUMAN,P7L,0.166,-,-,-
COL2A1_HUMAN,P7S,0.135,-,-,-
COL2A1_HUMAN,T9K,0.327,-,-,-
COL2A1_HUMAN,V20A,0.558,Loss of Pyrrolidone carboxylic acid at Q24 (Pr = 0.29 | P = 4.0e-04); Altered Signal peptide (Pr = 0.10 | P = 1.1e-03), None,-
COL2A1_HUMAN,G25S,0.346,-,-,-
COL2A1_HUMAN,Q26A,0.469,-,-,-
COL2A1_HUMAN,Q26R,0.385,-,-,-
COL2A1_HUMAN,V28L,0.178,-,-,-
COL2A1_HUMAN,E30A,0.247,-,-,-
COL2A1_HUMAN,E30D,0.156,-,-,-
COL2A1_HUMAN,A31G,0.186,-,-,-
COL2A1_HUMAN,A31N,0.272,-,-,-
COL2A1_HUMAN,V35E,0.582,Gain of Intrinsic disorder (Pr = 0.36 | P = 0.02); Gain of Loop (Pr = 0.28 | P = 0.01); Altered Transmembrane protein (Pr = 0.25 | P = 1.3e-03); Loss of Disulfide linkage at C34 (Pr = 0.17 | P = 0.03), None,-
COL2A1_HUMAN,V35F,0.459,-,-,-
COL2A1_HUMAN,D37N,0.202,-,-,-
COL2A1_HUMAN,G38R,0.825,Loss of Loop (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.26 | P = 8.4e-04); Loss of Disulfide linkage at C34 (Pr = 0.17 | P = 0.03); Gain of Pyrrolidone carboxylic acid at Q39 (Pr = 0.10 | P = 0.01); Loss of Sulfation at Y41 (Pr = 0.01 | P = 0.05), ELME000012|PS00008,-
COL2A1_HUMAN,Q39E,0.523,Gain of Loop (Pr = 0.30 | P = 5.3e-03); Altered Transmembrane protein (Pr = 0.26 | P = 1.2e-03); Gain of Disulfide linkage at C34 (Pr = 0.19 | P = 0.02); Gain of Sulfation at Y41 (Pr = 0.02 | P = 0.04), PS00008,-
COL2A1_HUMAN,Q39R,0.516,Altered Transmembrane protein (Pr = 0.23 | P = 2.5e-03); Gain of Disulfide linkage at C34 (Pr = 0.19 | P = 0.02); Loss of Sulfation at Y41 (Pr = 0.01 | P = 0.05), ELME000012|ELME000093|ELME000102|ELME000108|PS00008|PS00009,-
COL2A1_HUMAN,R40I,0.598,Altered Transmembrane protein (Pr = 0.29 | P = 3.8e-04); Loss of Sulfation at Y41 (Pr = 0.01 | P = 0.05), PS00008,-
COL2A1_HUMAN,V46L,0.558,Altered Transmembrane protein (Pr = 0.25 | P = 1.5e-03); Loss of SUMOylation at K48 (Pr = 0.19 | P = 0.04); Loss of Sulfation at Y41 (Pr = 0.01 | P = 0.05), ELME000155,-
COL2A1_HUMAN,K48Q,0.741,Loss of SUMOylation at K48 (Pr = 0.26 | P = 6.7e-03); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000155,-
COL2A1_HUMAN,P51A,0.408,-,-,-
COL2A1_HUMAN,C52A,0.906,Loss of Disulfide linkage at C57 (Pr = 0.20 | P = 0.02); Loss of SUMOylation at K48 (Pr = 0.19 | P = 0.04); Altered Transmembrane protein (Pr = 0.11 | P = 0.03), PS01208,-
COL2A1_HUMAN,T59E,0.49,-,-,-
COL2A1_HUMAN,T61F,0.477,-,-,-
COL2A1_HUMAN,D71E,0.233,-,-,-
COL2A1_HUMAN,V72K,0.268,-,-,-
COL2A1_HUMAN,V72P,0.198,-,-,-
COL2A1_HUMAN,C75A,0.776,Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Disulfide linkage at C75 (Pr = 0.15 | P = 0.03), ELME000136|ELME000146|ELME000155|ELME000159|ELME000321|PS01208,-
COL2A1_HUMAN,L76R,0.634,Gain of Intrinsic disorder (Pr = 0.35 | P = 0.02); Loss of Loop (Pr = 0.28 | P = 0.02); Gain of ADP-ribosylation at L76 (Pr = 0.24 | P = 9.6e-03); Loss of Disulfide linkage at C75 (Pr = 0.13 | P = 0.04), ELME000136|ELME000155|ELME000159|ELME000233|PS01208,-
COL2A1_HUMAN,S77Q,0.206,-,-,-
COL2A1_HUMAN,P78A,0.385,-,-,-
COL2A1_HUMAN,P81H,0.475,-,-,-
COL2A1_HUMAN,T91E,0.453,-,-,-
COL2A1_HUMAN,A94P,0.425,-,-,-
COL2A1_HUMAN,P102F,0.592,Loss of B-factor (Pr = 0.35 | P = 1.4e-03); Gain of Acetylation at K103 (Pr = 0.26 | P = 0.01); Loss of SUMOylation at K106 (Pr = 0.22 | P = 0.02); Loss of O-linked glycosylation at S97 (Pr = 0.21 | P = 0.02); Loss of Methylation at K106 (Pr = 0.17 | P = 0.01); Loss of Proteolytic cleavage at S97 (Pr = 0.12 | P = 0.03); Gain of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), None,-
COL2A1_HUMAN,P102I,0.593,Loss of B-factor (Pr = 0.35 | P = 1.1e-03); Loss of SUMOylation at K106 (Pr = 0.22 | P = 0.02); Gain of Acetylation at K103 (Pr = 0.21 | P = 0.03); Loss of O-linked glycosylation at S97 (Pr = 0.20 | P = 0.02); Gain of Methylation at K106 (Pr = 0.17 | P = 9.2e-03); Loss of Proteolytic cleavage at S97 (Pr = 0.12 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), None,-
COL2A1_HUMAN,K103S,0.531,Gain of Loop (Pr = 0.30 | P = 6.6e-03); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of SUMOylation at K106 (Pr = 0.22 | P = 0.02); Loss of Methylation at K103 (Pr = 0.19 | P = 8.2e-03); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), ELME000085|ELME000239,-
COL2A1_HUMAN,G104A,0.904,Loss of B-factor (Pr = 0.30 | P = 7.9e-03); Gain of SUMOylation at K106 (Pr = 0.23 | P = 0.02); Gain of Acetylation at K106 (Pr = 0.19 | P = 0.05); Gain of Methylation at K106 (Pr = 0.17 | P = 8.8e-03); Gain of Pyrrolidone carboxylic acid at Q105 (Pr = 0.07 | P = 0.02), None,-
COL2A1_HUMAN,K106R,0.555,Loss of SUMOylation at K106 (Pr = 0.32 | P = 2.3e-03); Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Acetylation at K106 (Pr = 0.23 | P = 0.02); Loss of Methylation at K106 (Pr = 0.20 | P = 7.1e-03); Gain of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), None,-
COL2A1_HUMAN,K106S,0.791,Loss of SUMOylation at K106 (Pr = 0.32 | P = 2.3e-03); Loss of B-factor (Pr = 0.26 | P = 0.03); Gain of Phosphorylation at K106 (Pr = 0.24 | P = 0.04); Loss of Acetylation at K106 (Pr = 0.23 | P = 0.02); Loss of Methylation at K106 (Pr = 0.21 | P = 5.3e-03); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), ELME000085,-
COL2A1_HUMAN,K106T,0.778,Loss of SUMOylation at K106 (Pr = 0.32 | P = 2.3e-03); Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Acetylation at K106 (Pr = 0.23 | P = 0.02); Loss of Methylation at K106 (Pr = 0.21 | P = 5.3e-03); Gain of O-linked glycosylation at K106 (Pr = 0.15 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), None,-
COL2A1_HUMAN,G107Y,0.959,Gain of Phosphorylation at G107 (Pr = 0.55 | P = 2.7e-03); Gain of Acetylation at K106 (Pr = 0.35 | P = 1.8e-03); Altered Disordered interface (Pr = 0.33 | P = 0.01); Loss of B-factor (Pr = 0.32 | P = 3.8e-03); Loss of SUMOylation at K106 (Pr = 0.22 | P = 0.02); Loss of Methylation at K106 (Pr = 0.17 | P = 0.01); Gain of Pyrrolidone carboxylic acid at Q105 (Pr = 0.07 | P = 0.02), ELME000081,-
COL2A1_HUMAN,E108A,0.745,Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of SUMOylation at K106 (Pr = 0.27 | P = 4.5e-03); Loss of Acetylation at K113 (Pr = 0.25 | P = 0.01); Gain of Methylation at K106 (Pr = 0.20 | P = 4.7e-03); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), None,-
COL2A1_HUMAN,I112L,0.28,-,-,-
COL2A1_HUMAN,K113R,0.251,-,-,-
COL2A1_HUMAN,K113S,0.519,Loss of Acetylation at K113 (Pr = 0.49 | P = 6.0e-04); Gain of Phosphorylation at K113 (Pr = 0.28 | P = 0.02); Loss of SUMOylation at K113 (Pr = 0.27 | P = 4.5e-03); Loss of Methylation at K113 (Pr = 0.24 | P = 2.8e-03); Gain of Proteolytic cleavage at D114 (Pr = 0.16 | P = 9.4e-03), None,-
COL2A1_HUMAN,A128V,0.259,-,-,-
COL2A1_HUMAN,E142A,0.379,-,-,-
COL2A1_HUMAN,E142Q,0.342,-,-,-
COL2A1_HUMAN,T157L,0.731,Loss of B-factor (Pr = 0.27 | P = 0.03), ELME000136|ELME000155|ELME000159|ELME000358,-
COL2A1_HUMAN,P169L,0.713,Loss of B-factor (Pr = 0.38 | P = 1.4e-04); Altered Disordered interface (Pr = 0.30 | P = 0.03); Gain of Loop (Pr = 0.29 | P = 0.01), ELME000057|ELME000155,-
COL2A1_HUMAN,P173A,0.329,-,-,-
COL2A1_HUMAN,M183L,0.604,Altered Disordered interface (Pr = 0.27 | P = 0.04); Gain of Proteolytic cleavage at Q182 (Pr = 0.12 | P = 0.03); Gain of Pyrrolidone carboxylic acid at Q182 (Pr = 0.08 | P = 0.02), None,-
COL2A1_HUMAN,G185T,0.686,Loss of SUMOylation at K190 (Pr = 0.19 | P = 0.04); Loss of Ubiquitylation at K190 (Pr = 0.19 | P = 0.01); Gain of Proteolytic cleavage at Q182 (Pr = 0.12 | P = 0.03); Loss of Methylation at K190 (Pr = 0.11 | P = 0.04); Loss of Pyrrolidone carboxylic acid at Q182 (Pr = 0.06 | P = 0.03), ELME000220|PS00006,-
COL2A1_HUMAN,F187Y,0.189,-,-,-
COL2A1_HUMAN,N226T,0.316,-,-,-
COL2A1_HUMAN,P245T,0.358,-,-,-
COL2A1_HUMAN,P247S,0.371,-,-,-
COL2A1_HUMAN,A263P,0.358,-,-,-
COL2A1_HUMAN,V307A,0.205,-,-,-
COL2A1_HUMAN,K374S,0.863,Loss of Methylation at K374 (Pr = 0.46 | P = 1.3e-04); Gain of Loop (Pr = 0.29 | P = 0.01); Loss of Acetylation at K374 (Pr = 0.29 | P = 5.5e-03); Loss of Ubiquitylation at K374 (Pr = 0.27 | P = 3.8e-04); Gain of O-linked glycosylation at K374 (Pr = 0.10 | P = 0.05), ELME000002|ELME000085|ELME000239|PS00008,-
COL2A1_HUMAN,P395S,0.287,-,-,-
COL2A1_HUMAN,E466D,0.296,-,-,-
COL2A1_HUMAN,S536A,0.182,-,-,-
COL2A1_HUMAN,S536V,0.302,-,-,-
COL2A1_HUMAN,A539V,0.224,-,-,-
COL2A1_HUMAN,A580I,0.263,-,-,-
COL2A1_HUMAN,A580V,0.201,-,-,-
COL2A1_HUMAN,P614A,0.496,-,-,-
COL2A1_HUMAN,A647E,0.39,-,-,-
COL2A1_HUMAN,G677S,0.334,-,-,-
COL2A1_HUMAN,P686T,0.711,, ELME000156,-
COL2A1_HUMAN,P697S,0.601,Loss of Methylation at R698 (Pr = 0.14 | P = 0.02), ELME000064|ELME000336|PS00006|PS00008,-
COL2A1_HUMAN,A712P,0.39,-,-,-
COL2A1_HUMAN,A712S,0.094,-,-,-
COL2A1_HUMAN,P718G,0.475,-,-,-
COL2A1_HUMAN,A737D,0.306,-,-,-
COL2A1_HUMAN,A737V,0.151,-,-,-
COL2A1_HUMAN,A761T,0.255,-,-,-
COL2A1_HUMAN,T827A,0.255,-,-,-
COL2A1_HUMAN,E850D,0.228,-,-,-
COL2A1_HUMAN,E853V,0.493,-,-,-
COL2A1_HUMAN,A854S,0.133,-,-,-
COL2A1_HUMAN,D859N,0.44,-,-,-
COL2A1_HUMAN,P865S,0.69,Loss of B-factor (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.12 | P = 0.03); Loss of O-linked glycosylation at S869 (Pr = 0.12 | P = 0.05), ELME000053|ELME000155|ELME000202|PS00008,-
COL2A1_HUMAN,G867S,0.957,Loss of O-linked glycosylation at S869 (Pr = 0.12 | P = 0.05); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000136|ELME000155|ELME000159,-
COL2A1_HUMAN,P872L,0.759,Loss of B-factor (Pr = 0.30 | P = 8.5e-03); Loss of O-linked glycosylation at S869 (Pr = 0.12 | P = 0.05); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000155,-
COL2A1_HUMAN,G873P,0.967,Gain of B-factor (Pr = 0.27 | P = 0.01); Gain of O-linked glycosylation at S869 (Pr = 0.13 | P = 0.04); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000155,-
COL2A1_HUMAN,A931V,0.107,-,-,-
COL2A1_HUMAN,S935G,0.267,-,-,-
COL2A1_HUMAN,P959A,0.237,-,-,-
COL2A1_HUMAN,D962E,0.223,-,-,-
COL2A1_HUMAN,A967L,0.226,-,-,-
COL2A1_HUMAN,A1012S,0.074,-,-,-
COL2A1_HUMAN,V1064L,0.078,-,-,-
COL2A1_HUMAN,S1075A,0.251,-,-,-
COL2A1_HUMAN,A1079S,0.091,-,-,-
WFS1_HUMAN,P7Q,0.05,-,-,-
WFS1_HUMAN,P16L,0.077,-,-,-
WFS1_HUMAN,V54G,0.216,-,-,-
WFS1_HUMAN,A57T,0.05,-,-,-
WFS1_HUMAN,Q66H,0.095,-,-,-
WFS1_HUMAN,M84V,0.031,-,-,-
WFS1_HUMAN,I86V,0.036,-,-,-
WFS1_HUMAN,V91I,0.031,-,-,-
WFS1_HUMAN,G115R,0.086,-,-,-
WFS1_HUMAN,T117M,0.059,-,-,-
WFS1_HUMAN,E120R,0.613,Loss of B-factor (Pr = 0.25 | P = 0.05), ELME000064|ELME000117|ELME000173|ELME000220|PS00006,-
WFS1_HUMAN,V131C,0.227,-,-,-
WFS1_HUMAN,V142L,0.467,-,-,-
WFS1_HUMAN,R161Q,0.038,-,-,-
WFS1_HUMAN,A214V,0.033,-,-,-
WFS1_HUMAN,M312R,0.679,Altered Transmembrane protein (Pr = 0.27 | P = 7.8e-04); Altered Ordered interface (Pr = 0.25 | P = 0.02), ELME000231|ELME000254,-
WFS1_HUMAN,T436A,0.141,-,-,-
WFS1_HUMAN,V498I,0.054,-,-,-
WFS1_HUMAN,V501I,0.103,-,-,-
WFS1_HUMAN,L506M,0.164,-,-,-
WFS1_HUMAN,V509I,0.089,-,-,-
WFS1_HUMAN,G576S,0.551,Altered Transmembrane protein (Pr = 0.29 | P = 2.5e-04), ELME000335|ELME000336,-
WFS1_HUMAN,R676H,0.497,-,-,-
WFS1_HUMAN,R685P,0.827,Loss of Helix (Pr = 0.32 | P = 2.5e-03); Altered Transmembrane protein (Pr = 0.30 | P = 1.7e-04); Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Disulfide linkage at C690 (Pr = 0.18 | P = 0.03); Gain of Catalytic site at C690 (Pr = 0.15 | P = 0.02); Gain of GPI-anchor amidation at N682 (Pr = 0.01 | P = 0.03), ELME000052|ELME000202|ELME000336,-
WFS1_HUMAN,S308C,0.749,Altered Transmembrane protein (Pr = 0.32 | P = 7.3e-05), None,-
WFS1_HUMAN,P504R,0.85,Altered Ordered interface (Pr = 0.24 | P = 0.03); Gain of N-linked glycosylation at N500 (Pr = 0.07 | P = 0.02), ELME000070|ELME000106|ELME000146|ELME000155|ELME000336|PS00005,-
WFS1_HUMAN,G702D,0.927,Altered Transmembrane protein (Pr = 0.34 | P = 2.4e-05); Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered DNA binding (Pr = 0.29 | P = 2.3e-03); Loss of Allosteric site at W700 (Pr = 0.27 | P = 8.9e-03); Gain of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Altered Metal binding (Pr = 0.21 | P = 0.03), ELME000062|ELME000080|ELME000220|PS00005|PS00006,-
WFS1_HUMAN,Q584P,0.832,Altered Transmembrane protein (Pr = 0.29 | P = 2.3e-04), None,-
WFS1_HUMAN,V707F,0.84,Altered DNA binding (Pr = 0.29 | P = 3.5e-03); Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Ordered interface (Pr = 0.26 | P = 0.02); Altered Metal binding (Pr = 0.17 | P = 0.01), ELME000062|ELME000083|ELME000120|ELME000182,-
WFS1_HUMAN,P504L,0.801,Gain of Helix (Pr = 0.30 | P = 9.6e-03); Altered Ordered interface (Pr = 0.24 | P = 0.04); Altered Transmembrane protein (Pr = 0.09 | P = 0.05); Loss of N-linked glycosylation at N500 (Pr = 0.07 | P = 0.02), ELME000070|ELME000155|ELME000335|ELME000336,-
WFS1_HUMAN,P292S,0.789,Gain of Helix (Pr = 0.27 | P = 0.04); Altered Transmembrane protein (Pr = 0.21 | P = 4.9e-03), ELME000155,-
WFS1_HUMAN,N714I,0.921,Loss of Relative solvent accessibility (Pr = 0.34 | P = 2.8e-03); Altered Disordered interface (Pr = 0.32 | P = 0.02); Altered Ordered interface (Pr = 0.31 | P = 0.02); Altered Metal binding (Pr = 0.23 | P = 4.1e-03); Altered DNA binding (Pr = 0.22 | P = 0.02); Altered Transmembrane protein (Pr = 0.19 | P = 6.9e-03), ELME000085|ELME000147|ELME000220|ELME000233|ELME000321,-
WFS1_HUMAN,G834D,0.888,Altered Transmembrane protein (Pr = 0.39 | P = 9.7e-06), None,-
WFS1_HUMAN,G674V,0.878,Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Transmembrane protein (Pr = 0.28 | P = 4.3e-04); Loss of Disulfide linkage at C673 (Pr = 0.18 | P = 0.03), None,-
WFS1_HUMAN,V288M,0.135,-,-,-
WFS1_HUMAN,G437R,0.461,-,-,-
WFS1_HUMAN,Y669H,0.881,Altered Ordered interface (Pr = 0.37 | P = 1.7e-03); Altered Transmembrane protein (Pr = 0.24 | P = 1.5e-03); Loss of Disulfide linkage at C673 (Pr = 0.18 | P = 0.03), ELME000120,-
WFS1_HUMAN,M518V,0.835,Altered Transmembrane protein (Pr = 0.26 | P = 9.8e-04); Gain of Pyrrolidone carboxylic acid at Q520 (Pr = 0.06 | P = 0.02), None,-
WFS1_HUMAN,W700C,0.968,Loss of Allosteric site at W700 (Pr = 0.35 | P = 1.3e-03); Altered Ordered interface (Pr = 0.34 | P = 2.6e-03); Altered Transmembrane protein (Pr = 0.30 | P = 1.9e-04); Altered Metal binding (Pr = 0.28 | P = 0.02); Altered DNA binding (Pr = 0.22 | P = 0.02); Gain of Disulfide linkage at W700 (Pr = 0.16 | P = 0.03), ELME000062|ELME000080|ELME000137,-
WFS1_HUMAN,Y669C,0.905,Altered Ordered interface (Pr = 0.49 | P = 2.3e-04); Altered Transmembrane protein (Pr = 0.39 | P = 9.7e-06); Gain of Disulfide linkage at C673 (Pr = 0.23 | P = 0.01), ELME000120,-
WFS1_HUMAN,P346L,0.887,Loss of Strand (Pr = 0.31 | P = 1.3e-03); Altered Transmembrane protein (Pr = 0.30 | P = 1.9e-04); Gain of Helix (Pr = 0.30 | P = 6.8e-03); Altered Ordered interface (Pr = 0.24 | P = 0.03), None,-
WFS1_HUMAN,R708C,0.686,Altered DNA binding (Pr = 0.55 | P = 3.4e-05); Loss of Relative solvent accessibility (Pr = 0.34 | P = 3.1e-03); Altered Ordered interface (Pr = 0.33 | P = 8.4e-03); Altered Disordered interface (Pr = 0.27 | P = 0.04); Altered Metal binding (Pr = 0.23 | P = 4.5e-03), ELME000062|ELME000083|ELME000120|ELME000182|ELME000220,-
WFS1_HUMAN,E158K,0.781,Altered Coiled coil (Pr = 0.37 | P = 0.01); Altered Disordered interface (Pr = 0.27 | P = 0.01); Gain of Acetylation at E158 (Pr = 0.23 | P = 0.02); Gain of SUMOylation at E158 (Pr = 0.20 | P = 0.03), ELME000064|PS00005|PS00006,-
WFS1_HUMAN,P320R,0.842,Gain of Helix (Pr = 0.28 | P = 0.03); Altered Transmembrane protein (Pr = 0.18 | P = 7.4e-03), ELME000052|ELME000053,-
WFS1_HUMAN,A559D,0.76,Altered Transmembrane protein (Pr = 0.36 | P = 1.9e-05); Altered Ordered interface (Pr = 0.25 | P = 0.03), ELME000062|ELME000313|ELME000336|PS00008,-
WFS1_HUMAN,G831A,0.759,Altered Transmembrane protein (Pr = 0.30 | P = 1.6e-04), ELME000220,-
WFS1_HUMAN,L303P,0.93,Altered Transmembrane protein (Pr = 0.31 | P = 1.2e-04); Altered Ordered interface (Pr = 0.31 | P = 4.1e-03); Altered Stability (Pr = 0.11 | P = 0.04), ELME000098|ELME000182,-
WFS1_HUMAN,I427S,0.814,Altered Transmembrane protein (Pr = 0.26 | P = 9.6e-04); Altered Stability (Pr = 0.10 | P = 0.04), ELME000007|ELME000053|ELME000063|ELME000136|ELME000159,-
WFS1_HUMAN,D797N,0.383,-,-,-
WFS1_HUMAN,V545M,0.413,-,-,-
WFS1_HUMAN,Y669S,0.923,Altered Ordered interface (Pr = 0.49 | P = 2.0e-04); Altered Transmembrane protein (Pr = 0.24 | P = 1.6e-03); Gain of Disulfide linkage at C673 (Pr = 0.19 | P = 0.02), ELME000053|ELME000085|ELME000120,-
WFS1_HUMAN,Y508C,0.705,Altered Ordered interface (Pr = 0.31 | P = 3.9e-03), ELME000020|ELME000083|ELME000120|ELME000182,-
WFS1_HUMAN,R859Q,0.331,-,-,-
WFS1_HUMAN,A684V,0.806,Loss of Helix (Pr = 0.29 | P = 9.9e-03); Altered Transmembrane protein (Pr = 0.26 | P = 7.2e-04), ELME000052|ELME000202|ELME000336,-
WFS1_HUMAN,E655K,0.855,Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Altered Ordered interface (Pr = 0.24 | P = 0.03); Loss of Sulfation at Y660 (Pr = 0.03 | P = 0.02), ELME000146,-
WFS1_HUMAN,N682D,0.597,Altered Transmembrane protein (Pr = 0.28 | P = 6.5e-04); Altered Ordered interface (Pr = 0.25 | P = 0.02), None,-
WFS1_HUMAN,R456H,0.622,Loss of Helix (Pr = 0.37 | P = 1.7e-04); Gain of Strand (Pr = 0.31 | P = 9.8e-04); Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03); Altered Ordered interface (Pr = 0.26 | P = 0.01), ELME000102|ELME000108|ELME000146|ELME000182|PS00005,-
WFS1_HUMAN,G786S,0.148,-,-,-
WFS1_HUMAN,V871M,0.369,-,-,-
WFS1_HUMAN,A671V,0.201,-,-,-
WFS1_HUMAN,V333F,0.695,Altered Transmembrane protein (Pr = 0.25 | P = 1.2e-03); Altered Ordered interface (Pr = 0.24 | P = 0.04); Loss of N-linked glycosylation at N335 (Pr = 0.08 | P = 0.02), ELME000328|ELME000336,-
WFS1_HUMAN,D866N,0.494,-,-,-
WFS1_HUMAN,P44T,0.089,-,-,-
WFS1_HUMAN,G51S,0.373,-,-,-
WFS1_HUMAN,G53S,0.053,-,-,-
WFS1_HUMAN,R71G,0.147,-,-,-
WFS1_HUMAN,A114R,0.499,-,-,-
WFS1_HUMAN,E119K,0.24,-,-,-
WFS1_HUMAN,L130P,0.898,Altered Stability (Pr = 0.12 | P = 0.03), ELME000155,-
WFS1_HUMAN,A141G,0.767,Altered Disordered interface (Pr = 0.27 | P = 0.02); Gain of Loop (Pr = 0.27 | P = 0.03); Altered Coiled coil (Pr = 0.26 | P = 0.02); Gain of Acetylation at K143 (Pr = 0.20 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q136 (Pr = 0.20 | P = 1.9e-03); Altered Stability (Pr = 0.17 | P = 0.02), ELME000149|ELME000233,-
WFS1_HUMAN,L144T,0.696,Altered Coiled coil (Pr = 0.27 | P = 0.01); Altered Disordered interface (Pr = 0.25 | P = 0.01); Gain of Proteolytic cleavage at R147 (Pr = 0.11 | P = 0.04); Gain of Disulfide linkage at C148 (Pr = 0.10 | P = 0.05); Altered Stability (Pr = 0.10 | P = 0.04), ELME000149|ELME000233|ELME000337|PS00005,-
WFS1_HUMAN,R147Q,0.335,-,-,-
WFS1_HUMAN,A150R,0.571,Altered Disordered interface (Pr = 0.59 | P = 5.6e-04); Gain of Intrinsic disorder (Pr = 0.33 | P = 0.03); Altered Coiled coil (Pr = 0.25 | P = 0.02); Loss of Proteolytic cleavage at R147 (Pr = 0.12 | P = 0.04), ELME000101,-
WFS1_HUMAN,H210Q,0.062,-,-,-
WFS1_HUMAN,I250V,0.103,-,-,-
WFS1_HUMAN,M306V,0.055,-,-,-
WFS1_HUMAN,A406V,0.14,-,-,-
WFS1_HUMAN,F413V,0.26,-,-,-
WFS1_HUMAN,I421L,0.141,-,-,-
WFS1_HUMAN,N477D,0.046,-,-,-
WFS1_HUMAN,L514V,0.469,-,-,-
WFS1_HUMAN,A602V,0.075,-,-,-
WFS1_HUMAN,V606M,0.151,-,-,-
WFS1_HUMAN,V624L,0.101,-,-,-
WFS1_HUMAN,S743R,0.154,-,-,-
WFS1_HUMAN,D788E,0.101,-,-,-
WFS1_HUMAN,T857A,0.033,-,-,-
WFS1_HUMAN,R832G,0.707,Altered Transmembrane protein (Pr = 0.28 | P = 4.6e-04); Altered Stability (Pr = 0.10 | P = 0.04), PS00008,-
WFS1_HUMAN,A844T,0.636,Altered Transmembrane protein (Pr = 0.27 | P = 8.4e-04); Altered Metal binding (Pr = 0.25 | P = 0.03), None,-
WFS1_HUMAN,P292T,0.815,Gain of Helix (Pr = 0.27 | P = 0.03); Altered Transmembrane protein (Pr = 0.19 | P = 6.6e-03), ELME000155|ELME000182,-
WFS1_HUMAN,W314R,0.677,Altered Ordered interface (Pr = 0.34 | P = 2.9e-03); Altered Transmembrane protein (Pr = 0.28 | P = 5.6e-04); Gain of Helix (Pr = 0.27 | P = 0.03), ELME000053|ELME000062|ELME000173|ELME000254,-
WFS1_HUMAN,T337I,0.681,Altered Transmembrane protein (Pr = 0.35 | P = 3.4e-05); Loss of N-linked glycosylation at N335 (Pr = 0.08 | P = 0.01), ELME000063|ELME000070|ELME000148|ELME000333|PS00001,-
WFS1_HUMAN,N188S,0.343,-,-,-
WFS1_HUMAN,G674E,0.815,Altered Metal binding (Pr = 0.39 | P = 9.1e-03); Altered Transmembrane protein (Pr = 0.33 | P = 4.9e-05); Altered Ordered interface (Pr = 0.33 | P = 7.4e-03); Gain of Disulfide linkage at C673 (Pr = 0.20 | P = 0.02), None,-
WFS1_HUMAN,F350I,0.819,Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.11 | P = 0.04), ELME000328|ELME000333|ELME000336,-
WFS1_HUMAN,S443I,0.73,Altered Ordered interface (Pr = 0.26 | P = 0.01); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000052|ELME000063|ELME000336,-
WFS1_HUMAN,N682S,0.465,-,-,-
WFS1_HUMAN,I845N,0.9,Altered Transmembrane protein (Pr = 0.43 | P = 0.0e+00); Altered Metal binding (Pr = 0.30 | P = 0.02), ELME000079,-
WFS1_HUMAN,S356P,0.798,Loss of Helix (Pr = 0.29 | P = 0.02); Altered Ordered interface (Pr = 0.24 | P = 0.03); Altered Transmembrane protein (Pr = 0.02 | P = 3.4e-03), ELME000063,-
WFS1_HUMAN,L506R,0.726,Loss of Helix (Pr = 0.28 | P = 0.03); Altered Ordered interface (Pr = 0.24 | P = 0.04), ELME000020,-
COL2A1_HUMAN,G1053E,0.959,Altered Disordered interface (Pr = 0.28 | P = 0.04); Loss of Acetylation at K1055 (Pr = 0.24 | P = 0.02); Loss of Methylation at K1055 (Pr = 0.23 | P = 3.1e-03); Loss of Ubiquitylation at K1055 (Pr = 0.19 | P = 0.01), None,-
COL2A1_HUMAN,G210E,0.956,Loss of Methylation at R209 (Pr = 0.35 | P = 2.8e-04); Gain of Loop (Pr = 0.32 | P = 2.2e-03); Loss of B-factor (Pr = 0.27 | P = 0.03), ELME000155,-
COL2A1_HUMAN,G378D,0.967,Gain of Loop (Pr = 0.29 | P = 7.3e-03); Loss of Methylation at K374 (Pr = 0.26 | P = 1.4e-03); Gain of Ubiquitylation at K374 (Pr = 0.22 | P = 4.7e-03); Loss of Acetylation at K374 (Pr = 0.21 | P = 0.03), None,-
COL2A1_HUMAN,G339D,0.96,Gain of Loop (Pr = 0.32 | P = 2.2e-03); Gain of Methylation at R344 (Pr = 0.21 | P = 2.8e-03), ELME000293|PS00008,-
COL2A1_HUMAN,D1469Y,0.955,Altered Metal binding (Pr = 0.82 | P = 3.4e-05); Altered Transmembrane protein (Pr = 0.33 | P = 5.8e-05); Loss of Catalytic site at D1464 (Pr = 0.32 | P = 1.3e-03); Altered Disordered interface (Pr = 0.28 | P = 0.04); Gain of Strand (Pr = 0.28 | P = 7.9e-03); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.04); Gain of Allosteric site at D1464 (Pr = 0.24 | P = 0.02); Gain of Sulfation at D1469 (Pr = 0.02 | P = 0.02), ELME000182,-
COL2A1_HUMAN,G630S,0.943,Loss of Acetylation at K634 (Pr = 0.25 | P = 0.01); Loss of Methylation at K634 (Pr = 0.22 | P = 4.2e-03); Loss of SUMOylation at K634 (Pr = 0.21 | P = 0.03); Loss of Ubiquitylation at K634 (Pr = 0.15 | P = 0.05); Gain of Proteolytic cleavage at R629 (Pr = 0.13 | P = 0.02), ELME000106,-
COL2A1_HUMAN,G333E,0.959,Gain of Loop (Pr = 0.30 | P = 4.8e-03); Loss of Methylation at R332 (Pr = 0.12 | P = 0.03), ELME000048,-
COL2A1_HUMAN,G1098E,0.96,Gain of Loop (Pr = 0.28 | P = 0.02), ELME000085|ELME000155,-
COL2A1_HUMAN,G678E,0.929,Gain of Loop (Pr = 0.28 | P = 0.02); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Acetylation at K679 (Pr = 0.25 | P = 0.01); Loss of Methylation at K679 (Pr = 0.25 | P = 1.9e-03); Gain of SUMOylation at K679 (Pr = 0.22 | P = 0.02), PS00008,-
COL2A1_HUMAN,A377T,0.602,Loss of Methylation at K374 (Pr = 0.27 | P = 1.2e-03); Gain of B-factor (Pr = 0.24 | P = 0.05); Gain of Acetylation at K374 (Pr = 0.21 | P = 0.03); Loss of Ubiquitylation at K374 (Pr = 0.21 | P = 5.4e-03), None,-
COL2A1_HUMAN,G582S,0.959,Gain of Loop (Pr = 0.27 | P = 0.04); Gain of O-linked glycosylation at S578 (Pr = 0.17 | P = 0.02); Loss of Methylation at R586 (Pr = 0.13 | P = 0.02), ELME000053,-
COL2A1_HUMAN,R437P,0.902,Gain of B-factor (Pr = 0.34 | P = 3.8e-04); Altered Disordered interface (Pr = 0.28 | P = 0.04); Loss of Loop (Pr = 0.27 | P = 0.03); Loss of Methylation at R437 (Pr = 0.20 | P = 6.3e-03), ELME000057|ELME000155,-
COL2A1_HUMAN,T1390N,0.894,Altered Transmembrane protein (Pr = 0.28 | P = 5.1e-04); Loss of Strand (Pr = 0.26 | P = 0.04); Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Metal binding (Pr = 0.23 | P = 0.05); Gain of Disulfide linkage at C1393 (Pr = 0.12 | P = 0.04); Gain of Catalytic site at Y1391 (Pr = 0.11 | P = 0.03); Loss of N-linked glycosylation at N1388 (Pr = 0.04 | P = 0.02), ELME000070|PS00001,-
COL2A1_HUMAN,G420E,0.967,Loss of Methylation at K419 (Pr = 0.28 | P = 8.5e-04); Altered Disordered interface (Pr = 0.27 | P = 0.05); Gain of Loop (Pr = 0.27 | P = 0.03); Gain of SUMOylation at K419 (Pr = 0.22 | P = 0.02); Loss of Ubiquitylation at K419 (Pr = 0.21 | P = 5.3e-03), ELME000085|ELME000239,-
COL2A1_HUMAN,G468V,0.954,Altered Disordered interface (Pr = 0.33 | P = 0.01); Loss of B-factor (Pr = 0.32 | P = 4.4e-03); Loss of Methylation at K464 (Pr = 0.29 | P = 7.4e-04); Gain of Acetylation at K464 (Pr = 0.27 | P = 7.1e-03); Gain of SUMOylation at K464 (Pr = 0.23 | P = 0.02), None,-
COL2A1_HUMAN,G393S,0.931,Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Methylation at R392 (Pr = 0.21 | P = 5.6e-03), ELME000005|ELME000053|ELME000155,-
COL2A1_HUMAN,G702S,0.962,Loss of Methylation at R701 (Pr = 0.15 | P = 0.02), ELME000147,-
COL2A1_HUMAN,G594E,0.962,Gain of Loop (Pr = 0.27 | P = 0.04); Loss of B-factor (Pr = 0.26 | P = 0.03); Loss of Methylation at R596 (Pr = 0.17 | P = 0.01); Gain of Pyrrolidone carboxylic acid at Q598 (Pr = 0.08 | P = 0.01); Loss of Hydroxylation at P590 (Pr = 0.01 | P = 9.7e-06), None,-
COL2A1_HUMAN,G795R,0.971,Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of B-factor (Pr = 0.29 | P = 0.01); Gain of Methylation at G795 (Pr = 0.10 | P = 0.04), ELME000006|ELME000135,-
COL2A1_HUMAN,G348V,0.971,Loss of B-factor (Pr = 0.32 | P = 5.0e-03); Loss of Methylation at R344 (Pr = 0.21 | P = 5.6e-03), None,-
COL2A1_HUMAN,G213D,0.965,Gain of Loop (Pr = 0.32 | P = 1.7e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Methylation at R209 (Pr = 0.26 | P = 1.8e-03), ELME000155,-
COL2A1_HUMAN,R515C,0.889,Altered Disordered interface (Pr = 0.39 | P = 5.2e-03); Gain of Loop (Pr = 0.26 | P = 0.05); Loss of Methylation at R515 (Pr = 0.25 | P = 2.0e-03), PS00008,-
COL2A1_HUMAN,G969S,0.928,Loss of B-factor (Pr = 0.27 | P = 0.03); Altered Metal binding (Pr = 0.10 | P = 0.05), ELME000053|ELME000136|ELME000155|ELME000159,-
COL2A1_HUMAN,T1439M,0.49,-,-,-
COL2A1_HUMAN,G675D,0.949,Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of Loop (Pr = 0.28 | P = 0.01); Loss of Acetylation at K679 (Pr = 0.25 | P = 0.01); Loss of Methylation at K679 (Pr = 0.25 | P = 1.9e-03); Loss of SUMOylation at K679 (Pr = 0.20 | P = 0.03), None,-
COL2A1_HUMAN,A181P,0.835,Loss of Proteolytic cleavage at Q182 (Pr = 0.11 | P = 0.04); Loss of Pyrrolidone carboxylic acid at Q182 (Pr = 0.06 | P = 0.03), None,-
COL2A1_HUMAN,G1143C,0.961,Loss of B-factor (Pr = 0.33 | P = 2.7e-03), ELME000057|ELME000155,-
COL2A1_HUMAN,G918C,0.959,Loss of B-factor (Pr = 0.36 | P = 6.3e-04); Loss of O-linked glycosylation at S923 (Pr = 0.16 | P = 0.03); Loss of GPI-anchor amidation at N913 (Pr = 0.01 | P = 0.03), None,-
COL2A1_HUMAN,G873E,0.961,Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of O-linked glycosylation at S869 (Pr = 0.12 | P = 0.04); Altered Metal binding (Pr = 0.10 | P = 0.04), ELME000155,-
COL2A1_HUMAN,G861V,0.962,Loss of B-factor (Pr = 0.29 | P = 0.01); Loss of Methylation at K857 (Pr = 0.29 | P = 7.6e-04); Loss of Acetylation at K857 (Pr = 0.23 | P = 0.02); Loss of SUMOylation at K857 (Pr = 0.23 | P = 0.02); Gain of Ubiquitylation at K857 (Pr = 0.17 | P = 0.02); Altered Metal binding (Pr = 0.13 | P = 0.03), None,-
COL2A1_HUMAN,G1164C,0.959,Loss of B-factor (Pr = 0.34 | P = 2.0e-03); Loss of Methylation at R1163 (Pr = 0.15 | P = 0.02), ELME000155,-
COL2A1_HUMAN,G912D,0.966,Gain of Loop (Pr = 0.28 | P = 0.02); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of GPI-anchor amidation at N911 (Pr = 0.01 | P = 0.02), ELME000155,-
COL2A1_HUMAN,G624D,0.964,Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Acetylation at K620 (Pr = 0.27 | P = 7.4e-03); Loss of Methylation at K620 (Pr = 0.22 | P = 4.1e-03); Loss of SUMOylation at K620 (Pr = 0.20 | P = 0.04); Gain of Ubiquitylation at K620 (Pr = 0.15 | P = 0.05), ELME000005|ELME000155|ELME000293,-
COL2A1_HUMAN,G501R,0.968,Loss of Loop (Pr = 0.30 | P = 5.8e-03); Altered Disordered interface (Pr = 0.26 | P = 0.05); Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of Methylation at G501 (Pr = 0.10 | P = 0.04), ELME000155,-
COL2A1_HUMAN,G507R,0.972,Loss of Loop (Pr = 0.31 | P = 5.3e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Methylation at R509 (Pr = 0.11 | P = 0.03), ELME000006|ELME000135,-
COL2A1_HUMAN,G891R,0.968,Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of Methylation at R887 (Pr = 0.23 | P = 1.6e-03); Loss of O-linked glycosylation at T896 (Pr = 0.22 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q890 (Pr = 0.04 | P = 0.04), None,-
COL2A1_HUMAN,G399V,0.959,Loss of B-factor (Pr = 0.33 | P = 2.3e-03), ELME000136|ELME000159|ELME000358,-
COL2A1_HUMAN,G456A,0.944,Altered Disordered interface (Pr = 0.30 | P = 0.03); Loss of Methylation at K452 (Pr = 0.23 | P = 3.3e-03); Gain of SUMOylation at K452 (Pr = 0.19 | P = 0.04); Gain of Ubiquitylation at K452 (Pr = 0.16 | P = 0.03); Gain of O-linked glycosylation at T455 (Pr = 0.12 | P = 0.04), None,-
COL2A1_HUMAN,G1149V,0.953,Loss of B-factor (Pr = 0.32 | P = 3.8e-03); Gain of Loop (Pr = 0.27 | P = 0.03); Gain of O-linked glycosylation at S1154 (Pr = 0.15 | P = 0.03), ELME000085|ELME000239,-
COL2A1_HUMAN,G213V,0.967,Loss of B-factor (Pr = 0.34 | P = 1.9e-03); Loss of Methylation at R209 (Pr = 0.29 | P = 6.9e-04); Gain of Loop (Pr = 0.28 | P = 0.02), ELME000155,-
COL2A1_HUMAN,T1383M,0.401,-,-,-
COL2A1_HUMAN,G870V,0.962,Loss of B-factor (Pr = 0.30 | P = 8.0e-03); Loss of O-linked glycosylation at S869 (Pr = 0.13 | P = 0.04); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000085,-
COL2A1_HUMAN,G1164S,0.938,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Phosphorylation at G1164 (Pr = 0.24 | P = 0.04); Loss of Methylation at R1163 (Pr = 0.14 | P = 0.02), ELME000053|ELME000136|ELME000155|ELME000159,-
COL2A1_HUMAN,G642V,0.939,Altered Disordered interface (Pr = 0.31 | P = 0.02); Loss of B-factor (Pr = 0.31 | P = 5.2e-03), ELME000155,-
COL2A1_HUMAN,G672A,0.907,Loss of B-factor (Pr = 0.32 | P = 3.8e-03); Gain of Loop (Pr = 0.27 | P = 0.03), None,-
COL2A1_HUMAN,G240D,0.963,Gain of Loop (Pr = 0.31 | P = 3.3e-03); Loss of B-factor (Pr = 0.26 | P = 0.05); Loss of Methylation at R242 (Pr = 0.15 | P = 0.02); Gain of O-linked glycosylation at S236 (Pr = 0.12 | P = 0.04), None,-
COL2A1_HUMAN,S1386Y,0.72,Altered Ordered interface (Pr = 0.27 | P = 6.0e-03); Gain of Allosteric site at Y1391 (Pr = 0.19 | P = 0.05); Altered Transmembrane protein (Pr = 0.15 | P = 0.02); Loss of Catalytic site at Y1391 (Pr = 0.11 | P = 0.03); Loss of N-linked glycosylation at N1388 (Pr = 0.04 | P = 0.02), ELME000053|ELME000081|ELME000084|ELME000095|ELME000120|ELME000122|ELME000202,-
COL2A1_HUMAN,G441C,0.968,Loss of B-factor (Pr = 0.33 | P = 2.3e-03); Altered Disordered interface (Pr = 0.30 | P = 0.02); Gain of Loop (Pr = 0.28 | P = 0.02); Loss of Methylation at R437 (Pr = 0.16 | P = 0.01), ELME000155,-
COL2A1_HUMAN,R550L,0.779,Altered Disordered interface (Pr = 0.32 | P = 0.02); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of ADP-ribosylation at R550 (Pr = 0.20 | P = 0.04); Loss of Methylation at R550 (Pr = 0.11 | P = 0.03), ELME000155,-
COL4A3_HUMAN,R1640K,0.273,-,-,-
COL4A3_HUMAN,I1646L,0.087,-,-,-
COL4A3_HUMAN,C1665V,0.848,Altered Disordered interface (Pr = 0.36 | P = 5.3e-03); Altered Metal binding (Pr = 0.32 | P = 0.01); Gain of Strand (Pr = 0.27 | P = 0.03); Altered DNA binding (Pr = 0.22 | P = 0.01), None,-
COL4A3_HUMAN,K1667E,0.47,-,-,-
COL4A3_HUMAN,G985V,0.928,Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Acetylation at K981 (Pr = 0.25 | P = 0.01); Gain of SUMOylation at K984 (Pr = 0.21 | P = 0.03); Loss of Methylation at K984 (Pr = 0.18 | P = 9.4e-03), ELME000106|ELME000146|ELME000167,-
COL4A3_HUMAN,C1616Y,0.882,Altered Metal binding (Pr = 0.55 | P = 3.0e-03); Altered Ordered interface (Pr = 0.41 | P = 5.5e-04); Altered Transmembrane protein (Pr = 0.36 | P = 1.5e-05); Gain of Strand (Pr = 0.27 | P = 0.03); Loss of Disulfide linkage at C1616 (Pr = 0.16 | P = 0.03); Gain of Catalytic site at C1616 (Pr = 0.12 | P = 0.03), ELME000162,-
COL4A3_HUMAN,F1581L,0.784,Altered Transmembrane protein (Pr = 0.28 | P = 4.0e-04); Altered Ordered interface (Pr = 0.24 | P = 0.03), ELME000106|ELME000137,-
COL4A3_HUMAN,N1508S,0.385,-,-,-
COL4A3_HUMAN,G333E,0.944,Gain of Loop (Pr = 0.30 | P = 6.6e-03); Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of Acetylation at K332 (Pr = 0.25 | P = 0.01); Altered Metal binding (Pr = 0.20 | P = 0.04); Loss of Methylation at K329 (Pr = 0.17 | P = 0.01), None,-
COL4A3_HUMAN,G230D,0.913,Gain of Loop (Pr = 0.27 | P = 0.02); Loss of Acetylation at K226 (Pr = 0.27 | P = 8.2e-03); Loss of SUMOylation at K226 (Pr = 0.25 | P = 9.3e-03); Loss of Methylation at K232 (Pr = 0.14 | P = 0.02), ELME000146,-
COL4A3_HUMAN,S1147F,0.19,-,-,-
COL4A3_HUMAN,G1412D,0.928,Loss of Acetylation at K1408 (Pr = 0.29 | P = 4.6e-03); Loss of Methylation at K1408 (Pr = 0.27 | P = 1.3e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of SUMOylation at K1414 (Pr = 0.25 | P = 9.4e-03), ELME000064|PS00008,-
COL4A3_HUMAN,C1548Y,0.94,Altered Metal binding (Pr = 0.46 | P = 4.7e-03); Altered Ordered interface (Pr = 0.34 | P = 5.6e-03); Altered Transmembrane protein (Pr = 0.30 | P = 1.4e-04); Gain of Strand (Pr = 0.27 | P = 0.02); Gain of Disulfide linkage at C1551 (Pr = 0.23 | P = 0.01); Gain of Catalytic site at R1547 (Pr = 0.10 | P = 0.04), ELME000062|ELME000063|ELME000064|ELME000182|ELME000220,-
COL4A3_HUMAN,G1225V,0.92,Altered Disordered interface (Pr = 0.31 | P = 0.02); Loss of B-factor (Pr = 0.31 | P = 7.3e-03); Gain of Loop (Pr = 0.26 | P = 0.05), ELME000057|ELME000155,-
COL4A3_HUMAN,G520D,0.946,, ELME000155,-
COL4A3_HUMAN,G563R,0.96,Loss of Loop (Pr = 0.28 | P = 0.02); Gain of SUMOylation at K565 (Pr = 0.21 | P = 0.03); Loss of Methylation at K565 (Pr = 0.18 | P = 0.01); Gain of Pyrrolidone carboxylic acid at Q561 (Pr = 0.05 | P = 0.03), ELME000012|ELME000093|ELME000102|ELME000103|ELME000108|ELME000231|PS00009,-
COL4A3_HUMAN,G407S,0.845,Loss of Acetylation at K403 (Pr = 0.25 | P = 0.01); Loss of SUMOylation at K403 (Pr = 0.25 | P = 9.1e-03); Altered Disordered interface (Pr = 0.17 | P = 0.04); Loss of Methylation at K411 (Pr = 0.17 | P = 0.01); Gain of Proteolytic cleavage at R406 (Pr = 0.10 | P = 0.05), ELME000012,-
COL4A3_HUMAN,G572R,0.954,Gain of Acetylation at K577 (Pr = 0.24 | P = 0.02); Loss of Methylation at K577 (Pr = 0.18 | P = 9.1e-03); Gain of SUMOylation at K577 (Pr = 0.18 | P = 0.05), ELME000052|ELME000136|ELME000155|ELME000159|ELME000358,-
COL4A3_HUMAN,S1492C,0.594,Altered Transmembrane protein (Pr = 0.10 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q1495 (Pr = 0.05 | P = 0.04), None,-
COL4A3_HUMAN,G532D,0.928,Gain of Loop (Pr = 0.31 | P = 3.7e-03); Loss of Acetylation at K537 (Pr = 0.21 | P = 0.03); Gain of SUMOylation at K537 (Pr = 0.20 | P = 0.03); Loss of Methylation at K537 (Pr = 0.16 | P = 0.01), None,-
COL4A3_HUMAN,G58S,0.899,Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Methylation at K63 (Pr = 0.18 | P = 0.01), ELME000136|ELME000159,-
COL4A3_HUMAN,G662R,0.937,Gain of Loop (Pr = 0.32 | P = 2.0e-03); Loss of B-factor (Pr = 0.31 | P = 5.8e-03), ELME000006|ELME000135|ELME000155,-
COL4A3_HUMAN,G1080R,0.949,Loss of Acetylation at K1081 (Pr = 0.35 | P = 2.1e-03); Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of SUMOylation at K1082 (Pr = 0.27 | P = 5.3e-03); Loss of Methylation at K1081 (Pr = 0.24 | P = 2.8e-03), ELME000093|ELME000102|PS00009,-
COL4A3_HUMAN,G484R,0.878,Loss of Loop (Pr = 0.38 | P = 4.8e-04); Loss of B-factor (Pr = 0.27 | P = 0.03), ELME000081|ELME000182,-
COL4A3_HUMAN,G464V,0.942,, ELME000333,-
COL4A3_HUMAN,G733R,0.94,Loss of Acetylation at K734 (Pr = 0.38 | P = 1.7e-03); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Methylation at K734 (Pr = 0.21 | P = 5.1e-03); Gain of SUMOylation at K734 (Pr = 0.21 | P = 0.03), ELME000006|ELME000102,-
COL4A3_HUMAN,G1152C,0.944,Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Methylation at R1154 (Pr = 0.13 | P = 0.03), None,-
COL4A3_HUMAN,G913R,0.95,Loss of Loop (Pr = 0.27 | P = 0.04); Loss of B-factor (Pr = 0.26 | P = 0.03); Loss of Methylation at R915 (Pr = 0.10 | P = 0.05), ELME000012|ELME000136|ELME000159|ELME000358|PS00005,-
COL4A3_HUMAN,G1415R,0.892,Loss of B-factor (Pr = 0.30 | P = 9.2e-03); Gain of SUMOylation at K1414 (Pr = 0.26 | P = 5.5e-03); Gain of Acetylation at K1414 (Pr = 0.24 | P = 0.02); Loss of Methylation at K1411 (Pr = 0.24 | P = 2.5e-03), ELME000064|ELME000100|ELME000108|PS00005|PS00006,-
COL4A3_HUMAN,P1109S,0.331,-,-,-
COL4A3_HUMAN,A1482V,0.328,-,-,-
COL4A3_HUMAN,E269K,0.077,-,-,-
COL4A3_HUMAN,D1347E,0.064,-,-,-
COL4A3_HUMAN,D1269E,0.11,-,-,-
COL4A3_HUMAN,P9S,0.063,-,-,-
COL4A3_HUMAN,T66H,0.384,-,-,-
COL4A3_HUMAN,E69L,0.618,, ELME000052|ELME000064|ELME000220|PS00006,-
COL4A3_HUMAN,G70C,0.894,Loss of B-factor (Pr = 0.28 | P = 0.02), ELME000220,-
COL4A3_HUMAN,P74N,0.402,-,-,-
COL4A3_HUMAN,Q75T,0.295,-,-,-
COL4A3_HUMAN,S89P,0.055,-,-,-
COL4A3_HUMAN,L141S,0.377,-,-,-
COL4A3_HUMAN,H225Q,0.041,-,-,-
COL4A3_HUMAN,P337L,0.235,-,-,-
COL4A3_HUMAN,P337S,0.252,-,-,-
COL4A3_HUMAN,A367V,0.061,-,-,-
COL4A3_HUMAN,T416I,0.162,-,-,-
COL4A3_HUMAN,D440G,0.175,-,-,-
COL4A3_HUMAN,H451R,0.072,-,-,-
COL4A3_HUMAN,P463T,0.2,-,-,-
COL4A3_HUMAN,P534R,0.286,-,-,-
COL4A3_HUMAN,T629M,0.104,-,-,-
COL4A3_HUMAN,Q711K,0.145,-,-,-
COL4A3_HUMAN,A740T,0.069,-,-,-
COL4A3_HUMAN,P744R,0.629,Loss of Loop (Pr = 0.28 | P = 0.01); Gain of Acetylation at K741 (Pr = 0.27 | P = 6.2e-03); Loss of Methylation at K741 (Pr = 0.18 | P = 9.2e-03); Loss of Ubiquitylation at K741 (Pr = 0.15 | P = 0.05); Gain of Proteolytic cleavage at P744 (Pr = 0.11 | P = 0.04), ELME000155,-
COL4A3_HUMAN,M867T,0.097,-,-,-
COL4A3_HUMAN,L870P,0.07,-,-,-
COL4A3_HUMAN,I900T,0.076,-,-,-
COL4A3_HUMAN,V974I,0.022,-,-,-
COL4A3_HUMAN,P1005A,0.209,-,-,-
COL4A3_HUMAN,L1010P,0.067,-,-,-
COL4A3_HUMAN,T1062G,0.376,-,-,-
COL4A3_HUMAN,D1078E,0.076,-,-,-
COL4A3_HUMAN,R1136K,0.034,-,-,-
COL4A3_HUMAN,I1153V,0.042,-,-,-
COL4A3_HUMAN,A1208V,0.062,-,-,-
COL4A3_HUMAN,Q1237R,0.11,-,-,-
COL4A3_HUMAN,P1255A,0.224,-,-,-
COL4A3_HUMAN,R1293H,0.033,-,-,-
COL4A3_HUMAN,P1341L,0.095,-,-,-
COL4A3_HUMAN,R1481Q,0.138,-,-,-
COL4A3_HUMAN,N1532D,0.059,-,-,-
COL4A3_HUMAN,T1564S,0.236,-,-,-
COL4A3_HUMAN,A1589S,0.506,Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered Transmembrane protein (Pr = 0.28 | P = 3.9e-04); Gain of B-factor (Pr = 0.28 | P = 8.1e-03), ELME000053|ELME000063|ELME000064|ELME000085|ELME000336|PS00006,-
COL4A3_HUMAN,S1600A,0.601,Altered Transmembrane protein (Pr = 0.29 | P = 2.9e-04); Gain of Loop (Pr = 0.28 | P = 0.01), ELME000063|ELME000064|ELME000136|ELME000159,-
COL4A3_HUMAN,Y1624W,0.82,Altered Ordered interface (Pr = 0.34 | P = 7.3e-03); Altered Transmembrane protein (Pr = 0.30 | P = 1.6e-04); Altered DNA binding (Pr = 0.25 | P = 9.1e-03); Altered Metal binding (Pr = 0.24 | P = 0.03); Loss of Disulfide linkage at C1622 (Pr = 0.20 | P = 0.02); Altered Stability (Pr = 0.10 | P = 0.04), ELME000053|ELME000062,-
COL4A3_HUMAN,L1636V,0.417,-,-,-
COL4A3_HUMAN,T1649A,0.506,Gain of Helix (Pr = 0.27 | P = 0.04); Altered Transmembrane protein (Pr = 0.25 | P = 1.2e-03); Gain of Methylation at K1651 (Pr = 0.09 | P = 0.04), ELME000085|ELME000239|PS00005,-
COL4A3_HUMAN,V1650W,0.67,Altered Transmembrane protein (Pr = 0.25 | P = 1.6e-03), PS00005,-
COL4A3_HUMAN,A1652T,0.357,-,-,-
COL4A3_HUMAN,L1655P,0.781,Gain of Intrinsic disorder (Pr = 0.37 | P = 0.01); Altered Transmembrane protein (Pr = 0.19 | P = 6.8e-03); Gain of Methylation at K1651 (Pr = 0.09 | P = 0.05), None,-
COL4A3_HUMAN,S1660L,0.721,Altered Metal binding (Pr = 0.26 | P = 0.02); Altered Disordered interface (Pr = 0.25 | P = 0.02); Altered DNA binding (Pr = 0.18 | P = 0.03), ELME000146,-
COL4A3_HUMAN,R1661K,0.626,Altered Disordered interface (Pr = 0.28 | P = 0.02); Altered Metal binding (Pr = 0.25 | P = 0.03); Altered DNA binding (Pr = 0.18 | P = 0.03); Altered Stability (Pr = 0.10 | P = 0.04), None,-
COL4A3_HUMAN,Q1663K,0.438,-,-,-
COL4A3_HUMAN,C1665M,0.899,Altered Disordered interface (Pr = 0.44 | P = 2.1e-03); Altered Metal binding (Pr = 0.34 | P = 9.1e-03); Gain of Intrinsic disorder (Pr = 0.32 | P = 0.03); Altered DNA binding (Pr = 0.18 | P = 0.03); Gain of N-terminal acetylation at C1665 (Pr = 0.02 | P = 6.7e-03), None,-
COL4A3_HUMAN,G712V,0.952,Altered Disordered interface (Pr = 0.31 | P = 0.02); Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Acetylation at K717 (Pr = 0.25 | P = 0.01); Loss of Methylation at K708 (Pr = 0.20 | P = 6.2e-03), None,-
COL4A3_HUMAN,L737H,0.188,-,-,-
COL4A3_HUMAN,G233E,0.929,Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Acetylation at K232 (Pr = 0.22 | P = 0.03); Gain of SUMOylation at K232 (Pr = 0.22 | P = 0.02); Loss of Methylation at K232 (Pr = 0.14 | P = 0.02), ELME000146,-
COL4A3_HUMAN,C1570R,0.817,Loss of Disulfide linkage at C1570 (Pr = 0.36 | P = 6.9e-04); Altered Transmembrane protein (Pr = 0.29 | P = 2.6e-04); Altered Ordered interface (Pr = 0.24 | P = 0.04), ELME000135|ELME000155|ELME000254,-
COL4A3_HUMAN,G1207R,0.948,Gain of SUMOylation at K1206 (Pr = 0.23 | P = 0.02); Loss of Methylation at K1206 (Pr = 0.19 | P = 7.3e-03); Loss of Ubiquitylation at K1206 (Pr = 0.16 | P = 0.04), ELME000100|ELME000108|ELME000271,-
COL4A3_HUMAN,R1496Q,0.423,-,-,-
COL4A3_HUMAN,G1089D,0.942,Loss of B-factor (Pr = 0.26 | P = 0.04), ELME000155,-
COL4A3_HUMAN,G1158R,0.96,Altered Disordered interface (Pr = 0.28 | P = 0.04); Loss of Methylation at R1154 (Pr = 0.12 | P = 0.03), ELME000102|ELME000103|ELME000108,-
COL4A3_HUMAN,G1015E,0.92,Altered Disordered interface (Pr = 0.26 | P = 0.05); Loss of Methylation at R1011 (Pr = 0.10 | P = 0.04), ELME000098|PS00008,-
COL4A3_HUMAN,V1550G,0.912,Altered Metal binding (Pr = 0.30 | P = 0.01); Loss of Strand (Pr = 0.26 | P = 0.04); Altered Transmembrane protein (Pr = 0.24 | P = 2.0e-03); Altered Stability (Pr = 0.18 | P = 0.01); Gain of Disulfide linkage at C1551 (Pr = 0.15 | P = 0.03), ELME000062|ELME000063|ELME000064|ELME000220|PS00006,-
COL4A3_HUMAN,G943R,0.914,Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Loop (Pr = 0.28 | P = 0.02); Gain of Acetylation at K939 (Pr = 0.19 | P = 0.05); Loss of Methylation at K939 (Pr = 0.15 | P = 0.02), ELME000062|ELME000133|ELME000239,-
COL4A3_HUMAN,G1077D,0.956,Loss of Acetylation at K1081 (Pr = 0.27 | P = 6.7e-03); Loss of SUMOylation at K1082 (Pr = 0.25 | P = 8.7e-03); Gain of B-factor (Pr = 0.24 | P = 0.05); Loss of Methylation at K1081 (Pr = 0.23 | P = 3.9e-03), None,-
COL4A3_HUMAN,G1137D,0.957,Gain of Loop (Pr = 0.30 | P = 5.8e-03); Loss of Methylation at R1136 (Pr = 0.09 | P = 0.05), ELME000005|ELME000155,-
COL4A3_HUMAN,G759R,0.937,Loss of Loop (Pr = 0.27 | P = 0.03), ELME000061,-
COL4A3_HUMAN,G1254R,0.924,Loss of B-factor (Pr = 0.31 | P = 6.8e-03); Gain of O-linked glycosylation at S1249 (Pr = 0.15 | P = 0.03), None,-
WFS1_HUMAN,A133T,0.525,Altered Disordered interface (Pr = 0.22 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q136 (Pr = 0.20 | P = 2.2e-03), ELME000333|ELME000336|PS00005,-
WFS1_HUMAN,F329I,0.756,Altered Transmembrane protein (Pr = 0.30 | P = 1.7e-04), ELME000148,-
WFS1_HUMAN,R818C,0.33,-,-,-
WFS1_HUMAN,M518I,0.815,Altered Transmembrane protein (Pr = 0.25 | P = 1.5e-03); Altered DNA binding (Pr = 0.15 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q520 (Pr = 0.06 | P = 0.03), None,-
WFS1_HUMAN,R611H,0.183,-,-,-
WFS1_HUMAN,A559T,0.414,-,-,-
MYO7A_HUMAN,F1927S,0.876,Gain of Intrinsic disorder (Pr = 0.38 | P = 0.01); Altered Metal binding (Pr = 0.24 | P = 0.04); Altered DNA binding (Pr = 0.18 | P = 0.03); Altered Stability (Pr = 0.09 | P = 0.05), ELME000239|ELME000313,-
MYO7A_HUMAN,Q1929A,0.51,Altered Metal binding (Pr = 0.22 | P = 0.05), ELME000313,-
MYO7A_HUMAN,Q1929R,0.433,-,-,-
MYO7A_HUMAN,L1935V,0.454,-,-,-
MYO7A_HUMAN,S1944G,0.852,, ELME000053,-
MYO7A_HUMAN,S1944Q,0.904,, ELME000053,-
MYO7A_HUMAN,A1950V,0.323,-,-,-
MYO7A_HUMAN,D1951F,0.902,Altered Transmembrane protein (Pr = 0.17 | P = 0.01), ELME000137|ELME000146,-
MYO7A_HUMAN,L1954I,0.034,-,-,-
MYO7A_HUMAN,I1983L,0.257,-,-,-
MYO7A_HUMAN,T2030S,0.203,-,-,-
MYO7A_HUMAN,V2044A,0.61,Altered Stability (Pr = 0.25 | P = 8.3e-03), ELME000002|ELME000137,-
MYO7A_HUMAN,V2082I,0.109,-,-,-
MYO7A_HUMAN,E2095D,0.313,-,-,-
MYO7A_HUMAN,A2099T,0.249,-,-,-
MYO7A_HUMAN,I2148L,0.268,-,-,-
MYO7A_HUMAN,T2155S,0.484,-,-,-
MYO7A_HUMAN,N2164M,0.859,Altered Ordered interface (Pr = 0.31 | P = 0.02); Gain of Loop (Pr = 0.28 | P = 0.01); Gain of Strand (Pr = 0.27 | P = 0.03); Gain of N-linked glycosylation at N2159 (Pr = 0.04 | P = 0.02), ELME000053|ELME000063|ELME000085,-
MYO7A_HUMAN,T2170C,0.898,Altered Metal binding (Pr = 0.33 | P = 0.01); Altered Ordered interface (Pr = 0.24 | P = 0.04); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000336,-
MYO7A_HUMAN,T2170S,0.66,Altered Ordered interface (Pr = 0.24 | P = 0.04); Altered Transmembrane protein (Pr = 0.15 | P = 0.01), ELME000336,-
MYO7A_HUMAN,I2171V,0.263,-,-,-
MYO7A_HUMAN,N2173E,0.749,Altered Metal binding (Pr = 0.23 | P = 0.05); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000064|ELME000220|ELME000331|PS00006,-
MYO7A_HUMAN,S2178P,0.869,Gain of Loop (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000062|ELME000149|ELME000155,-
MYO7A_HUMAN,K2179A,0.876,Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000062|ELME000085|ELME000149,-
MYO7A_HUMAN,T2184V,0.832,Altered Transmembrane protein (Pr = 0.11 | P = 0.04), ELME000147|ELME000233|ELME000336,-
MYO7A_HUMAN,Y2188D,0.906,Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000147|ELME000148|ELME000317|PS00006,-
MYO7A_HUMAN,T2195V,0.669,Altered Disordered interface (Pr = 0.38 | P = 5.5e-03), ELME000052|ELME000053|ELME000148|ELME000333|ELME000335|ELME000336,-
MYO7A_HUMAN,S2196A,0.381,-,-,-
MYO7A_HUMAN,M2201R,0.887,Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered Disordered interface (Pr = 0.27 | P = 0.05); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000062|ELME000063|ELME000202|PS00005,-
MYO7A_HUMAN,L2202S,0.818,Gain of Intrinsic disorder (Pr = 0.53 | P = 1.1e-03); Altered Disordered interface (Pr = 0.20 | P = 0.03); Altered DNA binding (Pr = 0.15 | P = 0.04); Gain of Ubiquitylation at K2207 (Pr = 0.15 | P = 0.05); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Altered Stability (Pr = 0.13 | P = 0.03); Gain of Methylation at K2207 (Pr = 0.10 | P = 0.04), ELME000063|ELME000202,-
MYO7A_HUMAN,A2204R,0.591,Altered Disordered interface (Pr = 0.63 | P = 3.7e-04); Gain of Intrinsic disorder (Pr = 0.44 | P = 4.8e-03); Gain of ADP-ribosylation at A2204 (Pr = 0.21 | P = 0.03); Altered DNA binding (Pr = 0.15 | P = 0.04); Loss of Methylation at K2207 (Pr = 0.09 | P = 0.05), ELME000062,-
MYO7A_HUMAN,S2206Q,0.401,-,-,-
MYO7A_HUMAN,Q2208F,0.798,Loss of Intrinsic disorder (Pr = 0.52 | P = 5.0e-03); Altered DNA binding (Pr = 0.41 | P = 1.0e-04); Altered Disordered interface (Pr = 0.32 | P = 0.02); Gain of Acetylation at K2207 (Pr = 0.19 | P = 0.04); Gain of Proteolytic cleavage at R2212 (Pr = 0.13 | P = 0.02); Loss of Methylation at K2207 (Pr = 0.09 | P = 0.05), ELME000062|ELME000336,-
MYO7A_HUMAN,R2209G,0.439,-,-,-
MYO7A_HUMAN,S2213A,0.073,-,-,-
MYO7A_HUMAN,K2215Q,0.123,-,-,-
MYO7A_HUMAN,L1197P,0.968,Gain of Allosteric site at W1192 (Pr = 0.30 | P = 1.9e-03); Loss of Helix (Pr = 0.28 | P = 0.02); Altered Ordered interface (Pr = 0.25 | P = 0.02), ELME000136|ELME000159,-
MYO7A_HUMAN,P1243R,0.662,Altered DNA binding (Pr = 0.24 | P = 7.7e-03), ELME000053|ELME000062|ELME000064|ELME000202|ELME000233|PS00005,-
MYO7A_HUMAN,R634Q,0.833,Altered Metal binding (Pr = 0.39 | P = 8.9e-03); Loss of Allosteric site at R634 (Pr = 0.26 | P = 0.01); Gain of Catalytic site at C635 (Pr = 0.18 | P = 0.01); Altered DNA binding (Pr = 0.18 | P = 0.03), ELME000146,-
MYO7A_HUMAN,E737G,0.883,Altered Metal binding (Pr = 0.25 | P = 0.01), ELME000047|ELME000333,-
MYO7A_HUMAN,G564S,0.778,Gain of Relative solvent accessibility (Pr = 0.32 | P = 4.2e-03); Altered Ordered interface (Pr = 0.30 | P = 0.02); Gain of Strand (Pr = 0.27 | P = 0.03); Altered Metal binding (Pr = 0.25 | P = 0.01); Altered Coiled coil (Pr = 0.23 | P = 0.02); Gain of Allosteric site at N569 (Pr = 0.19 | P = 0.05); Altered Transmembrane protein (Pr = 0.12 | P = 0.03); Gain of Catalytic site at E567 (Pr = 0.09 | P = 0.05); Loss of Sulfation at Y559 (Pr = 0.02 | P = 0.04), ELME000064|ELME000202|PS00006,-
MYO7A_HUMAN,G25R,0.843,Gain of ADP-ribosylation at G25 (Pr = 0.31 | P = 2.8e-03); Gain of Strand (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.26 | P = 7.4e-04), None,-
MYO7A_HUMAN,S160C,0.859,Altered Metal binding (Pr = 0.63 | P = 2.4e-03); Loss of Intrinsic disorder (Pr = 0.52 | P = 5.2e-03); Altered Ordered interface (Pr = 0.31 | P = 0.02); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Methylation at K164 (Pr = 0.23 | P = 3.3e-03); Gain of Allosteric site at E159 (Pr = 0.22 | P = 0.03); Loss of Catalytic site at S160 (Pr = 0.16 | P = 0.02), ELME000063|PS00017,-
MYO7A_HUMAN,S1920Y,0.895,Loss of Intrinsic disorder (Pr = 0.38 | P = 0.03); Altered Ordered interface (Pr = 0.36 | P = 3.1e-03); Altered Metal binding (Pr = 0.27 | P = 7.4e-03); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered DNA binding (Pr = 0.20 | P = 0.02), None,-
MYO7A_HUMAN,P1887L,0.881,Loss of Allosteric site at R1883 (Pr = 0.23 | P = 0.03); Altered DNA binding (Pr = 0.15 | P = 0.04), ELME000233|ELME000333,-
MYO7A_HUMAN,L436P,0.978,Gain of Allosteric site at F439 (Pr = 0.34 | P = 4.7e-04); Altered Ordered interface (Pr = 0.33 | P = 7.1e-03); Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Gain of Strand (Pr = 0.26 | P = 0.05); Altered Transmembrane protein (Pr = 0.24 | P = 1.5e-03); Altered Metal binding (Pr = 0.23 | P = 0.05); Altered Stability (Pr = 0.19 | P = 0.01); Loss of Catalytic site at D437 (Pr = 0.09 | P = 0.04), ELME000149|ELME000333|ELME000335,-
MYO7A_HUMAN,G955S,0.071,-,-,-
MYO7A_HUMAN,L1839P,0.962,Gain of Allosteric site at W1834 (Pr = 0.22 | P = 0.02), ELME000335,-
MYO7A_HUMAN,A2009T,0.692,Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered Stability (Pr = 0.23 | P = 9.8e-03); Loss of Allosteric site at H2014 (Pr = 0.20 | P = 0.05); Altered Transmembrane protein (Pr = 0.19 | P = 6.0e-03); Loss of Ubiquitylation at K2005 (Pr = 0.16 | P = 0.04); Altered Metal binding (Pr = 0.11 | P = 0.01), ELME000052|ELME000336,-
MYO7A_HUMAN,F464C,0.762,Altered Coiled coil (Pr = 0.38 | P = 0.01), None,-
MYO7A_HUMAN,R1168Q,0.822,Altered Ordered interface (Pr = 0.27 | P = 8.6e-03); Loss of Disulfide linkage at C1173 (Pr = 0.12 | P = 0.04), ELME000146,-
MYO7A_HUMAN,F1774V,0.88,Gain of Acetylation at K1779 (Pr = 0.19 | P = 0.05), ELME000041,-
MYO7A_HUMAN,A1224D,0.819,Gain of Loop (Pr = 0.27 | P = 0.03); Gain of B-factor (Pr = 0.26 | P = 0.02); Altered Metal binding (Pr = 0.24 | P = 0.04); Altered Transmembrane protein (Pr = 0.12 | P = 0.03); Gain of Disulfide linkage at C1227 (Pr = 0.10 | P = 0.05), None,-
MYO7A_HUMAN,T381M,0.398,-,-,-
MYO7A_HUMAN,A2204P,0.686,Gain of Intrinsic disorder (Pr = 0.39 | P = 9.8e-03); Loss of Helix (Pr = 0.29 | P = 0.01); Altered Disordered interface (Pr = 0.28 | P = 0.02); Altered DNA binding (Pr = 0.16 | P = 0.03); Loss of Methylation at K2207 (Pr = 0.09 | P = 0.05), ELME000136|ELME000159|ELME000358,-
MYO7A_HUMAN,G1942R,0.925,, ELME000053|ELME000062|ELME000197|PS00005,-
MYO7A_HUMAN,I487V,0.709,Gain of Allosteric site at W484 (Pr = 0.32 | P = 8.5e-04); Altered Metal binding (Pr = 0.27 | P = 1.7e-03); Altered Ordered interface (Pr = 0.27 | P = 0.05); Altered Transmembrane protein (Pr = 0.26 | P = 9.1e-04); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Gain of Catalytic site at N492 (Pr = 0.12 | P = 0.03); Altered Coiled coil (Pr = 0.11 | P = 0.04), ELME000193,-
MYO7A_HUMAN,D75H,0.826,Loss of Helix (Pr = 0.27 | P = 0.05); Loss of Loop (Pr = 0.27 | P = 0.03), None,-
MYO7A_HUMAN,A457V,0.774,Altered Coiled coil (Pr = 0.32 | P = 0.01); Altered Metal binding (Pr = 0.26 | P = 0.03), None,-
MYO7A_HUMAN,R848Q,0.796,Altered Disordered interface (Pr = 0.48 | P = 3.3e-03), ELME000134,-
MYO7A_HUMAN,G1218R,0.33,-,-,-
MYO7A_HUMAN,V1854M,0.429,-,-,-
MYO7A_HUMAN,E968D,0.483,-,-,-
MYO7A_HUMAN,T1423M,0.258,-,-,-
MYO7A_HUMAN,V1918E,0.952,Gain of Intrinsic disorder (Pr = 0.45 | P = 3.8e-03); Altered Metal binding (Pr = 0.33 | P = 0.01); Altered Ordered interface (Pr = 0.31 | P = 0.02); Gain of B-factor (Pr = 0.29 | P = 4.0e-03); Loss of Strand (Pr = 0.26 | P = 0.03); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Altered DNA binding (Pr = 0.19 | P = 0.03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000117,-
MYO7A_HUMAN,L618R,0.943,Gain of Intrinsic disorder (Pr = 0.37 | P = 0.01), ELME000106|ELME000125|ELME000146|ELME000149|ELME000335,-
MYO7A_HUMAN,I134N,0.944,Gain of Allosteric site at H133 (Pr = 0.36 | P = 2.8e-04); Gain of Relative solvent accessibility (Pr = 0.34 | P = 2.0e-03); Altered Ordered interface (Pr = 0.28 | P = 0.05); Altered Metal binding (Pr = 0.25 | P = 7.3e-03); Altered DNA binding (Pr = 0.22 | P = 0.01); Gain of Catalytic site at H133 (Pr = 0.16 | P = 0.02), ELME000058,-
MYO7A_HUMAN,N207S,0.804,Altered Disordered interface (Pr = 0.29 | P = 0.03); Gain of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered DNA binding (Pr = 0.27 | P = 3.6e-03); Altered Metal binding (Pr = 0.26 | P = 9.6e-03); Loss of Allosteric site at R212 (Pr = 0.26 | P = 0.01); Gain of Methylation at K203 (Pr = 0.23 | P = 1.6e-03); Gain of Catalytic site at S210 (Pr = 0.20 | P = 0.01); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Gain of N-linked glycosylation at N209 (Pr = 0.03 | P = 0.03), ELME000053|ELME000063,-
MYO7A_HUMAN,P131L,0.772,Altered Metal binding (Pr = 0.38 | P = 1.7e-03); Altered Ordered interface (Pr = 0.38 | P = 2.3e-03); Loss of Allosteric site at H133 (Pr = 0.31 | P = 3.3e-03); Gain of Helix (Pr = 0.30 | P = 8.4e-03); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered DNA binding (Pr = 0.20 | P = 0.02); Loss of Catalytic site at H133 (Pr = 0.10 | P = 0.04), ELME000058,-
MYO7A_HUMAN,V10A,0.895,Altered Metal binding (Pr = 0.31 | P = 0.01); Altered Stability (Pr = 0.18 | P = 0.01); Altered Transmembrane protein (Pr = 0.15 | P = 0.01), None,-
MYO7A_HUMAN,R241H,0.899,Altered Metal binding (Pr = 0.30 | P = 2.4e-03); Loss of Allosteric site at R241 (Pr = 0.30 | P = 4.7e-03); Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered DNA binding (Pr = 0.25 | P = 7.0e-03); Gain of Catalytic site at E238 (Pr = 0.10 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q245 (Pr = 0.06 | P = 0.03), ELME000336,-
MYO7A_HUMAN,L366P,0.844,Gain of Intrinsic disorder (Pr = 0.34 | P = 0.02); Gain of B-factor (Pr = 0.28 | P = 7.9e-03); Altered Stability (Pr = 0.09 | P = 0.05), ELME000053,-
MYO7A_HUMAN,G1982R,0.868,Loss of Loop (Pr = 0.27 | P = 0.04); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Gain of ADP-ribosylation at G1982 (Pr = 0.21 | P = 0.02); Altered Transmembrane protein (Pr = 0.18 | P = 8.7e-03); Gain of Proteolytic cleavage at D1981 (Pr = 0.15 | P = 0.01), PS00008,-
MYO7A_HUMAN,G660R,0.951,Loss of Allosteric site at R657 (Pr = 0.30 | P = 4.3e-03); Altered Metal binding (Pr = 0.29 | P = 5.1e-03); Loss of Strand (Pr = 0.29 | P = 3.8e-03); Altered Disordered interface (Pr = 0.27 | P = 0.01); Gain of Helix (Pr = 0.27 | P = 0.03); Altered DNA binding (Pr = 0.24 | P = 8.6e-03); Loss of Catalytic site at R657 (Pr = 0.20 | P = 0.01), ELME000051|ELME000062|ELME000085|ELME000120|ELME000233|ELME000336|PS00008,-
MYO7A_HUMAN,V1667E,0.888,Loss of Strand (Pr = 0.27 | P = 0.03); Altered Transmembrane protein (Pr = 0.26 | P = 1.3e-03); Altered Stability (Pr = 0.22 | P = 0.01); Gain of Sulfation at Y1668 (Pr = 0.03 | P = 0.02), ELME000052|ELME000064|ELME000220|ELME000239|ELME000337|PS00006,-
MYO7A_HUMAN,P638H,0.91,Altered Metal binding (Pr = 0.39 | P = 8.9e-03); Gain of Allosteric site at R634 (Pr = 0.23 | P = 0.02); Gain of Acetylation at K642 (Pr = 0.23 | P = 0.02); Altered DNA binding (Pr = 0.18 | P = 0.03); Loss of Catalytic site at C635 (Pr = 0.08 | P = 0.05), ELME000146,-
MYO7A_HUMAN,A1770D,0.923,, ELME000202|PS00006,-
MYO7A_HUMAN,R244C,0.768,Altered Ordered interface (Pr = 0.34 | P = 5.6e-03); Gain of Allosteric site at R241 (Pr = 0.29 | P = 2.9e-03); Altered DNA binding (Pr = 0.24 | P = 0.01); Gain of Catalytic site at R241 (Pr = 0.09 | P = 0.04); Loss of Pyrrolidone carboxylic acid at Q245 (Pr = 0.06 | P = 0.03), ELME000146|PS00007,-
MYO7A_HUMAN,G2214S,0.088,-,-,-
MYO7A_HUMAN,H1029R,0.724,Gain of Helix (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.17 | P = 9.5e-03); Loss of Sulfation at Y1028 (Pr = 0.03 | P = 0.02), None,-
MYO7A_HUMAN,Y1719C,0.738,Loss of Phosphorylation at Y1719 (Pr = 0.47 | P = 5.0e-03); Altered Disordered interface (Pr = 0.30 | P = 0.02); Gain of Helix (Pr = 0.28 | P = 0.03); Loss of Sulfation at Y1721 (Pr = 0.05 | P = 9.1e-03), ELME000120,-
MYO7A_HUMAN,M1L,0.947,Loss of N-terminal acetylation at M1 (Pr = 0.24 | P = 5.6e-04); Altered Metal binding (Pr = 0.05 | P = 0.04), ELME000355,-
MYO7A_HUMAN,M1P,0.977,Gain of Intrinsic disorder (Pr = 0.34 | P = 0.02); Loss of N-terminal acetylation at M1 (Pr = 0.24 | P = 5.6e-04); Altered Metal binding (Pr = 0.05 | P = 0.04), None,-
MYO7A_HUMAN,I3P,0.879,Gain of Intrinsic disorder (Pr = 0.49 | P = 1.9e-03); Gain of Loop (Pr = 0.27 | P = 0.04); Altered Metal binding (Pr = 0.23 | P = 0.04); Altered Stability (Pr = 0.23 | P = 9.4e-03); Loss of N-terminal acetylation at M1 (Pr = 0.18 | P = 9.6e-04), ELME000118,-
MYO7A_HUMAN,L4I,0.454,-,-,-
MYO7A_HUMAN,Q5D,0.764,Altered Metal binding (Pr = 0.25 | P = 0.04); Loss of N-terminal acetylation at M1 (Pr = 0.19 | P = 9.1e-04), ELME000333,-
MYO7A_HUMAN,Q5F,0.891,Loss of Intrinsic disorder (Pr = 0.62 | P = 1.1e-03); Altered Metal binding (Pr = 0.42 | P = 5.9e-03); Gain of Strand (Pr = 0.26 | P = 0.05); Loss of N-terminal acetylation at M1 (Pr = 0.22 | P = 7.1e-04), None,-
MYO7A_HUMAN,Q5Y,0.88,Loss of Intrinsic disorder (Pr = 0.51 | P = 6.3e-03); Altered Metal binding (Pr = 0.40 | P = 6.5e-03); Loss of N-terminal acetylation at M1 (Pr = 0.22 | P = 7.3e-04); Gain of Sulfation at Q5 (Pr = 0.01 | P = 0.04), None,-
MYO7A_HUMAN,R15Q,0.224,-,-,-
MYO7A_HUMAN,E19D,0.538,Altered Transmembrane protein (Pr = 0.23 | P = 1.9e-03); Gain of Pyrrolidone carboxylic acid at Q18 (Pr = 0.05 | P = 0.04), None,-
MYO7A_HUMAN,D32E,0.309,-,-,-
MYO7A_HUMAN,Q37H,0.492,-,-,-
MYO7A_HUMAN,D43G,0.104,-,-,-
MYO7A_HUMAN,Q51H,0.538,Altered Transmembrane protein (Pr = 0.25 | P = 1.3e-03); Altered Metal binding (Pr = 0.22 | P = 0.02); Loss of N-linked glycosylation at N52 (Pr = 0.09 | P = 0.01); Loss of GPI-anchor amidation at N52 (Pr = 0.01 | P = 0.03), ELME000070|ELME000136|ELME000159,-
MYO7A_HUMAN,N52H,0.24,-,-,-
MYO7A_HUMAN,N52S,0.14,-,-,-
MYO7A_HUMAN,A53S,0.304,-,-,-
MYO7A_HUMAN,E68Q,0.693,, ELME000148,-
MYO7A_HUMAN,S112P,0.568,Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.27 | P = 5.7e-04); Gain of Allosteric site at Y114 (Pr = 0.27 | P = 5.2e-03); Altered Metal binding (Pr = 0.26 | P = 0.03); Altered Ordered interface (Pr = 0.26 | P = 0.01); Loss of Catalytic site at Y108 (Pr = 0.12 | P = 0.03), ELME000063|ELME000136|ELME000159|ELME000249,-
MYO7A_HUMAN,K146Q,0.323,-,-,-
COL4A5_HUMAN,G609A,0.897,Loss of B-factor (Pr = 0.28 | P = 0.02), None,-
COL4A5_HUMAN,G1164A,0.921,Loss of B-factor (Pr = 0.32 | P = 4.4e-03); Loss of Methylation at K1168 (Pr = 0.24 | P = 2.7e-03); Gain of Acetylation at K1166 (Pr = 0.22 | P = 0.03); Gain of SUMOylation at K1166 (Pr = 0.21 | P = 0.03), None,-
COL4A5_HUMAN,G533E,0.937,, None,-
COL4A5_HUMAN,G204D,0.955,Gain of Loop (Pr = 0.33 | P = 1.3e-03); Loss of B-factor (Pr = 0.26 | P = 0.04), ELME000155,-
COL4A5_HUMAN,G805E,0.928,Gain of Loop (Pr = 0.28 | P = 0.02); Altered Metal binding (Pr = 0.12 | P = 0.03), None,-
COL4A5_HUMAN,G669R,0.93,Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Loop (Pr = 0.27 | P = 0.03); Gain of Acetylation at K664 (Pr = 0.27 | P = 7.1e-03); Loss of Methylation at K664 (Pr = 0.14 | P = 0.02), ELME000006,-
COL4A5_HUMAN,G1255R,0.951,Loss of Loop (Pr = 0.32 | P = 3.4e-03); Loss of B-factor (Pr = 0.30 | P = 8.9e-03); Loss of Methylation at K1251 (Pr = 0.27 | P = 1.2e-03); Gain of Acetylation at K1251 (Pr = 0.24 | P = 0.02); Gain of SUMOylation at K1251 (Pr = 0.23 | P = 0.02), ELME000155,-
COL4A5_HUMAN,G1241D,0.915,Gain of Loop (Pr = 0.32 | P = 2.0e-03); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of O-linked glycosylation at S1242 (Pr = 0.16 | P = 0.03), ELME000136|ELME000155|ELME000159,-
COL4A5_HUMAN,G1241V,0.91,Loss of B-factor (Pr = 0.37 | P = 4.9e-04); Gain of Loop (Pr = 0.27 | P = 0.04); Gain of O-linked glycosylation at S1242 (Pr = 0.20 | P = 0.02), ELME000136|ELME000155|ELME000159,-
COL4A5_HUMAN,P739S,0.196,-,-,-
COL4A5_HUMAN,G420R,0.863,Altered Disordered interface (Pr = 0.32 | P = 0.02); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of O-linked glycosylation at S417 (Pr = 0.14 | P = 0.04), ELME000155,-
COL4A5_HUMAN,G174R,0.961,Altered Disordered interface (Pr = 0.28 | P = 0.03); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Methylation at K170 (Pr = 0.20 | P = 6.0e-03); Loss of Sulfation at Y175 (Pr = 0.02 | P = 0.03), ELME000005|ELME000095|ELME000122|ELME000155,-
COL4A5_HUMAN,G1089E,0.94,Gain of Sulfation at Y1090 (Pr = 0.02 | P = 0.03), None,-
COL4A5_HUMAN,G696D,0.947,Gain of Loop (Pr = 0.30 | P = 4.4e-03); Loss of SUMOylation at K698 (Pr = 0.25 | P = 9.4e-03); Gain of Acetylation at K698 (Pr = 0.19 | P = 0.05); Loss of Methylation at K698 (Pr = 0.18 | P = 9.6e-03), ELME000064|PS00008,-
COL4A5_HUMAN,G878V,0.947,Loss of B-factor (Pr = 0.32 | P = 3.7e-03), ELME000136|ELME000155|ELME000159,-
COL4A5_HUMAN,G1066V,0.942,Loss of B-factor (Pr = 0.33 | P = 2.3e-03); Gain of Acetylation at K1062 (Pr = 0.23 | P = 0.02); Gain of SUMOylation at K1065 (Pr = 0.20 | P = 0.03); Loss of Methylation at K1062 (Pr = 0.19 | P = 7.4e-03); Gain of O-linked glycosylation at S1071 (Pr = 0.13 | P = 0.04), None,-
COL4A5_HUMAN,G772S,0.92,Gain of Phosphorylation at G772 (Pr = 0.36 | P = 8.6e-03); Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Acetylation at K768 (Pr = 0.25 | P = 0.01); Loss of SUMOylation at K768 (Pr = 0.18 | P = 0.05); Loss of Methylation at K768 (Pr = 0.17 | P = 0.01), ELME000136|ELME000146|ELME000159|PS00005,-
COL4A5_HUMAN,G1015E,0.943,Altered Disordered interface (Pr = 0.30 | P = 0.02), ELME000149,-
COL4A5_HUMAN,G1182R,0.961,Loss of Loop (Pr = 0.30 | P = 6.1e-03); Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of SUMOylation at K1181 (Pr = 0.26 | P = 5.9e-03); Gain of Acetylation at K1181 (Pr = 0.21 | P = 0.04); Loss of Methylation at K1181 (Pr = 0.20 | P = 7.2e-03), ELME000005|ELME000100|ELME000108|ELME000155,-
COL4A5_HUMAN,G54D,0.96,Gain of Loop (Pr = 0.29 | P = 7.2e-03), None,-
COL4A5_HUMAN,F222C,0.842,Gain of B-factor (Pr = 0.25 | P = 0.03); Loss of Acetylation at K226 (Pr = 0.24 | P = 0.02); Loss of Methylation at K226 (Pr = 0.19 | P = 8.3e-03), None,-
COL4A5_HUMAN,G852V,0.911,Loss of B-factor (Pr = 0.32 | P = 5.0e-03); Gain of Loop (Pr = 0.27 | P = 0.03), ELME000155,-
COL4A5_HUMAN,G189V,0.942,Gain of O-linked glycosylation at T188 (Pr = 0.33 | P = 4.2e-03); Altered Disordered interface (Pr = 0.29 | P = 0.03), None,-
COL4A5_HUMAN,G609R,0.944,Loss of Loop (Pr = 0.32 | P = 4.1e-03); Loss of B-factor (Pr = 0.28 | P = 0.02), None,-
COL4A5_HUMAN,G621V,0.915,Altered Disordered interface (Pr = 0.31 | P = 0.02); Loss of B-factor (Pr = 0.29 | P = 0.01), ELME000155,-
COL4A5_HUMAN,G1170S,0.952,Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Methylation at K1168 (Pr = 0.24 | P = 2.6e-03); Loss of Acetylation at K1166 (Pr = 0.21 | P = 0.04); Loss of SUMOylation at K1166 (Pr = 0.20 | P = 0.03), ELME000202,-
COL4A5_HUMAN,G1018D,0.941,Altered Disordered interface (Pr = 0.28 | P = 0.04); Loss of Loop (Pr = 0.26 | P = 0.05), None,-
COL4A5_HUMAN,K748N,0.608,Gain of Loop (Pr = 0.29 | P = 8.4e-03); Loss of Methylation at K748 (Pr = 0.25 | P = 1.9e-03); Loss of Acetylation at K748 (Pr = 0.24 | P = 0.02); Loss of SUMOylation at K748 (Pr = 0.18 | P = 0.05), ELME000002,-
COL4A5_HUMAN,G1083D,0.945,Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of Loop (Pr = 0.26 | P = 0.05); Loss of Methylation at K1082 (Pr = 0.23 | P = 3.5e-03), ELME000002|ELME000005|ELME000155,-
COL4A5_HUMAN,G828E,0.939,Gain of Loop (Pr = 0.35 | P = 5.7e-04); Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of B-factor (Pr = 0.26 | P = 0.03), ELME000155,-
COL4A5_HUMAN,G337S,0.91,Gain of Phosphorylation at G337 (Pr = 0.37 | P = 7.6e-03); Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Methylation at K333 (Pr = 0.25 | P = 2.4e-03); Loss of Acetylation at K333 (Pr = 0.21 | P = 0.03); Loss of SUMOylation at K333 (Pr = 0.19 | P = 0.04), ELME000136|ELME000155|ELME000159,-
COL4A5_HUMAN,G609V,0.951,Loss of B-factor (Pr = 0.30 | P = 7.6e-03), None,-
COL4A5_HUMAN,G1241R,0.921,Loss of B-factor (Pr = 0.31 | P = 5.8e-03); Loss of Loop (Pr = 0.29 | P = 9.1e-03); Gain of ADP-ribosylation at G1241 (Pr = 0.21 | P = 0.03); Loss of O-linked glycosylation at S1242 (Pr = 0.16 | P = 0.03); Gain of Methylation at G1241 (Pr = 0.09 | P = 0.05), ELME000006|ELME000135|ELME000136|ELME000155|ELME000159,-
COL4A5_HUMAN,G796V,0.957,Loss of B-factor (Pr = 0.32 | P = 5.2e-03); Altered Disordered interface (Pr = 0.28 | P = 0.04); Gain of Acetylation at K798 (Pr = 0.19 | P = 0.04); Loss of Methylation at K798 (Pr = 0.19 | P = 8.5e-03), None,-
COL4A5_HUMAN,C1638Y,0.95,Altered Metal binding (Pr = 0.65 | P = 1.5e-03); Altered Ordered interface (Pr = 0.41 | P = 6.3e-04); Loss of Disulfide linkage at C1638 (Pr = 0.36 | P = 6.8e-04); Altered Transmembrane protein (Pr = 0.30 | P = 1.3e-04); Gain of Loop (Pr = 0.27 | P = 0.04), ELME000062|ELME000162,-
COL4A5_HUMAN,G923R,0.961,Loss of Loop (Pr = 0.28 | P = 0.02); Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Acetylation at K922 (Pr = 0.25 | P = 0.01); Loss of Methylation at K922 (Pr = 0.18 | P = 0.01); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000100|ELME000108,-
COL4A5_HUMAN,G1448D,0.951,Loss of B-factor (Pr = 0.26 | P = 0.04), ELME000155,-
COL4A5_HUMAN,P300L,0.392,-,-,-
COL4A5_HUMAN,G1211R,0.951,Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of B-factor (Pr = 0.26 | P = 0.05), ELME000155|PS00008,-
COL4A5_HUMAN,G313S,0.94,Altered Disordered interface (Pr = 0.27 | P = 0.05); Altered Metal binding (Pr = 0.10 | P = 0.05), None,-
COL4A5_HUMAN,G1205S,0.934,Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of B-factor (Pr = 0.27 | P = 0.02); Loss of Methylation at K1204 (Pr = 0.25 | P = 1.9e-03); Loss of Acetylation at K1204 (Pr = 0.22 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q1203 (Pr = 0.04 | P = 0.05), ELME000053,-
COL4A5_HUMAN,G672R,0.933,Loss of B-factor (Pr = 0.27 | P = 0.03), ELME000006|ELME000012|ELME000102|ELME000108|ELME000233,-
COL4A5_HUMAN,G1354R,0.953,Loss of Loop (Pr = 0.30 | P = 5.8e-03); Loss of B-factor (Pr = 0.28 | P = 0.02), ELME000155,-
COL4A5_HUMAN,G763R,0.94,Loss of B-factor (Pr = 0.30 | P = 0.01); Loss of Loop (Pr = 0.29 | P = 9.4e-03); Gain of Acetylation at K768 (Pr = 0.28 | P = 4.9e-03); Altered Disordered interface (Pr = 0.27 | P = 0.04); Gain of SUMOylation at K768 (Pr = 0.19 | P = 0.04); Loss of Methylation at K768 (Pr = 0.17 | P = 0.01), ELME000006|ELME000135,-
COL4A5_HUMAN,G1223D,0.953,Gain of Loop (Pr = 0.30 | P = 5.0e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Methylation at K1222 (Pr = 0.18 | P = 0.01), ELME000002,-
COL4A5_HUMAN,G638D,0.95,Loss of Acetylation at K634 (Pr = 0.28 | P = 5.9e-03); Loss of Methylation at K634 (Pr = 0.20 | P = 6.4e-03), None,-
COL4A5_HUMAN,G641E,0.93,, ELME000155,-
COL4A5_HUMAN,G911E,0.954,Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of O-linked glycosylation at S916 (Pr = 0.12 | P = 0.04), None,-
COL4A5_HUMAN,G558D,0.919,Gain of Loop (Pr = 0.27 | P = 0.04); Gain of B-factor (Pr = 0.25 | P = 0.03); Loss of SUMOylation at K560 (Pr = 0.25 | P = 8.8e-03); Loss of Acetylation at K557 (Pr = 0.22 | P = 0.03); Loss of Methylation at K557 (Pr = 0.17 | P = 0.01), None,-
COL4A5_HUMAN,G1140V,0.964,Loss of B-factor (Pr = 0.34 | P = 1.5e-03); Altered Metal binding (Pr = 0.12 | P = 0.03); Gain of O-linked glycosylation at S1136 (Pr = 0.12 | P = 0.04), ELME000155,-
COL4A5_HUMAN,G893V,0.963,Gain of SUMOylation at K895 (Pr = 0.27 | P = 5.0e-03); Loss of Acetylation at K895 (Pr = 0.24 | P = 0.02); Loss of Methylation at K895 (Pr = 0.20 | P = 6.8e-03); Gain of O-linked glycosylation at S889 (Pr = 0.11 | P = 0.05), ELME000064|ELME000220,-
COL4A5_HUMAN,G374A,0.906,Loss of B-factor (Pr = 0.26 | P = 0.05); Gain of SUMOylation at K370 (Pr = 0.25 | P = 9.3e-03); Loss of Acetylation at K370 (Pr = 0.21 | P = 0.03); Loss of Methylation at K370 (Pr = 0.16 | P = 0.01), None,-
COL4A5_HUMAN,G545V,0.946,Loss of B-factor (Pr = 0.33 | P = 2.3e-03); Gain of SUMOylation at K544 (Pr = 0.30 | P = 3.3e-03); Gain of Loop (Pr = 0.29 | P = 9.6e-03); Loss of Methylation at K544 (Pr = 0.20 | P = 6.6e-03); Gain of Ubiquitylation at K544 (Pr = 0.16 | P = 0.04); Gain of Proteolytic cleavage at D549 (Pr = 0.13 | P = 0.02), ELME000064|PS00006,-
COL4A5_HUMAN,G567E,0.947,, ELME000136|ELME000155|ELME000159,-
COL4A5_HUMAN,G406D,0.949,Gain of B-factor (Pr = 0.25 | P = 0.03); Loss of Acetylation at K408 (Pr = 0.20 | P = 0.04); Gain of SUMOylation at K408 (Pr = 0.20 | P = 0.04); Loss of Methylation at K408 (Pr = 0.19 | P = 7.6e-03); Gain of Pyrrolidone carboxylic acid at Q407 (Pr = 0.05 | P = 0.03), None,-
COL4A5_HUMAN,G1015V,0.949,Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of B-factor (Pr = 0.27 | P = 0.02), None,-
COL4A5_HUMAN,G400E,0.923,Loss of B-factor (Pr = 0.26 | P = 0.04), ELME000155,-
COL4A5_HUMAN,G1205V,0.961,Loss of B-factor (Pr = 0.33 | P = 2.3e-03); Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of Methylation at K1204 (Pr = 0.27 | P = 1.2e-03); Gain of Acetylation at K1204 (Pr = 0.21 | P = 0.03); Gain of SUMOylation at K1204 (Pr = 0.19 | P = 0.04); Gain of O-linked glycosylation at S1201 (Pr = 0.13 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q1203 (Pr = 0.05 | P = 0.04), None,-
COL4A5_HUMAN,G896C,0.955,Loss of Acetylation at K895 (Pr = 0.29 | P = 4.9e-03); Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of SUMOylation at K895 (Pr = 0.26 | P = 6.8e-03); Loss of Methylation at K895 (Pr = 0.21 | P = 5.1e-03), ELME000064|ELME000220|PS00006,-
COL4A5_HUMAN,G802R,0.941,Loss of Loop (Pr = 0.27 | P = 0.03); Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of Acetylation at K798 (Pr = 0.23 | P = 0.02); Loss of Methylation at K798 (Pr = 0.19 | P = 8.7e-03); Altered Metal binding (Pr = 0.10 | P = 0.05), None,-
COL4A5_HUMAN,G1360S,0.924,Loss of B-factor (Pr = 0.27 | P = 0.02); Gain of Loop (Pr = 0.26 | P = 0.04); Gain of O-linked glycosylation at S1365 (Pr = 0.17 | P = 0.02), None,-
COL4A5_HUMAN,G183V,0.947,Altered Disordered interface (Pr = 0.29 | P = 0.03); Gain of O-linked glycosylation at T188 (Pr = 0.21 | P = 0.01), ELME000237,-
COL4A5_HUMAN,G213E,0.941,Gain of Loop (Pr = 0.27 | P = 0.02); Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of SUMOylation at K215 (Pr = 0.25 | P = 7.4e-03); Loss of Methylation at K215 (Pr = 0.21 | P = 5.6e-03), None,-
COL4A5_HUMAN,G1412R,0.956,, ELME000012,-
COL4A5_HUMAN,G941D,0.948,Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of SUMOylation at K943 (Pr = 0.26 | P = 7.4e-03); Loss of Methylation at K943 (Pr = 0.24 | P = 2.6e-03); Loss of Acetylation at K940 (Pr = 0.22 | P = 0.03), ELME000064,-
COL4A5_HUMAN,G204V,0.956,Loss of B-factor (Pr = 0.31 | P = 5.4e-03); Gain of Loop (Pr = 0.28 | P = 0.02), ELME000155,-
COL4A5_HUMAN,G681D,0.944,Gain of Loop (Pr = 0.30 | P = 6.4e-03); Gain of B-factor (Pr = 0.25 | P = 0.03), None,-
COL4A5_HUMAN,G1433V,0.959,Loss of B-factor (Pr = 0.26 | P = 0.04), ELME000052|PS00008,-
COL4A5_HUMAN,G1036V,0.954,Altered Disordered interface (Pr = 0.31 | P = 0.02), None,-
COL4A5_HUMAN,G740E,0.938,Altered Disordered interface (Pr = 0.28 | P = 0.04); Gain of Loop (Pr = 0.28 | P = 0.02); Loss of B-factor (Pr = 0.27 | P = 0.03), ELME000155,-
COL4A5_HUMAN,G1060E,0.914,Gain of Loop (Pr = 0.30 | P = 5.4e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Acetylation at K1062 (Pr = 0.23 | P = 0.02); Gain of SUMOylation at K1062 (Pr = 0.21 | P = 0.03); Loss of Methylation at K1062 (Pr = 0.19 | P = 8.1e-03), ELME000118,-
COL4A5_HUMAN,G573D,0.958,, ELME000155,-
COL4A5_HUMAN,G1205D,0.955,Gain of Loop (Pr = 0.30 | P = 4.6e-03); Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of Methylation at K1204 (Pr = 0.26 | P = 1.6e-03); Loss of Acetylation at K1204 (Pr = 0.21 | P = 0.03); Altered Metal binding (Pr = 0.11 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q1203 (Pr = 0.05 | P = 0.04), None,-
COL4A5_HUMAN,G644V,0.925,Loss of B-factor (Pr = 0.29 | P = 0.01), ELME000155,-
COL4A5_HUMAN,G746E,0.943,Altered Disordered interface (Pr = 0.27 | P = 0.05); Gain of Loop (Pr = 0.27 | P = 0.03); Gain of Acetylation at K748 (Pr = 0.19 | P = 0.04); Loss of Methylation at K748 (Pr = 0.19 | P = 8.1e-03), None,-
COL4A5_HUMAN,G273R,0.95,Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Loop (Pr = 0.27 | P = 0.03); Loss of Methylation at R275 (Pr = 0.11 | P = 0.03), ELME000006|ELME000012|ELME000135,-
COL4A5_HUMAN,G1448A,0.92,Loss of B-factor (Pr = 0.29 | P = 0.01), ELME000155,-
COL4A5_HUMAN,P324S,0.604,Gain of Phosphorylation at Y320 (Pr = 0.27 | P = 0.02); Loss of B-factor (Pr = 0.26 | P = 0.05); Loss of Sulfation at Y320 (Pr = 0.04 | P = 0.01), ELME000006|ELME000085|ELME000239|ELME000321|PS00005|PS00006,-
COL4A5_HUMAN,I450M,0.105,-,-,-
COL4A5_HUMAN,R777H,0.204,-,-,-
COL4A5_HUMAN,P396L,0.458,-,-,-
COL4A5_HUMAN,L12W,0.536,Altered Signal peptide (Pr = 0.12 | P = 2.2e-03), None,-
COL4A5_HUMAN,L19P,0.863,Gain of Loop (Pr = 0.27 | P = 0.03); Gain of Pyrrolidone carboxylic acid at Q22 (Pr = 0.16 | P = 4.1e-03); Altered Signal peptide (Pr = 0.02 | P = 6.8e-03), ELME000136|ELME000159|ELME000336,-
COL4A5_HUMAN,R74Q,0.189,-,-,-
COL4A5_HUMAN,I251T,0.215,-,-,-
COL4A5_HUMAN,E284V,0.057,-,-,-
COL4A5_HUMAN,T336I,0.042,-,-,-
COL4A5_HUMAN,I361M,0.133,-,-,-
COL4A5_HUMAN,A390T,0.037,-,-,-
COL4A5_HUMAN,V392A,0.126,-,-,-
COL4A5_HUMAN,M393V,0.068,-,-,-
COL4A5_HUMAN,P446R,0.284,-,-,-
COL4A5_HUMAN,P453A,0.045,-,-,-
COL4A5_HUMAN,V631A,0.099,-,-,-
COL4A5_HUMAN,I733T,0.1,-,-,-
COL4A5_HUMAN,P747L,0.135,-,-,-
COL4A5_HUMAN,L755V,0.098,-,-,-
COL4A5_HUMAN,A770I,0.126,-,-,-
COL4A5_HUMAN,L791I,0.058,-,-,-
COL4A5_HUMAN,P797S,0.185,-,-,-
MYO7A_HUMAN,R395C,0.946,Altered Metal binding (Pr = 0.58 | P = 3.1e-03); Loss of Allosteric site at R395 (Pr = 0.54 | P = 4.4e-05); Altered Ordered interface (Pr = 0.34 | P = 6.0e-03); Altered Disordered interface (Pr = 0.29 | P = 0.03); Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.02); Loss of Acetylation at K400 (Pr = 0.26 | P = 0.01); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Loss of Catalytic site at R395 (Pr = 0.09 | P = 0.05); Gain of Pyrrolidone carboxylic acid at Q390 (Pr = 0.08 | P = 0.02), ELME000146|ELME000321,-
MYO7A_HUMAN,S1605F,0.847,Gain of Loop (Pr = 0.27 | P = 0.04); Altered Ordered interface (Pr = 0.25 | P = 0.02); Loss of ADP-ribosylation at R1604 (Pr = 0.21 | P = 0.03); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Altered DNA binding (Pr = 0.15 | P = 0.05), ELME000008|ELME000100|ELME000108|ELME000146|ELME000193|ELME000233|ELME000271|ELME000278|PS00004,-
MYO7A_HUMAN,K527R,0.601,, ELME000202,-
MYO7A_HUMAN,R1168P,0.96,Loss of Helix (Pr = 0.30 | P = 6.3e-03); Altered Ordered interface (Pr = 0.25 | P = 0.02); Loss of Disulfide linkage at C1173 (Pr = 0.12 | P = 0.04), ELME000146|ELME000155,-
MYO7A_HUMAN,R616W,0.609,Loss of Intrinsic disorder (Pr = 0.40 | P = 0.02); Loss of Helix (Pr = 0.27 | P = 0.04), ELME000100|ELME000106|ELME000108|ELME000149,-
MYO7A_HUMAN,N106K,0.936,Altered Ordered interface (Pr = 0.31 | P = 0.02); Gain of Allosteric site at N106 (Pr = 0.29 | P = 2.5e-03); Altered Transmembrane protein (Pr = 0.28 | P = 3.9e-04); Altered Metal binding (Pr = 0.20 | P = 0.04); Altered DNA binding (Pr = 0.17 | P = 0.03); Gain of Catalytic site at Y108 (Pr = 0.13 | P = 0.03); Gain of Methylation at N106 (Pr = 0.10 | P = 0.04), None,-
MYO7A_HUMAN,D2010N,0.814,Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Loss of Allosteric site at Y2015 (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.19 | P = 6.8e-03); Loss of Ubiquitylation at K2005 (Pr = 0.16 | P = 0.04); Gain of Catalytic site at Y2015 (Pr = 0.15 | P = 0.02); Altered Metal binding (Pr = 0.11 | P = 8.0e-03); Loss of Sulfation at Y2015 (Pr = 0.02 | P = 0.03), ELME000122|ELME000336,-
MYO7A_HUMAN,L2181P,0.941,Altered Stability (Pr = 0.35 | P = 3.9e-03); Loss of Helix (Pr = 0.31 | P = 4.5e-03); Gain of Strand (Pr = 0.26 | P = 0.04); Altered Transmembrane protein (Pr = 0.15 | P = 0.02), ELME000062|ELME000149|ELME000336,-
MYO7A_HUMAN,A26E,0.849,Altered Transmembrane protein (Pr = 0.29 | P = 3.8e-04); Altered Metal binding (Pr = 0.24 | P = 0.04); Gain of Disulfide linkage at C31 (Pr = 0.14 | P = 0.04), ELME000335,-
MYO7A_HUMAN,D2010G,0.873,Loss of Relative solvent accessibility (Pr = 0.31 | P = 6.1e-03); Gain of Strand (Pr = 0.26 | P = 0.04); Loss of Allosteric site at Y2015 (Pr = 0.26 | P = 0.01); Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.20 | P = 5.7e-03); Loss of Catalytic site at Y2015 (Pr = 0.15 | P = 0.02); Loss of Ubiquitylation at K2005 (Pr = 0.15 | P = 0.05); Altered Stability (Pr = 0.14 | P = 0.02); Altered Metal binding (Pr = 0.11 | P = 9.2e-03); Loss of Sulfation at Y2015 (Pr = 0.02 | P = 0.03), ELME000336,-
MYO7A_HUMAN,G434R,0.954,Altered Ordered interface (Pr = 0.33 | P = 7.7e-03); Altered Transmembrane protein (Pr = 0.30 | P = 1.9e-04); Gain of Allosteric site at D437 (Pr = 0.30 | P = 1.8e-03); Loss of Strand (Pr = 0.28 | P = 6.2e-03); Altered Metal binding (Pr = 0.18 | P = 0.02); Loss of Catalytic site at D437 (Pr = 0.10 | P = 0.04), ELME000062|ELME000063|ELME000106|ELME000149|ELME000233|ELME000333|ELME000335|PS00005,-
MYO7A_HUMAN,S1187I,0.848,Loss of Intrinsic disorder (Pr = 0.52 | P = 5.2e-03); Loss of Allosteric site at W1192 (Pr = 0.29 | P = 5.8e-03); Loss of B-factor (Pr = 0.27 | P = 0.03); Altered Ordered interface (Pr = 0.26 | P = 0.02); Loss of Loop (Pr = 0.26 | P = 0.05), ELME000063|ELME000239|ELME000337,-
MYO7A_HUMAN,M645I,0.512,Gain of Acetylation at K643 (Pr = 0.25 | P = 0.01); Loss of Allosteric site at F647 (Pr = 0.20 | P = 0.05), ELME000137|ELME000146|ELME000313,-
MYO7A_HUMAN,L1837H,0.932,, ELME000149|ELME000335,-
MYO7A_HUMAN,R853C,0.697,Altered Disordered interface (Pr = 0.63 | P = 3.9e-04), ELME000012|ELME000102|ELME000108|ELME000134|PS00008,-
MYO7A_HUMAN,G214R,0.91,Loss of Acetylation at K215 (Pr = 0.62 | P = 2.3e-04); Altered DNA binding (Pr = 0.35 | P = 9.8e-04); Loss of Relative solvent accessibility (Pr = 0.33 | P = 3.8e-03); Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Disordered interface (Pr = 0.29 | P = 0.03); Altered Metal binding (Pr = 0.27 | P = 7.6e-03); Loss of Allosteric site at R212 (Pr = 0.26 | P = 0.01); Gain of Catalytic site at N209 (Pr = 0.21 | P = 0.01); Loss of Methylation at K215 (Pr = 0.18 | P = 9.8e-03); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Loss of N-linked glycosylation at N209 (Pr = 0.03 | P = 0.03), ELME000102|ELME000198|ELME000233,-
MYO7A_HUMAN,H133N,0.892,Altered Metal binding (Pr = 0.82 | P = 4.1e-04); Altered Ordered interface (Pr = 0.32 | P = 0.01); Gain of Relative solvent accessibility (Pr = 0.32 | P = 3.8e-03); Loss of Allosteric site at H133 (Pr = 0.27 | P = 0.01); Altered DNA binding (Pr = 0.19 | P = 0.03); Loss of Catalytic site at H133 (Pr = 0.10 | P = 0.04), ELME000058,-
MYO7A_HUMAN,T1427M,0.241,-,-,-
MYO7A_HUMAN,A198T,0.75,Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Transmembrane protein (Pr = 0.26 | P = 1.2e-03); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Gain of Allosteric site at F199 (Pr = 0.25 | P = 9.9e-03); Loss of Methylation at K203 (Pr = 0.24 | P = 2.9e-03); Gain of Catalytic site at N201 (Pr = 0.20 | P = 0.01); Altered Metal binding (Pr = 0.19 | P = 0.05); Gain of GPI-anchor amidation at N201 (Pr = 0.01 | P = 0.03), None,-
MYO7A_HUMAN,N84K,0.892,Altered Ordered interface (Pr = 0.27 | P = 7.8e-03); Gain of Helix (Pr = 0.27 | P = 0.04); Gain of Allosteric site at Y89 (Pr = 0.21 | P = 0.03); Altered Transmembrane protein (Pr = 0.15 | P = 0.02), ELME000045|ELME000102|ELME000106|ELME000146|PS00008,-
MYO7A_HUMAN,R649W,0.855,Loss of Allosteric site at F647 (Pr = 0.21 | P = 0.04), ELME000106|ELME000313,-
MYO7A_HUMAN,R666P,0.966,Altered Metal binding (Pr = 0.30 | P = 2.3e-03); Altered Ordered interface (Pr = 0.28 | P = 0.04); Gain of Strand (Pr = 0.28 | P = 0.01); Altered DNA binding (Pr = 0.25 | P = 9.1e-03); Gain of Allosteric site at R669 (Pr = 0.20 | P = 0.04); Gain of ADP-ribosylation at R669 (Pr = 0.20 | P = 0.04); Gain of Catalytic site at E663 (Pr = 0.12 | P = 0.03), ELME000012|ELME000052|ELME000101|PS00005,-
MYO7A_HUMAN,R395H,0.89,Altered Metal binding (Pr = 0.88 | P = 1.4e-04); Loss of Allosteric site at R395 (Pr = 0.39 | P = 6.7e-04); Altered Ordered interface (Pr = 0.30 | P = 0.02); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Loss of Acetylation at K400 (Pr = 0.25 | P = 0.01); Altered Transmembrane protein (Pr = 0.15 | P = 0.01); Loss of Catalytic site at R395 (Pr = 0.08 | P = 0.05); Gain of Pyrrolidone carboxylic acid at Q390 (Pr = 0.06 | P = 0.03), ELME000146|ELME000321,-
MYO7A_HUMAN,G158R,0.956,Loss of Catalytic site at E159 (Pr = 0.52 | P = 9.7e-05); Gain of Allosteric site at G158 (Pr = 0.35 | P = 3.2e-04); Altered Metal binding (Pr = 0.28 | P = 5.9e-03); Altered Ordered interface (Pr = 0.28 | P = 0.04), ELME000062|ELME000063|ELME000085|PS00017,-
MYO7A_HUMAN,G329D,0.895,Altered Metal binding (Pr = 0.40 | P = 4.9e-06); Altered Ordered interface (Pr = 0.28 | P = 0.04); Gain of Allosteric site at Y333 (Pr = 0.28 | P = 4.4e-03); Loss of Catalytic site at H327 (Pr = 0.22 | P = 9.4e-03); Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000095|ELME000122|ELME000193|ELME000333,-
MYO7A_HUMAN,G1481R,0.833,Loss of Strand (Pr = 0.29 | P = 5.1e-03); Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Transmembrane protein (Pr = 0.27 | P = 8.2e-04); Loss of Loop (Pr = 0.27 | P = 0.04); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.04); Loss of Sulfation at Y1477 (Pr = 0.01 | P = 0.04), ELME000062|ELME000063|ELME000085|ELME000155,-
MYO7A_HUMAN,T1496M,0.763,Altered Transmembrane protein (Pr = 0.29 | P = 2.1e-04); Altered Ordered interface (Pr = 0.29 | P = 0.04); Loss of Strand (Pr = 0.26 | P = 0.05); Loss of N-linked glycosylation at N1494 (Pr = 0.03 | P = 0.03), ELME000070|ELME000080|ELME000193|PS00001,-
MYO7A_HUMAN,D2010Y,0.921,Loss of Relative solvent accessibility (Pr = 0.32 | P = 4.8e-03); Altered Ordered interface (Pr = 0.27 | P = 0.05); Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Allosteric site at Y2015 (Pr = 0.25 | P = 0.01); Altered Transmembrane protein (Pr = 0.20 | P = 5.7e-03); Loss of Catalytic site at Y2015 (Pr = 0.16 | P = 0.02); Loss of Ubiquitylation at K2005 (Pr = 0.16 | P = 0.03); Altered Metal binding (Pr = 0.11 | P = 7.9e-03); Loss of Sulfation at Y2015 (Pr = 0.02 | P = 0.03), ELME000120|ELME000336,-
MYO7A_HUMAN,H468R,0.827,Altered Coiled coil (Pr = 0.24 | P = 0.01), ELME000012|ELME000102|ELME000108|ELME000146,-
MYO7A_HUMAN,D437N,0.944,Altered Ordered interface (Pr = 0.29 | P = 0.02); Gain of Allosteric site at D437 (Pr = 0.29 | P = 2.3e-03); Loss of Strand (Pr = 0.28 | P = 9.6e-03); Altered Metal binding (Pr = 0.20 | P = 0.02); Altered Transmembrane protein (Pr = 0.18 | P = 7.4e-03); Loss of Catalytic site at D437 (Pr = 0.09 | P = 0.04), ELME000193|ELME000333,-
MYO7A_HUMAN,W1745G,0.881,Gain of Intrinsic disorder (Pr = 0.55 | P = 7.6e-04); Altered Disordered interface (Pr = 0.40 | P = 6.8e-03); Loss of Proteolytic cleavage at W1745 (Pr = 0.12 | P = 0.03), ELME000173,-
MYO7A_HUMAN,S157N,0.867,Altered Ordered interface (Pr = 0.29 | P = 0.02); Altered Metal binding (Pr = 0.28 | P = 6.7e-03); Gain of Allosteric site at E159 (Pr = 0.23 | P = 0.02); Loss of Catalytic site at S160 (Pr = 0.16 | P = 0.02); Gain of GPI-anchor amidation at S157 (Pr = 0.03 | P = 8.0e-03), ELME000063|ELME000085,-
MYO7A_HUMAN,P1846H,0.911,, None,-
MYO7A_HUMAN,L1312P,0.959,Gain of Intrinsic disorder (Pr = 0.33 | P = 0.03); Gain of B-factor (Pr = 0.29 | P = 3.6e-03); Gain of Loop (Pr = 0.27 | P = 0.04); Altered Metal binding (Pr = 0.15 | P = 0.02), ELME000053|ELME000063|ELME000136|ELME000155|ELME000159,-
MYO7A_HUMAN,N458I,0.896,Altered Coiled coil (Pr = 0.33 | P = 0.01); Altered Metal binding (Pr = 0.31 | P = 0.01), None,-
MYO7A_HUMAN,G722R,0.951,Loss of Loop (Pr = 0.29 | P = 9.7e-03); Altered Metal binding (Pr = 0.26 | P = 0.01); Altered DNA binding (Pr = 0.18 | P = 0.03), ELME000062|ELME000102|ELME000233,-
MYO7A_HUMAN,L1837P,0.966,Loss of Helix (Pr = 0.27 | P = 0.04); Gain of Loop (Pr = 0.27 | P = 0.02); Gain of Allosteric site at W1834 (Pr = 0.22 | P = 0.03), ELME000149|ELME000335,-
MYO7A_HUMAN,G1298R,0.954,Loss of Strand (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.21 | P = 0.03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000051|ELME000062|ELME000172|ELME000233|ELME000336,-
MYO7A_HUMAN,R1883W,0.83,Gain of Acetylation at K1884 (Pr = 0.35 | P = 2.0e-03); Gain of Loop (Pr = 0.29 | P = 7.1e-03); Altered Ordered interface (Pr = 0.25 | P = 0.02); Loss of Allosteric site at R1883 (Pr = 0.24 | P = 0.02); Altered DNA binding (Pr = 0.15 | P = 0.05); Altered Coiled coil (Pr = 0.13 | P = 0.04); Gain of N-linked glycosylation at N1880 (Pr = 0.01 | P = 0.04), ELME000070|ELME000102|ELME000134|PS00001|PS00005,-
MYO7A_HUMAN,Y252C,0.94,Altered Metal binding (Pr = 0.67 | P = 2.0e-03); Loss of Allosteric site at Y256 (Pr = 0.28 | P = 6.9e-03); Altered Ordered interface (Pr = 0.25 | P = 0.03); Gain of Catalytic site at Y256 (Pr = 0.09 | P = 0.04), ELME000120|PS00007,-
MYO7A_HUMAN,E1170K,0.89,Altered Ordered interface (Pr = 0.25 | P = 0.03); Loss of Disulfide linkage at C1173 (Pr = 0.12 | P = 0.04), None,-
MYO7A_HUMAN,M1H,0.975,Altered Metal binding (Pr = 0.42 | P = 2.0e-03); Gain of Intrinsic disorder (Pr = 0.42 | P = 6.5e-03); Loss of N-terminal acetylation at M1 (Pr = 0.24 | P = 5.6e-04), None,-
MYO7A_HUMAN,V2F,0.883,Loss of Loop (Pr = 0.27 | P = 0.05); Loss of N-terminal acetylation at M1 (Pr = 0.20 | P = 8.0e-04); Altered Metal binding (Pr = 0.04 | P = 0.04), ELME000355,-
MYO7A_HUMAN,V2L,0.761,Gain of N-terminal acetylation at M1 (Pr = 0.26 | P = 2.3e-04); Altered Metal binding (Pr = 0.05 | P = 0.04), ELME000355,-
MYO7A_HUMAN,I3A,0.824,Gain of Intrinsic disorder (Pr = 0.42 | P = 6.5e-03); Altered Metal binding (Pr = 0.25 | P = 0.03); Altered Stability (Pr = 0.22 | P = 0.01); Gain of N-terminal acetylation at M1 (Pr = 0.20 | P = 5.9e-04), None,-
MYO7A_HUMAN,I3F,0.812,Altered Metal binding (Pr = 0.28 | P = 0.02); Loss of N-terminal acetylation at M1 (Pr = 0.20 | P = 8.0e-04), None,-
MYO7A_HUMAN,L4H,0.818,Gain of Intrinsic disorder (Pr = 0.53 | P = 1.2e-03); Altered Metal binding (Pr = 0.32 | P = 0.01); Altered Stability (Pr = 0.32 | P = 4.7e-03); Loss of N-terminal acetylation at M1 (Pr = 0.19 | P = 9.2e-04), None,-
MYO7A_HUMAN,Q5R,0.764,Altered Metal binding (Pr = 0.29 | P = 0.02); Loss of N-terminal acetylation at M1 (Pr = 0.21 | P = 7.7e-04), None,-
MYO7A_HUMAN,Q6K,0.424,-,-,-
MYO7A_HUMAN,Q6P,0.719,Altered Metal binding (Pr = 0.29 | P = 0.02); Loss of N-terminal acetylation at M1 (Pr = 0.19 | P = 9.5e-04), None,-
MYO7A_HUMAN,H9Y,0.075,-,-,-
MYO7A_HUMAN,I48V,0.168,-,-,-
MYO7A_HUMAN,S49T,0.15,-,-,-
MYO7A_HUMAN,V64I,0.104,-,-,-
MYO7A_HUMAN,H65Q,0.42,-,-,-
MYO7A_HUMAN,P116S,0.382,-,-,-
MYO7A_HUMAN,E117Q,0.626,Altered Metal binding (Pr = 0.34 | P = 9.5e-03); Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Altered Ordered interface (Pr = 0.26 | P = 0.01); Loss of Allosteric site at Y114 (Pr = 0.26 | P = 0.01), ELME000063|ELME000136|ELME000159|ELME000163,-
MYO7A_HUMAN,E117R,0.746,Altered Transmembrane protein (Pr = 0.36 | P = 1.9e-05); Altered Metal binding (Pr = 0.35 | P = 8.9e-03); Altered Ordered interface (Pr = 0.29 | P = 0.03); Loss of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Gain of Allosteric site at Y122 (Pr = 0.24 | P = 0.02), ELME000063|ELME000136|ELME000159|PS00005,-
MYO7A_HUMAN,P131S,0.741,Gain of Relative solvent accessibility (Pr = 0.31 | P = 5.9e-03); Loss of Allosteric site at H133 (Pr = 0.30 | P = 4.7e-03); Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Metal binding (Pr = 0.22 | P = 0.02); Altered DNA binding (Pr = 0.19 | P = 0.03); Gain of Catalytic site at H133 (Pr = 0.10 | P = 0.04), ELME000058|ELME000136|ELME000159,-
MYO7A_HUMAN,N144S,0.411,-,-,-
MYO7A_HUMAN,S149G,0.347,-,-,-
MYO7A_HUMAN,N251G,0.927,Loss of Allosteric site at Y256 (Pr = 0.26 | P = 0.01); Altered Metal binding (Pr = 0.25 | P = 0.01); Loss of Catalytic site at Y256 (Pr = 0.09 | P = 0.04), PS00007,-
MYO7A_HUMAN,M262S,0.61,Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered Ordered interface (Pr = 0.28 | P = 0.04); Gain of B-factor (Pr = 0.28 | P = 7.5e-03), PS00006,-
MYO7A_HUMAN,S263P,0.425,-,-,-
MYO7A_HUMAN,Q266P,0.581,Gain of B-factor (Pr = 0.27 | P = 0.01); Gain of Methylation at K268 (Pr = 0.10 | P = 0.04), ELME000271,-
MYO7A_HUMAN,K268R,0.106,-,-,-
MYO7A_HUMAN,G273E,0.247,-,-,-
MYO7A_HUMAN,Q274G,0.159,-,-,-
MYO7A_HUMAN,S276T,0.068,-,-,-
MYO7A_HUMAN,I287T,0.257,-,-,-
MYO7A_HUMAN,I287V,0.124,-,-,-
MYO7A_HUMAN,T288A,0.158,-,-,-
MYO7A_HUMAN,K306R,0.475,-,-,-
MYO7A_HUMAN,A324S,0.339,-,-,-
MYO7A_HUMAN,Q332E,0.287,-,-,-
MYO7A_HUMAN,L347I,0.096,-,-,-
MYO7A_HUMAN,S351A,0.213,-,-,-
MYO7A_HUMAN,S368N,0.068,-,-,-
MYO7A_HUMAN,P385L,0.759,Loss of Relative solvent accessibility (Pr = 0.30 | P = 1.0e-02); Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Transmembrane protein (Pr = 0.14 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q390 (Pr = 0.06 | P = 0.02), ELME000136|ELME000155|ELME000159|ELME000358,-
MYO7A_HUMAN,R388M,0.193,-,-,-
MYO7A_HUMAN,D412E,0.187,-,-,-
MYO7A_HUMAN,D425G,0.238,-,-,-
MYO7A_HUMAN,V426M,0.099,-,-,-
MYO7A_HUMAN,K427T,0.206,-,-,-
MYO7A_HUMAN,N428S,0.064,-,-,-
MYO7A_HUMAN,A445T,0.119,-,-,-
MYO7A_HUMAN,V446I,0.191,-,-,-
MYO7A_HUMAN,V446M,0.395,-,-,-
MYO7A_HUMAN,L452F,0.793,Altered Coiled coil (Pr = 0.34 | P = 0.01); Altered Metal binding (Pr = 0.30 | P = 0.02), ELME000328,-
MYO7A_HUMAN,M498L,0.666,Altered Metal binding (Pr = 0.30 | P = 2.8e-03); Gain of Allosteric site at L496 (Pr = 0.20 | P = 0.04); Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000149,-
MYO7A_HUMAN,I506V,0.278,-,-,-
MYO7A_HUMAN,M524L,0.614,Altered Metal binding (Pr = 0.16 | P = 0.05), ELME000052|ELME000147|PS00008,-
MYO7A_HUMAN,L525S,0.766,Gain of Intrinsic disorder (Pr = 0.41 | P = 6.9e-03); Gain of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Altered Stability (Pr = 0.21 | P = 0.01); Altered Metal binding (Pr = 0.20 | P = 0.03), ELME000052|ELME000147|PS00005,-
MYO7A_HUMAN,H526N,0.226,-,-,-
MYO7A_HUMAN,H526Y,0.249,-,-,-
MYO7A_HUMAN,S530F,0.412,-,-,-
MYO7A_HUMAN,A536N,0.209,-,-,-
MYO7A_HUMAN,N537T,0.32,-,-,-
MYO7A_HUMAN,F554L,0.78,Altered Metal binding (Pr = 0.29 | P = 4.7e-03); Altered Ordered interface (Pr = 0.25 | P = 0.03); Gain of Relative solvent accessibility (Pr = 0.23 | P = 0.05); Loss of Allosteric site at H553 (Pr = 0.21 | P = 0.04); Altered Transmembrane protein (Pr = 0.14 | P = 0.02); Gain of Sulfation at Y559 (Pr = 0.02 | P = 0.04), None,-
MYO7A_HUMAN,I557V,0.04,-,-,-
COL2A1_HUMAN,G1092S,0.939,Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Methylation at R1088 (Pr = 0.19 | P = 8.3e-03), ELME000085|ELME000147,-
COL2A1_HUMAN,Q1109P,0.293,-,-,-
COL2A1_HUMAN,P1124A,0.099,-,-,-
COL2A1_HUMAN,G1247A,0.183,-,-,-
COL2A1_HUMAN,G1247T,0.2,-,-,-
COL2A1_HUMAN,S1268N,0.135,-,-,-
COL2A1_HUMAN,W1293G,0.889,Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of B-factor (Pr = 0.29 | P = 5.2e-03); Altered Stability (Pr = 0.18 | P = 0.01); Altered Transmembrane protein (Pr = 0.10 | P = 0.04); Gain of Sulfation at Y1298 (Pr = 0.06 | P = 5.6e-03), None,-
COL2A1_HUMAN,K1294T,0.73,Altered Ordered interface (Pr = 0.23 | P = 0.05); Altered Transmembrane protein (Pr = 0.10 | P = 0.05); Gain of Catalytic site at W1299 (Pr = 0.10 | P = 0.04); Gain of Sulfation at Y1298 (Pr = 0.06 | P = 5.3e-03), ELME000085|ELME000220|PS00006,-
COL2A1_HUMAN,S1295P,0.942,Altered Transmembrane protein (Pr = 0.10 | P = 0.05); Loss of Catalytic site at W1299 (Pr = 0.10 | P = 0.04); Gain of Sulfation at Y1298 (Pr = 0.05 | P = 7.7e-03), ELME000085,-
COL2A1_HUMAN,S1295R,0.911,Altered Transmembrane protein (Pr = 0.10 | P = 0.05); Loss of Catalytic site at W1299 (Pr = 0.10 | P = 0.04); Gain of Sulfation at Y1298 (Pr = 0.05 | P = 8.0e-03), ELME000085|ELME000100|ELME000108|PS00016,-
COL2A1_HUMAN,M1317L,0.766,Altered Transmembrane protein (Pr = 0.31 | P = 1.3e-04); Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Metal binding (Pr = 0.26 | P = 0.02); Loss of Disulfide linkage at C1315 (Pr = 0.25 | P = 7.0e-03), None,-
COL2A1_HUMAN,S1338N,0.446,-,-,-
COL2A1_HUMAN,K1340D,0.77,Loss of B-factor (Pr = 0.27 | P = 0.03); Altered Transmembrane protein (Pr = 0.21 | P = 4.8e-03); Loss of GPI-anchor amidation at N1335 (Pr = 0.01 | P = 0.02), ELME000063|ELME000233|PS00005,-
COL2A1_HUMAN,S1341N,0.28,-,-,-
COL2A1_HUMAN,S1341T,0.192,-,-,-
COL2A1_HUMAN,E1343D,0.118,-,-,-
COL2A1_HUMAN,K1345R,0.488,-,-,-
COL2A1_HUMAN,P1368A,0.326,-,-,-
COL2A1_HUMAN,S1386A,0.338,-,-,-
COL2A1_HUMAN,K1394R,0.706,Altered Transmembrane protein (Pr = 0.28 | P = 4.9e-04); Altered Ordered interface (Pr = 0.25 | P = 0.02); Loss of Catalytic site at Y1391 (Pr = 0.11 | P = 0.04); Loss of Disulfide linkage at C1393 (Pr = 0.11 | P = 0.05); Altered Metal binding (Pr = 0.05 | P = 0.04), ELME000062|ELME000313,-
COL2A1_HUMAN,I1397V,0.37,-,-,-
COL2A1_HUMAN,A1404T,0.238,-,-,-
COL2A1_HUMAN,I1413V,0.288,-,-,-
COL2A1_HUMAN,V1449K,0.81,Gain of Relative solvent accessibility (Pr = 0.36 | P = 9.4e-04); Altered Ordered interface (Pr = 0.33 | P = 0.01); Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Altered Stability (Pr = 0.23 | P = 9.3e-03); Gain of Acetylation at K1444 (Pr = 0.20 | P = 0.04); Altered Disordered interface (Pr = 0.19 | P = 0.04), ELME000064|ELME000220|PS00006,-
COL2A1_HUMAN,S1454T,0.429,-,-,-
COL2A1_HUMAN,E1474D,0.277,-,-,-
COL2A1_HUMAN,E1474G,0.789,Altered Transmembrane protein (Pr = 0.37 | P = 1.9e-05); Altered Metal binding (Pr = 0.30 | P = 4.1e-03); Loss of Relative solvent accessibility (Pr = 0.30 | P = 9.8e-03); Altered Ordered interface (Pr = 0.28 | P = 0.04); Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Catalytic site at D1469 (Pr = 0.18 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q1475 (Pr = 0.14 | P = 5.4e-03), ELME000117|PS00008,-
COL2A1_HUMAN,D1480E,0.582,Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Metal binding (Pr = 0.28 | P = 6.7e-03); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.24 | P = 1.7e-03); Gain of Pyrrolidone carboxylic acid at Q1475 (Pr = 0.15 | P = 4.7e-03); Gain of Catalytic site at E1476 (Pr = 0.10 | P = 0.04), None,-
COL2A1_HUMAN,G738D,0.951,Gain of Loop (Pr = 0.29 | P = 8.3e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Altered Metal binding (Pr = 0.24 | P = 0.02); Gain of O-linked glycosylation at S734 (Pr = 0.13 | P = 0.04), ELME000155,-
COL2A1_HUMAN,R719C,0.823,Loss of Methylation at R719 (Pr = 0.16 | P = 0.01), ELME000005|ELME000106|ELME000155,-
COL2A1_HUMAN,C1485G,0.968,Altered Metal binding (Pr = 0.49 | P = 4.0e-03); Gain of Intrinsic disorder (Pr = 0.48 | P = 2.3e-03); Altered Transmembrane protein (Pr = 0.21 | P = 4.6e-03), None,-
COL2A1_HUMAN,R1276C,0.682,Loss of Intrinsic disorder (Pr = 0.38 | P = 0.03); Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Acetylation at K1277 (Pr = 0.23 | P = 0.02); Altered Transmembrane protein (Pr = 0.22 | P = 3.3e-03), ELME000102|ELME000162|ELME000239|ELME000337|PS00005,-
COL2A1_HUMAN,G888S,0.954,Loss of Methylation at R887 (Pr = 0.25 | P = 1.9e-03); Loss of SUMOylation at K884 (Pr = 0.21 | P = 0.03); Loss of Ubiquitylation at K884 (Pr = 0.16 | P = 0.03), ELME000085|PS00008,-
COL2A1_HUMAN,G504S,0.954,Gain of Phosphorylation at G504 (Pr = 0.39 | P = 6.7e-03); Gain of Loop (Pr = 0.27 | P = 0.02); Loss of Methylation at R509 (Pr = 0.11 | P = 0.03), ELME000136|ELME000155|ELME000159,-
COL2A1_HUMAN,R940Q,0.437,-,-,-
COL2A1_HUMAN,G1176V,0.963,Loss of B-factor (Pr = 0.29 | P = 0.01); Gain of Acetylation at K1174 (Pr = 0.24 | P = 0.01); Loss of Methylation at K1174 (Pr = 0.24 | P = 2.5e-03); Gain of SUMOylation at K1174 (Pr = 0.20 | P = 0.03); Gain of Ubiquitylation at K1174 (Pr = 0.18 | P = 0.02); Gain of O-linked glycosylation at S1172 (Pr = 0.13 | P = 0.04), ELME000321,-
COL2A1_HUMAN,I1450T,0.744,Altered Transmembrane protein (Pr = 0.31 | P = 1.2e-04); Altered Ordered interface (Pr = 0.31 | P = 0.01); Loss of Strand (Pr = 0.27 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Gain of Acetylation at K1447 (Pr = 0.19 | P = 0.05); Altered Stability (Pr = 0.15 | P = 0.02), ELME000053|ELME000064|ELME000146|ELME000220|PS00006,-
COL2A1_HUMAN,G771V,0.976,Loss of B-factor (Pr = 0.27 | P = 0.02); Loss of Acetylation at K773 (Pr = 0.26 | P = 1.0e-02); Loss of Methylation at K773 (Pr = 0.25 | P = 2.4e-03); Gain of SUMOylation at K773 (Pr = 0.21 | P = 0.02); Altered Metal binding (Pr = 0.20 | P = 0.04); Loss of Ubiquitylation at K773 (Pr = 0.17 | P = 0.03), None,-
COL2A1_HUMAN,G318R,0.96,Loss of B-factor (Pr = 0.29 | P = 0.01); Altered Metal binding (Pr = 0.18 | P = 0.05), ELME000070|ELME000136,-
COL2A1_HUMAN,G465S,0.944,Loss of Acetylation at K464 (Pr = 0.30 | P = 4.0e-03); Gain of Loop (Pr = 0.28 | P = 0.02); Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of Methylation at K464 (Pr = 0.25 | P = 1.8e-03); Gain of SUMOylation at K464 (Pr = 0.25 | P = 8.9e-03), ELME000002,-
COL2A1_HUMAN,G222V,0.968,Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of B-factor (Pr = 0.26 | P = 0.04), None,-
COL2A1_HUMAN,G546S,0.927,Loss of Methylation at K542 (Pr = 0.27 | P = 1.3e-03); Loss of B-factor (Pr = 0.26 | P = 0.05); Loss of Acetylation at K542 (Pr = 0.24 | P = 0.02); Loss of SUMOylation at K542 (Pr = 0.19 | P = 0.04); Loss of Ubiquitylation at K542 (Pr = 0.17 | P = 0.02), ELME000155,-
COL2A1_HUMAN,G453A,0.938,Altered Disordered interface (Pr = 0.28 | P = 0.04); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Methylation at K452 (Pr = 0.23 | P = 3.5e-03); Gain of SUMOylation at K452 (Pr = 0.21 | P = 0.03); Gain of Ubiquitylation at K452 (Pr = 0.16 | P = 0.04), ELME000173,-
COL2A1_HUMAN,G144V,0.955,Loss of B-factor (Pr = 0.31 | P = 5.7e-03); Loss of Methylation at R149 (Pr = 0.28 | P = 1.0e-03); Loss of Acetylation at K143 (Pr = 0.26 | P = 9.7e-03); Gain of SUMOylation at K140 (Pr = 0.26 | P = 6.2e-03); Gain of Ubiquitylation at K143 (Pr = 0.16 | P = 0.04), None,-
COL2A1_HUMAN,G1128V,0.962,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of SUMOylation at K1130 (Pr = 0.23 | P = 0.02); Loss of Methylation at K1130 (Pr = 0.12 | P = 0.03), ELME000146,-
COL2A1_HUMAN,G921R,0.961,Loss of B-factor (Pr = 0.31 | P = 5.9e-03); Gain of Acetylation at K925 (Pr = 0.30 | P = 3.9e-03); Loss of Methylation at K925 (Pr = 0.27 | P = 1.2e-03); Gain of SUMOylation at K925 (Pr = 0.19 | P = 0.04); Loss of O-linked glycosylation at S923 (Pr = 0.16 | P = 0.03), ELME000006|ELME000062|ELME000135|ELME000239,-
COL2A1_HUMAN,G855V,0.964,Loss of Methylation at K857 (Pr = 0.28 | P = 9.1e-04); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Acetylation at K857 (Pr = 0.23 | P = 0.02); Loss of SUMOylation at K857 (Pr = 0.23 | P = 0.02); Gain of Ubiquitylation at K857 (Pr = 0.18 | P = 0.02); Altered Metal binding (Pr = 0.12 | P = 0.04), None,-
COL2A1_HUMAN,G492V,0.97,Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of Loop (Pr = 0.26 | P = 0.05); Gain of SUMOylation at K490 (Pr = 0.26 | P = 6.0e-03); Loss of Methylation at K490 (Pr = 0.25 | P = 1.8e-03); Loss of Acetylation at K490 (Pr = 0.24 | P = 0.02), ELME000100|ELME000108,-
COL2A1_HUMAN,G750V,0.95,Loss of Methylation at R755 (Pr = 0.12 | P = 0.03), None,-
COL2A1_HUMAN,G381D,0.965,Gain of Loop (Pr = 0.30 | P = 4.6e-03); Loss of Methylation at R383 (Pr = 0.21 | P = 5.5e-03), ELME000293,-
COL2A1_HUMAN,G678R,0.937,Loss of B-factor (Pr = 0.32 | P = 4.0e-03); Loss of Loop (Pr = 0.31 | P = 4.9e-03); Loss of Acetylation at K679 (Pr = 0.29 | P = 4.7e-03); Loss of Methylation at K679 (Pr = 0.27 | P = 1.2e-03); Gain of SUMOylation at K679 (Pr = 0.22 | P = 0.02), ELME000093|ELME000102|PS00008|PS00009,-
COL2A1_HUMAN,L667F,0.445,-,-,-
COL2A1_HUMAN,G408D,0.97,Gain of Loop (Pr = 0.28 | P = 0.01); Loss of O-linked glycosylation at S407 (Pr = 0.14 | P = 0.04); Altered Metal binding (Pr = 0.13 | P = 0.03), ELME000085|ELME000239|PS00008,-
COL2A1_HUMAN,G453V,0.962,Loss of B-factor (Pr = 0.28 | P = 0.02); Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of Methylation at K452 (Pr = 0.24 | P = 2.5e-03); Gain of SUMOylation at K452 (Pr = 0.21 | P = 0.03), ELME000173,-
COL2A1_HUMAN,G1062C,0.96,Altered Disordered interface (Pr = 0.31 | P = 0.02); Loss of Methylation at R1058 (Pr = 0.14 | P = 0.02), ELME000052|ELME000155,-
COL2A1_HUMAN,G381R,0.964,Loss of Loop (Pr = 0.32 | P = 3.7e-03); Gain of Methylation at R383 (Pr = 0.21 | P = 3.8e-03); Gain of ADP-ribosylation at G381 (Pr = 0.19 | P = 0.05); Gain of O-linked glycosylation at T380 (Pr = 0.15 | P = 0.03), None,-
COL2A1_HUMAN,G345D,0.973,Loss of Methylation at R344 (Pr = 0.25 | P = 2.0e-03); Gain of B-factor (Pr = 0.24 | P = 0.04), None,-
COL2A1_HUMAN,G444D,0.967,Gain of Loop (Pr = 0.30 | P = 5.4e-03); Loss of B-factor (Pr = 0.26 | P = 0.04), ELME000052|ELME000293,-
COL2A1_HUMAN,G903S,0.936,Loss of Methylation at R904 (Pr = 0.13 | P = 0.02), ELME000097|ELME000155,-
COL2A1_HUMAN,G1173R,0.959,Loss of Acetylation at K1174 (Pr = 0.34 | P = 2.5e-03); Loss of Loop (Pr = 0.29 | P = 8.2e-03); Loss of B-factor (Pr = 0.27 | P = 0.02); Loss of Methylation at K1174 (Pr = 0.26 | P = 1.6e-03); Gain of SUMOylation at K1174 (Pr = 0.21 | P = 0.02); Gain of ADP-ribosylation at G1173 (Pr = 0.20 | P = 0.03); Loss of Ubiquitylation at K1174 (Pr = 0.18 | P = 0.02), ELME000006|ELME000085|ELME000102|ELME000321|PS00005|PS00006,-
COL2A1_HUMAN,G1155V,0.95,Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of O-linked glycosylation at S1154 (Pr = 0.12 | P = 0.05), ELME000085|ELME000155,-
COL2A1_HUMAN,R1192C,0.59,Loss of Methylation at R1190 (Pr = 0.30 | P = 5.1e-04); Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of Loop (Pr = 0.28 | P = 0.01); Loss of ADP-ribosylation at R1192 (Pr = 0.27 | P = 7.1e-03), ELME000012|ELME000085,-
COL2A1_HUMAN,G396V,0.953,Loss of B-factor (Pr = 0.32 | P = 5.1e-03); Loss of Methylation at R392 (Pr = 0.19 | P = 7.8e-03), ELME000005|ELME000136|ELME000155|ELME000159|ELME000358,-
COL2A1_HUMAN,G561S,0.963,Gain of Proteolytic cleavage at R560 (Pr = 0.14 | P = 0.02); Loss of Methylation at R560 (Pr = 0.12 | P = 0.03), ELME000146|ELME000173,-
COL2A1_HUMAN,G1074S,0.942,Gain of Loop (Pr = 0.29 | P = 9.3e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of O-linked glycosylation at S1075 (Pr = 0.14 | P = 0.04), ELME000136|ELME000155|ELME000159,-
COL2A1_HUMAN,G1182D,0.964,Altered Disordered interface (Pr = 0.28 | P = 0.04); Gain of Loop (Pr = 0.27 | P = 0.03), ELME000155,-
COL2A1_HUMAN,G1179R,0.949,Loss of Loop (Pr = 0.28 | P = 0.02); Gain of Acetylation at K1174 (Pr = 0.28 | P = 5.8e-03); Loss of Methylation at K1174 (Pr = 0.26 | P = 1.7e-03); Gain of SUMOylation at K1174 (Pr = 0.20 | P = 0.04); Loss of Ubiquitylation at K1174 (Pr = 0.18 | P = 0.02), None,-
COL2A1_HUMAN,A145V,0.104,-,-,-
COL2A1_HUMAN,G267D,0.959,Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Acetylation at K262 (Pr = 0.27 | P = 7.1e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Methylation at K262 (Pr = 0.26 | P = 1.5e-03); Loss of SUMOylation at K262 (Pr = 0.22 | P = 0.02); Gain of Ubiquitylation at K262 (Pr = 0.16 | P = 0.03), ELME000155,-
COL2A1_HUMAN,G690R,0.965,Loss of Loop (Pr = 0.28 | P = 0.02), ELME000149,-
COL2A1_HUMAN,G483R,0.969,Loss of B-factor (Pr = 0.27 | P = 0.02); Gain of Methylation at G483 (Pr = 0.15 | P = 0.01), None,-
COL2A1_HUMAN,G219E,0.966,, None,-
COL2A1_HUMAN,G654S,0.949,Loss of Methylation at R653 (Pr = 0.17 | P = 0.01), None,-
COL2A1_HUMAN,G984R,0.971,Loss of Loop (Pr = 0.31 | P = 4.6e-03); Altered Disordered interface (Pr = 0.30 | P = 0.02); Gain of Methylation at R980 (Pr = 0.12 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q979 (Pr = 0.05 | P = 0.04), ELME000155,-
COL2A1_HUMAN,G1017V,0.97,Loss of B-factor (Pr = 0.33 | P = 2.3e-03); Gain of O-linked glycosylation at S1013 (Pr = 0.16 | P = 0.03); Loss of Methylation at R1016 (Pr = 0.14 | P = 0.02), ELME000155|ELME000259,-
COL2A1_HUMAN,C1323W,0.968,Altered Metal binding (Pr = 0.73 | P = 8.2e-04); Loss of Disulfide linkage at C1323 (Pr = 0.42 | P = 5.1e-04); Altered Transmembrane protein (Pr = 0.31 | P = 1.2e-04); Altered Ordered interface (Pr = 0.28 | P = 0.04); Gain of Strand (Pr = 0.26 | P = 0.04); Gain of Catalytic site at C1323 (Pr = 0.10 | P = 0.04); Gain of GPI-anchor amidation at N1327 (Pr = 0.01 | P = 0.03), None,-
COL2A1_HUMAN,G519S,0.968,Altered Disordered interface (Pr = 0.27 | P = 0.04); Gain of Loop (Pr = 0.26 | P = 0.04); Loss of Methylation at R515 (Pr = 0.19 | P = 7.8e-03), ELME000202,-
COL2A1_HUMAN,G372R,0.961,Loss of Loop (Pr = 0.28 | P = 0.01); Loss of Methylation at K374 (Pr = 0.28 | P = 8.5e-04); Loss of B-factor (Pr = 0.26 | P = 0.03); Loss of Acetylation at K374 (Pr = 0.22 | P = 0.03); Loss of Ubiquitylation at K374 (Pr = 0.21 | P = 5.8e-03), PS00008,-
COL2A1_HUMAN,G1131A,0.94,Gain of SUMOylation at K1130 (Pr = 0.23 | P = 0.01); Loss of Methylation at K1130 (Pr = 0.12 | P = 0.03), ELME000146,-
COL2A1_HUMAN,G516D,0.975,Altered Disordered interface (Pr = 0.27 | P = 0.04); Gain of Loop (Pr = 0.27 | P = 0.02); Loss of Methylation at R515 (Pr = 0.23 | P = 3.5e-03), None,-
COL2A1_HUMAN,G780R,0.968,Loss of Acetylation at K781 (Pr = 0.36 | P = 1.9e-03); Loss of B-factor (Pr = 0.29 | P = 0.02); Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of Methylation at K781 (Pr = 0.24 | P = 2.6e-03); Gain of SUMOylation at K781 (Pr = 0.24 | P = 0.01); Altered Metal binding (Pr = 0.19 | P = 0.05), ELME000102,-
COL2A1_HUMAN,G348D,0.969,Gain of Loop (Pr = 0.26 | P = 0.05); Gain of B-factor (Pr = 0.25 | P = 0.03); Loss of Methylation at R344 (Pr = 0.21 | P = 5.4e-03), None,-
COL2A1_HUMAN,G759S,0.952,Altered Disordered interface (Pr = 0.27 | P = 0.05); Gain of Loop (Pr = 0.27 | P = 0.02); Loss of Methylation at K764 (Pr = 0.26 | P = 1.8e-03); Loss of Acetylation at K764 (Pr = 0.24 | P = 0.02); Loss of Ubiquitylation at K764 (Pr = 0.18 | P = 0.02), ELME000051,-
COL2A1_HUMAN,G774S,0.961,Gain of Phosphorylation at G774 (Pr = 0.51 | P = 3.3e-03); Loss of Acetylation at K773 (Pr = 0.28 | P = 5.7e-03); Loss of B-factor (Pr = 0.26 | P = 0.03); Loss of Methylation at K773 (Pr = 0.25 | P = 2.0e-03); Loss of SUMOylation at K773 (Pr = 0.21 | P = 0.03); Altered Metal binding (Pr = 0.19 | P = 0.04); Loss of Ubiquitylation at K773 (Pr = 0.17 | P = 0.03), ELME000136|ELME000159,-
COL2A1_HUMAN,G831R,0.955,Loss of B-factor (Pr = 0.29 | P = 0.01), ELME000135|ELME000155,-
COL2A1_HUMAN,A1051T,0.346,-,-,-
COL2A1_HUMAN,V1331I,0.138,-,-,-
COL2A1_HUMAN,P952T,0.146,-,-,-
COL2A1_HUMAN,G1405S,0.764,Altered Ordered interface (Pr = 0.36 | P = 3.3e-03); Altered Metal binding (Pr = 0.29 | P = 0.02); Gain of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered Transmembrane protein (Pr = 0.26 | P = 1.0e-03); Loss of Methylation at K1408 (Pr = 0.13 | P = 0.02), ELME000313,-
COL2A1_HUMAN,T9S,0.111,-,-,-
COL2A1_HUMAN,I2P,0.733,Loss of Helix (Pr = 0.28 | P = 0.02); Altered Stability (Pr = 0.21 | P = 0.01); Loss of N-terminal acetylation at M1 (Pr = 0.07 | P = 2.6e-03); Altered Signal peptide (Pr = 0.06 | P = 2.8e-03), ELME000355,-
COL2A1_HUMAN,A6T,0.198,-,-,-
COL2A1_HUMAN,P7A,0.147,-,-,-
COL2A1_HUMAN,Q8K,0.454,-,-,-
COL2A1_HUMAN,Q8P,0.715,Loss of Helix (Pr = 0.29 | P = 0.01); Altered Signal peptide (Pr = 0.26 | P = 3.5e-04), ELME000052|ELME000149|PS00008,-
COL2A1_HUMAN,Q8R,0.313,-,-,-
COL2A1_HUMAN,V17L,0.297,-,-,-
COL2A1_HUMAN,G25A,0.383,-,-,-
COL2A1_HUMAN,G25K,0.556,Loss of Pyrrolidone carboxylic acid at Q24 (Pr = 0.25 | P = 7.5e-04); Altered Signal peptide (Pr = 0.06 | P = 1.9e-03), None,-
COL4A5_HUMAN,G153D,0.961,Gain of Loop (Pr = 0.31 | P = 3.4e-03); Altered Disordered interface (Pr = 0.28 | P = 0.04); Loss of Methylation at K155 (Pr = 0.22 | P = 4.5e-03); Gain of SUMOylation at K155 (Pr = 0.19 | P = 0.04), None,-
COL4A5_HUMAN,G1080D,0.949,Gain of Loop (Pr = 0.27 | P = 0.04); Loss of B-factor (Pr = 0.25 | P = 0.05); Loss of Methylation at K1082 (Pr = 0.23 | P = 3.5e-03), None,-
COL4A5_HUMAN,G866E,0.95,Gain of Loop (Pr = 0.27 | P = 0.02), ELME000005|ELME000136|ELME000155|ELME000159,-
COL4A5_HUMAN,G192E,0.923,Altered Disordered interface (Pr = 0.30 | P = 0.02); Gain of O-linked glycosylation at T188 (Pr = 0.23 | P = 0.01), ELME000155,-
COL4A5_HUMAN,G875E,0.929,Gain of Loop (Pr = 0.28 | P = 0.02); Loss of B-factor (Pr = 0.26 | P = 0.05), ELME000155,-
COL4A5_HUMAN,G171R,0.934,Loss of B-factor (Pr = 0.29 | P = 0.01); Altered Disordered interface (Pr = 0.27 | P = 0.04); Gain of Phosphorylation at Y175 (Pr = 0.24 | P = 0.04); Loss of Methylation at K170 (Pr = 0.21 | P = 5.9e-03); Gain of SUMOylation at K170 (Pr = 0.19 | P = 0.04); Gain of Sulfation at Y175 (Pr = 0.02 | P = 0.03), ELME000005|ELME000095|ELME000100|ELME000108|ELME000122|ELME000155,-
COL4A5_HUMAN,G186D,0.943,Altered Disordered interface (Pr = 0.28 | P = 0.03); Loss of O-linked glycosylation at T188 (Pr = 0.22 | P = 0.02), None,-
COL4A5_HUMAN,E1084A,0.315,-,-,-
COL4A5_HUMAN,P94L,0.33,-,-,-
COL4A5_HUMAN,I161V,0.131,-,-,-
COL4A5_HUMAN,L184P,0.083,-,-,-
COL4A5_HUMAN,T188S,0.056,-,-,-
COL4A5_HUMAN,N306S,0.091,-,-,-
COL4A5_HUMAN,D448G,0.223,-,-,-
COL4A5_HUMAN,I450L,0.077,-,-,-
COL4A5_HUMAN,K465R,0.062,-,-,-
COL4A5_HUMAN,V473I,0.044,-,-,-
COL4A5_HUMAN,V473M,0.065,-,-,-
COL4A5_HUMAN,Q519H,0.043,-,-,-
COL4A5_HUMAN,T577S,0.089,-,-,-
COL4A5_HUMAN,D581N,0.298,-,-,-
COL4A5_HUMAN,I617M,0.066,-,-,-
COL4A5_HUMAN,I636V,0.06,-,-,-
COL4A5_HUMAN,D676E,0.042,-,-,-
COL4A5_HUMAN,A886D,0.191,-,-,-
COL4A5_HUMAN,P892K,0.516,Gain of Acetylation at P892 (Pr = 0.54 | P = 4.1e-04); Loss of Loop (Pr = 0.32 | P = 4.0e-03); Loss of SUMOylation at K895 (Pr = 0.26 | P = 6.5e-03); Gain of Methylation at P892 (Pr = 0.23 | P = 1.8e-03), ELME000064|ELME000220|ELME000336,-
COL4A5_HUMAN,M900V,0.109,-,-,-
COL4A5_HUMAN,N958D,0.083,-,-,-
COL4A5_HUMAN,P1005A,0.148,-,-,-
COL4A5_HUMAN,P1005S,0.07,-,-,-
COL4A5_HUMAN,V1040A,0.082,-,-,-
COL4A5_HUMAN,S1047P,0.052,-,-,-
COL4A5_HUMAN,S1099A,0.109,-,-,-
COL4A5_HUMAN,T1111A,0.077,-,-,-
COL4A5_HUMAN,N1191I,0.068,-,-,-
COL4A5_HUMAN,P1225S,0.2,-,-,-
COL4A5_HUMAN,P1272R,0.073,-,-,-
COL4A5_HUMAN,G1278E,0.596,Loss of Methylation at K1281 (Pr = 0.27 | P = 1.3e-03); Loss of SUMOylation at K1281 (Pr = 0.26 | P = 6.9e-03); Loss of Acetylation at K1281 (Pr = 0.24 | P = 0.02), PS00008,-
COL4A5_HUMAN,P1304Q,0.167,-,-,-
COL4A5_HUMAN,S1338P,0.295,-,-,-
COL4A5_HUMAN,A1344P,0.283,-,-,-
COL4A5_HUMAN,A1344T,0.04,-,-,-
COL4A5_HUMAN,P1392L,0.038,-,-,-
COL4A5_HUMAN,Q1393P,0.125,-,-,-
COL4A5_HUMAN,S1457P,0.823,Gain of B-factor (Pr = 0.25 | P = 0.02); Gain of O-linked glycosylation at S1456 (Pr = 0.15 | P = 0.03), ELME000052|ELME000136|ELME000159|ELME000239,-
COL4A5_HUMAN,S1457T,0.373,-,-,-
COL4A5_HUMAN,V1458I,0.034,-,-,-
COL4A5_HUMAN,T1471M,0.094,-,-,-
COL4A5_HUMAN,D1591N,0.187,-,-,-
COL4A5_HUMAN,G675D,0.957,Gain of Loop (Pr = 0.27 | P = 0.04); Gain of B-factor (Pr = 0.25 | P = 0.03), ELME000155,-
COL4A5_HUMAN,G669S,0.894,Gain of Loop (Pr = 0.27 | P = 0.02); Gain of Phosphorylation at G669 (Pr = 0.26 | P = 0.02); Loss of B-factor (Pr = 0.25 | P = 0.05); Loss of Acetylation at K664 (Pr = 0.21 | P = 0.03); Loss of Methylation at K664 (Pr = 0.14 | P = 0.02), ELME000006,-
COL4A5_HUMAN,G325R,0.944,Altered Disordered interface (Pr = 0.28 | P = 0.03); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Phosphorylation at Y320 (Pr = 0.26 | P = 0.03); Loss of Acetylation at K330 (Pr = 0.25 | P = 0.01); Loss of Methylation at K330 (Pr = 0.25 | P = 2.3e-03); Gain of SUMOylation at K330 (Pr = 0.19 | P = 0.04); Loss of Sulfation at Y320 (Pr = 0.04 | P = 0.01), ELME000006|ELME000012|ELME000102|ELME000108,-
COL4A5_HUMAN,G743D,0.95,Altered Disordered interface (Pr = 0.28 | P = 0.03); Gain of Loop (Pr = 0.27 | P = 0.02); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Methylation at K748 (Pr = 0.19 | P = 7.7e-03), None,-
COL4A5_HUMAN,G310E,0.941,Altered Disordered interface (Pr = 0.28 | P = 0.03); Gain of Loop (Pr = 0.27 | P = 0.03), ELME000155,-
COL4A5_HUMAN,G1066A,0.895,Loss of B-factor (Pr = 0.30 | P = 8.5e-03); Loss of Acetylation at K1062 (Pr = 0.23 | P = 0.02); Loss of Methylation at K1062 (Pr = 0.19 | P = 8.1e-03); Gain of SUMOylation at K1065 (Pr = 0.18 | P = 0.05); Gain of O-linked glycosylation at S1071 (Pr = 0.13 | P = 0.04), None,-
COL4A5_HUMAN,G1430E,0.957,, PS00008,-
COL4A5_HUMAN,G1083S,0.921,Gain of Loop (Pr = 0.28 | P = 0.02); Loss of B-factor (Pr = 0.27 | P = 0.02); Loss of Methylation at K1082 (Pr = 0.23 | P = 3.9e-03), ELME000002|ELME000005|ELME000155,-
COL4A5_HUMAN,G606R,0.942,Loss of Loop (Pr = 0.32 | P = 3.5e-03); Loss of B-factor (Pr = 0.29 | P = 0.01), ELME000005|ELME000135|ELME000155,-
COL4A5_HUMAN,G1244D,0.831,Gain of Loop (Pr = 0.28 | P = 0.02); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of O-linked glycosylation at S1242 (Pr = 0.15 | P = 0.03), ELME000136|ELME000159,-
COL4A5_HUMAN,G1086D,0.94,Loss of B-factor (Pr = 0.26 | P = 0.05); Loss of Methylation at K1082 (Pr = 0.23 | P = 3.6e-03); Gain of Sulfation at Y1090 (Pr = 0.01 | P = 0.04), ELME000005|ELME000155|PS00007,-
COL4A5_HUMAN,P1329H,0.622,, None,-
COL4A5_HUMAN,G672S,0.892,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Loop (Pr = 0.27 | P = 0.02), ELME000006,-
COL4A5_HUMAN,G123E,0.959,Altered Metal binding (Pr = 0.28 | P = 0.02); Gain of SUMOylation at K128 (Pr = 0.28 | P = 4.4e-03); Gain of Loop (Pr = 0.26 | P = 0.05); Loss of Methylation at K128 (Pr = 0.15 | P = 0.02); Gain of N-linked glycosylation at N125 (Pr = 0.02 | P = 0.03), PS00008,-
COL4A5_HUMAN,G1069D,0.815,Gain of B-factor (Pr = 0.25 | P = 0.03); Loss of Acetylation at K1065 (Pr = 0.22 | P = 0.03); Loss of Methylation at K1065 (Pr = 0.18 | P = 8.8e-03); Loss of O-linked glycosylation at S1071 (Pr = 0.12 | P = 0.05), None,-
COL4A5_HUMAN,G772D,0.954,Gain of Loop (Pr = 0.27 | P = 0.02); Loss of Acetylation at K768 (Pr = 0.27 | P = 7.1e-03); Altered Disordered interface (Pr = 0.26 | P = 0.05); Gain of SUMOylation at K768 (Pr = 0.18 | P = 0.04); Loss of Methylation at K768 (Pr = 0.17 | P = 0.01), ELME000146,-
COL4A5_HUMAN,G603V,0.941,Loss of B-factor (Pr = 0.33 | P = 2.9e-03); Gain of Acetylation at K599 (Pr = 0.24 | P = 0.02); Loss of Methylation at K599 (Pr = 0.20 | P = 6.3e-03); Gain of SUMOylation at K599 (Pr = 0.20 | P = 0.03), ELME000005|ELME000155|ELME000259,-
COL4A5_HUMAN,G902V,0.953,Loss of B-factor (Pr = 0.32 | P = 3.7e-03), ELME000155,-
COL4A5_HUMAN,G230D,0.937,Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of SUMOylation at K229 (Pr = 0.26 | P = 5.8e-03); Loss of Acetylation at K226 (Pr = 0.25 | P = 0.01); Loss of Methylation at K229 (Pr = 0.21 | P = 5.6e-03), None,-
COL4A5_HUMAN,G722R,0.961,Altered Disordered interface (Pr = 0.30 | P = 0.02); Loss of B-factor (Pr = 0.28 | P = 0.02), None,-
COL4A5_HUMAN,G1454R,0.922,Loss of B-factor (Pr = 0.29 | P = 0.01); Gain of O-linked glycosylation at T1455 (Pr = 0.14 | P = 0.03), ELME000006|ELME000052|ELME000062|ELME000065|ELME000135|ELME000239,-
COL4A5_HUMAN,K922I,0.645,Loss of Acetylation at K922 (Pr = 0.34 | P = 2.4e-03); Altered Disordered interface (Pr = 0.30 | P = 0.03); Loss of B-factor (Pr = 0.29 | P = 0.01); Loss of Methylation at K922 (Pr = 0.21 | P = 5.0e-03); Altered Metal binding (Pr = 0.11 | P = 0.04), None,-
COL4A5_HUMAN,G1276S,0.875,Gain of Loop (Pr = 0.27 | P = 0.02); Gain of SUMOylation at K1281 (Pr = 0.27 | P = 5.4e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Methylation at K1281 (Pr = 0.26 | P = 1.4e-03); Loss of Acetylation at K1281 (Pr = 0.24 | P = 0.02), PS00008,-
COL4A5_HUMAN,G860S,0.929,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Loop (Pr = 0.27 | P = 0.04), ELME000053|PS00005,-
COL4A5_HUMAN,G878E,0.935,Gain of Loop (Pr = 0.28 | P = 0.01); Loss of B-factor (Pr = 0.26 | P = 0.04), ELME000136|ELME000155|ELME000159,-
COL4A5_HUMAN,G1063D,0.939,Gain of Loop (Pr = 0.28 | P = 0.01); Gain of B-factor (Pr = 0.26 | P = 0.01); Loss of Acetylation at K1062 (Pr = 0.24 | P = 0.02); Loss of Methylation at K1062 (Pr = 0.19 | P = 8.5e-03), ELME000118,-
COL4A5_HUMAN,G1024E,0.886,Altered Disordered interface (Pr = 0.29 | P = 0.03); Gain of SUMOylation at K1026 (Pr = 0.26 | P = 6.3e-03); Loss of Methylation at K1026 (Pr = 0.16 | P = 0.01), PS00008,-
COL4A5_HUMAN,G582R,0.96,Loss of Loop (Pr = 0.29 | P = 8.9e-03), ELME000155,-
COL4A5_HUMAN,G641V,0.935,Loss of B-factor (Pr = 0.26 | P = 0.04), ELME000155,-
COL4A5_HUMAN,G635V,0.946,Loss of Acetylation at K634 (Pr = 0.29 | P = 4.8e-03); Loss of Methylation at K634 (Pr = 0.20 | P = 7.1e-03); Gain of SUMOylation at K634 (Pr = 0.20 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q637 (Pr = 0.04 | P = 0.05), None,-
COL4A5_HUMAN,G1258S,0.934,Gain of Loop (Pr = 0.33 | P = 1.2e-03); Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of Phosphorylation at G1258 (Pr = 0.25 | P = 0.03), ELME000136|ELME000155|ELME000159,-
COL4A5_HUMAN,G1439V,0.96,Loss of B-factor (Pr = 0.33 | P = 3.1e-03), ELME000106|ELME000155,-
COL4A5_HUMAN,G310R,0.952,Altered Disordered interface (Pr = 0.28 | P = 0.03), ELME000155,-
COL4A5_HUMAN,G289V,0.961,Loss of B-factor (Pr = 0.34 | P = 1.7e-03); Gain of SUMOylation at K288 (Pr = 0.29 | P = 3.6e-03); Gain of Loop (Pr = 0.27 | P = 0.03); Gain of Acetylation at K285 (Pr = 0.27 | P = 6.1e-03); Loss of Methylation at K288 (Pr = 0.27 | P = 1.2e-03), None,-
COL4A5_HUMAN,G763E,0.936,Gain of Loop (Pr = 0.28 | P = 0.01); Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Acetylation at K768 (Pr = 0.25 | P = 0.01); Gain of SUMOylation at K768 (Pr = 0.21 | P = 0.03); Loss of Methylation at K768 (Pr = 0.17 | P = 0.01), None,-
COL4A5_HUMAN,G635S,0.901,Loss of Acetylation at K634 (Pr = 0.30 | P = 4.4e-03); Loss of Methylation at K634 (Pr = 0.20 | P = 6.7e-03), ELME000147,-
COL4A5_HUMAN,G227S,0.879,Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of SUMOylation at K229 (Pr = 0.26 | P = 7.0e-03); Loss of Acetylation at K226 (Pr = 0.25 | P = 0.01); Loss of Methylation at K229 (Pr = 0.21 | P = 5.8e-03), ELME000002|PS00005,-
COL4A5_HUMAN,G201R,0.956,Altered Disordered interface (Pr = 0.28 | P = 0.04); Loss of B-factor (Pr = 0.28 | P = 0.02), ELME000006|ELME000135,-
COL4A5_HUMAN,G719R,0.957,Altered Disordered interface (Pr = 0.30 | P = 0.02); Gain of Loop (Pr = 0.28 | P = 0.02); Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of Acetylation at K715 (Pr = 0.25 | P = 0.01); Loss of Methylation at K715 (Pr = 0.22 | P = 4.4e-03); Gain of SUMOylation at K715 (Pr = 0.19 | P = 0.04), ELME000005|ELME000155,-
COL4A5_HUMAN,G383D,0.915,Gain of Loop (Pr = 0.27 | P = 0.03); Loss of B-factor (Pr = 0.26 | P = 0.05), ELME000155,-
COL4A5_HUMAN,G334V,0.924,Loss of B-factor (Pr = 0.31 | P = 6.4e-03); Gain of Acetylation at K330 (Pr = 0.27 | P = 7.6e-03); Loss of Methylation at K330 (Pr = 0.24 | P = 2.5e-03); Loss of SUMOylation at K333 (Pr = 0.19 | P = 0.04), ELME000173,-
COL4A5_HUMAN,G811V,0.924,Loss of B-factor (Pr = 0.32 | P = 3.9e-03), ELME000155,-
COL4A5_HUMAN,G852R,0.9,Loss of Loop (Pr = 0.29 | P = 9.5e-03); Loss of B-factor (Pr = 0.28 | P = 0.02), ELME000097|ELME000135|ELME000155,-
COL4A5_HUMAN,G1057E,0.943,Gain of Loop (Pr = 0.30 | P = 5.3e-03); Loss of Acetylation at K1062 (Pr = 0.24 | P = 0.02); Loss of Methylation at K1062 (Pr = 0.19 | P = 8.3e-03); Gain of SUMOylation at K1062 (Pr = 0.18 | P = 0.05), ELME000136|ELME000159,-
COL4A5_HUMAN,G1107R,0.959,Gain of O-linked glycosylation at T1111 (Pr = 0.12 | P = 0.04), ELME000155,-
COL4A5_HUMAN,G466E,0.915,Gain of Loop (Pr = 0.26 | P = 0.05); Loss of B-factor (Pr = 0.25 | P = 0.05); Loss of Acetylation at K465 (Pr = 0.21 | P = 0.04); Loss of Methylation at K465 (Pr = 0.19 | P = 8.5e-03), None,-
COL4A5_HUMAN,G1211E,0.936,Altered Disordered interface (Pr = 0.27 | P = 0.04); Gain of Loop (Pr = 0.27 | P = 0.04), ELME000155|PS00008,-
COL4A5_HUMAN,G796E,0.949,Gain of Loop (Pr = 0.30 | P = 4.5e-03); Loss of B-factor (Pr = 0.26 | P = 0.05); Gain of Acetylation at K798 (Pr = 0.20 | P = 0.04); Loss of Methylation at K798 (Pr = 0.18 | P = 8.8e-03); Altered Metal binding (Pr = 0.11 | P = 0.04), None,-
COL4A5_HUMAN,G635D,0.937,Loss of Acetylation at K634 (Pr = 0.27 | P = 7.1e-03); Loss of Methylation at K634 (Pr = 0.20 | P = 6.3e-03); Gain of SUMOylation at K634 (Pr = 0.18 | P = 0.05), None,-
COL4A5_HUMAN,G123R,0.968,Gain of SUMOylation at K128 (Pr = 0.25 | P = 7.9e-03); Gain of Acetylation at K128 (Pr = 0.20 | P = 0.04); Loss of Methylation at K128 (Pr = 0.15 | P = 0.02); Loss of N-linked glycosylation at N125 (Pr = 0.02 | P = 0.03), PS00008,-
COL4A5_HUMAN,G1158W,0.938,Loss of B-factor (Pr = 0.33 | P = 2.8e-03); Altered Disordered interface (Pr = 0.27 | P = 0.05); Altered Metal binding (Pr = 0.12 | P = 0.03), ELME000155|PS00008,-
COL2A1_HUMAN,V116I,0.087,-,-,-
COL2A1_HUMAN,V116T,0.275,-,-,-
COL2A1_HUMAN,R134K,0.483,-,-,-
COL2A1_HUMAN,A145V,0.104,-,-,-
COL2A1_HUMAN,P170A,0.694,Loss of B-factor (Pr = 0.35 | P = 1.1e-03); Gain of Loop (Pr = 0.31 | P = 3.8e-03); Altered Disordered interface (Pr = 0.27 | P = 0.04), ELME000155,-
COL2A1_HUMAN,P172T,0.729,Loss of B-factor (Pr = 0.32 | P = 3.6e-03); Gain of Loop (Pr = 0.29 | P = 8.3e-03); Altered Disordered interface (Pr = 0.27 | P = 0.04), ELME000052|ELME000136|ELME000155|ELME000159|ELME000358,-
COL2A1_HUMAN,P173K,0.648,Altered Disordered interface (Pr = 0.29 | P = 0.03); Gain of Loop (Pr = 0.29 | P = 9.8e-03); Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of SUMOylation at P173 (Pr = 0.23 | P = 0.02); Gain of Methylation at P173 (Pr = 0.21 | P = 2.9e-03); Gain of Ubiquitylation at P173 (Pr = 0.18 | P = 0.02), ELME000155,-
COL2A1_HUMAN,G185S,0.561,Altered Disordered interface (Pr = 0.27 | P = 0.05); Gain of Acetylation at K190 (Pr = 0.19 | P = 0.05); Loss of SUMOylation at K190 (Pr = 0.19 | P = 0.04); Loss of Ubiquitylation at K190 (Pr = 0.19 | P = 0.01); Gain of O-linked glycosylation at G185 (Pr = 0.13 | P = 0.04); Gain of Proteolytic cleavage at Q182 (Pr = 0.12 | P = 0.03); Loss of Methylation at K190 (Pr = 0.11 | P = 0.04); Loss of Pyrrolidone carboxylic acid at Q182 (Pr = 0.06 | P = 0.03), ELME000085|PS00006,-
COL2A1_HUMAN,M239L,0.259,-,-,-
COL2A1_HUMAN,P247L,0.371,-,-,-
COL2A1_HUMAN,P251A,0.294,-,-,-
COL2A1_HUMAN,A263S,0.034,-,-,-
COL2A1_HUMAN,P314S,0.297,-,-,-
COL2A1_HUMAN,A340T,0.413,-,-,-
COL2A1_HUMAN,A341V,0.504,Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Methylation at R344 (Pr = 0.22 | P = 4.2e-03), PS00008,-
COL2A1_HUMAN,P391S,0.321,-,-,-
COL2A1_HUMAN,P395A,0.181,-,-,-
COL2A1_HUMAN,T397S,0.115,-,-,-
COL2A1_HUMAN,S407A,0.228,-,-,-
COL2A1_HUMAN,T412S,0.175,-,-,-
COL2A1_HUMAN,P473T,0.173,-,-,-
COL2A1_HUMAN,V500A,0.063,-,-,-
COL2A1_HUMAN,I503F,0.332,-,-,-
COL2A1_HUMAN,P530L,0.741,Altered Disordered interface (Pr = 0.31 | P = 0.02); Loss of B-factor (Pr = 0.27 | P = 0.02); Loss of Methylation at K527 (Pr = 0.24 | P = 2.7e-03); Gain of Acetylation at K527 (Pr = 0.22 | P = 0.03); Gain of SUMOylation at K527 (Pr = 0.20 | P = 0.03); Gain of Ubiquitylation at K527 (Pr = 0.16 | P = 0.04), ELME000146,-
COL2A1_HUMAN,S536T,0.18,-,-,-
COL2A1_HUMAN,P548I,0.823,Altered Disordered interface (Pr = 0.43 | P = 2.5e-03); Loss of B-factor (Pr = 0.32 | P = 3.6e-03); Loss of Methylation at R550 (Pr = 0.10 | P = 0.04), ELME000155,-
COL2A1_HUMAN,P554A,0.393,-,-,-
COL2A1_HUMAN,P581A,0.304,-,-,-
COL2A1_HUMAN,A647S,0.113,-,-,-
COL2A1_HUMAN,P670T,0.666,Loss of B-factor (Pr = 0.33 | P = 2.9e-03); Gain of Loop (Pr = 0.27 | P = 0.03); Gain of O-linked glycosylation at P670 (Pr = 0.15 | P = 0.03), ELME000057|ELME000136|ELME000155|ELME000159|ELME000358,-
COL2A1_HUMAN,P674A,0.419,-,-,-
COL2A1_HUMAN,G677A,0.289,-,-,-
COL2A1_HUMAN,V685I,0.096,-,-,-
COL2A1_HUMAN,A712T,0.203,-,-,-
COL2A1_HUMAN,P718A,0.069,-,-,-
COL2A1_HUMAN,P718S,0.28,-,-,-
COL2A1_HUMAN,S734A,0.111,-,-,-
COL2A1_HUMAN,L787M,0.279,-,-,-
COL2A1_HUMAN,P809A,0.329,-,-,-
COL2A1_HUMAN,S814A,0.127,-,-,-
COL2A1_HUMAN,A815T,0.207,-,-,-
COL2A1_HUMAN,E826Q,0.568,Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of Methylation at R824 (Pr = 0.13 | P = 0.02); Gain of Pyrrolidone carboxylic acid at E826 (Pr = 0.04 | P = 0.05), ELME000048|ELME000133|ELME000155,-
COL2A1_HUMAN,G837A,0.889,, None,-
COL2A1_HUMAN,A847P,0.381,-,-,-
COL2A1_HUMAN,Q856H,0.56,Loss of Methylation at K857 (Pr = 0.33 | P = 3.9e-04); Loss of Acetylation at K857 (Pr = 0.23 | P = 0.02); Gain of SUMOylation at K857 (Pr = 0.23 | P = 0.01); Gain of Ubiquitylation at K857 (Pr = 0.18 | P = 0.02), None,-
COL2A1_HUMAN,A862S,0.131,-,-,-
COL2A1_HUMAN,A871R,0.609,Loss of Loop (Pr = 0.27 | P = 0.04); Gain of B-factor (Pr = 0.25 | P = 0.03); Gain of ADP-ribosylation at A871 (Pr = 0.24 | P = 0.01); Gain of O-linked glycosylation at S869 (Pr = 0.13 | P = 0.04); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000005|ELME000085|ELME000155|PS00005,-
COL2A1_HUMAN,P914A,0.6,Loss of B-factor (Pr = 0.32 | P = 3.9e-03); Gain of Loop (Pr = 0.27 | P = 0.04); Loss of GPI-anchor amidation at N911 (Pr = 0.01 | P = 0.02), ELME000155|PS00008,-
COL2A1_HUMAN,S923A,0.096,-,-,-
COL2A1_HUMAN,A931S,0.117,-,-,-
COL2A1_HUMAN,P938Q,0.465,-,-,-
COL2A1_HUMAN,E943D,0.033,-,-,-
COL2A1_HUMAN,P952S,0.141,-,-,-
COL2A1_HUMAN,E958D,0.287,-,-,-
COL2A1_HUMAN,D961E,0.103,-,-,-
COL2A1_HUMAN,D1057E,0.285,-,-,-
COL2A1_HUMAN,E1060D,0.33,-,-,-
COL2A1_HUMAN,A1063P,0.266,-,-,-
COL2A1_HUMAN,P1072A,0.231,-,-,-
COL2A1_HUMAN,A1079T,0.12,-,-,-
COL2A1_HUMAN,D1087E,0.378,-,-,-
COL2A1_HUMAN,I1108L,0.138,-,-,-
COL2A1_HUMAN,L1129V,0.145,-,-,-
COL2A1_HUMAN,A1199V,0.282,-,-,-
COL2A1_HUMAN,L1236M,0.137,-,-,-
COL2A1_HUMAN,R1240Q,0.623,Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of Proteolytic cleavage at Q1237 (Pr = 0.20 | P = 2.3e-03); Gain of Sulfation at Y1238 (Pr = 0.03 | P = 0.02), None,-
COL2A1_HUMAN,A1245G,0.189,-,-,-
COL2A1_HUMAN,G1246D,0.371,-,-,-
COL2A1_HUMAN,G1246S,0.145,-,-,-
COL2A1_HUMAN,Q1250P,0.775,Gain of Loop (Pr = 0.28 | P = 0.01); Altered Transmembrane protein (Pr = 0.19 | P = 6.9e-03); Altered Coiled coil (Pr = 0.13 | P = 0.04), None,-
COL2A1_HUMAN,A1253V,0.068,-,-,-
COL2A1_HUMAN,E1254D,0.537,Altered Transmembrane protein (Pr = 0.18 | P = 7.9e-03); Altered Coiled coil (Pr = 0.12 | P = 0.04), None,-
COL2A1_HUMAN,D1256E,0.31,-,-,-
COL2A1_HUMAN,R1284Q,0.71,Altered Transmembrane protein (Pr = 0.25 | P = 1.4e-03); Gain of Disulfide linkage at C1283 (Pr = 0.14 | P = 0.04), ELME000106|ELME000146|ELME000220|ELME000337|PS00005|PS00006,-
COL2A1_HUMAN,E1292D,0.553,Altered Transmembrane protein (Pr = 0.11 | P = 0.03), None,-
COL2A1_HUMAN,W1293R,0.896,Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Transmembrane protein (Pr = 0.10 | P = 0.04); Gain of Sulfation at Y1298 (Pr = 0.05 | P = 8.0e-03), ELME000062|ELME000102,-
COL2A1_HUMAN,K1294P,0.81,Gain of Loop (Pr = 0.27 | P = 0.03); Altered Transmembrane protein (Pr = 0.10 | P = 0.05); Gain of Catalytic site at W1299 (Pr = 0.10 | P = 0.04); Gain of Sulfation at Y1298 (Pr = 0.07 | P = 4.9e-03), ELME000085|ELME000155|ELME000157,-
COL2A1_HUMAN,E1318D,0.741,Altered Ordered interface (Pr = 0.29 | P = 0.04); Altered Metal binding (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.27 | P = 5.9e-04); Gain of Disulfide linkage at C1323 (Pr = 0.26 | P = 4.2e-03), None,-
COL2A1_HUMAN,K1340R,0.476,-,-,-
COL2A1_HUMAN,S1360G,0.562,Altered Transmembrane protein (Pr = 0.29 | P = 3.0e-04); Loss of Strand (Pr = 0.26 | P = 0.04); Altered Ordered interface (Pr = 0.24 | P = 0.03); Altered Stability (Pr = 0.23 | P = 9.7e-03); Altered Metal binding (Pr = 0.12 | P = 0.03), ELME000336|PS00006,-
COL2A1_HUMAN,N1365S,0.173,-,-,-
COL2A1_HUMAN,N1372S,0.178,-,-,-
COL2A1_HUMAN,S1386F,0.695,Altered Ordered interface (Pr = 0.27 | P = 0.05); Altered Transmembrane protein (Pr = 0.14 | P = 0.02); Loss of Catalytic site at Y1391 (Pr = 0.11 | P = 0.04); Gain of N-linked glycosylation at N1388 (Pr = 0.04 | P = 0.02), ELME000053|ELME000095|ELME000122|ELME000202,-
COL2A1_HUMAN,I1389V,0.262,-,-,-
COL2A1_HUMAN,N1406S,0.501,Altered Metal binding (Pr = 0.27 | P = 7.7e-03); Altered Transmembrane protein (Pr = 0.27 | P = 6.2e-04); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.03); Gain of Methylation at K1408 (Pr = 0.13 | P = 0.02), ELME000239|ELME000313|ELME000337|PS00005,-
COL2A1_HUMAN,T1432N,0.215,-,-,-
COL2A1_HUMAN,K1435M,0.375,-,-,-
COL2A1_HUMAN,K1435R,0.207,-,-,-
COL2A1_HUMAN,G1446D,0.534,Loss of Relative solvent accessibility (Pr = 0.33 | P = 4.0e-03); Altered Transmembrane protein (Pr = 0.31 | P = 1.2e-04); Altered Metal binding (Pr = 0.30 | P = 0.02); Loss of Acetylation at K1447 (Pr = 0.21 | P = 0.03); Altered DNA binding (Pr = 0.16 | P = 0.04), ELME000064|ELME000147|ELME000220,-
COL2A1_HUMAN,K1447E,0.759,Altered Transmembrane protein (Pr = 0.33 | P = 4.9e-05); Loss of Relative solvent accessibility (Pr = 0.32 | P = 5.2e-03); Loss of Acetylation at K1447 (Pr = 0.25 | P = 0.01); Altered Metal binding (Pr = 0.19 | P = 0.04), ELME000064|ELME000220,-
COL2A1_HUMAN,V1449M,0.393,-,-,-
COL2A1_HUMAN,G447A,0.943,Loss of Methylation at K452 (Pr = 0.23 | P = 3.3e-03); Gain of SUMOylation at K452 (Pr = 0.18 | P = 0.05); Gain of Ubiquitylation at K452 (Pr = 0.16 | P = 0.04); Gain of O-linked glycosylation at T446 (Pr = 0.14 | P = 0.03), ELME000052|ELME000155,-
COL2A1_HUMAN,G465A,0.935,Altered Disordered interface (Pr = 0.32 | P = 0.02); Loss of Acetylation at K464 (Pr = 0.28 | P = 6.1e-03); Gain of SUMOylation at K464 (Pr = 0.28 | P = 4.0e-03); Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Methylation at K464 (Pr = 0.24 | P = 1.1e-03), ELME000002,-
COL2A1_HUMAN,Y1391C,0.953,Altered Metal binding (Pr = 0.57 | P = 3.4e-03); Altered Ordered interface (Pr = 0.39 | P = 1.2e-03); Altered Transmembrane protein (Pr = 0.27 | P = 9.3e-04); Gain of Helix (Pr = 0.27 | P = 0.05); Loss of Strand (Pr = 0.27 | P = 0.02); Gain of Disulfide linkage at C1393 (Pr = 0.12 | P = 0.04); Loss of Catalytic site at Y1391 (Pr = 0.11 | P = 0.03); Loss of N-linked glycosylation at N1388 (Pr = 0.04 | P = 0.02), ELME000070|PS00001,-
COL2A1_HUMAN,G429D,0.969,Altered Disordered interface (Pr = 0.28 | P = 0.04), ELME000155|ELME000293,-
COL2A1_HUMAN,G207E,0.95,Gain of Loop (Pr = 0.32 | P = 1.7e-03); Loss of Methylation at R209 (Pr = 0.27 | P = 1.4e-03); Loss of B-factor (Pr = 0.26 | P = 0.04), None,-
COL2A1_HUMAN,G642R,0.929,Altered Disordered interface (Pr = 0.28 | P = 0.04); Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of Methylation at G642 (Pr = 0.18 | P = 6.8e-03), ELME000155,-
COL2A1_HUMAN,G1110C,0.947,Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Methylation at R1106 (Pr = 0.21 | P = 5.9e-03), ELME000155,-
COL2A1_HUMAN,G25A,0.383,-,-,-
COL2A1_HUMAN,G1089V,0.961,Altered Disordered interface (Pr = 0.30 | P = 0.02); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Methylation at R1088 (Pr = 0.23 | P = 3.6e-03); Loss of SUMOylation at K1084 (Pr = 0.21 | P = 0.03); Gain of Acetylation at K1084 (Pr = 0.20 | P = 0.04); Loss of Ubiquitylation at K1084 (Pr = 0.15 | P = 0.04), None,-
WFS1_HUMAN,V871G,0.733,Altered Stability (Pr = 0.24 | P = 8.9e-03); Altered Transmembrane protein (Pr = 0.22 | P = 3.1e-03); Altered Metal binding (Pr = 0.07 | P = 0.02), ELME000062|ELME000337,-
WFS1_HUMAN,S631F,0.683,Altered Transmembrane protein (Pr = 0.32 | P = 7.8e-05); Gain of Loop (Pr = 0.31 | P = 4.0e-03); Gain of Strand (Pr = 0.26 | P = 0.04); Altered Ordered interface (Pr = 0.24 | P = 0.04), ELME000062|ELME000148,-
WFS1_HUMAN,E864G,0.787,Loss of Helix (Pr = 0.29 | P = 0.01); Gain of Strand (Pr = 0.28 | P = 0.01); Altered Transmembrane protein (Pr = 0.21 | P = 4.1e-03); Altered Stability (Pr = 0.15 | P = 0.02), ELME000002,-
WFS1_HUMAN,K843M,0.572,Altered Metal binding (Pr = 0.33 | P = 9.8e-03); Altered Transmembrane protein (Pr = 0.26 | P = 7.4e-04), ELME000336,-
WFS1_HUMAN,L459R,0.935,Gain of Intrinsic disorder (Pr = 0.32 | P = 0.03); Altered Transmembrane protein (Pr = 0.30 | P = 2.3e-04); Altered Ordered interface (Pr = 0.26 | P = 0.01); Altered Stability (Pr = 0.17 | P = 0.02), ELME000012|ELME000062|ELME000146,-
WFS1_HUMAN,G831S,0.69,Altered Transmembrane protein (Pr = 0.29 | P = 2.7e-04), ELME000053|ELME000220,-
WFS1_HUMAN,C505S,0.636,Altered Ordered interface (Pr = 0.24 | P = 0.04); Altered Transmembrane protein (Pr = 0.15 | P = 0.01); Gain of N-linked glycosylation at N500 (Pr = 0.07 | P = 0.02), ELME000063|ELME000335,-
WFS1_HUMAN,R375H,0.357,-,-,-
WFS1_HUMAN,L592P,0.841,Altered Transmembrane protein (Pr = 0.41 | P = 0.0e+00); Loss of Helix (Pr = 0.28 | P = 0.03); Gain of Loop (Pr = 0.27 | P = 0.03), ELME000048|ELME000051|ELME000053|ELME000064|ELME000136|ELME000159|ELME000220|ELME000336|PS00006,-
WFS1_HUMAN,M683R,0.844,Altered Transmembrane protein (Pr = 0.33 | P = 5.8e-05); Gain of Helix (Pr = 0.28 | P = 0.03); Altered Ordered interface (Pr = 0.25 | P = 0.02), ELME000173|ELME000202|ELME000336|PS00005,-
WFS1_HUMAN,Y528D,0.932,Altered Ordered interface (Pr = 0.33 | P = 3.1e-03); Altered Transmembrane protein (Pr = 0.29 | P = 3.1e-04); Altered DNA binding (Pr = 0.17 | P = 0.03), ELME000120|ELME000182|ELME000336,-
WFS1_HUMAN,V709M,0.615,Altered DNA binding (Pr = 0.29 | P = 4.1e-03); Altered Ordered interface (Pr = 0.27 | P = 9.1e-03); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered Metal binding (Pr = 0.23 | P = 5.0e-03); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000062|ELME000083|ELME000120|ELME000182|ELME000220,-
WFS1_HUMAN,R177P,0.917,Altered Disordered interface (Pr = 0.44 | P = 5.0e-03); Loss of Helix (Pr = 0.29 | P = 0.01); Altered Coiled coil (Pr = 0.17 | P = 0.03), ELME000102|ELME000149|ELME000276,-
WFS1_HUMAN,S430L,0.774,Altered Transmembrane protein (Pr = 0.24 | P = 1.5e-03), ELME000007|ELME000335,-
WFS1_HUMAN,C742G,0.788,Loss of Disulfide linkage at C742 (Pr = 0.74 | P = 1.6e-04); Gain of Intrinsic disorder (Pr = 0.41 | P = 7.2e-03); Gain of B-factor (Pr = 0.26 | P = 0.02); Altered Ordered interface (Pr = 0.24 | P = 0.04); Altered Metal binding (Pr = 0.22 | P = 0.05); Altered Transmembrane protein (Pr = 0.22 | P = 3.8e-03); Loss of N-linked glycosylation at N746 (Pr = 0.09 | P = 0.01); Altered Stability (Pr = 0.09 | P = 0.05), ELME000053|ELME000136|ELME000159|PS00008,-
WFS1_HUMAN,K836T,0.568,Altered Transmembrane protein (Pr = 0.25 | P = 1.3e-03), ELME000052|ELME000336,-
WFS1_HUMAN,L664R,0.953,Altered Transmembrane protein (Pr = 0.27 | P = 6.7e-04); Gain of N-linked glycosylation at N661 (Pr = 0.27 | P = 3.5e-04); Altered Ordered interface (Pr = 0.26 | P = 0.01); Loss of Sulfation at Y660 (Pr = 0.03 | P = 0.02); Gain of GPI-anchor amidation at N661 (Pr = 0.01 | P = 0.03), ELME000063|ELME000070|PS00001|PS00005,-
WFS1_HUMAN,E202G,0.701,Altered Stability (Pr = 0.23 | P = 9.2e-03), None,-
WFS1_HUMAN,F350V,0.818,Altered Ordered interface (Pr = 0.27 | P = 9.5e-03); Altered Transmembrane protein (Pr = 0.11 | P = 0.04), ELME000328|ELME000333|ELME000336,-
WFS1_HUMAN,S446R,0.733,Altered Ordered interface (Pr = 0.26 | P = 0.01); Altered Transmembrane protein (Pr = 0.21 | P = 3.6e-03), ELME000052|ELME000062|ELME000063|ELME000064|ELME000120|ELME000182|ELME000336,-
WFS1_HUMAN,E462G,0.675,Loss of Helix (Pr = 0.37 | P = 1.8e-04); Gain of Strand (Pr = 0.34 | P = 2.1e-04); Altered Transmembrane protein (Pr = 0.20 | P = 5.1e-03), ELME000052|ELME000147|PS00008,-
WFS1_HUMAN,I720V,0.166,-,-,-
WFS1_HUMAN,M306T,0.267,-,-,-
WFS1_HUMAN,P17L,0.04,-,-,-
WFS1_HUMAN,P17S,0.057,-,-,-
WFS1_HUMAN,P19L,0.058,-,-,-
WFS1_HUMAN,P41L,0.114,-,-,-
WFS1_HUMAN,Q47P,0.26,-,-,-
WFS1_HUMAN,G49S,0.073,-,-,-
WFS1_HUMAN,Q64H,0.058,-,-,-
WFS1_HUMAN,D116N,0.065,-,-,-
WFS1_HUMAN,D116P,0.127,-,-,-
WFS1_HUMAN,N122K,0.653,, ELME000079,-
WFS1_HUMAN,D151T,0.45,-,-,-
WFS1_HUMAN,D245E,0.26,-,-,-
WFS1_HUMAN,V258I,0.024,-,-,-
WFS1_HUMAN,F264L,0.09,-,-,-
WFS1_HUMAN,L315M,0.458,-,-,-
WFS1_HUMAN,V333I,0.029,-,-,-
WFS1_HUMAN,V483F,0.262,-,-,-
WFS1_HUMAN,L484F,0.208,-,-,-
WFS1_HUMAN,Q520R,0.407,-,-,-
WFS1_HUMAN,F725L,0.208,-,-,-
WFS1_HUMAN,G786S,0.148,-,-,-
WFS1_HUMAN,S816G,0.072,-,-,-
WFS1_HUMAN,L822V,0.075,-,-,-
WFS1_HUMAN,V606L,0.175,-,-,-
WFS1_HUMAN,G494S,0.743,Gain of Strand (Pr = 0.27 | P = 0.02); Gain of Loop (Pr = 0.26 | P = 0.05); Altered Transmembrane protein (Pr = 0.23 | P = 2.6e-03), ELME000052|ELME000053,-
WFS1_HUMAN,A58E,0.162,-,-,-
WFS1_HUMAN,S807R,0.436,-,-,-
WFS1_HUMAN,G736R,0.929,Gain of Helix (Pr = 0.29 | P = 0.01); Altered Metal binding (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.28 | P = 4.2e-04); Loss of Loop (Pr = 0.26 | P = 0.05); Altered Ordered interface (Pr = 0.25 | P = 0.02); Loss of Disulfide linkage at C733 (Pr = 0.17 | P = 0.03), None,-
WFS1_HUMAN,K634T,0.717,Gain of Strand (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.22 | P = 3.1e-03); Gain of ADP-ribosylation at R629 (Pr = 0.19 | P = 0.05), ELME000052|ELME000062|ELME000063|ELME000146|ELME000335,-
WFS1_HUMAN,G780A,0.75,Loss of Strand (Pr = 0.26 | P = 0.04); Altered Transmembrane protein (Pr = 0.15 | P = 0.02), ELME000147|ELME000155|ELME000336|PS00008,-
WFS1_HUMAN,A874T,0.474,-,-,-
WFS1_HUMAN,G674R,0.863,Altered Ordered interface (Pr = 0.36 | P = 3.4e-03); Altered Transmembrane protein (Pr = 0.31 | P = 1.3e-04); Loss of Disulfide linkage at C673 (Pr = 0.18 | P = 0.03), None,-
WFS1_HUMAN,H696Y,0.837,Altered Ordered interface (Pr = 0.42 | P = 5.4e-04); Altered Transmembrane protein (Pr = 0.31 | P = 1.3e-04); Altered Metal binding (Pr = 0.30 | P = 0.01); Gain of Allosteric site at W700 (Pr = 0.29 | P = 2.9e-03); Gain of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Altered DNA binding (Pr = 0.21 | P = 0.02), ELME000062|ELME000137,-
WFS1_HUMAN,R457S,0.635,Loss of Helix (Pr = 0.40 | P = 3.9e-05); Gain of Strand (Pr = 0.33 | P = 3.3e-04); Gain of Loop (Pr = 0.27 | P = 0.04); Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.24 | P = 1.8e-03); Gain of Sulfation at Y454 (Pr = 0.02 | P = 0.04), ELME000053|ELME000085|ELME000102|ELME000108|ELME000146|ELME000182|PS00005,-
WFS1_HUMAN,A126T,0.769,, ELME000063|ELME000220|PS00006,-
WFS1_HUMAN,I427N,0.806,Altered Transmembrane protein (Pr = 0.30 | P = 1.4e-04), ELME000007,-
WFS1_HUMAN,V861G,0.633,Gain of Intrinsic disorder (Pr = 0.34 | P = 0.02); Altered Stability (Pr = 0.31 | P = 5.3e-03); Loss of Helix (Pr = 0.28 | P = 0.03); Gain of Strand (Pr = 0.26 | P = 0.04); Altered Transmembrane protein (Pr = 0.22 | P = 3.9e-03), ELME000002|ELME000146,-
WFS1_HUMAN,G702S,0.852,Altered Transmembrane protein (Pr = 0.29 | P = 2.9e-04); Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered DNA binding (Pr = 0.28 | P = 3.3e-03); Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Loss of Allosteric site at W700 (Pr = 0.26 | P = 0.01), ELME000062|ELME000080|PS00005,-
WFS1_HUMAN,R793P,0.143,-,-,-
WFS1_HUMAN,S888L,0.574,Loss of Intrinsic disorder (Pr = 0.67 | P = 2.1e-04); Altered Transmembrane protein (Pr = 0.33 | P = 5.4e-05); Altered Ordered interface (Pr = 0.28 | P = 0.04), ELME000085|ELME000086|ELME000091,-
WFS1_HUMAN,V248G,0.816,Altered Disordered interface (Pr = 0.27 | P = 0.04); Gain of Acetylation at K253 (Pr = 0.24 | P = 0.02); Altered Stability (Pr = 0.17 | P = 0.02), None,-
WFS1_HUMAN,P428R,0.82,Loss of Loop (Pr = 0.27 | P = 0.03); Altered Transmembrane protein (Pr = 0.26 | P = 9.8e-04), ELME000007|ELME000062,-
WFS1_HUMAN,D729N,0.497,-,-,-
WFS1_HUMAN,K705N,0.731,Altered Ordered interface (Pr = 0.34 | P = 5.7e-03); Altered DNA binding (Pr = 0.30 | P = 2.9e-03); Altered Transmembrane protein (Pr = 0.29 | P = 3.6e-04); Loss of Allosteric site at W700 (Pr = 0.26 | P = 0.01), None,-
WFS1_HUMAN,D771H,0.821,Altered Metal binding (Pr = 0.23 | P = 0.05); Altered DNA binding (Pr = 0.22 | P = 0.02); Loss of Acetylation at K768 (Pr = 0.19 | P = 0.05), ELME000233,-
WFS1_HUMAN,R232P,0.643,Loss of Helix (Pr = 0.28 | P = 0.03); Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Phosphorylation at S235 (Pr = 0.27 | P = 0.03), ELME000106|ELME000173|ELME000231|ELME000239,-
WFS1_HUMAN,Y650H,0.811,Altered Transmembrane protein (Pr = 0.30 | P = 1.4e-04); Altered Ordered interface (Pr = 0.29 | P = 5.2e-03); Loss of Sulfation at Y650 (Pr = 0.02 | P = 0.03), ELME000080|ELME000182,-
WFS1_HUMAN,D797Y,0.638,Loss of Intrinsic disorder (Pr = 0.48 | P = 8.8e-03); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Loop (Pr = 0.27 | P = 0.04); Gain of Phosphorylation at D797 (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.16 | P = 0.04); Loss of Ubiquitylation at K800 (Pr = 0.16 | P = 0.03); Altered Transmembrane protein (Pr = 0.14 | P = 0.02); Gain of Sulfation at D797 (Pr = 0.04 | P = 0.01), ELME000052|ELME000182|PS00007,-
WFS1_HUMAN,W678R,0.886,Altered Ordered interface (Pr = 0.30 | P = 4.3e-03); Altered Transmembrane protein (Pr = 0.29 | P = 2.6e-04); Gain of Helix (Pr = 0.28 | P = 0.02); Loss of Loop (Pr = 0.27 | P = 0.04); Gain of Disulfide linkage at C673 (Pr = 0.24 | P = 7.9e-03), ELME000008|ELME000012|ELME000061|ELME000102|PS00004,-
WFS1_HUMAN,G107R,0.814,Loss of Loop (Pr = 0.33 | P = 2.6e-03); Loss of Acetylation at K108 (Pr = 0.33 | P = 2.7e-03); Gain of Helix (Pr = 0.32 | P = 3.3e-03), ELME000102|ELME000233,-
WFS1_HUMAN,V546D,0.712,Altered Transmembrane protein (Pr = 0.25 | P = 1.4e-03), ELME000147|ELME000313|ELME000333|ELME000335,-
WFS1_HUMAN,N661S,0.709,Loss of N-linked glycosylation at N661 (Pr = 0.51 | P = 5.8e-05); Altered Transmembrane protein (Pr = 0.28 | P = 3.8e-04); Altered Ordered interface (Pr = 0.25 | P = 0.02); Loss of Sulfation at Y660 (Pr = 0.03 | P = 0.02), ELME000053|ELME000070|ELME000173|PS00001,-
WFS1_HUMAN,V709G,0.852,Altered Stability (Pr = 0.70 | P = 5.5e-04); Altered DNA binding (Pr = 0.27 | P = 3.8e-03); Altered Ordered interface (Pr = 0.26 | P = 0.02); Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered Metal binding (Pr = 0.23 | P = 0.02); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000062|ELME000083|ELME000120|ELME000182|ELME000220,-
WFS1_HUMAN,G780S,0.747,Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered Transmembrane protein (Pr = 0.16 | P = 0.01), ELME000053|ELME000147|ELME000155|ELME000197|ELME000336|PS00008,-
WFS1_HUMAN,E809K,0.612,, ELME000053|ELME000062|ELME000065|ELME000173|ELME000197|ELME000233|ELME000336|PS00005,-
WFS1_HUMAN,W678L,0.837,Altered Ordered interface (Pr = 0.34 | P = 2.7e-03); Altered Transmembrane protein (Pr = 0.29 | P = 3.9e-04); Gain of Disulfide linkage at C673 (Pr = 0.20 | P = 0.02), ELME000146|ELME000336,-
WFS1_HUMAN,R868P,0.826,Loss of Helix (Pr = 0.30 | P = 5.1e-03); Altered Transmembrane protein (Pr = 0.22 | P = 3.3e-03); Altered Metal binding (Pr = 0.20 | P = 0.03), ELME000062|ELME000337,-
WFS1_HUMAN,E794K,0.399,-,-,-
WFS1_HUMAN,R285H,0.273,-,-,-
WFS1_HUMAN,E776V,0.896,, ELME000120|ELME000147|ELME000155|ELME000233|ELME000336,-
WFS1_HUMAN,Q14R,0.046,-,-,-
WFS1_HUMAN,T5A,0.039,-,-,-
WFS1_HUMAN,P7A,0.041,-,-,-
WFS1_HUMAN,R40G,0.069,-,-,-
WFS1_HUMAN,P44S,0.07,-,-,-
WFS1_HUMAN,A57V,0.095,-,-,-
WFS1_HUMAN,A65T,0.082,-,-,-
WFS1_HUMAN,G76C,0.16,-,-,-
WFS1_HUMAN,D118V,0.465,-,-,-
WFS1_HUMAN,C124A,0.448,-,-,-
WFS1_HUMAN,R146S,0.631,Altered Disordered interface (Pr = 0.38 | P = 7.5e-03); Altered Coiled coil (Pr = 0.25 | P = 0.02); Loss of Acetylation at K143 (Pr = 0.19 | P = 0.05); Altered Transmembrane protein (Pr = 0.12 | P = 0.03); Loss of Proteolytic cleavage at R147 (Pr = 0.12 | P = 0.04); Gain of Disulfide linkage at C148 (Pr = 0.09 | P = 0.05), ELME000012|ELME000102|ELME000108|ELME000333,-
WFS1_HUMAN,G213E,0.113,-,-,-
WFS1_HUMAN,L223V,0.063,-,-,-
WFS1_HUMAN,A422S,0.307,-,-,-
WFS1_HUMAN,V503I,0.074,-,-,-
WFS1_HUMAN,T590M,0.079,-,-,-
WFS1_HUMAN,V620M,0.086,-,-,-
COL2A1_HUMAN,T59N,0.378,-,-,-
COL2A1_HUMAN,T61N,0.312,-,-,-
COL2A1_HUMAN,I67V,0.205,-,-,-
COL2A1_HUMAN,I68H,0.592,Altered Metal binding (Pr = 0.37 | P = 9.8e-03); Gain of Disulfide linkage at C64 (Pr = 0.20 | P = 0.02); Altered Stability (Pr = 0.16 | P = 0.02); Loss of Proteolytic cleavage at D65 (Pr = 0.11 | P = 0.04), ELME000007|PS01208,-
COL2A1_HUMAN,V72S,0.204,-,-,-
COL2A1_HUMAN,V72T,0.13,-,-,-
COL2A1_HUMAN,S77H,0.215,-,-,-
COL2A1_HUMAN,A94S,0.158,-,-,-
COL2A1_HUMAN,A94T,0.148,-,-,-
COL2A1_HUMAN,A96T,0.212,-,-,-
COL2A1_HUMAN,Q99P,0.471,-,-,-
COL2A1_HUMAN,Q99R,0.193,-,-,-
COL2A1_HUMAN,P100H,0.495,-,-,-
COL2A1_HUMAN,G101F,0.906,Loss of B-factor (Pr = 0.34 | P = 1.6e-03); Gain of Acetylation at K103 (Pr = 0.31 | P = 3.4e-03); Loss of SUMOylation at K106 (Pr = 0.22 | P = 0.02); Gain of O-linked glycosylation at S97 (Pr = 0.19 | P = 0.02); Loss of Methylation at K106 (Pr = 0.18 | P = 0.01); Loss of Proteolytic cleavage at A96 (Pr = 0.16 | P = 7.5e-03); Gain of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), None,-
COL2A1_HUMAN,G101T,0.896,Gain of O-linked glycosylation at G101 (Pr = 0.34 | P = 3.8e-03); Loss of B-factor (Pr = 0.30 | P = 0.01); Gain of Phosphorylation at G101 (Pr = 0.25 | P = 0.03); Gain of SUMOylation at K106 (Pr = 0.22 | P = 0.02); Loss of Methylation at K106 (Pr = 0.17 | P = 0.01); Gain of Proteolytic cleavage at A96 (Pr = 0.17 | P = 6.3e-03); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), ELME000136|ELME000159|ELME000358|PS00005,-
COL2A1_HUMAN,G104T,0.945,Loss of B-factor (Pr = 0.30 | P = 0.01); Gain of SUMOylation at K106 (Pr = 0.22 | P = 0.02); Loss of Methylation at K106 (Pr = 0.17 | P = 0.01); Gain of O-linked glycosylation at G104 (Pr = 0.13 | P = 0.04); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), ELME000202|PS00005,-
COL2A1_HUMAN,P109W,0.893,Altered Disordered interface (Pr = 0.42 | P = 3.2e-03); Loss of B-factor (Pr = 0.30 | P = 8.4e-03); Loss of Acetylation at K113 (Pr = 0.28 | P = 5.7e-03); Loss of SUMOylation at K106 (Pr = 0.23 | P = 0.02); Loss of Methylation at K113 (Pr = 0.21 | P = 5.0e-03); Gain of Proteolytic cleavage at D114 (Pr = 0.16 | P = 8.7e-03); Gain of Pyrrolidone carboxylic acid at Q105 (Pr = 0.08 | P = 0.02), None,-
COL2A1_HUMAN,D111L,0.77,Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Acetylation at K113 (Pr = 0.25 | P = 0.01); Loss of SUMOylation at K106 (Pr = 0.22 | P = 0.02); Loss of Methylation at K113 (Pr = 0.19 | P = 7.9e-03); Gain of Proteolytic cleavage at D114 (Pr = 0.14 | P = 0.02), None,-
COL2A1_HUMAN,D114Q,0.688,Loss of Acetylation at K113 (Pr = 0.31 | P = 3.8e-03); Gain of Methylation at K119 (Pr = 0.21 | P = 3.9e-03); Loss of SUMOylation at K113 (Pr = 0.21 | P = 0.03); Loss of Proteolytic cleavage at D114 (Pr = 0.14 | P = 0.02), None,-
COL2A1_HUMAN,K119R,0.185,-,-,-
COL2A1_HUMAN,A145P,0.238,-,-,-
COL2A1_HUMAN,A145T,0.104,-,-,-
COL2A1_HUMAN,P146S,0.536,Gain of Loop (Pr = 0.27 | P = 0.02); Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of Acetylation at K143 (Pr = 0.25 | P = 0.01); Loss of Methylation at K143 (Pr = 0.25 | P = 2.1e-03); Loss of SUMOylation at K143 (Pr = 0.21 | P = 0.03); Gain of Ubiquitylation at K143 (Pr = 0.15 | P = 0.04), ELME000085,-
COL2A1_HUMAN,N160L,0.763,Loss of B-factor (Pr = 0.31 | P = 6.9e-03); Altered Disordered interface (Pr = 0.27 | P = 0.04), ELME000052|ELME000057|ELME000155|ELME000159|ELME000358,-
COL2A1_HUMAN,P169H,0.759,Loss of B-factor (Pr = 0.34 | P = 1.5e-03); Gain of Loop (Pr = 0.29 | P = 0.01), ELME000155,-
COL2A1_HUMAN,P169R,0.796,Loss of B-factor (Pr = 0.34 | P = 2.0e-03); Gain of Loop (Pr = 0.28 | P = 0.01); Gain of ADP-ribosylation at P169 (Pr = 0.20 | P = 0.03); Gain of Methylation at P169 (Pr = 0.11 | P = 0.03), ELME000006|ELME000097|ELME000155,-
COL2A1_HUMAN,G171F,0.947,Altered Disordered interface (Pr = 0.42 | P = 3.1e-03); Loss of B-factor (Pr = 0.38 | P = 2.1e-04); Gain of Loop (Pr = 0.30 | P = 5.4e-03), ELME000155,-
COL2A1_HUMAN,G176S,0.599,Gain of Loop (Pr = 0.31 | P = 3.5e-03); Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of O-linked glycosylation at G176 (Pr = 0.19 | P = 0.02), ELME000085|ELME000197|PS00008,-
COL2A1_HUMAN,D188E,0.275,-,-,-
COL2A1_HUMAN,E189D,0.359,-,-,-
COL2A1_HUMAN,S236A,0.142,-,-,-
COL2A1_HUMAN,P305T,0.39,-,-,-
COL2A1_HUMAN,S313A,0.181,-,-,-
COL2A1_HUMAN,P314A,0.253,-,-,-
COL2A1_HUMAN,S319A,0.224,-,-,-
COL2A1_HUMAN,G360S,0.917,Gain of Loop (Pr = 0.32 | P = 1.7e-03); Loss of B-factor (Pr = 0.26 | P = 0.05), ELME000136|ELME000159,-
COL2A1_HUMAN,A404V,0.313,-,-,-
COL2A1_HUMAN,T412A,0.246,-,-,-
COL2A1_HUMAN,A418P,0.862,Gain of B-factor (Pr = 0.27 | P = 0.01); Altered Disordered interface (Pr = 0.26 | P = 0.05); Loss of Methylation at K419 (Pr = 0.26 | P = 1.5e-03); Loss of Ubiquitylation at K419 (Pr = 0.22 | P = 2.7e-03); Loss of SUMOylation at K419 (Pr = 0.19 | P = 0.04), ELME000239|PS00008,-
COL2A1_HUMAN,A476T,0.152,-,-,-
COL2A1_HUMAN,A493G,0.301,-,-,-
COL2A1_HUMAN,I503A,0.259,-,-,-
COL2A1_HUMAN,A539T,0.213,-,-,-
COL2A1_HUMAN,P548T,0.692,Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of Methylation at R550 (Pr = 0.10 | P = 0.04), ELME000155|PS00005,-
COL2A1_HUMAN,V575I,0.089,-,-,-
COL2A1_HUMAN,A580T,0.169,-,-,-
COL2A1_HUMAN,N611S,0.315,-,-,-
COL2A1_HUMAN,P646K,0.816,Gain of Methylation at P646 (Pr = 0.45 | P = 1.9e-05); Gain of Acetylation at P646 (Pr = 0.35 | P = 1.9e-03); Altered Disordered interface (Pr = 0.28 | P = 0.04); Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of SUMOylation at P646 (Pr = 0.25 | P = 8.4e-03); Gain of Ubiquitylation at P646 (Pr = 0.25 | P = 1.7e-03), ELME000155,-
COL2A1_HUMAN,A647T,0.169,-,-,-
COL2A1_HUMAN,P680Q,0.335,-,-,-
COL2A1_HUMAN,P686S,0.72,Gain of Loop (Pr = 0.27 | P = 0.04); Gain of O-linked glycosylation at P686 (Pr = 0.14 | P = 0.03), ELME000085|ELME000156,-
COL2A1_HUMAN,T727N,0.434,-,-,-
COL2A1_HUMAN,P730S,0.698,Loss of Methylation at K731 (Pr = 0.25 | P = 1.8e-03); Gain of Acetylation at K731 (Pr = 0.24 | P = 0.02); Loss of SUMOylation at K731 (Pr = 0.19 | P = 0.04); Gain of Ubiquitylation at K731 (Pr = 0.17 | P = 0.03); Loss of O-linked glycosylation at T727 (Pr = 0.13 | P = 0.04); Altered Metal binding (Pr = 0.10 | P = 0.05), ELME000053|PS00008,-
COL2A1_HUMAN,K731T,0.821,Loss of Methylation at K731 (Pr = 0.50 | P = 9.7e-05); Gain of Loop (Pr = 0.33 | P = 1.6e-03); Loss of Acetylation at K731 (Pr = 0.33 | P = 2.8e-03); Loss of SUMOylation at K731 (Pr = 0.24 | P = 0.01); Loss of Ubiquitylation at K731 (Pr = 0.21 | P = 5.0e-03); Loss of O-linked glycosylation at T727 (Pr = 0.12 | P = 0.05), ELME000053,-
COL2A1_HUMAN,S734P,0.376,-,-,-
COL2A1_HUMAN,P736A,0.479,-,-,-
COL2A1_HUMAN,P740T,0.344,-,-,-
COL2A1_HUMAN,V806A,0.16,-,-,-
COL2A1_HUMAN,V806I,0.085,-,-,-
COL2A1_HUMAN,P832S,0.642,Loss of B-factor (Pr = 0.28 | P = 0.02); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000085|ELME000155|ELME000197,-
COL2A1_HUMAN,G834T,0.962,Loss of B-factor (Pr = 0.26 | P = 0.03); Gain of O-linked glycosylation at G834 (Pr = 0.13 | P = 0.04), None,-
COL2A1_HUMAN,F835I,0.496,-,-,-
COL2A1_HUMAN,S869T,0.37,-,-,-
COL2A1_HUMAN,A871S,0.298,-,-,-
COL2A1_HUMAN,G915T,0.968,Loss of B-factor (Pr = 0.31 | P = 5.9e-03); Gain of Phosphorylation at G915 (Pr = 0.24 | P = 0.04); Gain of O-linked glycosylation at S910 (Pr = 0.13 | P = 0.04); Gain of GPI-anchor amidation at N911 (Pr = 0.02 | P = 0.02), ELME000136|ELME000155|ELME000159,-
COL2A1_HUMAN,P920H,0.554,Loss of B-factor (Pr = 0.34 | P = 1.7e-03); Loss of Methylation at K925 (Pr = 0.29 | P = 7.6e-04); Gain of Loop (Pr = 0.27 | P = 0.04); Gain of Acetylation at K925 (Pr = 0.26 | P = 7.7e-03); Loss of SUMOylation at K925 (Pr = 0.18 | P = 0.05); Loss of O-linked glycosylation at S923 (Pr = 0.16 | P = 0.03), ELME000239,-
COL2A1_HUMAN,D926E,0.288,-,-,-
COL2A1_HUMAN,P937A,0.284,-,-,-
COL2A1_HUMAN,P938A,0.328,-,-,-
COL2A1_HUMAN,E955D,0.19,-,-,-
COL2A1_HUMAN,E955L,0.455,-,-,-
COL2A1_HUMAN,S965A,0.214,-,-,-
COL2A1_HUMAN,A967P,0.132,-,-,-
COL2A1_HUMAN,A967S,0.09,-,-,-
COL2A1_HUMAN,A967V,0.109,-,-,-
COL2A1_HUMAN,E968D,0.047,-,-,-
COL2A1_HUMAN,S1039T,0.151,-,-,-
COL2A1_HUMAN,P1072S,0.364,-,-,-
COL2A1_HUMAN,S1100A,0.133,-,-,-
COL2A1_HUMAN,I1108M,0.127,-,-,-
COL2A1_HUMAN,Q1109A,0.232,-,-,-
COL2A1_HUMAN,S1148A,0.173,-,-,-
COL2A1_HUMAN,V1169I,0.101,-,-,-
COL2A1_HUMAN,N1204K,0.383,-,-,-
COL2A1_HUMAN,N1204T,0.395,-,-,-
COL2A1_HUMAN,P1228A,0.111,-,-,-
COL2A1_HUMAN,P1228G,0.283,-,-,-
COL2A1_HUMAN,A1244P,0.697,Gain of Intrinsic disorder (Pr = 0.35 | P = 0.02); Altered Disordered interface (Pr = 0.26 | P = 0.05); Loss of Proteolytic cleavage at D1242 (Pr = 0.19 | P = 3.1e-03); Altered Transmembrane protein (Pr = 0.17 | P = 0.01), None,-
COL2A1_HUMAN,H1290L,0.952,Altered Ordered interface (Pr = 0.29 | P = 0.02); Altered Metal binding (Pr = 0.23 | P = 0.04); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000233,-
COL2A1_HUMAN,E1292A,0.728,Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000239,-
COL2A1_HUMAN,N1327S,0.262,-,-,-
COL2A1_HUMAN,A1329V,0.189,-,-,-
COL2A1_HUMAN,N1330T,0.213,-,-,-
COL2A1_HUMAN,K1344Q,0.391,-,-,-
COL2A1_HUMAN,I1347V,0.116,-,-,-
COL2A1_HUMAN,I1353M,0.466,-,-,-
COL2A1_HUMAN,D1364G,0.452,-,-,-
COL2A1_HUMAN,V1373I,0.168,-,-,-
COL2A1_HUMAN,A1404S,0.26,-,-,-
COL2A1_HUMAN,N1406H,0.527,Altered Metal binding (Pr = 0.32 | P = 0.01); Altered Ordered interface (Pr = 0.32 | P = 0.01); Altered Transmembrane protein (Pr = 0.28 | P = 3.9e-04); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Loss of Methylation at K1408 (Pr = 0.14 | P = 0.02), ELME000313,-
SLC26A4_HUMAN,T508A,0.541,Loss of Strand (Pr = 0.27 | P = 0.01), ELME000052|ELME000335,-
SLC26A4_HUMAN,C466Y,0.365,-,-,-
SLC26A4_HUMAN,F667C,0.895,Loss of Strand (Pr = 0.27 | P = 0.01), ELME000007|ELME000162|ELME000313|PS00006|PS00008,-
SLC26A4_HUMAN,V480D,0.75,Gain of Helix (Pr = 0.34 | P = 8.9e-04); Loss of Strand (Pr = 0.32 | P = 4.8e-04); Altered Stability (Pr = 0.15 | P = 0.02), ELME000233,-
SLC26A4_HUMAN,Y536C,0.852,Altered Transmembrane protein (Pr = 0.28 | P = 6.2e-04); Altered Ordered interface (Pr = 0.28 | P = 0.04); Gain of Disulfide linkage at Y536 (Pr = 0.18 | P = 0.03), ELME000084|ELME000120,-
SLC26A4_HUMAN,N457D,0.865,Altered Transmembrane protein (Pr = 0.11 | P = 0.04), ELME000193,-
SLC26A4_HUMAN,P112S,0.601,Altered Ordered interface (Pr = 0.29 | P = 5.6e-03); Altered Transmembrane protein (Pr = 0.25 | P = 1.2e-03), ELME000239,-
SLC26A4_HUMAN,A456D,0.837,Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000193|ELME000333,-
SLC26A4_HUMAN,M147V,0.889,, ELME000053|ELME000148|ELME000335|ELME000336,-
SLC26A4_HUMAN,Q421L,0.901,Loss of Intrinsic disorder (Pr = 0.37 | P = 0.04); Loss of Pyrrolidone carboxylic acid at Q421 (Pr = 0.26 | P = 6.9e-04); Gain of Ubiquitylation at K419 (Pr = 0.16 | P = 0.03); Loss of Methylation at K419 (Pr = 0.15 | P = 0.02), ELME000106|ELME000202,-
SLC26A4_HUMAN,A664V,0.475,-,-,-
SLC26A4_HUMAN,F692L,0.656,, ELME000182,-
SLC26A4_HUMAN,I655N,0.787,Loss of Strand (Pr = 0.30 | P = 1.9e-03); Gain of N-linked glycosylation at I655 (Pr = 0.01 | P = 0.04), ELME000070|ELME000239|PS00001,-
SLC26A4_HUMAN,E384G,0.924,Altered Metal binding (Pr = 0.52 | P = 3.8e-04); Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Loss of Helix (Pr = 0.30 | P = 7.7e-03); Altered Ordered interface (Pr = 0.28 | P = 0.04); Loss of Catalytic site at E384 (Pr = 0.23 | P = 8.2e-03), None,-
SLC26A4_HUMAN,S666F,0.765,Loss of Catalytic site at D661 (Pr = 0.14 | P = 0.02); Altered Metal binding (Pr = 0.13 | P = 0.05), ELME000313|PS00006,-
SLC26A4_HUMAN,V231E,0.885,Gain of Helix (Pr = 0.28 | P = 0.03); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000117|ELME000202|ELME000333,-
SLC26A4_HUMAN,G595E,0.505,Altered Disordered interface (Pr = 0.46 | P = 4.1e-03); Gain of Helix (Pr = 0.27 | P = 0.03); Loss of Acetylation at K590 (Pr = 0.27 | P = 6.6e-03); Altered Coiled coil (Pr = 0.12 | P = 0.03), ELME000002|ELME000085|ELME000134|ELME000313|ELME000336|PS00008,-
SLC26A4_HUMAN,D724G,0.895,Altered Metal binding (Pr = 0.06 | P = 0.03), ELME000134|ELME000220|PS00006,-
SLC26A4_HUMAN,V653A,0.496,-,-,-
SLC26A4_HUMAN,K601N,0.501,Loss of Strand (Pr = 0.26 | P = 0.05); Altered Disordered interface (Pr = 0.19 | P = 0.04); Loss of Ubiquitylation at K601 (Pr = 0.15 | P = 0.04), ELME000062|ELME000336,-
SLC26A4_HUMAN,L458P,0.963,Loss of Helix (Pr = 0.31 | P = 4.3e-03); Altered Transmembrane protein (Pr = 0.18 | P = 8.4e-03); Altered Stability (Pr = 0.10 | P = 0.04), None,-
SLC26A4_HUMAN,L50P,0.732,Gain of Intrinsic disorder (Pr = 0.41 | P = 7.2e-03); Gain of Helix (Pr = 0.28 | P = 0.02); Altered Stability (Pr = 0.13 | P = 0.03), ELME000136|ELME000153|ELME000159|ELME000276|ELME000336,-
SLC26A4_HUMAN,G222A,0.865,Altered Transmembrane protein (Pr = 0.24 | P = 2.2e-03), PS00008,-
SLC26A4_HUMAN,G204V,0.897,Altered Transmembrane protein (Pr = 0.01 | P = 0.01), None,-
SLC26A4_HUMAN,S694P,0.66,, ELME000157|ELME000182|PS00006,-
SLC26A4_HUMAN,V306G,0.828,Gain of Helix (Pr = 0.31 | P = 5.2e-03); Altered Metal binding (Pr = 0.13 | P = 0.05), ELME000053|ELME000333|ELME000335|PS00008,-
SLC26A4_HUMAN,T420I,0.724,Loss of Intrinsic disorder (Pr = 0.41 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q421 (Pr = 0.20 | P = 1.9e-03); Loss of Ubiquitylation at K419 (Pr = 0.17 | P = 0.03); Loss of Methylation at K419 (Pr = 0.15 | P = 0.02), ELME000053|ELME000202,-
SLC26A4_HUMAN,D271G,0.774,Altered Transmembrane protein (Pr = 0.29 | P = 1.9e-04); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Gain of GPI-anchor amidation at N268 (Pr = 0.01 | P = 0.03), ELME000052|ELME000147,-
SLC26A4_HUMAN,L68P,0.758,, ELME000106|ELME000136|ELME000159|ELME000335|ELME000358|PS00008,-
SLC26A4_HUMAN,G424D,0.827,Altered Ordered interface (Pr = 0.29 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q421 (Pr = 0.20 | P = 2.1e-03); Gain of Ubiquitylation at K419 (Pr = 0.17 | P = 0.03); Loss of Methylation at K419 (Pr = 0.15 | P = 0.02), PS00008,-
SLC26A4_HUMAN,T404I,0.699,, ELME000052|ELME000053|ELME000336,-
SLC26A4_HUMAN,R409H,0.857,Loss of ADP-ribosylation at R409 (Pr = 0.23 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q413 (Pr = 0.04 | P = 0.04), ELME000336,-
SLC26A4_HUMAN,E414K,0.641,Gain of Methylation at E414 (Pr = 0.19 | P = 6.4e-03); Loss of Ubiquitylation at K419 (Pr = 0.17 | P = 0.03); Gain of Pyrrolidone carboxylic acid at Q413 (Pr = 0.05 | P = 0.04), ELME000053|ELME000117,-
SLC26A4_HUMAN,L506R,0.879,Gain of Strand (Pr = 0.28 | P = 0.01); Altered Stability (Pr = 0.12 | P = 0.03); Altered Transmembrane protein (Pr = 0.01 | P = 8.8e-03), ELME000052|ELME000062|PS00008,-
SLC26A4_HUMAN,A106V,0.69,Altered Transmembrane protein (Pr = 0.30 | P = 1.6e-04); Altered Ordered interface (Pr = 0.26 | P = 0.01), ELME000083|ELME000120|ELME000182|PS00008,-
SLC26A4_HUMAN,L668P,0.929,Loss of Helix (Pr = 0.29 | P = 0.01); Altered Stability (Pr = 0.19 | P = 0.01), ELME000313|PS00006,-
SLC26A4_HUMAN,H723Y,0.723,Altered Metal binding (Pr = 0.06 | P = 0.03), ELME000120|ELME000134|ELME000142|ELME000220|ELME000336|PS00006,-
SLC26A4_HUMAN,E704Q,0.327,-,-,-
SLC26A4_HUMAN,Y556H,0.779,Altered Ordered interface (Pr = 0.32 | P = 0.01); Altered DNA binding (Pr = 0.28 | P = 3.4e-03), ELME000020|ELME000084|ELME000120,-
SLC26A4_HUMAN,S28R,0.458,-,-,-
SLC26A4_HUMAN,Y105C,0.834,Altered Ordered interface (Pr = 0.53 | P = 1.1e-04); Altered Transmembrane protein (Pr = 0.31 | P = 9.7e-05); Gain of Catalytic site at Q101 (Pr = 0.09 | P = 0.04), ELME000120|PS00008,-
SLC26A4_HUMAN,Y556C,0.866,Altered Ordered interface (Pr = 0.32 | P = 0.01); Loss of Strand (Pr = 0.27 | P = 0.01); Altered DNA binding (Pr = 0.24 | P = 0.01), ELME000020|ELME000084|ELME000120,-
SLC26A4_HUMAN,T416P,0.805,Gain of B-factor (Pr = 0.26 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q421 (Pr = 0.19 | P = 2.4e-03); Loss of Ubiquitylation at K419 (Pr = 0.16 | P = 0.03); Gain of Methylation at K419 (Pr = 0.15 | P = 0.01), ELME000053|ELME000136|ELME000159,-
SLC26A4_HUMAN,F515S,0.754,Altered Ordered interface (Pr = 0.28 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q514 (Pr = 0.05 | P = 0.03); Gain of GPI-anchor amidation at N519 (Pr = 0.04 | P = 5.7e-03), ELME000136|ELME000137|ELME000155|ELME000159|ELME000173,-
SLC26A4_HUMAN,P297Q,0.459,-,-,-
SLC26A4_HUMAN,V233L,0.487,-,-,-
SLC26A4_HUMAN,E303Q,0.831,Loss of Helix (Pr = 0.28 | P = 0.02); Gain of Strand (Pr = 0.26 | P = 0.04); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000335,-
SLC26A4_HUMAN,I455F,0.864,Altered Transmembrane protein (Pr = 0.12 | P = 0.03), None,-
SLC26A4_HUMAN,L597S,0.655,Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered Disordered interface (Pr = 0.27 | P = 0.01); Loss of Helix (Pr = 0.27 | P = 0.04); Loss of Acetylation at K593 (Pr = 0.26 | P = 0.01), ELME000062|ELME000063|ELME000134|ELME000313|ELME000336|PS00008,-
SLC26A4_HUMAN,G6V,0.122,-,-,-
SLC26A4_HUMAN,N392S,0.814,, ELME000053|ELME000063|ELME000197|ELME000336|ELME000337,-
SLC26A4_HUMAN,S552R,0.82,Altered Ordered interface (Pr = 0.31 | P = 0.01); Altered DNA binding (Pr = 0.29 | P = 2.3e-03); Loss of Allosteric site at F550 (Pr = 0.27 | P = 8.1e-03); Gain of ADP-ribosylation at S552 (Pr = 0.26 | P = 6.2e-03), ELME000062|ELME000136|ELME000146|ELME000159|ELME000197|ELME000336,-
SLC26A4_HUMAN,S391R,0.863,Gain of Helix (Pr = 0.27 | P = 0.04); Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000053|ELME000146|ELME000197|ELME000336,-
SLC26A4_HUMAN,D716G,0.707,Altered Transmembrane protein (Pr = 0.16 | P = 0.01), ELME000008|ELME000052|ELME000053|ELME000233|PS00004,-
SLC26A4_HUMAN,G389R,0.952,Altered Metal binding (Pr = 0.30 | P = 3.8e-03); Gain of Helix (Pr = 0.27 | P = 0.04); Gain of Catalytic site at E384 (Pr = 0.24 | P = 5.5e-03); Altered Transmembrane protein (Pr = 0.20 | P = 5.6e-03), ELME000053|ELME000062|ELME000336,-
SLC26A4_HUMAN,Q514R,0.699,Gain of ADP-ribosylation at Q514 (Pr = 0.26 | P = 6.6e-03); Altered Transmembrane protein (Pr = 0.09 | P = 0.05); Loss of Pyrrolidone carboxylic acid at Q514 (Pr = 0.06 | P = 0.03); Loss of GPI-anchor amidation at N519 (Pr = 0.04 | P = 7.0e-03), ELME000012|ELME000061|ELME000137|ELME000155,-
SLC26A4_HUMAN,V196D,0.794,, ELME000052|ELME000063|ELME000220|ELME000321|ELME000333|ELME000335|PS00006,-
SLC26A4_HUMAN,F335S,0.895,Gain of Intrinsic disorder (Pr = 0.37 | P = 0.01); Altered Ordered interface (Pr = 0.34 | P = 4.7e-03); Altered Transmembrane protein (Pr = 0.30 | P = 1.4e-04); Gain of B-factor (Pr = 0.25 | P = 0.03); Gain of ADP-ribosylation at R333 (Pr = 0.20 | P = 0.03), ELME000062|ELME000146|ELME000155|ELME000239,-
SLC26A4_HUMAN,T132I,0.832,Loss of Strand (Pr = 0.27 | P = 0.03); Altered Ordered interface (Pr = 0.24 | P = 0.04), ELME000053|ELME000336|PS00005|PS01130,-
SLC26A4_HUMAN,I199T,0.459,-,-,-
SLC26A4_HUMAN,V64L,0.128,-,-,-
SLC26A4_HUMAN,I89V,0.149,-,-,-
SLC26A4_HUMAN,A98G,0.059,-,-,-
SLC26A4_HUMAN,T183I,0.208,-,-,-
SLC26A4_HUMAN,I254S,0.853,Altered Transmembrane protein (Pr = 0.49 | P = 0.0e+00); Altered Stability (Pr = 0.11 | P = 0.03), ELME000020|ELME000053|ELME000064|ELME000220|ELME000333|ELME000336,-
SLC26A4_HUMAN,L276S,0.829,, ELME000052|ELME000147|ELME000335,-
SLC26A4_HUMAN,P337S,0.423,-,-,-
SLC26A4_HUMAN,P342S,0.086,-,-,-
SLC26A4_HUMAN,L436V,0.044,-,-,-
SLC26A4_HUMAN,I503V,0.052,-,-,-
SLC26A4_HUMAN,L627P,0.312,-,-,-
SLC26A4_HUMAN,S735C,0.101,-,-,-
SLC26A4_HUMAN,E737Q,0.063,-,-,-
SLC26A4_HUMAN,G740D,0.031,-,-,-
SLC26A4_HUMAN,T761A,0.031,-,-,-
SLC26A4_HUMAN,G663E,0.808,Altered Metal binding (Pr = 0.16 | P = 0.03); Loss of Catalytic site at D661 (Pr = 0.14 | P = 0.03), ELME000313,-
SLC26A4_HUMAN,G131V,0.896,Altered Ordered interface (Pr = 0.24 | P = 0.05), ELME000053|ELME000336|PS01130,-
SLC26A4_HUMAN,I426N,0.758,Altered Ordered interface (Pr = 0.27 | P = 0.05); Loss of Pyrrolidone carboxylic acid at Q421 (Pr = 0.20 | P = 2.0e-03); Gain of GPI-anchor amidation at I426 (Pr = 0.10 | P = 1.5e-03), ELME000085|PS00008,-
SLC26A4_HUMAN,V670A,0.423,-,-,-
SLC26A4_HUMAN,P525L,0.514,Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04), ELME000053|ELME000063|PS00008,-
SLC26A4_HUMAN,V97E,0.847,Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03), ELME000052|ELME000064|ELME000147|ELME000220|ELME000336|PS00006,-
SLC26A4_HUMAN,G663R,0.831,Gain of ADP-ribosylation at G663 (Pr = 0.25 | P = 9.4e-03); Altered Metal binding (Pr = 0.16 | P = 0.03); Loss of Catalytic site at D661 (Pr = 0.14 | P = 0.03), ELME000137|ELME000313,-
SLC26A4_HUMAN,D669V,0.949,Loss of ADP-ribosylation at R674 (Pr = 0.20 | P = 0.05), ELME000313|ELME000335|PS00006,-
SLC26A4_HUMAN,A104V,0.795,Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Altered Ordered interface (Pr = 0.26 | P = 0.01), PS00008,-
SLC26A4_HUMAN,F161I,0.393,-,-,-
SLC26A4_HUMAN,G396E,0.77,Gain of Helix (Pr = 0.28 | P = 0.02), ELME000085|ELME000328|ELME000337,-
SLC26A4_HUMAN,D697A,0.512,, PS00006,-
SLC26A4_HUMAN,R677P,0.745,Gain of ADP-ribosylation at R674 (Pr = 0.24 | P = 0.01), ELME000106|ELME000313|ELME000335|ELME000337|PS00005,-
SLC26A4_HUMAN,S415R,0.55,Gain of ADP-ribosylation at S415 (Pr = 0.28 | P = 4.5e-03); Loss of Ubiquitylation at K419 (Pr = 0.17 | P = 0.03); Loss of Methylation at K419 (Pr = 0.15 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q413 (Pr = 0.06 | P = 0.03), ELME000053,-
SLC26A4_HUMAN,V570L,0.455,-,-,-
SLC26A4_HUMAN,S93R,0.65,Gain of Allosteric site at S93 (Pr = 0.25 | P = 0.01); Altered Transmembrane protein (Pr = 0.18 | P = 8.5e-03), ELME000052|ELME000063|PS00008,-
SLC26A4_HUMAN,Y530H,0.796,Gain of Intrinsic disorder (Pr = 0.37 | P = 0.01); Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Altered Stability (Pr = 0.22 | P = 0.01), None,-
SLC26A4_HUMAN,E29Q,0.377,-,-,-
SLC26A4_HUMAN,S399P,0.774,, ELME000337,-
SLC26A4_HUMAN,G139A,0.834,Gain of Helix (Pr = 0.28 | P = 0.03); Loss of Strand (Pr = 0.27 | P = 0.02); Altered Ordered interface (Pr = 0.23 | P = 0.05), ELME000065,-
SLC26A4_HUMAN,V239D,0.826,Altered Ordered interface (Pr = 0.33 | P = 6.4e-03); Altered Transmembrane protein (Pr = 0.31 | P = 1.2e-04); Loss of Strand (Pr = 0.26 | P = 0.04); Altered Stability (Pr = 0.11 | P = 0.03); Gain of N-linked glycosylation at N241 (Pr = 0.03 | P = 0.03), ELME000146|ELME000333,-
SLC26A4_HUMAN,V138D,0.841,Loss of Strand (Pr = 0.28 | P = 6.9e-03); Gain of Loop (Pr = 0.27 | P = 0.04); Altered Ordered interface (Pr = 0.23 | P = 0.05), ELME000065,-
SLC26A4_HUMAN,S532R,0.438,-,-,-
SLC26A4_HUMAN,G116V,0.898,Altered Ordered interface (Pr = 0.28 | P = 6.0e-03); Altered Transmembrane protein (Pr = 0.22 | P = 2.8e-03), ELME000182|PS00008|PS01130,-
SLC26A4_HUMAN,I539V,0.066,-,-,-
SLC26A4_HUMAN,Y214C,0.904,Altered Ordered interface (Pr = 0.30 | P = 4.3e-03); Altered Transmembrane protein (Pr = 0.29 | P = 2.1e-04); Gain of Helix (Pr = 0.27 | P = 0.04); Loss of Strand (Pr = 0.26 | P = 0.03), ELME000182|ELME000317,-
SLC26A4_HUMAN,V231M,0.624,Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000202|ELME000333|ELME000336,-
SLC26A4_HUMAN,E443Q,0.366,-,-,-
SLC26A4_HUMAN,N392Y,0.913,Altered Ordered interface (Pr = 0.30 | P = 0.02), ELME000053|ELME000182|ELME000197|ELME000336,-
SLC26A4_HUMAN,G497S,0.873,Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000147|ELME000335|ELME000336|PS00008,-
SLC26A4_HUMAN,S314L,0.837,Altered Ordered interface (Pr = 0.43 | P = 5.3e-04); Loss of Relative solvent accessibility (Pr = 0.32 | P = 5.1e-03); Altered Transmembrane protein (Pr = 0.27 | P = 6.5e-04); Altered Metal binding (Pr = 0.18 | P = 0.05), ELME000052,-
SLC26A4_HUMAN,A434D,0.634,Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000333|ELME000335,-
SLC26A4_HUMAN,S165R,0.254,-,-,-
SLC26A4_HUMAN,L441P,0.884,Loss of Helix (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.12 | P = 0.03); Altered Signal peptide (Pr = 0.01 | P = 8.1e-03), ELME000045|ELME000106|ELME000155,-
SLC26A4_HUMAN,P651L,0.637,, ELME000155,-
SLC26A4_HUMAN,D669E,0.831,Gain of ADP-ribosylation at R674 (Pr = 0.20 | P = 0.04), ELME000064|ELME000313|ELME000335|PS00006,-
SLC26A4_HUMAN,T193I,0.638,, ELME000052|ELME000063|ELME000335,-
SLC26A4_HUMAN,Y530S,0.875,Gain of Intrinsic disorder (Pr = 0.50 | P = 1.6e-03); Altered Transmembrane protein (Pr = 0.30 | P = 1.6e-04); Altered Ordered interface (Pr = 0.30 | P = 0.02); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.04); Altered Stability (Pr = 0.24 | P = 8.9e-03); Altered Metal binding (Pr = 0.20 | P = 0.04), ELME000063,-
SLC26A4_HUMAN,Q413R,0.744,Loss of Pyrrolidone carboxylic acid at Q413 (Pr = 0.05 | P = 0.04), ELME000053|ELME000062|ELME000117,-
SLC26A4_HUMAN,S657N,0.427,-,-,-
SLC26A4_HUMAN,E29G,0.584,Loss of Sulfation at Y27 (Pr = 0.02 | P = 0.04), ELME000085|ELME000120,-
SLC26A4_HUMAN,G222S,0.882,Altered Transmembrane protein (Pr = 0.30 | P = 1.3e-04), ELME000063|ELME000336|PS00008,-
SLC26A4_HUMAN,T307K,0.899,Altered Metal binding (Pr = 0.17 | P = 0.03), ELME000053|ELME000333,-
SLC26A4_HUMAN,Y375C,0.506,Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Transmembrane protein (Pr = 0.29 | P = 2.9e-04); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000147|ELME000220|PS00006,-
SLC26A4_HUMAN,F572L,0.684,Altered Disordered interface (Pr = 0.24 | P = 0.03); Altered Coiled coil (Pr = 0.10 | P = 0.04), ELME000052|ELME000233|ELME000276,-
SLC26A4_HUMAN,K81E,0.743,Altered Ordered interface (Pr = 0.26 | P = 0.02); Altered Transmembrane protein (Pr = 0.21 | P = 4.9e-03), None,-
SLC26A4_HUMAN,A434T,0.336,-,-,-
SLC26A4_HUMAN,H723R,0.783,Altered Metal binding (Pr = 0.06 | P = 0.03), ELME000134|ELME000220|ELME000321|ELME000336|PS00005|PS00006,-
SLC26A4_HUMAN,V328G,0.926,Altered Ordered interface (Pr = 0.31 | P = 0.02); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Loss of Strand (Pr = 0.26 | P = 0.05); Altered Transmembrane protein (Pr = 0.24 | P = 1.9e-03); Loss of ADP-ribosylation at R333 (Pr = 0.20 | P = 0.05); Gain of Acetylation at K329 (Pr = 0.19 | P = 0.04); Altered Stability (Pr = 0.18 | P = 0.01); Altered Metal binding (Pr = 0.10 | P = 0.05), PS00008,-
SLC26A4_HUMAN,Q514K,0.754,Loss of Pyrrolidone carboxylic acid at Q514 (Pr = 0.06 | P = 0.03); Loss of GPI-anchor amidation at N519 (Pr = 0.04 | P = 7.0e-03), ELME000137|ELME000155,-
SLC26A4_HUMAN,V402M,0.358,-,-,-
SLC26A4_HUMAN,M775T,0.398,-,-,-
SLC26A4_HUMAN,G222V,0.929,Altered Transmembrane protein (Pr = 0.26 | P = 9.6e-04), PS00008,-
SLC26A4_HUMAN,G740S,0.165,-,-,-
SLC26A4_HUMAN,A357T,0.58,Altered Transmembrane protein (Pr = 0.22 | P = 2.8e-03), ELME000053|ELME000335,-
SLC26A4_HUMAN,G5R,0.319,-,-,-
SLC26A4_HUMAN,S8L,0.086,-,-,-
SLC26A4_HUMAN,R39C,0.251,-,-,-
SLC26A4_HUMAN,V88I,0.034,-,-,-
SLC26A4_HUMAN,S154R,0.171,-,-,-
SLC26A4_HUMAN,K245Q,0.235,-,-,-
SLC26A4_HUMAN,T273I,0.066,-,-,-
SLC26A4_HUMAN,G316A,0.199,-,-,-
SLC26A4_HUMAN,I477T,0.13,-,-,-
SLC26A4_HUMAN,I605V,0.06,-,-,-
SLC26A4_HUMAN,I726V,0.083,-,-,-
SLC26A4_HUMAN,N731S,0.122,-,-,-
SLC26A4_HUMAN,E737K,0.077,-,-,-
SLC26A4_HUMAN,T745A,0.088,-,-,-
SLC26A4_HUMAN,G131R,0.902,Gain of Helix (Pr = 0.29 | P = 0.02); Loss of Strand (Pr = 0.27 | P = 0.02); Altered Ordered interface (Pr = 0.25 | P = 0.03), ELME000053|ELME000062|ELME000336|PS01130,-
SLC26A4_HUMAN,F515C,0.708,Loss of Strand (Pr = 0.26 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q514 (Pr = 0.05 | P = 0.03); Gain of GPI-anchor amidation at N519 (Pr = 0.04 | P = 6.5e-03), ELME000137|ELME000155,-
SLC26A4_HUMAN,A406T,0.712,, ELME000052|ELME000053|ELME000336,-
SLC26A4_HUMAN,R185T,0.799,Loss of Helix (Pr = 0.30 | P = 9.2e-03); Altered Transmembrane protein (Pr = 0.28 | P = 4.6e-04), ELME000051|ELME000052|ELME000062|ELME000106|ELME000335|PS00005,-
SLC26A4_HUMAN,V304E,0.934,Gain of Helix (Pr = 0.30 | P = 7.8e-03); Altered Metal binding (Pr = 0.28 | P = 3.7e-03); Altered Ordered interface (Pr = 0.27 | P = 0.05); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000053|ELME000117|ELME000333|ELME000335,-
SLC26A4_HUMAN,A429E,0.389,-,-,-
WFS1_HUMAN,M632I,0.095,-,-,-
WFS1_HUMAN,A741T,0.071,-,-,-
WFS1_HUMAN,A787T,0.064,-,-,-
WFS1_HUMAN,D788N,0.044,-,-,-
WFS1_HUMAN,I296S,0.708,Altered Transmembrane protein (Pr = 0.35 | P = 1.9e-05); Gain of Helix (Pr = 0.28 | P = 0.03); Altered Stability (Pr = 0.14 | P = 0.02), None,-
WFS1_HUMAN,L432R,0.944,Altered Metal binding (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.15 | P = 0.01), ELME000333|ELME000335|PS00005,-
WFS1_HUMAN,R859P,0.821,Loss of Helix (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.20 | P = 5.3e-03), ELME000102|ELME000108|ELME000146|ELME000155|PS00005,-
WFS1_HUMAN,F770C,0.856,Altered Metal binding (Pr = 0.31 | P = 0.02); Altered DNA binding (Pr = 0.22 | P = 0.02); Loss of Acetylation at K768 (Pr = 0.21 | P = 0.04); Gain of Disulfide linkage at C765 (Pr = 0.14 | P = 0.04), ELME000233,-
WFS1_HUMAN,F439C,0.821,Altered Ordered interface (Pr = 0.25 | P = 0.02), ELME000053|ELME000336,-
WFS1_HUMAN,T461P,0.669,Altered Transmembrane protein (Pr = 0.31 | P = 1.2e-04), ELME000106|ELME000147|ELME000248,-
WFS1_HUMAN,T699M,0.761,Altered Transmembrane protein (Pr = 0.32 | P = 6.3e-05); Altered Ordered interface (Pr = 0.29 | P = 0.03); Loss of Allosteric site at W700 (Pr = 0.25 | P = 0.01); Altered Metal binding (Pr = 0.22 | P = 0.05); Altered DNA binding (Pr = 0.22 | P = 0.02), ELME000062|ELME000137,-
WFS1_HUMAN,L557F,0.255,-,-,-
WFS1_HUMAN,E830A,0.777,Altered Transmembrane protein (Pr = 0.34 | P = 5.4e-05); Loss of Strand (Pr = 0.26 | P = 0.04), ELME000220|PS00006,-
WFS1_HUMAN,G780R,0.839,Altered Transmembrane protein (Pr = 0.15 | P = 0.02), ELME000147|ELME000155|ELME000336|PS00005|PS00008,-
WFS1_HUMAN,H766Y,0.782,Altered Metal binding (Pr = 0.64 | P = 1.6e-03); Gain of Helix (Pr = 0.28 | P = 0.02); Gain of Loop (Pr = 0.28 | P = 0.01); Gain of Acetylation at K768 (Pr = 0.28 | P = 5.8e-03); Altered DNA binding (Pr = 0.22 | P = 0.02); Gain of Disulfide linkage at C765 (Pr = 0.10 | P = 0.05), ELME000182,-
WFS1_HUMAN,W540G,0.895,Altered Ordered interface (Pr = 0.32 | P = 3.4e-03); Loss of Helix (Pr = 0.27 | P = 0.05), PS00008,-
WFS1_HUMAN,C690R,0.962,Altered Metal binding (Pr = 0.49 | P = 4.0e-03); Altered Transmembrane protein (Pr = 0.36 | P = 1.9e-05); Gain of Catalytic site at C690 (Pr = 0.28 | P = 2.1e-03); Gain of Helix (Pr = 0.27 | P = 0.04); Gain of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Loss of Disulfide linkage at C690 (Pr = 0.23 | P = 0.01); Gain of Allosteric site at C690 (Pr = 0.19 | P = 0.05), ELME000052|ELME000064,-
WFS1_HUMAN,I349K,0.782,Altered Ordered interface (Pr = 0.24 | P = 0.03); Altered Transmembrane protein (Pr = 0.22 | P = 3.6e-03), None,-
WFS1_HUMAN,R457G,0.728,Loss of Helix (Pr = 0.38 | P = 8.8e-05); Gain of Strand (Pr = 0.32 | P = 5.4e-04); Altered Ordered interface (Pr = 0.26 | P = 0.01); Altered Transmembrane protein (Pr = 0.25 | P = 1.6e-03); Gain of Sulfation at Y454 (Pr = 0.01 | P = 0.05), ELME000102|ELME000108|ELME000146|ELME000182|PS00005|PS00008,-
WFS1_HUMAN,P724S,0.89,Altered Transmembrane protein (Pr = 0.27 | P = 6.3e-04); Altered Disordered interface (Pr = 0.27 | P = 0.04); Gain of Helix (Pr = 0.27 | P = 0.04); Altered Metal binding (Pr = 0.24 | P = 0.02), None,-
WFS1_HUMAN,R375C,0.563,Altered Transmembrane protein (Pr = 0.34 | P = 5.4e-05), ELME000079|ELME000146|ELME000220,-
WFS1_HUMAN,Y528H,0.832,Altered Ordered interface (Pr = 0.30 | P = 4.6e-03); Altered Transmembrane protein (Pr = 0.27 | P = 5.7e-04); Altered DNA binding (Pr = 0.15 | P = 0.04), ELME000120|ELME000182|ELME000336,-
WFS1_HUMAN,C505Y,0.751,Altered Ordered interface (Pr = 0.30 | P = 2.7e-03); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Loss of N-linked glycosylation at N500 (Pr = 0.07 | P = 0.02), ELME000182,-
WFS1_HUMAN,Y110N,0.776,Loss of Acetylation at K108 (Pr = 0.24 | P = 0.02); Loss of Phosphorylation at Y110 (Pr = 0.24 | P = 0.05); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000120|ELME000182,-
WFS1_HUMAN,D171N,0.204,-,-,-
WFS1_HUMAN,S430W,0.858,Altered Ordered interface (Pr = 0.26 | P = 0.01); Altered Transmembrane protein (Pr = 0.24 | P = 1.5e-03), ELME000007|ELME000335,-
WFS1_HUMAN,W639G,0.805,Loss of Helix (Pr = 0.30 | P = 8.1e-03); Gain of Strand (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000052|ELME000333,-
WFS1_HUMAN,A761V,0.272,-,-,-
WFS1_HUMAN,G736D,0.936,Altered Metal binding (Pr = 0.54 | P = 3.8e-03); Gain of Helix (Pr = 0.28 | P = 0.03); Altered Transmembrane protein (Pr = 0.27 | P = 8.2e-04); Altered Ordered interface (Pr = 0.24 | P = 0.04); Loss of Disulfide linkage at C733 (Pr = 0.17 | P = 0.03); Gain of Sulfation at Y739 (Pr = 0.02 | P = 0.04), ELME000081|ELME000301|PS00007,-
WFS1_HUMAN,L672P,0.878,Altered Ordered interface (Pr = 0.35 | P = 3.6e-03); Altered Transmembrane protein (Pr = 0.34 | P = 4.9e-05); Gain of Disulfide linkage at C673 (Pr = 0.21 | P = 0.02), ELME000005|ELME000120|ELME000155,-
WFS1_HUMAN,H323R,0.651,Altered Transmembrane protein (Pr = 0.18 | P = 8.3e-03), ELME000052|ELME000148|ELME000149|ELME000254|PS00005,-
WFS1_HUMAN,L382P,0.772,Altered Transmembrane protein (Pr = 0.32 | P = 1.0e-04), ELME000045|ELME000047|ELME000052|ELME000335,-
WFS1_HUMAN,L511P,0.939,Altered Ordered interface (Pr = 0.26 | P = 0.02); Altered Transmembrane protein (Pr = 0.18 | P = 8.7e-03), ELME000020|ELME000081|ELME000083|ELME000120|ELME000182,-
WFS1_HUMAN,T321M,0.622,Gain of Helix (Pr = 0.27 | P = 0.05); Altered Transmembrane protein (Pr = 0.19 | P = 7.0e-03), ELME000052|ELME000053|ELME000148,-
WFS1_HUMAN,L432Q,0.879,Altered Metal binding (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.15 | P = 0.02), ELME000140|ELME000333|ELME000335,-
WFS1_HUMAN,G736S,0.898,Altered Metal binding (Pr = 0.26 | P = 0.03); Altered Transmembrane protein (Pr = 0.26 | P = 1.2e-03); Altered Ordered interface (Pr = 0.24 | P = 0.05); Gain of Disulfide linkage at C733 (Pr = 0.18 | P = 0.02), None,-
WFS1_HUMAN,S443R,0.716,Altered Ordered interface (Pr = 0.26 | P = 0.01); Gain of ADP-ribosylation at S443 (Pr = 0.20 | P = 0.04); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000052|ELME000063|ELME000106|ELME000336,-
WFS1_HUMAN,N721Y,0.809,Altered Disordered interface (Pr = 0.39 | P = 5.6e-03); Altered Ordered interface (Pr = 0.34 | P = 1.3e-03); Altered Transmembrane protein (Pr = 0.29 | P = 2.7e-04); Altered Metal binding (Pr = 0.23 | P = 0.02), ELME000063,-
WFS1_HUMAN,A806P,0.882,Gain of Intrinsic disorder (Pr = 0.33 | P = 0.03); Gain of Loop (Pr = 0.29 | P = 7.9e-03); Altered Metal binding (Pr = 0.16 | P = 0.03); Altered Stability (Pr = 0.15 | P = 0.02); Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000053|ELME000062|ELME000155|ELME000173|ELME000197,-
WFS1_HUMAN,V333I,0.029,-,-,-
WFS1_HUMAN,K193Q,0.296,-,-,-
WFS1_HUMAN,A602V,0.075,-,-,-
WFS1_HUMAN,L499F,0.542,Loss of Helix (Pr = 0.28 | P = 0.02); Gain of Strand (Pr = 0.28 | P = 0.01); Altered Transmembrane protein (Pr = 0.18 | P = 7.6e-03); Loss of N-linked glycosylation at N500 (Pr = 0.07 | P = 0.02), ELME000070|ELME000155|ELME000333|ELME000336,-
WFS1_HUMAN,G76V,0.115,-,-,-
WFS1_HUMAN,V779M,0.511,Gain of Intrinsic disorder (Pr = 0.32 | P = 0.03); Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000147|ELME000155|ELME000233|ELME000336,-
WFS1_HUMAN,A23T,0.103,-,-,-
WFS1_HUMAN,H67R,0.053,-,-,-
WFS1_HUMAN,K81R,0.039,-,-,-
WFS1_HUMAN,V106M,0.311,-,-,-
WFS1_HUMAN,G115S,0.047,-,-,-
WFS1_HUMAN,T117A,0.029,-,-,-
WFS1_HUMAN,T117K,0.099,-,-,-
WFS1_HUMAN,T117R,0.108,-,-,-
WFS1_HUMAN,S123A,0.183,-,-,-
WFS1_HUMAN,V131I,0.031,-,-,-
WFS1_HUMAN,L145A,0.881,Altered Disordered interface (Pr = 0.27 | P = 0.01); Altered Coiled coil (Pr = 0.25 | P = 0.02); Altered Stability (Pr = 0.21 | P = 0.01); Loss of Proteolytic cleavage at R147 (Pr = 0.11 | P = 0.04); Gain of Disulfide linkage at C148 (Pr = 0.10 | P = 0.05), ELME000012|ELME000149,-
WFS1_HUMAN,R153K,0.054,-,-,-
WFS1_HUMAN,I489L,0.092,-,-,-
WFS1_HUMAN,V491M,0.174,-,-,-
WFS1_HUMAN,F564C,0.642,Altered Transmembrane protein (Pr = 0.30 | P = 1.6e-04); Altered Ordered interface (Pr = 0.26 | P = 0.01), ELME000120|ELME000182|ELME000328,-
WFS1_HUMAN,T590V,0.06,-,-,-
WFS1_HUMAN,V601M,0.072,-,-,-
WFS1_HUMAN,H692P,0.936,Altered Metal binding (Pr = 0.68 | P = 1.2e-03); Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Transmembrane protein (Pr = 0.29 | P = 3.5e-04); Loss of Helix (Pr = 0.27 | P = 0.05); Gain of Allosteric site at C690 (Pr = 0.21 | P = 0.03); Gain of Disulfide linkage at C690 (Pr = 0.20 | P = 0.02); Gain of Catalytic site at C690 (Pr = 0.16 | P = 0.02), ELME000064|ELME000136|ELME000159|PS00006,-
WFS1_HUMAN,G728S,0.478,-,-,-
WFS1_HUMAN,G789S,0.101,-,-,-
WFS1_HUMAN,S792G,0.045,-,-,-
WFS1_HUMAN,V875I,0.065,-,-,-
WFS1_HUMAN,M518K,0.915,Altered Transmembrane protein (Pr = 0.32 | P = 7.8e-05); Gain of Pyrrolidone carboxylic acid at Q520 (Pr = 0.07 | P = 0.02), ELME000102,-
WFS1_HUMAN,L200P,0.844,Gain of Intrinsic disorder (Pr = 0.38 | P = 0.01); Altered Stability (Pr = 0.25 | P = 8.0e-03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000155,-
WFS1_HUMAN,S236R,0.281,-,-,-
WFS1_HUMAN,A684T,0.774,Loss of Helix (Pr = 0.29 | P = 0.01); Altered Transmembrane protein (Pr = 0.26 | P = 8.4e-04); Gain of N-linked glycosylation at N682 (Pr = 0.05 | P = 0.02), ELME000052|ELME000070|ELME000202|ELME000336|PS00001,-
WFS1_HUMAN,V624A,0.137,-,-,-
WFS1_HUMAN,R228H,0.174,-,-,-
WFS1_HUMAN,L543R,0.855,Altered Ordered interface (Pr = 0.24 | P = 0.03); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000147|ELME000313|ELME000335,-
WFS1_HUMAN,T156M,0.436,-,-,-
WFS1_HUMAN,L723P,0.949,Altered Transmembrane protein (Pr = 0.39 | P = 9.7e-06); Altered Ordered interface (Pr = 0.39 | P = 1.3e-03); Loss of Helix (Pr = 0.30 | P = 8.1e-03); Gain of Relative solvent accessibility (Pr = 0.28 | P = 0.01); Altered Disordered interface (Pr = 0.27 | P = 0.04); Altered Metal binding (Pr = 0.25 | P = 0.01), None,-
WFS1_HUMAN,H860D,0.538,Altered Transmembrane protein (Pr = 0.27 | P = 7.3e-04); Altered Stability (Pr = 0.10 | P = 0.04), ELME000102|ELME000108|ELME000146|ELME000220|PS00006,-
WFS1_HUMAN,R732C,0.77,Altered Metal binding (Pr = 0.37 | P = 0.01); Altered Transmembrane protein (Pr = 0.36 | P = 1.9e-05); Altered Ordered interface (Pr = 0.25 | P = 0.02); Loss of Disulfide linkage at C733 (Pr = 0.18 | P = 0.03), ELME000106,-
WFS1_HUMAN,R383C,0.465,-,-,-
WFS1_HUMAN,C690Y,0.961,Altered Metal binding (Pr = 0.49 | P = 4.0e-03); Altered Ordered interface (Pr = 0.33 | P = 8.6e-03); Loss of Helix (Pr = 0.29 | P = 0.02); Gain of Catalytic site at C690 (Pr = 0.28 | P = 2.4e-03); Altered Transmembrane protein (Pr = 0.26 | P = 9.9e-04); Loss of Disulfide linkage at C690 (Pr = 0.23 | P = 0.01), ELME000020|ELME000052|ELME000064|ELME000120,-
WFS1_HUMAN,R629W,0.417,-,-,-
WFS1_HUMAN,N714T,0.875,Loss of Relative solvent accessibility (Pr = 0.31 | P = 6.9e-03); Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Transmembrane protein (Pr = 0.25 | P = 1.1e-03); Altered Metal binding (Pr = 0.22 | P = 4.5e-03); Altered DNA binding (Pr = 0.21 | P = 0.02), ELME000053|ELME000064|ELME000085|ELME000147|ELME000220|ELME000321|PS00006,-
WFS1_HUMAN,T665P,0.802,Gain of Loop (Pr = 0.27 | P = 0.04); Gain of N-linked glycosylation at N661 (Pr = 0.27 | P = 3.6e-04); Altered Ordered interface (Pr = 0.26 | P = 0.02); Altered Transmembrane protein (Pr = 0.23 | P = 2.2e-03); Loss of Sulfation at Y660 (Pr = 0.03 | P = 0.02), ELME000063|ELME000070,-
WFS1_HUMAN,L402P,0.906,Altered Ordered interface (Pr = 0.26 | P = 0.01); Altered Transmembrane protein (Pr = 0.17 | P = 9.6e-03), None,-
WFS1_HUMAN,G695V,0.933,Altered Ordered interface (Pr = 0.35 | P = 3.8e-03); Altered Transmembrane protein (Pr = 0.29 | P = 3.8e-04); Altered Metal binding (Pr = 0.28 | P = 0.02); Gain of Allosteric site at W700 (Pr = 0.28 | P = 3.3e-03); Altered DNA binding (Pr = 0.21 | P = 0.02); Loss of Disulfide linkage at C690 (Pr = 0.18 | P = 0.03); Loss of Catalytic site at C690 (Pr = 0.13 | P = 0.03), ELME000137,-
WFS1_HUMAN,D797V,0.588,Loss of Intrinsic disorder (Pr = 0.43 | P = 0.02); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Loop (Pr = 0.27 | P = 0.04); Altered Metal binding (Pr = 0.19 | P = 0.05); Loss of Ubiquitylation at K800 (Pr = 0.16 | P = 0.04); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000052,-
WFS1_HUMAN,E864K,0.757,Loss of Strand (Pr = 0.28 | P = 0.01); Gain of Helix (Pr = 0.27 | P = 0.03); Altered Transmembrane protein (Pr = 0.19 | P = 5.8e-03); Altered Stability (Pr = 0.09 | P = 0.05), ELME000002,-
WFS1_HUMAN,P607R,0.77,Altered Disordered interface (Pr = 0.39 | P = 3.8e-03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000106|ELME000146|ELME000335|ELME000337|PS00005,-
WFS1_HUMAN,G831D,0.828,Altered Transmembrane protein (Pr = 0.31 | P = 1.3e-04), ELME000220,-
WFS1_HUMAN,R611C,0.383,-,-,-
WFS1_HUMAN,C690G,0.962,Altered Metal binding (Pr = 0.45 | P = 5.1e-03); Altered Ordered interface (Pr = 0.28 | P = 0.05); Loss of Helix (Pr = 0.28 | P = 0.03); Altered Transmembrane protein (Pr = 0.26 | P = 9.9e-04); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Loss of Disulfide linkage at C690 (Pr = 0.23 | P = 0.01); Gain of Catalytic site at C690 (Pr = 0.14 | P = 0.03); Altered Stability (Pr = 0.09 | P = 0.05), ELME000052|ELME000064,-
WFS1_HUMAN,R703H,0.543,Altered Transmembrane protein (Pr = 0.28 | P = 4.6e-04); Altered Ordered interface (Pr = 0.28 | P = 0.05); Altered DNA binding (Pr = 0.27 | P = 3.5e-03); Loss of Allosteric site at W700 (Pr = 0.26 | P = 0.01); Gain of Acetylation at K705 (Pr = 0.19 | P = 0.05), ELME000080|PS00005,-
WFS1_HUMAN,D211N,0.263,-,-,-
WFS1_HUMAN,P838L,0.775,Altered Transmembrane protein (Pr = 0.35 | P = 2.4e-05), ELME000106|ELME000137,-
WFS1_HUMAN,A716T,0.42,-,-,-
WFS1_HUMAN,A616S,0.081,-,-,-
WFS1_HUMAN,V779G,0.841,Altered Stability (Pr = 0.52 | P = 1.5e-03); Gain of Intrinsic disorder (Pr = 0.37 | P = 0.01); Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000147|ELME000155|ELME000233|ELME000336,-
WFS1_HUMAN,L757I,0.102,-,-,-
WFS1_HUMAN,G107E,0.767,Loss of Acetylation at K108 (Pr = 0.28 | P = 6.1e-03), ELME000064|ELME000220|PS00006,-
WFS1_HUMAN,A677T,0.573,Altered Transmembrane protein (Pr = 0.30 | P = 1.8e-04); Altered Ordered interface (Pr = 0.25 | P = 0.02); Loss of Disulfide linkage at C673 (Pr = 0.18 | P = 0.03), ELME000053|ELME000064|ELME000220|PS00005|PS00006,-
MYO7A_HUMAN,I1633V,0.243,-,-,-
MYO7A_HUMAN,N1650G,0.441,-,-,-
MYO7A_HUMAN,K1657R,0.619,Altered Transmembrane protein (Pr = 0.26 | P = 7.7e-04); Altered DNA binding (Pr = 0.19 | P = 0.03); Gain of Pyrrolidone carboxylic acid at Q1658 (Pr = 0.08 | P = 0.02), None,-
MYO7A_HUMAN,S1666C,0.062,-,-,-
MYO7A_HUMAN,T1674A,0.388,-,-,-
MYO7A_HUMAN,M1675T,0.258,-,-,-
MYO7A_HUMAN,P1677L,0.19,-,-,-
MYO7A_HUMAN,V1695I,0.034,-,-,-
MYO7A_HUMAN,L1700M,0.088,-,-,-
MYO7A_HUMAN,T1702A,0.109,-,-,-
MYO7A_HUMAN,D1720G,0.789,Loss of Phosphorylation at Y1721 (Pr = 0.29 | P = 0.02); Loss of Sulfation at Y1721 (Pr = 0.05 | P = 8.8e-03), ELME000120,-
MYO7A_HUMAN,P1724S,0.28,-,-,-
MYO7A_HUMAN,P1726A,0.307,-,-,-
MYO7A_HUMAN,H1728A,0.513,Gain of Helix (Pr = 0.27 | P = 0.05); Altered Disordered interface (Pr = 0.21 | P = 0.03), None,-
MYO7A_HUMAN,T1729A,0.271,-,-,-
MYO7A_HUMAN,L1730G,0.694,Gain of Intrinsic disorder (Pr = 0.32 | P = 0.03); Loss of Helix (Pr = 0.28 | P = 0.02); Altered Disordered interface (Pr = 0.25 | P = 0.02); Gain of B-factor (Pr = 0.25 | P = 0.03); Altered Stability (Pr = 0.12 | P = 0.03), None,-
MYO7A_HUMAN,S1731G,0.54,Altered Disordered interface (Pr = 0.25 | P = 0.02), None,-
MYO7A_HUMAN,S1731Q,0.699,Altered Disordered interface (Pr = 0.25 | P = 0.02), None,-
MYO7A_HUMAN,V1735W,0.524,Altered Disordered interface (Pr = 0.41 | P = 3.2e-03), ELME000137,-
MYO7A_HUMAN,S1736H,0.363,-,-,-
MYO7A_HUMAN,A1738T,0.117,-,-,-
MYO7A_HUMAN,G1740S,0.515,Gain of Intrinsic disorder (Pr = 0.39 | P = 1.0e-02); Altered Disordered interface (Pr = 0.25 | P = 0.02); Gain of Proteolytic cleavage at W1745 (Pr = 0.12 | P = 0.03), ELME000053|ELME000173,-
MYO7A_HUMAN,S1746G,0.389,-,-,-
MYO7A_HUMAN,L1752M,0.239,-,-,-
MYO7A_HUMAN,L1757V,0.463,-,-,-
MYO7A_HUMAN,K1758L,0.679,, ELME000045|ELME000106|ELME000146,-
MYO7A_HUMAN,K1758R,0.192,-,-,-
MYO7A_HUMAN,L1761V,0.142,-,-,-
MYO7A_HUMAN,E1764Q,0.316,-,-,-
MYO7A_HUMAN,E1765S,0.597,, ELME000053|ELME000202,-
MYO7A_HUMAN,Q1768M,0.552,, ELME000147|ELME000202,-
MYO7A_HUMAN,A1773T,0.552,, None,-
MYO7A_HUMAN,F1774S,0.925,Gain of Acetylation at K1779 (Pr = 0.22 | P = 0.03); Altered Stability (Pr = 0.10 | P = 0.04), ELME000041|ELME000335,-
MYO7A_HUMAN,I1775P,0.579,Gain of Allosteric site at Y1780 (Pr = 0.26 | P = 9.2e-03); Gain of Acetylation at K1779 (Pr = 0.23 | P = 0.02), ELME000041,-
MYO7A_HUMAN,I1775V,0.102,-,-,-
MYO7A_HUMAN,A1776P,0.877,Gain of Allosteric site at Y1780 (Pr = 0.25 | P = 9.6e-03); Gain of Acetylation at K1779 (Pr = 0.22 | P = 0.03), ELME000041,-
MYO7A_HUMAN,V1777A,0.531,Loss of Allosteric site at Y1780 (Pr = 0.25 | P = 0.02); Gain of Acetylation at K1779 (Pr = 0.19 | P = 0.05), ELME000041,-
MYO7A_HUMAN,T1789A,0.205,-,-,-
MYO7A_HUMAN,V1792I,0.168,-,-,-
MYO7A_HUMAN,K1805R,0.513,Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Gain of Allosteric site at F1800 (Pr = 0.22 | P = 0.03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000002|ELME000251,-
MYO7A_HUMAN,S1829R,0.915,Gain of Helix (Pr = 0.29 | P = 0.01); Loss of Loop (Pr = 0.28 | P = 0.02), ELME000062|ELME000233,-
MYO7A_HUMAN,R1832K,0.398,-,-,-
MYO7A_HUMAN,E1835Q,0.69,Altered Ordered interface (Pr = 0.24 | P = 0.05), ELME000149|ELME000335,-
MYO7A_HUMAN,L1843W,0.867,, None,-
MYO7A_HUMAN,L1858H,0.783,, ELME000336,-
MYO7A_HUMAN,H1863P,0.731,, ELME000233,-
MYO7A_HUMAN,P1865V,0.545,Altered Metal binding (Pr = 0.22 | P = 0.05); Altered Coiled coil (Pr = 0.13 | P = 0.03), ELME000233|ELME000313|ELME000333,-
MYO7A_HUMAN,L1871F,0.273,-,-,-
MYO7A_HUMAN,Q1872A,0.555,Gain of Acetylation at K1876 (Pr = 0.20 | P = 0.04); Altered DNA binding (Pr = 0.17 | P = 0.04); Altered Coiled coil (Pr = 0.15 | P = 0.03), ELME000134|ELME000313,-
MYO7A_HUMAN,K1876V,0.664,Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Acetylation at K1876 (Pr = 0.25 | P = 0.01); Altered DNA binding (Pr = 0.19 | P = 0.03); Altered Coiled coil (Pr = 0.15 | P = 0.03), ELME000134|ELME000313,-
MYO7A_HUMAN,E1914S,0.706,Altered Metal binding (Pr = 0.44 | P = 5.3e-03); Gain of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Stability (Pr = 0.09 | P = 0.05), ELME000064|ELME000085|ELME000321|PS00006,-
MYO7A_HUMAN,E1919S,0.816,Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Metal binding (Pr = 0.27 | P = 7.8e-03); Gain of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Altered DNA binding (Pr = 0.20 | P = 0.02), ELME000063|ELME000336,-
MYO7A_HUMAN,S1920A,0.665,Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Metal binding (Pr = 0.27 | P = 9.1e-03); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Loss of Strand (Pr = 0.26 | P = 0.05); Altered DNA binding (Pr = 0.19 | P = 0.03), None,-
MYO7A_HUMAN,S1921T,0.374,-,-,-
MYO7A_HUMAN,K1925P,0.651,Altered Metal binding (Pr = 0.33 | P = 0.01); Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Helix (Pr = 0.27 | P = 0.04); Altered DNA binding (Pr = 0.20 | P = 0.02), ELME000313,-
MYO7A_HUMAN,N1930R,0.438,-,-,-
MYO7A_HUMAN,A1932G,0.447,-,-,-
MYO7A_HUMAN,A1932S,0.243,-,-,-
MYO7A_HUMAN,T1933V,0.272,-,-,-
MYO7A_HUMAN,S1939D,0.596,, ELME000053|ELME000197|ELME000313,-
MYO7A_HUMAN,S1940A,0.3,-,-,-
MYO7A_HUMAN,S1940F,0.676,, ELME000053|ELME000197|ELME000313,-
MYO7A_HUMAN,E1941P,0.688,, ELME000053|ELME000136|ELME000159|ELME000197|ELME000336|ELME000337,-
MYO7A_HUMAN,F1943A,0.938,, ELME000053|ELME000197,-
MYO7A_HUMAN,K1948R,0.628,, None,-
MYO7A_HUMAN,K1952P,0.851,Loss of Strand (Pr = 0.26 | P = 0.04); Altered Transmembrane protein (Pr = 0.17 | P = 0.01), ELME000064|ELME000065|ELME000106|ELME000173,-
MYO7A_HUMAN,A2089T,0.259,-,-,-
MYO7A_HUMAN,K2102R,0.231,-,-,-
MYO7A_HUMAN,N2124S,0.337,-,-,-
MYO7A_HUMAN,Y2136H,0.228,-,-,-
MYO7A_HUMAN,V2138I,0.206,-,-,-
MYO7A_HUMAN,S2139L,0.509,Loss of Relative solvent accessibility (Pr = 0.35 | P = 2.3e-03); Altered Ordered interface (Pr = 0.31 | P = 0.02); Altered Transmembrane protein (Pr = 0.25 | P = 1.3e-03); Altered Metal binding (Pr = 0.24 | P = 0.02), ELME000120|ELME000333|PS00006,-
MYO7A_HUMAN,L2140R,0.928,Altered Ordered interface (Pr = 0.32 | P = 8.8e-03); Altered Transmembrane protein (Pr = 0.24 | P = 1.6e-03); Loss of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Altered Metal binding (Pr = 0.23 | P = 0.02); Altered Stability (Pr = 0.11 | P = 0.03), ELME000333|PS00006,-
MYO7A_HUMAN,P2143E,0.526,Altered Metal binding (Pr = 0.53 | P = 4.1e-03); Gain of Relative solvent accessibility (Pr = 0.30 | P = 8.4e-03); Gain of Strand (Pr = 0.28 | P = 8.3e-03); Altered Ordered interface (Pr = 0.27 | P = 0.05); Altered Transmembrane protein (Pr = 0.25 | P = 1.5e-03), ELME000052|ELME000333,-
MYO7A_HUMAN,K2144E,0.377,-,-,-
MYO7A_HUMAN,K2144R,0.037,-,-,-
MYO7A_HUMAN,K2144T,0.347,-,-,-
MYO7A_HUMAN,T2145G,0.571,Altered Ordered interface (Pr = 0.28 | P = 0.05); Altered Transmembrane protein (Pr = 0.27 | P = 8.4e-04); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.04); Altered Metal binding (Pr = 0.24 | P = 0.02), ELME000052,-
MYO7A_HUMAN,K2146N,0.436,-,-,-
MYO7A_HUMAN,I2148A,0.569,Altered Stability (Pr = 0.83 | P = 2.8e-04); Altered Transmembrane protein (Pr = 0.28 | P = 4.9e-04); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02), ELME000052|ELME000053|ELME000146,-
MYO7A_HUMAN,T2151K,0.805,Altered Transmembrane protein (Pr = 0.29 | P = 2.0e-04); Altered Ordered interface (Pr = 0.28 | P = 0.04); Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Loss of Strand (Pr = 0.26 | P = 0.03); Altered Stability (Pr = 0.10 | P = 0.04), ELME000053,-
MYO7A_HUMAN,S2161P,0.916,Gain of Loop (Pr = 0.27 | P = 0.03); Altered Ordered interface (Pr = 0.24 | P = 0.04); Altered Transmembrane protein (Pr = 0.19 | P = 5.9e-03); Loss of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000053|ELME000063|ELME000070|ELME000085|PS00001,-
MYO7A_HUMAN,S2162R,0.842,Loss of Loop (Pr = 0.32 | P = 4.1e-03); Altered Ordered interface (Pr = 0.31 | P = 0.01); Gain of ADP-ribosylation at S2162 (Pr = 0.22 | P = 0.02); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Gain of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000053|ELME000063|ELME000070|ELME000085|PS00001,-
MYO7A_HUMAN,N2164H,0.653,Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Loop (Pr = 0.29 | P = 7.9e-03); Altered Metal binding (Pr = 0.26 | P = 0.01); Gain of N-linked glycosylation at N2159 (Pr = 0.03 | P = 0.03), ELME000053|ELME000063|ELME000085,-
MYO7A_HUMAN,F2167L,0.759,Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Loop (Pr = 0.28 | P = 0.01); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000081|ELME000120|ELME000182|ELME000336,-
MYO7A_HUMAN,V2175R,0.919,Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000008|ELME000012|ELME000062|ELME000102|ELME000108|PS00004,-
MYO7A_HUMAN,G2177A,0.784,Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000062|ELME000149,-
MYO7A_HUMAN,G2177P,0.853,Altered Transmembrane protein (Pr = 0.15 | P = 0.01), ELME000062|ELME000149,-
MYO7A_HUMAN,C2182A,0.894,Altered Stability (Pr = 0.16 | P = 0.02); Altered Transmembrane protein (Pr = 0.15 | P = 0.01), ELME000147|ELME000239|ELME000336,-
MYO7A_HUMAN,I2198S,0.926,Gain of Intrinsic disorder (Pr = 0.61 | P = 2.7e-04); Altered Disordered interface (Pr = 0.33 | P = 0.01); Altered Transmembrane protein (Pr = 0.15 | P = 0.02); Gain of O-linked glycosylation at S2196 (Pr = 0.10 | P = 0.05); Altered Stability (Pr = 0.10 | P = 0.04), ELME000052|ELME000053|ELME000063|ELME000163|ELME000182|ELME000202|ELME000336,-
MYO7A_HUMAN,S2199G,0.684,Altered Disordered interface (Pr = 0.30 | P = 0.02), ELME000052|ELME000053|ELME000063|ELME000163|ELME000182|ELME000202|PS00008,-
MYO7A_HUMAN,T2203S,0.402,-,-,-
MYO7A_HUMAN,M2205F,0.55,Loss of Intrinsic disorder (Pr = 0.47 | P = 0.01); Altered Disordered interface (Pr = 0.30 | P = 0.01); Altered DNA binding (Pr = 0.19 | P = 0.02); Loss of Methylation at K2207 (Pr = 0.09 | P = 0.05), None,-
MYO7A_HUMAN,K2207R,0.323,-,-,-
MYO7A_HUMAN,G2210A,0.228,-,-,-
MYO7A_HUMAN,S2211A,0.082,-,-,-
MYO7A_HUMAN,R2212A,0.273,-,-,-
MYO7A_HUMAN,S2213T,0.098,-,-,-
MYO7A_HUMAN,G2214A,0.151,-,-,-
MYO7A_HUMAN,P1726L,0.413,-,-,-
COL4A5_HUMAN,L8Q,0.423,-,-,-
COL4A5_HUMAN,F13S,0.428,-,-,-
COL4A5_HUMAN,S41T,0.218,-,-,-
COL4A5_HUMAN,I43V,0.064,-,-,-
COL4A5_HUMAN,I121V,0.101,-,-,-
COL4A5_HUMAN,R131H,0.412,-,-,-
COL4A5_HUMAN,P269T,0.461,-,-,-
COL4A5_HUMAN,I353V,0.044,-,-,-
COL4A5_HUMAN,A522V,0.067,-,-,-
COL4A5_HUMAN,P525S,0.104,-,-,-
COL4A5_HUMAN,G595R,0.207,-,-,-
COL4A5_HUMAN,T597V,0.376,-,-,-
COL4A5_HUMAN,I617R,0.138,-,-,-
COL4A5_HUMAN,L708F,0.246,-,-,-
COL4A5_HUMAN,P709H,0.76,Loss of B-factor (Pr = 0.31 | P = 7.0e-03); Altered Disordered interface (Pr = 0.28 | P = 0.04); Gain of Loop (Pr = 0.27 | P = 0.02), ELME000057|ELME000155,-
COL4A5_HUMAN,P724A,0.321,-,-,-
COL4A5_HUMAN,T729I,0.129,-,-,-
COL4A5_HUMAN,R732I,0.347,-,-,-
COL4A5_HUMAN,R788H,0.095,-,-,-
COL4A5_HUMAN,V801I,0.033,-,-,-
COL4A5_HUMAN,I829L,0.095,-,-,-
COL4A5_HUMAN,I829T,0.133,-,-,-
COL4A5_HUMAN,M900I,0.104,-,-,-
COL4A5_HUMAN,V918I,0.04,-,-,-
COL4A5_HUMAN,L948F,0.119,-,-,-
COL4A5_HUMAN,P951L,0.206,-,-,-
COL4A5_HUMAN,V977I,0.035,-,-,-
COL4A5_HUMAN,Y983H,0.162,-,-,-
COL4A5_HUMAN,Q1016K,0.073,-,-,-
COL4A5_HUMAN,I1020T,0.059,-,-,-
COL4A5_HUMAN,D1064E,0.069,-,-,-
COL4A5_HUMAN,I1070V,0.027,-,-,-
COL4A5_HUMAN,N1093D,0.124,-,-,-
COL4A5_HUMAN,L1105S,0.275,-,-,-
COL4A5_HUMAN,P1132S,0.219,-,-,-
COL4A5_HUMAN,P1148T,0.299,-,-,-
COL4A5_HUMAN,V1233M,0.057,-,-,-
COL4A5_HUMAN,S1242P,0.356,-,-,-
COL4A5_HUMAN,K1284R,0.046,-,-,-
COL4A5_HUMAN,L1292Q,0.063,-,-,-
COL4A5_HUMAN,P1311L,0.412,-,-,-
COL4A5_HUMAN,G1420V,0.319,-,-,-
COL4A5_HUMAN,T1470A,0.235,-,-,-
COL4A5_HUMAN,L1481I,0.06,-,-,-
COL4A5_HUMAN,G681S,0.915,Gain of Loop (Pr = 0.29 | P = 8.0e-03), None,-
COL4A5_HUMAN,G808E,0.919,Gain of Loop (Pr = 0.28 | P = 0.02); Loss of B-factor (Pr = 0.25 | P = 0.05), ELME000155,-
COL4A5_HUMAN,G219S,0.876,Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Methylation at K215 (Pr = 0.21 | P = 5.8e-03), ELME000070|ELME000197|PS00001,-
COL4A5_HUMAN,G298R,0.956,Loss of Acetylation at K299 (Pr = 0.36 | P = 1.9e-03); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Loop (Pr = 0.26 | P = 0.05); Loss of Methylation at K296 (Pr = 0.26 | P = 1.7e-03); Loss of SUMOylation at K299 (Pr = 0.23 | P = 0.02), ELME000100|ELME000102|ELME000108|ELME000270|ELME000271|ELME000278,-
COL4A5_HUMAN,G650S,0.905,Gain of Phosphorylation at G650 (Pr = 0.34 | P = 9.6e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Methylation at K652 (Pr = 0.24 | P = 2.9e-03), ELME000136|ELME000159|PS00005,-
COL4A5_HUMAN,G1360C,0.949,Loss of B-factor (Pr = 0.33 | P = 3.1e-03); Altered Disordered interface (Pr = 0.31 | P = 0.02); Loss of O-linked glycosylation at S1365 (Pr = 0.17 | P = 0.03), None,-
COL4A5_HUMAN,G129V,0.965,Gain of SUMOylation at K128 (Pr = 0.27 | P = 4.7e-03); Loss of B-factor (Pr = 0.26 | P = 0.03); Loss of Methylation at K128 (Pr = 0.15 | P = 0.02); Gain of N-linked glycosylation at N125 (Pr = 0.02 | P = 0.03), ELME000064|ELME000070|ELME000220|PS00006,-
COL4A5_HUMAN,G319R,0.953,Altered Disordered interface (Pr = 0.30 | P = 0.02); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Loop (Pr = 0.26 | P = 0.05); Loss of Phosphorylation at Y320 (Pr = 0.26 | P = 0.03); Loss of Sulfation at Y320 (Pr = 0.04 | P = 0.01), ELME000155,-
COL4A5_HUMAN,G331V,0.958,Loss of B-factor (Pr = 0.33 | P = 2.7e-03); Gain of Acetylation at K330 (Pr = 0.25 | P = 0.01); Loss of Methylation at K333 (Pr = 0.25 | P = 2.1e-03); Loss of SUMOylation at K333 (Pr = 0.20 | P = 0.04), None,-
COL4A5_HUMAN,G509D,0.914,Gain of Loop (Pr = 0.27 | P = 0.03); Loss of SUMOylation at K514 (Pr = 0.26 | P = 7.2e-03); Loss of Acetylation at K514 (Pr = 0.23 | P = 0.02); Loss of Methylation at K514 (Pr = 0.20 | P = 6.1e-03), ELME000197,-
COL4A5_HUMAN,G521S,0.827,Loss of Methylation at K526 (Pr = 0.23 | P = 3.8e-03); Loss of Acetylation at K517 (Pr = 0.20 | P = 0.04), ELME000085|PS00008,-
COL4A5_HUMAN,G365E,0.92,Altered Disordered interface (Pr = 0.27 | P = 0.05); Gain of Loop (Pr = 0.27 | P = 0.04); Gain of SUMOylation at K370 (Pr = 0.27 | P = 4.5e-03); Loss of Acetylation at K370 (Pr = 0.22 | P = 0.03); Loss of Methylation at K370 (Pr = 0.16 | P = 0.01), ELME000133|ELME000155,-
COL4A5_HUMAN,G1086R,0.931,Loss of B-factor (Pr = 0.27 | P = 0.02); Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Methylation at K1082 (Pr = 0.23 | P = 3.3e-03); Gain of Phosphorylation at Y1090 (Pr = 0.23 | P = 0.05); Gain of Acetylation at K1082 (Pr = 0.19 | P = 0.05); Loss of Sulfation at Y1090 (Pr = 0.01 | P = 0.05), ELME000005|ELME000155,-
COL4A5_HUMAN,G1036R,0.952,Loss of Loop (Pr = 0.29 | P = 8.9e-03); Altered Disordered interface (Pr = 0.27 | P = 0.04), None,-
COL4A5_HUMAN,G743V,0.951,Loss of B-factor (Pr = 0.32 | P = 3.8e-03); Altered Disordered interface (Pr = 0.27 | P = 0.04); Gain of Acetylation at K748 (Pr = 0.19 | P = 0.05); Loss of Methylation at K748 (Pr = 0.19 | P = 7.3e-03), None,-
COL4A5_HUMAN,G426R,0.925,Loss of Loop (Pr = 0.28 | P = 0.02); Loss of B-factor (Pr = 0.25 | P = 0.05); Gain of Pyrrolidone carboxylic acid at Q427 (Pr = 0.07 | P = 0.02), ELME000155,-
COL4A5_HUMAN,G1235D,0.913,Gain of Loop (Pr = 0.32 | P = 2.0e-03); Loss of B-factor (Pr = 0.26 | P = 0.05), ELME000155,-
COL4A5_HUMAN,G216E,0.939,Gain of Loop (Pr = 0.27 | P = 0.03); Gain of SUMOylation at K215 (Pr = 0.23 | P = 0.02); Loss of Methylation at K215 (Pr = 0.21 | P = 5.8e-03), ELME000232,-
COL4A5_HUMAN,G230R,0.937,Loss of B-factor (Pr = 0.29 | P = 0.01); Gain of SUMOylation at K229 (Pr = 0.29 | P = 3.4e-03); Loss of Acetylation at K226 (Pr = 0.24 | P = 0.02); Loss of Methylation at K229 (Pr = 0.21 | P = 5.2e-03), ELME000100|ELME000108,-
COL4A5_HUMAN,G840R,0.945,Altered Disordered interface (Pr = 0.32 | P = 0.02); Gain of Acetylation at K845 (Pr = 0.22 | P = 0.02); Loss of Methylation at K845 (Pr = 0.20 | P = 7.0e-03); Loss of SUMOylation at K845 (Pr = 0.20 | P = 0.03), ELME000133,-
COL4A5_HUMAN,G521C,0.902,Loss of Methylation at K526 (Pr = 0.26 | P = 1.6e-03); Loss of B-factor (Pr = 0.25 | P = 0.05); Loss of Acetylation at K517 (Pr = 0.21 | P = 0.04), PS00008,-
COL4A5_HUMAN,G415R,0.766,Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of O-linked glycosylation at S417 (Pr = 0.15 | P = 0.04), ELME000062|ELME000135,-
COL4A5_HUMAN,G899V,0.961,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of SUMOylation at K895 (Pr = 0.26 | P = 6.6e-03); Loss of Acetylation at K895 (Pr = 0.24 | P = 0.02); Loss of Methylation at K895 (Pr = 0.20 | P = 6.6e-03), None,-
COL4A5_HUMAN,G432R,0.907,Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q427 (Pr = 0.04 | P = 0.04), None,-
COL4A5_HUMAN,G644D,0.926,Gain of Loop (Pr = 0.27 | P = 0.04), ELME000155,-
COL4A5_HUMAN,G787R,0.954,Loss of B-factor (Pr = 0.27 | P = 0.03), ELME000006|ELME000012|ELME000062|ELME000102|ELME000108|ELME000135|ELME000220|ELME000231,-
COL4A5_HUMAN,G831W,0.948,Altered Disordered interface (Pr = 0.41 | P = 4.0e-03); Gain of Loop (Pr = 0.29 | P = 7.9e-03); Loss of B-factor (Pr = 0.27 | P = 0.03), None,-
COL4A5_HUMAN,G389R,0.844,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of ADP-ribosylation at G389 (Pr = 0.20 | P = 0.03), ELME000135|ELME000155,-
COL4A5_HUMAN,G216R,0.949,Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Methylation at K215 (Pr = 0.21 | P = 5.3e-03); Gain of SUMOylation at K215 (Pr = 0.20 | P = 0.03), ELME000100|ELME000108|ELME000233,-
COL4A5_HUMAN,G638S,0.934,Loss of Acetylation at K634 (Pr = 0.26 | P = 9.3e-03); Loss of Methylation at K634 (Pr = 0.20 | P = 6.6e-03), None,-
COL4A5_HUMAN,G1333V,0.966,Loss of Acetylation at K1335 (Pr = 0.23 | P = 0.02); Loss of Methylation at K1335 (Pr = 0.21 | P = 5.8e-03); Gain of SUMOylation at K1335 (Pr = 0.19 | P = 0.04); Gain of O-linked glycosylation at S1338 (Pr = 0.11 | P = 0.05), None,-
COL4A5_HUMAN,G521D,0.897,Loss of Methylation at K526 (Pr = 0.23 | P = 3.5e-03); Loss of Acetylation at K517 (Pr = 0.22 | P = 0.03); Gain of Ubiquitylation at K526 (Pr = 0.15 | P = 0.05), ELME000293|PS00008,-
COL4A5_HUMAN,S1604F,0.749,Loss of Intrinsic disorder (Pr = 0.35 | P = 0.05); Altered Transmembrane protein (Pr = 0.34 | P = 4.4e-05), ELME000085|ELME000336,-
COL4A5_HUMAN,G1357E,0.947,Gain of Loop (Pr = 0.28 | P = 0.02); Loss of B-factor (Pr = 0.27 | P = 0.03), ELME000155,-
COL4A5_HUMAN,G650C,0.942,Loss of B-factor (Pr = 0.30 | P = 0.01); Loss of Methylation at K652 (Pr = 0.27 | P = 1.2e-03), None,-
COL4A5_HUMAN,G515E,0.937,Gain of SUMOylation at K514 (Pr = 0.32 | P = 2.7e-03); Gain of B-factor (Pr = 0.25 | P = 0.04); Loss of Acetylation at K514 (Pr = 0.23 | P = 0.02); Loss of Methylation at K517 (Pr = 0.21 | P = 5.5e-03), None,-
COL4A5_HUMAN,G48R,0.967,Gain of SUMOylation at K47 (Pr = 0.29 | P = 3.5e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Acetylation at K44 (Pr = 0.20 | P = 0.04); Loss of Methylation at K44 (Pr = 0.12 | P = 0.03), ELME000100|ELME000108,-
COL4A5_HUMAN,G603R,0.937,Loss of Loop (Pr = 0.32 | P = 3.2e-03); Loss of B-factor (Pr = 0.27 | P = 0.02); Gain of Acetylation at K599 (Pr = 0.24 | P = 0.02); Loss of Methylation at K599 (Pr = 0.20 | P = 7.0e-03), ELME000005|ELME000012|ELME000102|ELME000108|ELME000155,-
COL4A5_HUMAN,G1433A,0.928,, ELME000052|PS00008,-
COL4A5_HUMAN,G840E,0.938,Altered Disordered interface (Pr = 0.30 | P = 0.02); Loss of Acetylation at K845 (Pr = 0.22 | P = 0.03); Gain of SUMOylation at K845 (Pr = 0.22 | P = 0.02); Loss of Methylation at K845 (Pr = 0.19 | P = 7.7e-03), ELME000133,-
COL4A5_HUMAN,G749V,0.952,Loss of B-factor (Pr = 0.33 | P = 3.1e-03); Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of Methylation at K748 (Pr = 0.20 | P = 7.1e-03), ELME000002,-
COL4A5_HUMAN,G1339S,0.903,Loss of Acetylation at K1335 (Pr = 0.23 | P = 0.02); Loss of Methylation at K1335 (Pr = 0.21 | P = 5.7e-03), ELME000053|ELME000085|PS00008,-
COL4A5_HUMAN,G494D,0.946,Gain of Loop (Pr = 0.30 | P = 5.8e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of O-linked glycosylation at S490 (Pr = 0.17 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q495 (Pr = 0.07 | P = 0.02), ELME000155,-
COL4A5_HUMAN,G536D,0.952,, ELME000155|ELME000293,-
COL4A5_HUMAN,G1220D,0.945,Gain of Loop (Pr = 0.30 | P = 5.6e-03); Loss of B-factor (Pr = 0.25 | P = 0.05); Loss of Methylation at K1222 (Pr = 0.18 | P = 0.01), None,-
COL4A5_HUMAN,G239E,0.884,Loss of B-factor (Pr = 0.27 | P = 0.02), ELME000155,-
COL4A5_HUMAN,G198E,0.932,Gain of Loop (Pr = 0.33 | P = 1.5e-03); Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of B-factor (Pr = 0.27 | P = 0.03), None,-
COL4A5_HUMAN,G638A,0.923,Loss of Acetylation at K634 (Pr = 0.28 | P = 6.5e-03); Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Methylation at K634 (Pr = 0.19 | P = 7.6e-03), None,-
COL4A5_HUMAN,G766V,0.955,Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Acetylation at K768 (Pr = 0.25 | P = 0.01); Gain of SUMOylation at K768 (Pr = 0.19 | P = 0.04); Loss of Methylation at K768 (Pr = 0.17 | P = 0.01), None,-
COL4A5_HUMAN,G527R,0.917,Loss of Loop (Pr = 0.28 | P = 0.02); Gain of Acetylation at K526 (Pr = 0.24 | P = 0.02); Loss of Methylation at K526 (Pr = 0.24 | P = 2.9e-03); Gain of SUMOylation at K526 (Pr = 0.18 | P = 0.05), ELME000005|ELME000100|ELME000106|ELME000108|ELME000155,-
COL4A5_HUMAN,G603S,0.9,Gain of Phosphorylation at G603 (Pr = 0.38 | P = 7.4e-03); Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Acetylation at K599 (Pr = 0.25 | P = 0.01); Loss of Methylation at K599 (Pr = 0.19 | P = 7.6e-03); Gain of SUMOylation at K599 (Pr = 0.19 | P = 0.04), ELME000005|ELME000136|ELME000155|ELME000159,-
COL4A5_HUMAN,G406V,0.95,Loss of B-factor (Pr = 0.29 | P = 0.02); Altered Disordered interface (Pr = 0.27 | P = 0.05); Gain of Acetylation at K408 (Pr = 0.22 | P = 0.03); Gain of SUMOylation at K408 (Pr = 0.20 | P = 0.03); Loss of Methylation at K408 (Pr = 0.19 | P = 8.2e-03); Loss of Pyrrolidone carboxylic acid at Q407 (Pr = 0.05 | P = 0.03), None,-
COL4A5_HUMAN,G195D,0.946,Altered Disordered interface (Pr = 0.28 | P = 0.03); Loss of B-factor (Pr = 0.26 | P = 0.04), ELME000155,-
COL4A5_HUMAN,G893R,0.962,Loss of Loop (Pr = 0.30 | P = 6.0e-03); Loss of Acetylation at K895 (Pr = 0.28 | P = 6.5e-03); Gain of SUMOylation at K895 (Pr = 0.27 | P = 5.2e-03); Loss of Methylation at K895 (Pr = 0.20 | P = 6.6e-03); Gain of O-linked glycosylation at S889 (Pr = 0.12 | P = 0.04), ELME000064|ELME000220,-
COL4A5_HUMAN,G632R,0.927,Loss of Acetylation at K634 (Pr = 0.32 | P = 3.0e-03); Loss of B-factor (Pr = 0.25 | P = 0.05); Loss of Methylation at K634 (Pr = 0.21 | P = 5.7e-03); Gain of SUMOylation at K634 (Pr = 0.19 | P = 0.04), ELME000006,-
COL4A5_HUMAN,G621C,0.908,Altered Disordered interface (Pr = 0.32 | P = 0.01); Loss of B-factor (Pr = 0.29 | P = 0.01), ELME000155,-
COL2A1_HUMAN,G768D,0.969,Loss of Acetylation at K773 (Pr = 0.28 | P = 6.0e-03); Gain of Loop (Pr = 0.27 | P = 0.03); Gain of B-factor (Pr = 0.25 | P = 0.02); Loss of Methylation at K773 (Pr = 0.25 | P = 2.0e-03); Loss of SUMOylation at K773 (Pr = 0.21 | P = 0.03); Altered Metal binding (Pr = 0.19 | P = 0.04); Gain of Ubiquitylation at K764 (Pr = 0.19 | P = 0.01), PS00016,-
COL2A1_HUMAN,G543E,0.958,Gain of Loop (Pr = 0.30 | P = 5.8e-03); Loss of Methylation at K542 (Pr = 0.27 | P = 1.3e-03); Loss of Acetylation at K542 (Pr = 0.24 | P = 0.02); Gain of SUMOylation at K542 (Pr = 0.22 | P = 0.02); Loss of Ubiquitylation at K542 (Pr = 0.18 | P = 0.02), None,-
COL2A1_HUMAN,G1173V,0.962,Loss of B-factor (Pr = 0.30 | P = 8.6e-03); Loss of Acetylation at K1174 (Pr = 0.27 | P = 6.8e-03); Loss of Methylation at K1174 (Pr = 0.25 | P = 1.9e-03); Gain of SUMOylation at K1174 (Pr = 0.22 | P = 0.02); Gain of Ubiquitylation at K1174 (Pr = 0.18 | P = 0.02), ELME000085|ELME000321|PS00005|PS00006,-
COL2A1_HUMAN,G246R,0.941,Loss of B-factor (Pr = 0.30 | P = 7.6e-03); Loss of Loop (Pr = 0.29 | P = 0.01); Loss of Methylation at K250 (Pr = 0.28 | P = 9.3e-04); Gain of Acetylation at K250 (Pr = 0.26 | P = 9.2e-03); Gain of SUMOylation at K250 (Pr = 0.23 | P = 0.02); Loss of Ubiquitylation at K250 (Pr = 0.15 | P = 0.04), ELME000005|ELME000006|ELME000135|ELME000155,-
COL2A1_HUMAN,G1140A,0.93,Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of Loop (Pr = 0.27 | P = 0.04), ELME000155,-
COL2A1_HUMAN,G1158S,0.942,Gain of Methylation at R1163 (Pr = 0.13 | P = 0.02); Gain of O-linked glycosylation at S1154 (Pr = 0.12 | P = 0.04), ELME000053|ELME000136|ELME000155|ELME000159|ELME000239,-
COL2A1_HUMAN,A340T,0.413,-,-,-
COL2A1_HUMAN,G459D,0.952,Gain of Loop (Pr = 0.28 | P = 0.01); Loss of Acetylation at K464 (Pr = 0.28 | P = 5.5e-03); Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of Methylation at K464 (Pr = 0.26 | P = 1.4e-03); Gain of SUMOylation at K464 (Pr = 0.22 | P = 0.02), None,-
COL2A1_HUMAN,G705S,0.965,Loss of Methylation at R701 (Pr = 0.13 | P = 0.02), ELME000053|PS00005,-
COL2A1_HUMAN,R565C,0.624,Loss of ADP-ribosylation at R565 (Pr = 0.20 | P = 0.05); Loss of Methylation at R560 (Pr = 0.12 | P = 0.03), PS00005,-
COL2A1_HUMAN,G450A,0.942,Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of Methylation at K452 (Pr = 0.25 | P = 8.7e-04); Gain of SUMOylation at K452 (Pr = 0.19 | P = 0.04); Gain of Ubiquitylation at K452 (Pr = 0.16 | P = 0.03), ELME000052|ELME000155,-
COL2A1_HUMAN,G873R,0.967,Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of O-linked glycosylation at S869 (Pr = 0.18 | P = 0.02); Altered Metal binding (Pr = 0.11 | P = 0.04); Gain of Methylation at G873 (Pr = 0.10 | P = 0.04), ELME000155,-
COL2A1_HUMAN,K764E,0.862,Loss of Acetylation at K764 (Pr = 0.41 | P = 1.2e-03); Loss of Methylation at K764 (Pr = 0.40 | P = 1.9e-04); Gain of Loop (Pr = 0.31 | P = 2.8e-03); Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of Ubiquitylation at K764 (Pr = 0.23 | P = 1.9e-03); Altered Metal binding (Pr = 0.12 | P = 0.03), None,-
COL2A1_HUMAN,G1122R,0.95,Loss of Loop (Pr = 0.30 | P = 6.3e-03); Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of SUMOylation at K1118 (Pr = 0.26 | P = 6.7e-03); Loss of Methylation at K1118 (Pr = 0.21 | P = 5.8e-03); Loss of Ubiquitylation at K1118 (Pr = 0.15 | P = 0.05), None,-
COL2A1_HUMAN,G1305D,0.965,Altered Metal binding (Pr = 0.59 | P = 3.0e-03); Altered Ordered interface (Pr = 0.32 | P = 9.4e-03); Gain of Helix (Pr = 0.27 | P = 0.05); Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03); Loss of Disulfide linkage at C1306 (Pr = 0.21 | P = 0.02); Gain of Catalytic site at D1301 (Pr = 0.20 | P = 0.01), ELME000147,-
COL2A1_HUMAN,R437W,0.771,Altered Disordered interface (Pr = 0.41 | P = 3.7e-03); Loss of B-factor (Pr = 0.31 | P = 6.2e-03); Gain of Loop (Pr = 0.27 | P = 0.02); Loss of Methylation at R437 (Pr = 0.20 | P = 6.3e-03), ELME000155|ELME000328,-
COL2A1_HUMAN,G309V,0.965,Gain of SUMOylation at K308 (Pr = 0.32 | P = 2.6e-03); Loss of B-factor (Pr = 0.29 | P = 0.01); Loss of Methylation at K308 (Pr = 0.28 | P = 8.4e-04); Loss of Acetylation at K308 (Pr = 0.27 | P = 8.2e-03); Loss of Ubiquitylation at K308 (Pr = 0.17 | P = 0.03); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000002|ELME000173,-
COL2A1_HUMAN,G606R,0.969,Altered Disordered interface (Pr = 0.28 | P = 0.03); Loss of Loop (Pr = 0.27 | P = 0.03); Loss of B-factor (Pr = 0.26 | P = 0.05); Loss of Acetylation at K608 (Pr = 0.26 | P = 9.6e-03); Loss of Methylation at K608 (Pr = 0.24 | P = 2.9e-03); Gain of SUMOylation at K608 (Pr = 0.21 | P = 0.03); Loss of Ubiquitylation at K608 (Pr = 0.16 | P = 0.04), None,-
COL2A1_HUMAN,G1152R,0.948,Loss of Loop (Pr = 0.29 | P = 0.01); Loss of B-factor (Pr = 0.26 | P = 0.04), ELME000062,-
COL2A1_HUMAN,G510D,0.968,Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Methylation at R515 (Pr = 0.20 | P = 6.6e-03), ELME000293|PS00008,-
COL2A1_HUMAN,G354R,0.966,Loss of B-factor (Pr = 0.30 | P = 8.1e-03); Gain of Methylation at G354 (Pr = 0.11 | P = 0.03), ELME000155,-
COL2A1_HUMAN,G831V,0.959,Loss of B-factor (Pr = 0.33 | P = 3.0e-03), ELME000155,-
COL2A1_HUMAN,G444S,0.954,Gain of Loop (Pr = 0.30 | P = 5.2e-03); Loss of B-factor (Pr = 0.27 | P = 0.03), ELME000052|ELME000085,-
COL2A1_HUMAN,G459R,0.95,Altered Disordered interface (Pr = 0.28 | P = 0.04); Loss of Loop (Pr = 0.28 | P = 0.01); Loss of Methylation at K464 (Pr = 0.27 | P = 1.2e-03); Loss of Acetylation at K464 (Pr = 0.25 | P = 0.01); Loss of SUMOylation at K464 (Pr = 0.21 | P = 0.03), None,-
COL2A1_HUMAN,G717V,0.966,Loss of Methylation at R719 (Pr = 0.14 | P = 0.02), None,-
COL2A1_HUMAN,G375R,0.966,Loss of Loop (Pr = 0.28 | P = 0.02); Loss of Methylation at K374 (Pr = 0.28 | P = 8.5e-04); Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of Acetylation at K374 (Pr = 0.26 | P = 9.1e-03); Loss of Ubiquitylation at K374 (Pr = 0.21 | P = 5.8e-03), ELME000002|ELME000100|ELME000108,-
COL2A1_HUMAN,G1200C,0.952,Loss of B-factor (Pr = 0.33 | P = 3.0e-03); Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Hydroxylation at P1205 (Pr = 0.01 | P = 2.9e-05), ELME000155,-
COL2A1_HUMAN,G591D,0.967,Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Methylation at R596 (Pr = 0.16 | P = 0.01); Loss of Hydroxylation at P590 (Pr = 0.01 | P = 9.7e-06), ELME000005|ELME000097,-
COL2A1_HUMAN,G687R,0.97,, None,-
COL2A1_HUMAN,G909C,0.966,Loss of B-factor (Pr = 0.32 | P = 3.6e-03); Loss of Methylation at R904 (Pr = 0.13 | P = 0.02); Loss of O-linked glycosylation at S910 (Pr = 0.12 | P = 0.05); Loss of GPI-anchor amidation at N911 (Pr = 0.01 | P = 0.02), ELME000097,-
COL2A1_HUMAN,G1113C,0.944,Loss of B-factor (Pr = 0.31 | P = 7.5e-03); Gain of Loop (Pr = 0.26 | P = 0.05); Loss of SUMOylation at K1118 (Pr = 0.25 | P = 9.2e-03); Loss of Methylation at K1118 (Pr = 0.23 | P = 3.7e-03); Loss of Ubiquitylation at K1118 (Pr = 0.15 | P = 0.04), ELME000155,-
COL2A1_HUMAN,P434S,0.842,Altered Disordered interface (Pr = 0.30 | P = 0.02); Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of O-linked glycosylation at P434 (Pr = 0.20 | P = 0.02); Gain of Methylation at R437 (Pr = 0.16 | P = 0.01), ELME000085|ELME000155,-
COL2A1_HUMAN,G849D,0.956,Loss of Methylation at K848 (Pr = 0.28 | P = 1.1e-03); Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Acetylation at K848 (Pr = 0.24 | P = 0.02); Gain of Ubiquitylation at K848 (Pr = 0.17 | P = 0.03); Altered Metal binding (Pr = 0.13 | P = 0.03), ELME000002,-
COL2A1_HUMAN,G603V,0.966,Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of Acetylation at K608 (Pr = 0.24 | P = 0.02); Loss of Methylation at K608 (Pr = 0.23 | P = 3.4e-03); Gain of SUMOylation at K608 (Pr = 0.18 | P = 0.05); Loss of Ubiquitylation at K608 (Pr = 0.16 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q598 (Pr = 0.10 | P = 0.01), None,-
COL2A1_HUMAN,G1065V,0.962,Loss of B-factor (Pr = 0.26 | P = 0.04), ELME000052|ELME000155,-
COL2A1_HUMAN,Y1238C,0.77,Loss of Phosphorylation at Y1238 (Pr = 1.00 | P = 3.7e-04); Altered Disordered interface (Pr = 0.42 | P = 3.2e-03); Gain of Intrinsic disorder (Pr = 0.33 | P = 0.03); Loss of Proteolytic cleavage at Q1237 (Pr = 0.22 | P = 1.2e-03); Loss of Sulfation at Y1238 (Pr = 0.03 | P = 0.02), PS00007,-
COL2A1_HUMAN,G1152D,0.95,Gain of Loop (Pr = 0.27 | P = 0.03), ELME000085|ELME000293,-
COL2A1_HUMAN,G423D,0.968,Loss of Methylation at K419 (Pr = 0.29 | P = 7.6e-04); Altered Disordered interface (Pr = 0.27 | P = 0.05); Gain of Ubiquitylation at K419 (Pr = 0.23 | P = 2.6e-03); Loss of SUMOylation at K419 (Pr = 0.19 | P = 0.04), ELME000085|ELME000293,-
COL2A1_HUMAN,P133H,0.578,Loss of B-factor (Pr = 0.26 | P = 0.05); Loss of Methylation at R134 (Pr = 0.21 | P = 5.7e-03), None,-
COL2A1_HUMAN,G1197S,0.916,Gain of Loop (Pr = 0.28 | P = 0.01); Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of ADP-ribosylation at R1192 (Pr = 0.20 | P = 0.04); Loss of Methylation at R1192 (Pr = 0.10 | P = 0.05), ELME000053|ELME000063|ELME000136|ELME000155|ELME000159,-
COL2A1_HUMAN,G462D,0.952,Gain of Loop (Pr = 0.29 | P = 0.01); Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of Acetylation at K464 (Pr = 0.26 | P = 9.2e-03); Loss of Methylation at K464 (Pr = 0.26 | P = 1.5e-03); Gain of SUMOylation at K464 (Pr = 0.21 | P = 0.03), None,-
COL2A1_HUMAN,G969V,0.956,Loss of B-factor (Pr = 0.33 | P = 2.8e-03); Gain of O-linked glycosylation at S965 (Pr = 0.12 | P = 0.04), ELME000155,-
COL2A1_HUMAN,G867D,0.97,Loss of B-factor (Pr = 0.26 | P = 0.05); Altered Metal binding (Pr = 0.18 | P = 0.05); Loss of O-linked glycosylation at S869 (Pr = 0.12 | P = 0.05), ELME000085|ELME000155,-
COL2A1_HUMAN,G1188D,0.959,Altered Disordered interface (Pr = 0.32 | P = 0.02); Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Methylation at R1190 (Pr = 0.27 | P = 1.4e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of ADP-ribosylation at R1192 (Pr = 0.20 | P = 0.05), None,-
COL2A1_HUMAN,G1200S,0.934,Gain of Loop (Pr = 0.28 | P = 0.01); Gain of Phosphorylation at G1200 (Pr = 0.28 | P = 0.02); Loss of B-factor (Pr = 0.27 | P = 0.02); Gain of Hydroxylation at P1205 (Pr = 0.01 | P = 2.9e-05), ELME000053|ELME000136|ELME000155|ELME000159,-
COL2A1_HUMAN,G351V,0.965,Loss of B-factor (Pr = 0.32 | P = 3.7e-03), ELME000155,-
COL2A1_HUMAN,R1133C,0.828,Loss of SUMOylation at K1130 (Pr = 0.22 | P = 0.02); Loss of Methylation at K1130 (Pr = 0.12 | P = 0.03), ELME000146,-
COL2A1_HUMAN,G1095S,0.944,Gain of Loop (Pr = 0.27 | P = 0.04), ELME000136|ELME000155|ELME000159,-
COL2A1_HUMAN,G771A,0.959,Loss of B-factor (Pr = 0.26 | P = 0.03); Loss of Acetylation at K773 (Pr = 0.26 | P = 9.1e-03); Gain of Methylation at K773 (Pr = 0.26 | P = 4.9e-04); Gain of SUMOylation at K773 (Pr = 0.21 | P = 0.03); Altered Metal binding (Pr = 0.19 | P = 0.04); Gain of Ubiquitylation at K773 (Pr = 0.19 | P = 0.01), None,-
COL2A1_HUMAN,A302V,0.288,-,-,-
COL2A1_HUMAN,G552R,0.973,Loss of B-factor (Pr = 0.27 | P = 0.02); Gain of Methylation at R550 (Pr = 0.11 | P = 0.03), None,-
COL2A1_HUMAN,G537D,0.955,Gain of Loop (Pr = 0.31 | P = 3.4e-03); Loss of Methylation at K542 (Pr = 0.27 | P = 1.3e-03); Loss of Acetylation at K542 (Pr = 0.26 | P = 9.8e-03); Loss of SUMOylation at K542 (Pr = 0.19 | P = 0.04); Gain of Ubiquitylation at K542 (Pr = 0.19 | P = 0.01), ELME000085,-
COL2A1_HUMAN,G942D,0.96,Loss of Methylation at R940 (Pr = 0.11 | P = 0.04), None,-
COL2A1_HUMAN,G456R,0.968,Loss of Loop (Pr = 0.29 | P = 9.2e-03); Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of Methylation at K452 (Pr = 0.25 | P = 2.0e-03); Gain of Acetylation at K452 (Pr = 0.19 | P = 0.04); Gain of SUMOylation at K452 (Pr = 0.18 | P = 0.05); Loss of Ubiquitylation at K452 (Pr = 0.15 | P = 0.05), None,-
COL2A1_HUMAN,G600D,0.967,Altered Disordered interface (Pr = 0.29 | P = 0.03); Gain of Loop (Pr = 0.26 | P = 0.05); Gain of Methylation at R596 (Pr = 0.18 | P = 7.2e-03); Loss of Pyrrolidone carboxylic acid at Q598 (Pr = 0.08 | P = 0.02), None,-
COL2A1_HUMAN,D1219H,0.745,Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Proteolytic cleavage at M1220 (Pr = 0.12 | P = 0.03), ELME000085|ELME000147|PS00008,-
COL2A1_HUMAN,G909S,0.958,Loss of B-factor (Pr = 0.25 | P = 0.05); Loss of Methylation at R904 (Pr = 0.12 | P = 0.03); Gain of GPI-anchor amidation at N911 (Pr = 0.02 | P = 0.02), ELME000097,-
COL2A1_HUMAN,P478L,0.476,-,-,-
COL2A1_HUMAN,E142D,0.252,-,-,-
COL2A1_HUMAN,R3A,0.451,-,-,-
COL2A1_HUMAN,L4F,0.326,-,-,-
COL2A1_HUMAN,T14S,0.329,-,-,-
COL2A1_HUMAN,R22Q,0.302,-,-,-
COL2A1_HUMAN,Q24E,0.33,-,-,-
COL2A1_HUMAN,Q24H,0.247,-,-,-
COL2A1_HUMAN,Q26L,0.517,Loss of Pyrrolidone carboxylic acid at Q24 (Pr = 0.26 | P = 6.2e-04); Altered Signal peptide (Pr = 0.13 | P = 7.1e-04); Gain of Proteolytic cleavage at D27 (Pr = 0.11 | P = 0.05), None,-
COL2A1_HUMAN,D27E,0.536,Gain of Pyrrolidone carboxylic acid at Q24 (Pr = 0.24 | P = 9.1e-04); Altered Signal peptide (Pr = 0.06 | P = 1.9e-03), None,-
COL2A1_HUMAN,V28A,0.195,-,-,-
COL2A1_HUMAN,Q29V,0.666,Loss of Pyrrolidone carboxylic acid at Q24 (Pr = 0.24 | P = 8.8e-04); Gain of Disulfide linkage at C34 (Pr = 0.19 | P = 0.02); Altered Transmembrane protein (Pr = 0.13 | P = 0.02), None,-
COL2A1_HUMAN,A31H,0.338,-,-,-
COL2A1_HUMAN,A31P,0.484,-,-,-
COL2A1_HUMAN,G32R,0.511,Altered Transmembrane protein (Pr = 0.21 | P = 4.2e-03); Loss of Disulfide linkage at C34 (Pr = 0.17 | P = 0.03); Gain of Pyrrolidone carboxylic acid at Q29 (Pr = 0.05 | P = 0.03), None,-
COL2A1_HUMAN,D37A,0.421,-,-,-
COL2A1_HUMAN,Q39N,0.588,Altered Transmembrane protein (Pr = 0.24 | P = 1.8e-03); Gain of Disulfide linkage at C34 (Pr = 0.21 | P = 0.02); Loss of Sulfation at Y41 (Pr = 0.01 | P = 0.05), PS00008,-
COL2A1_HUMAN,R40W,0.478,-,-,-
COL2A1_HUMAN,P51S,0.461,-,-,-
COL2A1_HUMAN,R53Q,0.415,-,-,-
COL2A1_HUMAN,I54V,0.382,-,-,-
COL2A1_HUMAN,T59S,0.215,-,-,-
COL2A1_HUMAN,I68F,0.466,-,-,-
COL2A1_HUMAN,V72A,0.101,-,-,-
COL2A1_HUMAN,D74N,0.516,Loss of Loop (Pr = 0.28 | P = 0.02); Gain of Disulfide linkage at C69 (Pr = 0.16 | P = 0.03), ELME000136|ELME000159|PS01208,-
COL2A1_HUMAN,S77D,0.218,-,-,-
COL2A1_HUMAN,S77K,0.236,-,-,-
COL2A1_HUMAN,S77P,0.421,-,-,-
COL2A1_HUMAN,P78L,0.502,Loss of Intrinsic disorder (Pr = 0.35 | P = 0.05); Gain of Loop (Pr = 0.26 | P = 0.05); Gain of Disulfide linkage at C75 (Pr = 0.15 | P = 0.03), ELME000136|ELME000155|ELME000159|ELME000193|PS01208,-
COL2A1_HUMAN,P78S,0.463,-,-,-
COL2A1_HUMAN,P78T,0.421,-,-,-
COL2A1_HUMAN,P90S,0.271,-,-,-
COL2A1_HUMAN,Q99H,0.188,-,-,-
COL2A1_HUMAN,P100K,0.497,-,-,-
COL2A1_HUMAN,P100L,0.344,-,-,-
COL2A1_HUMAN,P102L,0.424,-,-,-
COL2A1_HUMAN,K103Q,0.466,-,-,-
COL2A1_HUMAN,K103R,0.281,-,-,-
COL2A1_HUMAN,Q105N,0.697,Gain of B-factor (Pr = 0.26 | P = 0.01); Loss of SUMOylation at K106 (Pr = 0.22 | P = 0.02); Loss of Methylation at K106 (Pr = 0.17 | P = 0.01); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), None,-
COL2A1_HUMAN,G107P,0.948,Gain of SUMOylation at K106 (Pr = 0.27 | P = 5.1e-03); Loss of B-factor (Pr = 0.26 | P = 0.05); Loss of Methylation at K106 (Pr = 0.17 | P = 0.01); Gain of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), None,-
COL2A1_HUMAN,G107S,0.926,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of SUMOylation at K106 (Pr = 0.23 | P = 0.01); Loss of Acetylation at K106 (Pr = 0.19 | P = 0.05); Loss of Methylation at K106 (Pr = 0.17 | P = 0.01); Gain of Proteolytic cleavage at K106 (Pr = 0.12 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), None,-
COL2A1_HUMAN,E108S,0.786,Gain of Phosphorylation at E108 (Pr = 0.48 | P = 3.8e-03); Loss of SUMOylation at K106 (Pr = 0.28 | P = 4.4e-03); Gain of Acetylation at K113 (Pr = 0.25 | P = 0.01); Loss of Methylation at K113 (Pr = 0.18 | P = 9.1e-03); Loss of Pyrrolidone carboxylic acid at Q105 (Pr = 0.06 | P = 0.03), ELME000136|ELME000159|PS00006,-
COL2A1_HUMAN,K113A,0.551,Loss of Acetylation at K113 (Pr = 0.49 | P = 6.0e-04); Loss of SUMOylation at K113 (Pr = 0.27 | P = 4.5e-03); Loss of Methylation at K113 (Pr = 0.24 | P = 2.8e-03); Gain of Proteolytic cleavage at D114 (Pr = 0.18 | P = 3.8e-03), None,-
COL2A1_HUMAN,D111S,0.602,Gain of Acetylation at K113 (Pr = 0.26 | P = 9.8e-03); Gain of Phosphorylation at D111 (Pr = 0.25 | P = 0.03); Loss of SUMOylation at K106 (Pr = 0.22 | P = 0.02); Loss of Methylation at K113 (Pr = 0.18 | P = 9.2e-03); Loss of Proteolytic cleavage at D114 (Pr = 0.14 | P = 0.02); Gain of O-linked glycosylation at D111 (Pr = 0.11 | P = 0.05), PS00005|PS00006,-
COL2A1_HUMAN,I112A,0.53,Gain of B-factor (Pr = 0.27 | P = 0.01); Loss of Acetylation at K113 (Pr = 0.27 | P = 8.3e-03); Gain of Methylation at K113 (Pr = 0.22 | P = 2.4e-03); Loss of SUMOylation at K113 (Pr = 0.20 | P = 0.03); Loss of Proteolytic cleavage at D114 (Pr = 0.14 | P = 0.02), None,-
COL2A1_HUMAN,I112V,0.138,-,-,-
COL2A1_HUMAN,K113L,0.657,Loss of Acetylation at K113 (Pr = 0.49 | P = 6.0e-04); Loss of SUMOylation at K113 (Pr = 0.27 | P = 4.5e-03); Loss of Methylation at K113 (Pr = 0.24 | P = 2.8e-03); Gain of Proteolytic cleavage at D114 (Pr = 0.22 | P = 1.0e-03), ELME000335,-
COL2A1_HUMAN,V116M,0.209,-,-,-
COL2A1_HUMAN,P164A,0.266,-,-,-
COL2A1_HUMAN,G186A,0.6,Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of Loop (Pr = 0.27 | P = 0.04); Gain of SUMOylation at K190 (Pr = 0.20 | P = 0.03); Gain of Ubiquitylation at K190 (Pr = 0.20 | P = 8.6e-03); Loss of Methylation at K190 (Pr = 0.11 | P = 0.04); Gain of Proteolytic cleavage at Q182 (Pr = 0.11 | P = 0.04); Loss of Pyrrolidone carboxylic acid at Q182 (Pr = 0.06 | P = 0.03), None,-
COL2A1_HUMAN,L196M,0.029,-,-,-
COL2A1_HUMAN,P248A,0.268,-,-,-
COL2A1_HUMAN,A298V,0.273,-,-,-
COL2A1_HUMAN,T335A,0.18,-,-,-
COL2A1_HUMAN,K374R,0.594,Loss of Methylation at K374 (Pr = 0.34 | P = 3.0e-04); Loss of Acetylation at K374 (Pr = 0.29 | P = 5.5e-03); Loss of Ubiquitylation at K374 (Pr = 0.27 | P = 3.8e-04), ELME000002|PS00008,-
COL2A1_HUMAN,T397N,0.177,-,-,-
COL2A1_HUMAN,T455M,0.176,-,-,-
COL2A1_HUMAN,P473L,0.233,-,-,-
COL2A1_HUMAN,P541R,0.769,Loss of Acetylation at K542 (Pr = 0.29 | P = 5.4e-03); Loss of Loop (Pr = 0.28 | P = 0.02); Loss of Methylation at K542 (Pr = 0.25 | P = 2.1e-03); Gain of SUMOylation at K542 (Pr = 0.20 | P = 0.03); Loss of Ubiquitylation at K542 (Pr = 0.18 | P = 0.02), ELME000093|ELME000102|PS00009,-
COL2A1_HUMAN,D547E,0.316,-,-,-
COL2A1_HUMAN,A580P,0.451,-,-,-
COL2A1_HUMAN,A617G,0.249,-,-,-
COL2A1_HUMAN,E655K,0.704,Loss of Loop (Pr = 0.27 | P = 0.02); Gain of Methylation at E655 (Pr = 0.26 | P = 5.1e-04); Gain of SUMOylation at E655 (Pr = 0.24 | P = 0.01); Gain of Ubiquitylation at E655 (Pr = 0.17 | P = 0.02), None,-
COL2A1_HUMAN,P673T,0.334,-,-,-
COL2A1_HUMAN,D682E,0.239,-,-,-
COL2A1_HUMAN,V685L,0.201,-,-,-
COL2A1_HUMAN,S709A,0.28,-,-,-
COL2A1_HUMAN,S709N,0.414,-,-,-
COL2A1_HUMAN,S709T,0.27,-,-,-
COL2A1_HUMAN,A737G,0.161,-,-,-
COL2A1_HUMAN,A812S,0.072,-,-,-
COL2A1_HUMAN,S814T,0.062,-,-,-
COL2A1_HUMAN,T827I,0.323,-,-,-
COL2A1_HUMAN,G831L,0.964,Loss of B-factor (Pr = 0.32 | P = 5.1e-03), ELME000004|ELME000155,-
COL2A1_HUMAN,A833R,0.558,Gain of Methylation at A833 (Pr = 0.26 | P = 6.4e-04); Gain of B-factor (Pr = 0.25 | P = 0.02); Gain of ADP-ribosylation at A833 (Pr = 0.24 | P = 0.01), None,-
COL2A1_HUMAN,F835Y,0.267,-,-,-
COL2A1_HUMAN,P838H,0.523,Loss of B-factor (Pr = 0.27 | P = 0.03), None,-
COL2A1_HUMAN,A847I,0.177,-,-,-
COL2A1_HUMAN,G852K,0.933,Gain of Methylation at G852 (Pr = 0.35 | P = 4.4e-05); Gain of SUMOylation at G852 (Pr = 0.30 | P = 3.1e-03); Gain of Acetylation at K848 (Pr = 0.24 | P = 0.01); Loss of Ubiquitylation at K857 (Pr = 0.18 | P = 0.02), None,-
COL2A1_HUMAN,A860S,0.101,-,-,-
COL2A1_HUMAN,A862P,0.548,Gain of B-factor (Pr = 0.30 | P = 2.4e-03); Loss of Methylation at K857 (Pr = 0.26 | P = 1.8e-03); Gain of Acetylation at K857 (Pr = 0.25 | P = 0.01); Loss of SUMOylation at K857 (Pr = 0.23 | P = 0.02); Loss of Ubiquitylation at K857 (Pr = 0.18 | P = 0.02); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000155|ELME000287,-
COL2A1_HUMAN,G864Q,0.973,Loss of B-factor (Pr = 0.26 | P = 0.03); Gain of O-linked glycosylation at S869 (Pr = 0.12 | P = 0.04); Altered Metal binding (Pr = 0.11 | P = 0.04); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000155,-
COL2A1_HUMAN,P865A,0.613,Loss of B-factor (Pr = 0.30 | P = 0.01); Gain of O-linked glycosylation at S869 (Pr = 0.13 | P = 0.04); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000155|PS00008,-
COL2A1_HUMAN,P865E,0.765,Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of O-linked glycosylation at S869 (Pr = 0.12 | P = 0.05); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000155,-
COL2A1_HUMAN,P865L,0.74,Loss of B-factor (Pr = 0.32 | P = 4.1e-03); Gain of O-linked glycosylation at S869 (Pr = 0.14 | P = 0.03); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000155,-
COL2A1_HUMAN,Q866L,0.806,Loss of B-factor (Pr = 0.28 | P = 0.02); Altered Metal binding (Pr = 0.12 | P = 0.03); Loss of O-linked glycosylation at S869 (Pr = 0.12 | P = 0.05), ELME000155,-
COL2A1_HUMAN,G870V,0.962,Loss of B-factor (Pr = 0.30 | P = 8.0e-03); Loss of O-linked glycosylation at S869 (Pr = 0.13 | P = 0.04); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000085,-
COL2A1_HUMAN,P874S,0.651,Loss of B-factor (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.12 | P = 0.03); Loss of O-linked glycosylation at S869 (Pr = 0.12 | P = 0.05), ELME000053|ELME000155|ELME000202|PS00008,-
COL2A1_HUMAN,A886S,0.173,-,-,-
COL2A1_HUMAN,S910A,0.249,-,-,-
COL2A1_HUMAN,P917A,0.229,-,-,-
COL2A1_HUMAN,P919V,0.584,Loss of B-factor (Pr = 0.40 | P = 3.4e-05); Gain of Loop (Pr = 0.26 | P = 0.04); Gain of O-linked glycosylation at S923 (Pr = 0.19 | P = 0.02), None,-
COL2A1_HUMAN,S935I,0.357,-,-,-
COL2A1_HUMAN,S935T,0.172,-,-,-
COL2A1_HUMAN,P944T,0.514,Loss of Methylation at R940 (Pr = 0.11 | P = 0.04), None,-
COL2A1_HUMAN,A950S,0.18,-,-,-
COL2A1_HUMAN,P952A,0.056,-,-,-
COL2A1_HUMAN,P953S,0.5,Loss of B-factor (Pr = 0.29 | P = 0.01); Loss of SUMOylation at K956 (Pr = 0.27 | P = 5.3e-03); Loss of Methylation at K956 (Pr = 0.25 | P = 2.1e-03); Gain of Acetylation at K956 (Pr = 0.22 | P = 0.03), ELME000085|ELME000133|ELME000239,-
COL2A1_HUMAN,S965P,0.503,Gain of B-factor (Pr = 0.28 | P = 5.4e-03); Altered Metal binding (Pr = 0.19 | P = 0.04), ELME000064|ELME000085|PS00006,-
COL2A1_HUMAN,S1001W,0.827,Altered Disordered interface (Pr = 0.42 | P = 3.2e-03); Loss of Methylation at K1006 (Pr = 0.37 | P = 2.4e-04); Loss of B-factor (Pr = 0.32 | P = 4.3e-03); Loss of Acetylation at K1006 (Pr = 0.26 | P = 8.7e-03); Loss of O-linked glycosylation at S1001 (Pr = 0.21 | P = 0.02); Loss of Ubiquitylation at K1006 (Pr = 0.16 | P = 0.04), ELME000085|ELME000239,-
COL2A1_HUMAN,P1034T,0.541,Loss of B-factor (Pr = 0.27 | P = 0.03), ELME000064|ELME000220|PS00005|PS00006,-
COL2A1_HUMAN,A1051T,0.346,-,-,-
COL2A1_HUMAN,V1064A,0.207,-,-,-
COL2A1_HUMAN,A1066G,0.277,-,-,-
COL2A1_HUMAN,P1067S,0.629,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of O-linked glycosylation at P1067 (Pr = 0.15 | P = 0.03), ELME000085|ELME000155|PS00008,-
COL2A1_HUMAN,A1069S,0.144,-,-,-
COL2A1_HUMAN,T1082I,0.302,-,-,-
COL2A1_HUMAN,A1091S,0.133,-,-,-
COL2A1_HUMAN,A1091T,0.239,-,-,-
COL2A1_HUMAN,G1095A,0.953,Altered Disordered interface (Pr = 0.30 | P = 0.02); Loss of B-factor (Pr = 0.25 | P = 0.05), ELME000155,-
COL2A1_HUMAN,E1120D,0.384,-,-,-
COL2A1_HUMAN,A1121S,0.088,-,-,-
COL2A1_HUMAN,A1121T,0.136,-,-,-
COL2A1_HUMAN,S1154A,0.231,-,-,-
COL2A1_HUMAN,A1177S,0.083,-,-,-
COL2A1_HUMAN,Q1243E,0.119,-,-,-
COL2A1_HUMAN,A1245D,0.295,-,-,-
COL2A1_HUMAN,G1247S,0.138,-,-,-
COL2A1_HUMAN,E1273D,0.2,-,-,-
COL2A1_HUMAN,S1295A,0.765,Altered Ordered interface (Pr = 0.23 | P = 0.05); Altered Transmembrane protein (Pr = 0.10 | P = 0.04); Loss of Catalytic site at W1299 (Pr = 0.10 | P = 0.04); Gain of Sulfation at Y1298 (Pr = 0.05 | P = 8.4e-03), ELME000085,-
COL2A1_HUMAN,S1295G,0.857,Altered Transmembrane protein (Pr = 0.10 | P = 0.05); Loss of Catalytic site at W1299 (Pr = 0.10 | P = 0.04); Loss of Sulfation at Y1298 (Pr = 0.05 | P = 8.8e-03), ELME000085,-
COL2A1_HUMAN,N1327R,0.645,Altered Ordered interface (Pr = 0.31 | P = 0.02); Altered Transmembrane protein (Pr = 0.25 | P = 1.4e-03); Gain of Disulfide linkage at C1323 (Pr = 0.24 | P = 7.5e-03); Gain of ADP-ribosylation at N1327 (Pr = 0.19 | P = 0.04); Loss of GPI-anchor amidation at N1330 (Pr = 0.02 | P = 0.02), ELME000084,-
COL2A1_HUMAN,N1330S,0.067,-,-,-
COL2A1_HUMAN,K1333R,0.215,-,-,-
COL2A1_HUMAN,S1339T,0.33,-,-,-
COL2A1_HUMAN,S1341G,0.191,-,-,-
COL2A1_HUMAN,E1343K,0.381,-,-,-
COL2A1_HUMAN,N1354H,0.566,Altered Transmembrane protein (Pr = 0.30 | P = 1.8e-04), ELME000336,-
COL2A1_HUMAN,N1354S,0.411,-,-,-
COL2A1_HUMAN,N1365T,0.344,-,-,-
COL2A1_HUMAN,A1367P,0.422,-,-,-
COL2A1_HUMAN,L1400M,0.221,-,-,-
COL2A1_HUMAN,A1403T,0.173,-,-,-
COL2A1_HUMAN,A1403V,0.164,-,-,-
COL2A1_HUMAN,K1435Q,0.289,-,-,-
COL2A1_HUMAN,G1437D,0.633,Altered Transmembrane protein (Pr = 0.35 | P = 1.9e-05); Altered Metal binding (Pr = 0.29 | P = 5.8e-03); Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Loss of Disulfide linkage at C1438 (Pr = 0.26 | P = 3.5e-03); Altered DNA binding (Pr = 0.15 | P = 0.04), None,-
COL2A1_HUMAN,K1447Q,0.621,Loss of Relative solvent accessibility (Pr = 0.33 | P = 4.5e-03); Altered Transmembrane protein (Pr = 0.29 | P = 3.4e-04); Loss of Acetylation at K1447 (Pr = 0.25 | P = 0.01), ELME000064|ELME000220,-
COL2A1_HUMAN,V1449I,0.263,-,-,-
COL2A1_HUMAN,V1449L,0.456,-,-,-
COL2A1_HUMAN,I1463L,0.426,-,-,-
COL2A1_HUMAN,A1466S,0.81,Loss of Catalytic site at D1464 (Pr = 0.30 | P = 1.9e-03); Altered Metal binding (Pr = 0.29 | P = 3.7e-03); Altered Transmembrane protein (Pr = 0.28 | P = 4.2e-04); Altered Disordered interface (Pr = 0.27 | P = 0.04); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Loss of Allosteric site at D1464 (Pr = 0.21 | P = 0.04), ELME000136|ELME000159|ELME000237|PS00006,-
COL2A1_HUMAN,M1468L,0.497,-,-,-
COL2A1_HUMAN,I1481L,0.554,Loss of Strand (Pr = 0.28 | P = 8.5e-03); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.22 | P = 3.7e-03); Altered Metal binding (Pr = 0.21 | P = 0.03); Gain of Catalytic site at E1476 (Pr = 0.11 | P = 0.03), None,-
COL4A3_HUMAN,P660T,0.307,-,-,-
COL4A3_HUMAN,G300R,0.958,Loss of Acetylation at K301 (Pr = 0.33 | P = 2.6e-03); Loss of B-factor (Pr = 0.29 | P = 0.01); Loss of Loop (Pr = 0.27 | P = 0.03); Gain of SUMOylation at K301 (Pr = 0.21 | P = 0.03); Loss of Methylation at K298 (Pr = 0.19 | P = 7.2e-03); Gain of Proteolytic cleavage at D302 (Pr = 0.11 | P = 0.04), ELME000102,-
COL4A3_HUMAN,G154A,0.902,Gain of Methylation at K156 (Pr = 0.21 | P = 2.9e-03); Gain of Ubiquitylation at K153 (Pr = 0.19 | P = 0.01); Gain of Pyrrolidone carboxylic acid at Q155 (Pr = 0.05 | P = 0.04), None,-
COL4A3_HUMAN,G955R,0.919,Gain of SUMOylation at K954 (Pr = 0.30 | P = 3.3e-03); Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Acetylation at K960 (Pr = 0.25 | P = 0.01); Loss of Methylation at K960 (Pr = 0.19 | P = 8.1e-03), ELME000100|ELME000108,-
COL4A3_HUMAN,F1502L,0.785,Altered Transmembrane protein (Pr = 0.27 | P = 5.4e-04); Loss of Strand (Pr = 0.27 | P = 0.03); Gain of Disulfide linkage at C1505 (Pr = 0.21 | P = 0.02), ELME000052,-
COL4A3_HUMAN,P432L,0.299,-,-,-
COL4A3_HUMAN,G369D,0.939,Gain of Loop (Pr = 0.28 | P = 0.01); Loss of Methylation at R365 (Pr = 0.17 | P = 0.01); Gain of O-linked glycosylation at S374 (Pr = 0.16 | P = 0.03), ELME000155,-
COL4A3_HUMAN,G596R,0.913,Loss of B-factor (Pr = 0.30 | P = 9.6e-03); Gain of Acetylation at K592 (Pr = 0.27 | P = 6.8e-03); Loss of Methylation at K592 (Pr = 0.23 | P = 3.2e-03); Gain of SUMOylation at K592 (Pr = 0.19 | P = 0.04); Altered Metal binding (Pr = 0.14 | P = 0.02), ELME000155,-
COL4A3_HUMAN,G780E,0.936,Altered Metal binding (Pr = 0.10 | P = 0.04), ELME000136|ELME000159|ELME000292|ELME000358|PS00008,-
COL4A3_HUMAN,G487C,0.84,Loss of Loop (Pr = 0.40 | P = 1.8e-04); Loss of B-factor (Pr = 0.30 | P = 8.3e-03), ELME000155,-
COL4A3_HUMAN,D326Y,0.287,-,-,-
COL4A3_HUMAN,P15Q,0.086,-,-,-
COL4A3_HUMAN,P68L,0.611,Loss of Methylation at K63 (Pr = 0.18 | P = 9.6e-03), ELME000064|ELME000220|PS00006,-
COL4A3_HUMAN,L71I,0.045,-,-,-
COL4A3_HUMAN,P72V,0.441,-,-,-
COL4A3_HUMAN,P77H,0.287,-,-,-
COL4A3_HUMAN,K161E,0.081,-,-,-
COL4A3_HUMAN,H225R,0.174,-,-,-
COL4A3_HUMAN,L295P,0.104,-,-,-
COL4A3_HUMAN,K301E,0.393,-,-,-
COL4A3_HUMAN,M323T,0.077,-,-,-
COL4A3_HUMAN,A367T,0.094,-,-,-
COL4A3_HUMAN,R408L,0.231,-,-,-
COL4A3_HUMAN,Y481C,0.158,-,-,-
COL4A3_HUMAN,F524I,0.181,-,-,-
COL4A3_HUMAN,Q531K,0.102,-,-,-
COL4A3_HUMAN,L626P,0.089,-,-,-
COL4A3_HUMAN,L679M,0.022,-,-,-
COL4A3_HUMAN,K725N,0.107,-,-,-
COL4A3_HUMAN,I891V,0.039,-,-,-
COL4A3_HUMAN,Q926H,0.085,-,-,-
COL4A3_HUMAN,S1016I,0.177,-,-,-
COL4A3_HUMAN,P1066R,0.248,-,-,-
COL4A3_HUMAN,L1094S,0.073,-,-,-
COL4A3_HUMAN,L1130P,0.057,-,-,-
COL4A3_HUMAN,L1141F,0.127,-,-,-
COL4A3_HUMAN,R1182K,0.07,-,-,-
COL4A3_HUMAN,A1196S,0.045,-,-,-
COL4A3_HUMAN,I1233M,0.102,-,-,-
COL4A3_HUMAN,A1252E,0.06,-,-,-
COL4A3_HUMAN,P1278L,0.1,-,-,-
COL4A3_HUMAN,K1339M,0.169,-,-,-
COL4A3_HUMAN,A1420P,0.038,-,-,-
COL4A3_HUMAN,S1588Y,0.847,Altered Transmembrane protein (Pr = 0.27 | P = 6.5e-04), ELME000053|ELME000063|ELME000085|ELME000304|ELME000336,-
COL4A3_HUMAN,A1597V,0.364,-,-,-
COL4A3_HUMAN,H1617E,0.886,Altered Metal binding (Pr = 0.49 | P = 4.1e-03); Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Transmembrane protein (Pr = 0.28 | P = 4.8e-04); Gain of Disulfide linkage at C1622 (Pr = 0.21 | P = 0.02), ELME000162,-
COL4A3_HUMAN,Y1625G,0.918,Altered Ordered interface (Pr = 0.45 | P = 4.8e-04); Altered Stability (Pr = 0.34 | P = 4.3e-03); Altered Transmembrane protein (Pr = 0.30 | P = 1.4e-04); Gain of Strand (Pr = 0.26 | P = 0.05); Altered DNA binding (Pr = 0.26 | P = 5.9e-03); Altered Metal binding (Pr = 0.24 | P = 0.03); Gain of Disulfide linkage at C1622 (Pr = 0.20 | P = 0.02), ELME000053|ELME000084,-
COL4A3_HUMAN,Y1629N,0.901,Altered Ordered interface (Pr = 0.43 | P = 5.9e-04); Gain of Helix (Pr = 0.30 | P = 8.4e-03); Altered Transmembrane protein (Pr = 0.29 | P = 3.4e-04); Loss of Strand (Pr = 0.27 | P = 0.02); Altered DNA binding (Pr = 0.27 | P = 6.6e-03); Altered Metal binding (Pr = 0.26 | P = 9.1e-03); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.04), ELME000053|ELME000197,-
COL4A3_HUMAN,S1630K,0.856,Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Altered Metal binding (Pr = 0.28 | P = 5.8e-03); Altered Ordered interface (Pr = 0.28 | P = 0.04); Gain of Helix (Pr = 0.27 | P = 0.03); Loss of Strand (Pr = 0.27 | P = 0.02); Altered DNA binding (Pr = 0.26 | P = 5.4e-03); Gain of Acetylation at S1630 (Pr = 0.19 | P = 0.05), ELME000053|ELME000197|PS00005,-
COL4A3_HUMAN,L1633P,0.939,Loss of Helix (Pr = 0.33 | P = 1.1e-03); Altered DNA binding (Pr = 0.32 | P = 1.7e-03); Altered Transmembrane protein (Pr = 0.31 | P = 9.3e-05); Gain of Strand (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.24 | P = 0.02); Altered Stability (Pr = 0.15 | P = 0.02), None,-
COL4A3_HUMAN,P1638E,0.52,Altered Transmembrane protein (Pr = 0.34 | P = 2.4e-05); Gain of Helix (Pr = 0.29 | P = 0.02); Loss of Strand (Pr = 0.28 | P = 6.2e-03), ELME000064|PS00006,-
COL4A3_HUMAN,M1641T,0.716,Altered Transmembrane protein (Pr = 0.31 | P = 1.3e-04); Altered Ordered interface (Pr = 0.30 | P = 0.02), ELME000147|ELME000337|PS00005,-
COL4A3_HUMAN,F1642L,0.711,Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Transmembrane protein (Pr = 0.28 | P = 4.3e-04); Gain of Helix (Pr = 0.27 | P = 0.03), ELME000102,-
COL4A3_HUMAN,S1648P,0.406,-,-,-
COL4A3_HUMAN,V1650K,0.68,Gain of Intrinsic disorder (Pr = 0.40 | P = 7.6e-03); Altered Transmembrane protein (Pr = 0.32 | P = 6.8e-05); Gain of Helix (Pr = 0.28 | P = 0.02); Gain of B-factor (Pr = 0.25 | P = 0.03); Altered Stability (Pr = 0.11 | P = 0.03), PS00005,-
COL4A3_HUMAN,G1653A,0.383,-,-,-
COL4A3_HUMAN,G1653S,0.424,-,-,-
COL4A3_HUMAN,E1656L,0.614,Altered Disordered interface (Pr = 0.18 | P = 0.04); Altered DNA binding (Pr = 0.18 | P = 0.03); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000333|ELME000335,-
COL4A3_HUMAN,C1662N,0.939,Altered Disordered interface (Pr = 0.32 | P = 6.8e-03); Altered Metal binding (Pr = 0.29 | P = 0.02); Gain of Strand (Pr = 0.26 | P = 0.05); Altered Stability (Pr = 0.20 | P = 0.01); Altered DNA binding (Pr = 0.17 | P = 0.03); Altered Transmembrane protein (Pr = 0.11 | P = 0.04), None,-
COL4A3_HUMAN,K1668H,0.246,-,-,-
COL4A3_HUMAN,R1669A,0.407,-,-,-
COL4A3_HUMAN,L1474P,0.945,Altered Transmembrane protein (Pr = 0.25 | P = 1.6e-03); Altered Stability (Pr = 0.18 | P = 0.02), ELME000063|ELME000197|ELME000234|ELME000328,-
COL4A3_HUMAN,F1504L,0.653,Loss of Strand (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.26 | P = 1.0e-03); Gain of Disulfide linkage at C1505 (Pr = 0.22 | P = 0.02), None,-
COL4A3_HUMAN,G818R,0.957,Altered Disordered interface (Pr = 0.20 | P = 0.03); Gain of Pyrrolidone carboxylic acid at Q817 (Pr = 0.06 | P = 0.02), None,-
COL4A3_HUMAN,G174R,0.924,Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of Loop (Pr = 0.26 | P = 0.05); Gain of Acetylation at K170 (Pr = 0.20 | P = 0.04); Loss of Ubiquitylation at K170 (Pr = 0.18 | P = 0.02); Loss of Methylation at K170 (Pr = 0.17 | P = 0.01), ELME000005|ELME000155,-
COL4A3_HUMAN,P797L,0.292,-,-,-
COL4A3_HUMAN,P1461L,0.502,Altered Transmembrane protein (Pr = 0.22 | P = 3.6e-03); Gain of Disulfide linkage at C1460 (Pr = 0.16 | P = 0.03), ELME000064|ELME000147|ELME000155|ELME000336|PS00006,-
COL4A3_HUMAN,G709E,0.924,Altered Disordered interface (Pr = 0.28 | P = 0.04); Loss of B-factor (Pr = 0.26 | P = 0.03); Loss of Acetylation at K708 (Pr = 0.22 | P = 0.03); Loss of Methylation at K708 (Pr = 0.20 | P = 6.6e-03), None,-
COL4A3_HUMAN,G1207E,0.931,Altered Disordered interface (Pr = 0.28 | P = 0.04); Gain of SUMOylation at K1206 (Pr = 0.24 | P = 0.01); Loss of Methylation at K1206 (Pr = 0.19 | P = 7.5e-03); Loss of Ubiquitylation at K1206 (Pr = 0.15 | P = 0.05), None,-
COL4A3_HUMAN,G1427D,0.929,Gain of Loop (Pr = 0.27 | P = 0.02); Loss of Acetylation at K1429 (Pr = 0.20 | P = 0.04); Loss of Methylation at K1429 (Pr = 0.19 | P = 8.5e-03); Gain of Ubiquitylation at K1431 (Pr = 0.15 | P = 0.04), None,-
COL4A3_HUMAN,G312R,0.948,Loss of Loop (Pr = 0.31 | P = 5.4e-03); Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of Acetylation at K314 (Pr = 0.27 | P = 7.6e-03); Gain of SUMOylation at K314 (Pr = 0.20 | P = 0.03); Loss of Methylation at K314 (Pr = 0.17 | P = 0.01), PS00005|PS00008,-
COL4A3_HUMAN,L1598R,0.92,Gain of Intrinsic disorder (Pr = 0.36 | P = 0.01); Altered Transmembrane protein (Pr = 0.34 | P = 4.4e-05); Loss of Loop (Pr = 0.27 | P = 0.02); Gain of ADP-ribosylation at L1598 (Pr = 0.20 | P = 0.03), ELME000136|ELME000159,-
COL4A3_HUMAN,G830D,0.919,Loss of Acetylation at K826 (Pr = 0.30 | P = 4.3e-03); Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Methylation at K834 (Pr = 0.19 | P = 7.5e-03); Loss of Pyrrolidone carboxylic acid at Q828 (Pr = 0.05 | P = 0.03), ELME000093|PS00009,-
COL4A3_HUMAN,G1257R,0.905,Loss of B-factor (Pr = 0.31 | P = 6.0e-03); Gain of O-linked glycosylation at S1261 (Pr = 0.17 | P = 0.02), ELME000135,-
COL4A3_HUMAN,G452R,0.886,Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Loop (Pr = 0.27 | P = 0.04); Gain of Phosphorylation at Y456 (Pr = 0.26 | P = 0.03); Loss of Sulfation at Y456 (Pr = 0.01 | P = 0.05), None,-
COL4A3_HUMAN,V465I,0.041,-,-,-
COL4A3_HUMAN,G1216R,0.92,Loss of Methylation at R1215 (Pr = 0.18 | P = 8.8e-03), ELME000008|ELME000012|ELME000062|ELME000064|ELME000102|ELME000108|ELME000155|ELME000220|PS00004,-
COL4A3_HUMAN,G372R,0.941,Loss of Loop (Pr = 0.32 | P = 4.1e-03); Loss of B-factor (Pr = 0.29 | P = 0.01); Gain of Methylation at R368 (Pr = 0.16 | P = 0.01); Gain of O-linked glycosylation at S374 (Pr = 0.16 | P = 0.03), ELME000062|ELME000155,-
COL4A3_HUMAN,G619R,0.827,Loss of Phosphorylation at Y618 (Pr = 0.27 | P = 0.03); Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of Methylation at G619 (Pr = 0.12 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q621 (Pr = 0.05 | P = 0.04); Loss of Sulfation at Y618 (Pr = 0.02 | P = 0.03), ELME000163,-
COL4A3_HUMAN,G1167R,0.961,Loss of Acetylation at K1169 (Pr = 0.30 | P = 4.2e-03); Loss of Loop (Pr = 0.29 | P = 0.01); Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of SUMOylation at K1169 (Pr = 0.27 | P = 4.6e-03); Loss of Methylation at K1169 (Pr = 0.19 | P = 8.5e-03); Loss of Ubiquitylation at K1169 (Pr = 0.15 | P = 0.05), None,-
COL4A3_HUMAN,G997E,0.931,Gain of Loop (Pr = 0.31 | P = 3.6e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Methylation at R996 (Pr = 0.14 | P = 0.02), PS00016,-
COL4A3_HUMAN,G336C,0.938,Altered Disordered interface (Pr = 0.41 | P = 3.9e-03); Loss of Acetylation at K332 (Pr = 0.25 | P = 0.01); Altered Metal binding (Pr = 0.23 | P = 0.02); Loss of Methylation at K332 (Pr = 0.17 | P = 0.01); Gain of Disulfide linkage at G336 (Pr = 0.12 | P = 0.04), None,-
COL4A3_HUMAN,G157R,0.908,Gain of Acetylation at K161 (Pr = 0.22 | P = 0.03); Loss of Methylation at K156 (Pr = 0.19 | P = 8.7e-03); Loss of Ubiquitylation at K153 (Pr = 0.18 | P = 0.02), ELME000100|ELME000108,-
COL4A3_HUMAN,G611R,0.944,Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Loop (Pr = 0.27 | P = 0.04); Gain of Methylation at G611 (Pr = 0.14 | P = 0.02); Gain of O-linked glycosylation at S606 (Pr = 0.11 | P = 0.05), ELME000155,-
COL4A3_HUMAN,G1045V,0.957,, ELME000231|ELME000233,-
COL4A3_HUMAN,G871C,0.894,Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of Methylation at R873 (Pr = 0.11 | P = 0.03); Loss of Sulfation at Y875 (Pr = 0.02 | P = 0.03), None,-
COL4A3_HUMAN,G853R,0.917,Loss of Loop (Pr = 0.30 | P = 7.9e-03); Altered Disordered interface (Pr = 0.27 | P = 0.04); Gain of Proteolytic cleavage at R848 (Pr = 0.16 | P = 8.0e-03); Gain of O-linked glycosylation at S849 (Pr = 0.12 | P = 0.04), ELME000062,-
COL4A3_HUMAN,P25S,0.286,-,-,-
COL4A3_HUMAN,M1209I,0.118,-,-,-
GJB2_HUMAN,W77R,0.945,Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Helix (Pr = 0.27 | P = 0.04); Loss of Strand (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.25 | P = 0.01); Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000012|ELME000106|ELME000149|ELME000233,-
GJB2_HUMAN,R127C,0.492,-,-,-
GJB2_HUMAN,R127L,0.593,Altered DNA binding (Pr = 0.34 | P = 1.1e-03); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Altered Coiled coil (Pr = 0.12 | P = 0.04), ELME000051|ELME000052|ELME000106|ELME000333,-
GJB2_HUMAN,R127H,0.335,-,-,-
GJB2_HUMAN,I121N,0.508,Gain of Intrinsic disorder (Pr = 0.38 | P = 0.01); Gain of B-factor (Pr = 0.24 | P = 0.04); Loss of Acetylation at K116 (Pr = 0.23 | P = 0.02); Altered DNA binding (Pr = 0.21 | P = 0.02); Altered Coiled coil (Pr = 0.13 | P = 0.04); Altered Transmembrane protein (Pr = 0.12 | P = 0.03); Altered Stability (Pr = 0.09 | P = 0.05); Gain of N-linked glycosylation at I121 (Pr = 0.06 | P = 0.02); Gain of GPI-anchor amidation at I121 (Pr = 0.02 | P = 0.02), ELME000052|ELME000070|ELME000202|PS00001,-
GJB2_HUMAN,L81R,0.908,Gain of Strand (Pr = 0.29 | P = 4.9e-03); Altered Ordered interface (Pr = 0.25 | P = 0.03), ELME000155|ELME000333,-
GJB2_HUMAN,L81V,0.588,Loss of Helix (Pr = 0.28 | P = 0.03); Gain of Strand (Pr = 0.28 | P = 9.7e-03); Altered Ordered interface (Pr = 0.25 | P = 0.02), ELME000155|ELME000333,-
GJB2_HUMAN,G200A,0.426,-,-,-
GJB2_HUMAN,D46E,0.852,Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.25 | P = 1.1e-03); Altered Metal binding (Pr = 0.23 | P = 0.04); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.6e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.05), None,-
GJB2_HUMAN,D46N,0.868,Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.26 | P = 9.4e-04); Altered Metal binding (Pr = 0.24 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.2e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.04), PS00008,-
GJB2_HUMAN,G45R,0.876,Altered Ordered interface (Pr = 0.36 | P = 3.3e-03); Altered Transmembrane protein (Pr = 0.34 | P = 3.4e-05); Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Altered Metal binding (Pr = 0.12 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.5e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.04), None,-
GJB2_HUMAN,G45E,0.902,Altered Ordered interface (Pr = 0.35 | P = 4.0e-03); Altered Metal binding (Pr = 0.32 | P = 0.01); Gain of Relative solvent accessibility (Pr = 0.31 | P = 6.2e-03); Altered Transmembrane protein (Pr = 0.26 | P = 7.2e-04); Gain of Pyrrolidone carboxylic acid at Q48 (Pr = 0.14 | P = 5.6e-03); Gain of Catalytic site at E47 (Pr = 0.10 | P = 0.04), None,-
GJB2_HUMAN,I82N,0.896,Loss of Strand (Pr = 0.26 | P = 0.03); Altered Ordered interface (Pr = 0.24 | P = 0.03); Altered Stability (Pr = 0.19 | P = 0.01), ELME000155|ELME000333,-
GJB2_HUMAN,I82M,0.568,Gain of Helix (Pr = 0.27 | P = 0.04); Loss of Strand (Pr = 0.27 | P = 0.01); Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Stability (Pr = 0.09 | P = 0.05), ELME000155|ELME000333|ELME000336,-
GJB2_HUMAN,M151R,0.829,Altered Ordered interface (Pr = 0.29 | P = 3.6e-03); Loss of Helix (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.27 | P = 7.8e-04); Gain of Sulfation at Y152 (Pr = 0.01 | P = 0.05), ELME000146|ELME000328,-
GJB2_HUMAN,P70S,0.876,Altered Metal binding (Pr = 0.30 | P = 0.02); Altered Ordered interface (Pr = 0.29 | P = 5.5e-03); Altered Transmembrane protein (Pr = 0.27 | P = 9.5e-04), ELME000120|ELME000182|ELME000336,-
GJB2_HUMAN,P70R,0.925,Altered Ordered interface (Pr = 0.32 | P = 0.01); Altered Metal binding (Pr = 0.30 | P = 4.1e-03); Altered Transmembrane protein (Pr = 0.26 | P = 1.0e-03), ELME000062|ELME000120|ELME000182|ELME000336,-
GJB2_HUMAN,P70L,0.904,Altered Ordered interface (Pr = 0.36 | P = 3.5e-03); Altered Transmembrane protein (Pr = 0.32 | P = 7.8e-05); Altered Metal binding (Pr = 0.30 | P = 4.4e-03), ELME000120|ELME000149|ELME000182|ELME000317|ELME000336,-
GJB2_HUMAN,P70A,0.845,Altered Ordered interface (Pr = 0.35 | P = 5.8e-03); Altered Transmembrane protein (Pr = 0.28 | P = 4.6e-04); Altered Metal binding (Pr = 0.26 | P = 7.9e-03), ELME000120|ELME000182|ELME000336,-
GJB2_HUMAN,P175T,0.875,Altered Metal binding (Pr = 0.26 | P = 0.03); Altered Transmembrane protein (Pr = 0.26 | P = 9.5e-04); Gain of Disulfide linkage at C174 (Pr = 0.26 | P = 3.1e-03); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03), ELME000052|PS00408,-
GJB2_HUMAN,P175H,0.905,Altered Metal binding (Pr = 0.39 | P = 8.5e-03); Altered Ordered interface (Pr = 0.31 | P = 0.02); Gain of Disulfide linkage at C174 (Pr = 0.26 | P = 3.2e-03); Altered Transmembrane protein (Pr = 0.24 | P = 1.7e-03); Loss of Relative solvent accessibility (Pr = 0.23 | P = 0.05), PS00408,-
GJB2_HUMAN,A78T,0.515,Altered Ordered interface (Pr = 0.27 | P = 0.05); Gain of Strand (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.24 | P = 0.01), ELME000052|ELME000173|ELME000334|ELME000335,-
GJB2_HUMAN,A78S,0.394,-,-,-
GJB2_HUMAN,Y158C,0.84,Altered Transmembrane protein (Pr = 0.48 | P = 0.0e+00); Altered Ordered interface (Pr = 0.40 | P = 1.0e-03); Gain of Helix (Pr = 0.27 | P = 0.05); Loss of Sulfation at Y158 (Pr = 0.01 | P = 0.05), ELME000120,-
GJB2_HUMAN,S199F,0.894,Altered Transmembrane protein (Pr = 0.01 | P = 0.01), ELME000085|ELME000148,-
GJB2_HUMAN,R32S,0.936,Altered Ordered interface (Pr = 0.26 | P = 0.01); Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000148|ELME000149|ELME000335|ELME000336,-
GJB2_HUMAN,R32C,0.937,Loss of Strand (Pr = 0.27 | P = 0.02); Altered Ordered interface (Pr = 0.26 | P = 0.02); Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000148|ELME000149,-
GJB2_HUMAN,R32G,0.948,Loss of Helix (Pr = 0.28 | P = 0.02); Altered Ordered interface (Pr = 0.27 | P = 0.01); Gain of Strand (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000148|ELME000149,-
GJB2_HUMAN,R32L,0.946,Loss of Strand (Pr = 0.33 | P = 3.5e-04); Gain of Helix (Pr = 0.30 | P = 7.2e-03); Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000148|ELME000149,-
GJB2_HUMAN,R32H,0.899,Loss of Helix (Pr = 0.27 | P = 0.05); Altered Ordered interface (Pr = 0.24 | P = 0.04); Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000148|ELME000149,-
GJB2_HUMAN,Q80P,0.936,Altered Ordered interface (Pr = 0.29 | P = 0.03); Loss of Strand (Pr = 0.26 | P = 0.05), ELME000237,-
GJB2_HUMAN,Q80K,0.835,Loss of Strand (Pr = 0.27 | P = 0.03); Altered Ordered interface (Pr = 0.25 | P = 0.02), ELME000137|ELME000146|ELME000313,-
GJB2_HUMAN,Q80H,0.828,Altered Ordered interface (Pr = 0.26 | P = 0.01), None,-
GJB2_HUMAN,Q80L,0.902,Loss of Strand (Pr = 0.30 | P = 2.1e-03); Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Helix (Pr = 0.28 | P = 0.02), ELME000045|ELME000149,-
GJB2_HUMAN,Q80R,0.851,Gain of Helix (Pr = 0.28 | P = 0.02); Loss of Strand (Pr = 0.27 | P = 0.02); Altered Ordered interface (Pr = 0.24 | P = 0.03), ELME000137|ELME000146|ELME000313,-
GJB2_HUMAN,Q7P,0.502,Altered Transmembrane protein (Pr = 0.27 | P = 5.9e-04); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.19 | P = 0.04), PS00008,-
GJB2_HUMAN,Q7H,0.138,-,-,-
GJB2_HUMAN,I20M,0.379,-,-,-
GJB2_HUMAN,I20T,0.623,Altered Stability (Pr = 0.51 | P = 1.6e-03); Gain of Intrinsic disorder (Pr = 0.30 | P = 0.05); Altered Transmembrane protein (Pr = 0.24 | P = 1.4e-03); Loss of Catalytic site at K22 (Pr = 0.15 | P = 0.02); Altered Metal binding (Pr = 0.04 | P = 0.05), ELME000052|ELME000063|PS00005,-
GJB2_HUMAN,I20F,0.617,Altered Transmembrane protein (Pr = 0.27 | P = 7.1e-04); Loss of Catalytic site at K22 (Pr = 0.16 | P = 0.02), ELME000184|ELME000197|ELME000198|ELME000328,-
GJB2_HUMAN,V43G,0.911,Altered Stability (Pr = 0.38 | P = 3.2e-03); Altered Transmembrane protein (Pr = 0.31 | P = 1.3e-04); Gain of Relative solvent accessibility (Pr = 0.31 | P = 6.8e-03); Altered Ordered interface (Pr = 0.28 | P = 0.03); Altered Metal binding (Pr = 0.13 | P = 0.05); Gain of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.2e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.05), None,-
GJB2_HUMAN,V43L,0.795,Altered Transmembrane protein (Pr = 0.28 | P = 6.0e-04); Loss of Strand (Pr = 0.28 | P = 9.9e-03); Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered Metal binding (Pr = 0.12 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.1e-03); Gain of Catalytic site at E47 (Pr = 0.09 | P = 0.04), None,-
GJB2_HUMAN,V43M,0.789,Gain of Relative solvent accessibility (Pr = 0.28 | P = 0.01); Loss of Strand (Pr = 0.26 | P = 0.03); Altered Transmembrane protein (Pr = 0.25 | P = 1.3e-03); Altered Metal binding (Pr = 0.14 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 6.9e-03); Gain of Catalytic site at E47 (Pr = 0.09 | P = 0.04), None,-
GJB2_HUMAN,W44C,0.959,Altered Metal binding (Pr = 0.44 | P = 6.9e-03); Loss of Relative solvent accessibility (Pr = 0.33 | P = 3.5e-03); Altered Transmembrane protein (Pr = 0.28 | P = 4.4e-04); Altered Ordered interface (Pr = 0.28 | P = 0.04); Loss of Strand (Pr = 0.26 | P = 0.03); Gain of Disulfide linkage at W44 (Pr = 0.12 | P = 0.04); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.3e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.05), None,-
GJB2_HUMAN,W44L,0.908,Loss of Relative solvent accessibility (Pr = 0.30 | P = 0.01); Loss of Strand (Pr = 0.29 | P = 5.3e-03); Altered Transmembrane protein (Pr = 0.26 | P = 9.0e-04); Altered Metal binding (Pr = 0.13 | P = 0.05); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.2e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.05); Gain of Methylation at K41 (Pr = 0.09 | P = 0.04), ELME000146,-
GJB2_HUMAN,W44S,0.952,Gain of Relative solvent accessibility (Pr = 0.38 | P = 6.1e-04); Altered Ordered interface (Pr = 0.35 | P = 3.9e-03); Altered Transmembrane protein (Pr = 0.31 | P = 1.1e-04); Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered Metal binding (Pr = 0.26 | P = 0.03); Gain of Ubiquitylation at K41 (Pr = 0.17 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.0e-03); Gain of Catalytic site at E47 (Pr = 0.11 | P = 0.04); Gain of Methylation at K41 (Pr = 0.11 | P = 0.03), ELME000064|ELME000085|PS00006,-
GJB2_HUMAN,W44G,0.94,Gain of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered Ordered interface (Pr = 0.27 | P = 0.04); Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03); Gain of B-factor (Pr = 0.26 | P = 0.02); Gain of Ubiquitylation at K41 (Pr = 0.17 | P = 0.03); Altered Metal binding (Pr = 0.13 | P = 0.05); Gain of Methylation at K41 (Pr = 0.12 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.4e-03); Gain of Catalytic site at E47 (Pr = 0.10 | P = 0.04), None,-
GJB2_HUMAN,F31I,0.92,Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000148,-
GJB2_HUMAN,W133S,0.898,Altered DNA binding (Pr = 0.31 | P = 1.3e-03); Altered Ordered interface (Pr = 0.29 | P = 5.0e-03); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Gain of Catalytic site at Y136 (Pr = 0.09 | P = 0.05), ELME000051|ELME000053|ELME000147|ELME000336,-
GJB2_HUMAN,W133G,0.892,Altered Ordered interface (Pr = 0.31 | P = 0.01); Altered DNA binding (Pr = 0.27 | P = 3.6e-03); Altered Stability (Pr = 0.14 | P = 0.02); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Loss of Catalytic site at Y136 (Pr = 0.08 | P = 0.05), ELME000051|ELME000053|ELME000147|ELME000336,-
GJB2_HUMAN,H100P,0.638,Loss of Helix (Pr = 0.28 | P = 0.03); Gain of B-factor (Pr = 0.25 | P = 0.03); Gain of Allosteric site at Y97 (Pr = 0.22 | P = 0.03); Altered Disordered interface (Pr = 0.18 | P = 0.05); Altered Coiled coil (Pr = 0.14 | P = 0.03), ELME000102|ELME000103|ELME000108|ELME000271,-
GJB2_HUMAN,H100Q,0.377,-,-,-
GJB2_HUMAN,H100Y,0.421,-,-,-
GJB2_HUMAN,L79P,0.933,Altered Ordered interface (Pr = 0.36 | P = 2.7e-03); Loss of Helix (Pr = 0.28 | P = 0.03); Gain of Strand (Pr = 0.28 | P = 7.2e-03); Gain of Allosteric site at W77 (Pr = 0.20 | P = 0.04); Altered Stability (Pr = 0.16 | P = 0.02), None,-
GJB2_HUMAN,L79V,0.647,Loss of Helix (Pr = 0.28 | P = 0.03); Gain of Strand (Pr = 0.28 | P = 1.0e-02); Altered Ordered interface (Pr = 0.25 | P = 0.02), None,-
GJB2_HUMAN,K105R,0.099,-,-,-
GJB2_HUMAN,N54S,0.847,Altered Metal binding (Pr = 0.29 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03); Loss of Disulfide linkage at C53 (Pr = 0.26 | P = 4.8e-03); Loss of Pyrrolidone carboxylic acid at Q57 (Pr = 0.11 | P = 8.3e-03), ELME000336|PS00407,-
GJB2_HUMAN,N54K,0.928,Altered Metal binding (Pr = 0.32 | P = 0.01); Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Altered Ordered interface (Pr = 0.30 | P = 0.03); Loss of Disulfide linkage at C53 (Pr = 0.27 | P = 3.3e-03); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Gain of Pyrrolidone carboxylic acid at Q57 (Pr = 0.12 | P = 7.7e-03), ELME000106|PS00407,-
GJB2_HUMAN,N54H,0.894,Altered Metal binding (Pr = 0.57 | P = 3.3e-03); Loss of Relative solvent accessibility (Pr = 0.33 | P = 3.5e-03); Altered Ordered interface (Pr = 0.31 | P = 0.02); Altered Transmembrane protein (Pr = 0.29 | P = 2.5e-04); Loss of Disulfide linkage at C53 (Pr = 0.27 | P = 2.6e-03); Loss of Pyrrolidone carboxylic acid at Q57 (Pr = 0.12 | P = 8.1e-03), PS00407,-
GJB2_HUMAN,V198M,0.475,-,-,-
GJB2_HUMAN,G130V,0.935,Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered DNA binding (Pr = 0.28 | P = 5.0e-03); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Altered Coiled coil (Pr = 0.08 | P = 0.05), ELME000051|ELME000053|ELME000147|ELME000233,-
GJB2_HUMAN,G130D,0.933,Altered Coiled coil (Pr = 0.41 | P = 6.7e-03); Altered Ordered interface (Pr = 0.28 | P = 0.04); Gain of Helix (Pr = 0.28 | P = 0.03); Loss of Strand (Pr = 0.28 | P = 0.01); Altered DNA binding (Pr = 0.27 | P = 4.3e-03); Altered Metal binding (Pr = 0.19 | P = 0.04); Altered Transmembrane protein (Pr = 0.17 | P = 1.0e-02), ELME000051|ELME000053|ELME000147,-
GJB2_HUMAN,V38A,0.74,Gain of Helix (Pr = 0.29 | P = 0.01); Loss of Strand (Pr = 0.29 | P = 3.7e-03); Altered Transmembrane protein (Pr = 0.28 | P = 5.4e-04); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02), ELME000148,-
GJB2_HUMAN,V37L,0.739,Loss of Strand (Pr = 0.31 | P = 1.0e-03); Gain of Helix (Pr = 0.30 | P = 8.5e-03); Gain of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered Transmembrane protein (Pr = 0.26 | P = 1.0e-03), ELME000148|ELME000149,-
GJB2_HUMAN,V37I,0.503,Loss of Strand (Pr = 0.26 | P = 0.03); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Altered Transmembrane protein (Pr = 0.24 | P = 1.5e-03), ELME000148|ELME000149,-
GJB2_HUMAN,D66H,0.94,Altered Metal binding (Pr = 0.58 | P = 7.8e-04); Altered Transmembrane protein (Pr = 0.35 | P = 2.4e-05); Altered Ordered interface (Pr = 0.30 | P = 3.1e-03); Loss of Relative solvent accessibility (Pr = 0.30 | P = 0.01); Loss of Disulfide linkage at C64 (Pr = 0.17 | P = 0.03), PS00407,-
GJB2_HUMAN,V84M,0.669,Loss of Strand (Pr = 0.27 | P = 0.02), ELME000052|ELME000136|ELME000155|ELME000159|ELME000333|ELME000358,-
GJB2_HUMAN,V84L,0.663,Loss of Strand (Pr = 0.30 | P = 2.1e-03); Gain of Helix (Pr = 0.28 | P = 0.03), ELME000052|ELME000136|ELME000155|ELME000159|ELME000333|ELME000358,-
GJB2_HUMAN,V84A,0.761,Loss of Strand (Pr = 0.28 | P = 8.2e-03), ELME000052|ELME000136|ELME000155|ELME000159|ELME000333|ELME000358,-
GJB2_HUMAN,K15T,0.56,Loss of Relative solvent accessibility (Pr = 0.30 | P = 8.5e-03); Altered Transmembrane protein (Pr = 0.26 | P = 1.0e-03); Altered Metal binding (Pr = 0.05 | P = 0.04), ELME000053|PS00008,-
GJB2_HUMAN,L214P,0.63,Altered Ordered interface (Pr = 0.30 | P = 2.7e-03), ELME000020|ELME000045|ELME000081|ELME000120|ELME000149|ELME000182,-
GJB2_HUMAN,L214M,0.119,-,-,-
GJB2_HUMAN,E120K,0.307,-,-,-
GJB2_HUMAN,V95M,0.531,Loss of Allosteric site at H94 (Pr = 0.22 | P = 0.03); Altered Coiled coil (Pr = 0.18 | P = 0.02); Altered Metal binding (Pr = 0.07 | P = 0.02), None,-
GJB2_HUMAN,G59R,0.951,Altered Ordered interface (Pr = 0.31 | P = 0.01); Altered Transmembrane protein (Pr = 0.29 | P = 4.0e-04); Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Altered Metal binding (Pr = 0.20 | P = 0.03); Loss of Disulfide linkage at C60 (Pr = 0.19 | P = 0.02); Loss of Catalytic site at C60 (Pr = 0.15 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q57 (Pr = 0.11 | P = 8.5e-03), PS00407,-
GJB2_HUMAN,G59V,0.958,Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Altered Ordered interface (Pr = 0.29 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.20 | P = 0.03); Loss of Disulfide linkage at C60 (Pr = 0.20 | P = 0.02); Loss of Catalytic site at C60 (Pr = 0.16 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q57 (Pr = 0.14 | P = 5.6e-03), PS00407,-
GJB2_HUMAN,G59A,0.912,Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Altered Ordered interface (Pr = 0.27 | P = 0.05); Altered Transmembrane protein (Pr = 0.23 | P = 2.7e-03); Gain of Disulfide linkage at C60 (Pr = 0.20 | P = 0.02); Altered Metal binding (Pr = 0.19 | P = 0.03); Loss of Catalytic site at C60 (Pr = 0.15 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q57 (Pr = 0.11 | P = 8.0e-03), PS00407,-
GJB2_HUMAN,G59S,0.907,Altered Ordered interface (Pr = 0.31 | P = 0.01); Gain of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered Transmembrane protein (Pr = 0.26 | P = 1.2e-03); Gain of Disulfide linkage at C60 (Pr = 0.20 | P = 0.02); Altered Metal binding (Pr = 0.19 | P = 0.03); Gain of Catalytic site at C60 (Pr = 0.16 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q57 (Pr = 0.11 | P = 8.7e-03), ELME000053|ELME000162|PS00005|PS00407,-
GJB2_HUMAN,R184Q,0.866,Altered Transmembrane protein (Pr = 0.33 | P = 4.9e-05); Loss of Strand (Pr = 0.26 | P = 0.05); Loss of Allosteric site at R184 (Pr = 0.24 | P = 0.02); Altered Metal binding (Pr = 0.14 | P = 0.04); Loss of Disulfide linkage at C180 (Pr = 0.13 | P = 0.04), ELME000062|ELME000063|ELME000155|ELME000202|PS00408,-
GJB2_HUMAN,R184W,0.918,Altered Ordered interface (Pr = 0.29 | P = 0.04); Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03); Loss of Allosteric site at R184 (Pr = 0.22 | P = 0.03); Loss of Disulfide linkage at C180 (Pr = 0.14 | P = 0.04); Altered Metal binding (Pr = 0.10 | P = 0.05), ELME000062|ELME000063|ELME000155|PS00408,-
GJB2_HUMAN,R184G,0.945,Altered Ordered interface (Pr = 0.33 | P = 8.1e-03); Altered Transmembrane protein (Pr = 0.28 | P = 6.5e-04); Loss of Allosteric site at R184 (Pr = 0.26 | P = 0.01); Loss of Disulfide linkage at C180 (Pr = 0.13 | P = 0.04); Altered Metal binding (Pr = 0.10 | P = 0.05); Gain of Methylation at K188 (Pr = 0.10 | P = 0.04), ELME000062|ELME000063|ELME000085|ELME000155|PS00408,-
GJB2_HUMAN,R184P,0.968,Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Transmembrane protein (Pr = 0.28 | P = 4.2e-04); Loss of Strand (Pr = 0.27 | P = 0.01); Loss of Allosteric site at R184 (Pr = 0.26 | P = 0.01); Gain of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Altered Metal binding (Pr = 0.13 | P = 0.05); Loss of Disulfide linkage at C180 (Pr = 0.13 | P = 0.04); Gain of Methylation at K188 (Pr = 0.10 | P = 0.04), ELME000062|ELME000063|ELME000136|ELME000155|ELME000159|PS00408,-
GJB2_HUMAN,C53Y,0.947,Loss of Disulfide linkage at C53 (Pr = 0.38 | P = 6.1e-04); Altered Metal binding (Pr = 0.37 | P = 7.8e-03); Altered Transmembrane protein (Pr = 0.32 | P = 1.0e-04); Altered Ordered interface (Pr = 0.32 | P = 8.4e-03); Gain of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.6e-03); Gain of Catalytic site at C53 (Pr = 0.08 | P = 0.05), ELME000017|ELME000120|PS00407,-
GJB2_HUMAN,C53R,0.961,Loss of Disulfide linkage at C53 (Pr = 0.38 | P = 6.1e-04); Altered Metal binding (Pr = 0.35 | P = 8.8e-03); Gain of Relative solvent accessibility (Pr = 0.33 | P = 3.3e-03); Altered Ordered interface (Pr = 0.31 | P = 0.01); Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Gain of Catalytic site at C53 (Pr = 0.16 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.5e-03), ELME000062|PS00407,-
GJB2_HUMAN,F142L,0.624,Gain of Helix (Pr = 0.33 | P = 1.4e-03); Loss of Strand (Pr = 0.30 | P = 2.2e-03), ELME000137|ELME000328,-
GJB2_HUMAN,V52L,0.17,-,-,-
GJB2_HUMAN,V52I,0.067,-,-,-
GJB2_HUMAN,V52T,0.156,-,-,-
GJB2_HUMAN,V13M,0.705,Altered Transmembrane protein (Pr = 0.32 | P = 7.3e-05); Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.02), None,-
GJB2_HUMAN,I203K,0.908,, ELME000106,-
GJB2_HUMAN,I203T,0.603,, ELME000053|ELME000335,-
GJB2_HUMAN,E47K,0.871,Altered Transmembrane protein (Pr = 0.31 | P = 1.2e-04); Gain of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered Metal binding (Pr = 0.26 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.5e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.04), None,-
GJB2_HUMAN,E47Q,0.8,Altered Transmembrane protein (Pr = 0.32 | P = 7.8e-05); Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Metal binding (Pr = 0.26 | P = 0.03); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Gain of Pyrrolidone carboxylic acid at E47 (Pr = 0.16 | P = 3.9e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.05), None,-
GJB2_HUMAN,G109E,0.403,-,-,-
GJB2_HUMAN,V190D,0.922,Altered Transmembrane protein (Pr = 0.32 | P = 9.3e-05); Altered Ordered interface (Pr = 0.27 | P = 0.05); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Stability (Pr = 0.18 | P = 0.01); Altered Metal binding (Pr = 0.10 | P = 0.05), ELME000133|ELME000146|ELME000147,-
GJB2_HUMAN,K122I,0.526,Altered DNA binding (Pr = 0.33 | P = 1.3e-03); Altered Transmembrane protein (Pr = 0.17 | P = 0.01); Altered Coiled coil (Pr = 0.13 | P = 0.04), ELME000052|ELME000193|ELME000202,-
GJB2_HUMAN,K122R,0.169,-,-,-
GJB2_HUMAN,S17Y,0.891,Altered Ordered interface (Pr = 0.32 | P = 1.6e-03); Altered Transmembrane protein (Pr = 0.27 | P = 9.0e-04); Gain of Strand (Pr = 0.27 | P = 0.03); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Loss of Catalytic site at K22 (Pr = 0.16 | P = 0.02), ELME000120|ELME000182,-
GJB2_HUMAN,S17F,0.879,Altered Transmembrane protein (Pr = 0.28 | P = 4.0e-04); Gain of Strand (Pr = 0.26 | P = 0.04); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Loss of Catalytic site at K22 (Pr = 0.17 | P = 0.02), ELME000146,-
GJB2_HUMAN,L205P,0.954,, ELME000070|ELME000333,-
GJB2_HUMAN,L205V,0.756,, ELME000070|ELME000333,-
GJB2_HUMAN,L205F,0.821,, ELME000070|ELME000333,-
GJB2_HUMAN,L132V,0.779,Loss of Helix (Pr = 0.33 | P = 1.2e-03); Altered Ordered interface (Pr = 0.31 | P = 0.02); Gain of Strand (Pr = 0.29 | P = 6.1e-03); Altered DNA binding (Pr = 0.27 | P = 6.0e-03); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Altered Coiled coil (Pr = 0.08 | P = 0.04); Loss of Catalytic site at Y136 (Pr = 0.08 | P = 0.05), ELME000051|ELME000053|ELME000147|ELME000336,-
GJB2_HUMAN,A40G,0.665,Loss of Helix (Pr = 0.33 | P = 1.2e-03); Gain of Strand (Pr = 0.30 | P = 3.1e-03); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.26 | P = 1.0e-03), None,-
GJB2_HUMAN,A40E,0.879,Altered Metal binding (Pr = 0.42 | P = 7.6e-03); Gain of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.27 | P = 9.4e-04); Loss of Strand (Pr = 0.26 | P = 0.05), None,-
GJB2_HUMAN,A40V,0.741,Loss of Helix (Pr = 0.29 | P = 0.01); Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.26 | P = 7.4e-04); Gain of Strand (Pr = 0.26 | P = 0.04), None,-
GJB2_HUMAN,N14Y,0.866,Altered Ordered interface (Pr = 0.37 | P = 5.5e-04); Gain of Strand (Pr = 0.27 | P = 0.01); Altered Transmembrane protein (Pr = 0.26 | P = 9.8e-04); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.03), None,-
GJB2_HUMAN,N14K,0.819,Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Loss of Strand (Pr = 0.27 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03), ELME000008|PS00004,-
GJB2_HUMAN,T8M,0.095,-,-,-
GJB2_HUMAN,T8K,0.227,-,-,-
GJB2_HUMAN,T8S,0.065,-,-,-
GJB2_HUMAN,V63L,0.845,Altered Metal binding (Pr = 0.30 | P = 4.2e-03); Altered Ordered interface (Pr = 0.27 | P = 9.1e-03); Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Gain of Disulfide linkage at C60 (Pr = 0.20 | P = 0.02); Loss of Catalytic site at C60 (Pr = 0.16 | P = 0.02), ELME000079|ELME000106|PS00407,-
GJB2_HUMAN,S72C,0.882,Altered Metal binding (Pr = 0.42 | P = 7.6e-03); Altered Transmembrane protein (Pr = 0.32 | P = 7.3e-05); Altered Ordered interface (Pr = 0.32 | P = 0.01), None,-
GJB2_HUMAN,D50A,0.807,Altered Transmembrane protein (Pr = 0.32 | P = 6.3e-05); Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.30 | P = 8.8e-03); Altered Metal binding (Pr = 0.29 | P = 0.02); Loss of Disulfide linkage at C53 (Pr = 0.27 | P = 2.5e-03); Gain of Pyrrolidone carboxylic acid at Q48 (Pr = 0.15 | P = 4.7e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.05), None,-
GJB2_HUMAN,D50N,0.68,Altered Metal binding (Pr = 0.26 | P = 0.03); Altered Transmembrane protein (Pr = 0.26 | P = 7.2e-04); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Loss of Disulfide linkage at C53 (Pr = 0.25 | P = 7.0e-03); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.3e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.04), None,-
GJB2_HUMAN,D50Y,0.878,Altered Transmembrane protein (Pr = 0.34 | P = 4.9e-05); Loss of Relative solvent accessibility (Pr = 0.31 | P = 6.4e-03); Altered Metal binding (Pr = 0.30 | P = 0.01); Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Disulfide linkage at C53 (Pr = 0.28 | P = 2.0e-03); Gain of Pyrrolidone carboxylic acid at Q48 (Pr = 0.14 | P = 5.0e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.04); Gain of Sulfation at D50 (Pr = 0.02 | P = 0.03), ELME000182,-
GJB2_HUMAN,I140S,0.829,Loss of Helix (Pr = 0.29 | P = 0.02); Gain of Strand (Pr = 0.26 | P = 0.04); Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered DNA binding (Pr = 0.19 | P = 0.03); Gain of Catalytic site at Y136 (Pr = 0.09 | P = 0.05), ELME000052|ELME000197|ELME000337,-
GJB2_HUMAN,G12V,0.798,Loss of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered Transmembrane protein (Pr = 0.28 | P = 4.6e-04), ELME000335,-
GJB2_HUMAN,G12D,0.807,Altered Transmembrane protein (Pr = 0.33 | P = 4.9e-05); Gain of Relative solvent accessibility (Pr = 0.31 | P = 5.3e-03), None,-
GJB2_HUMAN,G12R,0.767,Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Gain of Helix (Pr = 0.27 | P = 0.04); Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03), None,-
GJB2_HUMAN,G12C,0.827,Altered Transmembrane protein (Pr = 0.36 | P = 1.9e-05); Loss of Relative solvent accessibility (Pr = 0.34 | P = 3.2e-03); Altered Ordered interface (Pr = 0.29 | P = 0.03), None,-
GJB2_HUMAN,I128M,0.486,-,-,-
GJB2_HUMAN,I128V,0.286,-,-,-
GJB2_HUMAN,N206T,0.725,, ELME000064|ELME000070|ELME000220|ELME000333|PS00001|PS00006,-
GJB2_HUMAN,N206S,0.601,, ELME000064|ELME000070|ELME000333|PS00001|PS00006,-
GJB2_HUMAN,N206H,0.682,, ELME000070|ELME000333|PS00001,-
GJB2_HUMAN,K112N,0.204,-,-,-
GJB2_HUMAN,H73Y,0.855,Altered Metal binding (Pr = 0.38 | P = 1.6e-03); Altered Ordered interface (Pr = 0.31 | P = 0.02); Altered Transmembrane protein (Pr = 0.19 | P = 6.1e-03), ELME000020|ELME000083|ELME000120|ELME000182,-
GJB2_HUMAN,H73R,0.88,Altered Metal binding (Pr = 0.38 | P = 1.7e-03); Altered Ordered interface (Pr = 0.32 | P = 0.01); Gain of Helix (Pr = 0.28 | P = 0.02); Loss of Strand (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.20 | P = 5.7e-03), ELME000012|ELME000231|ELME000233,-
GJB2_HUMAN,G11E,0.666,Gain of Relative solvent accessibility (Pr = 0.32 | P = 4.7e-03); Altered Transmembrane protein (Pr = 0.28 | P = 4.6e-04), ELME000064|ELME000220|PS00006,-
GJB2_HUMAN,M163V,0.726,Altered Transmembrane protein (Pr = 0.30 | P = 2.1e-04); Altered Ordered interface (Pr = 0.29 | P = 5.6e-03); Gain of Sulfation at Y158 (Pr = 0.01 | P = 0.05), ELME000148,-
GJB2_HUMAN,M163L,0.685,Altered Ordered interface (Pr = 0.29 | P = 5.3e-03); Altered Transmembrane protein (Pr = 0.28 | P = 4.9e-04); Loss of Sulfation at Y158 (Pr = 0.01 | P = 0.05), ELME000148,-
GJB2_HUMAN,L90P,0.934,Gain of Allosteric site at H94 (Pr = 0.25 | P = 0.01); Altered Coiled coil (Pr = 0.13 | P = 0.04); Altered Metal binding (Pr = 0.07 | P = 0.02), ELME000052,-
GJB2_HUMAN,L90R,0.91,Gain of Allosteric site at H94 (Pr = 0.24 | P = 0.01); Altered Coiled coil (Pr = 0.13 | P = 0.04); Altered Metal binding (Pr = 0.07 | P = 0.02), ELME000052|ELME000313,-
GJB2_HUMAN,L90V,0.628,Loss of Allosteric site at H94 (Pr = 0.21 | P = 0.04); Altered Coiled coil (Pr = 0.12 | P = 0.04); Altered Metal binding (Pr = 0.07 | P = 0.02), ELME000052,-
GJB2_HUMAN,A88G,0.403,-,-,-
GJB2_HUMAN,A88V,0.448,-,-,-
GJB2_HUMAN,A88S,0.287,-,-,-
GJB2_HUMAN,A88P,0.775,Gain of Strand (Pr = 0.27 | P = 0.02); Altered Coiled coil (Pr = 0.11 | P = 0.04), ELME000052|ELME000136|ELME000159|ELME000358,-
GJB2_HUMAN,V226D,0.766,Altered DNA binding (Pr = 0.41 | P = 2.9e-04); Gain of B-factor (Pr = 0.37 | P = 5.8e-05); Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered Transmembrane protein (Pr = 0.29 | P = 0.03), ELME000011,-
GJB2_HUMAN,V226G,0.646,Gain of B-factor (Pr = 0.36 | P = 1.3e-04); Altered DNA binding (Pr = 0.36 | P = 7.4e-04); Gain of Intrinsic disorder (Pr = 0.33 | P = 0.03); Altered Transmembrane protein (Pr = 0.28 | P = 0.04), ELME000011,-
GJB2_HUMAN,V226A,0.353,-,-,-
GJB2_HUMAN,M34I,0.784,Gain of Strand (Pr = 0.26 | P = 0.05); Altered Transmembrane protein (Pr = 0.18 | P = 8.9e-03), ELME000148|ELME000149,-
GJB2_HUMAN,M34V,0.826,Loss of Helix (Pr = 0.27 | P = 0.04); Altered Transmembrane protein (Pr = 0.18 | P = 8.4e-03), ELME000148|ELME000149,-
GJB2_HUMAN,M34R,0.916,Gain of Strand (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.23 | P = 2.4e-03); Gain of Catalytic site at R32 (Pr = 0.09 | P = 0.04), ELME000012|ELME000106|ELME000148|ELME000149,-
GJB2_HUMAN,M34T,0.86,Loss of Helix (Pr = 0.30 | P = 7.9e-03); Gain of Strand (Pr = 0.28 | P = 8.4e-03); Altered Transmembrane protein (Pr = 0.22 | P = 3.1e-03), ELME000052|ELME000062|ELME000148|ELME000149|ELME000335|ELME000336,-
GJB2_HUMAN,M34L,0.729,Gain of Helix (Pr = 0.28 | P = 0.03); Loss of Strand (Pr = 0.28 | P = 5.9e-03); Altered Transmembrane protein (Pr = 0.18 | P = 8.3e-03), ELME000106|ELME000148|ELME000149,-
GJB2_HUMAN,T186M,0.858,Altered Transmembrane protein (Pr = 0.30 | P = 1.6e-04); Loss of Allosteric site at R184 (Pr = 0.21 | P = 0.04); Altered Metal binding (Pr = 0.10 | P = 0.04), ELME000062|ELME000063|ELME000147|ELME000336|PS00005,-
GJB2_HUMAN,T186K,0.932,Altered Transmembrane protein (Pr = 0.32 | P = 1.1e-04); Altered Ordered interface (Pr = 0.28 | P = 0.04); Gain of Strand (Pr = 0.26 | P = 0.05); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Gain of Allosteric site at R184 (Pr = 0.23 | P = 0.02); Altered Metal binding (Pr = 0.10 | P = 0.05); Gain of Methylation at K188 (Pr = 0.09 | P = 0.05), ELME000062|ELME000063|ELME000147|PS00005,-
GJB2_HUMAN,C202F,0.91,Altered Transmembrane protein (Pr = 0.01 | P = 0.01), ELME000197,-
GJB2_HUMAN,C202R,0.907,, ELME000106|ELME000146,-
GJB2_HUMAN,S139N,0.755,Gain of Helix (Pr = 0.30 | P = 9.2e-03); Loss of Strand (Pr = 0.27 | P = 0.02); Altered Ordered interface (Pr = 0.24 | P = 0.03); Altered DNA binding (Pr = 0.19 | P = 0.03); Loss of Catalytic site at Y136 (Pr = 0.08 | P = 0.05), ELME000052|ELME000182|ELME000197|ELME000337,-
GJB2_HUMAN,S139C,0.79,Altered Ordered interface (Pr = 0.34 | P = 6.0e-03); Gain of Helix (Pr = 0.30 | P = 8.2e-03); Loss of Strand (Pr = 0.27 | P = 0.02); Altered DNA binding (Pr = 0.20 | P = 0.02); Loss of Catalytic site at Y136 (Pr = 0.08 | P = 0.05), ELME000052|ELME000182|ELME000197|ELME000337,-
GJB2_HUMAN,C64Y,0.952,Altered Metal binding (Pr = 0.66 | P = 1.3e-03); Altered Disordered interface (Pr = 0.34 | P = 0.01); Altered Transmembrane protein (Pr = 0.30 | P = 1.7e-04); Altered Ordered interface (Pr = 0.30 | P = 0.02); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Loss of Disulfide linkage at C64 (Pr = 0.21 | P = 0.02); Loss of Catalytic site at C60 (Pr = 0.16 | P = 0.02), ELME000079|PS00407,-
GJB2_HUMAN,I71N,0.894,Altered Metal binding (Pr = 0.31 | P = 4.6e-03); Altered Ordered interface (Pr = 0.31 | P = 0.01); Altered Transmembrane protein (Pr = 0.30 | P = 2.2e-04); Gain of Relative solvent accessibility (Pr = 0.23 | P = 0.05); Gain of Allosteric site at R75 (Pr = 0.18 | P = 0.05), ELME000120|ELME000182,-
GJB2_HUMAN,I71V,0.221,-,-,-
GJB2_HUMAN,N176D,0.796,Altered Transmembrane protein (Pr = 0.27 | P = 7.9e-04); Loss of Disulfide linkage at C174 (Pr = 0.25 | P = 6.1e-03); Altered Metal binding (Pr = 0.24 | P = 0.03); Gain of Catalytic site at C180 (Pr = 0.08 | P = 0.05), PS00408,-
GJB2_HUMAN,N176T,0.847,Altered Metal binding (Pr = 0.31 | P = 0.01); Altered Transmembrane protein (Pr = 0.28 | P = 4.3e-04); Altered Ordered interface (Pr = 0.28 | P = 0.05); Loss of Disulfide linkage at C174 (Pr = 0.26 | P = 4.2e-03), ELME000220|PS00006|PS00408,-
GJB2_HUMAN,E114K,0.247,-,-,-
GJB2_HUMAN,E114G,0.285,-,-,-
GJB2_HUMAN,S113R,0.127,-,-,-
GJB2_HUMAN,S113N,0.049,-,-,-
GJB2_HUMAN,S113T,0.064,-,-,-
GJB2_HUMAN,M93T,0.798,Altered Ordered interface (Pr = 0.24 | P = 0.04); Gain of Allosteric site at H94 (Pr = 0.22 | P = 0.02); Altered Stability (Pr = 0.14 | P = 0.02); Altered Coiled coil (Pr = 0.13 | P = 0.04); Altered Metal binding (Pr = 0.07 | P = 0.02), ELME000336,-
GJB2_HUMAN,L89P,0.905,Gain of Strand (Pr = 0.27 | P = 0.02); Gain of Allosteric site at H94 (Pr = 0.25 | P = 0.01); Altered Coiled coil (Pr = 0.12 | P = 0.04); Altered Stability (Pr = 0.09 | P = 0.05); Altered Metal binding (Pr = 0.08 | P = 0.02), ELME000052|ELME000141|ELME000159|ELME000358,-
GJB2_HUMAN,S183F,0.926,Altered Ordered interface (Pr = 0.33 | P = 8.7e-03); Altered Transmembrane protein (Pr = 0.30 | P = 1.8e-04); Loss of Strand (Pr = 0.26 | P = 0.04); Altered Metal binding (Pr = 0.25 | P = 0.03); Loss of Allosteric site at R184 (Pr = 0.22 | P = 0.03); Loss of Disulfide linkage at C180 (Pr = 0.14 | P = 0.04), ELME000062|ELME000063|ELME000155|PS00408,-
GJB2_HUMAN,C218Y,0.479,-,-,-
GJB2_HUMAN,I30N,0.945,Altered Transmembrane protein (Pr = 0.24 | P = 2.1e-03); Gain of Catalytic site at R32 (Pr = 0.08 | P = 0.05), ELME000148|ELME000335,-
GJB2_HUMAN,I30V,0.628,Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000148|ELME000335,-
GJB2_HUMAN,R143Q,0.717,Gain of Strand (Pr = 0.28 | P = 7.4e-03), ELME000137|ELME000146|ELME000328,-
GJB2_HUMAN,R143L,0.865,Loss of Strand (Pr = 0.27 | P = 0.02), ELME000041|ELME000047|ELME000137|ELME000146|ELME000328,-
GJB2_HUMAN,R143W,0.851,Gain of Strand (Pr = 0.28 | P = 0.01), ELME000137|ELME000146|ELME000328,-
GJB2_HUMAN,T55A,0.848,Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Altered Metal binding (Pr = 0.25 | P = 0.03); Altered Transmembrane protein (Pr = 0.25 | P = 1.1e-03); Loss of Disulfide linkage at C53 (Pr = 0.24 | P = 0.01); Loss of Catalytic site at C60 (Pr = 0.15 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q57 (Pr = 0.11 | P = 8.0e-03), PS00407,-
GJB2_HUMAN,T55P,0.931,Altered Metal binding (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.28 | P = 3.6e-04); Altered Ordered interface (Pr = 0.28 | P = 0.03); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Gain of Loop (Pr = 0.26 | P = 0.05); Loss of Disulfide linkage at C53 (Pr = 0.24 | P = 8.5e-03); Loss of Catalytic site at C60 (Pr = 0.15 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q57 (Pr = 0.12 | P = 7.4e-03), ELME000155|PS00407,-
GJB2_HUMAN,T55N,0.879,Gain of Relative solvent accessibility (Pr = 0.33 | P = 2.6e-03); Altered Metal binding (Pr = 0.31 | P = 0.02); Altered Transmembrane protein (Pr = 0.30 | P = 1.8e-04); Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Disulfide linkage at C53 (Pr = 0.28 | P = 1.4e-03); Loss of Catalytic site at C60 (Pr = 0.15 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q57 (Pr = 0.11 | P = 8.7e-03), PS00407,-
GJB2_HUMAN,L56P,0.884,Altered Transmembrane protein (Pr = 0.28 | P = 4.2e-04); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Gain of Loop (Pr = 0.27 | P = 0.04); Altered Metal binding (Pr = 0.26 | P = 0.03); Loss of Disulfide linkage at C53 (Pr = 0.24 | P = 8.7e-03); Gain of Catalytic site at C60 (Pr = 0.18 | P = 0.02); Altered Stability (Pr = 0.12 | P = 0.03); Gain of Pyrrolidone carboxylic acid at Q57 (Pr = 0.11 | P = 8.0e-03), ELME000136|ELME000159|PS00407,-
GJB2_HUMAN,L56Q,0.692,Altered Transmembrane protein (Pr = 0.30 | P = 1.4e-04); Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Metal binding (Pr = 0.29 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Loss of Disulfide linkage at C53 (Pr = 0.25 | P = 6.6e-03); Gain of Catalytic site at C60 (Pr = 0.20 | P = 0.01); Gain of Pyrrolidone carboxylic acid at L56 (Pr = 0.14 | P = 5.3e-03), ELME000202|PS00407,-
GJB2_HUMAN,A197S,0.187,-,-,-
GJB2_HUMAN,A197V,0.379,-,-,-
GJB2_HUMAN,K61Q,0.55,Gain of Catalytic site at C60 (Pr = 0.31 | P = 1.1e-03); Loss of Relative solvent accessibility (Pr = 0.30 | P = 0.01); Altered Metal binding (Pr = 0.29 | P = 4.8e-03); Altered Ordered interface (Pr = 0.27 | P = 7.9e-03); Altered Transmembrane protein (Pr = 0.26 | P = 1.2e-03); Loss of Disulfide linkage at C60 (Pr = 0.20 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q57 (Pr = 0.13 | P = 6.7e-03), PS00407,-
GJB2_HUMAN,R98Q,0.181,-,-,-
GJB2_HUMAN,R98W,0.317,-,-,-
GJB2_HUMAN,R98P,0.568,Loss of Helix (Pr = 0.33 | P = 1.6e-03); Gain of Allosteric site at H94 (Pr = 0.24 | P = 0.01); Altered Disordered interface (Pr = 0.20 | P = 0.04); Altered Coiled coil (Pr = 0.14 | P = 0.03); Altered Metal binding (Pr = 0.08 | P = 0.01), ELME000012|ELME000102|ELME000108|ELME000155,-
GJB2_HUMAN,R98H,0.184,-,-,-
GJB2_HUMAN,R98Y,0.377,-,-,-
GJB2_HUMAN,S85P,0.858,Loss of Strand (Pr = 0.26 | P = 0.03); Altered Coiled coil (Pr = 0.10 | P = 0.04), ELME000052|ELME000136|ELME000155|ELME000159|ELME000333|ELME000358,-
GJB2_HUMAN,S85T,0.458,-,-,-
GJB2_HUMAN,T86R,0.748,Loss of Strand (Pr = 0.26 | P = 0.03); Altered Coiled coil (Pr = 0.10 | P = 0.04), ELME000052|ELME000136|ELME000146|ELME000149|ELME000155|ELME000159|ELME000333|ELME000358,-
GJB2_HUMAN,T86A,0.502,Loss of Strand (Pr = 0.30 | P = 2.5e-03); Altered Coiled coil (Pr = 0.13 | P = 0.03), ELME000041|ELME000052|ELME000085|ELME000136|ELME000155|ELME000159|ELME000333|ELME000358,-
GJB2_HUMAN,K22N,0.693,Loss of Strand (Pr = 0.26 | P = 0.05); Altered Transmembrane protein (Pr = 0.19 | P = 7.3e-03); Gain of Catalytic site at K22 (Pr = 0.15 | P = 0.02), None,-
GJB2_HUMAN,P58R,0.878,Gain of Relative solvent accessibility (Pr = 0.30 | P = 9.0e-03); Altered Transmembrane protein (Pr = 0.28 | P = 4.0e-04); Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Metal binding (Pr = 0.26 | P = 0.02); Gain of Disulfide linkage at C53 (Pr = 0.25 | P = 4.9e-03); Loss of Catalytic site at C60 (Pr = 0.16 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q57 (Pr = 0.13 | P = 5.8e-03), PS00407,-
GJB2_HUMAN,P58A,0.789,Loss of Relative solvent accessibility (Pr = 0.30 | P = 0.01); Altered Transmembrane protein (Pr = 0.26 | P = 9.8e-04); Altered Metal binding (Pr = 0.25 | P = 0.03); Gain of Disulfide linkage at C53 (Pr = 0.24 | P = 8.7e-03); Gain of Catalytic site at C60 (Pr = 0.15 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q57 (Pr = 0.12 | P = 6.9e-03), PS00407,-
GJB2_HUMAN,R75W,0.856,Altered Ordered interface (Pr = 0.27 | P = 0.01); Altered Metal binding (Pr = 0.26 | P = 9.5e-03); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), None,-
GJB2_HUMAN,R75Q,0.727,Altered Metal binding (Pr = 0.26 | P = 9.4e-03); Altered Ordered interface (Pr = 0.24 | P = 0.03); Altered Transmembrane protein (Pr = 0.15 | P = 0.01), None,-
GJB2_HUMAN,E119K,0.44,-,-,-
GJB2_HUMAN,F115C,0.403,-,-,-
GJB2_HUMAN,F115Y,0.106,-,-,-
GJB2_HUMAN,I33T,0.802,Loss of Helix (Pr = 0.29 | P = 0.01); Gain of Strand (Pr = 0.28 | P = 9.9e-03); Altered Transmembrane protein (Pr = 0.14 | P = 0.02); Gain of Catalytic site at R32 (Pr = 0.08 | P = 0.05), ELME000052|ELME000148|ELME000149,-
GJB2_HUMAN,I33V,0.353,-,-,-
GJB2_HUMAN,T18I,0.86,Altered Transmembrane protein (Pr = 0.27 | P = 8.5e-04); Loss of Catalytic site at K22 (Pr = 0.16 | P = 0.02), None,-
GJB2_HUMAN,H16R,0.73,Altered Transmembrane protein (Pr = 0.29 | P = 3.1e-04); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02), ELME000008|ELME000062|ELME000065|ELME000100|ELME000108|PS00004,-
GJB2_HUMAN,H16Y,0.423,-,-,-
GJB2_HUMAN,E42D,0.333,-,-,-
GJB2_HUMAN,E42K,0.471,-,-,-
GJB2_HUMAN,L10P,0.917,Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered Transmembrane protein (Pr = 0.28 | P = 4.4e-04); Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered Stability (Pr = 0.16 | P = 0.02), None,-
GJB2_HUMAN,L10W,0.841,Altered Transmembrane protein (Pr = 0.29 | P = 2.9e-04); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Gain of GPI-anchor amidation at N14 (Pr = 0.02 | P = 0.02), None,-
GJB2_HUMAN,P225L,0.4,-,-,-
GJB2_HUMAN,L6P,0.852,Gain of Intrinsic disorder (Pr = 0.51 | P = 1.6e-03); Altered Transmembrane protein (Pr = 0.28 | P = 4.6e-04); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.20 | P = 0.03); Gain of N-terminal acetylation at M1 (Pr = 0.14 | P = 1.1e-03), ELME000136|ELME000159|ELME000358|PS00008,-
GJB2_HUMAN,C169Y,0.957,Loss of Disulfide linkage at C169 (Pr = 0.48 | P = 4.0e-04); Altered Metal binding (Pr = 0.46 | P = 4.7e-03); Altered Ordered interface (Pr = 0.27 | P = 6.6e-03); Altered Transmembrane protein (Pr = 0.26 | P = 1.3e-03); Loss of Relative solvent accessibility (Pr = 0.23 | P = 0.05); Gain of Catalytic site at C169 (Pr = 0.09 | P = 0.04), ELME000146|PS00408,-
GJB2_HUMAN,C60G,0.96,Altered Metal binding (Pr = 0.73 | P = 8.4e-04); Altered Ordered interface (Pr = 0.32 | P = 0.01); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.26 | P = 7.4e-04); Loss of Disulfide linkage at C60 (Pr = 0.26 | P = 3.9e-03); Gain of B-factor (Pr = 0.25 | P = 0.04); Gain of Catalytic site at C60 (Pr = 0.20 | P = 0.01); Loss of Pyrrolidone carboxylic acid at Q57 (Pr = 0.12 | P = 8.2e-03); Altered Stability (Pr = 0.09 | P = 0.05), PS00407,-
GJB2_HUMAN,E101G,0.461,-,-,-
GJB2_HUMAN,L36P,0.952,Loss of Helix (Pr = 0.34 | P = 9.4e-04); Altered Ordered interface (Pr = 0.33 | P = 7.4e-03); Gain of Relative solvent accessibility (Pr = 0.32 | P = 4.3e-03); Gain of Strand (Pr = 0.31 | P = 9.0e-04); Altered Transmembrane protein (Pr = 0.28 | P = 6.3e-04); Altered Metal binding (Pr = 0.25 | P = 0.04), ELME000148|ELME000149,-
GJB2_HUMAN,W172R,0.632,Altered Transmembrane protein (Pr = 0.33 | P = 5.8e-05); Altered Metal binding (Pr = 0.32 | P = 0.01); Loss of Disulfide linkage at C169 (Pr = 0.26 | P = 3.9e-03); Loss of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Gain of ADP-ribosylation at W172 (Pr = 0.20 | P = 0.04), PS00408,-
GJB2_HUMAN,W172C,0.717,Altered Metal binding (Pr = 0.39 | P = 8.5e-03); Loss of Disulfide linkage at C169 (Pr = 0.34 | P = 7.8e-04); Altered Transmembrane protein (Pr = 0.28 | P = 4.8e-04); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02), ELME000079|PS00408,-
GJB2_HUMAN,D159V,0.341,-,-,-
GJB2_HUMAN,D159N,0.096,-,-,-
GJB2_HUMAN,S19T,0.377,-,-,-
GJB2_HUMAN,P173R,0.941,Altered Metal binding (Pr = 0.33 | P = 9.8e-03); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Gain of Disulfide linkage at C169 (Pr = 0.26 | P = 3.2e-03); Altered Transmembrane protein (Pr = 0.24 | P = 1.4e-03), ELME000051|PS00408,-
GJB2_HUMAN,C174Y,0.953,Altered Metal binding (Pr = 0.49 | P = 4.0e-03); Loss of Disulfide linkage at C174 (Pr = 0.37 | P = 6.4e-04); Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Transmembrane protein (Pr = 0.27 | P = 8.7e-04); Gain of Strand (Pr = 0.26 | P = 0.04); Gain of Relative solvent accessibility (Pr = 0.23 | P = 0.05); Gain of Catalytic site at C174 (Pr = 0.19 | P = 0.01), ELME000084|PS00408,-
GJB2_HUMAN,C174R,0.958,Altered Metal binding (Pr = 0.47 | P = 4.5e-03); Loss of Disulfide linkage at C174 (Pr = 0.37 | P = 6.4e-04); Altered Ordered interface (Pr = 0.32 | P = 0.01); Altered Transmembrane protein (Pr = 0.29 | P = 2.6e-04); Loss of Relative solvent accessibility (Pr = 0.24 | P = 0.05); Gain of Catalytic site at C174 (Pr = 0.17 | P = 0.02), PS00408,-
GJB2_HUMAN,E147K,0.793,Altered Transmembrane protein (Pr = 0.16 | P = 0.01), ELME000137|ELME000146,-
GJB2_HUMAN,F161S,0.749,Altered Transmembrane protein (Pr = 0.30 | P = 1.4e-04); Altered Ordered interface (Pr = 0.29 | P = 4.0e-03); Gain of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered Metal binding (Pr = 0.11 | P = 0.04); Loss of Sulfation at Y158 (Pr = 0.01 | P = 0.05), ELME000120|ELME000148,-
GJB2_HUMAN,T208P,0.584,Altered Ordered interface (Pr = 0.30 | P = 2.9e-03), ELME000070|ELME000333|PS00001,-
GJB2_HUMAN,W134R,0.776,Altered Ordered interface (Pr = 0.31 | P = 4.0e-03); Gain of Helix (Pr = 0.30 | P = 0.01); Altered DNA binding (Pr = 0.30 | P = 1.5e-03); Loss of Strand (Pr = 0.28 | P = 8.2e-03); Gain of Allosteric site at W133 (Pr = 0.18 | P = 0.05); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Loss of Catalytic site at Y136 (Pr = 0.08 | P = 0.05), ELME000053|ELME000147|ELME000173|ELME000336,-
GJB2_HUMAN,V153A,0.467,-,-,-
GJB2_HUMAN,V153I,0.218,-,-,-
GJB2_HUMAN,V178M,0.909,Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Metal binding (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.26 | P = 8.5e-04); Gain of Disulfide linkage at C174 (Pr = 0.26 | P = 3.2e-03), PS00408,-
GJB2_HUMAN,V178E,0.968,Altered Transmembrane protein (Pr = 0.36 | P = 1.9e-05); Gain of Disulfide linkage at C174 (Pr = 0.28 | P = 1.5e-03); Altered Metal binding (Pr = 0.27 | P = 0.02); Gain of Catalytic site at C180 (Pr = 0.11 | P = 0.04), PS00408,-
GJB2_HUMAN,I35S,0.906,Altered Transmembrane protein (Pr = 0.30 | P = 1.7e-04); Loss of Helix (Pr = 0.28 | P = 0.03); Gain of Strand (Pr = 0.27 | P = 0.03); Gain of Catalytic site at R32 (Pr = 0.09 | P = 0.04), ELME000148|ELME000149|ELME000335,-
GJB2_HUMAN,S138N,0.336,-,-,-
GJB2_HUMAN,S138G,0.28,-,-,-
GJB2_HUMAN,I111V,0.043,-,-,-
GJB2_HUMAN,I111M,0.069,-,-,-
GJB2_HUMAN,I111T,0.07,-,-,-
GJB2_HUMAN,W24L,0.927,Gain of Helix (Pr = 0.31 | P = 4.2e-03); Loss of Strand (Pr = 0.30 | P = 1.9e-03); Altered Ordered interface (Pr = 0.26 | P = 0.01); Altered Transmembrane protein (Pr = 0.18 | P = 7.7e-03); Loss of Catalytic site at K22 (Pr = 0.16 | P = 0.02), ELME000106|ELME000146|ELME000333,-
GJB2_HUMAN,D179N,0.888,Altered Metal binding (Pr = 0.49 | P = 4.0e-03); Altered Transmembrane protein (Pr = 0.31 | P = 9.7e-05); Altered Ordered interface (Pr = 0.31 | P = 0.01); Loss of Strand (Pr = 0.26 | P = 0.04); Loss of Disulfide linkage at C174 (Pr = 0.24 | P = 8.4e-03); Loss of Allosteric site at R184 (Pr = 0.21 | P = 0.04), ELME000155|PS00408,-
GJB2_HUMAN,V27I,0.562,Gain of Helix (Pr = 0.27 | P = 0.05); Loss of Strand (Pr = 0.26 | P = 0.03); Altered Transmembrane protein (Pr = 0.19 | P = 7.5e-03); Loss of Catalytic site at K22 (Pr = 0.16 | P = 0.02); Altered DNA binding (Pr = 0.14 | P = 0.05), ELME000335,-
GJB2_HUMAN,G4S,0.097,-,-,-
GJB2_HUMAN,T5A,0.126,-,-,-
GJB2_HUMAN,T5G,0.34,-,-,-
GJB2_HUMAN,L28I,0.47,-,-,-
GJB2_HUMAN,Y68F,0.202,-,-,-
GJB2_HUMAN,Y68H,0.423,-,-,-
GJB2_HUMAN,Y97H,0.609,Altered Metal binding (Pr = 0.38 | P = 9.6e-03); Gain of Intrinsic disorder (Pr = 0.33 | P = 0.03); Altered Ordered interface (Pr = 0.28 | P = 7.1e-03); Loss of Allosteric site at H94 (Pr = 0.23 | P = 0.02); Altered Coiled coil (Pr = 0.13 | P = 0.04); Altered Stability (Pr = 0.11 | P = 0.03), ELME000012,-
GJB2_HUMAN,K102M,0.441,-,-,-
GJB2_HUMAN,I107M,0.094,-,-,-
GJB2_HUMAN,I107V,0.071,-,-,-
GJB2_HUMAN,K108R,0.104,-,-,-
GJB2_HUMAN,D117N,0.241,-,-,-
GJB2_HUMAN,I118L,0.091,-,-,-
GJB2_HUMAN,T123K,0.137,-,-,-
GJB2_HUMAN,T123N,0.111,-,-,-
GJB2_HUMAN,T123S,0.044,-,-,-
GJB2_HUMAN,V126I,0.1,-,-,-
GJB2_HUMAN,S131P,0.515,Altered Ordered interface (Pr = 0.25 | P = 0.03); Altered DNA binding (Pr = 0.25 | P = 8.6e-03); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Loss of Catalytic site at Y136 (Pr = 0.08 | P = 0.05), ELME000051|ELME000053|ELME000147,-
GJB2_HUMAN,V144I,0.082,-,-,-
GJB2_HUMAN,I145V,0.048,-,-,-
GJB2_HUMAN,A149V,0.063,-,-,-
GJB2_HUMAN,V156I,0.031,-,-,-
GJB2_HUMAN,S162A,0.051,-,-,-
GJB2_HUMAN,S162F,0.128,-,-,-
GJB2_HUMAN,Q164K,0.252,-,-,-
GJB2_HUMAN,N170G,0.366,-,-,-
GJB2_HUMAN,N170S,0.129,-,-,-
GJB2_HUMAN,N170T,0.291,-,-,-
GJB2_HUMAN,V182I,0.246,-,-,-
GJB2_HUMAN,I196V,0.122,-,-,-
GJB2_HUMAN,V207I,0.104,-,-,-
GJB2_HUMAN,Y217F,0.092,-,-,-
GJB2_HUMAN,G220A,0.101,-,-,-
GJB2_HUMAN,G220K,0.142,-,-,-
GJB2_HUMAN,K221R,0.08,-,-,-
GJB2_HUMAN,K223R,0.09,-,-,-
GJB2_HUMAN,W77R,0.945,Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Helix (Pr = 0.27 | P = 0.04); Loss of Strand (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.25 | P = 0.01); Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000012|ELME000106|ELME000149|ELME000233,-
GJB2_HUMAN,R127C,0.492,-,-,-
GJB2_HUMAN,R127L,0.593,Altered DNA binding (Pr = 0.34 | P = 1.1e-03); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Altered Coiled coil (Pr = 0.12 | P = 0.04), ELME000051|ELME000052|ELME000106|ELME000333,-
GJB2_HUMAN,R127H,0.335,-,-,-
GJB2_HUMAN,I121N,0.508,Gain of Intrinsic disorder (Pr = 0.38 | P = 0.01); Gain of B-factor (Pr = 0.24 | P = 0.04); Loss of Acetylation at K116 (Pr = 0.23 | P = 0.02); Altered DNA binding (Pr = 0.21 | P = 0.02); Altered Coiled coil (Pr = 0.13 | P = 0.04); Altered Transmembrane protein (Pr = 0.12 | P = 0.03); Altered Stability (Pr = 0.09 | P = 0.05); Gain of N-linked glycosylation at I121 (Pr = 0.06 | P = 0.02); Gain of GPI-anchor amidation at I121 (Pr = 0.02 | P = 0.02), ELME000052|ELME000070|ELME000202|PS00001,-
GJB2_HUMAN,L81R,0.908,Gain of Strand (Pr = 0.29 | P = 4.9e-03); Altered Ordered interface (Pr = 0.25 | P = 0.03), ELME000155|ELME000333,-
GJB2_HUMAN,L81V,0.588,Loss of Helix (Pr = 0.28 | P = 0.03); Gain of Strand (Pr = 0.28 | P = 9.7e-03); Altered Ordered interface (Pr = 0.25 | P = 0.02), ELME000155|ELME000333,-
GJB2_HUMAN,G200A,0.426,-,-,-
GJB2_HUMAN,D46E,0.852,Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.25 | P = 1.1e-03); Altered Metal binding (Pr = 0.23 | P = 0.04); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.6e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.05), None,-
GJB2_HUMAN,D46N,0.868,Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.26 | P = 9.4e-04); Altered Metal binding (Pr = 0.24 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.2e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.04), PS00008,-
GJB2_HUMAN,G45R,0.876,Altered Ordered interface (Pr = 0.36 | P = 3.3e-03); Altered Transmembrane protein (Pr = 0.34 | P = 3.4e-05); Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Altered Metal binding (Pr = 0.12 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.5e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.04), None,-
GJB2_HUMAN,G45E,0.902,Altered Ordered interface (Pr = 0.35 | P = 4.0e-03); Altered Metal binding (Pr = 0.32 | P = 0.01); Gain of Relative solvent accessibility (Pr = 0.31 | P = 6.2e-03); Altered Transmembrane protein (Pr = 0.26 | P = 7.2e-04); Gain of Pyrrolidone carboxylic acid at Q48 (Pr = 0.14 | P = 5.6e-03); Gain of Catalytic site at E47 (Pr = 0.10 | P = 0.04), None,-
GJB2_HUMAN,I82N,0.896,Loss of Strand (Pr = 0.26 | P = 0.03); Altered Ordered interface (Pr = 0.24 | P = 0.03); Altered Stability (Pr = 0.19 | P = 0.01), ELME000155|ELME000333,-
GJB2_HUMAN,I82M,0.568,Gain of Helix (Pr = 0.27 | P = 0.04); Loss of Strand (Pr = 0.27 | P = 0.01); Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Stability (Pr = 0.09 | P = 0.05), ELME000155|ELME000333|ELME000336,-
GJB2_HUMAN,M151R,0.829,Altered Ordered interface (Pr = 0.29 | P = 3.6e-03); Loss of Helix (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.27 | P = 7.8e-04); Gain of Sulfation at Y152 (Pr = 0.01 | P = 0.05), ELME000146|ELME000328,-
GJB2_HUMAN,P70S,0.876,Altered Metal binding (Pr = 0.30 | P = 0.02); Altered Ordered interface (Pr = 0.29 | P = 5.5e-03); Altered Transmembrane protein (Pr = 0.27 | P = 9.5e-04), ELME000120|ELME000182|ELME000336,-
GJB2_HUMAN,P70R,0.925,Altered Ordered interface (Pr = 0.32 | P = 0.01); Altered Metal binding (Pr = 0.30 | P = 4.1e-03); Altered Transmembrane protein (Pr = 0.26 | P = 1.0e-03), ELME000062|ELME000120|ELME000182|ELME000336,-
GJB2_HUMAN,P70L,0.904,Altered Ordered interface (Pr = 0.36 | P = 3.5e-03); Altered Transmembrane protein (Pr = 0.32 | P = 7.8e-05); Altered Metal binding (Pr = 0.30 | P = 4.4e-03), ELME000120|ELME000149|ELME000182|ELME000317|ELME000336,-
GJB2_HUMAN,P70A,0.845,Altered Ordered interface (Pr = 0.35 | P = 5.8e-03); Altered Transmembrane protein (Pr = 0.28 | P = 4.6e-04); Altered Metal binding (Pr = 0.26 | P = 7.9e-03), ELME000120|ELME000182|ELME000336,-
GJB2_HUMAN,P175T,0.875,Altered Metal binding (Pr = 0.26 | P = 0.03); Altered Transmembrane protein (Pr = 0.26 | P = 9.5e-04); Gain of Disulfide linkage at C174 (Pr = 0.26 | P = 3.1e-03); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03), ELME000052|PS00408,-
GJB2_HUMAN,P175H,0.905,Altered Metal binding (Pr = 0.39 | P = 8.5e-03); Altered Ordered interface (Pr = 0.31 | P = 0.02); Gain of Disulfide linkage at C174 (Pr = 0.26 | P = 3.2e-03); Altered Transmembrane protein (Pr = 0.24 | P = 1.7e-03); Loss of Relative solvent accessibility (Pr = 0.23 | P = 0.05), PS00408,-
GJB2_HUMAN,A78T,0.515,Altered Ordered interface (Pr = 0.27 | P = 0.05); Gain of Strand (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.24 | P = 0.01), ELME000052|ELME000173|ELME000334|ELME000335,-
GJB2_HUMAN,A78S,0.394,-,-,-
GJB2_HUMAN,Y158C,0.84,Altered Transmembrane protein (Pr = 0.48 | P = 0.0e+00); Altered Ordered interface (Pr = 0.40 | P = 1.0e-03); Gain of Helix (Pr = 0.27 | P = 0.05); Loss of Sulfation at Y158 (Pr = 0.01 | P = 0.05), ELME000120,-
GJB2_HUMAN,S199F,0.894,Altered Transmembrane protein (Pr = 0.01 | P = 0.01), ELME000085|ELME000148,-
GJB2_HUMAN,R32S,0.936,Altered Ordered interface (Pr = 0.26 | P = 0.01); Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000148|ELME000149|ELME000335|ELME000336,-
GJB2_HUMAN,R32C,0.937,Loss of Strand (Pr = 0.27 | P = 0.02); Altered Ordered interface (Pr = 0.26 | P = 0.02); Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000148|ELME000149,-
GJB2_HUMAN,R32G,0.948,Loss of Helix (Pr = 0.28 | P = 0.02); Altered Ordered interface (Pr = 0.27 | P = 0.01); Gain of Strand (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000148|ELME000149,-
GJB2_HUMAN,R32L,0.946,Loss of Strand (Pr = 0.33 | P = 3.5e-04); Gain of Helix (Pr = 0.30 | P = 7.2e-03); Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000148|ELME000149,-
GJB2_HUMAN,R32H,0.899,Loss of Helix (Pr = 0.27 | P = 0.05); Altered Ordered interface (Pr = 0.24 | P = 0.04); Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000148|ELME000149,-
GJB2_HUMAN,Q80P,0.936,Altered Ordered interface (Pr = 0.29 | P = 0.03); Loss of Strand (Pr = 0.26 | P = 0.05), ELME000237,-
GJB2_HUMAN,Q80K,0.835,Loss of Strand (Pr = 0.27 | P = 0.03); Altered Ordered interface (Pr = 0.25 | P = 0.02), ELME000137|ELME000146|ELME000313,-
GJB2_HUMAN,Q80H,0.828,Altered Ordered interface (Pr = 0.26 | P = 0.01), None,-
GJB2_HUMAN,Q80L,0.902,Loss of Strand (Pr = 0.30 | P = 2.1e-03); Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Helix (Pr = 0.28 | P = 0.02), ELME000045|ELME000149,-
GJB2_HUMAN,Q80R,0.851,Gain of Helix (Pr = 0.28 | P = 0.02); Loss of Strand (Pr = 0.27 | P = 0.02); Altered Ordered interface (Pr = 0.24 | P = 0.03), ELME000137|ELME000146|ELME000313,-
GJB2_HUMAN,Q7P,0.502,Altered Transmembrane protein (Pr = 0.27 | P = 5.9e-04); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.19 | P = 0.04), PS00008,-
GJB2_HUMAN,Q7H,0.138,-,-,-
GJB2_HUMAN,I20M,0.379,-,-,-
GJB2_HUMAN,I20T,0.623,Altered Stability (Pr = 0.51 | P = 1.6e-03); Gain of Intrinsic disorder (Pr = 0.30 | P = 0.05); Altered Transmembrane protein (Pr = 0.24 | P = 1.4e-03); Loss of Catalytic site at K22 (Pr = 0.15 | P = 0.02); Altered Metal binding (Pr = 0.04 | P = 0.05), ELME000052|ELME000063|PS00005,-
GJB2_HUMAN,I20F,0.617,Altered Transmembrane protein (Pr = 0.27 | P = 7.1e-04); Loss of Catalytic site at K22 (Pr = 0.16 | P = 0.02), ELME000184|ELME000197|ELME000198|ELME000328,-
GJB2_HUMAN,V43G,0.911,Altered Stability (Pr = 0.38 | P = 3.2e-03); Altered Transmembrane protein (Pr = 0.31 | P = 1.3e-04); Gain of Relative solvent accessibility (Pr = 0.31 | P = 6.8e-03); Altered Ordered interface (Pr = 0.28 | P = 0.03); Altered Metal binding (Pr = 0.13 | P = 0.05); Gain of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.2e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.05), None,-
GJB2_HUMAN,V43L,0.795,Altered Transmembrane protein (Pr = 0.28 | P = 6.0e-04); Loss of Strand (Pr = 0.28 | P = 9.9e-03); Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered Metal binding (Pr = 0.12 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.1e-03); Gain of Catalytic site at E47 (Pr = 0.09 | P = 0.04), None,-
GJB2_HUMAN,V43M,0.789,Gain of Relative solvent accessibility (Pr = 0.28 | P = 0.01); Loss of Strand (Pr = 0.26 | P = 0.03); Altered Transmembrane protein (Pr = 0.25 | P = 1.3e-03); Altered Metal binding (Pr = 0.14 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 6.9e-03); Gain of Catalytic site at E47 (Pr = 0.09 | P = 0.04), None,-
GJB2_HUMAN,W44C,0.959,Altered Metal binding (Pr = 0.44 | P = 6.9e-03); Loss of Relative solvent accessibility (Pr = 0.33 | P = 3.5e-03); Altered Transmembrane protein (Pr = 0.28 | P = 4.4e-04); Altered Ordered interface (Pr = 0.28 | P = 0.04); Loss of Strand (Pr = 0.26 | P = 0.03); Gain of Disulfide linkage at W44 (Pr = 0.12 | P = 0.04); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.3e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.05), None,-
GJB2_HUMAN,W44L,0.908,Loss of Relative solvent accessibility (Pr = 0.30 | P = 0.01); Loss of Strand (Pr = 0.29 | P = 5.3e-03); Altered Transmembrane protein (Pr = 0.26 | P = 9.0e-04); Altered Metal binding (Pr = 0.13 | P = 0.05); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.2e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.05); Gain of Methylation at K41 (Pr = 0.09 | P = 0.04), ELME000146,-
GJB2_HUMAN,W44S,0.952,Gain of Relative solvent accessibility (Pr = 0.38 | P = 6.1e-04); Altered Ordered interface (Pr = 0.35 | P = 3.9e-03); Altered Transmembrane protein (Pr = 0.31 | P = 1.1e-04); Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered Metal binding (Pr = 0.26 | P = 0.03); Gain of Ubiquitylation at K41 (Pr = 0.17 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.0e-03); Gain of Catalytic site at E47 (Pr = 0.11 | P = 0.04); Gain of Methylation at K41 (Pr = 0.11 | P = 0.03), ELME000064|ELME000085|PS00006,-
GJB2_HUMAN,W44G,0.94,Gain of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered Ordered interface (Pr = 0.27 | P = 0.04); Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03); Gain of B-factor (Pr = 0.26 | P = 0.02); Gain of Ubiquitylation at K41 (Pr = 0.17 | P = 0.03); Altered Metal binding (Pr = 0.13 | P = 0.05); Gain of Methylation at K41 (Pr = 0.12 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.4e-03); Gain of Catalytic site at E47 (Pr = 0.10 | P = 0.04), None,-
GJB2_HUMAN,F31I,0.92,Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000148,-
GJB2_HUMAN,W133S,0.898,Altered DNA binding (Pr = 0.31 | P = 1.3e-03); Altered Ordered interface (Pr = 0.29 | P = 5.0e-03); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Gain of Catalytic site at Y136 (Pr = 0.09 | P = 0.05), ELME000051|ELME000053|ELME000147|ELME000336,-
GJB2_HUMAN,W133G,0.892,Altered Ordered interface (Pr = 0.31 | P = 0.01); Altered DNA binding (Pr = 0.27 | P = 3.6e-03); Altered Stability (Pr = 0.14 | P = 0.02); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Loss of Catalytic site at Y136 (Pr = 0.08 | P = 0.05), ELME000051|ELME000053|ELME000147|ELME000336,-
GJB2_HUMAN,H100P,0.638,Loss of Helix (Pr = 0.28 | P = 0.03); Gain of B-factor (Pr = 0.25 | P = 0.03); Gain of Allosteric site at Y97 (Pr = 0.22 | P = 0.03); Altered Disordered interface (Pr = 0.18 | P = 0.05); Altered Coiled coil (Pr = 0.14 | P = 0.03), ELME000102|ELME000103|ELME000108|ELME000271,-
GJB2_HUMAN,H100Q,0.377,-,-,-
GJB2_HUMAN,H100Y,0.421,-,-,-
GJB2_HUMAN,L79P,0.933,Altered Ordered interface (Pr = 0.36 | P = 2.7e-03); Loss of Helix (Pr = 0.28 | P = 0.03); Gain of Strand (Pr = 0.28 | P = 7.2e-03); Gain of Allosteric site at W77 (Pr = 0.20 | P = 0.04); Altered Stability (Pr = 0.16 | P = 0.02), None,-
GJB2_HUMAN,L79V,0.647,Loss of Helix (Pr = 0.28 | P = 0.03); Gain of Strand (Pr = 0.28 | P = 1.0e-02); Altered Ordered interface (Pr = 0.25 | P = 0.02), None,-
GJB2_HUMAN,K105R,0.099,-,-,-
GJB2_HUMAN,N54S,0.847,Altered Metal binding (Pr = 0.29 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03); Loss of Disulfide linkage at C53 (Pr = 0.26 | P = 4.8e-03); Loss of Pyrrolidone carboxylic acid at Q57 (Pr = 0.11 | P = 8.3e-03), ELME000336|PS00407,-
GJB2_HUMAN,N54K,0.928,Altered Metal binding (Pr = 0.32 | P = 0.01); Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Altered Ordered interface (Pr = 0.30 | P = 0.03); Loss of Disulfide linkage at C53 (Pr = 0.27 | P = 3.3e-03); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Gain of Pyrrolidone carboxylic acid at Q57 (Pr = 0.12 | P = 7.7e-03), ELME000106|PS00407,-
GJB2_HUMAN,N54H,0.894,Altered Metal binding (Pr = 0.57 | P = 3.3e-03); Loss of Relative solvent accessibility (Pr = 0.33 | P = 3.5e-03); Altered Ordered interface (Pr = 0.31 | P = 0.02); Altered Transmembrane protein (Pr = 0.29 | P = 2.5e-04); Loss of Disulfide linkage at C53 (Pr = 0.27 | P = 2.6e-03); Loss of Pyrrolidone carboxylic acid at Q57 (Pr = 0.12 | P = 8.1e-03), PS00407,-
GJB2_HUMAN,V198M,0.475,-,-,-
GJB2_HUMAN,G130V,0.935,Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered DNA binding (Pr = 0.28 | P = 5.0e-03); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Altered Coiled coil (Pr = 0.08 | P = 0.05), ELME000051|ELME000053|ELME000147|ELME000233,-
GJB2_HUMAN,G130D,0.933,Altered Coiled coil (Pr = 0.41 | P = 6.7e-03); Altered Ordered interface (Pr = 0.28 | P = 0.04); Gain of Helix (Pr = 0.28 | P = 0.03); Loss of Strand (Pr = 0.28 | P = 0.01); Altered DNA binding (Pr = 0.27 | P = 4.3e-03); Altered Metal binding (Pr = 0.19 | P = 0.04); Altered Transmembrane protein (Pr = 0.17 | P = 1.0e-02), ELME000051|ELME000053|ELME000147,-
GJB2_HUMAN,V38A,0.74,Gain of Helix (Pr = 0.29 | P = 0.01); Loss of Strand (Pr = 0.29 | P = 3.7e-03); Altered Transmembrane protein (Pr = 0.28 | P = 5.4e-04); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02), ELME000148,-
GJB2_HUMAN,V37L,0.739,Loss of Strand (Pr = 0.31 | P = 1.0e-03); Gain of Helix (Pr = 0.30 | P = 8.5e-03); Gain of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered Transmembrane protein (Pr = 0.26 | P = 1.0e-03), ELME000148|ELME000149,-
GJB2_HUMAN,V37I,0.503,Loss of Strand (Pr = 0.26 | P = 0.03); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Altered Transmembrane protein (Pr = 0.24 | P = 1.5e-03), ELME000148|ELME000149,-
GJB2_HUMAN,D66H,0.94,Altered Metal binding (Pr = 0.58 | P = 7.8e-04); Altered Transmembrane protein (Pr = 0.35 | P = 2.4e-05); Altered Ordered interface (Pr = 0.30 | P = 3.1e-03); Loss of Relative solvent accessibility (Pr = 0.30 | P = 0.01); Loss of Disulfide linkage at C64 (Pr = 0.17 | P = 0.03), PS00407,-
GJB2_HUMAN,V84M,0.669,Loss of Strand (Pr = 0.27 | P = 0.02), ELME000052|ELME000136|ELME000155|ELME000159|ELME000333|ELME000358,-
GJB2_HUMAN,V84L,0.663,Loss of Strand (Pr = 0.30 | P = 2.1e-03); Gain of Helix (Pr = 0.28 | P = 0.03), ELME000052|ELME000136|ELME000155|ELME000159|ELME000333|ELME000358,-
GJB2_HUMAN,V84A,0.761,Loss of Strand (Pr = 0.28 | P = 8.2e-03), ELME000052|ELME000136|ELME000155|ELME000159|ELME000333|ELME000358,-
GJB2_HUMAN,K15T,0.56,Loss of Relative solvent accessibility (Pr = 0.30 | P = 8.5e-03); Altered Transmembrane protein (Pr = 0.26 | P = 1.0e-03); Altered Metal binding (Pr = 0.05 | P = 0.04), ELME000053|PS00008,-
GJB2_HUMAN,L214P,0.63,Altered Ordered interface (Pr = 0.30 | P = 2.7e-03), ELME000020|ELME000045|ELME000081|ELME000120|ELME000149|ELME000182,-
GJB2_HUMAN,L214M,0.119,-,-,-
GJB2_HUMAN,E120K,0.307,-,-,-
GJB2_HUMAN,V95M,0.531,Loss of Allosteric site at H94 (Pr = 0.22 | P = 0.03); Altered Coiled coil (Pr = 0.18 | P = 0.02); Altered Metal binding (Pr = 0.07 | P = 0.02), None,-
GJB2_HUMAN,G59R,0.951,Altered Ordered interface (Pr = 0.31 | P = 0.01); Altered Transmembrane protein (Pr = 0.29 | P = 4.0e-04); Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Altered Metal binding (Pr = 0.20 | P = 0.03); Loss of Disulfide linkage at C60 (Pr = 0.19 | P = 0.02); Loss of Catalytic site at C60 (Pr = 0.15 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q57 (Pr = 0.11 | P = 8.5e-03), PS00407,-
GJB2_HUMAN,G59V,0.958,Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Altered Ordered interface (Pr = 0.29 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.20 | P = 0.03); Loss of Disulfide linkage at C60 (Pr = 0.20 | P = 0.02); Loss of Catalytic site at C60 (Pr = 0.16 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q57 (Pr = 0.14 | P = 5.6e-03), PS00407,-
GJB2_HUMAN,G59A,0.912,Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Altered Ordered interface (Pr = 0.27 | P = 0.05); Altered Transmembrane protein (Pr = 0.23 | P = 2.7e-03); Gain of Disulfide linkage at C60 (Pr = 0.20 | P = 0.02); Altered Metal binding (Pr = 0.19 | P = 0.03); Loss of Catalytic site at C60 (Pr = 0.15 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q57 (Pr = 0.11 | P = 8.0e-03), PS00407,-
GJB2_HUMAN,G59S,0.907,Altered Ordered interface (Pr = 0.31 | P = 0.01); Gain of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered Transmembrane protein (Pr = 0.26 | P = 1.2e-03); Gain of Disulfide linkage at C60 (Pr = 0.20 | P = 0.02); Altered Metal binding (Pr = 0.19 | P = 0.03); Gain of Catalytic site at C60 (Pr = 0.16 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q57 (Pr = 0.11 | P = 8.7e-03), ELME000053|ELME000162|PS00005|PS00407,-
GJB2_HUMAN,R184Q,0.866,Altered Transmembrane protein (Pr = 0.33 | P = 4.9e-05); Loss of Strand (Pr = 0.26 | P = 0.05); Loss of Allosteric site at R184 (Pr = 0.24 | P = 0.02); Altered Metal binding (Pr = 0.14 | P = 0.04); Loss of Disulfide linkage at C180 (Pr = 0.13 | P = 0.04), ELME000062|ELME000063|ELME000155|ELME000202|PS00408,-
GJB2_HUMAN,R184W,0.918,Altered Ordered interface (Pr = 0.29 | P = 0.04); Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03); Loss of Allosteric site at R184 (Pr = 0.22 | P = 0.03); Loss of Disulfide linkage at C180 (Pr = 0.14 | P = 0.04); Altered Metal binding (Pr = 0.10 | P = 0.05), ELME000062|ELME000063|ELME000155|PS00408,-
GJB2_HUMAN,R184G,0.945,Altered Ordered interface (Pr = 0.33 | P = 8.1e-03); Altered Transmembrane protein (Pr = 0.28 | P = 6.5e-04); Loss of Allosteric site at R184 (Pr = 0.26 | P = 0.01); Loss of Disulfide linkage at C180 (Pr = 0.13 | P = 0.04); Altered Metal binding (Pr = 0.10 | P = 0.05); Gain of Methylation at K188 (Pr = 0.10 | P = 0.04), ELME000062|ELME000063|ELME000085|ELME000155|PS00408,-
GJB2_HUMAN,R184P,0.968,Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Transmembrane protein (Pr = 0.28 | P = 4.2e-04); Loss of Strand (Pr = 0.27 | P = 0.01); Loss of Allosteric site at R184 (Pr = 0.26 | P = 0.01); Gain of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Altered Metal binding (Pr = 0.13 | P = 0.05); Loss of Disulfide linkage at C180 (Pr = 0.13 | P = 0.04); Gain of Methylation at K188 (Pr = 0.10 | P = 0.04), ELME000062|ELME000063|ELME000136|ELME000155|ELME000159|PS00408,-
GJB2_HUMAN,C53Y,0.947,Loss of Disulfide linkage at C53 (Pr = 0.38 | P = 6.1e-04); Altered Metal binding (Pr = 0.37 | P = 7.8e-03); Altered Transmembrane protein (Pr = 0.32 | P = 1.0e-04); Altered Ordered interface (Pr = 0.32 | P = 8.4e-03); Gain of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.6e-03); Gain of Catalytic site at C53 (Pr = 0.08 | P = 0.05), ELME000017|ELME000120|PS00407,-
GJB2_HUMAN,C53R,0.961,Loss of Disulfide linkage at C53 (Pr = 0.38 | P = 6.1e-04); Altered Metal binding (Pr = 0.35 | P = 8.8e-03); Gain of Relative solvent accessibility (Pr = 0.33 | P = 3.3e-03); Altered Ordered interface (Pr = 0.31 | P = 0.01); Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Gain of Catalytic site at C53 (Pr = 0.16 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.5e-03), ELME000062|PS00407,-
GJB2_HUMAN,F142L,0.624,Gain of Helix (Pr = 0.33 | P = 1.4e-03); Loss of Strand (Pr = 0.30 | P = 2.2e-03), ELME000137|ELME000328,-
GJB2_HUMAN,V52L,0.17,-,-,-
GJB2_HUMAN,V52I,0.067,-,-,-
GJB2_HUMAN,V52T,0.156,-,-,-
GJB2_HUMAN,V13M,0.705,Altered Transmembrane protein (Pr = 0.32 | P = 7.3e-05); Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.02), None,-
GJB2_HUMAN,I203K,0.908,, ELME000106,-
GJB2_HUMAN,I203T,0.603,, ELME000053|ELME000335,-
GJB2_HUMAN,E47K,0.871,Altered Transmembrane protein (Pr = 0.31 | P = 1.2e-04); Gain of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered Metal binding (Pr = 0.26 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.5e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.04), None,-
GJB2_HUMAN,E47Q,0.8,Altered Transmembrane protein (Pr = 0.32 | P = 7.8e-05); Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Metal binding (Pr = 0.26 | P = 0.03); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Gain of Pyrrolidone carboxylic acid at E47 (Pr = 0.16 | P = 3.9e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.05), None,-
GJB2_HUMAN,G109E,0.403,-,-,-
GJB2_HUMAN,V190D,0.922,Altered Transmembrane protein (Pr = 0.32 | P = 9.3e-05); Altered Ordered interface (Pr = 0.27 | P = 0.05); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Stability (Pr = 0.18 | P = 0.01); Altered Metal binding (Pr = 0.10 | P = 0.05), ELME000133|ELME000146|ELME000147,-
GJB2_HUMAN,K122I,0.526,Altered DNA binding (Pr = 0.33 | P = 1.3e-03); Altered Transmembrane protein (Pr = 0.17 | P = 0.01); Altered Coiled coil (Pr = 0.13 | P = 0.04), ELME000052|ELME000193|ELME000202,-
GJB2_HUMAN,K122R,0.169,-,-,-
GJB2_HUMAN,S17Y,0.891,Altered Ordered interface (Pr = 0.32 | P = 1.6e-03); Altered Transmembrane protein (Pr = 0.27 | P = 9.0e-04); Gain of Strand (Pr = 0.27 | P = 0.03); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Loss of Catalytic site at K22 (Pr = 0.16 | P = 0.02), ELME000120|ELME000182,-
GJB2_HUMAN,S17F,0.879,Altered Transmembrane protein (Pr = 0.28 | P = 4.0e-04); Gain of Strand (Pr = 0.26 | P = 0.04); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Loss of Catalytic site at K22 (Pr = 0.17 | P = 0.02), ELME000146,-
GJB2_HUMAN,L205P,0.954,, ELME000070|ELME000333,-
GJB2_HUMAN,L205V,0.756,, ELME000070|ELME000333,-
GJB2_HUMAN,L205F,0.821,, ELME000070|ELME000333,-
GJB2_HUMAN,L132V,0.779,Loss of Helix (Pr = 0.33 | P = 1.2e-03); Altered Ordered interface (Pr = 0.31 | P = 0.02); Gain of Strand (Pr = 0.29 | P = 6.1e-03); Altered DNA binding (Pr = 0.27 | P = 6.0e-03); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Altered Coiled coil (Pr = 0.08 | P = 0.04); Loss of Catalytic site at Y136 (Pr = 0.08 | P = 0.05), ELME000051|ELME000053|ELME000147|ELME000336,-
GJB2_HUMAN,A40G,0.665,Loss of Helix (Pr = 0.33 | P = 1.2e-03); Gain of Strand (Pr = 0.30 | P = 3.1e-03); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.26 | P = 1.0e-03), None,-
GJB2_HUMAN,A40E,0.879,Altered Metal binding (Pr = 0.42 | P = 7.6e-03); Gain of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.27 | P = 9.4e-04); Loss of Strand (Pr = 0.26 | P = 0.05), None,-
GJB2_HUMAN,A40V,0.741,Loss of Helix (Pr = 0.29 | P = 0.01); Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.26 | P = 7.4e-04); Gain of Strand (Pr = 0.26 | P = 0.04), None,-
GJB2_HUMAN,N14Y,0.866,Altered Ordered interface (Pr = 0.37 | P = 5.5e-04); Gain of Strand (Pr = 0.27 | P = 0.01); Altered Transmembrane protein (Pr = 0.26 | P = 9.8e-04); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.03), None,-
GJB2_HUMAN,N14K,0.819,Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Loss of Strand (Pr = 0.27 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03), ELME000008|PS00004,-
GJB2_HUMAN,T8M,0.095,-,-,-
GJB2_HUMAN,T8K,0.227,-,-,-
GJB2_HUMAN,T8S,0.065,-,-,-
GJB2_HUMAN,V63L,0.845,Altered Metal binding (Pr = 0.30 | P = 4.2e-03); Altered Ordered interface (Pr = 0.27 | P = 9.1e-03); Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Gain of Disulfide linkage at C60 (Pr = 0.20 | P = 0.02); Loss of Catalytic site at C60 (Pr = 0.16 | P = 0.02), ELME000079|ELME000106|PS00407,-
GJB2_HUMAN,S72C,0.882,Altered Metal binding (Pr = 0.42 | P = 7.6e-03); Altered Transmembrane protein (Pr = 0.32 | P = 7.3e-05); Altered Ordered interface (Pr = 0.32 | P = 0.01), None,-
GJB2_HUMAN,D50A,0.807,Altered Transmembrane protein (Pr = 0.32 | P = 6.3e-05); Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.30 | P = 8.8e-03); Altered Metal binding (Pr = 0.29 | P = 0.02); Loss of Disulfide linkage at C53 (Pr = 0.27 | P = 2.5e-03); Gain of Pyrrolidone carboxylic acid at Q48 (Pr = 0.15 | P = 4.7e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.05), None,-
GJB2_HUMAN,D50N,0.68,Altered Metal binding (Pr = 0.26 | P = 0.03); Altered Transmembrane protein (Pr = 0.26 | P = 7.2e-04); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Loss of Disulfide linkage at C53 (Pr = 0.25 | P = 7.0e-03); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.3e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.04), None,-
GJB2_HUMAN,D50Y,0.878,Altered Transmembrane protein (Pr = 0.34 | P = 4.9e-05); Loss of Relative solvent accessibility (Pr = 0.31 | P = 6.4e-03); Altered Metal binding (Pr = 0.30 | P = 0.01); Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Disulfide linkage at C53 (Pr = 0.28 | P = 2.0e-03); Gain of Pyrrolidone carboxylic acid at Q48 (Pr = 0.14 | P = 5.0e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.04); Gain of Sulfation at D50 (Pr = 0.02 | P = 0.03), ELME000182,-
GJB2_HUMAN,I140S,0.829,Loss of Helix (Pr = 0.29 | P = 0.02); Gain of Strand (Pr = 0.26 | P = 0.04); Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered DNA binding (Pr = 0.19 | P = 0.03); Gain of Catalytic site at Y136 (Pr = 0.09 | P = 0.05), ELME000052|ELME000197|ELME000337,-
GJB2_HUMAN,G12V,0.798,Loss of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered Transmembrane protein (Pr = 0.28 | P = 4.6e-04), ELME000335,-
GJB2_HUMAN,G12D,0.807,Altered Transmembrane protein (Pr = 0.33 | P = 4.9e-05); Gain of Relative solvent accessibility (Pr = 0.31 | P = 5.3e-03), None,-
GJB2_HUMAN,G12R,0.767,Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Gain of Helix (Pr = 0.27 | P = 0.04); Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03), None,-
GJB2_HUMAN,G12C,0.827,Altered Transmembrane protein (Pr = 0.36 | P = 1.9e-05); Loss of Relative solvent accessibility (Pr = 0.34 | P = 3.2e-03); Altered Ordered interface (Pr = 0.29 | P = 0.03), None,-
GJB2_HUMAN,I128M,0.486,-,-,-
GJB2_HUMAN,I128V,0.286,-,-,-
GJB2_HUMAN,N206T,0.725,, ELME000064|ELME000070|ELME000220|ELME000333|PS00001|PS00006,-
GJB2_HUMAN,N206S,0.601,, ELME000064|ELME000070|ELME000333|PS00001|PS00006,-
GJB2_HUMAN,N206H,0.682,, ELME000070|ELME000333|PS00001,-
GJB2_HUMAN,K112N,0.204,-,-,-
GJB2_HUMAN,H73Y,0.855,Altered Metal binding (Pr = 0.38 | P = 1.6e-03); Altered Ordered interface (Pr = 0.31 | P = 0.02); Altered Transmembrane protein (Pr = 0.19 | P = 6.1e-03), ELME000020|ELME000083|ELME000120|ELME000182,-
GJB2_HUMAN,H73R,0.88,Altered Metal binding (Pr = 0.38 | P = 1.7e-03); Altered Ordered interface (Pr = 0.32 | P = 0.01); Gain of Helix (Pr = 0.28 | P = 0.02); Loss of Strand (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.20 | P = 5.7e-03), ELME000012|ELME000231|ELME000233,-
GJB2_HUMAN,G11E,0.666,Gain of Relative solvent accessibility (Pr = 0.32 | P = 4.7e-03); Altered Transmembrane protein (Pr = 0.28 | P = 4.6e-04), ELME000064|ELME000220|PS00006,-
GJB2_HUMAN,M163V,0.726,Altered Transmembrane protein (Pr = 0.30 | P = 2.1e-04); Altered Ordered interface (Pr = 0.29 | P = 5.6e-03); Gain of Sulfation at Y158 (Pr = 0.01 | P = 0.05), ELME000148,-
GJB2_HUMAN,M163L,0.685,Altered Ordered interface (Pr = 0.29 | P = 5.3e-03); Altered Transmembrane protein (Pr = 0.28 | P = 4.9e-04); Loss of Sulfation at Y158 (Pr = 0.01 | P = 0.05), ELME000148,-
GJB2_HUMAN,L90P,0.934,Gain of Allosteric site at H94 (Pr = 0.25 | P = 0.01); Altered Coiled coil (Pr = 0.13 | P = 0.04); Altered Metal binding (Pr = 0.07 | P = 0.02), ELME000052,-
GJB2_HUMAN,L90R,0.91,Gain of Allosteric site at H94 (Pr = 0.24 | P = 0.01); Altered Coiled coil (Pr = 0.13 | P = 0.04); Altered Metal binding (Pr = 0.07 | P = 0.02), ELME000052|ELME000313,-
GJB2_HUMAN,L90V,0.628,Loss of Allosteric site at H94 (Pr = 0.21 | P = 0.04); Altered Coiled coil (Pr = 0.12 | P = 0.04); Altered Metal binding (Pr = 0.07 | P = 0.02), ELME000052,-
GJB2_HUMAN,A88G,0.403,-,-,-
GJB2_HUMAN,A88V,0.448,-,-,-
GJB2_HUMAN,A88S,0.287,-,-,-
GJB2_HUMAN,A88P,0.775,Gain of Strand (Pr = 0.27 | P = 0.02); Altered Coiled coil (Pr = 0.11 | P = 0.04), ELME000052|ELME000136|ELME000159|ELME000358,-
GJB2_HUMAN,V226D,0.766,Altered DNA binding (Pr = 0.41 | P = 2.9e-04); Gain of B-factor (Pr = 0.37 | P = 5.8e-05); Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered Transmembrane protein (Pr = 0.29 | P = 0.03), ELME000011,-
GJB2_HUMAN,V226G,0.646,Gain of B-factor (Pr = 0.36 | P = 1.3e-04); Altered DNA binding (Pr = 0.36 | P = 7.4e-04); Gain of Intrinsic disorder (Pr = 0.33 | P = 0.03); Altered Transmembrane protein (Pr = 0.28 | P = 0.04), ELME000011,-
GJB2_HUMAN,V226A,0.353,-,-,-
GJB2_HUMAN,M34I,0.784,Gain of Strand (Pr = 0.26 | P = 0.05); Altered Transmembrane protein (Pr = 0.18 | P = 8.9e-03), ELME000148|ELME000149,-
GJB2_HUMAN,M34V,0.826,Loss of Helix (Pr = 0.27 | P = 0.04); Altered Transmembrane protein (Pr = 0.18 | P = 8.4e-03), ELME000148|ELME000149,-
GJB2_HUMAN,M34R,0.916,Gain of Strand (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.23 | P = 2.4e-03); Gain of Catalytic site at R32 (Pr = 0.09 | P = 0.04), ELME000012|ELME000106|ELME000148|ELME000149,-
GJB2_HUMAN,M34T,0.86,Loss of Helix (Pr = 0.30 | P = 7.9e-03); Gain of Strand (Pr = 0.28 | P = 8.4e-03); Altered Transmembrane protein (Pr = 0.22 | P = 3.1e-03), ELME000052|ELME000062|ELME000148|ELME000149|ELME000335|ELME000336,-
GJB2_HUMAN,M34L,0.729,Gain of Helix (Pr = 0.28 | P = 0.03); Loss of Strand (Pr = 0.28 | P = 5.9e-03); Altered Transmembrane protein (Pr = 0.18 | P = 8.3e-03), ELME000106|ELME000148|ELME000149,-
GJB2_HUMAN,T186M,0.858,Altered Transmembrane protein (Pr = 0.30 | P = 1.6e-04); Loss of Allosteric site at R184 (Pr = 0.21 | P = 0.04); Altered Metal binding (Pr = 0.10 | P = 0.04), ELME000062|ELME000063|ELME000147|ELME000336|PS00005,-
GJB2_HUMAN,T186K,0.932,Altered Transmembrane protein (Pr = 0.32 | P = 1.1e-04); Altered Ordered interface (Pr = 0.28 | P = 0.04); Gain of Strand (Pr = 0.26 | P = 0.05); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Gain of Allosteric site at R184 (Pr = 0.23 | P = 0.02); Altered Metal binding (Pr = 0.10 | P = 0.05); Gain of Methylation at K188 (Pr = 0.09 | P = 0.05), ELME000062|ELME000063|ELME000147|PS00005,-
GJB2_HUMAN,C202F,0.91,Altered Transmembrane protein (Pr = 0.01 | P = 0.01), ELME000197,-
GJB2_HUMAN,C202R,0.907,, ELME000106|ELME000146,-
GJB2_HUMAN,S139N,0.755,Gain of Helix (Pr = 0.30 | P = 9.2e-03); Loss of Strand (Pr = 0.27 | P = 0.02); Altered Ordered interface (Pr = 0.24 | P = 0.03); Altered DNA binding (Pr = 0.19 | P = 0.03); Loss of Catalytic site at Y136 (Pr = 0.08 | P = 0.05), ELME000052|ELME000182|ELME000197|ELME000337,-
GJB2_HUMAN,S139C,0.79,Altered Ordered interface (Pr = 0.34 | P = 6.0e-03); Gain of Helix (Pr = 0.30 | P = 8.2e-03); Loss of Strand (Pr = 0.27 | P = 0.02); Altered DNA binding (Pr = 0.20 | P = 0.02); Loss of Catalytic site at Y136 (Pr = 0.08 | P = 0.05), ELME000052|ELME000182|ELME000197|ELME000337,-
GJB2_HUMAN,C64Y,0.952,Altered Metal binding (Pr = 0.66 | P = 1.3e-03); Altered Disordered interface (Pr = 0.34 | P = 0.01); Altered Transmembrane protein (Pr = 0.30 | P = 1.7e-04); Altered Ordered interface (Pr = 0.30 | P = 0.02); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Loss of Disulfide linkage at C64 (Pr = 0.21 | P = 0.02); Loss of Catalytic site at C60 (Pr = 0.16 | P = 0.02), ELME000079|PS00407,-
GJB2_HUMAN,I71N,0.894,Altered Metal binding (Pr = 0.31 | P = 4.6e-03); Altered Ordered interface (Pr = 0.31 | P = 0.01); Altered Transmembrane protein (Pr = 0.30 | P = 2.2e-04); Gain of Relative solvent accessibility (Pr = 0.23 | P = 0.05); Gain of Allosteric site at R75 (Pr = 0.18 | P = 0.05), ELME000120|ELME000182,-
GJB2_HUMAN,I71V,0.221,-,-,-
GJB2_HUMAN,N176D,0.796,Altered Transmembrane protein (Pr = 0.27 | P = 7.9e-04); Loss of Disulfide linkage at C174 (Pr = 0.25 | P = 6.1e-03); Altered Metal binding (Pr = 0.24 | P = 0.03); Gain of Catalytic site at C180 (Pr = 0.08 | P = 0.05), PS00408,-
GJB2_HUMAN,N176T,0.847,Altered Metal binding (Pr = 0.31 | P = 0.01); Altered Transmembrane protein (Pr = 0.28 | P = 4.3e-04); Altered Ordered interface (Pr = 0.28 | P = 0.05); Loss of Disulfide linkage at C174 (Pr = 0.26 | P = 4.2e-03), ELME000220|PS00006|PS00408,-
GJB2_HUMAN,E114K,0.247,-,-,-
GJB2_HUMAN,E114G,0.285,-,-,-
GJB2_HUMAN,S113R,0.127,-,-,-
GJB2_HUMAN,S113N,0.049,-,-,-
GJB2_HUMAN,S113T,0.064,-,-,-
GJB2_HUMAN,M93T,0.798,Altered Ordered interface (Pr = 0.24 | P = 0.04); Gain of Allosteric site at H94 (Pr = 0.22 | P = 0.02); Altered Stability (Pr = 0.14 | P = 0.02); Altered Coiled coil (Pr = 0.13 | P = 0.04); Altered Metal binding (Pr = 0.07 | P = 0.02), ELME000336,-
GJB2_HUMAN,L89P,0.905,Gain of Strand (Pr = 0.27 | P = 0.02); Gain of Allosteric site at H94 (Pr = 0.25 | P = 0.01); Altered Coiled coil (Pr = 0.12 | P = 0.04); Altered Stability (Pr = 0.09 | P = 0.05); Altered Metal binding (Pr = 0.08 | P = 0.02), ELME000052|ELME000141|ELME000159|ELME000358,-
GJB2_HUMAN,S183F,0.926,Altered Ordered interface (Pr = 0.33 | P = 8.7e-03); Altered Transmembrane protein (Pr = 0.30 | P = 1.8e-04); Loss of Strand (Pr = 0.26 | P = 0.04); Altered Metal binding (Pr = 0.25 | P = 0.03); Loss of Allosteric site at R184 (Pr = 0.22 | P = 0.03); Loss of Disulfide linkage at C180 (Pr = 0.14 | P = 0.04), ELME000062|ELME000063|ELME000155|PS00408,-
GJB2_HUMAN,C218Y,0.479,-,-,-
GJB2_HUMAN,I30N,0.945,Altered Transmembrane protein (Pr = 0.24 | P = 2.1e-03); Gain of Catalytic site at R32 (Pr = 0.08 | P = 0.05), ELME000148|ELME000335,-
GJB2_HUMAN,I30V,0.628,Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000148|ELME000335,-
GJB2_HUMAN,R143Q,0.717,Gain of Strand (Pr = 0.28 | P = 7.4e-03), ELME000137|ELME000146|ELME000328,-
GJB2_HUMAN,R143L,0.865,Loss of Strand (Pr = 0.27 | P = 0.02), ELME000041|ELME000047|ELME000137|ELME000146|ELME000328,-
GJB2_HUMAN,R143W,0.851,Gain of Strand (Pr = 0.28 | P = 0.01), ELME000137|ELME000146|ELME000328,-
GJB2_HUMAN,T55A,0.848,Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Altered Metal binding (Pr = 0.25 | P = 0.03); Altered Transmembrane protein (Pr = 0.25 | P = 1.1e-03); Loss of Disulfide linkage at C53 (Pr = 0.24 | P = 0.01); Loss of Catalytic site at C60 (Pr = 0.15 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q57 (Pr = 0.11 | P = 8.0e-03), PS00407,-
GJB2_HUMAN,T55P,0.931,Altered Metal binding (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.28 | P = 3.6e-04); Altered Ordered interface (Pr = 0.28 | P = 0.03); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Gain of Loop (Pr = 0.26 | P = 0.05); Loss of Disulfide linkage at C53 (Pr = 0.24 | P = 8.5e-03); Loss of Catalytic site at C60 (Pr = 0.15 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q57 (Pr = 0.12 | P = 7.4e-03), ELME000155|PS00407,-
GJB2_HUMAN,T55N,0.879,Gain of Relative solvent accessibility (Pr = 0.33 | P = 2.6e-03); Altered Metal binding (Pr = 0.31 | P = 0.02); Altered Transmembrane protein (Pr = 0.30 | P = 1.8e-04); Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Disulfide linkage at C53 (Pr = 0.28 | P = 1.4e-03); Loss of Catalytic site at C60 (Pr = 0.15 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q57 (Pr = 0.11 | P = 8.7e-03), PS00407,-
GJB2_HUMAN,L56P,0.884,Altered Transmembrane protein (Pr = 0.28 | P = 4.2e-04); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Gain of Loop (Pr = 0.27 | P = 0.04); Altered Metal binding (Pr = 0.26 | P = 0.03); Loss of Disulfide linkage at C53 (Pr = 0.24 | P = 8.7e-03); Gain of Catalytic site at C60 (Pr = 0.18 | P = 0.02); Altered Stability (Pr = 0.12 | P = 0.03); Gain of Pyrrolidone carboxylic acid at Q57 (Pr = 0.11 | P = 8.0e-03), ELME000136|ELME000159|PS00407,-
GJB2_HUMAN,L56Q,0.692,Altered Transmembrane protein (Pr = 0.30 | P = 1.4e-04); Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Metal binding (Pr = 0.29 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Loss of Disulfide linkage at C53 (Pr = 0.25 | P = 6.6e-03); Gain of Catalytic site at C60 (Pr = 0.20 | P = 0.01); Gain of Pyrrolidone carboxylic acid at L56 (Pr = 0.14 | P = 5.3e-03), ELME000202|PS00407,-
GJB2_HUMAN,A197S,0.187,-,-,-
GJB2_HUMAN,A197V,0.379,-,-,-
GJB2_HUMAN,K61Q,0.55,Gain of Catalytic site at C60 (Pr = 0.31 | P = 1.1e-03); Loss of Relative solvent accessibility (Pr = 0.30 | P = 0.01); Altered Metal binding (Pr = 0.29 | P = 4.8e-03); Altered Ordered interface (Pr = 0.27 | P = 7.9e-03); Altered Transmembrane protein (Pr = 0.26 | P = 1.2e-03); Loss of Disulfide linkage at C60 (Pr = 0.20 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q57 (Pr = 0.13 | P = 6.7e-03), PS00407,-
GJB2_HUMAN,R98Q,0.181,-,-,-
GJB2_HUMAN,R98W,0.317,-,-,-
GJB2_HUMAN,R98P,0.568,Loss of Helix (Pr = 0.33 | P = 1.6e-03); Gain of Allosteric site at H94 (Pr = 0.24 | P = 0.01); Altered Disordered interface (Pr = 0.20 | P = 0.04); Altered Coiled coil (Pr = 0.14 | P = 0.03); Altered Metal binding (Pr = 0.08 | P = 0.01), ELME000012|ELME000102|ELME000108|ELME000155,-
GJB2_HUMAN,R98H,0.184,-,-,-
GJB2_HUMAN,R98Y,0.377,-,-,-
GJB2_HUMAN,S85P,0.858,Loss of Strand (Pr = 0.26 | P = 0.03); Altered Coiled coil (Pr = 0.10 | P = 0.04), ELME000052|ELME000136|ELME000155|ELME000159|ELME000333|ELME000358,-
GJB2_HUMAN,S85T,0.458,-,-,-
GJB2_HUMAN,T86R,0.748,Loss of Strand (Pr = 0.26 | P = 0.03); Altered Coiled coil (Pr = 0.10 | P = 0.04), ELME000052|ELME000136|ELME000146|ELME000149|ELME000155|ELME000159|ELME000333|ELME000358,-
GJB2_HUMAN,T86A,0.502,Loss of Strand (Pr = 0.30 | P = 2.5e-03); Altered Coiled coil (Pr = 0.13 | P = 0.03), ELME000041|ELME000052|ELME000085|ELME000136|ELME000155|ELME000159|ELME000333|ELME000358,-
GJB2_HUMAN,K22N,0.693,Loss of Strand (Pr = 0.26 | P = 0.05); Altered Transmembrane protein (Pr = 0.19 | P = 7.3e-03); Gain of Catalytic site at K22 (Pr = 0.15 | P = 0.02), None,-
GJB2_HUMAN,P58R,0.878,Gain of Relative solvent accessibility (Pr = 0.30 | P = 9.0e-03); Altered Transmembrane protein (Pr = 0.28 | P = 4.0e-04); Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Metal binding (Pr = 0.26 | P = 0.02); Gain of Disulfide linkage at C53 (Pr = 0.25 | P = 4.9e-03); Loss of Catalytic site at C60 (Pr = 0.16 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q57 (Pr = 0.13 | P = 5.8e-03), PS00407,-
GJB2_HUMAN,P58A,0.789,Loss of Relative solvent accessibility (Pr = 0.30 | P = 0.01); Altered Transmembrane protein (Pr = 0.26 | P = 9.8e-04); Altered Metal binding (Pr = 0.25 | P = 0.03); Gain of Disulfide linkage at C53 (Pr = 0.24 | P = 8.7e-03); Gain of Catalytic site at C60 (Pr = 0.15 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q57 (Pr = 0.12 | P = 6.9e-03), PS00407,-
GJB2_HUMAN,R75W,0.856,Altered Ordered interface (Pr = 0.27 | P = 0.01); Altered Metal binding (Pr = 0.26 | P = 9.5e-03); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), None,-
GJB2_HUMAN,R75Q,0.727,Altered Metal binding (Pr = 0.26 | P = 9.4e-03); Altered Ordered interface (Pr = 0.24 | P = 0.03); Altered Transmembrane protein (Pr = 0.15 | P = 0.01), None,-
GJB2_HUMAN,E119K,0.44,-,-,-
GJB2_HUMAN,F115C,0.403,-,-,-
GJB2_HUMAN,F115Y,0.106,-,-,-
GJB2_HUMAN,I33T,0.802,Loss of Helix (Pr = 0.29 | P = 0.01); Gain of Strand (Pr = 0.28 | P = 9.9e-03); Altered Transmembrane protein (Pr = 0.14 | P = 0.02); Gain of Catalytic site at R32 (Pr = 0.08 | P = 0.05), ELME000052|ELME000148|ELME000149,-
GJB2_HUMAN,I33V,0.353,-,-,-
GJB2_HUMAN,T18I,0.86,Altered Transmembrane protein (Pr = 0.27 | P = 8.5e-04); Loss of Catalytic site at K22 (Pr = 0.16 | P = 0.02), None,-
GJB2_HUMAN,H16R,0.73,Altered Transmembrane protein (Pr = 0.29 | P = 3.1e-04); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02), ELME000008|ELME000062|ELME000065|ELME000100|ELME000108|PS00004,-
GJB2_HUMAN,H16Y,0.423,-,-,-
GJB2_HUMAN,E42D,0.333,-,-,-
GJB2_HUMAN,E42K,0.471,-,-,-
GJB2_HUMAN,L10P,0.917,Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered Transmembrane protein (Pr = 0.28 | P = 4.4e-04); Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered Stability (Pr = 0.16 | P = 0.02), None,-
GJB2_HUMAN,L10W,0.841,Altered Transmembrane protein (Pr = 0.29 | P = 2.9e-04); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Gain of GPI-anchor amidation at N14 (Pr = 0.02 | P = 0.02), None,-
GJB2_HUMAN,P225L,0.4,-,-,-
GJB2_HUMAN,L6P,0.852,Gain of Intrinsic disorder (Pr = 0.51 | P = 1.6e-03); Altered Transmembrane protein (Pr = 0.28 | P = 4.6e-04); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.20 | P = 0.03); Gain of N-terminal acetylation at M1 (Pr = 0.14 | P = 1.1e-03), ELME000136|ELME000159|ELME000358|PS00008,-
GJB2_HUMAN,C169Y,0.957,Loss of Disulfide linkage at C169 (Pr = 0.48 | P = 4.0e-04); Altered Metal binding (Pr = 0.46 | P = 4.7e-03); Altered Ordered interface (Pr = 0.27 | P = 6.6e-03); Altered Transmembrane protein (Pr = 0.26 | P = 1.3e-03); Loss of Relative solvent accessibility (Pr = 0.23 | P = 0.05); Gain of Catalytic site at C169 (Pr = 0.09 | P = 0.04), ELME000146|PS00408,-
GJB2_HUMAN,C60G,0.96,Altered Metal binding (Pr = 0.73 | P = 8.4e-04); Altered Ordered interface (Pr = 0.32 | P = 0.01); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.26 | P = 7.4e-04); Loss of Disulfide linkage at C60 (Pr = 0.26 | P = 3.9e-03); Gain of B-factor (Pr = 0.25 | P = 0.04); Gain of Catalytic site at C60 (Pr = 0.20 | P = 0.01); Loss of Pyrrolidone carboxylic acid at Q57 (Pr = 0.12 | P = 8.2e-03); Altered Stability (Pr = 0.09 | P = 0.05), PS00407,-
GJB2_HUMAN,E101G,0.461,-,-,-
GJB2_HUMAN,L36P,0.952,Loss of Helix (Pr = 0.34 | P = 9.4e-04); Altered Ordered interface (Pr = 0.33 | P = 7.4e-03); Gain of Relative solvent accessibility (Pr = 0.32 | P = 4.3e-03); Gain of Strand (Pr = 0.31 | P = 9.0e-04); Altered Transmembrane protein (Pr = 0.28 | P = 6.3e-04); Altered Metal binding (Pr = 0.25 | P = 0.04), ELME000148|ELME000149,-
GJB2_HUMAN,W172R,0.632,Altered Transmembrane protein (Pr = 0.33 | P = 5.8e-05); Altered Metal binding (Pr = 0.32 | P = 0.01); Loss of Disulfide linkage at C169 (Pr = 0.26 | P = 3.9e-03); Loss of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Gain of ADP-ribosylation at W172 (Pr = 0.20 | P = 0.04), PS00408,-
GJB2_HUMAN,W172C,0.717,Altered Metal binding (Pr = 0.39 | P = 8.5e-03); Loss of Disulfide linkage at C169 (Pr = 0.34 | P = 7.8e-04); Altered Transmembrane protein (Pr = 0.28 | P = 4.8e-04); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02), ELME000079|PS00408,-
GJB2_HUMAN,D159V,0.341,-,-,-
GJB2_HUMAN,D159N,0.096,-,-,-
GJB2_HUMAN,S19T,0.377,-,-,-
GJB2_HUMAN,P173R,0.941,Altered Metal binding (Pr = 0.33 | P = 9.8e-03); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Gain of Disulfide linkage at C169 (Pr = 0.26 | P = 3.2e-03); Altered Transmembrane protein (Pr = 0.24 | P = 1.4e-03), ELME000051|PS00408,-
GJB2_HUMAN,C174Y,0.953,Altered Metal binding (Pr = 0.49 | P = 4.0e-03); Loss of Disulfide linkage at C174 (Pr = 0.37 | P = 6.4e-04); Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Transmembrane protein (Pr = 0.27 | P = 8.7e-04); Gain of Strand (Pr = 0.26 | P = 0.04); Gain of Relative solvent accessibility (Pr = 0.23 | P = 0.05); Gain of Catalytic site at C174 (Pr = 0.19 | P = 0.01), ELME000084|PS00408,-
GJB2_HUMAN,C174R,0.958,Altered Metal binding (Pr = 0.47 | P = 4.5e-03); Loss of Disulfide linkage at C174 (Pr = 0.37 | P = 6.4e-04); Altered Ordered interface (Pr = 0.32 | P = 0.01); Altered Transmembrane protein (Pr = 0.29 | P = 2.6e-04); Loss of Relative solvent accessibility (Pr = 0.24 | P = 0.05); Gain of Catalytic site at C174 (Pr = 0.17 | P = 0.02), PS00408,-
GJB2_HUMAN,E147K,0.793,Altered Transmembrane protein (Pr = 0.16 | P = 0.01), ELME000137|ELME000146,-
GJB2_HUMAN,F161S,0.749,Altered Transmembrane protein (Pr = 0.30 | P = 1.4e-04); Altered Ordered interface (Pr = 0.29 | P = 4.0e-03); Gain of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered Metal binding (Pr = 0.11 | P = 0.04); Loss of Sulfation at Y158 (Pr = 0.01 | P = 0.05), ELME000120|ELME000148,-
GJB2_HUMAN,T208P,0.584,Altered Ordered interface (Pr = 0.30 | P = 2.9e-03), ELME000070|ELME000333|PS00001,-
GJB2_HUMAN,W134R,0.776,Altered Ordered interface (Pr = 0.31 | P = 4.0e-03); Gain of Helix (Pr = 0.30 | P = 0.01); Altered DNA binding (Pr = 0.30 | P = 1.5e-03); Loss of Strand (Pr = 0.28 | P = 8.2e-03); Gain of Allosteric site at W133 (Pr = 0.18 | P = 0.05); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Loss of Catalytic site at Y136 (Pr = 0.08 | P = 0.05), ELME000053|ELME000147|ELME000173|ELME000336,-
GJB2_HUMAN,V153A,0.467,-,-,-
GJB2_HUMAN,V153I,0.218,-,-,-
GJB2_HUMAN,V178M,0.909,Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Metal binding (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.26 | P = 8.5e-04); Gain of Disulfide linkage at C174 (Pr = 0.26 | P = 3.2e-03), PS00408,-
GJB2_HUMAN,V178E,0.968,Altered Transmembrane protein (Pr = 0.36 | P = 1.9e-05); Gain of Disulfide linkage at C174 (Pr = 0.28 | P = 1.5e-03); Altered Metal binding (Pr = 0.27 | P = 0.02); Gain of Catalytic site at C180 (Pr = 0.11 | P = 0.04), PS00408,-
GJB2_HUMAN,I35S,0.906,Altered Transmembrane protein (Pr = 0.30 | P = 1.7e-04); Loss of Helix (Pr = 0.28 | P = 0.03); Gain of Strand (Pr = 0.27 | P = 0.03); Gain of Catalytic site at R32 (Pr = 0.09 | P = 0.04), ELME000148|ELME000149|ELME000335,-
GJB2_HUMAN,S138N,0.336,-,-,-
GJB2_HUMAN,S138G,0.28,-,-,-
GJB2_HUMAN,I111V,0.043,-,-,-
GJB2_HUMAN,I111M,0.069,-,-,-
GJB2_HUMAN,I111T,0.07,-,-,-
GJB2_HUMAN,W24L,0.927,Gain of Helix (Pr = 0.31 | P = 4.2e-03); Loss of Strand (Pr = 0.30 | P = 1.9e-03); Altered Ordered interface (Pr = 0.26 | P = 0.01); Altered Transmembrane protein (Pr = 0.18 | P = 7.7e-03); Loss of Catalytic site at K22 (Pr = 0.16 | P = 0.02), ELME000106|ELME000146|ELME000333,-
GJB2_HUMAN,D179N,0.888,Altered Metal binding (Pr = 0.49 | P = 4.0e-03); Altered Transmembrane protein (Pr = 0.31 | P = 9.7e-05); Altered Ordered interface (Pr = 0.31 | P = 0.01); Loss of Strand (Pr = 0.26 | P = 0.04); Loss of Disulfide linkage at C174 (Pr = 0.24 | P = 8.4e-03); Loss of Allosteric site at R184 (Pr = 0.21 | P = 0.04), ELME000155|PS00408,-
GJB2_HUMAN,V27I,0.562,Gain of Helix (Pr = 0.27 | P = 0.05); Loss of Strand (Pr = 0.26 | P = 0.03); Altered Transmembrane protein (Pr = 0.19 | P = 7.5e-03); Loss of Catalytic site at K22 (Pr = 0.16 | P = 0.02); Altered DNA binding (Pr = 0.14 | P = 0.05), ELME000335,-
GJB2_HUMAN,G4S,0.097,-,-,-
GJB2_HUMAN,T5A,0.126,-,-,-
GJB2_HUMAN,T5G,0.34,-,-,-
GJB2_HUMAN,L28I,0.47,-,-,-
GJB2_HUMAN,Y68F,0.202,-,-,-
GJB2_HUMAN,Y68H,0.423,-,-,-
GJB2_HUMAN,Y97H,0.609,Altered Metal binding (Pr = 0.38 | P = 9.6e-03); Gain of Intrinsic disorder (Pr = 0.33 | P = 0.03); Altered Ordered interface (Pr = 0.28 | P = 7.1e-03); Loss of Allosteric site at H94 (Pr = 0.23 | P = 0.02); Altered Coiled coil (Pr = 0.13 | P = 0.04); Altered Stability (Pr = 0.11 | P = 0.03), ELME000012,-
GJB2_HUMAN,K102M,0.441,-,-,-
GJB2_HUMAN,I107M,0.094,-,-,-
GJB2_HUMAN,I107V,0.071,-,-,-
GJB2_HUMAN,K108R,0.104,-,-,-
GJB2_HUMAN,D117N,0.241,-,-,-
GJB2_HUMAN,I118L,0.091,-,-,-
GJB2_HUMAN,T123K,0.137,-,-,-
GJB2_HUMAN,T123N,0.111,-,-,-
GJB2_HUMAN,T123S,0.044,-,-,-
GJB2_HUMAN,V126I,0.1,-,-,-
GJB2_HUMAN,S131P,0.515,Altered Ordered interface (Pr = 0.25 | P = 0.03); Altered DNA binding (Pr = 0.25 | P = 8.6e-03); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Loss of Catalytic site at Y136 (Pr = 0.08 | P = 0.05), ELME000051|ELME000053|ELME000147,-
GJB2_HUMAN,V144I,0.082,-,-,-
GJB2_HUMAN,I145V,0.048,-,-,-
GJB2_HUMAN,A149V,0.063,-,-,-
GJB2_HUMAN,V156I,0.031,-,-,-
GJB2_HUMAN,S162A,0.051,-,-,-
GJB2_HUMAN,S162F,0.128,-,-,-
GJB2_HUMAN,Q164K,0.252,-,-,-
GJB2_HUMAN,N170G,0.366,-,-,-
GJB2_HUMAN,N170S,0.129,-,-,-
GJB2_HUMAN,N170T,0.291,-,-,-
GJB2_HUMAN,V182I,0.246,-,-,-
GJB2_HUMAN,I196V,0.122,-,-,-
GJB2_HUMAN,V207I,0.104,-,-,-
GJB2_HUMAN,Y217F,0.092,-,-,-
GJB2_HUMAN,G220A,0.101,-,-,-
GJB2_HUMAN,G220K,0.142,-,-,-
GJB2_HUMAN,K221R,0.08,-,-,-
GJB2_HUMAN,K223R,0.09,-,-,-
